data_2glw_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2glw _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.399 0 N-CA-C 109.568 -0.53 . . . . 1.02 109.568 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 35.0 mt -86.71 -18.0 32.28 Favored 'General case' 0 N--CA 1.496 1.825 0 C-N-CA 120.251 -0.58 . . . . 1.02 110.515 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.77 152.71 3.13 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.388 -0.82 . . . . 1.02 109.094 177.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 46.6 tttt -133.85 125.16 27.8 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.674 -0.641 . . . . 1.52 110.054 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.446 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 14.6 p90 -150.94 162.28 41.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.575 -0.703 . . . . 0.09 110.782 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -113.41 139.12 49.17 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.713 -0.617 . . . . 2.05 110.235 -177.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.57 162.3 40.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.742 -0.599 . . . . 1.01 109.604 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.1 157.95 18.82 Favored 'General case' 0 N--CA 1.496 1.869 0 C-N-CA 119.764 -0.774 . . . . 1.03 110.063 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.29 134.92 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 C-N-CA 120.289 -0.564 . . . . 1.03 110.161 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -113.46 171.93 7.27 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.23 0.538 . . . . 0.14 109.685 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.33 152.54 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.53 -0.731 . . . . 3.25 112.003 -175.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.5 mt 62.74 7.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.674 0 O-C-N 121.516 -0.74 . . . . 1.05 112.533 -174.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.09 80.66 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.815 -1.178 . . . . 0.09 110.377 179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 70.2 ttp85 -85.54 142.96 28.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.297 -1.12 . . . . 2.75 110.367 -176.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.2 157.74 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.658 -0.651 . . . . 1.02 109.602 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 49.2 mm -117.06 129.58 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.632 -0.668 . . . . 1.03 110.113 176.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.427 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.8 mt -79.98 147.01 64.9 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.147 -0.621 . . . . 1.03 109.396 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.06 143.15 90.06 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 122.979 0.989 . . . . 0.16 109.878 174.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.98 -26.5 62.41 Favored 'General case' 0 N--CA 1.496 1.845 0 C-N-CA 120.404 -0.518 . . . . 1.05 110.448 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.76 -43.73 95.82 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.998 -1.241 . . . . 0.11 109.998 -179.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.4 m -69.69 -39.17 77.1 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.547 -0.973 . . . . 1.03 110.051 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.8 mtt180 -56.49 -42.56 78.5 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 121.353 -0.842 . . . . 0.12 109.403 177.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.2 tttt -67.45 -50.25 60.05 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.025 0.441 . . . . 2.76 110.222 -176.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -58.09 -36.16 72.47 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.735 -0.603 . . . . 0.22 110.581 178.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.449 ' CE2' ' CD1' ' A' ' 84' ' ' LEU . 11.5 t80 -86.77 -14.28 42.74 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.739 -0.601 . . . . 0.91 111.331 -174.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.2 39.94 35.48 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.661 -1.376 . . . . 0.12 109.661 177.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.424 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 85.1 mt -93.2 132.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.502 -0.999 . . . . 1.04 110.633 -175.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.15 161.65 29.59 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 109.304 -0.628 . . . . 1.99 109.304 172.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -57.76 138.72 55.26 Favored 'General case' 0 N--CA 1.503 2.217 0 O-C-N 121.477 -0.764 . . . . 2.54 110.397 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.47 -16.11 61.82 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.855 -0.898 . . . . 0.12 110.855 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -77.51 160.89 28.32 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.085 -1.244 . . . . 0.09 110.234 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -112.62 139.27 48.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.13 109.728 175.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.2 155.82 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 N-CA-C 109.152 -0.684 . . . . 1.02 109.152 173.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -118.75 123.83 45.78 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.36 -0.978 . . . . 1.0 108.36 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 6.9 tt -140.33 158.53 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 C-N-CA 119.58 -0.848 . . . . 1.02 111.144 -167.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 36.4 tttt -132.92 146.09 51.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.91 -0.494 . . . . 1.93 110.384 177.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 pt -114.81 151.01 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.624 -0.672 . . . . 0.99 110.528 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t -138.38 124.75 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 CA-C-O 121.136 0.493 . . . . 1.05 109.678 176.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.9 tttm -132.84 144.87 50.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.29 -0.633 . . . . 2.46 109.29 175.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 42.4 t80 . . . . . 0 N--CA 1.496 1.842 0 C-N-CA 120.09 -0.644 . . . . 0.93 110.55 -177.291 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo . . . . . 0 N--CA 1.483 0.88 0 N-CA-C 110.423 -0.645 . . . . 0.55 110.423 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -110.36 137.51 47.98 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.577 -0.702 . . . . 1.85 109.536 172.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -134.61 162.43 32.33 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.645 -0.659 . . . . 1.69 110.996 -177.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.89 135.92 4.45 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.418 . . . . 0.11 109.554 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -124.06 138.05 54.49 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.651 -0.911 . . . . 1.03 109.785 177.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.4 p90 -155.97 173.47 16.74 Favored 'General case' 0 N--CA 1.497 1.902 0 C-N-CA 119.884 -0.726 . . . . 0.1 110.986 177.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.5 m -106.91 142.07 37.13 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.65 -0.656 . . . . 1.03 109.464 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.07 146.17 36.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.61 -0.681 . . . . 1.02 110.756 -175.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.65 146.0 24.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.841 -0.537 . . . . 2.89 109.63 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.4 ' CG2' ' CG2' ' A' ' 29' ' ' ILE . 96.9 t -79.01 124.82 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 120.294 -0.562 . . . . 1.01 110.062 179.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.95 -166.54 25.07 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.088 -1.205 . . . . 0.11 110.088 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.71 152.95 29.67 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.766 -0.843 . . . . 1.44 110.187 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 53.51 21.1 2.32 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.668 -0.645 . . . . 2.42 112.014 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.62 20.51 79.82 Favored Glycine 0 N--CA 1.5 2.907 0 C-N-CA 119.643 -1.265 . . . . 0.08 110.83 171.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.0 148.19 34.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.438 -1.036 . . . . 1.56 110.27 -177.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.4 p -138.74 145.97 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 N-CA-C 109.535 -0.543 . . . . 1.0 109.535 175.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.3 mm -110.81 122.73 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.561 -0.712 . . . . 1.04 110.709 -174.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 50.9 mt -78.38 144.62 66.5 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.567 -0.708 . . . . 1.05 109.465 172.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.0 Cg_endo -64.25 133.26 37.08 Favored 'Trans proline' 0 N--CA 1.495 1.582 0 O-C-N 122.879 0.936 . . . . 0.14 110.69 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -55.23 -34.23 63.79 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.482 -0.761 . . . . 2.75 110.788 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.71 -37.87 77.07 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.747 -0.596 . . . . 1.02 110.336 -178.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.4 mt -77.08 -32.71 56.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.748 -0.595 . . . . 1.03 110.475 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.4 mtt180 -57.67 -45.49 85.49 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.258 -0.901 . . . . 0.11 109.841 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.15 62.61 Favored 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 120.534 -0.467 . . . . 1.49 110.465 -175.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.55 -38.25 77.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.646 -0.659 . . . . 1.06 109.89 -178.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -82.63 -17.63 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.841 -0.537 . . . . 1.06 110.89 -176.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.6 35.29 36.93 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 109.814 -1.315 . . . . 0.17 109.814 175.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.3 mm -89.47 142.75 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.603 -0.94 . . . . 1.04 110.587 -174.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -129.09 157.47 75.82 Favored Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.829 -0.544 . . . . 3.0 110.7 -177.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -55.31 133.98 61.21 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 O-C-N 122.934 0.965 . . . . 0.82 111.287 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.95 0.23 71.88 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 111.191 -0.763 . . . . 0.15 111.191 175.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -97.48 134.42 40.75 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-N 118.677 1.239 . . . . 0.42 110.559 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -91.95 132.79 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-O 121.67 0.748 . . . . 0.97 111.173 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.5 pt -121.86 159.49 24.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 109.387 -0.597 . . . . 1.02 109.387 175.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -97.69 131.57 44.12 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.98 -0.748 . . . . 1.13 108.98 175.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.437 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 87.4 t -115.78 130.24 70.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 CA-C-O 121.324 0.583 . . . . 1.02 110.266 -170.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.5 mt -116.5 131.01 57.06 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.264 -0.643 . . . . 1.03 109.264 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.449 ' CD1' ' CE2' ' A' ' 27' ' ' TYR . 4.3 mt -80.28 141.6 35.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.415 -0.803 . . . . 1.02 109.971 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.47 -32.52 6.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.765 -0.585 . . . . 1.09 110.868 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.8 -178.31 40.24 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.738 -1.22 . . . . 0.14 111.014 -177.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -148.82 151.22 34.38 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.702 -0.881 . . . . 0.39 110.572 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.58 -0.7 . . . . 1.04 109.893 175.055 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.486 1.33 0 N-CA-C 109.78 -0.452 . . . . 1.16 109.78 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 30.7 mt -87.8 -18.0 30.32 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 120.238 -0.585 . . . . 1.16 110.662 -177.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.21 156.67 3.98 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.206 -0.934 . . . . 1.09 109.853 176.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -134.04 126.77 30.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.758 -0.589 . . . . 2.69 110.167 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.446 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 18.2 p90 -149.42 161.81 41.34 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.614 -0.679 . . . . 0.22 110.874 178.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.0 m-70 -111.54 137.89 48.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.574 -0.704 . . . . 2.35 110.141 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.48 162.33 41.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.69 -0.631 . . . . 1.03 109.748 177.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.4 t -111.5 159.28 18.24 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.535 -0.728 . . . . 1.03 109.996 176.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -78.73 136.44 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.816 -0.553 . . . . 1.16 110.191 -177.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -114.26 171.95 7.3 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.285 0.564 . . . . 1.04 109.651 174.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -46.5 151.95 0.5 Allowed 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.531 -0.731 . . . . 3.63 112.036 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 56.2 mt 62.52 7.93 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.651 0 O-C-N 121.547 -0.721 . . . . 1.12 112.585 -175.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.68 16.06 80.59 Favored Glycine 0 N--CA 1.497 2.738 0 O-C-N 120.934 -1.104 . . . . 0.26 110.432 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.2 ttt180 -84.49 142.51 30.0 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.256 -1.143 . . . . 2.55 110.134 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.2 pt -133.28 154.3 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.649 -0.657 . . . . 1.1 109.671 174.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.53 128.51 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.623 -0.673 . . . . 1.04 109.952 175.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 30.4 mt -79.99 144.34 59.08 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.986 -0.686 . . . . 1.05 109.437 175.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.31 143.23 88.67 Favored 'Trans proline' 0 N--CA 1.489 1.219 0 O-C-N 122.969 0.984 . . . . 0.38 109.772 175.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.58 -26.77 61.97 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 120.442 -0.503 . . . . 1.12 110.472 -178.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -44.21 95.47 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.965 -1.254 . . . . 0.42 109.965 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.3 m -69.82 -38.39 76.54 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.593 -0.945 . . . . 1.08 110.132 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.8 mtt180 -56.06 -40.49 73.63 Favored 'General case' 0 N--CA 1.513 2.687 0 O-C-N 121.337 -0.852 . . . . 0.49 109.378 176.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 84.7 tttt -65.27 -50.05 67.24 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.065 0.459 . . . . 3.4 110.164 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -57.72 -39.08 76.44 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 121.773 -0.579 . . . . 0.74 110.681 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.436 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 22.7 t80 -87.28 -14.2 41.58 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.789 -0.569 . . . . 1.76 111.258 -176.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.78 42.9 24.63 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.536 -1.425 . . . . 0.32 109.536 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.436 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.0 mt -87.41 127.22 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.497 -1.002 . . . . 1.15 110.532 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -128.23 159.39 35.35 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.098 -0.704 . . . . 1.82 109.098 170.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.41 138.71 54.66 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.403 -0.81 . . . . 2.7 110.486 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.74 -16.02 62.12 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.874 -0.89 . . . . 0.21 110.874 179.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -77.09 156.9 31.39 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 118.686 1.243 . . . . 1.12 110.148 177.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -111.36 138.69 47.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.682 -0.636 . . . . 0.24 109.648 174.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.81 153.32 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.709 -0.619 . . . . 1.06 109.34 174.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -116.32 123.01 46.57 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.331 -0.989 . . . . 1.09 108.331 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 6.4 tt -138.6 157.87 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.57 -0.852 . . . . 1.05 111.324 -166.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.89 143.34 50.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.865 -0.522 . . . . 1.77 110.156 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.7 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.553 -0.717 . . . . 1.06 110.551 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.6 t -138.89 127.57 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.756 -0.461 . . . . 1.03 109.756 177.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.0 tttm -133.68 148.36 51.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.701 -0.625 . . . . 2.39 109.633 173.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.1 t80 . . . . . 0 N--CA 1.495 1.79 0 C-N-CA 120.156 -0.618 . . . . 0.91 110.129 178.761 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.483 0.869 0 N-CA-C 110.026 -0.798 . . . . 0.38 110.026 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 mttt -122.49 147.74 45.99 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.404 -0.81 . . . . 1.71 110.098 171.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -136.71 169.05 18.37 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 120.338 -0.545 . . . . 1.42 110.991 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.71 4.38 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.341 -1.503 . . . . 0.18 109.341 177.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -127.15 136.94 52.79 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 1.07 109.927 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.425 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.3 p90 -156.71 173.77 16.47 Favored 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 119.939 -0.704 . . . . 0.18 110.922 176.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.2 m -106.5 140.37 39.5 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.696 -0.627 . . . . 1.01 109.422 173.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.425 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.37 146.6 36.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.706 -0.621 . . . . 1.01 110.749 -175.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.66 145.24 24.7 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.855 -0.528 . . . . 2.71 109.617 175.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 89.9 t -79.44 125.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.356 0.598 . . . . 1.08 109.814 179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.66 -165.33 25.27 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.084 -1.206 . . . . 0.22 110.084 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -61.69 151.76 32.86 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.786 -0.832 . . . . 1.39 110.107 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 53.3 21.88 2.5 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.565 -0.709 . . . . 1.13 112.087 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.32 20.53 79.92 Favored Glycine 0 N--CA 1.5 2.923 0 C-N-CA 119.765 -1.207 . . . . 0.2 110.795 171.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.8 m -78.26 145.55 35.37 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.458 -1.025 . . . . 1.74 110.365 -176.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 9.0 p -139.27 147.77 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.773 -0.579 . . . . 1.04 109.721 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -108.7 123.68 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.525 -0.735 . . . . 1.12 110.658 -175.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.9 mt -78.64 143.02 62.37 Favored Pre-proline 0 N--CA 1.499 1.975 0 O-C-N 121.592 -0.692 . . . . 1.17 109.596 172.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.418 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.0 Cg_endo -64.28 134.21 41.16 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.914 0.955 . . . . 0.29 110.908 -178.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 36.0 tptt -54.98 -34.84 63.72 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.517 -0.739 . . . . 3.08 110.859 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.95 -38.16 78.4 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.765 -0.584 . . . . 1.16 110.313 -178.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.3 mt -77.16 -32.67 56.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.739 -0.601 . . . . 2.43 110.682 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.3 mtt180 -58.35 -46.1 86.91 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.281 -0.887 . . . . 3.27 109.769 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.52 65.24 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 120.481 -0.488 . . . . 1.68 110.44 -175.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 97.3 t -60.59 -38.82 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.685 -0.634 . . . . 1.08 109.903 -178.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.8 mt -82.95 -16.32 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.821 -0.549 . . . . 1.08 111.063 -176.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.11 35.25 44.37 Favored Glycine 0 N--CA 1.498 2.794 0 N-CA-C 109.929 -1.268 . . . . 0.23 109.929 176.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.4 mm -89.33 145.83 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.522 -0.987 . . . . 1.42 110.777 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmt -134.46 162.99 54.39 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.849 -0.532 . . . . 3.68 110.454 -178.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -57.42 134.09 61.3 Favored 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 122.896 0.945 . . . . 0.8 111.137 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 0.98 67.38 Favored Glycine 0 N--CA 1.496 2.675 0 C-N-CA 120.676 -0.773 . . . . 0.26 111.343 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -94.1 129.87 40.49 Favored 'General case' 0 N--CA 1.501 2.102 0 CA-C-N 118.753 1.277 . . . . 1.11 110.322 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.1 132.74 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 CA-C-O 121.616 0.722 . . . . 1.06 111.174 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.6 pt -124.33 159.49 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 109.451 -0.574 . . . . 1.06 109.451 176.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.5 tt0 -97.83 132.1 43.73 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.088 -0.708 . . . . 1.14 109.088 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.445 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 98.7 t -115.04 128.83 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 121.347 0.594 . . . . 1.05 110.143 -171.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.8 mt -115.37 128.8 56.32 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.186 -0.672 . . . . 1.08 109.186 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.42 HD22 ' CE2' ' A' ' 27' ' ' TYR . 4.6 mt -79.38 140.4 37.46 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.431 -0.793 . . . . 1.11 109.729 172.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.71 -32.24 7.16 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.718 -0.614 . . . . 2.19 110.971 -176.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.8 -179.07 40.23 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.674 -1.25 . . . . 0.25 110.985 -176.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.0 p80 -142.96 150.47 39.75 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.746 -0.855 . . . . 2.53 110.658 -177.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.586 -0.696 . . . . 1.1 110.045 175.848 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.485 1.299 0 N-CA-C 109.758 -0.46 . . . . 1.16 109.758 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -86.91 -20.87 26.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.85 -0.531 . . . . 1.16 110.464 -178.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.06 157.23 4.28 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.363 -0.836 . . . . 1.09 109.685 176.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -132.87 126.67 32.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.715 -0.615 . . . . 2.69 110.223 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.45 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 19.6 p90 -149.27 162.48 39.95 Favored 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 120.143 -0.623 . . . . 0.22 110.665 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.59 138.18 50.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.548 -0.72 . . . . 2.35 110.286 -176.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.37 40.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.797 -0.564 . . . . 1.03 109.543 177.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.05 160.35 16.94 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 119.812 -0.755 . . . . 1.03 110.107 177.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.4 t -79.06 136.13 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 C-N-CA 120.329 -0.548 . . . . 1.16 110.318 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -116.2 172.04 7.43 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.24 0.543 . . . . 1.04 109.58 174.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -46.21 152.47 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.543 -0.723 . . . . 3.63 112.048 -175.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.1 mt 62.76 7.32 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.703 0 O-C-N 121.622 -0.674 . . . . 1.12 112.593 -175.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.07 80.67 Favored Glycine 0 N--CA 1.496 2.635 0 O-C-N 120.857 -1.152 . . . . 0.26 110.438 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttp180 -84.63 145.06 28.2 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.292 -1.123 . . . . 2.55 110.191 -177.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 45.1 pt -132.58 155.78 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 N-CA-C 109.315 -0.624 . . . . 1.1 109.315 172.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.1 mm -115.82 128.18 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 C-N-CA 120.034 -0.666 . . . . 1.04 109.904 176.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 33.7 mt -79.58 143.83 59.88 Favored Pre-proline 0 N--CA 1.495 1.794 0 C-N-CA 120.052 -0.659 . . . . 1.05 109.435 176.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.08 143.08 89.79 Favored 'Trans proline' 0 N--CA 1.489 1.231 0 O-C-N 122.989 0.994 . . . . 0.38 109.845 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.62 -26.9 62.24 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.882 -0.511 . . . . 1.12 110.52 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.06 95.61 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.951 -1.26 . . . . 0.42 109.951 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.9 m -69.94 -38.38 76.15 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.585 -0.95 . . . . 1.08 110.116 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -55.87 -40.81 73.47 Favored 'General case' 0 N--CA 1.512 2.664 0 O-C-N 121.286 -0.884 . . . . 0.49 109.429 176.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -65.75 -50.07 66.11 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.1 0.476 . . . . 3.4 110.212 -177.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -57.6 -39.67 77.34 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.707 -0.621 . . . . 0.74 110.756 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.438 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 20.0 t80 -87.69 -14.29 40.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.774 -0.579 . . . . 1.76 111.275 -176.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.87 42.52 25.19 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.576 -1.409 . . . . 0.32 109.576 178.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.438 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.2 mt -87.74 125.55 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.543 -0.975 . . . . 1.15 110.445 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.55 159.94 33.07 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.235 -0.654 . . . . 1.82 109.235 172.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -57.27 138.19 55.06 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.33 -0.856 . . . . 2.7 110.557 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.81 -16.09 61.99 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 110.832 -0.907 . . . . 0.21 110.832 178.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -77.23 155.96 31.79 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.693 1.246 . . . . 1.12 109.998 177.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -111.27 138.78 47.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.6 -0.688 . . . . 0.24 109.492 174.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 155.06 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.199 -0.6 . . . . 1.06 109.386 174.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.99 122.55 45.58 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.198 -1.038 . . . . 1.09 108.198 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.7 tt -139.15 158.22 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.596 -0.841 . . . . 1.05 110.936 -167.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -133.15 145.62 50.83 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.859 -0.525 . . . . 1.77 110.505 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 pt -114.93 151.13 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.648 -0.657 . . . . 1.06 110.604 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t -138.67 127.93 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 121.174 0.512 . . . . 1.03 109.72 176.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 33.3 tptt -137.82 147.13 44.29 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.83 -0.544 . . . . 2.39 109.632 175.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 44.9 t80 . . . . . 0 N--CA 1.496 1.828 0 C-N-CA 120.266 -0.574 . . . . 0.91 110.384 -176.794 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo . . . . . 0 N--CA 1.483 0.893 0 N-CA-C 109.994 -0.81 . . . . 0.38 109.994 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 37.1 mttp -118.71 151.75 37.41 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.498 -0.751 . . . . 1.71 110.309 173.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -140.03 169.09 18.34 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-O 121.216 0.532 . . . . 1.42 110.737 -178.373 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.61 135.9 4.47 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.428 -1.469 . . . . 0.18 109.428 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -122.64 137.48 54.89 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.629 -0.924 . . . . 1.07 109.847 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.42 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 13.7 p90 -156.14 173.1 17.32 Favored 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.899 -0.721 . . . . 0.18 110.901 176.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.06 141.31 38.5 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.669 -0.644 . . . . 1.01 109.493 173.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.42 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 145.51 35.19 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.675 -0.641 . . . . 1.01 110.695 -175.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -93.68 146.0 24.15 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.855 -0.528 . . . . 2.71 109.626 175.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.15 125.45 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.778 -0.576 . . . . 1.08 109.919 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.33 -167.08 25.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.944 -1.262 . . . . 0.22 109.944 178.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.68 152.93 29.58 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.79 -0.829 . . . . 1.39 110.138 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.28 21.4 2.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.652 -0.655 . . . . 1.13 112.095 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.1 20.6 79.66 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.684 -1.246 . . . . 0.2 110.832 171.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.0 m -77.96 144.56 36.67 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.388 -1.066 . . . . 1.74 110.343 -176.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.64 146.51 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.881 -0.512 . . . . 1.04 109.684 175.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -110.53 123.21 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.51 -0.744 . . . . 1.12 110.783 -175.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 70.5 mt -78.27 144.37 66.54 Favored Pre-proline 0 N--CA 1.498 1.938 0 O-C-N 121.637 -0.664 . . . . 1.17 109.494 172.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.41 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.9 Cg_endo -64.17 133.82 39.74 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 O-C-N 122.98 0.99 . . . . 0.29 110.796 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -55.21 -34.23 63.75 Favored 'General case' 0 N--CA 1.502 2.171 0 O-C-N 121.481 -0.762 . . . . 3.08 110.768 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.84 -37.99 77.7 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.797 -0.564 . . . . 1.16 110.275 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -77.13 -32.66 56.56 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 120.151 -0.62 . . . . 2.43 110.593 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.01 -46.33 85.44 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.349 -0.844 . . . . 3.27 109.771 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.91 -46.51 65.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 120.543 -0.463 . . . . 1.68 110.401 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.5 t -60.58 -38.81 79.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.692 -0.63 . . . . 1.08 109.843 -178.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -82.64 -16.63 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.845 -0.535 . . . . 1.08 111.083 -176.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.24 35.18 43.86 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 109.878 -1.289 . . . . 0.23 109.878 176.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.2 mm -90.6 142.86 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.056 0 O-C-N 121.519 -0.989 . . . . 1.42 110.63 -174.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.0 ptmt -130.27 162.35 54.83 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.801 -0.562 . . . . 3.68 110.644 -178.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.51 135.55 68.37 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 O-C-N 122.946 0.971 . . . . 0.8 110.919 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.61 -0.35 70.51 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.612 -0.804 . . . . 0.26 111.264 176.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -94.73 130.29 41.31 Favored 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 118.741 1.271 . . . . 1.11 109.849 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.92 129.9 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 121.527 0.679 . . . . 1.06 110.809 -175.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 45.7 pt -118.79 159.39 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 109.418 -0.586 . . . . 1.06 109.418 177.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -97.91 131.91 43.96 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.017 -0.735 . . . . 1.14 109.017 174.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 90.9 t -116.2 129.72 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.355 0.598 . . . . 1.05 110.301 -170.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.6 mt -115.85 130.11 56.7 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 109.208 -0.664 . . . . 1.08 109.208 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.419 HD21 ' CE2' ' A' ' 27' ' ' TYR . 5.3 mt -80.29 140.55 36.13 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.345 -0.847 . . . . 1.11 109.803 172.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.8 mt -111.37 -33.1 6.51 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.649 -0.657 . . . . 2.19 110.97 -176.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.21 -175.79 38.14 Favored Glycine 0 N--CA 1.504 3.181 0 C-N-CA 119.689 -1.244 . . . . 0.25 111.089 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -144.25 154.26 42.9 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.728 -0.866 . . . . 2.53 110.624 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 . . . . . 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 1.1 110.21 176.482 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.488 1.473 0 N-CA-C 109.626 -0.509 . . . . 1.16 109.626 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 34.6 mt -86.67 -18.5 31.12 Favored 'General case' 0 N--CA 1.496 1.827 0 C-N-CA 120.164 -0.614 . . . . 1.16 110.574 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.69 155.69 3.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.251 -0.905 . . . . 1.09 109.518 175.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.8 tttt -134.76 124.66 25.54 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.696 -0.627 . . . . 2.69 110.117 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.448 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.0 p90 -150.82 163.66 38.09 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.621 -0.674 . . . . 0.22 110.898 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -114.05 138.0 50.97 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.623 -0.673 . . . . 2.35 110.34 -177.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.39 162.31 41.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.66 -0.65 . . . . 1.03 109.648 177.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -109.64 160.47 16.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.367 -0.833 . . . . 1.03 110.264 177.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -78.92 137.37 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.843 -0.536 . . . . 1.16 110.289 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.82 171.97 7.55 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.286 0.565 . . . . 1.04 109.628 174.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.1 mtt-85 -46.37 152.54 0.43 Allowed 'General case' 0 N--CA 1.506 2.354 0 O-C-N 121.509 -0.745 . . . . 3.63 111.999 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.8 mt 62.62 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.673 0 O-C-N 121.536 -0.727 . . . . 1.12 112.604 -175.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.78 16.1 80.45 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.901 -1.125 . . . . 0.26 110.335 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.9 ttp180 -85.16 144.85 27.93 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.269 -1.136 . . . . 2.55 110.28 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 pt -133.3 154.76 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.706 -0.621 . . . . 1.1 109.398 172.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.2 mm -116.7 127.77 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.563 -0.711 . . . . 1.04 110.034 176.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 38.2 mt -79.9 144.18 59.16 Favored Pre-proline 0 N--CA 1.495 1.824 0 C-N-CA 120.087 -0.645 . . . . 1.05 109.479 176.05 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.38 143.52 88.87 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 122.927 0.961 . . . . 0.38 109.724 174.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.56 61.28 Favored 'General case' 0 N--CA 1.497 1.895 0 C-N-CA 120.391 -0.523 . . . . 1.12 110.56 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.55 -44.5 95.03 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.848 -1.301 . . . . 0.42 109.848 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.1 m -69.94 -38.13 76.07 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.662 -0.905 . . . . 1.08 110.09 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -55.89 -40.61 73.24 Favored 'General case' 0 N--CA 1.514 2.741 0 O-C-N 121.26 -0.9 . . . . 0.49 109.385 176.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -64.95 -49.78 69.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.184 0.516 . . . . 3.4 110.133 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -57.24 -38.45 73.83 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.704 -0.622 . . . . 0.74 110.727 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.443 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 20.8 t80 -88.09 -14.43 38.87 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.756 -0.59 . . . . 1.76 111.216 -177.037 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.77 42.81 24.91 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.529 -1.429 . . . . 0.32 109.529 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.443 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.6 mt -87.26 128.32 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.481 -1.011 . . . . 1.15 110.644 -176.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -127.85 158.85 36.63 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.115 -0.698 . . . . 1.82 109.115 170.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -57.3 138.51 54.72 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.329 -0.857 . . . . 2.7 110.522 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.88 -15.89 62.44 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 110.873 -0.891 . . . . 0.21 110.873 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -76.95 155.61 32.59 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-N 118.71 1.255 . . . . 1.12 110.0 177.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -110.72 138.83 46.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.636 -0.665 . . . . 0.24 109.646 174.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.57 154.05 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.262 -0.644 . . . . 1.06 109.262 175.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -115.45 123.42 48.54 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.279 -1.008 . . . . 1.09 108.279 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.4 tt -139.87 158.45 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 C-N-CA 119.69 -0.804 . . . . 1.05 110.861 -167.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.6 ttpt -133.03 146.06 51.38 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.767 -0.583 . . . . 1.77 110.577 177.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.8 pt -114.88 151.07 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.63 -0.669 . . . . 1.06 110.333 177.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.4 t -138.92 125.04 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-O 121.133 0.492 . . . . 1.03 109.71 176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 39.1 tptt -135.17 147.58 49.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.763 -0.585 . . . . 2.39 109.655 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.9 t80 . . . . . 0 N--CA 1.496 1.856 0 C-N-CA 120.233 -0.587 . . . . 0.91 110.33 -177.628 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo . . . . . 0 N--CA 1.482 0.82 0 N-CA-C 110.108 -0.766 . . . . 0.38 110.108 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 22.8 mmtt -117.62 137.31 52.71 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.522 -0.736 . . . . 1.71 109.716 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -135.05 166.4 23.14 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.662 -0.649 . . . . 1.42 110.747 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.64 4.34 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.53 -1.428 . . . . 0.18 109.53 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.03 136.43 54.83 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.711 -0.876 . . . . 1.07 109.73 176.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.1 p90 -155.43 173.29 16.88 Favored 'General case' 0 N--CA 1.497 1.899 0 C-N-CA 119.956 -0.698 . . . . 0.18 111.014 178.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.0 140.57 39.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.619 -0.675 . . . . 1.01 109.525 173.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.86 146.5 35.89 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.709 -0.619 . . . . 1.01 110.613 -175.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -93.48 145.18 24.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.757 -0.589 . . . . 2.71 109.766 175.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.2 t -79.5 125.95 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.744 -0.597 . . . . 1.08 109.908 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.05 -167.37 25.96 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.992 -1.243 . . . . 0.22 109.992 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -61.68 153.45 28.12 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.67 -0.9 . . . . 1.39 110.148 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 53.71 21.09 2.48 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.53 -0.731 . . . . 1.13 111.984 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.14 20.55 79.98 Favored Glycine 0 N--CA 1.499 2.853 0 C-N-CA 119.804 -1.188 . . . . 0.2 110.876 171.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 12.4 t -78.64 144.62 35.24 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.455 -1.027 . . . . 1.74 110.294 -176.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.43 145.79 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 N-CA-C 109.577 -0.527 . . . . 1.04 109.577 175.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.1 mm -111.39 123.84 67.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.546 -0.721 . . . . 1.12 110.685 -175.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.2 mt -78.16 145.0 68.14 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.602 -0.686 . . . . 1.17 109.458 172.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.405 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -64.14 134.45 42.63 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 O-C-N 122.957 0.977 . . . . 0.29 110.68 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -55.21 -34.28 63.79 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.437 -0.789 . . . . 3.08 110.797 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -37.8 77.39 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.659 -0.651 . . . . 1.16 110.322 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.2 mt -77.12 -32.7 56.65 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.18 -0.608 . . . . 2.43 110.579 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.7 mtt180 -57.94 -46.1 85.57 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.297 -0.877 . . . . 3.27 109.944 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.01 63.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.52 -0.472 . . . . 1.68 110.385 -175.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.59 -38.18 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.678 -0.639 . . . . 1.08 109.943 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -82.22 -18.12 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.855 -0.528 . . . . 1.08 110.817 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.92 35.05 40.49 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.648 -1.381 . . . . 0.23 109.648 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.4 mm -91.69 142.58 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.592 -0.946 . . . . 1.42 110.549 -174.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.67 161.41 61.16 Favored Pre-proline 0 N--CA 1.498 1.944 0 O-C-N 121.782 -0.574 . . . . 3.68 110.735 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.49 137.31 79.64 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.937 0.967 . . . . 0.8 111.033 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.08 72.33 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 111.166 -0.774 . . . . 0.26 111.166 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -94.17 130.17 40.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-N 118.692 1.246 . . . . 1.11 110.202 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.74 128.86 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 CA-C-O 121.444 0.64 . . . . 1.06 110.759 -175.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 47.9 pt -118.3 159.43 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 109.459 -0.571 . . . . 1.06 109.459 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.4 tt0 -97.95 129.96 44.83 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.909 -0.774 . . . . 1.14 108.909 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.448 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 94.7 t -115.18 129.29 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.288 0.566 . . . . 1.05 110.303 -170.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.7 mt -115.66 128.43 55.9 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 109.167 -0.679 . . . . 1.08 109.167 179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.418 HD21 ' CE2' ' A' ' 27' ' ' TYR . 5.2 mt -79.78 138.5 37.28 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.39 -0.819 . . . . 1.11 109.542 171.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -109.91 -31.29 7.46 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.723 -0.611 . . . . 2.19 110.968 -174.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.12 -177.33 39.25 Favored Glycine 0 N--CA 1.503 3.12 0 C-N-CA 119.672 -1.251 . . . . 0.25 111.039 -177.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -143.54 152.43 41.43 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.707 -0.878 . . . . 2.53 110.648 -177.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 . . . . . 0 N--CA 1.494 1.755 0 O-C-N 121.468 -0.77 . . . . 1.1 110.356 176.532 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 109.595 -0.521 . . . . 1.16 109.595 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 24.7 mt -82.51 -20.85 35.93 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.816 -0.553 . . . . 1.16 110.195 179.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -170.69 152.56 3.81 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.459 -0.776 . . . . 1.09 109.199 175.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.6 tttt -133.92 125.1 27.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.69 110.293 -175.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.45 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.6 p90 -150.99 162.55 40.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.651 -0.655 . . . . 0.22 110.925 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.4 m-70 -111.94 138.49 48.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.582 -0.698 . . . . 2.35 110.188 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.59 162.34 41.15 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.694 -0.629 . . . . 1.03 109.701 177.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.3 t -110.83 160.21 16.96 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.461 -0.774 . . . . 1.03 109.83 176.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.402 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 61.4 t -77.65 137.47 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.754 -0.591 . . . . 1.16 110.169 -177.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.3 m80 -116.14 171.99 7.45 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.66 -0.496 . . . . 1.04 109.66 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -46.02 151.53 0.47 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.639 -0.663 . . . . 3.63 112.122 -174.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.5 mt 62.74 7.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.606 -0.684 . . . . 1.12 112.639 -175.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.96 80.63 Favored Glycine 0 N--CA 1.498 2.801 0 N-CA-C 110.322 -1.111 . . . . 0.26 110.322 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -85.34 145.52 27.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 2.55 110.211 -177.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -134.36 154.68 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.626 -0.671 . . . . 1.1 109.476 172.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -117.19 127.99 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.57 -0.706 . . . . 1.04 110.031 176.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.25 144.98 59.15 Favored Pre-proline 0 N--CA 1.496 1.834 0 C-N-CA 120.038 -0.665 . . . . 1.05 109.491 175.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -63.44 143.44 88.34 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 O-C-N 123.023 1.012 . . . . 0.38 109.776 174.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.39 -26.57 61.27 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.845 -0.534 . . . . 1.12 110.495 -178.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.45 -44.37 95.36 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.932 -1.267 . . . . 0.42 109.932 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 83.9 m -70.22 -38.0 75.16 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.592 -0.946 . . . . 1.08 110.13 -179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -55.86 -41.23 74.04 Favored 'General case' 0 N--CA 1.514 2.775 0 O-C-N 121.263 -0.898 . . . . 0.49 109.342 176.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -65.41 -49.24 69.95 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.048 0.451 . . . . 3.4 110.287 -178.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.34 -38.42 74.07 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.787 -0.57 . . . . 0.74 110.781 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.428 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 22.9 t80 -87.58 -14.22 40.74 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.817 -0.552 . . . . 1.76 111.257 -177.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.12 42.79 23.24 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.522 -1.431 . . . . 0.32 109.522 178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.412 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.0 mt -87.44 129.67 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.511 -0.993 . . . . 1.15 110.574 -177.163 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.42 155.46 43.62 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 109.077 -0.712 . . . . 1.82 109.077 171.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -55.45 137.44 48.27 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.256 -0.903 . . . . 2.7 110.794 -177.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.69 -14.66 64.91 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.91 -0.876 . . . . 0.21 110.91 178.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -76.26 155.55 34.25 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 118.848 1.324 . . . . 1.12 109.907 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -109.33 138.24 45.98 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.518 -0.739 . . . . 0.24 109.508 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.73 154.85 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.263 -0.643 . . . . 1.06 109.263 175.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -115.95 122.95 46.79 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.277 -1.008 . . . . 1.09 108.277 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.405 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 13.1 tt -139.37 157.83 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.7 -0.8 . . . . 1.05 110.87 -167.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -132.83 146.03 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.814 -0.554 . . . . 1.77 110.518 178.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.3 pt -114.95 150.93 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.663 -0.648 . . . . 1.06 110.51 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.18 126.54 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-O 121.085 0.469 . . . . 1.03 109.765 176.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 47.1 tttp -133.35 146.33 51.2 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.798 -0.564 . . . . 2.39 109.57 174.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 37.4 t80 . . . . . 0 N--CA 1.496 1.863 0 C-N-CA 120.133 -0.627 . . . . 0.91 110.151 179.234 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo . . . . . 0 N--CA 1.483 0.861 0 N-CA-C 109.992 -0.811 . . . . 0.38 109.992 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -111.97 137.65 49.68 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.529 -0.732 . . . . 1.71 109.583 172.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.17 164.86 26.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.582 -0.698 . . . . 1.42 110.773 -175.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.26 135.94 4.42 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.58 -1.408 . . . . 0.18 109.58 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.2 m -123.28 137.39 54.87 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.733 -0.863 . . . . 1.07 109.695 176.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.9 p90 -156.23 173.09 17.36 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.845 -0.742 . . . . 0.18 111.037 176.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.6 m -107.47 141.02 39.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.668 -0.645 . . . . 1.01 109.5 173.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.92 145.95 35.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.717 -0.614 . . . . 1.01 110.45 -176.038 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -93.72 144.23 25.59 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.749 -0.594 . . . . 2.71 109.687 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.1 t -78.82 125.98 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.267 0.556 . . . . 1.08 110.009 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.37 -169.9 25.81 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.848 -1.301 . . . . 0.22 109.848 177.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -61.81 155.82 22.13 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.707 -0.878 . . . . 1.39 109.913 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.06 19.34 2.71 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.486 -0.759 . . . . 1.13 112.018 -177.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.56 20.59 79.58 Favored Glycine 0 N--CA 1.499 2.839 0 C-N-CA 119.813 -1.184 . . . . 0.2 110.66 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 32.4 t -78.4 144.72 35.65 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.437 -1.037 . . . . 1.74 110.479 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.75 146.27 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 109.637 -0.505 . . . . 1.04 109.637 175.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -111.79 123.97 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.6 -0.688 . . . . 1.12 110.655 -175.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 68.7 mt -78.33 143.47 64.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.612 -0.68 . . . . 1.17 109.477 172.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.408 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.0 Cg_endo -64.79 136.81 50.92 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 O-C-N 122.982 0.991 . . . . 0.29 110.814 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.1 tptt -54.91 -34.46 63.14 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.395 -0.816 . . . . 3.08 110.714 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.46 79.15 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.789 -0.569 . . . . 1.16 110.287 -178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -77.18 -32.82 56.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.742 -0.599 . . . . 2.43 110.656 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -58.35 -45.24 88.56 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.265 -0.897 . . . . 3.27 109.91 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.14 -47.41 61.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.55 -0.46 . . . . 1.68 110.408 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.1 t -60.54 -38.08 77.1 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 121.666 -0.646 . . . . 1.08 109.845 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.1 mt -82.6 -17.74 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.84 -0.537 . . . . 1.08 110.829 -176.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.06 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.621 -1.392 . . . . 0.23 109.621 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.402 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 49.9 mm -93.71 141.86 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.558 -0.966 . . . . 1.42 110.728 -174.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.67 162.4 56.46 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.757 -0.589 . . . . 3.68 110.691 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -51.88 135.86 51.01 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.025 1.013 . . . . 0.8 111.807 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.08 -1.92 71.06 Favored Glycine 0 N--CA 1.497 2.702 0 C-N-CA 120.72 -0.752 . . . . 0.26 111.431 174.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -96.4 131.53 42.87 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-N 118.74 1.27 . . . . 1.11 110.64 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.26 132.95 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.607 0.718 . . . . 1.06 111.229 -173.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.6 pt -124.72 159.52 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.948 -0.47 . . . . 1.06 109.757 177.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.421 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 41.6 tt0 -97.59 130.94 44.59 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.0 t -114.41 129.48 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.803 -0.56 . . . . 1.05 110.207 -171.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.2 mt -118.09 128.78 55.07 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.113 -0.699 . . . . 1.08 109.113 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.42 HD12 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -79.79 140.45 36.87 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.305 -0.872 . . . . 1.11 109.757 172.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.49 -33.51 6.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.718 -0.614 . . . . 2.19 110.887 -175.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.63 -172.97 36.03 Favored Glycine 0 N--CA 1.502 3.094 0 C-N-CA 119.778 -1.201 . . . . 0.25 110.942 -176.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -142.88 159.0 43.07 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.706 -0.879 . . . . 2.53 110.655 -177.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.683 . . . . 1.1 110.322 177.602 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 109.605 -0.517 . . . . 1.16 109.605 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.412 HD12 ' CE2' ' A' ' 27' ' ' TYR . 26.0 mt -84.16 -19.92 33.3 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.738 -0.601 . . . . 1.16 110.398 -179.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.32 153.93 3.76 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.362 -0.836 . . . . 1.09 109.427 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.6 tttt -133.75 125.24 28.11 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.679 -0.638 . . . . 2.69 110.128 -177.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.449 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.6 p90 -150.9 163.12 39.43 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.627 -0.67 . . . . 0.22 110.871 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.44 138.93 49.38 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.706 -0.621 . . . . 2.35 110.376 -176.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.28 162.3 41.15 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.653 -0.655 . . . . 1.03 109.717 177.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.2 t -111.4 159.69 17.78 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.427 -0.796 . . . . 1.03 109.917 175.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -77.56 138.64 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 120.302 -0.559 . . . . 1.16 110.275 -176.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -118.31 172.01 7.75 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.583 -0.525 . . . . 1.04 109.583 174.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -46.28 152.57 0.41 Allowed 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.574 -0.704 . . . . 3.63 112.014 -175.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.1 mt 62.75 7.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.607 0 O-C-N 121.58 -0.7 . . . . 1.12 112.61 -175.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.47 16.12 80.68 Favored Glycine 0 N--CA 1.497 2.7 0 O-C-N 120.901 -1.124 . . . . 0.26 110.327 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.8 ttp180 -84.88 145.96 27.54 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.294 -1.121 . . . . 2.55 110.247 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -133.08 154.85 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 109.284 -0.636 . . . . 1.1 109.284 171.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -115.1 128.04 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 120.039 -0.664 . . . . 1.04 110.054 176.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.0 mt -79.98 144.63 59.69 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.048 -0.661 . . . . 1.05 109.424 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -62.87 142.6 89.16 Favored 'Trans proline' 0 N--CA 1.488 1.2 0 O-C-N 122.971 0.985 . . . . 0.38 109.871 174.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.64 -27.36 62.74 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 120.401 -0.519 . . . . 1.12 110.478 -178.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.54 -43.99 95.78 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.902 -1.279 . . . . 0.42 109.902 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.2 m -70.12 -38.0 75.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.608 -0.937 . . . . 1.08 109.914 -179.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -55.82 -40.94 73.49 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 121.233 -0.917 . . . . 0.49 109.436 176.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -65.27 -50.08 67.14 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.14 0.495 . . . . 3.4 110.131 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.4 -38.43 74.28 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.786 -0.571 . . . . 0.74 110.756 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.428 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.5 t80 -87.4 -14.25 41.12 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.821 -0.549 . . . . 1.76 111.343 -176.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.93 42.76 24.28 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 109.581 -1.408 . . . . 0.32 109.581 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.418 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.5 mt -87.63 128.45 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.57 -0.959 . . . . 1.15 110.559 -177.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.95 158.38 38.01 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.943 -0.762 . . . . 1.82 108.943 170.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -57.4 140.18 51.04 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.342 -0.849 . . . . 2.7 110.465 -178.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -16.07 61.71 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.828 -0.909 . . . . 0.21 110.828 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.74 157.72 31.47 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.094 -1.239 . . . . 1.12 110.146 178.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -111.92 138.76 48.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.569 -0.707 . . . . 0.24 109.579 174.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 154.75 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 120.15 -0.62 . . . . 1.06 109.354 174.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -115.58 123.72 49.17 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.303 -0.999 . . . . 1.09 108.303 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.0 tt -139.9 158.79 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.754 -0.778 . . . . 1.05 110.982 -167.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.2 tttt -133.33 146.21 51.12 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.885 -0.509 . . . . 1.77 110.29 177.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 21.2 pt -114.82 150.94 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.716 -0.615 . . . . 1.06 110.302 178.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.99 123.84 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.181 0.515 . . . . 1.03 109.678 177.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 46.7 tttp -132.76 146.97 52.29 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.357 -0.609 . . . . 2.39 109.357 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.0 t80 . . . . . 0 N--CA 1.496 1.844 0 C-N-CA 119.957 -0.697 . . . . 0.91 110.41 -178.798 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo . . . . . 0 N--CA 1.482 0.852 0 N-CA-C 110.298 -0.693 . . . . 0.38 110.298 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -109.48 137.72 46.9 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.554 -0.716 . . . . 1.71 109.456 172.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.6 163.22 30.62 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.62 -0.675 . . . . 1.42 110.93 -176.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.08 135.93 4.43 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.549 -1.421 . . . . 0.18 109.549 177.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.5 m -123.23 138.2 54.69 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.568 -0.96 . . . . 1.07 109.841 176.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 13.2 p90 -156.15 173.17 17.23 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.975 -0.69 . . . . 0.18 110.955 176.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -107.36 141.27 38.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.718 -0.614 . . . . 1.01 109.479 173.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.17 146.22 36.69 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 120.212 -0.595 . . . . 1.01 110.73 -175.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -93.01 145.13 24.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.811 -0.556 . . . . 2.71 109.59 175.195 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -79.47 125.8 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.827 -0.546 . . . . 1.08 109.779 179.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.1 -170.38 27.25 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.707 -1.357 . . . . 0.22 109.707 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -61.84 155.75 22.4 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.644 -0.915 . . . . 1.39 109.961 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 54.87 19.64 2.71 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.569 -0.707 . . . . 1.13 112.008 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.18 20.55 79.97 Favored Glycine 0 N--CA 1.499 2.837 0 C-N-CA 119.793 -1.194 . . . . 0.2 110.816 172.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.6 m -77.91 144.04 37.21 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.46 -1.024 . . . . 1.74 110.288 -176.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.22 145.93 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.751 -0.593 . . . . 1.04 109.596 175.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -111.4 123.17 67.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.541 -0.725 . . . . 1.12 110.699 -174.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 77.3 mt -78.62 143.87 64.07 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.532 -0.73 . . . . 1.17 109.429 172.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.413 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.1 Cg_endo -65.1 136.68 49.03 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 O-C-N 122.926 0.961 . . . . 0.29 110.757 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 43.2 tttm -55.07 -34.17 63.36 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.48 -0.763 . . . . 3.08 110.774 179.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.11 78.34 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.711 -0.618 . . . . 1.16 110.288 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -77.15 -32.76 56.52 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 120.208 -0.597 . . . . 2.43 110.519 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -58.29 -45.46 87.91 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.305 -0.872 . . . . 3.27 109.845 178.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.03 -46.53 64.87 Favored 'General case' 0 N--CA 1.496 1.857 0 C-N-CA 120.476 -0.489 . . . . 1.68 110.457 -175.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.7 t -60.45 -38.48 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 C-N-CA 120.168 -0.613 . . . . 1.08 109.945 -178.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.5 mt -82.56 -17.51 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.803 -0.561 . . . . 1.08 110.876 -177.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.69 35.13 41.54 Favored Glycine 0 N--CA 1.497 2.742 0 N-CA-C 109.768 -1.333 . . . . 0.23 109.768 176.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.0 mm -93.19 142.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.613 -0.934 . . . . 1.42 110.721 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.49 162.17 57.69 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.724 -0.61 . . . . 3.68 110.309 178.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -56.51 138.11 83.16 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 O-C-N 122.817 0.904 . . . . 0.8 111.331 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 -2.63 71.83 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 120.696 -0.764 . . . . 0.26 111.24 176.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -96.62 131.9 42.81 Favored 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 118.715 1.258 . . . . 1.11 110.599 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.6 p -92.43 133.45 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 121.669 0.747 . . . . 1.06 111.244 -173.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.8 pt -124.59 159.49 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 109.507 -0.553 . . . . 1.06 109.507 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -98.88 132.24 44.37 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.029 -0.73 . . . . 1.14 109.029 175.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 92.8 t -115.9 131.6 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.754 -0.591 . . . . 1.05 110.363 -170.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.9 mt -117.94 129.55 55.68 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 109.269 -0.641 . . . . 1.08 109.269 179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.419 HD22 ' CE2' ' A' ' 27' ' ' TYR . 5.5 mt -80.05 142.26 35.09 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.398 -0.814 . . . . 1.11 109.798 171.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 15.6 mt -117.95 -26.72 6.36 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.701 -0.625 . . . . 2.19 111.117 -174.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.78 40.58 Favored Glycine 0 N--CA 1.504 3.195 0 C-N-CA 119.66 -1.257 . . . . 0.25 110.966 -176.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -146.45 150.76 36.24 Favored 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.669 -0.9 . . . . 2.53 110.597 -178.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 N--CA 1.494 1.741 0 O-C-N 121.475 -0.766 . . . . 1.1 110.136 175.445 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.486 1.354 0 N-CA-C 109.612 -0.514 . . . . 1.16 109.612 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.87 -20.79 34.84 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.298 -0.561 . . . . 1.16 110.312 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.52 153.68 3.56 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.423 -0.798 . . . . 1.09 109.272 176.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 tttt -134.04 125.98 29.22 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.732 -0.605 . . . . 2.69 110.177 -176.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.447 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.5 p90 -150.61 163.56 38.2 Favored 'General case' 0 N--CA 1.498 1.941 0 C-N-CA 120.052 -0.659 . . . . 0.22 110.957 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.424 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 91.7 m-70 -113.02 138.58 49.67 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.695 -0.628 . . . . 2.35 110.117 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.35 162.31 41.14 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.727 -0.608 . . . . 1.03 109.664 176.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -111.28 159.74 17.66 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.873 -0.731 . . . . 1.03 109.983 176.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.8 t -78.82 134.09 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.803 -0.56 . . . . 1.16 110.2 -177.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -113.77 171.89 7.31 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-O 121.214 0.53 . . . . 1.04 109.751 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -46.57 152.82 0.42 Allowed 'General case' 0 N--CA 1.507 2.412 0 O-C-N 121.663 -0.648 . . . . 3.63 111.996 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.2 mt 62.77 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.598 -0.689 . . . . 1.12 112.576 -175.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.42 16.11 80.73 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.906 -1.121 . . . . 0.26 110.332 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -85.57 143.99 28.16 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.231 -1.158 . . . . 2.55 110.418 -175.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.3 pt -133.68 154.49 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.701 -0.624 . . . . 1.1 109.616 172.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.2 mm -116.84 128.11 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.557 -0.715 . . . . 1.04 110.132 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 36.1 mt -80.04 144.86 59.82 Favored Pre-proline 0 N--CA 1.496 1.861 0 C-N-CA 120.026 -0.67 . . . . 1.05 109.415 175.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.37 143.35 88.58 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 122.893 0.944 . . . . 0.38 109.77 174.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.63 -26.49 61.65 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.416 -0.514 . . . . 1.12 110.499 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.47 95.14 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.894 -1.282 . . . . 0.42 109.894 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.2 m -69.97 -38.12 75.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.531 -0.982 . . . . 1.08 110.193 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.5 mtt180 -55.92 -40.94 73.83 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.23 -0.918 . . . . 0.49 109.454 176.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -65.61 -49.98 66.74 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.204 0.526 . . . . 3.4 110.215 -177.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -57.49 -37.72 73.42 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.689 -0.632 . . . . 0.74 110.668 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.424 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.3 t80 -87.67 -14.19 40.57 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.752 -0.593 . . . . 1.76 111.287 -176.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.91 42.87 24.05 Favored Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.587 -1.405 . . . . 0.32 109.587 178.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.407 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.1 mt -88.1 129.73 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.068 0 O-C-N 121.552 -0.969 . . . . 1.15 110.615 -176.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -127.9 158.71 37.06 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 109.079 -0.711 . . . . 1.82 109.079 170.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -57.34 137.68 55.79 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.333 -0.854 . . . . 2.7 110.636 -178.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.57 -14.49 65.21 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.9 -0.88 . . . . 0.21 110.9 178.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.19 156.9 33.23 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 118.857 1.328 . . . . 1.12 110.072 177.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -110.62 138.14 47.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.626 -0.671 . . . . 0.24 109.517 174.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.62 154.27 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.247 -0.649 . . . . 1.06 109.247 174.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.5 123.55 48.83 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.287 -1.005 . . . . 1.09 108.287 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.2 tt -140.09 157.16 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 119.611 -0.835 . . . . 1.05 110.953 -167.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -132.2 145.99 51.72 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.846 -0.534 . . . . 1.77 110.528 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 29.2 pt -115.3 151.14 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.726 -0.609 . . . . 1.06 110.584 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.4 t -138.51 125.76 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.264 0.554 . . . . 1.03 109.882 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.3 tptm -130.76 146.49 52.24 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.156 -0.683 . . . . 2.39 109.156 174.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.7 t80 . . . . . 0 N--CA 1.495 1.814 0 C-N-CA 120.263 -0.575 . . . . 0.91 110.471 -178.75 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo . . . . . 0 N--CA 1.483 0.859 0 N-CA-C 110.208 -0.728 . . . . 0.38 110.208 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 31.4 mmtt -114.69 137.73 51.56 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.564 -0.71 . . . . 1.71 109.617 173.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.65 164.18 28.09 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.675 -0.641 . . . . 1.42 110.775 -176.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.78 135.91 4.46 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.484 -1.446 . . . . 0.18 109.484 178.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -123.18 137.65 54.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.65 -0.912 . . . . 1.07 109.784 176.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 12.7 p90 -156.13 172.89 17.66 Favored 'General case' 0 N--CA 1.498 1.932 0 C-N-CA 119.833 -0.747 . . . . 0.18 111.014 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.4 m -107.32 140.74 39.76 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.705 -0.622 . . . . 1.01 109.499 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.7 145.21 34.61 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 1.01 110.585 -175.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -94.13 144.88 25.11 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.828 -0.545 . . . . 2.71 109.647 175.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.7 t -78.79 126.37 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.833 -0.542 . . . . 1.08 110.015 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.86 -165.95 25.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.123 -1.191 . . . . 0.22 110.123 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -61.68 152.07 31.95 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.771 -0.841 . . . . 1.39 110.201 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 73.7 mt-30 53.35 21.52 2.38 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.572 -0.705 . . . . 1.13 112.062 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.54 20.48 79.84 Favored Glycine 0 N--CA 1.5 2.906 0 C-N-CA 119.777 -1.201 . . . . 0.2 110.866 171.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.3 t -78.34 144.67 35.81 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.468 -1.019 . . . . 1.74 110.25 -177.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.34 146.28 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 N-CA-C 109.55 -0.537 . . . . 1.04 109.55 175.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.9 mm -110.68 122.78 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.609 -0.682 . . . . 1.12 110.566 -174.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.6 mt -78.72 142.61 61.47 Favored Pre-proline 0 N--CA 1.498 1.975 0 O-C-N 121.589 -0.694 . . . . 1.17 109.437 172.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.411 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.1 Cg_endo -64.35 133.93 39.7 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 O-C-N 122.915 0.955 . . . . 0.29 110.763 -179.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -55.28 -34.2 63.88 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.508 -0.745 . . . . 3.08 110.832 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.7 76.78 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.783 -0.573 . . . . 1.16 110.334 -178.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.3 mt -77.09 -32.73 56.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.779 -0.575 . . . . 2.43 110.521 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -57.76 -46.13 84.96 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.275 -0.891 . . . . 3.27 109.833 178.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -47.2 62.59 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.503 -0.479 . . . . 1.68 110.502 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.2 t -60.48 -38.22 77.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.708 -0.62 . . . . 1.08 109.962 -178.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.2 mt -82.58 -17.76 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.818 -0.551 . . . . 1.08 110.884 -176.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.64 35.11 41.9 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 109.726 -1.35 . . . . 0.23 109.726 176.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 49.9 mm -92.2 138.94 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.535 -0.979 . . . . 1.42 110.591 -174.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.4 mmtt -123.75 161.23 47.53 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.665 -0.647 . . . . 3.68 110.531 -176.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -60.39 135.61 62.52 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 122.951 0.974 . . . . 0.8 110.677 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.89 -0.48 73.08 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 111.139 -0.784 . . . . 0.26 111.139 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -97.17 132.95 42.44 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.063 -1.257 . . . . 1.11 110.44 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.78 132.27 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 121.504 0.668 . . . . 1.06 111.008 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.7 pt -119.59 159.42 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 109.531 -0.544 . . . . 1.06 109.531 176.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.424 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 46.9 tt0 -98.31 130.16 45.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.815 -0.809 . . . . 1.14 108.815 173.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 89.1 t -115.32 130.22 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-O 121.292 0.568 . . . . 1.05 110.27 -170.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 31.5 mt -116.71 129.53 56.18 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 109.136 -0.691 . . . . 1.08 109.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.411 HD11 ' CD2' ' A' ' 27' ' ' TYR . 5.8 mt -80.15 142.46 34.74 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.3 -0.875 . . . . 1.11 109.694 171.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.6 mt -119.5 -25.66 5.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.668 -0.645 . . . . 2.19 111.183 -174.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.41 -179.22 40.13 Favored Glycine 0 N--CA 1.503 3.16 0 C-N-CA 119.643 -1.265 . . . . 0.25 111.1 -177.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -146.96 152.91 39.41 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.669 -0.901 . . . . 2.53 110.571 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 . . . . . 0 N--CA 1.494 1.773 0 O-C-N 121.538 -0.726 . . . . 1.1 110.159 176.203 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 109.566 -0.531 . . . . 1.16 109.566 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 35.3 mt -85.94 -20.12 29.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.781 -0.574 . . . . 1.16 110.523 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.68 156.16 3.47 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.301 -0.875 . . . . 1.09 109.436 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -134.26 124.2 25.51 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.777 -0.577 . . . . 2.69 110.104 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.45 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 16.6 p90 -150.28 162.61 40.17 Favored 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 120.006 -0.678 . . . . 0.22 111.047 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.418 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 92.5 m-70 -112.39 138.57 48.93 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.582 -0.699 . . . . 2.35 110.074 -177.461 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.0 t -151.47 162.37 41.06 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.65 -0.656 . . . . 1.03 109.741 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.42 158.42 19.12 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.857 -0.737 . . . . 1.03 110.072 177.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.6 t -78.95 137.18 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 C-N-CA 120.279 -0.569 . . . . 1.16 110.323 -176.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.2 m80 -116.2 171.91 7.51 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.298 0.57 . . . . 1.04 109.734 174.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.5 ttt85 -46.92 153.02 0.45 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.492 -0.755 . . . . 3.63 111.76 -175.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.9 mt 62.93 6.93 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.684 0 O-C-N 121.507 -0.746 . . . . 1.12 112.636 -174.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.67 16.03 80.63 Favored Glycine 0 N--CA 1.496 2.64 0 O-C-N 120.789 -1.194 . . . . 0.26 110.294 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -84.94 144.48 28.31 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.317 -1.108 . . . . 2.55 110.352 -177.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -131.79 154.62 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.751 -0.593 . . . . 1.1 109.41 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.5 128.49 73.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.598 -0.689 . . . . 1.04 110.003 176.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 40.1 mt -79.99 145.42 61.24 Favored Pre-proline 0 N--CA 1.496 1.826 0 C-N-CA 119.968 -0.693 . . . . 1.05 109.39 175.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.48 143.42 88.09 Favored 'Trans proline' 0 N--CA 1.489 1.206 0 O-C-N 122.936 0.966 . . . . 0.38 109.706 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.48 61.47 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 120.41 -0.516 . . . . 1.12 110.496 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.61 -44.48 94.98 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.862 -1.295 . . . . 0.42 109.862 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 84.4 m -69.92 -38.11 76.12 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.599 -0.942 . . . . 1.08 110.16 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -56.0 -40.74 73.79 Favored 'General case' 0 N--CA 1.513 2.696 0 O-C-N 121.289 -0.882 . . . . 0.49 109.448 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -65.17 -50.06 67.41 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.086 0.469 . . . . 3.4 110.058 -177.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.26 -38.77 74.38 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.854 -0.529 . . . . 0.74 110.772 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.447 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 18.9 t80 -88.42 -14.29 38.37 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.753 -0.592 . . . . 1.76 111.163 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.9 42.59 24.85 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.497 -1.441 . . . . 0.32 109.497 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.447 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.2 mt -87.47 125.5 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.429 -1.042 . . . . 1.15 110.455 -177.037 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -128.17 155.35 44.62 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.996 -0.742 . . . . 1.82 108.996 171.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -55.5 140.15 41.43 Favored 'General case' 0 N--CA 1.503 2.179 0 O-C-N 121.289 -0.882 . . . . 2.7 110.576 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.82 -16.19 61.39 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.812 -0.915 . . . . 0.21 110.812 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -77.43 158.33 30.07 Favored 'General case' 0 N--CA 1.499 2.022 0 CA-C-N 118.72 1.26 . . . . 1.12 110.042 177.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -113.18 139.19 48.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.604 -0.685 . . . . 0.24 109.581 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.28 154.54 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.35 -0.611 . . . . 1.06 109.35 174.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.418 ' HB2' ' CE2' ' A' ' 88' ' ' TYR . 48.9 tt0 -116.0 123.62 48.46 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.219 -1.03 . . . . 1.09 108.219 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.7 tt -139.16 157.99 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 C-N-CA 119.588 -0.845 . . . . 1.05 111.213 -167.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.84 143.48 50.21 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.9 -0.5 . . . . 1.77 109.951 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.0 pt -114.91 150.99 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.593 -0.692 . . . . 1.06 110.527 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -138.4 123.19 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 CA-C-O 121.238 0.542 . . . . 1.03 109.721 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.2 tttm -130.98 147.1 52.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.191 -0.67 . . . . 2.39 109.191 174.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.4 t80 . . . . . 0 N--CA 1.496 1.873 0 C-N-CA 119.968 -0.693 . . . . 0.91 110.471 -178.565 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.482 0.845 0 N-CA-C 110.529 -0.604 . . . . 0.38 110.529 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp -111.63 137.73 49.1 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.462 -0.774 . . . . 1.71 109.486 171.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.53 164.33 27.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.608 -0.682 . . . . 1.42 110.929 -176.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.03 135.78 4.37 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.536 -1.425 . . . . 0.18 109.536 177.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -127.55 137.05 52.5 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.793 -0.828 . . . . 1.07 109.791 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.0 p90 -156.57 173.94 16.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 119.883 -0.727 . . . . 0.18 110.916 177.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.4 m -106.94 140.74 39.26 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.407 -0.59 . . . . 1.01 109.407 173.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.425 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.1 146.18 36.76 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.608 -0.683 . . . . 1.01 110.69 -175.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -93.35 145.81 24.19 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 109.628 -0.508 . . . . 2.71 109.628 175.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 88.0 t -78.56 126.01 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.754 -0.591 . . . . 1.08 109.858 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.0 -167.34 26.0 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.982 -1.247 . . . . 0.22 109.982 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.64 153.23 28.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.782 -0.834 . . . . 1.39 110.151 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 53.51 21.12 2.34 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.579 -0.7 . . . . 1.13 112.099 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.54 79.89 Favored Glycine 0 N--CA 1.499 2.892 0 C-N-CA 119.716 -1.231 . . . . 0.2 110.921 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.6 p -78.28 147.11 34.45 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.445 -1.032 . . . . 1.74 110.262 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.82 145.99 26.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 109.548 -0.538 . . . . 1.04 109.548 175.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -110.73 123.37 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.446 -0.784 . . . . 1.12 110.738 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.3 mt -78.31 144.71 66.99 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.576 -0.703 . . . . 1.17 109.452 172.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.413 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.7 Cg_endo -64.67 135.89 47.23 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 122.929 0.963 . . . . 0.29 110.755 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.03 -34.36 63.44 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.499 -0.75 . . . . 3.08 110.759 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -38.04 77.92 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.757 -0.589 . . . . 1.16 110.317 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.1 mt -77.14 -32.79 56.58 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.734 -0.604 . . . . 2.43 110.475 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.09 -45.66 86.82 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.319 -0.863 . . . . 3.27 109.811 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.09 -47.25 62.64 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.515 -0.474 . . . . 1.68 110.463 -175.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.6 t -60.52 -38.34 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.116 0 O-C-N 121.726 -0.609 . . . . 1.08 109.916 -178.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -82.38 -17.65 11.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.886 -0.509 . . . . 1.08 110.917 -176.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.09 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.697 -1.361 . . . . 0.23 109.697 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.1 mm -91.39 142.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.564 -0.962 . . . . 1.42 110.707 -173.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.13 159.05 72.19 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.8 -0.562 . . . . 3.68 110.757 -178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -54.57 134.79 63.82 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 122.913 0.954 . . . . 0.8 111.414 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -0.94 72.17 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 120.696 -0.764 . . . . 0.26 111.27 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -97.19 133.28 42.04 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.058 -1.26 . . . . 1.11 110.552 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.3 p -92.98 136.35 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 CA-C-O 121.835 0.826 . . . . 1.06 111.389 -174.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.89 159.59 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.247 -0.649 . . . . 1.06 109.247 177.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.418 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 52.4 tt0 -97.98 131.25 44.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.046 -0.724 . . . . 1.14 109.046 175.389 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.3 t -117.06 130.7 71.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 CA-C-O 121.438 0.637 . . . . 1.05 110.391 -170.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.8 mt -117.27 129.82 56.16 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.194 -0.669 . . . . 1.08 109.194 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.416 HD21 ' CE2' ' A' ' 27' ' ' TYR . 5.6 mt -80.08 140.75 36.33 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.36 -0.838 . . . . 1.11 109.903 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.7 mt -111.5 -30.47 7.37 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.672 -0.642 . . . . 2.19 111.011 -175.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.29 178.62 41.31 Favored Glycine 0 N--CA 1.505 3.254 0 C-N-CA 119.61 -1.281 . . . . 0.25 111.012 -176.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.408 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 30.1 p80 -140.81 145.63 36.55 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.783 -0.834 . . . . 2.53 109.99 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.418 ' CE2' ' HB2' ' A' ' 36' ' ' GLU . 18.3 m-85 . . . . . 0 N--CA 1.498 1.945 0 O-C-N 121.665 -0.647 . . . . 1.1 109.961 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.486 1.365 0 N-CA-C 109.519 -0.548 . . . . 1.16 109.519 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 28.7 mt -85.18 -18.72 33.24 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.221 -0.592 . . . . 1.16 110.246 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -174.79 151.83 1.48 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.214 -0.929 . . . . 1.09 109.045 176.042 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 17.5 ttpt -134.63 128.19 32.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.625 -0.672 . . . . 2.69 110.356 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.451 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.6 p90 -149.91 162.93 39.37 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.822 -0.549 . . . . 0.22 110.685 -177.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.422 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.1 m170 -112.58 137.63 50.53 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.662 -0.649 . . . . 2.35 110.144 -176.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.37 162.35 41.07 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.724 -0.61 . . . . 1.03 109.636 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.48 157.85 19.15 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 119.81 -0.756 . . . . 1.03 110.137 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.4 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 59.3 t -80.13 136.56 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 CA-C-O 121.276 0.56 . . . . 1.16 110.339 -176.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.3 m80 -113.98 171.96 7.28 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.229 0.538 . . . . 1.04 109.672 174.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.7 mtt85 -45.99 152.44 0.38 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.558 -0.714 . . . . 3.63 112.127 -175.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.0 mt 62.75 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.654 0 O-C-N 121.611 -0.68 . . . . 1.12 112.578 -175.057 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.48 16.06 80.74 Favored Glycine 0 N--CA 1.497 2.709 0 O-C-N 120.783 -1.198 . . . . 0.26 110.34 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -85.47 142.63 29.07 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -1.113 . . . . 2.55 110.234 -177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -133.12 156.54 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.728 -0.607 . . . . 1.1 109.695 174.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.52 129.16 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.65 -0.656 . . . . 1.04 109.957 176.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 28.2 mt -79.69 145.81 63.46 Favored Pre-proline 0 N--CA 1.495 1.814 0 C-N-CA 120.04 -0.664 . . . . 1.05 109.331 175.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -62.84 142.74 89.82 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 122.994 0.997 . . . . 0.38 109.848 174.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.27 62.93 Favored 'General case' 0 N--CA 1.497 1.885 0 C-N-CA 120.44 -0.504 . . . . 1.12 110.464 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -43.85 95.99 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 109.968 -1.253 . . . . 0.42 109.968 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 98.6 m -69.81 -38.53 76.63 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.559 -0.966 . . . . 1.08 109.958 -179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -56.03 -41.27 74.7 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.252 -0.905 . . . . 0.49 109.39 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -65.75 -50.14 65.84 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.111 0.481 . . . . 3.4 110.224 -177.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 82.2 t80 -57.47 -38.3 74.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.788 -0.57 . . . . 0.74 110.683 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.424 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 21.5 t80 -87.36 -14.16 41.49 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.739 -0.601 . . . . 1.76 111.3 -175.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.46 42.78 26.51 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.573 -1.411 . . . . 0.32 109.573 178.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.424 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.3 mt -88.38 128.48 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.522 -0.987 . . . . 1.15 110.556 -176.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -128.25 155.44 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 171.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -55.71 138.72 46.96 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 121.241 -0.912 . . . . 2.7 110.646 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.62 -15.98 62.15 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.868 -0.893 . . . . 0.21 110.868 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -77.16 158.18 30.53 Favored 'General case' 0 N--CA 1.499 1.997 0 CA-C-N 118.677 1.239 . . . . 1.12 110.11 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -112.09 138.94 48.05 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.594 -0.691 . . . . 0.24 109.62 174.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.48 154.11 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 N-CA-C 109.312 -0.625 . . . . 1.06 109.312 173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.98 123.57 48.35 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.277 -1.009 . . . . 1.09 108.277 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.7 tt -140.08 158.17 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.559 -0.856 . . . . 1.05 111.128 -167.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -133.04 146.1 51.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.799 -0.563 . . . . 1.77 110.418 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 27.5 pt -114.88 151.1 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.743 -0.598 . . . . 1.06 110.571 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -137.62 128.72 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 109.65 -0.5 . . . . 1.03 109.65 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -136.82 148.26 47.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.783 -0.573 . . . . 2.39 109.645 177.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.8 t80 . . . . . 0 N--CA 1.496 1.861 0 O-C-N 121.703 -0.623 . . . . 0.91 110.491 -178.327 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo . . . . . 0 N--CA 1.485 0.99 0 N-CA-C 110.327 -0.682 . . . . 0.38 110.327 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.1 mttp -121.37 149.8 42.42 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.426 -0.796 . . . . 1.71 110.172 171.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.3 mp0 -136.99 166.96 22.43 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 120.22 -0.592 . . . . 1.42 110.995 -177.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.32 135.9 4.51 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.305 -1.518 . . . . 0.18 109.305 175.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.4 m -123.84 138.48 54.49 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.546 -0.973 . . . . 1.07 109.894 178.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.425 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 13.6 p90 -156.62 173.09 17.46 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 119.868 -0.733 . . . . 0.18 110.986 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.2 m -107.37 141.4 38.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.67 -0.644 . . . . 1.01 109.395 173.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.425 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.04 145.64 36.15 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.681 -0.637 . . . . 1.01 110.709 -175.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.1 ttt180 -93.51 145.13 24.74 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 109.573 -0.529 . . . . 2.71 109.573 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.06 125.05 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.223 0.535 . . . . 1.08 109.838 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.08 -164.91 24.86 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.135 -1.186 . . . . 0.22 110.135 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 33.4 tp10 -61.67 152.69 30.16 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.819 . . . . 1.39 110.013 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 53.43 21.04 2.23 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.59 -0.694 . . . . 1.13 112.043 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.69 79.96 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 119.732 -1.223 . . . . 0.2 110.842 172.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.6 p -77.92 147.12 35.17 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.45 -1.029 . . . . 1.74 110.365 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.401 ' CG2' ' CB ' ' A' ' 54' ' ' ALA . 8.7 p -139.15 146.55 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.82 -0.55 . . . . 1.04 109.628 175.558 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -111.04 123.1 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.579 -0.701 . . . . 1.12 110.748 -175.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 86.7 mt -78.57 144.65 65.76 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.614 -0.679 . . . . 1.17 109.535 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.416 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.6 Cg_endo -64.13 133.27 37.45 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 O-C-N 122.873 0.933 . . . . 0.29 110.767 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.2 tttt -55.01 -34.45 63.46 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.551 -0.718 . . . . 3.08 110.831 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -38.22 77.89 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.737 -0.602 . . . . 1.16 110.275 -178.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 72.8 mt -76.99 -32.8 57.48 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 120.25 -0.58 . . . . 2.43 110.547 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.8 mtt180 -57.93 -45.61 86.32 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.287 -0.883 . . . . 3.27 109.808 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.75 -46.67 65.34 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.479 -0.489 . . . . 1.68 110.307 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 98.8 t -60.72 -39.11 80.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.626 -0.671 . . . . 1.08 109.951 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.7 mt -83.65 -14.42 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.839 -0.538 . . . . 1.08 111.191 -176.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.67 35.38 40.87 Favored Glycine 0 N--CA 1.499 2.857 0 N-CA-C 110.169 -1.172 . . . . 0.23 110.169 175.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.4 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 51.3 mm -88.66 140.56 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.536 -0.979 . . . . 1.42 110.787 -174.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -131.38 162.62 54.88 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.782 -0.574 . . . . 3.68 110.606 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.88 134.82 59.26 Favored 'Trans proline' 0 N--CA 1.487 1.09 0 O-C-N 122.954 0.976 . . . . 0.8 110.858 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.97 0.91 70.84 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 120.639 -0.791 . . . . 0.26 111.234 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -96.87 133.7 41.15 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.019 -1.283 . . . . 1.11 110.498 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.08 133.22 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-O 121.584 0.706 . . . . 1.06 111.2 -175.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 45.4 pt -123.18 159.5 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 109.499 -0.556 . . . . 1.06 109.499 176.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.422 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 58.8 tt0 -97.35 131.52 43.94 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.986 -0.746 . . . . 1.14 108.986 174.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.451 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 96.2 t -116.08 128.46 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.438 0.637 . . . . 1.05 110.222 -171.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.4 mt -115.45 128.75 56.24 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 109.466 -0.568 . . . . 1.08 109.466 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.411 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.52 140.8 37.13 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.451 -0.781 . . . . 1.11 109.948 172.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.43 -32.31 6.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.791 -0.568 . . . . 2.19 110.828 -176.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.19 -177.19 39.19 Favored Glycine 0 N--CA 1.505 3.259 0 C-N-CA 119.706 -1.235 . . . . 0.25 111.025 -176.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.3 p80 -145.17 151.71 38.88 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.708 -0.878 . . . . 2.53 110.792 -177.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 N--CA 1.494 1.769 0 O-C-N 121.515 -0.741 . . . . 1.1 109.994 175.061 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.486 1.369 0 N-CA-C 109.475 -0.565 . . . . 1.16 109.475 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.1 mt -82.56 -20.15 37.13 Favored 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 120.248 -0.581 . . . . 1.16 110.425 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.94 153.21 3.15 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.415 -0.803 . . . . 1.09 109.289 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.6 tttt -133.96 125.92 29.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.639 -0.663 . . . . 2.69 110.222 -176.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 16.7 p90 -151.2 163.41 38.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.605 -0.684 . . . . 0.22 110.833 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.86 138.61 50.06 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.615 -0.678 . . . . 2.35 110.349 -176.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 162.37 41.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.774 -0.578 . . . . 1.03 109.684 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -110.21 158.95 17.82 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.48 -0.763 . . . . 1.03 109.933 176.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.0 t -79.46 136.39 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.272 -0.571 . . . . 1.16 110.241 -176.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -114.69 171.91 7.35 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.312 0.577 . . . . 1.04 109.831 175.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.39 152.97 0.39 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.609 -0.682 . . . . 3.63 112.008 -176.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.5 mt 63.09 7.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.702 0 O-C-N 121.605 -0.684 . . . . 1.12 112.522 -175.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.51 15.98 80.8 Favored Glycine 0 N--CA 1.497 2.729 0 O-C-N 120.899 -1.125 . . . . 0.26 110.312 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -86.02 143.81 27.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.304 -1.115 . . . . 2.55 110.361 -176.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.4 154.67 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.631 -0.668 . . . . 1.1 109.613 172.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.6 128.79 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.623 -0.673 . . . . 1.04 109.978 176.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 27.3 mt -79.44 145.35 63.48 Favored Pre-proline 0 N--CA 1.495 1.781 0 C-N-CA 120.056 -0.658 . . . . 1.05 109.423 175.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -63.4 143.64 89.03 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 O-C-N 122.96 0.979 . . . . 0.38 109.748 174.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.96 -27.0 60.82 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 120.389 -0.524 . . . . 1.12 110.484 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.39 -44.76 94.89 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.02 -1.232 . . . . 0.42 110.02 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 91.6 m -69.31 -36.64 77.2 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.686 -0.891 . . . . 1.08 110.061 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -56.38 -42.56 78.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.371 -0.83 . . . . 0.49 109.812 178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -66.2 -49.97 65.45 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 120.209 -0.596 . . . . 3.4 110.203 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 74.7 t80 -56.26 -37.93 70.46 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.831 -0.543 . . . . 0.74 110.589 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.425 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.1 t80 -88.34 -14.31 38.52 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.892 -0.505 . . . . 1.76 111.228 -178.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.55 42.82 25.97 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.609 -1.396 . . . . 0.32 109.609 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.416 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.6 mt -87.52 126.95 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.526 -0.985 . . . . 1.15 110.538 -176.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -127.19 158.98 35.65 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 170.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -57.26 137.53 55.88 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.361 -0.837 . . . . 2.7 110.662 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.23 63.84 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.998 -0.841 . . . . 0.21 110.998 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.31 157.11 32.8 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-N 118.674 1.237 . . . . 1.12 110.053 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -111.11 138.39 47.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.629 -0.67 . . . . 0.24 109.631 174.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 153.44 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.3 -0.63 . . . . 1.06 109.3 174.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -115.06 123.14 48.25 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.3 tt -140.47 159.21 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.688 -0.805 . . . . 1.05 110.882 -167.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -133.55 145.99 50.61 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.783 -0.573 . . . . 1.77 110.415 176.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.0 pt -115.0 151.08 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.575 -0.703 . . . . 1.06 110.385 177.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.79 124.5 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 120.499 -0.48 . . . . 1.03 109.806 176.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 22.0 ttpp -131.21 144.68 51.52 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.735 -0.603 . . . . 2.39 109.381 176.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 t80 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.654 -0.654 . . . . 0.91 110.335 -178.916 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.482 0.85 0 N-CA-C 110.097 -0.77 . . . . 0.38 110.097 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 mmtt -111.59 137.37 49.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.593 -0.692 . . . . 1.71 109.666 173.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -135.17 165.3 25.72 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.645 -0.659 . . . . 1.42 110.71 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.71 135.68 4.35 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.406 -1.478 . . . . 0.18 109.406 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.9 m -123.55 136.66 54.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.782 -0.834 . . . . 1.07 109.779 176.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 10.8 p90 -156.05 173.53 16.68 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 119.942 -0.703 . . . . 0.18 111.079 178.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.22 140.71 39.67 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.615 -0.678 . . . . 1.01 109.472 173.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.63 146.08 35.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.656 -0.653 . . . . 1.01 110.655 -175.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.4 ttp-105 -93.63 144.78 25.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.79 -0.569 . . . . 2.71 109.647 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.03 127.28 39.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.794 -0.566 . . . . 1.08 109.95 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.72 -171.37 26.61 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.841 -1.304 . . . . 0.22 109.841 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 -61.85 156.61 20.24 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.636 -0.92 . . . . 1.39 109.893 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 55.07 19.06 2.59 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.441 -0.787 . . . . 1.13 112.075 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.64 20.49 79.62 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.831 -1.176 . . . . 0.2 110.695 172.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.4 t -78.75 144.87 34.8 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.423 -1.046 . . . . 1.74 110.333 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -137.73 146.15 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 109.555 -0.535 . . . . 1.04 109.555 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.1 mm -110.86 123.69 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.53 -0.731 . . . . 1.12 110.714 -174.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 68.2 mt -78.66 143.29 62.81 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.585 -0.697 . . . . 1.17 109.455 172.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.411 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.4 Cg_endo -65.02 137.11 51.2 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 O-C-N 122.959 0.979 . . . . 0.29 110.817 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 17.1 tptp -54.84 -34.79 63.27 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.446 -0.784 . . . . 3.08 110.781 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.86 -38.35 78.56 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.792 -0.568 . . . . 1.16 110.363 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.3 mt -77.2 -32.73 56.19 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 120.15 -0.62 . . . . 2.43 110.683 179.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.31 -45.55 87.81 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.347 -0.846 . . . . 3.27 109.831 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -70.32 -48.19 57.69 Favored 'General case' 0 N--CA 1.495 1.822 0 C-N-CA 120.519 -0.472 . . . . 1.68 110.421 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.53 -38.02 76.84 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.732 -0.605 . . . . 1.08 109.938 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.3 mt -82.52 -17.8 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.844 -0.535 . . . . 1.08 110.947 -176.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.45 35.17 42.72 Favored Glycine 0 N--CA 1.497 2.721 0 N-CA-C 109.7 -1.36 . . . . 0.23 109.7 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.1 mm -91.13 142.01 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.514 -0.992 . . . . 1.42 110.695 -174.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 44.9 mttt -130.88 162.34 55.97 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.699 -0.626 . . . . 3.68 110.663 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.93 135.58 64.07 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 O-C-N 123.037 1.019 . . . . 0.8 110.818 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.16 -0.16 71.77 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 120.686 -0.769 . . . . 0.26 111.246 176.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -95.37 131.12 41.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.055 -1.262 . . . . 1.11 110.377 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.5 p -91.66 135.87 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 CA-C-O 121.762 0.792 . . . . 1.06 111.106 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 159.43 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 109.477 -0.564 . . . . 1.06 109.477 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -98.61 128.18 44.82 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.751 -0.833 . . . . 1.14 108.751 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 85.5 t -113.28 128.98 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-O 121.341 0.591 . . . . 1.05 110.148 -171.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 31.8 mt -116.75 127.35 54.28 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.02 -0.733 . . . . 1.08 109.02 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.418 HD23 ' CE2' ' A' ' 27' ' ' TYR . 4.4 mt -79.98 140.9 36.43 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.363 -0.835 . . . . 1.11 109.757 172.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 mt -113.9 -30.13 6.83 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.658 -0.651 . . . . 2.19 110.966 -174.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.93 -177.93 39.54 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.709 -1.234 . . . . 0.25 111.008 -177.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 25.5 p80 -145.09 153.53 41.53 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.729 -0.865 . . . . 2.53 110.694 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.6 -0.687 . . . . 1.1 110.162 176.236 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.486 1.37 0 N-CA-C 109.556 -0.535 . . . . 1.16 109.556 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.4 mt -82.08 -20.77 37.51 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.25 -0.58 . . . . 1.16 110.252 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.17 153.42 3.69 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -0.835 . . . . 1.09 109.245 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.6 tttt -133.55 125.72 29.46 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.741 -0.6 . . . . 2.69 110.173 -176.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.447 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.2 p90 -150.23 162.87 39.64 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.555 -0.716 . . . . 0.22 110.94 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 95.5 m-70 -112.83 137.73 50.72 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.718 -0.614 . . . . 2.35 110.172 -176.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.1 162.3 41.12 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.729 -0.607 . . . . 1.03 109.582 176.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -110.11 159.77 17.05 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.736 -0.786 . . . . 1.03 110.075 177.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.5 t -78.74 136.24 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 C-N-CA 120.3 -0.56 . . . . 1.16 110.233 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -115.44 171.88 7.44 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.22 0.533 . . . . 1.04 109.589 174.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 69.8 mtp85 -46.27 152.54 0.41 Allowed 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.573 -0.704 . . . . 3.63 112.067 -175.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.7 mt 62.41 7.99 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.665 0 O-C-N 121.656 -0.653 . . . . 1.12 112.631 -176.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.9 16.18 80.27 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.832 -1.168 . . . . 0.26 110.446 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -84.45 143.27 29.51 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.314 -1.11 . . . . 2.55 110.33 -176.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -134.51 154.95 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.672 -0.642 . . . . 1.1 109.545 172.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.7 mm -117.46 128.44 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.586 -0.696 . . . . 1.04 109.936 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 35.6 mt -79.79 144.04 59.4 Favored Pre-proline 0 N--CA 1.495 1.786 0 C-N-CA 120.075 -0.65 . . . . 1.05 109.407 176.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.37 143.5 88.91 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.004 1.002 . . . . 0.38 109.729 174.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.51 -26.49 61.41 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.858 -0.526 . . . . 1.12 110.527 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.37 95.17 Favored Glycine 0 N--CA 1.497 2.722 0 N-CA-C 109.935 -1.266 . . . . 0.42 109.935 -179.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 75.0 m -69.97 -38.2 76.02 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.58 -0.953 . . . . 1.08 110.18 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.6 mtt180 -55.95 -41.11 74.21 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.349 -0.844 . . . . 0.49 109.413 176.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.2 tttp -65.56 -49.95 66.96 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.145 0.498 . . . . 3.4 110.197 -177.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -57.14 -38.34 73.38 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.769 -0.582 . . . . 0.74 110.735 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.439 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 20.7 t80 -88.12 -14.25 39.24 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.779 -0.575 . . . . 1.76 111.291 -176.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.81 42.69 25.05 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.484 -1.447 . . . . 0.32 109.484 178.264 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.439 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.6 mt -87.49 129.17 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.492 -1.005 . . . . 1.15 110.437 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.08 154.65 45.46 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.962 -0.755 . . . . 1.82 108.962 172.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -55.21 139.67 41.37 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.288 -0.882 . . . . 2.7 110.691 -177.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.86 -15.98 61.88 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.936 -0.866 . . . . 0.21 110.936 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -76.21 156.73 33.35 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.097 -1.237 . . . . 1.12 110.069 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -110.18 138.59 46.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.638 -0.664 . . . . 0.24 109.595 174.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.32 154.79 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 109.271 -0.64 . . . . 1.06 109.271 174.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -116.09 123.37 47.74 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.207 -1.034 . . . . 1.09 108.207 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.6 tt -139.45 158.25 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 119.661 -0.816 . . . . 1.05 110.95 -167.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -132.7 145.86 51.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.867 -0.521 . . . . 1.77 110.386 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 34.1 pt -114.94 150.97 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.667 -0.645 . . . . 1.06 110.568 177.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.7 t -139.27 126.0 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 CA-C-O 121.231 0.539 . . . . 1.03 109.778 176.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 29.5 tptp -136.26 148.79 48.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.812 -0.555 . . . . 2.39 109.511 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.9 t80 . . . . . 0 N--CA 1.495 1.808 0 C-N-CA 120.19 -0.604 . . . . 0.91 110.251 -178.135 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo . . . . . 0 N--CA 1.483 0.906 0 N-CA-C 110.566 -0.59 . . . . 0.38 110.566 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -114.47 136.89 52.51 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.545 -0.722 . . . . 1.71 109.496 171.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -137.5 168.92 18.69 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.603 -0.686 . . . . 1.42 110.713 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -160.22 135.95 4.31 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.592 -1.403 . . . . 0.18 109.592 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -121.55 137.49 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.755 -0.85 . . . . 1.07 109.721 177.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 13.8 p90 -155.78 173.02 17.36 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 119.911 -0.716 . . . . 0.18 110.965 176.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.4 m -107.44 140.82 39.81 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.71 -0.619 . . . . 1.01 109.586 174.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.66 145.12 34.56 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.614 -0.679 . . . . 1.01 110.552 -176.25 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.2 ttp-105 -93.4 145.31 24.58 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.773 -0.58 . . . . 2.71 109.679 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.11 126.13 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.847 -0.533 . . . . 1.08 109.975 -179.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.45 -170.7 26.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.79 -1.324 . . . . 0.22 109.79 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -61.88 156.03 21.83 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.61 -0.935 . . . . 1.39 109.905 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 54.91 19.44 2.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.611 -0.68 . . . . 1.13 112.084 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.68 20.5 79.67 Favored Glycine 0 N--CA 1.499 2.838 0 C-N-CA 119.821 -1.18 . . . . 0.2 110.783 172.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 54.1 p -77.97 145.7 35.88 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.451 -1.029 . . . . 1.74 110.534 -175.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.9 p -139.81 146.2 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.875 -0.515 . . . . 1.04 109.628 174.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.62 123.61 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.499 -0.75 . . . . 1.12 110.653 -175.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.3 144.15 65.97 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.679 -0.638 . . . . 1.17 109.652 174.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.416 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.4 Cg_endo -64.41 134.35 41.33 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 O-C-N 123.002 1.001 . . . . 0.29 110.808 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -55.19 -34.29 63.76 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.532 -0.73 . . . . 3.08 110.847 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.78 -37.69 76.87 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.74 -0.6 . . . . 1.16 110.324 -178.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.4 mt -77.18 -32.79 56.34 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.723 -0.61 . . . . 2.43 110.544 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -57.82 -45.73 85.72 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.282 -0.886 . . . . 3.27 109.911 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.27 -47.22 62.26 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.44 -0.504 . . . . 1.68 110.465 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.56 -38.12 77.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.712 -0.618 . . . . 1.08 109.987 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.9 mt -82.31 -18.06 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.849 -0.532 . . . . 1.08 110.788 -176.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.28 40.7 Favored Glycine 0 N--CA 1.497 2.763 0 N-CA-C 109.684 -1.366 . . . . 0.23 109.684 176.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.9 mm -90.89 144.58 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.53 -0.982 . . . . 1.42 110.613 -174.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.04 159.31 73.19 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.743 -0.598 . . . . 3.68 110.906 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -52.8 134.79 55.67 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 O-C-N 123.067 1.035 . . . . 0.8 111.688 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.07 -0.63 69.38 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.66 -0.781 . . . . 0.26 111.331 175.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.65 129.0 40.1 Favored 'General case' 0 N--CA 1.501 2.083 0 CA-C-N 118.724 1.262 . . . . 1.11 110.173 178.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.7 p -91.15 128.51 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 121.4 0.619 . . . . 1.06 110.606 -175.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 46.6 pt -118.79 159.56 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.639 -0.504 . . . . 1.06 109.639 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.3 tt0 -97.6 130.13 44.66 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.938 -0.764 . . . . 1.14 108.938 174.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 87.4 t -115.48 129.2 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-O 121.373 0.606 . . . . 1.05 110.257 -171.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.38 129.08 56.05 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.204 -0.665 . . . . 1.08 109.204 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.42 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -79.8 139.66 37.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.342 -0.849 . . . . 1.11 109.791 172.546 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -109.34 -33.45 6.83 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.767 -0.583 . . . . 2.19 110.927 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.22 -175.2 37.69 Favored Glycine 0 N--CA 1.504 3.184 0 C-N-CA 119.674 -1.251 . . . . 0.25 111.031 -176.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p80 -143.79 153.91 42.88 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.759 -0.847 . . . . 2.53 110.719 -177.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.537 -0.727 . . . . 1.1 110.236 176.04 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.487 1.42 0 N-CA-C 109.588 -0.523 . . . . 1.16 109.588 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.8 mt -80.96 -21.49 40.32 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.269 -0.572 . . . . 1.16 110.189 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.11 152.18 3.4 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.442 -0.786 . . . . 1.09 109.127 176.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 67.2 tttt -132.61 125.18 29.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.702 -0.624 . . . . 2.69 110.214 -176.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.446 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 16.0 p90 -150.21 162.76 39.84 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.072 -0.651 . . . . 0.22 110.989 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 96.2 m-70 -112.52 138.23 49.58 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.626 -0.671 . . . . 2.35 110.154 -176.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.06 162.26 41.18 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.696 -0.628 . . . . 1.03 109.627 176.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.62 158.78 18.2 Favored 'General case' 0 N--CA 1.498 1.939 0 C-N-CA 119.818 -0.753 . . . . 1.03 110.136 177.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.3 t -79.24 134.89 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 C-N-CA 120.257 -0.577 . . . . 1.16 110.245 -177.089 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.28 171.89 7.34 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-O 121.277 0.561 . . . . 1.04 109.647 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -47.16 152.99 0.5 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.579 -0.701 . . . . 3.63 111.776 -175.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 56.7 mt 62.65 7.37 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.652 0 O-C-N 121.46 -0.775 . . . . 1.12 112.681 -174.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.1 80.63 Favored Glycine 0 N--CA 1.497 2.747 0 O-C-N 120.935 -1.103 . . . . 0.26 110.363 179.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -84.64 142.84 29.63 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.248 -1.148 . . . . 2.55 110.391 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.57 155.22 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.721 -0.612 . . . . 1.1 109.39 172.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.6 mm -116.56 128.45 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.579 -0.701 . . . . 1.04 109.977 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 37.4 mt -79.99 144.32 59.04 Favored Pre-proline 0 N--CA 1.495 1.792 0 C-N-CA 120.015 -0.674 . . . . 1.05 109.422 175.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -63.54 143.46 87.8 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 122.943 0.97 . . . . 0.38 109.751 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.75 61.57 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 120.44 -0.504 . . . . 1.12 110.481 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.17 95.56 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.954 -1.258 . . . . 0.42 109.954 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.7 m -69.87 -38.43 76.39 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.562 -0.964 . . . . 1.08 110.148 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.9 mtt180 -56.03 -40.58 73.66 Favored 'General case' 0 N--CA 1.513 2.689 0 O-C-N 121.29 -0.881 . . . . 0.49 109.386 176.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -65.64 -50.01 66.56 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.043 0.449 . . . . 3.4 110.213 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -57.74 -38.85 76.07 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.751 -0.593 . . . . 0.74 110.683 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.422 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 26.7 t80 -86.74 -14.17 43.17 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.804 -0.56 . . . . 1.76 111.346 -176.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 43.14 23.45 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.603 -1.399 . . . . 0.32 109.603 178.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 76.9 mt -87.73 128.79 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 121.523 -0.986 . . . . 1.15 110.537 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.1 153.97 46.24 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.868 -0.79 . . . . 1.82 108.868 170.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -55.27 140.39 39.33 Favored 'General case' 0 N--CA 1.504 2.241 0 O-C-N 121.238 -0.913 . . . . 2.7 110.626 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.8 -16.03 61.74 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.859 -0.896 . . . . 0.21 110.859 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.91 157.54 31.3 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.67 1.235 . . . . 1.12 110.115 178.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -111.71 138.92 47.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.622 -0.674 . . . . 0.24 109.557 174.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.55 155.12 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 C-N-CA 120.224 -0.59 . . . . 1.06 109.454 174.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.92 123.6 48.49 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.364 -0.976 . . . . 1.09 108.364 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.4 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 9.4 tt -139.96 156.01 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.682 -0.807 . . . . 1.05 110.95 -167.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -131.13 146.07 52.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.747 -0.596 . . . . 1.77 110.55 177.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 29.6 pt -114.94 151.08 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 121.731 -0.605 . . . . 1.06 110.699 178.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.6 t -138.23 126.58 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.152 0.501 . . . . 1.03 109.734 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 32.1 tptt -136.69 146.89 46.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.741 -0.6 . . . . 2.39 109.602 175.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 t80 . . . . . 0 N--CA 1.495 1.816 0 C-N-CA 120.231 -0.587 . . . . 0.91 110.427 -177.275 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.482 0.801 0 N-CA-C 110.159 -0.746 . . . . 0.38 110.159 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 55.0 mmtt -120.48 138.17 53.96 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.545 -0.722 . . . . 1.71 109.564 172.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -134.57 163.41 29.79 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.635 -0.665 . . . . 1.42 110.718 -176.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.91 135.89 4.43 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.618 -1.393 . . . . 0.18 109.618 178.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.3 m -122.17 137.45 54.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.715 -0.873 . . . . 1.07 109.75 176.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.5 p90 -155.55 172.77 17.7 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.972 -0.691 . . . . 0.18 111.036 176.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.7 m -106.9 141.03 38.77 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.691 -0.63 . . . . 1.01 109.464 173.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.31 145.4 35.42 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.564 -0.71 . . . . 1.01 110.58 -176.048 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -92.96 144.79 24.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.809 -0.557 . . . . 2.71 109.605 175.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.1 t -79.14 125.23 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-O 121.332 0.587 . . . . 1.08 109.79 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.68 -167.31 26.34 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.939 -1.264 . . . . 0.22 109.939 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.6 153.45 27.78 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.724 -0.868 . . . . 1.39 110.101 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.64 21.03 2.39 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.54 -0.725 . . . . 1.13 112.061 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.07 20.58 79.68 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.784 -1.198 . . . . 0.2 110.793 171.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.2 m -77.88 144.92 36.54 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.488 -1.007 . . . . 1.74 110.375 -176.311 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.8 p -138.43 144.96 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.553 -0.536 . . . . 1.04 109.553 174.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.65 123.33 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.49 -0.756 . . . . 1.12 110.641 -175.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.7 mt -78.44 144.43 65.93 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.643 -0.661 . . . . 1.17 109.518 173.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.408 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -64.21 133.63 38.77 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.934 0.965 . . . . 0.29 110.764 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.08 -34.23 63.46 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.443 -0.786 . . . . 3.08 110.866 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.76 -38.09 77.71 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.745 -0.597 . . . . 1.16 110.329 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 71.0 mt -77.15 -32.67 56.45 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 120.259 -0.576 . . . . 2.43 110.552 178.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.88 -46.03 85.49 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.3 -0.875 . . . . 3.27 109.897 178.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -70.16 -46.79 63.95 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 120.456 -0.498 . . . . 1.68 110.473 -175.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.5 t -60.38 -38.45 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.678 -0.639 . . . . 1.08 109.865 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -82.53 -17.99 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.844 -0.535 . . . . 1.08 110.822 -176.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.25 35.11 38.88 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 109.665 -1.374 . . . . 0.23 109.665 176.07 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.5 mm -90.65 142.54 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.619 -0.93 . . . . 1.42 110.581 -175.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -129.64 162.11 55.14 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.674 -0.641 . . . . 3.68 110.807 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.91 135.32 62.41 Favored 'Trans proline' 0 N--CA 1.488 1.159 0 O-C-N 123.063 1.033 . . . . 0.8 110.835 -179.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.9 -0.05 72.44 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 120.591 -0.814 . . . . 0.26 111.235 176.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -96.18 131.61 42.47 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 118.715 1.257 . . . . 1.11 110.445 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.87 130.1 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 CA-C-O 121.511 0.672 . . . . 1.06 110.837 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 47.3 pt -118.72 159.51 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 109.591 -0.522 . . . . 1.06 109.591 177.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.421 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.5 tt0 -97.01 130.69 44.3 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.026 -0.731 . . . . 1.14 109.026 174.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.444 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 91.6 t -115.85 128.9 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.366 0.603 . . . . 1.05 110.241 -171.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.7 mt -116.31 128.75 55.83 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.324 -0.621 . . . . 1.08 109.324 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.415 HD12 ' CD2' ' A' ' 27' ' ' TYR . 6.0 mt -79.65 142.51 35.49 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.402 -0.811 . . . . 1.11 109.808 171.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.7 mt -120.65 -24.95 5.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.655 . . . . 2.19 111.206 -174.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.28 -179.92 40.49 Favored Glycine 0 N--CA 1.505 3.28 0 C-N-CA 119.642 -1.266 . . . . 0.25 111.066 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 p80 -146.95 152.62 38.94 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.745 -0.856 . . . . 2.53 110.685 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 N--CA 1.495 1.807 0 O-C-N 121.582 -0.699 . . . . 1.1 110.07 175.657 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 109.719 -0.474 . . . . 1.16 109.719 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.3 mt -86.61 -18.44 31.39 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.262 -0.575 . . . . 1.16 110.547 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.79 153.74 3.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.357 -0.839 . . . . 1.09 109.299 175.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -133.77 125.42 28.46 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.703 -0.623 . . . . 2.69 110.079 -177.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.447 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 15.3 p90 -150.68 162.09 41.35 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.603 -0.686 . . . . 0.22 110.869 -179.322 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -112.78 138.84 49.01 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.661 -0.649 . . . . 2.35 110.161 -176.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.29 41.07 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.728 -0.607 . . . . 1.03 109.59 178.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -111.0 158.68 18.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.417 -0.802 . . . . 1.03 110.044 177.152 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.404 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -79.16 136.29 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.295 -0.562 . . . . 1.16 110.343 -176.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -115.25 171.94 7.38 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.42 0.629 . . . . 1.04 109.796 175.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 -46.52 153.04 0.4 Allowed 'General case' 0 N--CA 1.505 2.31 0 O-C-N 121.536 -0.728 . . . . 3.63 111.981 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.8 mt 62.89 7.45 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.671 0 O-C-N 121.569 -0.707 . . . . 1.12 112.567 -175.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.73 15.99 80.63 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.344 -1.102 . . . . 0.26 110.344 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -85.5 144.0 28.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.235 -1.156 . . . . 2.55 110.429 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -132.67 154.95 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.748 -0.595 . . . . 1.1 109.46 172.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.11 128.76 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 C-N-CA 120.073 -0.651 . . . . 1.04 110.065 176.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.08 145.21 60.39 Favored Pre-proline 0 N--CA 1.496 1.828 0 C-N-CA 120.062 -0.655 . . . . 1.05 109.406 175.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.34 143.73 89.59 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 O-C-N 123.024 1.013 . . . . 0.38 109.755 174.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.41 61.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.87 -0.519 . . . . 1.12 110.471 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.74 -44.22 95.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 110.026 -1.23 . . . . 0.42 110.026 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 78.5 m -69.85 -38.21 76.41 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.964 . . . . 1.08 110.124 -179.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.4 mtt180 -56.3 -41.65 76.28 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 121.276 -0.89 . . . . 0.49 109.377 176.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -65.9 -50.09 65.7 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.14 0.495 . . . . 3.4 110.221 -177.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.27 -37.79 72.91 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.732 -0.605 . . . . 0.74 110.633 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.437 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 18.5 t80 -88.06 -14.15 39.65 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.805 -0.559 . . . . 1.76 111.229 -175.764 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.33 42.49 27.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.563 -1.415 . . . . 0.32 109.563 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.437 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 78.3 mt -89.62 131.14 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.453 -1.027 . . . . 1.15 110.645 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.27 158.94 36.78 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.091 -0.707 . . . . 1.82 109.091 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -57.47 139.45 53.23 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.38 -0.825 . . . . 2.7 110.513 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.74 -15.25 63.49 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.887 -0.885 . . . . 0.21 110.887 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.12 158.16 32.07 Favored 'General case' 0 N--CA 1.501 2.123 0 CA-C-N 118.724 1.262 . . . . 1.12 109.932 178.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -110.53 138.16 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.591 -0.693 . . . . 0.24 109.588 175.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.35 154.16 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 109.13 -0.693 . . . . 1.06 109.13 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -116.05 123.8 48.84 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.8 tt -140.51 158.13 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 119.635 -0.826 . . . . 1.05 110.961 -167.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 ttpt -132.29 146.11 51.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.837 -0.539 . . . . 1.77 110.386 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.2 pt -114.88 150.98 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.667 -0.646 . . . . 1.06 110.278 176.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.4 t -139.53 123.64 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 CA-C-O 121.251 0.548 . . . . 1.03 109.729 177.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 53.2 tttm -132.92 147.5 52.29 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.248 -0.649 . . . . 2.39 109.248 176.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 t80 . . . . . 0 N--CA 1.498 1.952 0 C-N-CA 119.903 -0.719 . . . . 0.91 110.531 -178.271 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.483 0.855 0 N-CA-C 110.399 -0.654 . . . . 0.38 110.399 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -111.37 136.89 49.85 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.657 -0.652 . . . . 1.71 109.466 172.063 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.7 164.49 27.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.703 -0.623 . . . . 1.42 110.996 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.59 135.75 4.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.469 -1.453 . . . . 0.18 109.469 176.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.8 m -124.85 136.91 54.24 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.712 -0.875 . . . . 1.07 109.732 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 11.1 p90 -155.88 173.38 16.85 Favored 'General case' 0 N--CA 1.497 1.911 0 C-N-CA 119.867 -0.733 . . . . 0.18 111.089 178.159 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.7 m -106.95 140.39 39.83 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.722 -0.611 . . . . 1.01 109.551 173.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -142.28 146.11 34.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.633 -0.667 . . . . 1.01 110.443 -175.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.65 145.58 24.45 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.774 -0.579 . . . . 2.71 109.711 175.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 97.9 t -77.84 126.41 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.2 0.524 . . . . 1.08 109.973 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.53 -167.56 26.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.931 -1.268 . . . . 0.22 109.931 179.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -61.71 153.34 28.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.7 -0.882 . . . . 1.39 109.965 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 54.14 20.49 2.57 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.531 -0.731 . . . . 1.13 111.98 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 20.44 79.94 Favored Glycine 0 N--CA 1.5 2.928 0 C-N-CA 119.803 -1.189 . . . . 0.2 110.826 171.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.5 p -78.37 146.9 34.37 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -1.01 . . . . 1.74 110.203 -177.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.88 145.8 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.758 -0.589 . . . . 1.04 109.565 175.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.15 123.15 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.588 -0.695 . . . . 1.12 110.654 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 65.5 mt -78.41 144.02 65.29 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.504 -0.748 . . . . 1.17 109.432 172.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.6 Cg_endo -64.77 134.43 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 O-C-N 122.861 0.927 . . . . 0.29 110.648 -179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -55.15 -34.21 63.59 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.505 -0.747 . . . . 3.08 110.802 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -37.87 77.12 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.802 -0.562 . . . . 1.16 110.271 -178.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.8 mt -77.11 -32.75 56.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.748 -0.595 . . . . 2.43 110.553 178.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.78 -46.0 85.21 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.306 -0.871 . . . . 3.27 109.923 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.32 -47.23 62.05 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.5 -0.48 . . . . 1.68 110.493 -175.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.6 t -60.51 -38.15 77.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.684 -0.635 . . . . 1.08 109.966 -178.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.1 mt -82.57 -17.81 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.792 -0.568 . . . . 1.08 110.934 -176.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.32 35.14 43.53 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.787 -1.325 . . . . 0.23 109.787 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.404 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 49.9 mm -92.24 138.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.522 -0.987 . . . . 1.42 110.715 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 57.0 mmtt -124.25 161.1 49.42 Favored Pre-proline 0 N--CA 1.498 1.931 0 O-C-N 121.675 -0.64 . . . . 3.68 110.61 -176.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.76 136.36 66.01 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 O-C-N 123.027 1.014 . . . . 0.8 110.78 179.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.63 -0.65 74.24 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 111.123 -0.791 . . . . 0.26 111.123 176.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -98.14 134.44 41.2 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 118.682 1.241 . . . . 1.11 110.567 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.07 133.41 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 CA-C-O 121.684 0.754 . . . . 1.06 111.227 -174.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.7 pt -122.93 159.48 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 109.211 -0.663 . . . . 1.06 109.211 175.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 49.7 tt0 -98.82 131.41 44.96 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 109.021 -0.733 . . . . 1.14 109.021 175.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.443 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 88.5 t -115.8 129.93 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.435 0.636 . . . . 1.05 110.365 -170.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.2 mt -115.73 130.7 56.95 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 109.237 -0.653 . . . . 1.08 109.237 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.41 HD21 ' CE2' ' A' ' 27' ' ' TYR . 4.1 mt -80.09 139.88 36.7 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.449 -0.782 . . . . 1.11 109.781 171.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.0 mt -108.71 -34.4 6.71 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.8 -0.563 . . . . 2.19 110.887 -176.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -169.03 -174.63 37.74 Favored Glycine 0 N--CA 1.502 3.079 0 C-N-CA 119.738 -1.22 . . . . 0.25 111.015 -177.106 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -143.91 155.62 44.14 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.738 -0.86 . . . . 2.53 110.743 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.494 1.745 0 O-C-N 121.577 -0.702 . . . . 1.1 110.208 176.563 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 109.578 -0.527 . . . . 1.16 109.578 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.8 mt -83.72 -19.6 34.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.761 -0.587 . . . . 1.16 110.276 177.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -174.46 152.7 1.76 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.262 -0.899 . . . . 1.09 109.124 176.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.1 ttpt -135.42 128.23 31.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.635 -0.665 . . . . 2.69 110.382 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.448 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 19.2 p90 -149.81 163.56 37.68 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.391 -0.524 . . . . 0.22 110.508 -178.277 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.61 137.59 51.37 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.602 -0.686 . . . . 2.35 110.4 -176.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.56 162.28 41.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.756 -0.59 . . . . 1.03 109.568 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -109.63 158.56 17.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.468 -0.77 . . . . 1.03 110.02 176.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.9 t -79.47 138.06 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.779 -0.576 . . . . 1.16 110.355 -176.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -116.66 171.87 7.59 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.347 0.594 . . . . 1.04 109.86 176.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -46.29 153.05 0.37 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.629 -0.669 . . . . 3.63 112.075 -175.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.9 mt 62.94 7.2 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.648 0 O-C-N 121.651 -0.655 . . . . 1.12 112.578 -175.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.61 16.09 80.6 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.331 -1.108 . . . . 0.26 110.331 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 36.7 ttp180 -85.76 144.29 27.85 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.354 -1.086 . . . . 2.55 110.198 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -132.42 155.03 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.681 -0.637 . . . . 1.1 109.359 172.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.4 mm -115.71 128.55 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.595 -0.691 . . . . 1.04 109.952 176.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 25.5 mt -79.58 144.5 61.15 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.052 -0.659 . . . . 1.05 109.417 175.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -63.48 143.39 87.98 Favored 'Trans proline' 0 N--CA 1.488 1.191 0 O-C-N 123.002 1.001 . . . . 0.38 109.689 174.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.0 -26.37 60.13 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.838 -0.539 . . . . 1.12 110.46 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.31 -45.32 93.78 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 109.999 -1.24 . . . . 0.42 109.999 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 m -69.5 -36.87 76.9 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.617 -0.931 . . . . 1.08 110.202 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -56.3 -42.05 76.94 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.418 -0.801 . . . . 0.49 109.734 178.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -65.97 -50.2 65.16 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.364 0.602 . . . . 3.4 110.162 -177.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -56.67 -37.87 71.42 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.835 -0.541 . . . . 0.74 110.69 -178.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.427 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 25.0 t80 -87.89 -14.17 40.06 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.825 -0.547 . . . . 1.76 111.364 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 43.03 23.24 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.586 -1.406 . . . . 0.32 109.586 178.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.405 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.1 mt -87.53 127.44 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.422 -1.046 . . . . 1.15 110.575 -177.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.29 154.92 44.32 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.008 -0.738 . . . . 1.82 109.008 170.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.52 137.75 47.95 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.253 -0.904 . . . . 2.7 110.751 -177.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.46 -15.1 64.01 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.927 -0.869 . . . . 0.21 110.927 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -75.97 157.51 33.02 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.735 1.268 . . . . 1.12 109.851 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -111.21 138.17 47.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.606 -0.684 . . . . 0.24 109.679 175.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.39 153.52 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 109.249 -0.649 . . . . 1.06 109.249 174.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -115.33 122.98 47.55 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.242 -1.021 . . . . 1.09 108.242 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 tt -139.97 157.99 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 119.604 -0.838 . . . . 1.05 110.987 -167.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.5 tttt -132.61 145.98 51.53 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.8 -0.562 . . . . 1.77 110.596 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 28.0 pt -115.13 151.03 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.728 -0.608 . . . . 1.06 110.62 178.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -138.77 125.61 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.143 0.497 . . . . 1.03 109.772 176.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.401 ' CE ' ' CD1' ' A' ' 74' ' ' ILE . 21.4 ttpp -131.9 143.36 50.08 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.222 -0.659 . . . . 2.39 109.222 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 t80 . . . . . 0 N--CA 1.495 1.819 0 C-N-CA 120.137 -0.625 . . . . 0.91 110.456 -178.139 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo . . . . . 0 N--CA 1.482 0.844 0 N-CA-C 110.127 -0.759 . . . . 0.38 110.127 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 68.7 mmtt -110.85 137.17 48.83 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.548 -0.72 . . . . 1.71 109.622 172.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -135.5 164.23 28.28 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.614 -0.679 . . . . 1.42 110.796 -176.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.15 135.96 4.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.605 -1.398 . . . . 0.18 109.605 178.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.3 m -123.09 137.34 54.95 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.68 -0.894 . . . . 1.07 109.735 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.424 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.8 p90 -155.87 172.55 18.16 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.843 -0.743 . . . . 0.18 111.017 176.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.0 m -107.78 140.85 40.23 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.694 -0.629 . . . . 1.01 109.545 174.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.424 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -142.09 145.78 34.69 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.723 -0.61 . . . . 1.01 110.641 -175.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.7 ttp180 -93.9 145.25 24.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.73 -0.606 . . . . 2.71 109.598 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 98.8 t -78.44 126.47 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.783 -0.573 . . . . 1.08 109.928 -178.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.04 -166.51 24.98 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.099 -1.201 . . . . 0.22 110.099 178.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -61.63 153.08 28.94 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.872 -0.781 . . . . 1.39 110.218 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.57 21.18 2.41 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.547 -0.721 . . . . 1.13 112.001 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.81 20.48 79.76 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.747 -1.216 . . . . 0.2 110.806 171.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 14.2 m -77.99 145.25 36.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.414 -1.05 . . . . 1.74 110.232 -176.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.27 145.51 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.789 -0.569 . . . . 1.04 109.609 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -112.03 123.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.55 -0.719 . . . . 1.12 110.734 -174.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 80.3 mt -78.5 145.12 66.99 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.591 -0.693 . . . . 1.17 109.484 172.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.419 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.2 Cg_endo -64.38 136.68 52.08 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 O-C-N 122.889 0.941 . . . . 0.29 110.821 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 20.2 tptt -54.93 -34.85 63.59 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.47 -0.769 . . . . 3.08 110.845 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.91 -38.2 78.4 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.764 -0.585 . . . . 1.16 110.298 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.0 mt -77.17 -32.78 56.4 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.727 -0.608 . . . . 2.43 110.658 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.2 mtt180 -58.3 -45.85 87.24 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.22 -0.925 . . . . 3.27 109.884 178.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.3 -47.42 61.26 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 120.383 -0.527 . . . . 1.68 110.51 -175.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.9 t -60.58 -38.18 77.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 O-C-N 121.653 -0.654 . . . . 1.08 109.91 -178.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.1 mt -82.28 -17.61 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.882 -0.512 . . . . 1.08 110.966 -176.224 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.23 40.83 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.835 -1.306 . . . . 0.23 109.835 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.401 ' CD1' ' CE ' ' A' ' 41' ' ' LYS . 51.2 mm -90.58 141.11 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.511 -0.994 . . . . 1.42 110.704 -173.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -127.67 156.28 75.8 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.732 -0.605 . . . . 3.68 110.631 -177.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -55.98 135.42 69.67 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 122.974 0.986 . . . . 0.8 111.275 177.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.12 -0.76 72.71 Favored Glycine 0 N--CA 1.496 2.65 0 C-N-CA 120.694 -0.765 . . . . 0.26 111.241 176.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -96.36 132.6 41.7 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-N 118.734 1.267 . . . . 1.11 110.477 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.3 p -91.21 132.08 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-O 121.639 0.733 . . . . 1.06 110.979 -174.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.4 pt -123.23 159.42 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 109.464 -0.569 . . . . 1.06 109.464 177.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.7 tt0 -98.13 131.57 44.4 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.919 -0.771 . . . . 1.14 108.919 173.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.448 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 99.9 t -115.1 128.01 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 1.05 110.166 -171.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.1 mt -114.79 128.46 56.31 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.365 -0.605 . . . . 1.08 109.365 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.418 HD23 ' CE2' ' A' ' 27' ' ' TYR . 4.8 mt -79.88 139.92 36.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.485 -0.76 . . . . 1.11 109.821 172.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.7 mt -110.93 -31.75 7.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.769 -0.582 . . . . 2.19 110.85 -175.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.25 -177.04 39.12 Favored Glycine 0 N--CA 1.504 3.225 0 C-N-CA 119.745 -1.216 . . . . 0.25 110.958 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -144.72 152.56 40.59 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.667 -0.902 . . . . 2.53 110.72 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 1.1 109.995 175.91 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.486 1.365 0 N-CA-C 109.723 -0.473 . . . . 1.16 109.723 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 34.4 mt -89.58 -18.02 27.38 Favored 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 120.309 -0.556 . . . . 1.16 110.654 -177.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.75 154.99 3.8 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.249 -0.907 . . . . 1.09 109.577 177.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -133.63 127.1 32.27 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.707 -0.621 . . . . 2.69 110.126 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.444 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 13.2 p90 -148.75 162.64 39.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.643 -0.661 . . . . 0.22 110.702 177.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.81 138.37 50.36 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.596 -0.69 . . . . 2.35 110.34 -176.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.04 162.21 41.28 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 109.459 -0.571 . . . . 1.03 109.459 177.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -109.31 158.45 17.87 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.436 -0.79 . . . . 1.03 110.152 177.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 61.2 t -79.22 136.43 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.32 -0.552 . . . . 1.16 110.097 -177.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.41 171.87 7.36 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-O 121.269 0.556 . . . . 1.04 109.612 173.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -46.86 152.61 0.49 Allowed 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.579 -0.7 . . . . 3.63 111.978 -176.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.61 0 O-C-N 121.529 -0.732 . . . . 1.12 112.631 -175.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.01 16.17 80.18 Favored Glycine 0 N--CA 1.497 2.742 0 O-C-N 120.964 -1.085 . . . . 0.26 110.463 179.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -83.89 141.15 31.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.298 -1.119 . . . . 2.55 110.316 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.7 pt -133.72 155.75 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.569 -0.707 . . . . 1.1 109.816 173.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.17 129.75 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.529 -0.732 . . . . 1.04 109.878 175.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.425 HG12 ' CE2' ' A' ' 7' ' ' PHE . 24.2 mt -79.76 145.91 63.35 Favored Pre-proline 0 N--CA 1.495 1.806 0 C-N-CA 119.962 -0.695 . . . . 1.05 109.322 175.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.22 143.25 89.29 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.005 1.002 . . . . 0.38 109.819 174.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.84 -26.43 62.03 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 120.404 -0.518 . . . . 1.12 110.462 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.94 -43.86 95.37 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 110.027 -1.229 . . . . 0.42 110.027 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.7 m -69.87 -38.61 76.47 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.63 -0.924 . . . . 1.08 110.136 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 -56.24 -43.27 78.48 Favored 'General case' 0 N--CA 1.513 2.694 0 O-C-N 121.346 -0.846 . . . . 0.49 109.571 176.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -67.16 -50.2 62.02 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-O 121.18 0.514 . . . . 3.4 110.316 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -57.6 -36.35 71.65 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.764 -0.585 . . . . 0.74 110.661 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.446 ' CD2' ' CD1' ' A' ' 84' ' ' LEU . 16.8 t80 -88.15 -14.06 39.65 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.705 -0.622 . . . . 1.76 111.371 -174.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 74.92 41.74 32.23 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.657 -1.377 . . . . 0.32 109.657 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.419 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 81.9 mt -90.91 132.79 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.504 -0.998 . . . . 1.15 110.615 -176.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.18 159.29 36.52 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.047 -0.723 . . . . 1.82 109.047 172.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -57.96 140.23 52.66 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.388 -0.82 . . . . 2.7 110.367 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.77 -16.0 61.79 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.849 -0.901 . . . . 0.21 110.849 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.04 158.5 30.51 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.72 1.26 . . . . 1.12 110.223 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -111.86 139.68 47.14 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.661 -0.649 . . . . 0.24 109.598 174.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.09 155.02 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 109.235 -0.654 . . . . 1.06 109.235 174.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -116.35 123.22 47.08 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.345 -0.984 . . . . 1.09 108.345 -178.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.403 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 6.0 tt -140.53 158.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.553 -0.859 . . . . 1.05 111.232 -166.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -132.54 145.61 51.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.878 -0.514 . . . . 1.77 110.519 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.1 pt -115.06 151.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.664 -0.647 . . . . 1.06 110.6 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.2 t -139.2 126.01 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 CA-C-O 121.31 0.576 . . . . 1.03 110.049 176.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 17.2 tptt -132.59 148.7 52.37 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 109.004 -0.739 . . . . 2.39 109.004 174.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.8 t80 . . . . . 0 N--CA 1.495 1.785 0 C-N-CA 120.137 -0.625 . . . . 0.91 110.246 -179.699 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo . . . . . 0 N--CA 1.483 0.888 0 N-CA-C 110.298 -0.693 . . . . 0.38 110.298 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -113.62 137.35 51.72 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.556 -0.715 . . . . 1.71 109.559 172.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -137.97 166.27 24.49 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.59 -0.694 . . . . 1.42 110.756 -178.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.83 135.94 4.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.692 -1.363 . . . . 0.18 109.692 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 m -119.93 137.95 53.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.661 -0.905 . . . . 1.07 109.766 176.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 15.0 p90 -156.04 173.89 16.15 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 120.0 -0.68 . . . . 0.18 110.981 176.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.0 m -106.32 140.91 38.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.731 -0.606 . . . . 1.01 109.475 173.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 144.9 35.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.679 -0.638 . . . . 1.01 110.636 -175.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.815 -0.553 . . . . 2.71 109.732 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.47 125.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.321 0.581 . . . . 1.08 109.871 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.08 -171.31 27.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.617 -1.393 . . . . 0.22 109.617 178.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -61.87 156.1 21.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.569 -0.959 . . . . 1.39 109.837 178.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 54.99 19.4 2.68 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.446 -0.784 . . . . 1.13 112.079 -177.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.21 20.47 79.93 Favored Glycine 0 N--CA 1.5 2.91 0 C-N-CA 119.81 -1.186 . . . . 0.2 110.728 172.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -78.0 146.02 35.63 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.503 -0.998 . . . . 1.74 110.409 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.9 p -138.51 146.52 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.719 -0.613 . . . . 1.04 109.627 173.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -108.89 122.21 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 121.555 -0.715 . . . . 1.12 110.533 -174.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.2 mt -79.01 142.07 59.43 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.606 -0.684 . . . . 1.17 109.625 173.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.413 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.0 Cg_endo -65.1 131.83 29.94 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.862 0.927 . . . . 0.29 110.729 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -55.17 -33.07 62.66 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.497 -0.752 . . . . 3.08 110.88 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.8 -37.99 77.59 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.785 -0.572 . . . . 1.16 110.189 -178.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.01 -32.74 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.747 -0.596 . . . . 2.43 110.403 177.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.1 mtt180 -57.73 -46.08 84.93 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 121.352 -0.842 . . . . 3.27 109.85 178.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -70.08 -47.87 60.08 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.528 -0.469 . . . . 1.68 110.413 -175.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.6 t -60.57 -38.1 77.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 C-N-CA 120.157 -0.617 . . . . 1.08 109.924 -178.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.3 mt -82.76 -17.66 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.866 -0.521 . . . . 1.08 110.919 -176.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.498 2.829 0 N-CA-C 109.68 -1.368 . . . . 0.23 109.68 175.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.3 mm -89.56 143.82 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.515 -0.991 . . . . 1.42 110.644 -174.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -129.22 156.96 77.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.764 -0.585 . . . . 3.68 110.719 -177.171 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.28 134.14 62.1 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.022 1.012 . . . . 0.8 111.412 177.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.37 -0.17 71.07 Favored Glycine 0 N--CA 1.497 2.761 0 C-N-CA 120.617 -0.801 . . . . 0.26 111.205 175.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -96.26 132.39 41.77 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-N 118.732 1.266 . . . . 1.11 110.4 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.03 130.05 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.46 0.648 . . . . 1.06 110.961 -174.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 46.5 pt -117.67 159.34 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.462 -0.57 . . . . 1.06 109.462 176.705 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -98.49 130.87 45.08 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.893 -0.781 . . . . 1.14 108.893 173.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.421 HG13 ' CE1' ' A' ' 7' ' ' PHE . 90.5 t -114.6 128.53 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 CA-C-O 121.381 0.61 . . . . 1.05 110.18 -171.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.0 mt -114.96 129.8 56.79 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 109.269 -0.641 . . . . 1.08 109.269 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.446 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.22 141.57 35.49 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 1.11 109.996 173.406 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.52 -32.38 6.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.839 -0.538 . . . . 2.19 110.779 -177.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -169.16 -174.46 37.69 Favored Glycine 0 N--CA 1.504 3.171 0 C-N-CA 119.681 -1.247 . . . . 0.25 111.058 -177.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.0 p80 -146.35 153.71 40.83 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.664 -0.904 . . . . 2.53 110.614 -179.246 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 . . . . . 0 N--CA 1.493 1.703 0 O-C-N 121.545 -0.722 . . . . 1.1 110.108 176.325 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 109.513 -0.551 . . . . 1.16 109.513 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 23.2 mt -85.32 -18.04 35.03 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 120.279 -0.568 . . . . 1.16 110.462 -176.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.96 155.47 3.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.368 -0.833 . . . . 1.09 109.589 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.2 ttmt -132.95 127.02 33.33 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.715 -0.615 . . . . 2.69 110.124 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.445 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.3 p90 -149.77 162.51 40.13 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.634 -0.667 . . . . 0.22 110.728 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -113.33 138.96 49.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.604 -0.685 . . . . 2.35 110.32 -176.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.75 162.3 40.99 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.739 -0.601 . . . . 1.03 109.619 177.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.49 159.02 17.88 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 119.787 -0.765 . . . . 1.03 110.01 176.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.32 135.94 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.233 -0.587 . . . . 1.16 110.333 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.3 m80 -115.39 171.97 7.38 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.528 -0.545 . . . . 1.04 109.528 174.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -46.26 152.31 0.43 Allowed 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.562 -0.711 . . . . 3.63 112.033 -175.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.1 mt 62.64 7.4 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.495 -0.753 . . . . 1.12 112.632 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.72 16.01 80.61 Favored Glycine 0 N--CA 1.497 2.723 0 O-C-N 120.915 -1.115 . . . . 0.26 110.423 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 70.2 ttp85 -84.91 143.41 29.02 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.199 -1.177 . . . . 2.55 110.294 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.7 pt -133.21 157.49 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.759 -0.588 . . . . 1.1 109.532 173.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 mm -116.29 129.6 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.591 -0.693 . . . . 1.04 109.96 176.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.6 mt -79.19 145.5 64.92 Favored Pre-proline 0 N--CA 1.496 1.859 0 C-N-CA 119.961 -0.695 . . . . 1.05 109.375 175.343 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.2 142.86 88.31 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.102 1.054 . . . . 0.38 109.79 174.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.56 -26.6 61.66 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.84 -0.538 . . . . 1.12 110.447 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.8 95.0 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.036 -1.225 . . . . 0.42 110.036 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.1 m -69.73 -37.45 76.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.699 -0.883 . . . . 1.08 109.848 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.6 mtt180 -55.95 -42.42 76.2 Favored 'General case' 0 N--CA 1.509 2.499 0 O-C-N 121.343 -0.848 . . . . 0.49 109.801 178.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -66.75 -50.37 62.96 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.302 0.573 . . . . 3.4 110.284 -176.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -57.2 -37.15 71.76 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.868 -0.52 . . . . 0.74 110.622 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.444 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 17.6 t80 -87.83 -14.17 40.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.85 -0.531 . . . . 1.76 111.275 -176.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.36 42.37 28.11 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.57 -1.412 . . . . 0.32 109.57 177.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.444 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.8 mt -89.6 129.41 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.559 -0.965 . . . . 1.15 110.653 -176.566 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -128.48 159.51 35.21 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 109.173 -0.677 . . . . 1.82 109.173 171.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -57.75 138.59 55.37 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.411 -0.805 . . . . 2.7 110.478 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.1 62.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.857 -0.897 . . . . 0.21 110.857 179.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -77.09 157.47 31.03 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-N 118.763 1.281 . . . . 1.12 110.03 177.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -111.44 138.87 47.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.671 -0.643 . . . . 0.24 109.644 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 155.34 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 1.06 109.269 174.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -117.34 123.89 47.61 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.276 -1.009 . . . . 1.09 108.276 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.401 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.96 157.56 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.553 -0.859 . . . . 1.05 111.044 -167.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.68 146.09 51.59 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.789 -0.569 . . . . 1.77 110.427 177.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 29.6 pt -114.89 151.09 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.732 -0.605 . . . . 1.06 110.595 178.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.4 t -138.0 126.72 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.123 0.487 . . . . 1.03 109.707 176.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 30.6 tptt -138.09 147.12 43.71 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.726 -0.609 . . . . 2.39 109.636 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 39.5 t80 . . . . . 0 N--CA 1.495 1.784 0 C-N-CA 120.291 -0.564 . . . . 0.91 110.369 -176.867 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.482 0.818 0 N-CA-C 110.114 -0.764 . . . . 0.38 110.114 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 31.4 mttm -122.5 149.24 44.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.491 -0.756 . . . . 1.71 110.105 171.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -136.75 167.74 20.86 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.758 -0.589 . . . . 1.42 110.835 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.67 135.87 4.45 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.49 -1.444 . . . . 0.18 109.49 177.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -122.88 138.23 54.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.931 . . . . 1.07 109.978 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.423 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 14.8 p90 -156.3 172.92 17.64 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 119.858 -0.737 . . . . 0.18 110.89 175.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -106.95 141.29 38.4 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.704 -0.623 . . . . 1.01 109.473 173.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.423 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 145.99 36.7 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.591 -0.693 . . . . 1.01 110.759 -175.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -93.47 145.24 24.65 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.582 -0.525 . . . . 2.71 109.582 175.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.3 t -78.96 125.07 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.295 0.569 . . . . 1.08 109.823 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.62 -166.62 25.38 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.117 -1.193 . . . . 0.22 110.117 178.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.74 153.51 28.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.768 -0.842 . . . . 1.39 110.158 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 53.39 21.21 2.28 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.595 -0.69 . . . . 1.13 112.167 -179.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.22 20.51 79.64 Favored Glycine 0 N--CA 1.501 2.982 0 C-N-CA 119.663 -1.256 . . . . 0.2 110.764 171.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.5 m -77.87 145.2 36.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.456 -1.026 . . . . 1.74 110.441 -175.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.46 146.65 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.806 -0.559 . . . . 1.04 109.645 175.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.44 122.72 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.509 -0.744 . . . . 1.12 110.787 -174.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 70.8 mt -79.11 144.33 62.81 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.584 -0.698 . . . . 1.17 109.624 172.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.416 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.8 Cg_endo -64.76 134.39 40.39 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 O-C-N 122.952 0.975 . . . . 0.29 110.841 -179.637 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -55.19 -34.16 63.65 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.491 -0.756 . . . . 3.08 110.814 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.66 76.68 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.729 -0.607 . . . . 1.16 110.32 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.6 mt -77.13 -32.69 56.62 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.73 -0.607 . . . . 2.43 110.5 178.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.85 -46.05 85.35 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.328 -0.857 . . . . 3.27 109.858 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.92 -46.61 64.99 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 120.512 -0.475 . . . . 1.68 110.411 -175.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.0 t -60.55 -38.7 79.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.679 -0.638 . . . . 1.08 109.949 -178.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.6 mt -82.8 -16.44 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.791 -0.568 . . . . 1.08 111.102 -176.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 75.77 35.18 46.45 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.91 -1.276 . . . . 0.23 109.91 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.2 mm -90.77 142.32 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.53 -0.982 . . . . 1.42 110.589 -174.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.2 mttt -128.9 158.73 71.63 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.82 -0.55 . . . . 3.68 110.586 -177.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -54.56 134.21 60.8 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.063 1.033 . . . . 0.8 111.429 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.1 -0.5 72.42 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.69 -0.766 . . . . 0.26 111.292 175.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -97.37 133.51 41.87 Favored 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 118.711 1.255 . . . . 1.11 110.559 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.95 131.17 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-O 121.479 0.657 . . . . 1.06 111.095 -174.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 45.7 pt -119.0 159.48 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.286 -0.635 . . . . 1.06 109.286 175.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -97.93 131.59 44.25 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.445 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 90.8 t -115.65 129.5 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.348 0.594 . . . . 1.05 110.263 -170.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.5 mt -115.13 130.8 57.02 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 109.279 -0.638 . . . . 1.08 109.279 179.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.417 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.35 139.9 36.34 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.365 -0.835 . . . . 1.11 110.037 173.052 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -106.65 -36.4 6.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.836 -0.54 . . . . 2.19 110.837 -176.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.88 -175.2 38.11 Favored Glycine 0 N--CA 1.502 3.061 0 C-N-CA 119.79 -1.195 . . . . 0.25 110.935 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -143.81 153.46 42.4 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.682 -0.893 . . . . 2.53 110.728 -177.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.622 -0.674 . . . . 1.1 110.205 175.975 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.487 1.395 0 N-CA-C 109.47 -0.567 . . . . 1.16 109.47 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.4 mt -82.73 -19.86 37.13 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.764 -0.585 . . . . 1.16 110.454 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.71 153.63 3.42 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.38 -0.825 . . . . 1.09 109.241 175.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -133.48 125.17 28.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.804 -0.56 . . . . 2.69 110.07 -176.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 12.9 p90 -151.0 162.55 40.61 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.638 -0.664 . . . . 0.22 110.794 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -113.48 139.11 49.21 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.61 -0.681 . . . . 2.35 110.246 -176.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.96 162.37 40.95 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.785 -0.572 . . . . 1.03 109.63 177.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 t -111.28 158.76 18.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.433 -0.792 . . . . 1.03 109.986 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.5 t -79.33 134.7 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 C-N-CA 120.296 -0.561 . . . . 1.16 110.239 -176.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -113.44 171.89 7.29 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.22 0.534 . . . . 1.04 109.646 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -46.49 152.98 0.4 Allowed 'General case' 0 N--CA 1.506 2.334 0 O-C-N 121.594 -0.691 . . . . 3.63 111.957 -176.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.2 mt 62.76 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.675 0 O-C-N 121.573 -0.705 . . . . 1.12 112.601 -174.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.2 16.1 80.92 Favored Glycine 0 N--CA 1.498 2.787 0 O-C-N 120.875 -1.14 . . . . 0.26 110.276 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -85.65 143.41 28.43 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.265 -1.138 . . . . 2.55 110.443 -176.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.1 pt -133.37 155.53 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.787 -0.571 . . . . 1.1 109.491 172.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -116.54 129.18 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.629 -0.669 . . . . 1.04 110.038 176.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.428 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -79.47 145.12 62.83 Favored Pre-proline 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 1.05 109.404 175.573 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -63.49 143.32 87.75 Favored 'Trans proline' 0 N--CA 1.488 1.17 0 O-C-N 122.966 0.982 . . . . 0.38 109.775 174.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.91 -26.52 59.34 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.799 -0.563 . . . . 1.12 110.504 -178.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.4 -45.14 94.15 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.016 -1.233 . . . . 0.42 110.016 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 76.4 m -69.38 -37.09 77.41 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.621 -0.929 . . . . 1.08 110.178 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -56.32 -42.15 77.16 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.369 -0.832 . . . . 0.49 109.687 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.8 tptm -66.43 -50.2 64.19 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-O 121.244 0.545 . . . . 3.4 110.214 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -57.05 -37.99 72.59 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.928 -0.482 . . . . 0.74 110.698 -178.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.427 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 21.6 t80 -86.87 -14.31 42.36 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.812 -0.555 . . . . 1.76 111.277 -177.345 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 42.52 24.61 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.631 -1.388 . . . . 0.32 109.631 178.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.418 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.4 mt -88.58 129.1 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.52 -0.988 . . . . 1.15 110.483 -177.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.06 158.47 37.86 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.919 -0.771 . . . . 1.82 108.919 170.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -57.24 140.04 50.97 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.309 -0.869 . . . . 2.7 110.492 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.01 -16.02 61.84 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.842 -0.903 . . . . 0.21 110.842 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.88 157.94 31.08 Favored 'General case' 0 N--CA 1.5 2.047 0 CA-C-N 118.739 1.27 . . . . 1.12 110.198 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -111.36 138.74 47.46 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.635 -0.666 . . . . 0.24 109.603 174.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.22 153.78 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.282 -0.636 . . . . 1.06 109.282 174.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -115.86 123.54 48.4 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.305 -0.998 . . . . 1.09 108.305 -179.077 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.5 tt -139.99 158.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 C-N-CA 119.587 -0.845 . . . . 1.05 111.004 -167.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -133.09 145.97 51.22 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.874 -0.516 . . . . 1.77 110.505 177.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.5 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.79 -0.569 . . . . 1.06 110.619 178.325 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.3 t -138.96 125.5 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.917 -0.489 . . . . 1.03 109.787 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -132.28 144.49 50.63 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.774 -0.579 . . . . 2.39 109.533 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.9 t80 . . . . . 0 N--CA 1.496 1.858 0 C-N-CA 120.197 -0.601 . . . . 0.91 110.459 -178.488 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.482 0.828 0 N-CA-C 110.133 -0.757 . . . . 0.38 110.133 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 16.6 mmtp -110.78 137.75 48.04 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 1.71 109.682 173.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -134.94 163.94 28.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.683 -0.636 . . . . 1.42 110.786 -177.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.95 135.92 4.44 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.56 -1.416 . . . . 0.18 109.56 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.4 m -122.25 137.83 54.7 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.735 -0.862 . . . . 1.07 109.766 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.423 ' CD2' ' HD3' ' A' ' 65' ' ' PRO . 13.2 p90 -155.82 172.88 17.59 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.562 -0.711 . . . . 0.18 110.937 176.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -106.6 140.3 39.68 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.707 -0.621 . . . . 1.01 109.556 173.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.42 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -140.84 144.51 35.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.664 -0.648 . . . . 1.01 110.49 -176.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -93.5 144.73 25.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.845 -0.534 . . . . 2.71 109.569 176.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.4 t -78.47 125.75 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.789 -0.569 . . . . 1.08 109.862 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.77 -167.54 26.26 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.892 -1.283 . . . . 0.22 109.892 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.68 153.52 27.91 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.756 -0.849 . . . . 1.39 110.163 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 53.57 21.09 2.37 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.51 -0.744 . . . . 1.13 112.008 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.95 20.52 79.72 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.814 -1.184 . . . . 0.2 110.837 171.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.3 m -77.99 145.26 36.09 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.462 -1.022 . . . . 1.74 110.296 -176.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.27 146.21 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.772 -0.58 . . . . 1.04 109.559 174.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.8 mm -110.92 122.94 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.521 -0.737 . . . . 1.12 110.671 -174.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 84.7 mt -78.88 143.0 61.26 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.572 -0.705 . . . . 1.17 109.568 172.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.423 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.5 Cg_endo -64.57 133.48 37.15 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 O-C-N 122.954 0.976 . . . . 0.29 110.755 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -55.2 -34.0 63.53 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.484 -0.76 . . . . 3.08 110.84 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.95 77.34 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.734 -0.604 . . . . 1.16 110.232 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.5 mt -77.1 -32.65 56.78 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.21 -0.596 . . . . 2.43 110.513 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.79 -45.52 85.92 Favored 'General case' 0 N--CA 1.504 2.248 0 O-C-N 121.331 -0.856 . . . . 3.27 109.827 178.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.28 -47.67 60.16 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 120.506 -0.478 . . . . 1.68 110.467 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 90.8 t -60.58 -38.1 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.106 0 O-C-N 121.683 -0.636 . . . . 1.08 109.816 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -82.71 -17.47 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.795 -0.566 . . . . 1.08 110.914 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.4 35.2 37.97 Favored Glycine 0 N--CA 1.498 2.797 0 N-CA-C 109.78 -1.328 . . . . 0.23 109.78 175.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.81 144.15 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.979 . . . . 1.42 110.673 -174.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -131.39 163.45 49.42 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.776 -0.577 . . . . 3.68 110.685 -177.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.83 134.44 57.14 Favored 'Trans proline' 0 N--CA 1.487 1.142 0 O-C-N 122.934 0.965 . . . . 0.8 110.865 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.83 0.82 71.38 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 111.149 -0.78 . . . . 0.26 111.149 176.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -97.24 132.43 43.01 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 118.733 1.266 . . . . 1.11 110.515 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.0 p -93.46 137.18 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.901 0.858 . . . . 1.06 111.433 -173.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.41 159.52 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.391 -0.596 . . . . 1.06 109.391 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -97.52 130.58 44.58 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.942 -0.762 . . . . 1.14 108.942 174.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.424 HG11 ' CE1' ' A' ' 7' ' ' PHE . 91.0 t -115.08 129.96 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 CA-C-O 121.318 0.58 . . . . 1.05 110.158 -171.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 35.3 mt -117.13 129.51 56.02 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 109.047 -0.723 . . . . 1.08 109.047 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.408 HD22 ' CE2' ' A' ' 27' ' ' TYR . 4.7 mt -79.77 140.61 36.84 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.718 -0.793 . . . . 1.11 109.848 172.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.9 mt -110.39 -33.38 6.64 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.788 -0.57 . . . . 2.19 110.859 -175.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.56 -175.89 38.42 Favored Glycine 0 N--CA 1.503 3.148 0 C-N-CA 119.763 -1.208 . . . . 0.25 110.953 -176.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -143.81 153.65 42.59 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.725 -0.867 . . . . 2.53 110.675 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 . . . . . 0 N--CA 1.494 1.732 0 O-C-N 121.498 -0.751 . . . . 1.1 110.198 176.423 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.486 1.347 0 N-CA-C 109.671 -0.492 . . . . 1.16 109.671 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 29.4 mt -84.06 -21.62 31.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.789 -0.569 . . . . 1.16 110.323 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.28 155.46 3.58 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.36 -0.837 . . . . 1.09 109.175 176.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -133.47 125.56 29.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.668 -0.645 . . . . 2.69 110.175 -177.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.447 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 15.8 p90 -150.84 162.78 40.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.22 110.757 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -113.24 139.07 49.11 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.562 -0.711 . . . . 2.35 110.264 -176.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.04 162.32 41.07 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.825 -0.547 . . . . 1.03 109.646 177.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -111.2 158.7 18.64 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.818 -0.753 . . . . 1.03 110.038 177.165 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.0 t -79.4 135.67 25.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.742 -0.599 . . . . 1.16 110.288 -176.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.0 m80 -114.79 171.9 7.36 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.354 0.597 . . . . 1.04 109.661 174.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -46.65 153.04 0.41 Allowed 'General case' 0 N--CA 1.505 2.318 0 O-C-N 121.532 -0.73 . . . . 3.63 111.956 -176.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.3 mt 62.75 7.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.662 0 O-C-N 121.599 -0.688 . . . . 1.12 112.619 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.86 16.07 80.43 Favored Glycine 0 N--CA 1.496 2.682 0 O-C-N 120.932 -1.105 . . . . 0.26 110.369 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.4 ttp180 -83.78 143.04 30.24 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.167 -1.196 . . . . 2.55 110.382 -176.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -131.89 154.66 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 109.365 -0.606 . . . . 1.1 109.365 171.17 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.65 129.19 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 C-N-CA 120.08 -0.648 . . . . 1.04 109.999 176.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 29.1 mt -79.75 145.08 61.54 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.04 -0.664 . . . . 1.05 109.359 175.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -63.5 143.66 88.51 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.986 0.993 . . . . 0.38 109.723 174.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.04 -26.5 60.42 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 120.449 -0.5 . . . . 1.12 110.426 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.35 -45.19 94.07 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 109.958 -1.257 . . . . 0.42 109.958 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 85.3 m -69.37 -36.98 77.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.66 -0.906 . . . . 1.08 110.117 -179.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.8 mtt180 -56.41 -41.91 77.12 Favored 'General case' 0 N--CA 1.509 2.502 0 O-C-N 121.323 -0.861 . . . . 0.49 109.662 178.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.5 tptp -66.37 -50.14 64.51 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 120.275 -0.57 . . . . 3.4 110.262 -177.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.8 t80 -57.06 -38.19 72.92 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.925 -0.484 . . . . 0.74 110.694 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.428 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.1 t80 -87.03 -14.28 42.01 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.803 -0.561 . . . . 1.76 111.249 -177.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.94 42.71 24.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.493 -1.443 . . . . 0.32 109.493 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.415 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.7 mt -88.06 127.5 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.566 -0.961 . . . . 1.15 110.501 -177.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.26 154.24 45.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.877 -0.786 . . . . 1.82 108.877 171.384 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -55.18 139.42 42.07 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.245 -0.91 . . . . 2.7 110.706 -177.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -15.76 62.41 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 110.898 -0.881 . . . . 0.21 110.898 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -76.19 158.5 31.61 Favored 'General case' 0 N--CA 1.5 2.031 0 CA-C-N 118.749 1.274 . . . . 1.12 109.992 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -111.57 138.63 47.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.568 -0.708 . . . . 0.24 109.614 175.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.72 154.79 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 109.213 -0.662 . . . . 1.06 109.213 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.85 123.6 48.57 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.318 -0.993 . . . . 1.09 108.318 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.2 tt -140.11 159.5 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.627 -0.829 . . . . 1.05 110.897 -168.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.6 ttpt -133.77 146.01 50.33 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.784 -0.573 . . . . 1.77 110.374 177.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.1 pt -114.74 150.4 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.627 -0.671 . . . . 1.06 110.359 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.9 t -140.89 124.53 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.219 0.533 . . . . 1.03 109.807 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.0 tttm -132.06 149.86 52.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.363 -0.606 . . . . 2.39 109.363 175.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 3.1 t80 . . . . . 0 N--CA 1.497 1.923 0 C-N-CA 119.993 -0.683 . . . . 0.91 110.367 -179.202 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo . . . . . 0 N--CA 1.483 0.879 0 N-CA-C 110.598 -0.578 . . . . 0.38 110.598 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 44.5 mmtt -112.93 136.58 52.44 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.502 -0.749 . . . . 1.71 109.583 171.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -138.62 167.9 20.96 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.664 -0.647 . . . . 1.42 110.974 -178.154 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.64 135.71 4.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.405 -1.478 . . . . 0.18 109.405 177.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -122.74 137.28 54.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.645 -0.915 . . . . 1.07 109.862 177.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.423 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 11.3 p90 -155.81 173.6 16.52 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.013 -0.675 . . . . 0.18 110.942 178.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 m -106.69 140.38 39.64 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.737 -0.602 . . . . 1.01 109.575 173.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.423 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.81 146.03 35.41 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.739 -0.6 . . . . 1.01 110.563 -175.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.9 ttp-105 -93.69 145.28 24.68 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.797 -0.565 . . . . 2.71 109.684 175.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 98.3 t -78.85 126.57 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.244 0.545 . . . . 1.08 109.861 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.66 -170.6 26.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.834 -1.306 . . . . 0.22 109.834 177.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -61.78 156.04 21.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.673 -0.898 . . . . 1.39 109.909 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.04 19.05 2.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.506 -0.746 . . . . 1.13 112.138 -177.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.45 20.46 79.41 Favored Glycine 0 N--CA 1.498 2.827 0 C-N-CA 119.863 -1.161 . . . . 0.2 110.714 172.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.64 146.76 33.91 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -1.005 . . . . 1.74 110.373 -176.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.9 146.44 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.751 -0.593 . . . . 1.04 109.553 174.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.3 mm -109.04 122.15 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.513 -0.742 . . . . 1.12 110.704 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.2 mt -78.84 142.25 60.44 Favored Pre-proline 0 N--CA 1.498 1.96 0 O-C-N 121.423 -0.798 . . . . 1.17 109.486 172.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.419 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.6 Cg_endo -64.83 135.01 42.72 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.938 0.967 . . . . 0.29 110.705 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -55.12 -34.21 63.53 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.499 -0.751 . . . . 3.08 110.766 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.69 -37.73 76.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.752 -0.592 . . . . 1.16 110.319 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.0 mt -77.03 -32.82 57.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.636 -0.665 . . . . 2.43 110.482 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -57.72 -45.85 85.2 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.419 -0.801 . . . . 3.27 109.951 178.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.33 -47.29 61.76 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 120.532 -0.467 . . . . 1.68 110.483 -175.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.49 -38.25 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 O-C-N 121.699 -0.626 . . . . 1.08 109.932 -178.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.7 mt -82.49 -18.01 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.791 -0.568 . . . . 1.08 110.915 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.34 35.19 43.26 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.704 -1.358 . . . . 0.23 109.704 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.7 mm -92.65 142.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.576 -0.955 . . . . 1.42 110.64 -174.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 34.9 mtpt -130.25 163.22 49.36 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.748 -0.595 . . . . 3.68 110.792 -177.181 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.76 135.41 63.58 Favored 'Trans proline' 0 N--CA 1.487 1.111 0 O-C-N 122.922 0.959 . . . . 0.8 110.92 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.72 -0.15 73.18 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 111.08 -0.808 . . . . 0.26 111.08 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -97.47 133.11 42.49 Favored 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 118.691 1.246 . . . . 1.11 110.552 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.02 133.37 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.67 0.747 . . . . 1.06 111.26 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 41.4 pt -123.48 159.52 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 109.272 -0.64 . . . . 1.06 109.272 176.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -98.44 131.1 44.98 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.963 -0.754 . . . . 1.14 108.963 176.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 83.9 t -114.95 130.24 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.394 0.616 . . . . 1.05 110.28 -170.524 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.5 mt -116.3 130.74 56.93 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 109.074 -0.713 . . . . 1.08 109.074 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.411 HD23 ' CE2' ' A' ' 27' ' ' TYR . 5.7 mt -80.55 140.86 35.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.356 -0.84 . . . . 1.11 109.791 172.204 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -113.18 -31.01 6.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.654 -0.654 . . . . 2.19 111.046 -175.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.18 -177.78 39.58 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.65 -1.262 . . . . 0.25 110.978 -176.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 p80 -144.94 153.52 41.62 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.719 -0.871 . . . . 2.53 110.59 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.527 -0.733 . . . . 1.1 110.278 176.033 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.655 -0.498 . . . . 1.16 109.655 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.7 mt -83.91 -19.1 35.34 Favored 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 120.198 -0.601 . . . . 1.16 110.378 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.4 153.3 3.51 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.292 -0.88 . . . . 1.09 109.335 176.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -134.16 125.45 27.93 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.697 -0.627 . . . . 2.69 110.089 -177.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.445 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 14.8 p90 -150.26 162.62 40.14 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.591 -0.693 . . . . 0.22 110.852 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -113.53 138.29 50.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.61 -0.681 . . . . 2.35 110.102 -176.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.08 162.29 41.12 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.661 -0.649 . . . . 1.03 109.679 177.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.11 157.83 18.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.465 -0.772 . . . . 1.03 110.03 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.401 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.61 136.43 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.783 -0.573 . . . . 1.16 110.319 -176.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -113.32 171.95 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.215 0.531 . . . . 1.04 109.686 173.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -46.67 152.31 0.49 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.607 -0.683 . . . . 3.63 111.896 -175.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.6 mt 62.6 7.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.635 0 O-C-N 121.559 -0.713 . . . . 1.12 112.601 -175.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.84 16.12 80.39 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 110.364 -1.095 . . . . 0.26 110.364 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.8 ttt180 -83.92 140.73 31.76 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.18 -1.188 . . . . 2.55 110.249 -176.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.6 pt -133.67 155.48 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.698 -0.626 . . . . 1.1 109.757 174.091 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.16 129.79 73.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.62 -0.675 . . . . 1.04 109.998 175.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.5 mt -79.61 145.97 64.19 Favored Pre-proline 0 N--CA 1.495 1.777 0 C-N-CA 120.052 -0.659 . . . . 1.05 109.396 175.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.16 142.89 88.66 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 O-C-N 123.012 1.006 . . . . 0.38 109.823 174.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.22 -26.56 60.91 Favored 'General case' 0 N--CA 1.498 1.955 0 C-N-CA 120.403 -0.519 . . . . 1.12 110.49 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.43 -45.01 94.45 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 109.973 -1.251 . . . . 0.42 109.973 -179.015 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 96.6 m -69.66 -37.0 76.54 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.63 -0.923 . . . . 1.08 109.878 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -56.2 -42.27 76.93 Favored 'General case' 0 N--CA 1.509 2.508 0 O-C-N 121.298 -0.876 . . . . 0.49 109.77 178.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -65.91 -50.14 65.5 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.282 0.563 . . . . 3.4 110.116 -177.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -56.46 -37.54 70.43 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.136 0.493 . . . . 0.74 110.725 -179.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.427 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.0 t80 -88.19 -14.15 39.33 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.784 -0.572 . . . . 1.76 111.315 -176.649 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 42.89 24.18 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.543 -1.423 . . . . 0.32 109.543 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.421 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.4 mt -87.84 126.92 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.519 -0.989 . . . . 1.15 110.653 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.91 155.64 43.87 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.134 -0.691 . . . . 1.82 109.134 171.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.56 137.49 48.71 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.308 -0.87 . . . . 2.7 110.79 -177.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.51 -15.08 64.07 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.926 -0.87 . . . . 0.21 110.926 178.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -76.01 157.55 32.9 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 118.76 1.28 . . . . 1.12 109.862 177.146 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -111.51 138.16 48.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.631 -0.668 . . . . 0.24 109.611 175.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.99 152.06 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 120.087 -0.645 . . . . 1.06 109.309 174.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -113.74 123.51 50.05 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.172 -1.047 . . . . 1.09 108.172 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.2 tt -139.87 157.57 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.584 -0.846 . . . . 1.05 110.886 -167.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -133.1 146.06 51.29 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.801 -0.562 . . . . 1.77 110.474 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 27.9 pt -114.9 151.1 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.758 -0.589 . . . . 1.06 110.54 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.38 127.37 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.674 -0.491 . . . . 1.03 109.674 176.333 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -133.47 144.43 49.45 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 109.538 -0.542 . . . . 2.39 109.538 175.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 52.6 t80 . . . . . 0 N--CA 1.495 1.808 0 C-N-CA 120.262 -0.575 . . . . 0.91 110.355 -178.528 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo . . . . . 0 N--CA 1.483 0.89 0 N-CA-C 109.936 -0.832 . . . . 0.38 109.936 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -120.73 149.77 42.01 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.34 -0.85 . . . . 1.71 110.147 171.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -137.2 167.66 21.14 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.851 -0.531 . . . . 1.42 110.731 -177.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.57 135.86 4.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.342 -1.503 . . . . 0.18 109.342 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.2 m -122.95 137.99 54.8 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.658 -0.907 . . . . 1.07 109.887 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.424 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.3 p90 -155.96 172.61 18.09 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.88 -0.728 . . . . 0.18 110.969 175.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.2 m -107.54 140.45 40.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.685 -0.634 . . . . 1.01 109.598 174.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.424 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 144.49 34.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.62 -0.675 . . . . 1.01 110.527 -176.032 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.78 145.7 24.4 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.693 -0.629 . . . . 2.71 109.67 175.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 99.3 t -78.11 126.66 38.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.821 -0.55 . . . . 1.08 109.93 -178.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.92 -166.4 25.08 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.101 -1.2 . . . . 0.22 110.101 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.71 152.79 30.08 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.779 -0.836 . . . . 1.39 110.131 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.4 mt-30 53.64 21.02 2.39 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.557 -0.715 . . . . 1.13 112.03 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.49 79.91 Favored Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.802 -1.189 . . . . 0.2 110.776 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 51.5 p -79.08 148.36 32.45 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.465 -1.021 . . . . 1.74 110.43 -176.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.9 p -139.67 147.14 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.878 -0.514 . . . . 1.04 109.67 174.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.2 mm -108.5 121.85 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.536 -0.728 . . . . 1.12 110.535 -175.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 78.6 mt -78.68 143.02 62.16 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.6 -0.687 . . . . 1.17 109.619 173.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.0 Cg_endo -64.92 131.46 29.03 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.936 0.966 . . . . 0.29 110.784 -179.02 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 50.3 tttp -55.12 -34.07 63.4 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.424 -0.797 . . . . 3.08 110.846 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.72 -37.72 76.77 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.722 -0.611 . . . . 1.16 110.269 -178.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.9 mt -77.16 -32.71 56.43 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.21 -0.596 . . . . 2.43 110.494 178.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtt180 -57.55 -45.57 84.96 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.231 -0.918 . . . . 3.27 109.829 178.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.97 64.26 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 120.441 -0.504 . . . . 1.68 110.371 -174.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.8 t -60.56 -38.6 78.76 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.678 -0.639 . . . . 1.08 109.901 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.8 mt -83.26 -15.8 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.896 -0.503 . . . . 1.08 111.143 -176.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.931 -1.268 . . . . 0.23 109.931 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 51.4 mm -89.96 141.06 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.574 -0.957 . . . . 1.42 110.716 -174.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -130.61 159.26 71.8 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.808 -0.558 . . . . 3.68 110.69 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -54.63 133.63 57.97 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 122.98 0.99 . . . . 0.8 111.391 177.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.02 0.34 71.51 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 111.205 -0.758 . . . . 0.26 111.205 175.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -98.05 134.1 41.6 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-N 118.769 1.285 . . . . 1.11 110.603 179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.34 132.9 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 CA-C-O 121.55 0.691 . . . . 1.06 111.15 -174.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.8 pt -122.39 159.4 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 109.353 -0.61 . . . . 1.06 109.353 175.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 48.3 tt0 -98.85 131.71 44.75 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.007 -0.738 . . . . 1.14 109.007 175.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.424 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.1 t -116.16 129.88 71.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 CA-C-O 121.298 0.57 . . . . 1.05 110.362 -170.207 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.1 mt -115.83 130.94 57.04 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.188 -0.671 . . . . 1.08 109.188 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.416 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.27 140.18 36.32 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.375 -0.828 . . . . 1.11 109.797 171.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -109.36 -31.21 7.63 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.825 -0.547 . . . . 2.19 110.898 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.05 179.39 41.29 Favored Glycine 0 N--CA 1.503 3.136 0 C-N-CA 119.728 -1.225 . . . . 0.25 110.986 -177.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.406 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 29.2 p80 -140.6 145.67 37.0 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.728 -0.866 . . . . 2.53 110.072 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.406 ' CD1' ' O ' ' A' ' 87' ' ' HIS . 17.8 m-85 . . . . . 0 N--CA 1.496 1.851 0 O-C-N 121.506 -0.746 . . . . 1.1 109.943 179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 N--CA 1.487 1.375 0 N-CA-C 109.644 -0.502 . . . . 1.16 109.644 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 30.9 mt -87.57 -17.93 30.87 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.744 -0.598 . . . . 1.16 110.708 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.83 155.96 4.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.253 -0.904 . . . . 1.09 109.742 176.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -133.29 126.6 31.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.762 -0.586 . . . . 2.69 110.096 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 17.2 p90 -149.48 161.94 41.12 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.651 -0.656 . . . . 0.22 110.871 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.6 m-70 -111.73 138.02 48.86 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.617 -0.677 . . . . 2.35 110.17 -176.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.41 162.29 41.2 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.727 -0.608 . . . . 1.03 109.774 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.5 t -111.71 159.33 18.34 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 119.925 -0.71 . . . . 1.03 109.89 176.094 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.8 t -77.83 138.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 120.304 -0.558 . . . . 1.16 110.103 -177.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.67 171.9 7.57 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.327 0.584 . . . . 1.04 109.672 174.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -46.91 153.13 0.44 Allowed 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.537 -0.727 . . . . 3.63 111.927 -175.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.0 mt 63.1 7.22 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.681 0 O-C-N 121.601 -0.687 . . . . 1.12 112.643 -175.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.54 15.98 80.79 Favored Glycine 0 N--CA 1.498 2.791 0 O-C-N 120.829 -1.169 . . . . 0.26 110.292 179.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.0 ttm180 -85.94 145.39 27.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.324 -1.104 . . . . 2.55 110.352 -177.221 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.18 154.52 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.727 -0.608 . . . . 1.1 109.466 172.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.83 128.72 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.57 -0.706 . . . . 1.04 109.99 176.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.7 mt -79.98 145.09 60.57 Favored Pre-proline 0 N--CA 1.495 1.802 0 C-N-CA 120.084 -0.646 . . . . 1.05 109.37 175.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.27 143.06 88.53 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 122.917 0.956 . . . . 0.38 109.812 174.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.6 -26.42 61.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.867 -0.521 . . . . 1.12 110.489 -178.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.82 -44.37 94.8 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.42 109.914 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.8 m -69.69 -38.13 76.89 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.637 -0.919 . . . . 1.08 110.179 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -56.18 -41.23 75.19 Favored 'General case' 0 N--CA 1.512 2.648 0 O-C-N 121.274 -0.891 . . . . 0.49 109.493 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.5 tttp -65.53 -50.0 66.83 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.166 0.508 . . . . 3.4 110.142 -176.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -57.39 -37.96 73.5 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.749 -0.594 . . . . 0.74 110.725 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.448 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 18.6 t80 -87.99 -14.31 39.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.766 -0.584 . . . . 1.76 111.239 -176.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.48 42.45 27.32 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.548 -1.421 . . . . 0.32 109.548 177.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.448 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.4 mt -88.49 129.18 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.545 -0.974 . . . . 1.15 110.572 -176.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -129.07 158.76 38.02 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.929 -0.767 . . . . 1.82 108.929 170.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -57.45 140.54 50.26 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.315 -0.865 . . . . 2.7 110.426 -178.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.73 -16.06 61.65 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.843 -0.903 . . . . 0.21 110.843 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -77.06 157.95 30.81 Favored 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 118.724 1.262 . . . . 1.12 110.121 178.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -111.55 138.67 47.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.582 -0.699 . . . . 0.24 109.611 174.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.88 154.16 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 109.272 -0.64 . . . . 1.06 109.272 174.179 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -116.32 124.07 49.21 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.274 -1.01 . . . . 1.09 108.274 -179.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.402 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -140.23 157.91 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.558 -0.857 . . . . 1.05 111.053 -167.181 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.81 146.07 51.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.76 -0.587 . . . . 1.77 110.517 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.94 150.94 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.598 -0.689 . . . . 1.06 110.544 178.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.9 t -138.08 125.13 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.177 0.513 . . . . 1.03 109.655 176.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -134.17 147.48 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.725 -0.609 . . . . 2.39 109.495 175.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.1 t80 . . . . . 0 N--CA 1.494 1.769 0 C-N-CA 120.092 -0.643 . . . . 0.91 110.266 179.836 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo . . . . . 0 N--CA 1.481 0.768 0 N-CA-C 110.198 -0.731 . . . . 0.38 110.198 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 66.1 mmtt -111.06 137.78 48.29 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.527 -0.733 . . . . 1.71 109.432 172.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.65 164.46 27.81 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.555 -0.716 . . . . 1.42 110.997 -176.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.9 4.37 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.659 -1.377 . . . . 0.18 109.659 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.68 137.72 54.66 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.638 -0.919 . . . . 1.07 109.792 176.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.6 p90 -156.36 172.76 17.95 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.963 -0.695 . . . . 0.18 111.047 176.264 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.6 m -106.68 140.91 38.79 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.677 -0.639 . . . . 1.01 109.414 173.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.16 145.89 36.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.652 -0.655 . . . . 1.01 110.697 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.0 ttt180 -93.29 145.33 24.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.833 -0.542 . . . . 2.71 109.616 175.559 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -79.01 125.96 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 121.419 0.628 . . . . 1.08 109.722 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.7 -166.47 26.25 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.961 -1.256 . . . . 0.22 109.961 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -61.73 151.98 32.43 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.804 -0.821 . . . . 1.39 110.139 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 53.32 21.53 2.36 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.523 -0.736 . . . . 1.13 112.054 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.77 20.42 79.77 Favored Glycine 0 N--CA 1.498 2.832 0 C-N-CA 119.796 -1.192 . . . . 0.2 110.879 171.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.1 p -78.56 147.02 33.93 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.518 -0.989 . . . . 1.74 110.22 -178.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -139.26 146.39 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.8 -0.563 . . . . 1.04 109.525 175.293 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.95 123.81 66.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.58 -0.7 . . . . 1.12 110.583 -175.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 86.4 mt -78.32 144.06 65.72 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.643 -0.661 . . . . 1.17 109.432 172.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.4 Cg_endo -64.49 135.36 45.53 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.966 0.982 . . . . 0.29 110.73 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 38.2 tttp -55.08 -34.21 63.44 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.545 -0.722 . . . . 3.08 110.75 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.87 -38.33 78.57 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.779 -0.576 . . . . 1.16 110.343 -178.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.3 mt -77.13 -32.87 56.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.747 -0.595 . . . . 2.43 110.617 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.05 -45.82 86.38 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.35 -0.843 . . . . 3.27 109.882 178.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -46.76 63.96 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 120.511 -0.476 . . . . 1.68 110.425 -175.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.8 t -60.58 -38.28 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.704 -0.623 . . . . 1.08 109.853 -178.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.5 mt -82.68 -17.52 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.874 -0.516 . . . . 1.08 110.872 -176.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.89 35.11 40.51 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.693 -1.363 . . . . 0.23 109.693 175.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.1 mm -93.07 142.89 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.599 -0.942 . . . . 1.42 110.77 -173.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.2 ptmt -132.94 162.64 56.35 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.742 -0.599 . . . . 3.68 110.652 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -51.97 135.44 51.11 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.056 1.03 . . . . 0.8 111.887 178.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.95 -1.51 70.87 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 120.704 -0.76 . . . . 0.26 111.357 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -96.33 130.92 43.33 Favored 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 118.767 1.284 . . . . 1.11 110.614 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.79 134.35 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 CA-C-O 121.684 0.754 . . . . 1.06 111.296 -173.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.4 pt -125.58 159.46 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 109.567 -0.531 . . . . 1.06 109.567 177.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.421 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.1 tt0 -97.61 132.04 43.63 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.075 -0.713 . . . . 1.14 109.075 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 96.7 t -116.32 129.89 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.344 0.592 . . . . 1.05 110.264 -171.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -115.34 130.3 56.86 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.262 -0.644 . . . . 1.08 109.262 178.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.412 HD12 ' CD2' ' A' ' 27' ' ' TYR . 4.2 mt -79.96 138.81 37.16 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.345 -0.847 . . . . 1.11 109.914 172.479 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -105.76 -35.9 7.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.726 -0.609 . . . . 2.19 110.918 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.83 -176.03 38.69 Favored Glycine 0 N--CA 1.503 3.166 0 C-N-CA 119.79 -1.195 . . . . 0.25 110.817 -176.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -142.72 152.65 42.57 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.677 -0.896 . . . . 2.53 110.798 -177.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 N--CA 1.493 1.705 0 O-C-N 121.535 -0.728 . . . . 1.1 110.064 175.483 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.487 1.391 0 N-CA-C 109.522 -0.547 . . . . 1.16 109.522 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 29.0 mt -85.62 -18.36 33.49 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.728 -0.608 . . . . 1.16 110.32 178.119 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -174.5 151.27 1.51 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.244 -0.91 . . . . 1.09 108.997 176.08 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -134.96 127.82 31.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.649 -0.657 . . . . 2.69 110.295 -178.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.45 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 16.8 p90 -150.36 163.14 39.09 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 120.345 -0.542 . . . . 0.22 110.595 -177.426 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.7 m170 -112.65 137.7 50.54 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.648 -0.657 . . . . 2.35 110.256 -176.776 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.83 162.31 40.99 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.752 -0.592 . . . . 1.03 109.585 177.13 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.06 159.29 17.44 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.765 -0.774 . . . . 1.03 110.139 177.675 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.6 t -79.05 136.27 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 120.298 -0.561 . . . . 1.16 110.254 -177.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -115.42 171.95 7.39 Favored 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.253 0.549 . . . . 1.04 109.726 175.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -46.64 153.03 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.583 -0.698 . . . . 3.63 111.882 -176.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 53.9 mt 62.94 7.07 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.666 0 O-C-N 121.525 -0.735 . . . . 1.12 112.629 -175.439 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.6 16.11 80.59 Favored Glycine 0 N--CA 1.498 2.792 0 O-C-N 120.895 -1.128 . . . . 0.26 110.33 179.389 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 ttm180 -85.43 144.16 28.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.255 -1.144 . . . . 2.55 110.293 -177.147 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.46 155.09 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.725 -0.609 . . . . 1.1 109.463 172.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.74 129.43 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.665 -0.647 . . . . 1.04 109.991 176.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.3 mt -79.61 145.99 64.23 Favored Pre-proline 0 N--CA 1.494 1.768 0 C-N-CA 120.061 -0.656 . . . . 1.05 109.321 175.682 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -63.47 143.21 87.66 Favored 'Trans proline' 0 N--CA 1.489 1.228 0 O-C-N 123.069 1.036 . . . . 0.38 109.698 174.652 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.31 -26.34 60.74 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.813 -0.555 . . . . 1.12 110.438 -178.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.34 -45.23 93.98 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.015 -1.234 . . . . 0.42 110.015 -179.323 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.1 m -69.27 -37.3 77.84 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.706 -0.879 . . . . 1.08 110.187 -179.579 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -56.24 -42.06 76.73 Favored 'General case' 0 N--CA 1.509 2.487 0 O-C-N 121.434 -0.791 . . . . 0.49 109.751 178.378 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -66.62 -50.24 63.66 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 121.272 0.558 . . . . 3.4 110.233 -177.024 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -57.27 -37.87 73.04 Favored 'General case' 0 N--CA 1.501 2.109 0 CA-C-O 121.205 0.526 . . . . 0.74 110.704 -179.039 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.451 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 17.5 t80 -87.69 -14.21 40.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.744 -0.597 . . . . 1.76 111.223 -176.795 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.17 26.76 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.598 -1.401 . . . . 0.32 109.598 177.674 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.451 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.1 mt -89.44 127.79 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.452 -1.028 . . . . 1.15 110.462 -176.545 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -128.21 159.7 34.39 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.114 -0.699 . . . . 1.82 109.114 171.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -57.2 139.36 52.88 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.364 -0.835 . . . . 2.7 110.541 -178.219 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.43 -15.77 62.2 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 110.843 -0.903 . . . . 0.21 110.843 178.232 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.07 158.74 31.49 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 118.701 1.25 . . . . 1.12 109.991 178.037 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -111.71 138.16 48.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.634 -0.666 . . . . 0.24 109.645 175.408 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.36 153.5 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 N-CA-C 109.164 -0.68 . . . . 1.06 109.164 173.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.3 123.16 48.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.227 -1.027 . . . . 1.09 108.227 -179.628 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.6 tt -140.38 158.33 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.593 -0.843 . . . . 1.05 110.946 -167.564 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -132.07 146.14 51.87 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.815 -0.553 . . . . 1.77 110.428 177.286 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.9 pt -114.92 150.55 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 1.06 110.305 176.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.3 t -139.58 124.35 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 CA-C-O 121.292 0.567 . . . . 1.03 109.692 177.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -135.99 147.89 48.19 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.731 -0.605 . . . . 2.39 109.415 176.758 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.7 t80 . . . . . 0 N--CA 1.496 1.834 0 C-N-CA 120.071 -0.652 . . . . 0.91 110.403 -177.566 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo . . . . . 0 N--CA 1.48 0.735 0 N-CA-C 110.198 -0.731 . . . . 0.38 110.198 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -110.69 137.27 48.57 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.56 -0.712 . . . . 1.71 109.577 173.217 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.09 163.91 28.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.595 -0.691 . . . . 1.42 111.027 -176.328 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.75 135.72 4.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.488 -1.445 . . . . 0.18 109.488 176.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.8 m -124.5 136.86 54.34 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.733 -0.863 . . . . 1.07 109.823 177.288 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 11.6 p90 -155.93 173.62 16.53 Favored 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.888 -0.725 . . . . 0.18 111.046 178.267 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.71 141.02 39.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.713 -0.617 . . . . 1.01 109.518 173.583 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.89 145.84 35.06 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.64 -0.663 . . . . 1.01 110.672 -175.709 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 43.6 ttp180 -93.72 146.03 24.15 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.758 -0.589 . . . . 2.71 109.674 175.248 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 99.0 t -78.28 127.16 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.821 -0.55 . . . . 1.08 109.995 -178.401 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.96 -168.06 26.1 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.995 -1.242 . . . . 0.22 109.995 178.869 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.7 153.47 28.15 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.712 -0.875 . . . . 1.39 110.175 -179.727 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.68 20.89 2.37 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.596 -0.69 . . . . 1.13 112.105 -179.698 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.6 20.46 79.82 Favored Glycine 0 N--CA 1.5 2.957 0 C-N-CA 119.763 -1.208 . . . . 0.2 110.826 171.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.9 p -78.67 147.26 33.61 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.541 -0.976 . . . . 1.74 110.328 -177.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.75 146.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 109.515 -0.55 . . . . 1.04 109.515 174.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.8 123.89 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.527 -0.733 . . . . 1.12 110.612 -174.559 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.5 mt -78.23 144.27 66.52 Favored Pre-proline 0 N--CA 1.499 2.024 0 O-C-N 121.59 -0.694 . . . . 1.17 109.392 172.368 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.418 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.1 Cg_endo -64.34 135.61 47.22 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 O-C-N 122.965 0.981 . . . . 0.29 110.71 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 23.0 tptm -55.02 -34.85 63.82 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.368 -0.833 . . . . 3.08 110.769 -179.772 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.92 -38.3 78.65 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.79 -0.569 . . . . 1.16 110.276 -178.494 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.4 mt -77.05 -32.81 57.13 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.727 -0.608 . . . . 2.43 110.695 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -58.15 -46.22 86.05 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.351 -0.843 . . . . 3.27 109.845 178.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.43 -47.38 61.01 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.49 -0.484 . . . . 1.68 110.468 -175.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 88.8 t -60.64 -37.96 77.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.702 -0.624 . . . . 1.08 109.94 -178.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.7 mt -82.56 -17.82 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.833 -0.542 . . . . 1.08 110.823 -176.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.7 35.22 41.23 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.776 -1.33 . . . . 0.23 109.776 175.706 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.5 mm -90.12 142.69 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.46 -1.023 . . . . 1.42 110.665 -173.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.94 156.29 76.3 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.789 -0.569 . . . . 3.68 110.618 -177.807 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -55.44 135.87 71.16 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.018 1.009 . . . . 0.8 111.257 178.197 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -1.53 73.06 Favored Glycine 0 N--CA 1.496 2.678 0 C-N-CA 120.622 -0.799 . . . . 0.26 111.235 176.191 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.2 mt-10 -96.2 132.27 41.81 Favored 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 118.729 1.264 . . . . 1.11 110.429 179.033 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.57 130.71 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.49 0.662 . . . . 1.06 110.98 -174.822 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 46.6 pt -119.34 159.48 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 N-CA-C 109.579 -0.526 . . . . 1.06 109.579 178.055 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.416 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 82.0 tt0 -97.34 130.05 44.54 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.012 -0.736 . . . . 1.14 109.012 174.933 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 89.0 t -115.46 127.77 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.339 0.59 . . . . 1.05 110.235 -171.809 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.3 mt -115.07 129.19 56.63 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.411 -0.589 . . . . 1.08 109.411 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.419 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.5 mt -79.72 140.61 36.91 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.433 -0.792 . . . . 1.11 109.856 172.651 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.09 -31.99 6.93 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.857 -0.527 . . . . 2.19 110.798 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.56 -176.95 39.22 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.71 -1.233 . . . . 0.25 110.965 -177.429 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -145.06 152.6 40.36 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.715 -0.874 . . . . 2.53 110.742 -177.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 . . . . . 0 N--CA 1.494 1.75 0 O-C-N 121.507 -0.746 . . . . 1.1 110.028 175.711 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 109.565 -0.531 . . . . 1.16 109.565 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.23 -20.22 38.12 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.213 -0.595 . . . . 1.16 110.386 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.74 154.58 3.69 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.418 -0.801 . . . . 1.09 109.327 175.742 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.6 tttt -134.66 125.17 26.57 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.657 -0.652 . . . . 2.69 110.246 -176.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . 0.449 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.2 p90 -150.65 162.76 40.05 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.536 -0.727 . . . . 0.22 110.842 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.69 138.74 49.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.623 -0.673 . . . . 2.35 110.231 -177.368 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.11 162.31 41.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.732 -0.605 . . . . 1.03 109.72 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.0 157.81 18.91 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.52 -0.737 . . . . 1.03 109.997 177.324 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.33 135.82 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.748 -0.595 . . . . 1.16 110.259 -176.665 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -113.84 171.87 7.33 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.294 0.568 . . . . 1.04 109.787 174.088 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtm-85 -46.66 152.67 0.45 Allowed 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.522 -0.736 . . . . 3.63 112.026 -175.694 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 56.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.599 0 O-C-N 121.596 -0.69 . . . . 1.12 112.598 -175.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.71 16.17 80.43 Favored Glycine 0 N--CA 1.498 2.789 0 O-C-N 120.891 -1.131 . . . . 0.26 110.325 179.404 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -84.05 141.8 30.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.271 -1.135 . . . . 2.55 110.36 -176.473 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.9 pt -133.98 154.36 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.654 . . . . 1.1 109.532 172.832 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mm -117.71 128.46 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 C-N-CA 120.051 -0.66 . . . . 1.04 109.857 176.19 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 34.0 mt -80.07 144.09 58.31 Favored Pre-proline 0 N--CA 1.496 1.829 0 C-N-CA 120.02 -0.672 . . . . 1.05 109.36 176.043 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.32 143.55 89.35 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 122.953 0.975 . . . . 0.38 109.731 174.656 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.5 -26.5 61.41 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.889 -0.507 . . . . 1.12 110.47 -178.347 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.48 -44.46 95.18 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 109.914 -1.275 . . . . 0.42 109.914 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.2 m -69.97 -38.34 76.04 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.618 -0.931 . . . . 1.08 110.162 -179.392 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -55.89 -40.79 73.52 Favored 'General case' 0 N--CA 1.514 2.75 0 O-C-N 121.245 -0.91 . . . . 0.49 109.43 176.42 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -64.94 -49.66 69.51 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.167 0.508 . . . . 3.4 110.119 -177.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.19 -38.55 73.82 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.785 -0.572 . . . . 0.74 110.726 -179.709 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.43 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 22.3 t80 -88.07 -14.23 39.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.847 -0.533 . . . . 1.76 111.308 -176.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.97 24.59 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.55 -1.42 . . . . 0.32 109.55 178.562 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.43 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.9 mt -87.25 129.14 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.499 -1.001 . . . . 1.15 110.563 -177.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.31 158.97 36.73 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 109.11 -0.7 . . . . 1.82 109.11 170.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.25 138.66 54.45 Favored 'General case' 0 N--CA 1.503 2.201 0 O-C-N 121.396 -0.815 . . . . 2.7 110.539 -179.149 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.05 62.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 110.869 -0.892 . . . . 0.21 110.869 178.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.82 155.54 32.96 Favored 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 118.708 1.254 . . . . 1.12 110.076 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -110.43 138.65 46.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.557 -0.714 . . . . 0.24 109.462 174.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.38 154.43 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 C-N-CA 120.204 -0.598 . . . . 1.06 109.398 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -114.89 123.38 49.01 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.158 -1.053 . . . . 1.09 108.158 179.695 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.7 tt -139.94 158.65 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.662 -0.815 . . . . 1.05 110.812 -167.787 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 ttpt -132.67 146.21 51.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.887 -0.508 . . . . 1.77 110.42 178.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.0 pt -114.72 149.12 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.718 -0.614 . . . . 1.06 110.252 177.107 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.5 t -140.1 123.95 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 CA-C-O 121.138 0.494 . . . . 1.03 109.69 178.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -132.25 148.47 52.45 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.34 -0.615 . . . . 2.39 109.34 175.922 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 33.1 t80 . . . . . 0 N--CA 1.496 1.864 0 C-N-CA 120.008 -0.677 . . . . 0.91 110.328 179.909 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo . . . . . 0 N--CA 1.483 0.87 0 N-CA-C 110.504 -0.614 . . . . 0.38 110.504 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 31.7 mmtp -111.13 136.0 50.81 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.588 -0.695 . . . . 1.71 109.714 172.743 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -133.27 156.89 46.74 Favored 'General case' 0 C--N 1.311 -1.068 0 O-C-N 121.531 -0.731 . . . . 1.42 110.582 -171.381 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.67 135.86 4.57 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.544 -1.422 . . . . 0.18 109.544 176.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -126.83 138.31 53.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.647 -0.913 . . . . 1.07 109.714 177.257 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 11.1 p90 -156.26 173.79 16.34 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 119.949 -0.701 . . . . 0.18 111.107 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.9 m -106.89 141.07 38.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.633 -0.667 . . . . 1.01 109.606 173.289 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -142.24 145.77 34.44 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.754 -0.591 . . . . 1.01 110.551 -175.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 57.0 ttt180 -93.77 145.26 24.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.741 -0.6 . . . . 2.71 109.778 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -79.68 125.5 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 CA-C-O 121.384 0.611 . . . . 1.08 109.825 179.675 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.9 -165.91 25.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.989 -1.244 . . . . 0.22 109.989 178.482 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -61.62 153.07 28.92 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.85 -0.794 . . . . 1.39 110.178 -179.335 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.55 21.15 2.38 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.602 -0.686 . . . . 1.13 112.056 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.51 79.88 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 119.812 -1.185 . . . . 0.2 110.817 172.008 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 59.4 p -78.41 146.68 34.42 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.563 -0.963 . . . . 1.74 110.439 -176.244 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.8 p -139.55 145.62 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.631 -0.507 . . . . 1.04 109.631 174.203 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.3 mm -111.09 123.03 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.552 -0.718 . . . . 1.12 110.478 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.8 mt -78.2 144.47 67.02 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.613 -0.679 . . . . 1.17 109.656 174.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.41 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.9 Cg_endo -64.31 134.58 42.67 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 O-C-N 122.928 0.962 . . . . 0.29 110.802 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -54.88 -35.02 63.63 Favored 'General case' 0 N--CA 1.503 2.207 0 O-C-N 121.489 -0.757 . . . . 3.08 110.767 -179.806 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.84 -38.29 78.38 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.738 -0.601 . . . . 1.16 110.364 -178.063 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 72.6 mt -77.21 -32.66 56.09 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 120.172 -0.611 . . . . 2.43 110.729 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -58.28 -46.49 85.96 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.301 -0.874 . . . . 3.27 109.761 178.551 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.02 -46.12 65.77 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.542 -0.463 . . . . 1.68 110.455 -175.179 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.4 t -60.38 -38.46 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.61 -0.681 . . . . 1.08 109.825 -178.835 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.3 mt -82.17 -18.27 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.918 -0.489 . . . . 1.08 110.912 -177.059 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.59 35.13 42.08 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 109.75 -1.34 . . . . 0.23 109.75 176.476 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 49.8 mm -92.0 140.72 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.468 -1.019 . . . . 1.42 110.569 -174.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 23.1 mmmt -125.32 161.58 49.14 Favored Pre-proline 0 N--CA 1.498 1.964 0 O-C-N 121.637 -0.665 . . . . 3.68 110.498 -175.366 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -60.75 134.6 54.89 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 O-C-N 123.0 1.0 . . . . 0.8 110.748 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.47 0.87 72.37 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 111.118 -0.793 . . . . 0.26 111.118 176.645 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -100.33 135.86 41.12 Favored 'General case' 0 N--CA 1.498 1.975 0 CA-C-N 118.704 1.252 . . . . 1.11 110.737 -179.633 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.72 133.9 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.696 0.76 . . . . 1.06 111.463 -172.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.1 pt -124.59 159.47 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 109.399 -0.593 . . . . 1.06 109.399 175.427 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -98.6 132.0 44.35 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.067 -0.716 . . . . 1.14 109.067 175.9 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.6 t -115.39 129.41 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 CA-C-O 121.302 0.572 . . . . 1.05 110.282 -171.408 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.1 129.36 56.3 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 109.168 -0.679 . . . . 1.08 109.168 178.869 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.419 HD11 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.09 139.25 36.96 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.396 -0.815 . . . . 1.11 109.755 171.798 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.21 -31.25 7.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.724 -0.61 . . . . 2.19 110.971 -174.899 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.06 -175.9 38.14 Favored Glycine 0 N--CA 1.504 3.176 0 C-N-CA 119.671 -1.252 . . . . 0.25 111.086 -176.944 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -144.44 154.05 42.54 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.681 -0.893 . . . . 2.53 110.744 -177.277 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.536 -0.727 . . . . 1.1 110.131 175.972 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.3 mtt . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.128 0.49 . . . . 3.68 110.533 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -73.64 144.01 46.07 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.876 -0.515 . . . . 1.27 110.048 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -128.13 137.45 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.802 -0.562 . . . . 1.02 109.568 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 35.0 mt -86.71 -18.0 32.28 Favored 'General case' 0 N--CA 1.496 1.825 0 C-N-CA 120.251 -0.58 . . . . 1.02 110.515 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.77 152.71 3.13 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.388 -0.82 . . . . 1.02 109.094 177.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 46.6 tttt -133.85 125.16 27.8 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.674 -0.641 . . . . 1.52 110.054 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.446 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 14.6 p90 -150.94 162.28 41.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.575 -0.703 . . . . 0.09 110.782 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -113.41 139.12 49.17 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.713 -0.617 . . . . 2.05 110.235 -177.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.57 162.3 40.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.742 -0.599 . . . . 1.01 109.604 177.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.1 157.95 18.82 Favored 'General case' 0 N--CA 1.496 1.869 0 C-N-CA 119.764 -0.774 . . . . 1.03 110.063 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.29 134.92 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 C-N-CA 120.289 -0.564 . . . . 1.03 110.161 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -113.46 171.93 7.27 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.23 0.538 . . . . 0.14 109.685 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.33 152.54 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.53 -0.731 . . . . 3.25 112.003 -175.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.5 mt 62.74 7.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.674 0 O-C-N 121.516 -0.74 . . . . 1.05 112.533 -174.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.09 80.66 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.815 -1.178 . . . . 0.09 110.377 179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 70.2 ttp85 -85.54 142.96 28.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.297 -1.12 . . . . 2.75 110.367 -176.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.2 157.74 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.658 -0.651 . . . . 1.02 109.602 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 49.2 mm -117.06 129.58 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.632 -0.668 . . . . 1.03 110.113 176.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.427 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.8 mt -79.98 147.01 64.9 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.147 -0.621 . . . . 1.03 109.396 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.06 143.15 90.06 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 122.979 0.989 . . . . 0.16 109.878 174.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.98 -26.5 62.41 Favored 'General case' 0 N--CA 1.496 1.845 0 C-N-CA 120.404 -0.518 . . . . 1.05 110.448 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.76 -43.73 95.82 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.998 -1.241 . . . . 0.11 109.998 -179.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.4 m -69.69 -39.17 77.1 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.547 -0.973 . . . . 1.03 110.051 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.8 mtt180 -56.49 -42.56 78.5 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 121.353 -0.842 . . . . 0.12 109.403 177.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.2 tttt -67.45 -50.25 60.05 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.025 0.441 . . . . 2.76 110.222 -176.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -58.09 -36.16 72.47 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.735 -0.603 . . . . 0.22 110.581 178.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.449 ' CE2' ' CD1' ' A' ' 84' ' ' LEU . 11.5 t80 -86.77 -14.28 42.74 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.739 -0.601 . . . . 0.91 111.331 -174.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.2 39.94 35.48 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.661 -1.376 . . . . 0.12 109.661 177.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.424 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 85.1 mt -93.2 132.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.502 -0.999 . . . . 1.04 110.633 -175.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.15 161.65 29.59 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 109.304 -0.628 . . . . 1.99 109.304 172.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -57.76 138.72 55.26 Favored 'General case' 0 N--CA 1.503 2.217 0 O-C-N 121.477 -0.764 . . . . 2.54 110.397 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.47 -16.11 61.82 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.855 -0.898 . . . . 0.12 110.855 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -77.51 160.89 28.32 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.085 -1.244 . . . . 0.09 110.234 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -112.62 139.27 48.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.13 109.728 175.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.2 155.82 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 N-CA-C 109.152 -0.684 . . . . 1.02 109.152 173.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -118.75 123.83 45.78 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.36 -0.978 . . . . 1.0 108.36 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 6.9 tt -140.33 158.53 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 C-N-CA 119.58 -0.848 . . . . 1.02 111.144 -167.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 36.4 tttt -132.92 146.09 51.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.91 -0.494 . . . . 1.93 110.384 177.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 pt -114.81 151.01 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.624 -0.672 . . . . 0.99 110.528 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t -138.38 124.75 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 CA-C-O 121.136 0.493 . . . . 1.05 109.678 176.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.9 tttm -132.84 144.87 50.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.29 -0.633 . . . . 2.46 109.29 175.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 42.4 t80 -103.14 130.01 50.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 120.09 -0.644 . . . . 0.93 110.55 -177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.8 129.67 40.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.713 -0.617 . . . . 1.77 109.988 177.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.79 -128.27 46.18 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 109.816 -1.314 . . . . 0.45 109.816 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -105.06 13.9 30.12 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.744 -0.856 . . . . 1.14 111.616 177.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -131.12 129.06 22.37 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.248 -0.907 . . . . 1.48 110.878 -178.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.15 139.72 24.22 Favored 'Trans proline' 0 N--CA 1.483 0.88 0 O-C-N 122.752 0.869 . . . . 0.55 110.423 175.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -110.36 137.51 47.98 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.577 -0.702 . . . . 1.85 109.536 172.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -134.61 162.43 32.33 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.645 -0.659 . . . . 1.69 110.996 -177.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.89 135.92 4.45 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.418 . . . . 0.11 109.554 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -124.06 138.05 54.49 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.651 -0.911 . . . . 1.03 109.785 177.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.4 p90 -155.97 173.47 16.74 Favored 'General case' 0 N--CA 1.497 1.902 0 C-N-CA 119.884 -0.726 . . . . 0.1 110.986 177.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.5 m -106.91 142.07 37.13 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.65 -0.656 . . . . 1.03 109.464 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.07 146.17 36.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.61 -0.681 . . . . 1.02 110.756 -175.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.65 146.0 24.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.841 -0.537 . . . . 2.89 109.63 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.4 ' CG2' ' CG2' ' A' ' 29' ' ' ILE . 96.9 t -79.01 124.82 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 120.294 -0.562 . . . . 1.01 110.062 179.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.95 -166.54 25.07 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.088 -1.205 . . . . 0.11 110.088 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.71 152.95 29.67 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.766 -0.843 . . . . 1.44 110.187 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 53.51 21.1 2.32 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.668 -0.645 . . . . 2.42 112.014 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.62 20.51 79.82 Favored Glycine 0 N--CA 1.5 2.907 0 C-N-CA 119.643 -1.265 . . . . 0.08 110.83 171.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.0 148.19 34.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.438 -1.036 . . . . 1.56 110.27 -177.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.4 p -138.74 145.97 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 N-CA-C 109.535 -0.543 . . . . 1.0 109.535 175.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.3 mm -110.81 122.73 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.561 -0.712 . . . . 1.04 110.709 -174.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 50.9 mt -78.38 144.62 66.5 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.567 -0.708 . . . . 1.05 109.465 172.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.0 Cg_endo -64.25 133.26 37.08 Favored 'Trans proline' 0 N--CA 1.495 1.582 0 O-C-N 122.879 0.936 . . . . 0.14 110.69 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -55.23 -34.23 63.79 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.482 -0.761 . . . . 2.75 110.788 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.71 -37.87 77.07 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.747 -0.596 . . . . 1.02 110.336 -178.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.4 mt -77.08 -32.71 56.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.748 -0.595 . . . . 1.03 110.475 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.4 mtt180 -57.67 -45.49 85.49 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.258 -0.901 . . . . 0.11 109.841 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.15 62.61 Favored 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 120.534 -0.467 . . . . 1.49 110.465 -175.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.55 -38.25 77.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.646 -0.659 . . . . 1.06 109.89 -178.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -82.63 -17.63 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.841 -0.537 . . . . 1.06 110.89 -176.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.6 35.29 36.93 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 109.814 -1.315 . . . . 0.17 109.814 175.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.3 mm -89.47 142.75 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.603 -0.94 . . . . 1.04 110.587 -174.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -129.09 157.47 75.82 Favored Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.829 -0.544 . . . . 3.0 110.7 -177.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -55.31 133.98 61.21 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 O-C-N 122.934 0.965 . . . . 0.82 111.287 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.95 0.23 71.88 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 111.191 -0.763 . . . . 0.15 111.191 175.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -97.48 134.42 40.75 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-N 118.677 1.239 . . . . 0.42 110.559 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -91.95 132.79 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-O 121.67 0.748 . . . . 0.97 111.173 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.5 pt -121.86 159.49 24.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 109.387 -0.597 . . . . 1.02 109.387 175.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -97.69 131.57 44.12 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.98 -0.748 . . . . 1.13 108.98 175.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.437 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 87.4 t -115.78 130.24 70.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 CA-C-O 121.324 0.583 . . . . 1.02 110.266 -170.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.5 mt -116.5 131.01 57.06 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.264 -0.643 . . . . 1.03 109.264 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.449 ' CD1' ' CE2' ' A' ' 27' ' ' TYR . 4.3 mt -80.28 141.6 35.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.415 -0.803 . . . . 1.02 109.971 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.47 -32.52 6.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.765 -0.585 . . . . 1.09 110.868 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.8 -178.31 40.24 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.738 -1.22 . . . . 0.14 111.014 -177.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -148.82 151.22 34.38 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.702 -0.881 . . . . 0.39 110.572 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -133.22 139.19 46.84 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.58 -0.7 . . . . 1.04 109.893 175.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 ttmt -123.05 149.93 58.19 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.689 -0.632 . . . . 4.05 110.442 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.28 148.51 60.49 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 O-C-N 123.262 1.138 . . . . 1.23 110.856 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 58.4 ttt85 -121.96 141.07 51.69 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.731 -0.606 . . . . 5.78 110.169 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 59.0 t30 . . . . . 0 N--CA 1.495 1.783 0 CA-C-O 117.999 -1.0 . . . . 4.86 110.192 -179.573 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.7 ttm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.015 0.436 . . . . 3.14 110.203 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.31 141.26 40.01 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.676 -0.64 . . . . 1.7 109.989 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p -127.43 140.53 48.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.747 -0.596 . . . . 1.16 109.78 178.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 30.7 mt -87.8 -18.0 30.32 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 120.238 -0.585 . . . . 1.16 110.662 -177.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.21 156.67 3.98 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.206 -0.934 . . . . 1.09 109.853 176.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -134.04 126.77 30.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.758 -0.589 . . . . 2.69 110.167 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.446 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 18.2 p90 -149.42 161.81 41.34 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.614 -0.679 . . . . 0.22 110.874 178.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.0 m-70 -111.54 137.89 48.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.574 -0.704 . . . . 2.35 110.141 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.48 162.33 41.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.69 -0.631 . . . . 1.03 109.748 177.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.4 t -111.5 159.28 18.24 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.535 -0.728 . . . . 1.03 109.996 176.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -78.73 136.44 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.816 -0.553 . . . . 1.16 110.191 -177.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -114.26 171.95 7.3 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.285 0.564 . . . . 1.04 109.651 174.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -46.5 151.95 0.5 Allowed 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.531 -0.731 . . . . 3.63 112.036 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 56.2 mt 62.52 7.93 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.651 0 O-C-N 121.547 -0.721 . . . . 1.12 112.585 -175.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.68 16.06 80.59 Favored Glycine 0 N--CA 1.497 2.738 0 O-C-N 120.934 -1.104 . . . . 0.26 110.432 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.2 ttt180 -84.49 142.51 30.0 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.256 -1.143 . . . . 2.55 110.134 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.2 pt -133.28 154.3 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.649 -0.657 . . . . 1.1 109.671 174.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.53 128.51 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.623 -0.673 . . . . 1.04 109.952 175.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 30.4 mt -79.99 144.34 59.08 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.986 -0.686 . . . . 1.05 109.437 175.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.31 143.23 88.67 Favored 'Trans proline' 0 N--CA 1.489 1.219 0 O-C-N 122.969 0.984 . . . . 0.38 109.772 175.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.58 -26.77 61.97 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 120.442 -0.503 . . . . 1.12 110.472 -178.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -44.21 95.47 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.965 -1.254 . . . . 0.42 109.965 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.3 m -69.82 -38.39 76.54 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.593 -0.945 . . . . 1.08 110.132 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.8 mtt180 -56.06 -40.49 73.63 Favored 'General case' 0 N--CA 1.513 2.687 0 O-C-N 121.337 -0.852 . . . . 0.49 109.378 176.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 84.7 tttt -65.27 -50.05 67.24 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.065 0.459 . . . . 3.4 110.164 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -57.72 -39.08 76.44 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 121.773 -0.579 . . . . 0.74 110.681 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.436 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 22.7 t80 -87.28 -14.2 41.58 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.789 -0.569 . . . . 1.76 111.258 -176.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.78 42.9 24.63 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.536 -1.425 . . . . 0.32 109.536 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.436 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.0 mt -87.41 127.22 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.497 -1.002 . . . . 1.15 110.532 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -128.23 159.39 35.35 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.098 -0.704 . . . . 1.82 109.098 170.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.41 138.71 54.66 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.403 -0.81 . . . . 2.7 110.486 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.74 -16.02 62.12 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.874 -0.89 . . . . 0.21 110.874 179.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -77.09 156.9 31.39 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 118.686 1.243 . . . . 1.12 110.148 177.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -111.36 138.69 47.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.682 -0.636 . . . . 0.24 109.648 174.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.81 153.32 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.709 -0.619 . . . . 1.06 109.34 174.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -116.32 123.01 46.57 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.331 -0.989 . . . . 1.09 108.331 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 6.4 tt -138.6 157.87 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.57 -0.852 . . . . 1.05 111.324 -166.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.89 143.34 50.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.865 -0.522 . . . . 1.77 110.156 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.7 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.553 -0.717 . . . . 1.06 110.551 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.6 t -138.89 127.57 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.756 -0.461 . . . . 1.03 109.756 177.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.0 tttm -133.68 148.36 51.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.701 -0.625 . . . . 2.39 109.633 173.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -101.47 129.21 47.47 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.156 -0.618 . . . . 0.91 110.129 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -137.57 134.75 35.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.675 -0.641 . . . . 1.48 110.226 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.09 45.66 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.686 -1.366 . . . . 0.46 109.686 -177.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.07 7.27 33.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.706 -0.879 . . . . 1.27 111.763 178.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -131.24 138.06 32.0 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 121.169 -0.957 . . . . 1.37 110.977 -178.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.47 144.89 29.25 Favored 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 122.717 0.851 . . . . 0.38 110.026 172.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 mttt -122.49 147.74 45.99 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.404 -0.81 . . . . 1.71 110.098 171.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -136.71 169.05 18.37 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 120.338 -0.545 . . . . 1.42 110.991 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.71 4.38 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.341 -1.503 . . . . 0.18 109.341 177.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -127.15 136.94 52.79 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 1.07 109.927 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.425 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.3 p90 -156.71 173.77 16.47 Favored 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 119.939 -0.704 . . . . 0.18 110.922 176.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.2 m -106.5 140.37 39.5 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.696 -0.627 . . . . 1.01 109.422 173.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.425 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.37 146.6 36.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.706 -0.621 . . . . 1.01 110.749 -175.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.66 145.24 24.7 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.855 -0.528 . . . . 2.71 109.617 175.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 89.9 t -79.44 125.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.356 0.598 . . . . 1.08 109.814 179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.66 -165.33 25.27 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.084 -1.206 . . . . 0.22 110.084 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -61.69 151.76 32.86 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.786 -0.832 . . . . 1.39 110.107 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 53.3 21.88 2.5 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.565 -0.709 . . . . 1.13 112.087 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.32 20.53 79.92 Favored Glycine 0 N--CA 1.5 2.923 0 C-N-CA 119.765 -1.207 . . . . 0.2 110.795 171.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.8 m -78.26 145.55 35.37 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.458 -1.025 . . . . 1.74 110.365 -176.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 9.0 p -139.27 147.77 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.773 -0.579 . . . . 1.04 109.721 175.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -108.7 123.68 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.525 -0.735 . . . . 1.12 110.658 -175.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.9 mt -78.64 143.02 62.37 Favored Pre-proline 0 N--CA 1.499 1.975 0 O-C-N 121.592 -0.692 . . . . 1.17 109.596 172.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.418 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.0 Cg_endo -64.28 134.21 41.16 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.914 0.955 . . . . 0.29 110.908 -178.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 36.0 tptt -54.98 -34.84 63.72 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.517 -0.739 . . . . 3.08 110.859 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.95 -38.16 78.4 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.765 -0.584 . . . . 1.16 110.313 -178.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.3 mt -77.16 -32.67 56.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.739 -0.601 . . . . 2.43 110.682 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.3 mtt180 -58.35 -46.1 86.91 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.281 -0.887 . . . . 3.27 109.769 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.52 65.24 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 120.481 -0.488 . . . . 1.68 110.44 -175.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 97.3 t -60.59 -38.82 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.685 -0.634 . . . . 1.08 109.903 -178.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.8 mt -82.95 -16.32 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.821 -0.549 . . . . 1.08 111.063 -176.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.11 35.25 44.37 Favored Glycine 0 N--CA 1.498 2.794 0 N-CA-C 109.929 -1.268 . . . . 0.23 109.929 176.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.4 mm -89.33 145.83 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.522 -0.987 . . . . 1.42 110.777 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmt -134.46 162.99 54.39 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.849 -0.532 . . . . 3.68 110.454 -178.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -57.42 134.09 61.3 Favored 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 122.896 0.945 . . . . 0.8 111.137 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 0.98 67.38 Favored Glycine 0 N--CA 1.496 2.675 0 C-N-CA 120.676 -0.773 . . . . 0.26 111.343 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -94.1 129.87 40.49 Favored 'General case' 0 N--CA 1.501 2.102 0 CA-C-N 118.753 1.277 . . . . 1.11 110.322 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.1 132.74 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 CA-C-O 121.616 0.722 . . . . 1.06 111.174 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.6 pt -124.33 159.49 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 109.451 -0.574 . . . . 1.06 109.451 176.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.5 tt0 -97.83 132.1 43.73 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.088 -0.708 . . . . 1.14 109.088 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.445 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 98.7 t -115.04 128.83 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 121.347 0.594 . . . . 1.05 110.143 -171.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.8 mt -115.37 128.8 56.32 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.186 -0.672 . . . . 1.08 109.186 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.42 HD22 ' CE2' ' A' ' 27' ' ' TYR . 4.6 mt -79.38 140.4 37.46 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.431 -0.793 . . . . 1.11 109.729 172.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.71 -32.24 7.16 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.718 -0.614 . . . . 2.19 110.971 -176.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.8 -179.07 40.23 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.674 -1.25 . . . . 0.25 110.985 -176.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.0 p80 -142.96 150.47 39.75 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.746 -0.855 . . . . 2.53 110.658 -177.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -134.41 139.67 45.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.586 -0.696 . . . . 1.1 110.045 175.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 tttm -105.16 144.6 29.1 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.73 -0.606 . . . . 3.48 110.214 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -55.37 144.22 73.28 Favored 'Trans proline' 0 N--CA 1.497 1.68 0 O-C-N 123.197 1.104 . . . . 2.02 110.998 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 44.7 ptt85 -136.1 158.26 44.84 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.735 -0.603 . . . . 7.62 110.419 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 . . . . . 0 N--CA 1.504 2.256 0 CA-C-O 118.039 -0.981 . . . . 7.16 110.956 -179.84 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.8 mtp . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.271 0.558 . . . . 3.14 110.529 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.99 142.68 38.13 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.843 -0.536 . . . . 1.7 110.023 178.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -128.06 140.28 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.779 -0.575 . . . . 1.16 109.758 177.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 mt -86.91 -20.87 26.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.85 -0.531 . . . . 1.16 110.464 -178.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.06 157.23 4.28 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.363 -0.836 . . . . 1.09 109.685 176.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -132.87 126.67 32.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.715 -0.615 . . . . 2.69 110.223 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.45 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 19.6 p90 -149.27 162.48 39.95 Favored 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 120.143 -0.623 . . . . 0.22 110.665 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.59 138.18 50.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.548 -0.72 . . . . 2.35 110.286 -176.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.37 40.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.797 -0.564 . . . . 1.03 109.543 177.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.05 160.35 16.94 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 119.812 -0.755 . . . . 1.03 110.107 177.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.4 t -79.06 136.13 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 C-N-CA 120.329 -0.548 . . . . 1.16 110.318 -176.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -116.2 172.04 7.43 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.24 0.543 . . . . 1.04 109.58 174.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -46.21 152.47 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.543 -0.723 . . . . 3.63 112.048 -175.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.1 mt 62.76 7.32 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.703 0 O-C-N 121.622 -0.674 . . . . 1.12 112.593 -175.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.07 80.67 Favored Glycine 0 N--CA 1.496 2.635 0 O-C-N 120.857 -1.152 . . . . 0.26 110.438 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttp180 -84.63 145.06 28.2 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.292 -1.123 . . . . 2.55 110.191 -177.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 45.1 pt -132.58 155.78 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 N-CA-C 109.315 -0.624 . . . . 1.1 109.315 172.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.1 mm -115.82 128.18 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 C-N-CA 120.034 -0.666 . . . . 1.04 109.904 176.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 33.7 mt -79.58 143.83 59.88 Favored Pre-proline 0 N--CA 1.495 1.794 0 C-N-CA 120.052 -0.659 . . . . 1.05 109.435 176.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.08 143.08 89.79 Favored 'Trans proline' 0 N--CA 1.489 1.231 0 O-C-N 122.989 0.994 . . . . 0.38 109.845 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.62 -26.9 62.24 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.882 -0.511 . . . . 1.12 110.52 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.06 95.61 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.951 -1.26 . . . . 0.42 109.951 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.9 m -69.94 -38.38 76.15 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.585 -0.95 . . . . 1.08 110.116 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -55.87 -40.81 73.47 Favored 'General case' 0 N--CA 1.512 2.664 0 O-C-N 121.286 -0.884 . . . . 0.49 109.429 176.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -65.75 -50.07 66.11 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.1 0.476 . . . . 3.4 110.212 -177.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -57.6 -39.67 77.34 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.707 -0.621 . . . . 0.74 110.756 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.438 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 20.0 t80 -87.69 -14.29 40.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.774 -0.579 . . . . 1.76 111.275 -176.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.87 42.52 25.19 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.576 -1.409 . . . . 0.32 109.576 178.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.438 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.2 mt -87.74 125.55 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.543 -0.975 . . . . 1.15 110.445 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.55 159.94 33.07 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.235 -0.654 . . . . 1.82 109.235 172.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -57.27 138.19 55.06 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.33 -0.856 . . . . 2.7 110.557 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.81 -16.09 61.99 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 110.832 -0.907 . . . . 0.21 110.832 178.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -77.23 155.96 31.79 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.693 1.246 . . . . 1.12 109.998 177.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -111.27 138.78 47.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.6 -0.688 . . . . 0.24 109.492 174.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 155.06 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.199 -0.6 . . . . 1.06 109.386 174.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.99 122.55 45.58 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.198 -1.038 . . . . 1.09 108.198 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.7 tt -139.15 158.22 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.596 -0.841 . . . . 1.05 110.936 -167.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -133.15 145.62 50.83 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.859 -0.525 . . . . 1.77 110.505 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 pt -114.93 151.13 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.648 -0.657 . . . . 1.06 110.604 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t -138.67 127.93 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 121.174 0.512 . . . . 1.03 109.72 176.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 33.3 tptt -137.82 147.13 44.29 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.83 -0.544 . . . . 2.39 109.632 175.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -101.99 128.9 48.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.266 -0.574 . . . . 0.91 110.384 -176.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -131.92 132.86 43.95 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.676 -0.64 . . . . 1.48 109.974 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.89 -128.23 45.95 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 109.768 -1.333 . . . . 0.46 109.768 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -105.19 12.57 31.8 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.677 -0.896 . . . . 1.27 111.608 177.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -131.17 127.6 21.94 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.255 -0.903 . . . . 1.37 110.991 -177.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -75.3 139.41 23.5 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 O-C-N 122.743 0.865 . . . . 0.38 109.994 173.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 37.1 mttp -118.71 151.75 37.41 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.498 -0.751 . . . . 1.71 110.309 173.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -140.03 169.09 18.34 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-O 121.216 0.532 . . . . 1.42 110.737 -178.373 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.61 135.9 4.47 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.428 -1.469 . . . . 0.18 109.428 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -122.64 137.48 54.89 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.629 -0.924 . . . . 1.07 109.847 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.42 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 13.7 p90 -156.14 173.1 17.32 Favored 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.899 -0.721 . . . . 0.18 110.901 176.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.06 141.31 38.5 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.669 -0.644 . . . . 1.01 109.493 173.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.42 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 145.51 35.19 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.675 -0.641 . . . . 1.01 110.695 -175.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -93.68 146.0 24.15 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.855 -0.528 . . . . 2.71 109.626 175.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.15 125.45 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.778 -0.576 . . . . 1.08 109.919 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.33 -167.08 25.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.944 -1.262 . . . . 0.22 109.944 178.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.68 152.93 29.58 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.79 -0.829 . . . . 1.39 110.138 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.28 21.4 2.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.652 -0.655 . . . . 1.13 112.095 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.1 20.6 79.66 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.684 -1.246 . . . . 0.2 110.832 171.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.0 m -77.96 144.56 36.67 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.388 -1.066 . . . . 1.74 110.343 -176.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.64 146.51 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.881 -0.512 . . . . 1.04 109.684 175.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -110.53 123.21 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.51 -0.744 . . . . 1.12 110.783 -175.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 70.5 mt -78.27 144.37 66.54 Favored Pre-proline 0 N--CA 1.498 1.938 0 O-C-N 121.637 -0.664 . . . . 1.17 109.494 172.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.41 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.9 Cg_endo -64.17 133.82 39.74 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 O-C-N 122.98 0.99 . . . . 0.29 110.796 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -55.21 -34.23 63.75 Favored 'General case' 0 N--CA 1.502 2.171 0 O-C-N 121.481 -0.762 . . . . 3.08 110.768 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.84 -37.99 77.7 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.797 -0.564 . . . . 1.16 110.275 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -77.13 -32.66 56.56 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 120.151 -0.62 . . . . 2.43 110.593 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.01 -46.33 85.44 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.349 -0.844 . . . . 3.27 109.771 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.91 -46.51 65.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 120.543 -0.463 . . . . 1.68 110.401 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.5 t -60.58 -38.81 79.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.692 -0.63 . . . . 1.08 109.843 -178.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -82.64 -16.63 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.845 -0.535 . . . . 1.08 111.083 -176.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.24 35.18 43.86 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 109.878 -1.289 . . . . 0.23 109.878 176.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.2 mm -90.6 142.86 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.056 0 O-C-N 121.519 -0.989 . . . . 1.42 110.63 -174.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.0 ptmt -130.27 162.35 54.83 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.801 -0.562 . . . . 3.68 110.644 -178.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.51 135.55 68.37 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 O-C-N 122.946 0.971 . . . . 0.8 110.919 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.61 -0.35 70.51 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.612 -0.804 . . . . 0.26 111.264 176.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -94.73 130.29 41.31 Favored 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 118.741 1.271 . . . . 1.11 109.849 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.92 129.9 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 121.527 0.679 . . . . 1.06 110.809 -175.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 45.7 pt -118.79 159.39 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 109.418 -0.586 . . . . 1.06 109.418 177.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -97.91 131.91 43.96 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.017 -0.735 . . . . 1.14 109.017 174.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 90.9 t -116.2 129.72 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.355 0.598 . . . . 1.05 110.301 -170.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.6 mt -115.85 130.11 56.7 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 109.208 -0.664 . . . . 1.08 109.208 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.419 HD21 ' CE2' ' A' ' 27' ' ' TYR . 5.3 mt -80.29 140.55 36.13 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.345 -0.847 . . . . 1.11 109.803 172.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.8 mt -111.37 -33.1 6.51 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.649 -0.657 . . . . 2.19 110.97 -176.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.21 -175.79 38.14 Favored Glycine 0 N--CA 1.504 3.181 0 C-N-CA 119.689 -1.244 . . . . 0.25 111.089 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -144.25 154.26 42.9 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.728 -0.866 . . . . 2.53 110.624 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -141.05 147.95 39.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 1.1 110.21 176.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 10.2 pttt -123.77 154.85 67.21 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.621 -0.674 . . . . 3.48 110.253 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -56.38 140.79 89.28 Favored 'Trans proline' 0 N--CA 1.496 1.639 0 O-C-N 123.182 1.096 . . . . 2.02 110.868 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -73.34 146.77 44.99 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.706 -0.621 . . . . 7.62 110.121 178.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 43.5 p-10 . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.044 -0.979 . . . . 7.16 110.342 179.829 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.0 ttp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 120.995 0.426 . . . . 3.14 110.196 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -75.79 144.29 41.46 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.76 -0.587 . . . . 1.7 110.025 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.1 p -127.75 137.82 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.75 -0.594 . . . . 1.16 109.626 178.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 34.6 mt -86.67 -18.5 31.12 Favored 'General case' 0 N--CA 1.496 1.827 0 C-N-CA 120.164 -0.614 . . . . 1.16 110.574 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.69 155.69 3.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.251 -0.905 . . . . 1.09 109.518 175.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.8 tttt -134.76 124.66 25.54 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.696 -0.627 . . . . 2.69 110.117 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.448 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.0 p90 -150.82 163.66 38.09 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.621 -0.674 . . . . 0.22 110.898 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -114.05 138.0 50.97 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.623 -0.673 . . . . 2.35 110.34 -177.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.39 162.31 41.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.66 -0.65 . . . . 1.03 109.648 177.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -109.64 160.47 16.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.367 -0.833 . . . . 1.03 110.264 177.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -78.92 137.37 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.843 -0.536 . . . . 1.16 110.289 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.82 171.97 7.55 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.286 0.565 . . . . 1.04 109.628 174.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.1 mtt-85 -46.37 152.54 0.43 Allowed 'General case' 0 N--CA 1.506 2.354 0 O-C-N 121.509 -0.745 . . . . 3.63 111.999 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.8 mt 62.62 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.673 0 O-C-N 121.536 -0.727 . . . . 1.12 112.604 -175.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.78 16.1 80.45 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.901 -1.125 . . . . 0.26 110.335 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.9 ttp180 -85.16 144.85 27.93 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.269 -1.136 . . . . 2.55 110.28 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 pt -133.3 154.76 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.706 -0.621 . . . . 1.1 109.398 172.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.2 mm -116.7 127.77 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.563 -0.711 . . . . 1.04 110.034 176.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 38.2 mt -79.9 144.18 59.16 Favored Pre-proline 0 N--CA 1.495 1.824 0 C-N-CA 120.087 -0.645 . . . . 1.05 109.479 176.05 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.38 143.52 88.87 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 122.927 0.961 . . . . 0.38 109.724 174.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.56 61.28 Favored 'General case' 0 N--CA 1.497 1.895 0 C-N-CA 120.391 -0.523 . . . . 1.12 110.56 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.55 -44.5 95.03 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.848 -1.301 . . . . 0.42 109.848 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.1 m -69.94 -38.13 76.07 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.662 -0.905 . . . . 1.08 110.09 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -55.89 -40.61 73.24 Favored 'General case' 0 N--CA 1.514 2.741 0 O-C-N 121.26 -0.9 . . . . 0.49 109.385 176.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -64.95 -49.78 69.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.184 0.516 . . . . 3.4 110.133 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -57.24 -38.45 73.83 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.704 -0.622 . . . . 0.74 110.727 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.443 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 20.8 t80 -88.09 -14.43 38.87 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.756 -0.59 . . . . 1.76 111.216 -177.037 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.77 42.81 24.91 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.529 -1.429 . . . . 0.32 109.529 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.443 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.6 mt -87.26 128.32 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.481 -1.011 . . . . 1.15 110.644 -176.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -127.85 158.85 36.63 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.115 -0.698 . . . . 1.82 109.115 170.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -57.3 138.51 54.72 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.329 -0.857 . . . . 2.7 110.522 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.88 -15.89 62.44 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 110.873 -0.891 . . . . 0.21 110.873 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -76.95 155.61 32.59 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-N 118.71 1.255 . . . . 1.12 110.0 177.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.414 ' CD1' ' HG3' ' A' ' 90' ' ' PRO . 76.3 m-85 -110.72 138.83 46.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.636 -0.665 . . . . 0.24 109.646 174.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.57 154.05 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.262 -0.644 . . . . 1.06 109.262 175.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -115.45 123.42 48.54 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.279 -1.008 . . . . 1.09 108.279 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.4 tt -139.87 158.45 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 C-N-CA 119.69 -0.804 . . . . 1.05 110.861 -167.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.6 ttpt -133.03 146.06 51.38 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.767 -0.583 . . . . 1.77 110.577 177.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.8 pt -114.88 151.07 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.63 -0.669 . . . . 1.06 110.333 177.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.4 t -138.92 125.04 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-O 121.133 0.492 . . . . 1.03 109.71 176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 39.1 tptt -135.17 147.58 49.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.763 -0.585 . . . . 2.39 109.655 177.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -106.15 129.88 54.14 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 120.233 -0.587 . . . . 0.91 110.33 -177.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -138.25 138.15 38.19 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.585 -0.697 . . . . 1.48 110.238 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.75 -128.13 45.93 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.891 -1.284 . . . . 0.46 109.891 -178.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.24 7.18 33.44 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.763 -0.845 . . . . 1.27 111.851 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -131.27 138.54 33.06 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.181 -0.949 . . . . 1.37 111.17 -177.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.45 142.43 26.52 Favored 'Trans proline' 0 N--CA 1.482 0.82 0 O-C-N 122.861 0.927 . . . . 0.38 110.108 172.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 22.8 mmtt -117.62 137.31 52.71 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.522 -0.736 . . . . 1.71 109.716 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -135.05 166.4 23.14 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.662 -0.649 . . . . 1.42 110.747 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.64 4.34 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.53 -1.428 . . . . 0.18 109.53 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.03 136.43 54.83 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.711 -0.876 . . . . 1.07 109.73 176.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.1 p90 -155.43 173.29 16.88 Favored 'General case' 0 N--CA 1.497 1.899 0 C-N-CA 119.956 -0.698 . . . . 0.18 111.014 178.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.0 140.57 39.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.619 -0.675 . . . . 1.01 109.525 173.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.86 146.5 35.89 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.709 -0.619 . . . . 1.01 110.613 -175.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -93.48 145.18 24.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.757 -0.589 . . . . 2.71 109.766 175.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.2 t -79.5 125.95 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.744 -0.597 . . . . 1.08 109.908 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.05 -167.37 25.96 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.992 -1.243 . . . . 0.22 109.992 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -61.68 153.45 28.12 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.67 -0.9 . . . . 1.39 110.148 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 53.71 21.09 2.48 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.53 -0.731 . . . . 1.13 111.984 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.14 20.55 79.98 Favored Glycine 0 N--CA 1.499 2.853 0 C-N-CA 119.804 -1.188 . . . . 0.2 110.876 171.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 12.4 t -78.64 144.62 35.24 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.455 -1.027 . . . . 1.74 110.294 -176.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.43 145.79 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 N-CA-C 109.577 -0.527 . . . . 1.04 109.577 175.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.1 mm -111.39 123.84 67.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.546 -0.721 . . . . 1.12 110.685 -175.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.2 mt -78.16 145.0 68.14 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.602 -0.686 . . . . 1.17 109.458 172.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.405 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -64.14 134.45 42.63 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 O-C-N 122.957 0.977 . . . . 0.29 110.68 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -55.21 -34.28 63.79 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.437 -0.789 . . . . 3.08 110.797 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -37.8 77.39 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.659 -0.651 . . . . 1.16 110.322 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.2 mt -77.12 -32.7 56.65 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.18 -0.608 . . . . 2.43 110.579 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.7 mtt180 -57.94 -46.1 85.57 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.297 -0.877 . . . . 3.27 109.944 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.01 63.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.52 -0.472 . . . . 1.68 110.385 -175.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.59 -38.18 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.678 -0.639 . . . . 1.08 109.943 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -82.22 -18.12 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.855 -0.528 . . . . 1.08 110.817 -176.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.92 35.05 40.49 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.648 -1.381 . . . . 0.23 109.648 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.4 mm -91.69 142.58 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.592 -0.946 . . . . 1.42 110.549 -174.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.67 161.41 61.16 Favored Pre-proline 0 N--CA 1.498 1.944 0 O-C-N 121.782 -0.574 . . . . 3.68 110.735 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.49 137.31 79.64 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.937 0.967 . . . . 0.8 111.033 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.08 72.33 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 111.166 -0.774 . . . . 0.26 111.166 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -94.17 130.17 40.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-N 118.692 1.246 . . . . 1.11 110.202 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.74 128.86 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 CA-C-O 121.444 0.64 . . . . 1.06 110.759 -175.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 47.9 pt -118.3 159.43 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 109.459 -0.571 . . . . 1.06 109.459 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.4 tt0 -97.95 129.96 44.83 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.909 -0.774 . . . . 1.14 108.909 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.448 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 94.7 t -115.18 129.29 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.288 0.566 . . . . 1.05 110.303 -170.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.7 mt -115.66 128.43 55.9 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 109.167 -0.679 . . . . 1.08 109.167 179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.418 HD21 ' CE2' ' A' ' 27' ' ' TYR . 5.2 mt -79.78 138.5 37.28 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.39 -0.819 . . . . 1.11 109.542 171.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -109.91 -31.29 7.46 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.723 -0.611 . . . . 2.19 110.968 -174.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.12 -177.33 39.25 Favored Glycine 0 N--CA 1.503 3.12 0 C-N-CA 119.672 -1.251 . . . . 0.25 111.039 -177.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -143.54 152.43 41.43 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.707 -0.878 . . . . 2.53 110.648 -177.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -133.75 138.88 46.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.468 -0.77 . . . . 1.1 110.356 176.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.0 mttt -115.74 110.1 44.75 Favored Pre-proline 0 N--CA 1.495 1.801 0 O-C-N 121.832 -0.543 . . . . 3.48 110.161 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.414 ' HG3' ' CD1' ' A' ' 34' ' ' PHE . 85.1 Cg_exo -54.33 146.82 49.1 Favored 'Trans proline' 0 N--CA 1.499 1.802 0 O-C-N 123.033 1.018 . . . . 2.02 111.165 -179.658 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.4 ttt180 -123.48 141.94 51.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.714 -0.616 . . . . 7.62 110.154 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 47.8 t30 . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 118.038 -0.982 . . . . 7.16 110.18 -179.862 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.7 mtp . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.308 0.575 . . . . 3.14 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -73.35 146.91 44.86 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.776 -0.577 . . . . 1.7 109.973 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.2 p -128.15 135.78 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 O-C-N 121.815 -0.553 . . . . 1.16 109.595 178.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 24.7 mt -82.51 -20.85 35.93 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.816 -0.553 . . . . 1.16 110.195 179.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -170.69 152.56 3.81 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.459 -0.776 . . . . 1.09 109.199 175.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.6 tttt -133.92 125.1 27.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.69 110.293 -175.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.45 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.6 p90 -150.99 162.55 40.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.651 -0.655 . . . . 0.22 110.925 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.4 m-70 -111.94 138.49 48.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.582 -0.698 . . . . 2.35 110.188 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.59 162.34 41.15 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.694 -0.629 . . . . 1.03 109.701 177.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.3 t -110.83 160.21 16.96 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.461 -0.774 . . . . 1.03 109.83 176.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.402 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 61.4 t -77.65 137.47 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.754 -0.591 . . . . 1.16 110.169 -177.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.3 m80 -116.14 171.99 7.45 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.66 -0.496 . . . . 1.04 109.66 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -46.02 151.53 0.47 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.639 -0.663 . . . . 3.63 112.122 -174.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.5 mt 62.74 7.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.606 -0.684 . . . . 1.12 112.639 -175.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.96 80.63 Favored Glycine 0 N--CA 1.498 2.801 0 N-CA-C 110.322 -1.111 . . . . 0.26 110.322 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -85.34 145.52 27.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 2.55 110.211 -177.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -134.36 154.68 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.626 -0.671 . . . . 1.1 109.476 172.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -117.19 127.99 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.57 -0.706 . . . . 1.04 110.031 176.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.25 144.98 59.15 Favored Pre-proline 0 N--CA 1.496 1.834 0 C-N-CA 120.038 -0.665 . . . . 1.05 109.491 175.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -63.44 143.44 88.34 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 O-C-N 123.023 1.012 . . . . 0.38 109.776 174.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.39 -26.57 61.27 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.845 -0.534 . . . . 1.12 110.495 -178.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.45 -44.37 95.36 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.932 -1.267 . . . . 0.42 109.932 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 83.9 m -70.22 -38.0 75.16 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.592 -0.946 . . . . 1.08 110.13 -179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -55.86 -41.23 74.04 Favored 'General case' 0 N--CA 1.514 2.775 0 O-C-N 121.263 -0.898 . . . . 0.49 109.342 176.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -65.41 -49.24 69.95 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.048 0.451 . . . . 3.4 110.287 -178.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.34 -38.42 74.07 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.787 -0.57 . . . . 0.74 110.781 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.428 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 22.9 t80 -87.58 -14.22 40.74 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.817 -0.552 . . . . 1.76 111.257 -177.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.12 42.79 23.24 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.522 -1.431 . . . . 0.32 109.522 178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.412 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.0 mt -87.44 129.67 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.511 -0.993 . . . . 1.15 110.574 -177.163 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.42 155.46 43.62 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 109.077 -0.712 . . . . 1.82 109.077 171.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -55.45 137.44 48.27 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.256 -0.903 . . . . 2.7 110.794 -177.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.69 -14.66 64.91 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.91 -0.876 . . . . 0.21 110.91 178.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -76.26 155.55 34.25 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 118.848 1.324 . . . . 1.12 109.907 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -109.33 138.24 45.98 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.518 -0.739 . . . . 0.24 109.508 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.73 154.85 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.263 -0.643 . . . . 1.06 109.263 175.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -115.95 122.95 46.79 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.277 -1.008 . . . . 1.09 108.277 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.405 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 13.1 tt -139.37 157.83 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.7 -0.8 . . . . 1.05 110.87 -167.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -132.83 146.03 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.814 -0.554 . . . . 1.77 110.518 178.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.3 pt -114.95 150.93 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.663 -0.648 . . . . 1.06 110.51 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.18 126.54 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-O 121.085 0.469 . . . . 1.03 109.765 176.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 47.1 tttp -133.35 146.33 51.2 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.798 -0.564 . . . . 2.39 109.57 174.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -105.43 126.38 52.05 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.133 -0.627 . . . . 0.91 110.151 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -139.71 141.21 36.94 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.664 . . . . 1.48 110.408 178.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.22 46.01 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.731 -1.348 . . . . 0.46 109.731 -177.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -105.08 5.25 32.29 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.734 -0.862 . . . . 1.27 111.872 178.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.3 140.32 38.14 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.097 -1.002 . . . . 1.37 111.262 -176.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -75.44 138.28 21.82 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 O-C-N 122.864 0.928 . . . . 0.38 109.992 171.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -111.97 137.65 49.68 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.529 -0.732 . . . . 1.71 109.583 172.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.17 164.86 26.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.582 -0.698 . . . . 1.42 110.773 -175.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.26 135.94 4.42 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.58 -1.408 . . . . 0.18 109.58 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.2 m -123.28 137.39 54.87 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.733 -0.863 . . . . 1.07 109.695 176.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.9 p90 -156.23 173.09 17.36 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.845 -0.742 . . . . 0.18 111.037 176.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.6 m -107.47 141.02 39.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.668 -0.645 . . . . 1.01 109.5 173.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.92 145.95 35.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.717 -0.614 . . . . 1.01 110.45 -176.038 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -93.72 144.23 25.59 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.749 -0.594 . . . . 2.71 109.687 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.1 t -78.82 125.98 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.267 0.556 . . . . 1.08 110.009 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.37 -169.9 25.81 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.848 -1.301 . . . . 0.22 109.848 177.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -61.81 155.82 22.13 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.707 -0.878 . . . . 1.39 109.913 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.06 19.34 2.71 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.486 -0.759 . . . . 1.13 112.018 -177.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.56 20.59 79.58 Favored Glycine 0 N--CA 1.499 2.839 0 C-N-CA 119.813 -1.184 . . . . 0.2 110.66 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 32.4 t -78.4 144.72 35.65 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.437 -1.037 . . . . 1.74 110.479 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.75 146.27 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 109.637 -0.505 . . . . 1.04 109.637 175.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -111.79 123.97 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.6 -0.688 . . . . 1.12 110.655 -175.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 68.7 mt -78.33 143.47 64.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.612 -0.68 . . . . 1.17 109.477 172.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.408 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.0 Cg_endo -64.79 136.81 50.92 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 O-C-N 122.982 0.991 . . . . 0.29 110.814 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.1 tptt -54.91 -34.46 63.14 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.395 -0.816 . . . . 3.08 110.714 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.46 79.15 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.789 -0.569 . . . . 1.16 110.287 -178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -77.18 -32.82 56.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.742 -0.599 . . . . 2.43 110.656 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -58.35 -45.24 88.56 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.265 -0.897 . . . . 3.27 109.91 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.14 -47.41 61.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.55 -0.46 . . . . 1.68 110.408 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.1 t -60.54 -38.08 77.1 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 121.666 -0.646 . . . . 1.08 109.845 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.1 mt -82.6 -17.74 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.84 -0.537 . . . . 1.08 110.829 -176.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.06 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.621 -1.392 . . . . 0.23 109.621 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.402 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 49.9 mm -93.71 141.86 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.558 -0.966 . . . . 1.42 110.728 -174.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.67 162.4 56.46 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.757 -0.589 . . . . 3.68 110.691 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -51.88 135.86 51.01 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.025 1.013 . . . . 0.8 111.807 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.08 -1.92 71.06 Favored Glycine 0 N--CA 1.497 2.702 0 C-N-CA 120.72 -0.752 . . . . 0.26 111.431 174.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -96.4 131.53 42.87 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-N 118.74 1.27 . . . . 1.11 110.64 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.26 132.95 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.607 0.718 . . . . 1.06 111.229 -173.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.6 pt -124.72 159.52 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.948 -0.47 . . . . 1.06 109.757 177.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.421 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 41.6 tt0 -97.59 130.94 44.59 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.0 t -114.41 129.48 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.803 -0.56 . . . . 1.05 110.207 -171.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.2 mt -118.09 128.78 55.07 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.113 -0.699 . . . . 1.08 109.113 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.42 HD12 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -79.79 140.45 36.87 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.305 -0.872 . . . . 1.11 109.757 172.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.49 -33.51 6.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.718 -0.614 . . . . 2.19 110.887 -175.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.63 -172.97 36.03 Favored Glycine 0 N--CA 1.502 3.094 0 C-N-CA 119.778 -1.201 . . . . 0.25 110.942 -176.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -142.88 159.0 43.07 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.706 -0.879 . . . . 2.53 110.655 -177.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 -141.92 147.36 36.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.683 . . . . 1.1 110.322 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -119.48 160.03 43.48 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.656 -0.653 . . . . 3.48 110.167 178.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -54.59 142.76 71.01 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 O-C-N 123.158 1.083 . . . . 2.02 111.02 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 15.7 tpt180 -127.54 141.44 51.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.725 -0.609 . . . . 7.62 110.259 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 33.7 t30 . . . . . 0 N--CA 1.503 2.197 0 CA-C-O 118.022 -0.989 . . . . 7.16 110.997 179.988 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mtm . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.2 0.524 . . . . 3.14 110.624 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -74.26 143.86 44.87 Favored 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 120.505 -0.478 . . . . 1.7 110.081 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 p -128.06 137.22 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.738 -0.601 . . . . 1.16 109.605 178.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.412 HD12 ' CE2' ' A' ' 27' ' ' TYR . 26.0 mt -84.16 -19.92 33.3 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.738 -0.601 . . . . 1.16 110.398 -179.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.32 153.93 3.76 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.362 -0.836 . . . . 1.09 109.427 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.6 tttt -133.75 125.24 28.11 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.679 -0.638 . . . . 2.69 110.128 -177.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.449 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.6 p90 -150.9 163.12 39.43 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.627 -0.67 . . . . 0.22 110.871 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.44 138.93 49.38 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.706 -0.621 . . . . 2.35 110.376 -176.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.28 162.3 41.15 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.653 -0.655 . . . . 1.03 109.717 177.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.2 t -111.4 159.69 17.78 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.427 -0.796 . . . . 1.03 109.917 175.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -77.56 138.64 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 120.302 -0.559 . . . . 1.16 110.275 -176.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -118.31 172.01 7.75 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.583 -0.525 . . . . 1.04 109.583 174.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -46.28 152.57 0.41 Allowed 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.574 -0.704 . . . . 3.63 112.014 -175.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.1 mt 62.75 7.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.607 0 O-C-N 121.58 -0.7 . . . . 1.12 112.61 -175.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.47 16.12 80.68 Favored Glycine 0 N--CA 1.497 2.7 0 O-C-N 120.901 -1.124 . . . . 0.26 110.327 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.8 ttp180 -84.88 145.96 27.54 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.294 -1.121 . . . . 2.55 110.247 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -133.08 154.85 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 109.284 -0.636 . . . . 1.1 109.284 171.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -115.1 128.04 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 120.039 -0.664 . . . . 1.04 110.054 176.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.0 mt -79.98 144.63 59.69 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.048 -0.661 . . . . 1.05 109.424 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -62.87 142.6 89.16 Favored 'Trans proline' 0 N--CA 1.488 1.2 0 O-C-N 122.971 0.985 . . . . 0.38 109.871 174.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.64 -27.36 62.74 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 120.401 -0.519 . . . . 1.12 110.478 -178.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.54 -43.99 95.78 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.902 -1.279 . . . . 0.42 109.902 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.2 m -70.12 -38.0 75.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.608 -0.937 . . . . 1.08 109.914 -179.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -55.82 -40.94 73.49 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 121.233 -0.917 . . . . 0.49 109.436 176.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -65.27 -50.08 67.14 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.14 0.495 . . . . 3.4 110.131 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.4 -38.43 74.28 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.786 -0.571 . . . . 0.74 110.756 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.428 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.5 t80 -87.4 -14.25 41.12 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.821 -0.549 . . . . 1.76 111.343 -176.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.93 42.76 24.28 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 109.581 -1.408 . . . . 0.32 109.581 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.418 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.5 mt -87.63 128.45 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.57 -0.959 . . . . 1.15 110.559 -177.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.95 158.38 38.01 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.943 -0.762 . . . . 1.82 108.943 170.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -57.4 140.18 51.04 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.342 -0.849 . . . . 2.7 110.465 -178.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -16.07 61.71 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.828 -0.909 . . . . 0.21 110.828 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.74 157.72 31.47 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.094 -1.239 . . . . 1.12 110.146 178.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -111.92 138.76 48.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.569 -0.707 . . . . 0.24 109.579 174.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 154.75 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 120.15 -0.62 . . . . 1.06 109.354 174.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -115.58 123.72 49.17 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.303 -0.999 . . . . 1.09 108.303 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.0 tt -139.9 158.79 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.754 -0.778 . . . . 1.05 110.982 -167.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.2 tttt -133.33 146.21 51.12 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.885 -0.509 . . . . 1.77 110.29 177.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 21.2 pt -114.82 150.94 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.716 -0.615 . . . . 1.06 110.302 178.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.99 123.84 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.181 0.515 . . . . 1.03 109.678 177.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 46.7 tttp -132.76 146.97 52.29 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.357 -0.609 . . . . 2.39 109.357 175.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -102.09 129.73 48.5 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.957 -0.697 . . . . 0.91 110.41 -178.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.21 134.43 40.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.682 -0.636 . . . . 1.48 110.048 178.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.9 -128.16 45.8 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.838 -1.305 . . . . 0.46 109.838 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 17.8 pt-20 -105.15 9.8 34.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.706 -0.879 . . . . 1.27 111.791 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.15 138.4 32.81 Favored Pre-proline 0 N--CA 1.498 1.936 0 O-C-N 121.301 -0.875 . . . . 1.37 110.961 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -75.18 138.7 22.94 Favored 'Trans proline' 0 N--CA 1.482 0.852 0 O-C-N 122.854 0.923 . . . . 0.38 110.298 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -109.48 137.72 46.9 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.554 -0.716 . . . . 1.71 109.456 172.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.6 163.22 30.62 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.62 -0.675 . . . . 1.42 110.93 -176.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.08 135.93 4.43 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.549 -1.421 . . . . 0.18 109.549 177.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.5 m -123.23 138.2 54.69 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.568 -0.96 . . . . 1.07 109.841 176.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 13.2 p90 -156.15 173.17 17.23 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.975 -0.69 . . . . 0.18 110.955 176.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -107.36 141.27 38.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.718 -0.614 . . . . 1.01 109.479 173.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.17 146.22 36.69 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 120.212 -0.595 . . . . 1.01 110.73 -175.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -93.01 145.13 24.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.811 -0.556 . . . . 2.71 109.59 175.195 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -79.47 125.8 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.827 -0.546 . . . . 1.08 109.779 179.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.1 -170.38 27.25 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.707 -1.357 . . . . 0.22 109.707 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -61.84 155.75 22.4 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.644 -0.915 . . . . 1.39 109.961 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 54.87 19.64 2.71 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.569 -0.707 . . . . 1.13 112.008 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.18 20.55 79.97 Favored Glycine 0 N--CA 1.499 2.837 0 C-N-CA 119.793 -1.194 . . . . 0.2 110.816 172.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.6 m -77.91 144.04 37.21 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.46 -1.024 . . . . 1.74 110.288 -176.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.22 145.93 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.751 -0.593 . . . . 1.04 109.596 175.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -111.4 123.17 67.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.541 -0.725 . . . . 1.12 110.699 -174.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 77.3 mt -78.62 143.87 64.07 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.532 -0.73 . . . . 1.17 109.429 172.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.413 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.1 Cg_endo -65.1 136.68 49.03 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 O-C-N 122.926 0.961 . . . . 0.29 110.757 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 43.2 tttm -55.07 -34.17 63.36 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.48 -0.763 . . . . 3.08 110.774 179.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.11 78.34 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.711 -0.618 . . . . 1.16 110.288 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -77.15 -32.76 56.52 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 120.208 -0.597 . . . . 2.43 110.519 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -58.29 -45.46 87.91 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.305 -0.872 . . . . 3.27 109.845 178.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.03 -46.53 64.87 Favored 'General case' 0 N--CA 1.496 1.857 0 C-N-CA 120.476 -0.489 . . . . 1.68 110.457 -175.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.7 t -60.45 -38.48 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 C-N-CA 120.168 -0.613 . . . . 1.08 109.945 -178.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.5 mt -82.56 -17.51 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.803 -0.561 . . . . 1.08 110.876 -177.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.69 35.13 41.54 Favored Glycine 0 N--CA 1.497 2.742 0 N-CA-C 109.768 -1.333 . . . . 0.23 109.768 176.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.0 mm -93.19 142.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.613 -0.934 . . . . 1.42 110.721 -174.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.49 162.17 57.69 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.724 -0.61 . . . . 3.68 110.309 178.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -56.51 138.11 83.16 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 O-C-N 122.817 0.904 . . . . 0.8 111.331 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 -2.63 71.83 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 120.696 -0.764 . . . . 0.26 111.24 176.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -96.62 131.9 42.81 Favored 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 118.715 1.258 . . . . 1.11 110.599 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.6 p -92.43 133.45 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 121.669 0.747 . . . . 1.06 111.244 -173.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.8 pt -124.59 159.49 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 109.507 -0.553 . . . . 1.06 109.507 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -98.88 132.24 44.37 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.029 -0.73 . . . . 1.14 109.029 175.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 92.8 t -115.9 131.6 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.754 -0.591 . . . . 1.05 110.363 -170.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.9 mt -117.94 129.55 55.68 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 109.269 -0.641 . . . . 1.08 109.269 179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.419 HD22 ' CE2' ' A' ' 27' ' ' TYR . 5.5 mt -80.05 142.26 35.09 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.398 -0.814 . . . . 1.11 109.798 171.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 15.6 mt -117.95 -26.72 6.36 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.701 -0.625 . . . . 2.19 111.117 -174.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.78 40.58 Favored Glycine 0 N--CA 1.504 3.195 0 C-N-CA 119.66 -1.257 . . . . 0.25 110.966 -176.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -146.45 150.76 36.24 Favored 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.669 -0.9 . . . . 2.53 110.597 -178.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -135.74 139.06 43.31 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.475 -0.766 . . . . 1.1 110.136 175.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.0 mttt -124.04 157.41 63.84 Favored Pre-proline 0 N--CA 1.494 1.773 0 O-C-N 121.716 -0.615 . . . . 3.48 110.175 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -56.1 144.77 78.77 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 O-C-N 123.22 1.116 . . . . 2.02 110.852 178.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -127.13 139.76 52.74 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.705 -0.622 . . . . 7.62 110.221 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 . . . . . 0 N--CA 1.505 2.312 0 CA-C-O 117.97 -1.014 . . . . 7.16 110.948 -179.98 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mtm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.246 0.545 . . . . 3.14 110.571 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -77.52 141.18 39.75 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.876 -0.515 . . . . 1.7 110.058 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.95 135.85 61.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.71 -0.619 . . . . 1.16 109.612 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.87 -20.79 34.84 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.298 -0.561 . . . . 1.16 110.312 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.52 153.68 3.56 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.423 -0.798 . . . . 1.09 109.272 176.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 tttt -134.04 125.98 29.22 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.732 -0.605 . . . . 2.69 110.177 -176.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.447 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.5 p90 -150.61 163.56 38.2 Favored 'General case' 0 N--CA 1.498 1.941 0 C-N-CA 120.052 -0.659 . . . . 0.22 110.957 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.424 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 91.7 m-70 -113.02 138.58 49.67 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.695 -0.628 . . . . 2.35 110.117 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.35 162.31 41.14 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.727 -0.608 . . . . 1.03 109.664 176.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -111.28 159.74 17.66 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.873 -0.731 . . . . 1.03 109.983 176.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.8 t -78.82 134.09 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.803 -0.56 . . . . 1.16 110.2 -177.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -113.77 171.89 7.31 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-O 121.214 0.53 . . . . 1.04 109.751 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -46.57 152.82 0.42 Allowed 'General case' 0 N--CA 1.507 2.412 0 O-C-N 121.663 -0.648 . . . . 3.63 111.996 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.2 mt 62.77 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.598 -0.689 . . . . 1.12 112.576 -175.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.42 16.11 80.73 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.906 -1.121 . . . . 0.26 110.332 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -85.57 143.99 28.16 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.231 -1.158 . . . . 2.55 110.418 -175.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.3 pt -133.68 154.49 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.701 -0.624 . . . . 1.1 109.616 172.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.2 mm -116.84 128.11 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.557 -0.715 . . . . 1.04 110.132 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 36.1 mt -80.04 144.86 59.82 Favored Pre-proline 0 N--CA 1.496 1.861 0 C-N-CA 120.026 -0.67 . . . . 1.05 109.415 175.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.37 143.35 88.58 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 122.893 0.944 . . . . 0.38 109.77 174.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.63 -26.49 61.65 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.416 -0.514 . . . . 1.12 110.499 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.47 95.14 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.894 -1.282 . . . . 0.42 109.894 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.2 m -69.97 -38.12 75.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.531 -0.982 . . . . 1.08 110.193 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.5 mtt180 -55.92 -40.94 73.83 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.23 -0.918 . . . . 0.49 109.454 176.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -65.61 -49.98 66.74 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.204 0.526 . . . . 3.4 110.215 -177.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -57.49 -37.72 73.42 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.689 -0.632 . . . . 0.74 110.668 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.424 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.3 t80 -87.67 -14.19 40.57 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.752 -0.593 . . . . 1.76 111.287 -176.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.91 42.87 24.05 Favored Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.587 -1.405 . . . . 0.32 109.587 178.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.407 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.1 mt -88.1 129.73 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.068 0 O-C-N 121.552 -0.969 . . . . 1.15 110.615 -176.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -127.9 158.71 37.06 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 109.079 -0.711 . . . . 1.82 109.079 170.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -57.34 137.68 55.79 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.333 -0.854 . . . . 2.7 110.636 -178.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.57 -14.49 65.21 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.9 -0.88 . . . . 0.21 110.9 178.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.19 156.9 33.23 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 118.857 1.328 . . . . 1.12 110.072 177.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -110.62 138.14 47.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.626 -0.671 . . . . 0.24 109.517 174.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.62 154.27 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.247 -0.649 . . . . 1.06 109.247 174.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.5 123.55 48.83 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.287 -1.005 . . . . 1.09 108.287 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.2 tt -140.09 157.16 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 119.611 -0.835 . . . . 1.05 110.953 -167.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -132.2 145.99 51.72 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.846 -0.534 . . . . 1.77 110.528 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 29.2 pt -115.3 151.14 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.726 -0.609 . . . . 1.06 110.584 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.4 t -138.51 125.76 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.264 0.554 . . . . 1.03 109.882 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.3 tptm -130.76 146.49 52.24 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.156 -0.683 . . . . 2.39 109.156 174.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -107.89 130.11 55.04 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.263 -0.575 . . . . 0.91 110.471 -178.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -133.91 129.84 36.91 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.658 -0.651 . . . . 1.48 110.138 177.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.23 45.97 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.826 -1.309 . . . . 0.46 109.826 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -105.12 14.62 28.88 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.716 -0.873 . . . . 1.27 111.649 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -131.14 126.69 21.65 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.296 -0.877 . . . . 1.37 111.009 -178.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.23 140.18 24.56 Favored 'Trans proline' 0 N--CA 1.483 0.859 0 O-C-N 122.725 0.855 . . . . 0.38 110.208 174.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 31.4 mmtt -114.69 137.73 51.56 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.564 -0.71 . . . . 1.71 109.617 173.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.65 164.18 28.09 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.675 -0.641 . . . . 1.42 110.775 -176.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.78 135.91 4.46 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.484 -1.446 . . . . 0.18 109.484 178.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -123.18 137.65 54.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.65 -0.912 . . . . 1.07 109.784 176.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 12.7 p90 -156.13 172.89 17.66 Favored 'General case' 0 N--CA 1.498 1.932 0 C-N-CA 119.833 -0.747 . . . . 0.18 111.014 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.4 m -107.32 140.74 39.76 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.705 -0.622 . . . . 1.01 109.499 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.7 145.21 34.61 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 1.01 110.585 -175.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -94.13 144.88 25.11 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.828 -0.545 . . . . 2.71 109.647 175.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.7 t -78.79 126.37 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.833 -0.542 . . . . 1.08 110.015 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.86 -165.95 25.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.123 -1.191 . . . . 0.22 110.123 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -61.68 152.07 31.95 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.771 -0.841 . . . . 1.39 110.201 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 73.7 mt-30 53.35 21.52 2.38 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.572 -0.705 . . . . 1.13 112.062 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.54 20.48 79.84 Favored Glycine 0 N--CA 1.5 2.906 0 C-N-CA 119.777 -1.201 . . . . 0.2 110.866 171.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.3 t -78.34 144.67 35.81 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.468 -1.019 . . . . 1.74 110.25 -177.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.34 146.28 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 N-CA-C 109.55 -0.537 . . . . 1.04 109.55 175.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.9 mm -110.68 122.78 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.609 -0.682 . . . . 1.12 110.566 -174.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.6 mt -78.72 142.61 61.47 Favored Pre-proline 0 N--CA 1.498 1.975 0 O-C-N 121.589 -0.694 . . . . 1.17 109.437 172.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.411 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.1 Cg_endo -64.35 133.93 39.7 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 O-C-N 122.915 0.955 . . . . 0.29 110.763 -179.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -55.28 -34.2 63.88 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.508 -0.745 . . . . 3.08 110.832 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.7 76.78 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.783 -0.573 . . . . 1.16 110.334 -178.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.3 mt -77.09 -32.73 56.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.779 -0.575 . . . . 2.43 110.521 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -57.76 -46.13 84.96 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.275 -0.891 . . . . 3.27 109.833 178.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -47.2 62.59 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.503 -0.479 . . . . 1.68 110.502 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.2 t -60.48 -38.22 77.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.708 -0.62 . . . . 1.08 109.962 -178.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.2 mt -82.58 -17.76 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.818 -0.551 . . . . 1.08 110.884 -176.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.64 35.11 41.9 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 109.726 -1.35 . . . . 0.23 109.726 176.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 49.9 mm -92.2 138.94 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.535 -0.979 . . . . 1.42 110.591 -174.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.4 mmtt -123.75 161.23 47.53 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.665 -0.647 . . . . 3.68 110.531 -176.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -60.39 135.61 62.52 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 122.951 0.974 . . . . 0.8 110.677 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.89 -0.48 73.08 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 111.139 -0.784 . . . . 0.26 111.139 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -97.17 132.95 42.44 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.063 -1.257 . . . . 1.11 110.44 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.78 132.27 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 121.504 0.668 . . . . 1.06 111.008 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.7 pt -119.59 159.42 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 109.531 -0.544 . . . . 1.06 109.531 176.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.424 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 46.9 tt0 -98.31 130.16 45.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.815 -0.809 . . . . 1.14 108.815 173.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 89.1 t -115.32 130.22 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-O 121.292 0.568 . . . . 1.05 110.27 -170.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 31.5 mt -116.71 129.53 56.18 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 109.136 -0.691 . . . . 1.08 109.136 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.411 HD11 ' CD2' ' A' ' 27' ' ' TYR . 5.8 mt -80.15 142.46 34.74 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.3 -0.875 . . . . 1.11 109.694 171.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.6 mt -119.5 -25.66 5.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.668 -0.645 . . . . 2.19 111.183 -174.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.41 -179.22 40.13 Favored Glycine 0 N--CA 1.503 3.16 0 C-N-CA 119.643 -1.265 . . . . 0.25 111.1 -177.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -146.96 152.91 39.41 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.669 -0.901 . . . . 2.53 110.571 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -139.38 144.41 38.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.538 -0.726 . . . . 1.1 110.159 176.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -114.34 154.97 46.35 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.622 -0.674 . . . . 3.48 110.268 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -56.04 142.48 85.56 Favored 'Trans proline' 0 N--CA 1.498 1.747 0 O-C-N 123.299 1.157 . . . . 2.02 110.89 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 -136.08 158.21 44.96 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.754 -0.591 . . . . 7.62 110.435 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 . . . . . 0 N--CA 1.503 2.187 0 CA-C-O 117.992 -1.004 . . . . 7.16 111.013 179.772 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.26 0.552 . . . . 3.14 110.516 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -75.82 149.41 37.89 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.882 -0.511 . . . . 1.7 109.964 178.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -128.01 137.36 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.731 -0.606 . . . . 1.16 109.566 178.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 35.3 mt -85.94 -20.12 29.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.781 -0.574 . . . . 1.16 110.523 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.68 156.16 3.47 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.301 -0.875 . . . . 1.09 109.436 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -134.26 124.2 25.51 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.777 -0.577 . . . . 2.69 110.104 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.45 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 16.6 p90 -150.28 162.61 40.17 Favored 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 120.006 -0.678 . . . . 0.22 111.047 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.418 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 92.5 m-70 -112.39 138.57 48.93 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.582 -0.699 . . . . 2.35 110.074 -177.461 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.0 t -151.47 162.37 41.06 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.65 -0.656 . . . . 1.03 109.741 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.42 158.42 19.12 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.857 -0.737 . . . . 1.03 110.072 177.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.6 t -78.95 137.18 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 C-N-CA 120.279 -0.569 . . . . 1.16 110.323 -176.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.2 m80 -116.2 171.91 7.51 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.298 0.57 . . . . 1.04 109.734 174.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.5 ttt85 -46.92 153.02 0.45 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.492 -0.755 . . . . 3.63 111.76 -175.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.9 mt 62.93 6.93 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.684 0 O-C-N 121.507 -0.746 . . . . 1.12 112.636 -174.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.67 16.03 80.63 Favored Glycine 0 N--CA 1.496 2.64 0 O-C-N 120.789 -1.194 . . . . 0.26 110.294 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -84.94 144.48 28.31 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.317 -1.108 . . . . 2.55 110.352 -177.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -131.79 154.62 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.751 -0.593 . . . . 1.1 109.41 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.5 128.49 73.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.598 -0.689 . . . . 1.04 110.003 176.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 40.1 mt -79.99 145.42 61.24 Favored Pre-proline 0 N--CA 1.496 1.826 0 C-N-CA 119.968 -0.693 . . . . 1.05 109.39 175.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.48 143.42 88.09 Favored 'Trans proline' 0 N--CA 1.489 1.206 0 O-C-N 122.936 0.966 . . . . 0.38 109.706 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.48 61.47 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 120.41 -0.516 . . . . 1.12 110.496 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.61 -44.48 94.98 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.862 -1.295 . . . . 0.42 109.862 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 84.4 m -69.92 -38.11 76.12 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.599 -0.942 . . . . 1.08 110.16 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.2 mtt180 -56.0 -40.74 73.79 Favored 'General case' 0 N--CA 1.513 2.696 0 O-C-N 121.289 -0.882 . . . . 0.49 109.448 176.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -65.17 -50.06 67.41 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.086 0.469 . . . . 3.4 110.058 -177.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.26 -38.77 74.38 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.854 -0.529 . . . . 0.74 110.772 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.447 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 18.9 t80 -88.42 -14.29 38.37 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.753 -0.592 . . . . 1.76 111.163 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.9 42.59 24.85 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.497 -1.441 . . . . 0.32 109.497 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.447 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.2 mt -87.47 125.5 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.429 -1.042 . . . . 1.15 110.455 -177.037 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -128.17 155.35 44.62 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.996 -0.742 . . . . 1.82 108.996 171.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -55.5 140.15 41.43 Favored 'General case' 0 N--CA 1.503 2.179 0 O-C-N 121.289 -0.882 . . . . 2.7 110.576 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.82 -16.19 61.39 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.812 -0.915 . . . . 0.21 110.812 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -77.43 158.33 30.07 Favored 'General case' 0 N--CA 1.499 2.022 0 CA-C-N 118.72 1.26 . . . . 1.12 110.042 177.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -113.18 139.19 48.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.604 -0.685 . . . . 0.24 109.581 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.28 154.54 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.35 -0.611 . . . . 1.06 109.35 174.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.418 ' HB2' ' CE2' ' A' ' 88' ' ' TYR . 48.9 tt0 -116.0 123.62 48.46 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.219 -1.03 . . . . 1.09 108.219 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.7 tt -139.16 157.99 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 C-N-CA 119.588 -0.845 . . . . 1.05 111.213 -167.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.84 143.48 50.21 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.9 -0.5 . . . . 1.77 109.951 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 35.0 pt -114.91 150.99 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.593 -0.692 . . . . 1.06 110.527 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -138.4 123.19 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 CA-C-O 121.238 0.542 . . . . 1.03 109.721 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.2 tttm -130.98 147.1 52.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.191 -0.67 . . . . 2.39 109.191 174.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -102.37 130.97 49.27 Favored 'General case' 0 N--CA 1.496 1.873 0 C-N-CA 119.968 -0.693 . . . . 0.91 110.471 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -132.77 130.45 39.95 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.648 -0.657 . . . . 1.48 109.993 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.85 -128.08 45.68 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 109.79 -1.324 . . . . 0.46 109.79 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -105.14 11.57 33.01 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.733 -0.863 . . . . 1.27 111.653 177.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.0 pt-20 -131.16 136.29 28.55 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.231 -0.918 . . . . 1.37 110.815 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -75.16 141.18 25.89 Favored 'Trans proline' 0 N--CA 1.482 0.845 0 O-C-N 122.855 0.924 . . . . 0.38 110.529 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 19.2 mmtp -111.63 137.73 49.1 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.462 -0.774 . . . . 1.71 109.486 171.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.53 164.33 27.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.608 -0.682 . . . . 1.42 110.929 -176.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.03 135.78 4.37 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.536 -1.425 . . . . 0.18 109.536 177.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -127.55 137.05 52.5 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.793 -0.828 . . . . 1.07 109.791 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.0 p90 -156.57 173.94 16.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 119.883 -0.727 . . . . 0.18 110.916 177.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.4 m -106.94 140.74 39.26 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.407 -0.59 . . . . 1.01 109.407 173.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.425 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.1 146.18 36.76 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.608 -0.683 . . . . 1.01 110.69 -175.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -93.35 145.81 24.19 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 109.628 -0.508 . . . . 2.71 109.628 175.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 88.0 t -78.56 126.01 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.754 -0.591 . . . . 1.08 109.858 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.0 -167.34 26.0 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.982 -1.247 . . . . 0.22 109.982 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.64 153.23 28.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.782 -0.834 . . . . 1.39 110.151 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 53.51 21.12 2.34 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.579 -0.7 . . . . 1.13 112.099 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.54 79.89 Favored Glycine 0 N--CA 1.499 2.892 0 C-N-CA 119.716 -1.231 . . . . 0.2 110.921 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.6 p -78.28 147.11 34.45 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.445 -1.032 . . . . 1.74 110.262 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.82 145.99 26.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 109.548 -0.538 . . . . 1.04 109.548 175.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -110.73 123.37 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.446 -0.784 . . . . 1.12 110.738 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.3 mt -78.31 144.71 66.99 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.576 -0.703 . . . . 1.17 109.452 172.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.413 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.7 Cg_endo -64.67 135.89 47.23 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 122.929 0.963 . . . . 0.29 110.755 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.03 -34.36 63.44 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.499 -0.75 . . . . 3.08 110.759 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -38.04 77.92 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.757 -0.589 . . . . 1.16 110.317 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.1 mt -77.14 -32.79 56.58 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.734 -0.604 . . . . 2.43 110.475 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.09 -45.66 86.82 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.319 -0.863 . . . . 3.27 109.811 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.09 -47.25 62.64 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.515 -0.474 . . . . 1.68 110.463 -175.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.6 t -60.52 -38.34 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.116 0 O-C-N 121.726 -0.609 . . . . 1.08 109.916 -178.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -82.38 -17.65 11.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.886 -0.509 . . . . 1.08 110.917 -176.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.09 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.697 -1.361 . . . . 0.23 109.697 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.1 mm -91.39 142.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.564 -0.962 . . . . 1.42 110.707 -173.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.13 159.05 72.19 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.8 -0.562 . . . . 3.68 110.757 -178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -54.57 134.79 63.82 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 122.913 0.954 . . . . 0.8 111.414 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -0.94 72.17 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 120.696 -0.764 . . . . 0.26 111.27 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -97.19 133.28 42.04 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.058 -1.26 . . . . 1.11 110.552 179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.3 p -92.98 136.35 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 CA-C-O 121.835 0.826 . . . . 1.06 111.389 -174.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.89 159.59 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.247 -0.649 . . . . 1.06 109.247 177.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.418 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 52.4 tt0 -97.98 131.25 44.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.046 -0.724 . . . . 1.14 109.046 175.389 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.3 t -117.06 130.7 71.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 CA-C-O 121.438 0.637 . . . . 1.05 110.391 -170.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.8 mt -117.27 129.82 56.16 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.194 -0.669 . . . . 1.08 109.194 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.416 HD21 ' CE2' ' A' ' 27' ' ' TYR . 5.6 mt -80.08 140.75 36.33 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.36 -0.838 . . . . 1.11 109.903 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.7 mt -111.5 -30.47 7.37 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.672 -0.642 . . . . 2.19 111.011 -175.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.29 178.62 41.31 Favored Glycine 0 N--CA 1.505 3.254 0 C-N-CA 119.61 -1.281 . . . . 0.25 111.012 -176.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.408 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 30.1 p80 -140.81 145.63 36.55 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.783 -0.834 . . . . 2.53 109.99 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.418 ' CE2' ' HB2' ' A' ' 36' ' ' GLU . 18.3 m-85 -131.32 141.35 49.92 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.665 -0.647 . . . . 1.1 109.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -124.0 156.55 65.72 Favored Pre-proline 0 N--CA 1.495 1.789 0 O-C-N 121.714 -0.616 . . . . 3.48 110.075 178.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -56.01 139.54 85.03 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 O-C-N 123.208 1.11 . . . . 2.02 110.903 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 35.0 ptt-85 -136.12 158.29 44.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.707 -0.621 . . . . 7.62 110.433 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 58.8 t30 . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 117.979 -1.01 . . . . 7.16 110.244 -179.906 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.6 ttp . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.056 0.455 . . . . 3.14 110.153 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -73.2 143.17 47.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.69 -0.631 . . . . 1.7 110.088 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.6 p -127.71 136.61 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.651 -0.655 . . . . 1.16 109.519 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 28.7 mt -85.18 -18.72 33.24 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.221 -0.592 . . . . 1.16 110.246 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -174.79 151.83 1.48 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.214 -0.929 . . . . 1.09 109.045 176.042 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 17.5 ttpt -134.63 128.19 32.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.625 -0.672 . . . . 2.69 110.356 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.451 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.6 p90 -149.91 162.93 39.37 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.822 -0.549 . . . . 0.22 110.685 -177.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.422 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.1 m170 -112.58 137.63 50.53 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.662 -0.649 . . . . 2.35 110.144 -176.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.37 162.35 41.07 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.724 -0.61 . . . . 1.03 109.636 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.48 157.85 19.15 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 119.81 -0.756 . . . . 1.03 110.137 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.4 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 59.3 t -80.13 136.56 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 CA-C-O 121.276 0.56 . . . . 1.16 110.339 -176.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.3 m80 -113.98 171.96 7.28 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.229 0.538 . . . . 1.04 109.672 174.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.7 mtt85 -45.99 152.44 0.38 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.558 -0.714 . . . . 3.63 112.127 -175.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.0 mt 62.75 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.654 0 O-C-N 121.611 -0.68 . . . . 1.12 112.578 -175.057 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.48 16.06 80.74 Favored Glycine 0 N--CA 1.497 2.709 0 O-C-N 120.783 -1.198 . . . . 0.26 110.34 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -85.47 142.63 29.07 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -1.113 . . . . 2.55 110.234 -177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -133.12 156.54 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.728 -0.607 . . . . 1.1 109.695 174.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.52 129.16 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.65 -0.656 . . . . 1.04 109.957 176.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 28.2 mt -79.69 145.81 63.46 Favored Pre-proline 0 N--CA 1.495 1.814 0 C-N-CA 120.04 -0.664 . . . . 1.05 109.331 175.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -62.84 142.74 89.82 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 122.994 0.997 . . . . 0.38 109.848 174.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.27 62.93 Favored 'General case' 0 N--CA 1.497 1.885 0 C-N-CA 120.44 -0.504 . . . . 1.12 110.464 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -43.85 95.99 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 109.968 -1.253 . . . . 0.42 109.968 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 98.6 m -69.81 -38.53 76.63 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.559 -0.966 . . . . 1.08 109.958 -179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.0 mtt180 -56.03 -41.27 74.7 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.252 -0.905 . . . . 0.49 109.39 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -65.75 -50.14 65.84 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.111 0.481 . . . . 3.4 110.224 -177.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 82.2 t80 -57.47 -38.3 74.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.788 -0.57 . . . . 0.74 110.683 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.424 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 21.5 t80 -87.36 -14.16 41.49 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.739 -0.601 . . . . 1.76 111.3 -175.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.46 42.78 26.51 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.573 -1.411 . . . . 0.32 109.573 178.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.424 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.3 mt -88.38 128.48 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.522 -0.987 . . . . 1.15 110.556 -176.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -128.25 155.44 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 171.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -55.71 138.72 46.96 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 121.241 -0.912 . . . . 2.7 110.646 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.62 -15.98 62.15 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.868 -0.893 . . . . 0.21 110.868 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -77.16 158.18 30.53 Favored 'General case' 0 N--CA 1.499 1.997 0 CA-C-N 118.677 1.239 . . . . 1.12 110.11 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -112.09 138.94 48.05 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.594 -0.691 . . . . 0.24 109.62 174.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.48 154.11 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 N-CA-C 109.312 -0.625 . . . . 1.06 109.312 173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.98 123.57 48.35 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.277 -1.009 . . . . 1.09 108.277 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.7 tt -140.08 158.17 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.559 -0.856 . . . . 1.05 111.128 -167.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -133.04 146.1 51.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.799 -0.563 . . . . 1.77 110.418 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 27.5 pt -114.88 151.1 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.743 -0.598 . . . . 1.06 110.571 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -137.62 128.72 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 109.65 -0.5 . . . . 1.03 109.65 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -136.82 148.26 47.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.783 -0.573 . . . . 2.39 109.645 177.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -101.0 128.94 46.8 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.703 -0.623 . . . . 0.91 110.491 -178.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -133.66 133.18 41.59 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.589 -0.694 . . . . 1.48 110.149 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.79 -128.15 45.92 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.771 -1.332 . . . . 0.46 109.771 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.08 9.83 34.19 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.778 -0.836 . . . . 1.27 111.764 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.15 137.1 29.91 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.229 -0.919 . . . . 1.37 111.155 -177.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -75.57 145.38 29.5 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 O-C-N 122.778 0.883 . . . . 0.38 110.327 173.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.1 mttp -121.37 149.8 42.42 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.426 -0.796 . . . . 1.71 110.172 171.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.3 mp0 -136.99 166.96 22.43 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 120.22 -0.592 . . . . 1.42 110.995 -177.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.32 135.9 4.51 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.305 -1.518 . . . . 0.18 109.305 175.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.4 m -123.84 138.48 54.49 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.546 -0.973 . . . . 1.07 109.894 178.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.425 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 13.6 p90 -156.62 173.09 17.46 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 119.868 -0.733 . . . . 0.18 110.986 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.2 m -107.37 141.4 38.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.67 -0.644 . . . . 1.01 109.395 173.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.425 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.04 145.64 36.15 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.681 -0.637 . . . . 1.01 110.709 -175.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.1 ttt180 -93.51 145.13 24.74 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 109.573 -0.529 . . . . 2.71 109.573 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.06 125.05 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.223 0.535 . . . . 1.08 109.838 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.08 -164.91 24.86 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.135 -1.186 . . . . 0.22 110.135 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 33.4 tp10 -61.67 152.69 30.16 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.819 . . . . 1.39 110.013 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 53.43 21.04 2.23 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.59 -0.694 . . . . 1.13 112.043 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.69 79.96 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 119.732 -1.223 . . . . 0.2 110.842 172.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.6 p -77.92 147.12 35.17 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.45 -1.029 . . . . 1.74 110.365 -176.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.401 ' CG2' ' CB ' ' A' ' 54' ' ' ALA . 8.7 p -139.15 146.55 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.82 -0.55 . . . . 1.04 109.628 175.558 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -111.04 123.1 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.579 -0.701 . . . . 1.12 110.748 -175.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 86.7 mt -78.57 144.65 65.76 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.614 -0.679 . . . . 1.17 109.535 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.416 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.6 Cg_endo -64.13 133.27 37.45 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 O-C-N 122.873 0.933 . . . . 0.29 110.767 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.2 tttt -55.01 -34.45 63.46 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.551 -0.718 . . . . 3.08 110.831 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -38.22 77.89 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.737 -0.602 . . . . 1.16 110.275 -178.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 72.8 mt -76.99 -32.8 57.48 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 120.25 -0.58 . . . . 2.43 110.547 178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.8 mtt180 -57.93 -45.61 86.32 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.287 -0.883 . . . . 3.27 109.808 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.75 -46.67 65.34 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.479 -0.489 . . . . 1.68 110.307 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 98.8 t -60.72 -39.11 80.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.626 -0.671 . . . . 1.08 109.951 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.7 mt -83.65 -14.42 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.839 -0.538 . . . . 1.08 111.191 -176.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.67 35.38 40.87 Favored Glycine 0 N--CA 1.499 2.857 0 N-CA-C 110.169 -1.172 . . . . 0.23 110.169 175.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.4 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 51.3 mm -88.66 140.56 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.536 -0.979 . . . . 1.42 110.787 -174.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -131.38 162.62 54.88 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.782 -0.574 . . . . 3.68 110.606 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.88 134.82 59.26 Favored 'Trans proline' 0 N--CA 1.487 1.09 0 O-C-N 122.954 0.976 . . . . 0.8 110.858 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.97 0.91 70.84 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 120.639 -0.791 . . . . 0.26 111.234 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -96.87 133.7 41.15 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.019 -1.283 . . . . 1.11 110.498 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.08 133.22 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-O 121.584 0.706 . . . . 1.06 111.2 -175.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 45.4 pt -123.18 159.5 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 109.499 -0.556 . . . . 1.06 109.499 176.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.422 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 58.8 tt0 -97.35 131.52 43.94 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.986 -0.746 . . . . 1.14 108.986 174.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.451 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 96.2 t -116.08 128.46 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.438 0.637 . . . . 1.05 110.222 -171.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.4 mt -115.45 128.75 56.24 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 109.466 -0.568 . . . . 1.08 109.466 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.411 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.52 140.8 37.13 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.451 -0.781 . . . . 1.11 109.948 172.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.43 -32.31 6.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.791 -0.568 . . . . 2.19 110.828 -176.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.19 -177.19 39.19 Favored Glycine 0 N--CA 1.505 3.259 0 C-N-CA 119.706 -1.235 . . . . 0.25 111.025 -176.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.3 p80 -145.17 151.71 38.88 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.708 -0.878 . . . . 2.53 110.792 -177.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -135.8 140.23 44.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.515 -0.741 . . . . 1.1 109.994 175.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.1 pttm -123.42 153.33 65.62 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.691 -0.631 . . . . 3.48 110.589 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.38 152.61 38.55 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 O-C-N 123.314 1.165 . . . . 2.02 110.905 178.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -118.16 142.36 47.52 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.753 -0.592 . . . . 7.62 110.164 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 27.1 m120 . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 118.029 -0.986 . . . . 7.16 110.179 -179.938 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.5 mtt . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.213 0.53 . . . . 3.14 110.404 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.43 139.12 39.62 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.848 -0.533 . . . . 1.7 110.066 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 p -128.84 135.79 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.724 -0.61 . . . . 1.16 109.475 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.1 mt -82.56 -20.15 37.13 Favored 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 120.248 -0.581 . . . . 1.16 110.425 -179.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.94 153.21 3.15 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.415 -0.803 . . . . 1.09 109.289 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.6 tttt -133.96 125.92 29.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.639 -0.663 . . . . 2.69 110.222 -176.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 16.7 p90 -151.2 163.41 38.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.605 -0.684 . . . . 0.22 110.833 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.86 138.61 50.06 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.615 -0.678 . . . . 2.35 110.349 -176.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 162.37 41.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.774 -0.578 . . . . 1.03 109.684 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -110.21 158.95 17.82 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.48 -0.763 . . . . 1.03 109.933 176.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.0 t -79.46 136.39 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.272 -0.571 . . . . 1.16 110.241 -176.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -114.69 171.91 7.35 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.312 0.577 . . . . 1.04 109.831 175.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.39 152.97 0.39 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.609 -0.682 . . . . 3.63 112.008 -176.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.5 mt 63.09 7.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.702 0 O-C-N 121.605 -0.684 . . . . 1.12 112.522 -175.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.51 15.98 80.8 Favored Glycine 0 N--CA 1.497 2.729 0 O-C-N 120.899 -1.125 . . . . 0.26 110.312 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -86.02 143.81 27.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.304 -1.115 . . . . 2.55 110.361 -176.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.4 154.67 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.631 -0.668 . . . . 1.1 109.613 172.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.6 128.79 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.623 -0.673 . . . . 1.04 109.978 176.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 27.3 mt -79.44 145.35 63.48 Favored Pre-proline 0 N--CA 1.495 1.781 0 C-N-CA 120.056 -0.658 . . . . 1.05 109.423 175.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -63.4 143.64 89.03 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 O-C-N 122.96 0.979 . . . . 0.38 109.748 174.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.96 -27.0 60.82 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 120.389 -0.524 . . . . 1.12 110.484 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.39 -44.76 94.89 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.02 -1.232 . . . . 0.42 110.02 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 91.6 m -69.31 -36.64 77.2 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.686 -0.891 . . . . 1.08 110.061 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -56.38 -42.56 78.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.371 -0.83 . . . . 0.49 109.812 178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -66.2 -49.97 65.45 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 120.209 -0.596 . . . . 3.4 110.203 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 74.7 t80 -56.26 -37.93 70.46 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.831 -0.543 . . . . 0.74 110.589 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.425 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.1 t80 -88.34 -14.31 38.52 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.892 -0.505 . . . . 1.76 111.228 -178.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.55 42.82 25.97 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.609 -1.396 . . . . 0.32 109.609 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.416 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.6 mt -87.52 126.95 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.526 -0.985 . . . . 1.15 110.538 -176.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -127.19 158.98 35.65 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 170.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -57.26 137.53 55.88 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.361 -0.837 . . . . 2.7 110.662 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.23 63.84 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.998 -0.841 . . . . 0.21 110.998 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.31 157.11 32.8 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-N 118.674 1.237 . . . . 1.12 110.053 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -111.11 138.39 47.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.629 -0.67 . . . . 0.24 109.631 174.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 153.44 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.3 -0.63 . . . . 1.06 109.3 174.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -115.06 123.14 48.25 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.3 tt -140.47 159.21 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.688 -0.805 . . . . 1.05 110.882 -167.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -133.55 145.99 50.61 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.783 -0.573 . . . . 1.77 110.415 176.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.0 pt -115.0 151.08 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.575 -0.703 . . . . 1.06 110.385 177.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.9 t -139.79 124.5 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 120.499 -0.48 . . . . 1.03 109.806 176.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 22.0 ttpp -131.21 144.68 51.52 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.735 -0.603 . . . . 2.39 109.381 176.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 t80 -104.96 129.4 53.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.654 -0.654 . . . . 0.91 110.335 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -133.95 130.37 37.59 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.717 -0.614 . . . . 1.48 110.144 177.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.18 45.98 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.796 -1.322 . . . . 0.46 109.796 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -105.09 14.14 29.69 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.769 -0.842 . . . . 1.27 111.644 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -131.17 125.6 21.09 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.239 -0.913 . . . . 1.37 111.081 -177.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.28 135.82 19.06 Favored 'Trans proline' 0 N--CA 1.482 0.85 0 O-C-N 122.796 0.893 . . . . 0.38 110.097 173.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 25.1 mmtt -111.59 137.37 49.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.593 -0.692 . . . . 1.71 109.666 173.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -135.17 165.3 25.72 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.645 -0.659 . . . . 1.42 110.71 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.71 135.68 4.35 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.406 -1.478 . . . . 0.18 109.406 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.9 m -123.55 136.66 54.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.782 -0.834 . . . . 1.07 109.779 176.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 10.8 p90 -156.05 173.53 16.68 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 119.942 -0.703 . . . . 0.18 111.079 178.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.22 140.71 39.67 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.615 -0.678 . . . . 1.01 109.472 173.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.63 146.08 35.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.656 -0.653 . . . . 1.01 110.655 -175.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.4 ttp-105 -93.63 144.78 25.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.79 -0.569 . . . . 2.71 109.647 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.03 127.28 39.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.794 -0.566 . . . . 1.08 109.95 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.72 -171.37 26.61 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.841 -1.304 . . . . 0.22 109.841 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 -61.85 156.61 20.24 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.636 -0.92 . . . . 1.39 109.893 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 55.07 19.06 2.59 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.441 -0.787 . . . . 1.13 112.075 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.64 20.49 79.62 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.831 -1.176 . . . . 0.2 110.695 172.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.4 t -78.75 144.87 34.8 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.423 -1.046 . . . . 1.74 110.333 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -137.73 146.15 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 109.555 -0.535 . . . . 1.04 109.555 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.1 mm -110.86 123.69 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.53 -0.731 . . . . 1.12 110.714 -174.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 68.2 mt -78.66 143.29 62.81 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.585 -0.697 . . . . 1.17 109.455 172.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.411 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.4 Cg_endo -65.02 137.11 51.2 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 O-C-N 122.959 0.979 . . . . 0.29 110.817 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 17.1 tptp -54.84 -34.79 63.27 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.446 -0.784 . . . . 3.08 110.781 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.86 -38.35 78.56 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.792 -0.568 . . . . 1.16 110.363 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.3 mt -77.2 -32.73 56.19 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 120.15 -0.62 . . . . 2.43 110.683 179.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.31 -45.55 87.81 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.347 -0.846 . . . . 3.27 109.831 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -70.32 -48.19 57.69 Favored 'General case' 0 N--CA 1.495 1.822 0 C-N-CA 120.519 -0.472 . . . . 1.68 110.421 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.53 -38.02 76.84 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.732 -0.605 . . . . 1.08 109.938 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.3 mt -82.52 -17.8 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.844 -0.535 . . . . 1.08 110.947 -176.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.45 35.17 42.72 Favored Glycine 0 N--CA 1.497 2.721 0 N-CA-C 109.7 -1.36 . . . . 0.23 109.7 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.1 mm -91.13 142.01 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.514 -0.992 . . . . 1.42 110.695 -174.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 44.9 mttt -130.88 162.34 55.97 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.699 -0.626 . . . . 3.68 110.663 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.93 135.58 64.07 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 O-C-N 123.037 1.019 . . . . 0.8 110.818 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.16 -0.16 71.77 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 120.686 -0.769 . . . . 0.26 111.246 176.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -95.37 131.12 41.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.055 -1.262 . . . . 1.11 110.377 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.5 p -91.66 135.87 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 CA-C-O 121.762 0.792 . . . . 1.06 111.106 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 159.43 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 109.477 -0.564 . . . . 1.06 109.477 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -98.61 128.18 44.82 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.751 -0.833 . . . . 1.14 108.751 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 85.5 t -113.28 128.98 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-O 121.341 0.591 . . . . 1.05 110.148 -171.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 31.8 mt -116.75 127.35 54.28 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.02 -0.733 . . . . 1.08 109.02 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.418 HD23 ' CE2' ' A' ' 27' ' ' TYR . 4.4 mt -79.98 140.9 36.43 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.363 -0.835 . . . . 1.11 109.757 172.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 mt -113.9 -30.13 6.83 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.658 -0.651 . . . . 2.19 110.966 -174.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.93 -177.93 39.54 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.709 -1.234 . . . . 0.25 111.008 -177.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 25.5 p80 -145.09 153.53 41.53 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.729 -0.865 . . . . 2.53 110.694 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -139.23 144.54 38.49 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.6 -0.687 . . . . 1.1 110.162 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -118.21 151.0 48.68 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.682 -0.636 . . . . 3.48 110.28 178.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -56.04 143.1 84.57 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 O-C-N 123.143 1.075 . . . . 2.02 110.885 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 44.1 ptt85 -136.08 159.05 42.91 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.725 -0.61 . . . . 7.62 110.419 178.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 42.8 t-20 . . . . . 0 N--CA 1.495 1.818 0 CA-C-O 117.981 -1.009 . . . . 7.16 110.152 179.832 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.3 mtm . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.16 0.505 . . . . 3.14 110.564 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -74.61 141.47 44.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.894 -0.504 . . . . 1.7 110.096 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -129.0 134.2 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.702 -0.624 . . . . 1.16 109.556 177.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.4 mt -82.08 -20.77 37.51 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.25 -0.58 . . . . 1.16 110.252 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.17 153.42 3.69 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -0.835 . . . . 1.09 109.245 176.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.6 tttt -133.55 125.72 29.46 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.741 -0.6 . . . . 2.69 110.173 -176.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.447 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.2 p90 -150.23 162.87 39.64 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.555 -0.716 . . . . 0.22 110.94 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 95.5 m-70 -112.83 137.73 50.72 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.718 -0.614 . . . . 2.35 110.172 -176.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.1 162.3 41.12 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.729 -0.607 . . . . 1.03 109.582 176.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -110.11 159.77 17.05 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.736 -0.786 . . . . 1.03 110.075 177.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.5 t -78.74 136.24 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 C-N-CA 120.3 -0.56 . . . . 1.16 110.233 -177.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -115.44 171.88 7.44 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.22 0.533 . . . . 1.04 109.589 174.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 69.8 mtp85 -46.27 152.54 0.41 Allowed 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.573 -0.704 . . . . 3.63 112.067 -175.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.7 mt 62.41 7.99 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.665 0 O-C-N 121.656 -0.653 . . . . 1.12 112.631 -176.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.9 16.18 80.27 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.832 -1.168 . . . . 0.26 110.446 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -84.45 143.27 29.51 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.314 -1.11 . . . . 2.55 110.33 -176.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -134.51 154.95 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.672 -0.642 . . . . 1.1 109.545 172.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.7 mm -117.46 128.44 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.586 -0.696 . . . . 1.04 109.936 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 35.6 mt -79.79 144.04 59.4 Favored Pre-proline 0 N--CA 1.495 1.786 0 C-N-CA 120.075 -0.65 . . . . 1.05 109.407 176.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.37 143.5 88.91 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.004 1.002 . . . . 0.38 109.729 174.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.51 -26.49 61.41 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.858 -0.526 . . . . 1.12 110.527 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.37 95.17 Favored Glycine 0 N--CA 1.497 2.722 0 N-CA-C 109.935 -1.266 . . . . 0.42 109.935 -179.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 75.0 m -69.97 -38.2 76.02 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.58 -0.953 . . . . 1.08 110.18 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.6 mtt180 -55.95 -41.11 74.21 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.349 -0.844 . . . . 0.49 109.413 176.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.2 tttp -65.56 -49.95 66.96 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.145 0.498 . . . . 3.4 110.197 -177.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -57.14 -38.34 73.38 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.769 -0.582 . . . . 0.74 110.735 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.439 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 20.7 t80 -88.12 -14.25 39.24 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.779 -0.575 . . . . 1.76 111.291 -176.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.81 42.69 25.05 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.484 -1.447 . . . . 0.32 109.484 178.264 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.439 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.6 mt -87.49 129.17 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.492 -1.005 . . . . 1.15 110.437 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.08 154.65 45.46 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.962 -0.755 . . . . 1.82 108.962 172.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -55.21 139.67 41.37 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.288 -0.882 . . . . 2.7 110.691 -177.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.86 -15.98 61.88 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.936 -0.866 . . . . 0.21 110.936 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -76.21 156.73 33.35 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.097 -1.237 . . . . 1.12 110.069 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -110.18 138.59 46.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.638 -0.664 . . . . 0.24 109.595 174.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.32 154.79 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 109.271 -0.64 . . . . 1.06 109.271 174.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -116.09 123.37 47.74 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.207 -1.034 . . . . 1.09 108.207 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.6 tt -139.45 158.25 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 119.661 -0.816 . . . . 1.05 110.95 -167.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -132.7 145.86 51.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.867 -0.521 . . . . 1.77 110.386 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 34.1 pt -114.94 150.97 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.667 -0.645 . . . . 1.06 110.568 177.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.7 t -139.27 126.0 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 CA-C-O 121.231 0.539 . . . . 1.03 109.778 176.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 29.5 tptp -136.26 148.79 48.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.812 -0.555 . . . . 2.39 109.511 176.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -100.63 129.0 46.49 Favored 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 120.19 -0.604 . . . . 0.91 110.251 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -135.08 135.09 40.97 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.635 -0.666 . . . . 1.48 110.011 178.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.15 45.9 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.741 -1.344 . . . . 0.46 109.741 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.1 pt-20 -105.13 7.73 33.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.748 -0.854 . . . . 1.27 111.806 178.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.3 pt-20 -131.17 141.47 42.02 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.129 -0.982 . . . . 1.37 111.004 -177.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -75.4 139.75 23.63 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 O-C-N 123.037 1.02 . . . . 0.38 110.566 175.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -114.47 136.89 52.51 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.545 -0.722 . . . . 1.71 109.496 171.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -137.5 168.92 18.69 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.603 -0.686 . . . . 1.42 110.713 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -160.22 135.95 4.31 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.592 -1.403 . . . . 0.18 109.592 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -121.55 137.49 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.755 -0.85 . . . . 1.07 109.721 177.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 13.8 p90 -155.78 173.02 17.36 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 119.911 -0.716 . . . . 0.18 110.965 176.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.4 m -107.44 140.82 39.81 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.71 -0.619 . . . . 1.01 109.586 174.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.66 145.12 34.56 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.614 -0.679 . . . . 1.01 110.552 -176.25 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.2 ttp-105 -93.4 145.31 24.58 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.773 -0.58 . . . . 2.71 109.679 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 94.7 t -79.11 126.13 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.847 -0.533 . . . . 1.08 109.975 -179.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.45 -170.7 26.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.79 -1.324 . . . . 0.22 109.79 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -61.88 156.03 21.83 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.61 -0.935 . . . . 1.39 109.905 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 54.91 19.44 2.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.611 -0.68 . . . . 1.13 112.084 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.68 20.5 79.67 Favored Glycine 0 N--CA 1.499 2.838 0 C-N-CA 119.821 -1.18 . . . . 0.2 110.783 172.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 54.1 p -77.97 145.7 35.88 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.451 -1.029 . . . . 1.74 110.534 -175.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.9 p -139.81 146.2 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.875 -0.515 . . . . 1.04 109.628 174.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.62 123.61 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.499 -0.75 . . . . 1.12 110.653 -175.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.3 144.15 65.97 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.679 -0.638 . . . . 1.17 109.652 174.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.416 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.4 Cg_endo -64.41 134.35 41.33 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 O-C-N 123.002 1.001 . . . . 0.29 110.808 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -55.19 -34.29 63.76 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.532 -0.73 . . . . 3.08 110.847 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.78 -37.69 76.87 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.74 -0.6 . . . . 1.16 110.324 -178.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.4 mt -77.18 -32.79 56.34 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.723 -0.61 . . . . 2.43 110.544 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -57.82 -45.73 85.72 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.282 -0.886 . . . . 3.27 109.911 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.27 -47.22 62.26 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.44 -0.504 . . . . 1.68 110.465 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.56 -38.12 77.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.712 -0.618 . . . . 1.08 109.987 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.9 mt -82.31 -18.06 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.849 -0.532 . . . . 1.08 110.788 -176.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.28 40.7 Favored Glycine 0 N--CA 1.497 2.763 0 N-CA-C 109.684 -1.366 . . . . 0.23 109.684 176.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.9 mm -90.89 144.58 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.53 -0.982 . . . . 1.42 110.613 -174.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.04 159.31 73.19 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.743 -0.598 . . . . 3.68 110.906 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -52.8 134.79 55.67 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 O-C-N 123.067 1.035 . . . . 0.8 111.688 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.07 -0.63 69.38 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.66 -0.781 . . . . 0.26 111.331 175.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.65 129.0 40.1 Favored 'General case' 0 N--CA 1.501 2.083 0 CA-C-N 118.724 1.262 . . . . 1.11 110.173 178.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.7 p -91.15 128.51 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 121.4 0.619 . . . . 1.06 110.606 -175.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 46.6 pt -118.79 159.56 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.639 -0.504 . . . . 1.06 109.639 179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.3 tt0 -97.6 130.13 44.66 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.938 -0.764 . . . . 1.14 108.938 174.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 87.4 t -115.48 129.2 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-O 121.373 0.606 . . . . 1.05 110.257 -171.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.38 129.08 56.05 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.204 -0.665 . . . . 1.08 109.204 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.42 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -79.8 139.66 37.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.342 -0.849 . . . . 1.11 109.791 172.546 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -109.34 -33.45 6.83 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.767 -0.583 . . . . 2.19 110.927 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.22 -175.2 37.69 Favored Glycine 0 N--CA 1.504 3.184 0 C-N-CA 119.674 -1.251 . . . . 0.25 111.031 -176.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p80 -143.79 153.91 42.88 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.759 -0.847 . . . . 2.53 110.719 -177.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -137.92 139.43 39.8 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.537 -0.727 . . . . 1.1 110.236 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 5.4 pttm -81.72 152.53 69.51 Favored Pre-proline 0 N--CA 1.496 1.875 0 O-C-N 121.715 -0.615 . . . . 3.48 110.313 178.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -55.82 143.53 80.79 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 O-C-N 123.227 1.119 . . . . 2.02 110.933 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 28.2 ptt180 -136.14 158.37 44.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.708 -0.62 . . . . 7.62 110.426 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 117.981 -1.009 . . . . 7.16 110.178 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.4 mtp . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.137 0.494 . . . . 3.14 110.613 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -74.12 142.67 45.55 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.915 -0.49 . . . . 1.7 110.082 178.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -129.11 133.76 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.766 -0.584 . . . . 1.16 109.588 178.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.8 mt -80.96 -21.49 40.32 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.269 -0.572 . . . . 1.16 110.189 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.11 152.18 3.4 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.442 -0.786 . . . . 1.09 109.127 176.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 67.2 tttt -132.61 125.18 29.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.702 -0.624 . . . . 2.69 110.214 -176.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.446 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 16.0 p90 -150.21 162.76 39.84 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.072 -0.651 . . . . 0.22 110.989 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 96.2 m-70 -112.52 138.23 49.58 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.626 -0.671 . . . . 2.35 110.154 -176.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.06 162.26 41.18 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.696 -0.628 . . . . 1.03 109.627 176.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.62 158.78 18.2 Favored 'General case' 0 N--CA 1.498 1.939 0 C-N-CA 119.818 -0.753 . . . . 1.03 110.136 177.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.3 t -79.24 134.89 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 C-N-CA 120.257 -0.577 . . . . 1.16 110.245 -177.089 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.28 171.89 7.34 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-O 121.277 0.561 . . . . 1.04 109.647 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -47.16 152.99 0.5 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.579 -0.701 . . . . 3.63 111.776 -175.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 56.7 mt 62.65 7.37 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.652 0 O-C-N 121.46 -0.775 . . . . 1.12 112.681 -174.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.1 80.63 Favored Glycine 0 N--CA 1.497 2.747 0 O-C-N 120.935 -1.103 . . . . 0.26 110.363 179.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -84.64 142.84 29.63 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.248 -1.148 . . . . 2.55 110.391 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.57 155.22 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.721 -0.612 . . . . 1.1 109.39 172.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.6 mm -116.56 128.45 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.579 -0.701 . . . . 1.04 109.977 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 37.4 mt -79.99 144.32 59.04 Favored Pre-proline 0 N--CA 1.495 1.792 0 C-N-CA 120.015 -0.674 . . . . 1.05 109.422 175.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -63.54 143.46 87.8 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 122.943 0.97 . . . . 0.38 109.751 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.75 61.57 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 120.44 -0.504 . . . . 1.12 110.481 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.17 95.56 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.954 -1.258 . . . . 0.42 109.954 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.7 m -69.87 -38.43 76.39 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.562 -0.964 . . . . 1.08 110.148 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.9 mtt180 -56.03 -40.58 73.66 Favored 'General case' 0 N--CA 1.513 2.689 0 O-C-N 121.29 -0.881 . . . . 0.49 109.386 176.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -65.64 -50.01 66.56 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.043 0.449 . . . . 3.4 110.213 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -57.74 -38.85 76.07 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.751 -0.593 . . . . 0.74 110.683 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.422 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 26.7 t80 -86.74 -14.17 43.17 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.804 -0.56 . . . . 1.76 111.346 -176.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 43.14 23.45 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.603 -1.399 . . . . 0.32 109.603 178.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 76.9 mt -87.73 128.79 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 121.523 -0.986 . . . . 1.15 110.537 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.1 153.97 46.24 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.868 -0.79 . . . . 1.82 108.868 170.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -55.27 140.39 39.33 Favored 'General case' 0 N--CA 1.504 2.241 0 O-C-N 121.238 -0.913 . . . . 2.7 110.626 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.8 -16.03 61.74 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.859 -0.896 . . . . 0.21 110.859 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.91 157.54 31.3 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.67 1.235 . . . . 1.12 110.115 178.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -111.71 138.92 47.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.622 -0.674 . . . . 0.24 109.557 174.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.55 155.12 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 C-N-CA 120.224 -0.59 . . . . 1.06 109.454 174.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.92 123.6 48.49 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.364 -0.976 . . . . 1.09 108.364 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.4 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 9.4 tt -139.96 156.01 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.682 -0.807 . . . . 1.05 110.95 -167.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -131.13 146.07 52.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.747 -0.596 . . . . 1.77 110.55 177.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 29.6 pt -114.94 151.08 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 121.731 -0.605 . . . . 1.06 110.699 178.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.6 t -138.23 126.58 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.152 0.501 . . . . 1.03 109.734 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 32.1 tptt -136.69 146.89 46.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.741 -0.6 . . . . 2.39 109.602 175.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -105.96 130.98 53.79 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.231 -0.587 . . . . 0.91 110.427 -177.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -136.59 135.35 38.31 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.677 -0.639 . . . . 1.48 110.145 176.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.24 46.09 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.833 -1.307 . . . . 0.46 109.833 -178.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.14 9.81 34.07 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.819 -0.812 . . . . 1.27 111.878 179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -131.15 135.36 27.09 Favored Pre-proline 0 N--CA 1.499 2.001 0 O-C-N 121.189 -0.945 . . . . 1.37 111.076 -177.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.36 146.52 31.51 Favored 'Trans proline' 0 N--CA 1.482 0.801 0 O-C-N 122.811 0.901 . . . . 0.38 110.159 173.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 55.0 mmtt -120.48 138.17 53.96 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.545 -0.722 . . . . 1.71 109.564 172.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -134.57 163.41 29.79 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.635 -0.665 . . . . 1.42 110.718 -176.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.91 135.89 4.43 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.618 -1.393 . . . . 0.18 109.618 178.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.3 m -122.17 137.45 54.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.715 -0.873 . . . . 1.07 109.75 176.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.5 p90 -155.55 172.77 17.7 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.972 -0.691 . . . . 0.18 111.036 176.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.7 m -106.9 141.03 38.77 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.691 -0.63 . . . . 1.01 109.464 173.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.31 145.4 35.42 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.564 -0.71 . . . . 1.01 110.58 -176.048 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -92.96 144.79 24.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.809 -0.557 . . . . 2.71 109.605 175.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.1 t -79.14 125.23 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-O 121.332 0.587 . . . . 1.08 109.79 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.68 -167.31 26.34 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.939 -1.264 . . . . 0.22 109.939 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.6 153.45 27.78 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.724 -0.868 . . . . 1.39 110.101 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.64 21.03 2.39 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.54 -0.725 . . . . 1.13 112.061 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.07 20.58 79.68 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.784 -1.198 . . . . 0.2 110.793 171.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.2 m -77.88 144.92 36.54 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.488 -1.007 . . . . 1.74 110.375 -176.311 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.8 p -138.43 144.96 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.553 -0.536 . . . . 1.04 109.553 174.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.65 123.33 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.49 -0.756 . . . . 1.12 110.641 -175.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 54.7 mt -78.44 144.43 65.93 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.643 -0.661 . . . . 1.17 109.518 173.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.408 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.8 Cg_endo -64.21 133.63 38.77 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.934 0.965 . . . . 0.29 110.764 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.08 -34.23 63.46 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.443 -0.786 . . . . 3.08 110.866 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.76 -38.09 77.71 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.745 -0.597 . . . . 1.16 110.329 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 71.0 mt -77.15 -32.67 56.45 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 120.259 -0.576 . . . . 2.43 110.552 178.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.88 -46.03 85.49 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.3 -0.875 . . . . 3.27 109.897 178.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -70.16 -46.79 63.95 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 120.456 -0.498 . . . . 1.68 110.473 -175.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.5 t -60.38 -38.45 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.678 -0.639 . . . . 1.08 109.865 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -82.53 -17.99 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.844 -0.535 . . . . 1.08 110.822 -176.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.25 35.11 38.88 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 109.665 -1.374 . . . . 0.23 109.665 176.07 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.5 mm -90.65 142.54 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.619 -0.93 . . . . 1.42 110.581 -175.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -129.64 162.11 55.14 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.674 -0.641 . . . . 3.68 110.807 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.91 135.32 62.41 Favored 'Trans proline' 0 N--CA 1.488 1.159 0 O-C-N 123.063 1.033 . . . . 0.8 110.835 -179.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.9 -0.05 72.44 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 120.591 -0.814 . . . . 0.26 111.235 176.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -96.18 131.61 42.47 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 118.715 1.257 . . . . 1.11 110.445 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.87 130.1 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 CA-C-O 121.511 0.672 . . . . 1.06 110.837 -174.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 47.3 pt -118.72 159.51 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 109.591 -0.522 . . . . 1.06 109.591 177.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.421 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.5 tt0 -97.01 130.69 44.3 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.026 -0.731 . . . . 1.14 109.026 174.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.444 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 91.6 t -115.85 128.9 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.366 0.603 . . . . 1.05 110.241 -171.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.7 mt -116.31 128.75 55.83 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.324 -0.621 . . . . 1.08 109.324 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.415 HD12 ' CD2' ' A' ' 27' ' ' TYR . 6.0 mt -79.65 142.51 35.49 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.402 -0.811 . . . . 1.11 109.808 171.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.7 mt -120.65 -24.95 5.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.655 . . . . 2.19 111.206 -174.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.28 -179.92 40.49 Favored Glycine 0 N--CA 1.505 3.28 0 C-N-CA 119.642 -1.266 . . . . 0.25 111.066 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 p80 -146.95 152.62 38.94 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.745 -0.856 . . . . 2.53 110.685 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -138.28 142.92 39.82 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.582 -0.699 . . . . 1.1 110.07 175.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.3 mmtt -120.87 154.53 57.66 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 3.48 110.224 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -55.96 142.33 85.08 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 O-C-N 123.162 1.085 . . . . 2.02 110.934 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 74.9 mtt85 -126.29 147.64 49.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.755 -0.591 . . . . 7.62 110.198 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 31.7 t30 . . . . . 0 N--CA 1.494 1.771 0 CA-C-O 117.991 -1.004 . . . . 7.16 110.153 -179.936 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.8 ttm . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 121.01 0.433 . . . . 3.14 110.173 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -78.03 145.29 36.0 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.806 -0.558 . . . . 1.7 110.131 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -127.77 138.03 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.695 -0.628 . . . . 1.16 109.719 178.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.3 mt -86.61 -18.44 31.39 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.262 -0.575 . . . . 1.16 110.547 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.79 153.74 3.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.357 -0.839 . . . . 1.09 109.299 175.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -133.77 125.42 28.46 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.703 -0.623 . . . . 2.69 110.079 -177.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.447 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 15.3 p90 -150.68 162.09 41.35 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.603 -0.686 . . . . 0.22 110.869 -179.322 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -112.78 138.84 49.01 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.661 -0.649 . . . . 2.35 110.161 -176.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.29 41.07 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.728 -0.607 . . . . 1.03 109.59 178.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -111.0 158.68 18.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.417 -0.802 . . . . 1.03 110.044 177.152 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.404 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -79.16 136.29 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.295 -0.562 . . . . 1.16 110.343 -176.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -115.25 171.94 7.38 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.42 0.629 . . . . 1.04 109.796 175.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 -46.52 153.04 0.4 Allowed 'General case' 0 N--CA 1.505 2.31 0 O-C-N 121.536 -0.728 . . . . 3.63 111.981 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.8 mt 62.89 7.45 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.671 0 O-C-N 121.569 -0.707 . . . . 1.12 112.567 -175.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.73 15.99 80.63 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.344 -1.102 . . . . 0.26 110.344 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -85.5 144.0 28.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.235 -1.156 . . . . 2.55 110.429 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -132.67 154.95 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.748 -0.595 . . . . 1.1 109.46 172.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.11 128.76 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 C-N-CA 120.073 -0.651 . . . . 1.04 110.065 176.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.08 145.21 60.39 Favored Pre-proline 0 N--CA 1.496 1.828 0 C-N-CA 120.062 -0.655 . . . . 1.05 109.406 175.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.34 143.73 89.59 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 O-C-N 123.024 1.013 . . . . 0.38 109.755 174.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.41 61.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.87 -0.519 . . . . 1.12 110.471 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.74 -44.22 95.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 110.026 -1.23 . . . . 0.42 110.026 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 78.5 m -69.85 -38.21 76.41 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.964 . . . . 1.08 110.124 -179.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.4 mtt180 -56.3 -41.65 76.28 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 121.276 -0.89 . . . . 0.49 109.377 176.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -65.9 -50.09 65.7 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.14 0.495 . . . . 3.4 110.221 -177.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.27 -37.79 72.91 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.732 -0.605 . . . . 0.74 110.633 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.437 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 18.5 t80 -88.06 -14.15 39.65 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.805 -0.559 . . . . 1.76 111.229 -175.764 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.33 42.49 27.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.563 -1.415 . . . . 0.32 109.563 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.437 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 78.3 mt -89.62 131.14 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.453 -1.027 . . . . 1.15 110.645 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.27 158.94 36.78 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.091 -0.707 . . . . 1.82 109.091 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -57.47 139.45 53.23 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.38 -0.825 . . . . 2.7 110.513 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.74 -15.25 63.49 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.887 -0.885 . . . . 0.21 110.887 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.12 158.16 32.07 Favored 'General case' 0 N--CA 1.501 2.123 0 CA-C-N 118.724 1.262 . . . . 1.12 109.932 178.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -110.53 138.16 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.591 -0.693 . . . . 0.24 109.588 175.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.35 154.16 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 109.13 -0.693 . . . . 1.06 109.13 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -116.05 123.8 48.84 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.8 tt -140.51 158.13 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 119.635 -0.826 . . . . 1.05 110.961 -167.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 ttpt -132.29 146.11 51.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.837 -0.539 . . . . 1.77 110.386 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.2 pt -114.88 150.98 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.667 -0.646 . . . . 1.06 110.278 176.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.4 t -139.53 123.64 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 CA-C-O 121.251 0.548 . . . . 1.03 109.729 177.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 53.2 tttm -132.92 147.5 52.29 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.248 -0.649 . . . . 2.39 109.248 176.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -101.18 130.92 47.35 Favored 'General case' 0 N--CA 1.498 1.952 0 C-N-CA 119.903 -0.719 . . . . 0.91 110.531 -178.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -132.04 131.42 42.45 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.653 -0.654 . . . . 1.48 110.016 177.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.85 -128.05 45.63 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.814 -1.315 . . . . 0.46 109.814 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 pt-20 -104.97 10.64 34.1 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.726 -0.867 . . . . 1.27 111.729 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.2 137.99 31.86 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 1.37 110.719 -179.258 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -75.23 140.08 24.44 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 O-C-N 122.887 0.941 . . . . 0.38 110.399 174.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 55.5 mmtt -111.37 136.89 49.85 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.657 -0.652 . . . . 1.71 109.466 172.063 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.7 164.49 27.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.703 -0.623 . . . . 1.42 110.996 -176.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.59 135.75 4.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.469 -1.453 . . . . 0.18 109.469 176.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.8 m -124.85 136.91 54.24 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.712 -0.875 . . . . 1.07 109.732 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 11.1 p90 -155.88 173.38 16.85 Favored 'General case' 0 N--CA 1.497 1.911 0 C-N-CA 119.867 -0.733 . . . . 0.18 111.089 178.159 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.7 m -106.95 140.39 39.83 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.722 -0.611 . . . . 1.01 109.551 173.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -142.28 146.11 34.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.633 -0.667 . . . . 1.01 110.443 -175.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.65 145.58 24.45 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.774 -0.579 . . . . 2.71 109.711 175.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 97.9 t -77.84 126.41 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.2 0.524 . . . . 1.08 109.973 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.53 -167.56 26.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.931 -1.268 . . . . 0.22 109.931 179.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -61.71 153.34 28.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.7 -0.882 . . . . 1.39 109.965 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 54.14 20.49 2.57 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.531 -0.731 . . . . 1.13 111.98 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 20.44 79.94 Favored Glycine 0 N--CA 1.5 2.928 0 C-N-CA 119.803 -1.189 . . . . 0.2 110.826 171.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.5 p -78.37 146.9 34.37 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -1.01 . . . . 1.74 110.203 -177.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.88 145.8 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.758 -0.589 . . . . 1.04 109.565 175.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.15 123.15 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.588 -0.695 . . . . 1.12 110.654 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 65.5 mt -78.41 144.02 65.29 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.504 -0.748 . . . . 1.17 109.432 172.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.6 Cg_endo -64.77 134.43 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 O-C-N 122.861 0.927 . . . . 0.29 110.648 -179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -55.15 -34.21 63.59 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.505 -0.747 . . . . 3.08 110.802 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -37.87 77.12 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.802 -0.562 . . . . 1.16 110.271 -178.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.8 mt -77.11 -32.75 56.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.748 -0.595 . . . . 2.43 110.553 178.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.78 -46.0 85.21 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.306 -0.871 . . . . 3.27 109.923 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.32 -47.23 62.05 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.5 -0.48 . . . . 1.68 110.493 -175.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.6 t -60.51 -38.15 77.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.684 -0.635 . . . . 1.08 109.966 -178.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.1 mt -82.57 -17.81 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.792 -0.568 . . . . 1.08 110.934 -176.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.32 35.14 43.53 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.787 -1.325 . . . . 0.23 109.787 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.404 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 49.9 mm -92.24 138.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.522 -0.987 . . . . 1.42 110.715 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 57.0 mmtt -124.25 161.1 49.42 Favored Pre-proline 0 N--CA 1.498 1.931 0 O-C-N 121.675 -0.64 . . . . 3.68 110.61 -176.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.76 136.36 66.01 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 O-C-N 123.027 1.014 . . . . 0.8 110.78 179.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.63 -0.65 74.24 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 111.123 -0.791 . . . . 0.26 111.123 176.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -98.14 134.44 41.2 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 118.682 1.241 . . . . 1.11 110.567 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.07 133.41 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 CA-C-O 121.684 0.754 . . . . 1.06 111.227 -174.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.7 pt -122.93 159.48 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 109.211 -0.663 . . . . 1.06 109.211 175.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 49.7 tt0 -98.82 131.41 44.96 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 109.021 -0.733 . . . . 1.14 109.021 175.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.443 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 88.5 t -115.8 129.93 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.435 0.636 . . . . 1.05 110.365 -170.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.2 mt -115.73 130.7 56.95 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 109.237 -0.653 . . . . 1.08 109.237 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.41 HD21 ' CE2' ' A' ' 27' ' ' TYR . 4.1 mt -80.09 139.88 36.7 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.449 -0.782 . . . . 1.11 109.781 171.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.0 mt -108.71 -34.4 6.71 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.8 -0.563 . . . . 2.19 110.887 -176.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -169.03 -174.63 37.74 Favored Glycine 0 N--CA 1.502 3.079 0 C-N-CA 119.738 -1.22 . . . . 0.25 111.015 -177.106 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -143.91 155.62 44.14 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.738 -0.86 . . . . 2.53 110.743 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -141.17 146.69 37.3 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.577 -0.702 . . . . 1.1 110.208 176.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 18.1 mtmm -112.07 159.92 31.88 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.722 -0.611 . . . . 3.48 110.133 178.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -55.53 141.56 82.71 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 O-C-N 123.187 1.099 . . . . 2.02 110.963 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -130.22 141.72 50.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.685 -0.634 . . . . 7.62 110.204 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 117.994 -1.003 . . . . 7.16 110.165 179.822 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.224 0.535 . . . . 3.14 110.544 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -75.35 141.98 43.23 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.867 -0.521 . . . . 1.7 110.101 179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -127.96 135.71 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.811 -0.556 . . . . 1.16 109.578 177.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.8 mt -83.72 -19.6 34.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.761 -0.587 . . . . 1.16 110.276 177.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -174.46 152.7 1.76 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.262 -0.899 . . . . 1.09 109.124 176.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.1 ttpt -135.42 128.23 31.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.635 -0.665 . . . . 2.69 110.382 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.448 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 19.2 p90 -149.81 163.56 37.68 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.391 -0.524 . . . . 0.22 110.508 -178.277 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.61 137.59 51.37 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.602 -0.686 . . . . 2.35 110.4 -176.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.56 162.28 41.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.756 -0.59 . . . . 1.03 109.568 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -109.63 158.56 17.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.468 -0.77 . . . . 1.03 110.02 176.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.9 t -79.47 138.06 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.779 -0.576 . . . . 1.16 110.355 -176.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -116.66 171.87 7.59 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.347 0.594 . . . . 1.04 109.86 176.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -46.29 153.05 0.37 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.629 -0.669 . . . . 3.63 112.075 -175.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.9 mt 62.94 7.2 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.648 0 O-C-N 121.651 -0.655 . . . . 1.12 112.578 -175.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.61 16.09 80.6 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.331 -1.108 . . . . 0.26 110.331 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 36.7 ttp180 -85.76 144.29 27.85 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.354 -1.086 . . . . 2.55 110.198 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -132.42 155.03 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.681 -0.637 . . . . 1.1 109.359 172.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.4 mm -115.71 128.55 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.595 -0.691 . . . . 1.04 109.952 176.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 25.5 mt -79.58 144.5 61.15 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.052 -0.659 . . . . 1.05 109.417 175.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -63.48 143.39 87.98 Favored 'Trans proline' 0 N--CA 1.488 1.191 0 O-C-N 123.002 1.001 . . . . 0.38 109.689 174.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.0 -26.37 60.13 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.838 -0.539 . . . . 1.12 110.46 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.31 -45.32 93.78 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 109.999 -1.24 . . . . 0.42 109.999 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 m -69.5 -36.87 76.9 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.617 -0.931 . . . . 1.08 110.202 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -56.3 -42.05 76.94 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.418 -0.801 . . . . 0.49 109.734 178.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -65.97 -50.2 65.16 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.364 0.602 . . . . 3.4 110.162 -177.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -56.67 -37.87 71.42 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.835 -0.541 . . . . 0.74 110.69 -178.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.427 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 25.0 t80 -87.89 -14.17 40.06 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.825 -0.547 . . . . 1.76 111.364 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 43.03 23.24 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.586 -1.406 . . . . 0.32 109.586 178.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.405 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.1 mt -87.53 127.44 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.422 -1.046 . . . . 1.15 110.575 -177.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.29 154.92 44.32 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.008 -0.738 . . . . 1.82 109.008 170.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.52 137.75 47.95 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.253 -0.904 . . . . 2.7 110.751 -177.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.46 -15.1 64.01 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.927 -0.869 . . . . 0.21 110.927 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -75.97 157.51 33.02 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.735 1.268 . . . . 1.12 109.851 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -111.21 138.17 47.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.606 -0.684 . . . . 0.24 109.679 175.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.39 153.52 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 109.249 -0.649 . . . . 1.06 109.249 174.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -115.33 122.98 47.55 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.242 -1.021 . . . . 1.09 108.242 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 tt -139.97 157.99 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 119.604 -0.838 . . . . 1.05 110.987 -167.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.5 tttt -132.61 145.98 51.53 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.8 -0.562 . . . . 1.77 110.596 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 28.0 pt -115.13 151.03 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.728 -0.608 . . . . 1.06 110.62 178.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -138.77 125.61 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.143 0.497 . . . . 1.03 109.772 176.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.401 ' CE ' ' CD1' ' A' ' 74' ' ' ILE . 21.4 ttpp -131.9 143.36 50.08 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.222 -0.659 . . . . 2.39 109.222 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -105.03 130.14 53.3 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.137 -0.625 . . . . 0.91 110.456 -178.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -135.02 131.33 36.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.745 -0.597 . . . . 1.48 110.149 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.82 -128.18 45.94 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.857 -1.297 . . . . 0.46 109.857 -178.253 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -105.11 12.86 31.6 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.767 -0.843 . . . . 1.27 111.672 179.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -131.27 128.02 21.97 Favored Pre-proline 0 N--CA 1.498 1.957 0 O-C-N 121.31 -0.869 . . . . 1.37 110.982 -178.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.33 137.99 21.71 Favored 'Trans proline' 0 N--CA 1.482 0.844 0 O-C-N 122.73 0.858 . . . . 0.38 110.127 173.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 68.7 mmtt -110.85 137.17 48.83 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.548 -0.72 . . . . 1.71 109.622 172.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -135.5 164.23 28.28 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.614 -0.679 . . . . 1.42 110.796 -176.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.15 135.96 4.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.605 -1.398 . . . . 0.18 109.605 178.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.3 m -123.09 137.34 54.95 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.68 -0.894 . . . . 1.07 109.735 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.424 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 12.8 p90 -155.87 172.55 18.16 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.843 -0.743 . . . . 0.18 111.017 176.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.0 m -107.78 140.85 40.23 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.694 -0.629 . . . . 1.01 109.545 174.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.424 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -142.09 145.78 34.69 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.723 -0.61 . . . . 1.01 110.641 -175.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.7 ttp180 -93.9 145.25 24.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.73 -0.606 . . . . 2.71 109.598 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 98.8 t -78.44 126.47 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.783 -0.573 . . . . 1.08 109.928 -178.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.04 -166.51 24.98 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.099 -1.201 . . . . 0.22 110.099 178.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -61.63 153.08 28.94 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.872 -0.781 . . . . 1.39 110.218 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.57 21.18 2.41 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.547 -0.721 . . . . 1.13 112.001 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.81 20.48 79.76 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.747 -1.216 . . . . 0.2 110.806 171.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 14.2 m -77.99 145.25 36.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.414 -1.05 . . . . 1.74 110.232 -176.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.27 145.51 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.789 -0.569 . . . . 1.04 109.609 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -112.03 123.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.55 -0.719 . . . . 1.12 110.734 -174.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 80.3 mt -78.5 145.12 66.99 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.591 -0.693 . . . . 1.17 109.484 172.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.419 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.2 Cg_endo -64.38 136.68 52.08 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 O-C-N 122.889 0.941 . . . . 0.29 110.821 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 20.2 tptt -54.93 -34.85 63.59 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.47 -0.769 . . . . 3.08 110.845 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.91 -38.2 78.4 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.764 -0.585 . . . . 1.16 110.298 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.0 mt -77.17 -32.78 56.4 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.727 -0.608 . . . . 2.43 110.658 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.2 mtt180 -58.3 -45.85 87.24 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.22 -0.925 . . . . 3.27 109.884 178.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.3 -47.42 61.26 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 120.383 -0.527 . . . . 1.68 110.51 -175.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.9 t -60.58 -38.18 77.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 O-C-N 121.653 -0.654 . . . . 1.08 109.91 -178.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.1 mt -82.28 -17.61 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.882 -0.512 . . . . 1.08 110.966 -176.224 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.23 40.83 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.835 -1.306 . . . . 0.23 109.835 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.401 ' CD1' ' CE ' ' A' ' 41' ' ' LYS . 51.2 mm -90.58 141.11 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.511 -0.994 . . . . 1.42 110.704 -173.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -127.67 156.28 75.8 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.732 -0.605 . . . . 3.68 110.631 -177.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -55.98 135.42 69.67 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 122.974 0.986 . . . . 0.8 111.275 177.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.12 -0.76 72.71 Favored Glycine 0 N--CA 1.496 2.65 0 C-N-CA 120.694 -0.765 . . . . 0.26 111.241 176.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -96.36 132.6 41.7 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-N 118.734 1.267 . . . . 1.11 110.477 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.3 p -91.21 132.08 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-O 121.639 0.733 . . . . 1.06 110.979 -174.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.4 pt -123.23 159.42 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 109.464 -0.569 . . . . 1.06 109.464 177.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.7 tt0 -98.13 131.57 44.4 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.919 -0.771 . . . . 1.14 108.919 173.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.448 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 99.9 t -115.1 128.01 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 1.05 110.166 -171.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.1 mt -114.79 128.46 56.31 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.365 -0.605 . . . . 1.08 109.365 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.418 HD23 ' CE2' ' A' ' 27' ' ' TYR . 4.8 mt -79.88 139.92 36.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.485 -0.76 . . . . 1.11 109.821 172.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.7 mt -110.93 -31.75 7.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.769 -0.582 . . . . 2.19 110.85 -175.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.25 -177.04 39.12 Favored Glycine 0 N--CA 1.504 3.225 0 C-N-CA 119.745 -1.216 . . . . 0.25 110.958 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -144.72 152.56 40.59 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.667 -0.902 . . . . 2.53 110.72 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -136.29 139.92 43.01 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 1.1 109.995 175.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -123.84 160.05 53.3 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.698 -0.626 . . . . 3.48 110.279 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -55.86 147.66 60.96 Favored 'Trans proline' 0 N--CA 1.497 1.678 0 O-C-N 123.141 1.074 . . . . 2.02 111.043 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 82.7 mmt-85 -121.12 146.86 46.3 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.719 -0.613 . . . . 7.62 110.216 178.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 . . . . . 0 N--CA 1.504 2.249 0 CA-C-O 117.969 -1.015 . . . . 7.16 110.998 -179.959 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 121.232 0.539 . . . . 3.14 110.597 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.16 142.05 39.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.837 -0.539 . . . . 1.7 110.126 179.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 p -127.57 141.82 45.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.708 -0.62 . . . . 1.16 109.723 178.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 34.4 mt -89.58 -18.02 27.38 Favored 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 120.309 -0.556 . . . . 1.16 110.654 -177.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.75 154.99 3.8 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.249 -0.907 . . . . 1.09 109.577 177.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -133.63 127.1 32.27 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.707 -0.621 . . . . 2.69 110.126 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.444 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 13.2 p90 -148.75 162.64 39.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.643 -0.661 . . . . 0.22 110.702 177.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.81 138.37 50.36 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.596 -0.69 . . . . 2.35 110.34 -176.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.04 162.21 41.28 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 109.459 -0.571 . . . . 1.03 109.459 177.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -109.31 158.45 17.87 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.436 -0.79 . . . . 1.03 110.152 177.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 61.2 t -79.22 136.43 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.32 -0.552 . . . . 1.16 110.097 -177.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.41 171.87 7.36 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-O 121.269 0.556 . . . . 1.04 109.612 173.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -46.86 152.61 0.49 Allowed 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.579 -0.7 . . . . 3.63 111.978 -176.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.61 0 O-C-N 121.529 -0.732 . . . . 1.12 112.631 -175.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.01 16.17 80.18 Favored Glycine 0 N--CA 1.497 2.742 0 O-C-N 120.964 -1.085 . . . . 0.26 110.463 179.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -83.89 141.15 31.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.298 -1.119 . . . . 2.55 110.316 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.7 pt -133.72 155.75 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.569 -0.707 . . . . 1.1 109.816 173.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.17 129.75 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.529 -0.732 . . . . 1.04 109.878 175.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.425 HG12 ' CE2' ' A' ' 7' ' ' PHE . 24.2 mt -79.76 145.91 63.35 Favored Pre-proline 0 N--CA 1.495 1.806 0 C-N-CA 119.962 -0.695 . . . . 1.05 109.322 175.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.22 143.25 89.29 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.005 1.002 . . . . 0.38 109.819 174.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.84 -26.43 62.03 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 120.404 -0.518 . . . . 1.12 110.462 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.94 -43.86 95.37 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 110.027 -1.229 . . . . 0.42 110.027 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.7 m -69.87 -38.61 76.47 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.63 -0.924 . . . . 1.08 110.136 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 -56.24 -43.27 78.48 Favored 'General case' 0 N--CA 1.513 2.694 0 O-C-N 121.346 -0.846 . . . . 0.49 109.571 176.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -67.16 -50.2 62.02 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-O 121.18 0.514 . . . . 3.4 110.316 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -57.6 -36.35 71.65 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.764 -0.585 . . . . 0.74 110.661 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.446 ' CD2' ' CD1' ' A' ' 84' ' ' LEU . 16.8 t80 -88.15 -14.06 39.65 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.705 -0.622 . . . . 1.76 111.371 -174.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 74.92 41.74 32.23 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.657 -1.377 . . . . 0.32 109.657 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.419 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 81.9 mt -90.91 132.79 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.504 -0.998 . . . . 1.15 110.615 -176.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.18 159.29 36.52 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.047 -0.723 . . . . 1.82 109.047 172.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -57.96 140.23 52.66 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.388 -0.82 . . . . 2.7 110.367 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.77 -16.0 61.79 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.849 -0.901 . . . . 0.21 110.849 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.04 158.5 30.51 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.72 1.26 . . . . 1.12 110.223 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -111.86 139.68 47.14 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.661 -0.649 . . . . 0.24 109.598 174.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.09 155.02 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 109.235 -0.654 . . . . 1.06 109.235 174.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -116.35 123.22 47.08 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.345 -0.984 . . . . 1.09 108.345 -178.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.403 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 6.0 tt -140.53 158.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.553 -0.859 . . . . 1.05 111.232 -166.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -132.54 145.61 51.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.878 -0.514 . . . . 1.77 110.519 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.1 pt -115.06 151.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.664 -0.647 . . . . 1.06 110.6 178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.2 t -139.2 126.01 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 CA-C-O 121.31 0.576 . . . . 1.03 110.049 176.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 17.2 tptt -132.59 148.7 52.37 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 109.004 -0.739 . . . . 2.39 109.004 174.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.8 t80 -102.76 128.16 49.62 Favored 'General case' 0 N--CA 1.495 1.785 0 C-N-CA 120.137 -0.625 . . . . 0.91 110.246 -179.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -134.79 134.37 40.82 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.645 -0.659 . . . . 1.48 110.089 179.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.22 46.01 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 109.803 -1.319 . . . . 0.46 109.803 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -105.08 10.24 34.04 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.714 -0.874 . . . . 1.27 111.713 178.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.14 138.11 32.16 Favored Pre-proline 0 N--CA 1.499 1.976 0 O-C-N 121.242 -0.911 . . . . 1.37 111.073 -177.531 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -75.11 139.18 23.7 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 O-C-N 122.86 0.926 . . . . 0.38 110.298 173.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -113.62 137.35 51.72 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.556 -0.715 . . . . 1.71 109.559 172.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -137.97 166.27 24.49 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.59 -0.694 . . . . 1.42 110.756 -178.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.83 135.94 4.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.692 -1.363 . . . . 0.18 109.692 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 m -119.93 137.95 53.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.661 -0.905 . . . . 1.07 109.766 176.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.422 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 15.0 p90 -156.04 173.89 16.15 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 120.0 -0.68 . . . . 0.18 110.981 176.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.0 m -106.32 140.91 38.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.731 -0.606 . . . . 1.01 109.475 173.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.422 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 144.9 35.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.679 -0.638 . . . . 1.01 110.636 -175.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.815 -0.553 . . . . 2.71 109.732 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.47 125.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.321 0.581 . . . . 1.08 109.871 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.08 -171.31 27.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.617 -1.393 . . . . 0.22 109.617 178.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -61.87 156.1 21.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.569 -0.959 . . . . 1.39 109.837 178.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 54.99 19.4 2.68 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.446 -0.784 . . . . 1.13 112.079 -177.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.21 20.47 79.93 Favored Glycine 0 N--CA 1.5 2.91 0 C-N-CA 119.81 -1.186 . . . . 0.2 110.728 172.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -78.0 146.02 35.63 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.503 -0.998 . . . . 1.74 110.409 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.9 p -138.51 146.52 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.719 -0.613 . . . . 1.04 109.627 173.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -108.89 122.21 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 121.555 -0.715 . . . . 1.12 110.533 -174.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.2 mt -79.01 142.07 59.43 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.606 -0.684 . . . . 1.17 109.625 173.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.413 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.0 Cg_endo -65.1 131.83 29.94 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.862 0.927 . . . . 0.29 110.729 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -55.17 -33.07 62.66 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.497 -0.752 . . . . 3.08 110.88 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.8 -37.99 77.59 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.785 -0.572 . . . . 1.16 110.189 -178.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.01 -32.74 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.747 -0.596 . . . . 2.43 110.403 177.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.1 mtt180 -57.73 -46.08 84.93 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 121.352 -0.842 . . . . 3.27 109.85 178.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -70.08 -47.87 60.08 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.528 -0.469 . . . . 1.68 110.413 -175.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.6 t -60.57 -38.1 77.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 C-N-CA 120.157 -0.617 . . . . 1.08 109.924 -178.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.3 mt -82.76 -17.66 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.866 -0.521 . . . . 1.08 110.919 -176.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.498 2.829 0 N-CA-C 109.68 -1.368 . . . . 0.23 109.68 175.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.3 mm -89.56 143.82 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.515 -0.991 . . . . 1.42 110.644 -174.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -129.22 156.96 77.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.764 -0.585 . . . . 3.68 110.719 -177.171 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.28 134.14 62.1 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.022 1.012 . . . . 0.8 111.412 177.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.37 -0.17 71.07 Favored Glycine 0 N--CA 1.497 2.761 0 C-N-CA 120.617 -0.801 . . . . 0.26 111.205 175.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -96.26 132.39 41.77 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-N 118.732 1.266 . . . . 1.11 110.4 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.03 130.05 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.46 0.648 . . . . 1.06 110.961 -174.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 46.5 pt -117.67 159.34 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.462 -0.57 . . . . 1.06 109.462 176.705 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -98.49 130.87 45.08 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.893 -0.781 . . . . 1.14 108.893 173.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.421 HG13 ' CE1' ' A' ' 7' ' ' PHE . 90.5 t -114.6 128.53 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 CA-C-O 121.381 0.61 . . . . 1.05 110.18 -171.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.0 mt -114.96 129.8 56.79 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 109.269 -0.641 . . . . 1.08 109.269 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.446 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.22 141.57 35.49 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 1.11 109.996 173.406 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.52 -32.38 6.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.839 -0.538 . . . . 2.19 110.779 -177.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -169.16 -174.46 37.69 Favored Glycine 0 N--CA 1.504 3.171 0 C-N-CA 119.681 -1.247 . . . . 0.25 111.058 -177.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.0 p80 -146.35 153.71 40.83 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.664 -0.904 . . . . 2.53 110.614 -179.246 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -135.63 141.42 45.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.545 -0.722 . . . . 1.1 110.108 176.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.2 ptpp? -108.12 160.02 28.49 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.696 -0.628 . . . . 3.48 110.354 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -54.76 144.35 66.08 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 O-C-N 123.161 1.085 . . . . 2.02 111.042 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 91.1 mtm-85 -123.44 147.82 46.78 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.727 -0.608 . . . . 7.62 110.163 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 33.7 t30 . . . . . 0 N--CA 1.499 1.985 0 CA-C-O 118.019 -0.991 . . . . 7.16 110.126 179.666 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.0 mtt . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.165 0.507 . . . . 3.14 110.519 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -102.85 147.42 26.9 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.784 -0.573 . . . . 1.7 110.014 178.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 p -121.16 137.59 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.778 -0.576 . . . . 1.16 109.513 176.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 23.2 mt -85.32 -18.04 35.03 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 120.279 -0.568 . . . . 1.16 110.462 -176.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.96 155.47 3.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.368 -0.833 . . . . 1.09 109.589 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.2 ttmt -132.95 127.02 33.33 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.715 -0.615 . . . . 2.69 110.124 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.445 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.3 p90 -149.77 162.51 40.13 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.634 -0.667 . . . . 0.22 110.728 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -113.33 138.96 49.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.604 -0.685 . . . . 2.35 110.32 -176.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.75 162.3 40.99 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.739 -0.601 . . . . 1.03 109.619 177.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.49 159.02 17.88 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 119.787 -0.765 . . . . 1.03 110.01 176.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.1 t -79.32 135.94 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.233 -0.587 . . . . 1.16 110.333 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.3 m80 -115.39 171.97 7.38 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.528 -0.545 . . . . 1.04 109.528 174.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -46.26 152.31 0.43 Allowed 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.562 -0.711 . . . . 3.63 112.033 -175.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.1 mt 62.64 7.4 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.495 -0.753 . . . . 1.12 112.632 -174.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.72 16.01 80.61 Favored Glycine 0 N--CA 1.497 2.723 0 O-C-N 120.915 -1.115 . . . . 0.26 110.423 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 70.2 ttp85 -84.91 143.41 29.02 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.199 -1.177 . . . . 2.55 110.294 -177.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.7 pt -133.21 157.49 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.759 -0.588 . . . . 1.1 109.532 173.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 mm -116.29 129.6 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.591 -0.693 . . . . 1.04 109.96 176.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.6 mt -79.19 145.5 64.92 Favored Pre-proline 0 N--CA 1.496 1.859 0 C-N-CA 119.961 -0.695 . . . . 1.05 109.375 175.343 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.2 142.86 88.31 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.102 1.054 . . . . 0.38 109.79 174.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.56 -26.6 61.66 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.84 -0.538 . . . . 1.12 110.447 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.8 95.0 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.036 -1.225 . . . . 0.42 110.036 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.1 m -69.73 -37.45 76.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.699 -0.883 . . . . 1.08 109.848 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.6 mtt180 -55.95 -42.42 76.2 Favored 'General case' 0 N--CA 1.509 2.499 0 O-C-N 121.343 -0.848 . . . . 0.49 109.801 178.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -66.75 -50.37 62.96 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.302 0.573 . . . . 3.4 110.284 -176.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -57.2 -37.15 71.76 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.868 -0.52 . . . . 0.74 110.622 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.444 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 17.6 t80 -87.83 -14.17 40.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.85 -0.531 . . . . 1.76 111.275 -176.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.36 42.37 28.11 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.57 -1.412 . . . . 0.32 109.57 177.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.444 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 77.8 mt -89.6 129.41 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.559 -0.965 . . . . 1.15 110.653 -176.566 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -128.48 159.51 35.21 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 109.173 -0.677 . . . . 1.82 109.173 171.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -57.75 138.59 55.37 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.411 -0.805 . . . . 2.7 110.478 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.1 62.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.857 -0.897 . . . . 0.21 110.857 179.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -77.09 157.47 31.03 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-N 118.763 1.281 . . . . 1.12 110.03 177.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -111.44 138.87 47.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.671 -0.643 . . . . 0.24 109.644 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 155.34 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 1.06 109.269 174.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -117.34 123.89 47.61 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.276 -1.009 . . . . 1.09 108.276 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.401 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.96 157.56 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.553 -0.859 . . . . 1.05 111.044 -167.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.68 146.09 51.59 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.789 -0.569 . . . . 1.77 110.427 177.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 29.6 pt -114.89 151.09 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.732 -0.605 . . . . 1.06 110.595 178.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.4 t -138.0 126.72 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.123 0.487 . . . . 1.03 109.707 176.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 30.6 tptt -138.09 147.12 43.71 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.726 -0.609 . . . . 2.39 109.636 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 39.5 t80 -102.09 130.28 48.65 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 120.291 -0.564 . . . . 0.91 110.369 -176.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -134.37 135.76 42.9 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.616 -0.678 . . . . 1.48 110.042 177.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.16 45.88 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.774 -1.33 . . . . 0.46 109.774 -178.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.12 8.91 34.36 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.835 -0.803 . . . . 1.27 111.825 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.24 135.13 26.66 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.185 -0.947 . . . . 1.37 111.033 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.35 144.88 29.65 Favored 'Trans proline' 0 N--CA 1.482 0.818 0 O-C-N 122.801 0.895 . . . . 0.38 110.114 173.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 31.4 mttm -122.5 149.24 44.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.491 -0.756 . . . . 1.71 110.105 171.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -136.75 167.74 20.86 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.758 -0.589 . . . . 1.42 110.835 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.67 135.87 4.45 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.49 -1.444 . . . . 0.18 109.49 177.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -122.88 138.23 54.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.931 . . . . 1.07 109.978 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.423 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 14.8 p90 -156.3 172.92 17.64 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 119.858 -0.737 . . . . 0.18 110.89 175.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -106.95 141.29 38.4 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.704 -0.623 . . . . 1.01 109.473 173.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.423 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 145.99 36.7 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.591 -0.693 . . . . 1.01 110.759 -175.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -93.47 145.24 24.65 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.582 -0.525 . . . . 2.71 109.582 175.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.3 t -78.96 125.07 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.295 0.569 . . . . 1.08 109.823 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.62 -166.62 25.38 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.117 -1.193 . . . . 0.22 110.117 178.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.74 153.51 28.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.768 -0.842 . . . . 1.39 110.158 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 53.39 21.21 2.28 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.595 -0.69 . . . . 1.13 112.167 -179.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.22 20.51 79.64 Favored Glycine 0 N--CA 1.501 2.982 0 C-N-CA 119.663 -1.256 . . . . 0.2 110.764 171.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.5 m -77.87 145.2 36.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.456 -1.026 . . . . 1.74 110.441 -175.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.46 146.65 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.806 -0.559 . . . . 1.04 109.645 175.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.44 122.72 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.509 -0.744 . . . . 1.12 110.787 -174.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 70.8 mt -79.11 144.33 62.81 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.584 -0.698 . . . . 1.17 109.624 172.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.416 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.8 Cg_endo -64.76 134.39 40.39 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 O-C-N 122.952 0.975 . . . . 0.29 110.841 -179.637 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -55.19 -34.16 63.65 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.491 -0.756 . . . . 3.08 110.814 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.66 76.68 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.729 -0.607 . . . . 1.16 110.32 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.6 mt -77.13 -32.69 56.62 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.73 -0.607 . . . . 2.43 110.5 178.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.85 -46.05 85.35 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.328 -0.857 . . . . 3.27 109.858 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.92 -46.61 64.99 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 120.512 -0.475 . . . . 1.68 110.411 -175.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.0 t -60.55 -38.7 79.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.679 -0.638 . . . . 1.08 109.949 -178.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.6 mt -82.8 -16.44 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.791 -0.568 . . . . 1.08 111.102 -176.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 75.77 35.18 46.45 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.91 -1.276 . . . . 0.23 109.91 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 51.2 mm -90.77 142.32 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.53 -0.982 . . . . 1.42 110.589 -174.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.2 mttt -128.9 158.73 71.63 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.82 -0.55 . . . . 3.68 110.586 -177.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -54.56 134.21 60.8 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.063 1.033 . . . . 0.8 111.429 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.1 -0.5 72.42 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.69 -0.766 . . . . 0.26 111.292 175.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -97.37 133.51 41.87 Favored 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 118.711 1.255 . . . . 1.11 110.559 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.2 p -91.95 131.17 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-O 121.479 0.657 . . . . 1.06 111.095 -174.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 45.7 pt -119.0 159.48 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.286 -0.635 . . . . 1.06 109.286 175.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -97.93 131.59 44.25 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.445 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 90.8 t -115.65 129.5 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.348 0.594 . . . . 1.05 110.263 -170.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.5 mt -115.13 130.8 57.02 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 109.279 -0.638 . . . . 1.08 109.279 179.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.417 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.35 139.9 36.34 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.365 -0.835 . . . . 1.11 110.037 173.052 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -106.65 -36.4 6.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.836 -0.54 . . . . 2.19 110.837 -176.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.88 -175.2 38.11 Favored Glycine 0 N--CA 1.502 3.061 0 C-N-CA 119.79 -1.195 . . . . 0.25 110.935 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -143.81 153.46 42.4 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.682 -0.893 . . . . 2.53 110.728 -177.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -134.1 138.65 45.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.622 -0.674 . . . . 1.1 110.205 175.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.4 mttt -122.64 104.22 36.9 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.79 -0.569 . . . . 3.48 110.23 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_exo -54.37 145.19 57.74 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 O-C-N 123.104 1.055 . . . . 2.02 111.097 -179.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 72.8 mtp85 -121.94 149.04 44.01 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.688 -0.632 . . . . 7.62 110.209 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.9 m120 . . . . . 0 N--CA 1.497 1.892 0 CA-C-O 118.01 -0.995 . . . . 7.16 110.16 179.986 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.6 mtm . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.2 0.524 . . . . 3.14 110.622 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -81.03 138.35 36.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.822 -0.548 . . . . 1.7 110.1 178.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 p -128.69 134.32 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.725 -0.61 . . . . 1.16 109.47 177.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.4 mt -82.73 -19.86 37.13 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.764 -0.585 . . . . 1.16 110.454 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.71 153.63 3.42 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.38 -0.825 . . . . 1.09 109.241 175.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -133.48 125.17 28.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.804 -0.56 . . . . 2.69 110.07 -176.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 12.9 p90 -151.0 162.55 40.61 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.638 -0.664 . . . . 0.22 110.794 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -113.48 139.11 49.21 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.61 -0.681 . . . . 2.35 110.246 -176.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.96 162.37 40.95 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.785 -0.572 . . . . 1.03 109.63 177.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 t -111.28 158.76 18.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.433 -0.792 . . . . 1.03 109.986 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.5 t -79.33 134.7 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 C-N-CA 120.296 -0.561 . . . . 1.16 110.239 -176.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -113.44 171.89 7.29 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.22 0.534 . . . . 1.04 109.646 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -46.49 152.98 0.4 Allowed 'General case' 0 N--CA 1.506 2.334 0 O-C-N 121.594 -0.691 . . . . 3.63 111.957 -176.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.2 mt 62.76 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.675 0 O-C-N 121.573 -0.705 . . . . 1.12 112.601 -174.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.2 16.1 80.92 Favored Glycine 0 N--CA 1.498 2.787 0 O-C-N 120.875 -1.14 . . . . 0.26 110.276 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -85.65 143.41 28.43 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.265 -1.138 . . . . 2.55 110.443 -176.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.1 pt -133.37 155.53 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.787 -0.571 . . . . 1.1 109.491 172.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -116.54 129.18 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.629 -0.669 . . . . 1.04 110.038 176.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.428 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -79.47 145.12 62.83 Favored Pre-proline 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 1.05 109.404 175.573 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -63.49 143.32 87.75 Favored 'Trans proline' 0 N--CA 1.488 1.17 0 O-C-N 122.966 0.982 . . . . 0.38 109.775 174.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.91 -26.52 59.34 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.799 -0.563 . . . . 1.12 110.504 -178.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.4 -45.14 94.15 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.016 -1.233 . . . . 0.42 110.016 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 76.4 m -69.38 -37.09 77.41 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.621 -0.929 . . . . 1.08 110.178 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -56.32 -42.15 77.16 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.369 -0.832 . . . . 0.49 109.687 178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.8 tptm -66.43 -50.2 64.19 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-O 121.244 0.545 . . . . 3.4 110.214 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -57.05 -37.99 72.59 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.928 -0.482 . . . . 0.74 110.698 -178.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.427 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 21.6 t80 -86.87 -14.31 42.36 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.812 -0.555 . . . . 1.76 111.277 -177.345 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 42.52 24.61 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.631 -1.388 . . . . 0.32 109.631 178.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.418 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.4 mt -88.58 129.1 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.52 -0.988 . . . . 1.15 110.483 -177.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.06 158.47 37.86 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.919 -0.771 . . . . 1.82 108.919 170.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -57.24 140.04 50.97 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.309 -0.869 . . . . 2.7 110.492 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.01 -16.02 61.84 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.842 -0.903 . . . . 0.21 110.842 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.88 157.94 31.08 Favored 'General case' 0 N--CA 1.5 2.047 0 CA-C-N 118.739 1.27 . . . . 1.12 110.198 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -111.36 138.74 47.46 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.635 -0.666 . . . . 0.24 109.603 174.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.22 153.78 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.282 -0.636 . . . . 1.06 109.282 174.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -115.86 123.54 48.4 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.305 -0.998 . . . . 1.09 108.305 -179.077 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.5 tt -139.99 158.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 C-N-CA 119.587 -0.845 . . . . 1.05 111.004 -167.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -133.09 145.97 51.22 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.874 -0.516 . . . . 1.77 110.505 177.489 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.5 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.79 -0.569 . . . . 1.06 110.619 178.325 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.3 t -138.96 125.5 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.917 -0.489 . . . . 1.03 109.787 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -132.28 144.49 50.63 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.774 -0.579 . . . . 2.39 109.533 174.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -104.87 129.36 53.21 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.197 -0.601 . . . . 0.91 110.459 -178.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -133.53 129.95 37.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.672 -0.642 . . . . 1.48 110.073 177.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.78 -128.17 45.96 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.811 -1.316 . . . . 0.46 109.811 -177.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.11 14.17 29.62 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 1.27 111.562 178.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -131.06 124.44 20.54 Favored Pre-proline 0 N--CA 1.498 1.947 0 O-C-N 121.251 -0.906 . . . . 1.37 110.994 -177.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.25 137.0 20.62 Favored 'Trans proline' 0 N--CA 1.482 0.828 0 O-C-N 122.704 0.844 . . . . 0.38 110.133 174.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 16.6 mmtp -110.78 137.75 48.04 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 1.71 109.682 173.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -134.94 163.94 28.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.683 -0.636 . . . . 1.42 110.786 -177.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.95 135.92 4.44 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.56 -1.416 . . . . 0.18 109.56 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.4 m -122.25 137.83 54.7 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.735 -0.862 . . . . 1.07 109.766 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.423 ' CD2' ' HD3' ' A' ' 65' ' ' PRO . 13.2 p90 -155.82 172.88 17.59 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.562 -0.711 . . . . 0.18 110.937 176.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -106.6 140.3 39.68 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.707 -0.621 . . . . 1.01 109.556 173.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.42 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -140.84 144.51 35.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.664 -0.648 . . . . 1.01 110.49 -176.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -93.5 144.73 25.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.845 -0.534 . . . . 2.71 109.569 176.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.4 t -78.47 125.75 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.789 -0.569 . . . . 1.08 109.862 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.77 -167.54 26.26 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.892 -1.283 . . . . 0.22 109.892 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.68 153.52 27.91 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.756 -0.849 . . . . 1.39 110.163 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 53.57 21.09 2.37 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.51 -0.744 . . . . 1.13 112.008 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.95 20.52 79.72 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.814 -1.184 . . . . 0.2 110.837 171.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.3 m -77.99 145.26 36.09 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.462 -1.022 . . . . 1.74 110.296 -176.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.5 p -138.27 146.21 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.772 -0.58 . . . . 1.04 109.559 174.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.8 mm -110.92 122.94 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.521 -0.737 . . . . 1.12 110.671 -174.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 84.7 mt -78.88 143.0 61.26 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.572 -0.705 . . . . 1.17 109.568 172.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.423 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.5 Cg_endo -64.57 133.48 37.15 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 O-C-N 122.954 0.976 . . . . 0.29 110.755 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -55.2 -34.0 63.53 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.484 -0.76 . . . . 3.08 110.84 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.95 77.34 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.734 -0.604 . . . . 1.16 110.232 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.5 mt -77.1 -32.65 56.78 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.21 -0.596 . . . . 2.43 110.513 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.79 -45.52 85.92 Favored 'General case' 0 N--CA 1.504 2.248 0 O-C-N 121.331 -0.856 . . . . 3.27 109.827 178.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.28 -47.67 60.16 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 120.506 -0.478 . . . . 1.68 110.467 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 90.8 t -60.58 -38.1 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.106 0 O-C-N 121.683 -0.636 . . . . 1.08 109.816 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.4 mt -82.71 -17.47 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.795 -0.566 . . . . 1.08 110.914 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.4 35.2 37.97 Favored Glycine 0 N--CA 1.498 2.797 0 N-CA-C 109.78 -1.328 . . . . 0.23 109.78 175.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.81 144.15 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.979 . . . . 1.42 110.673 -174.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -131.39 163.45 49.42 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.776 -0.577 . . . . 3.68 110.685 -177.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.83 134.44 57.14 Favored 'Trans proline' 0 N--CA 1.487 1.142 0 O-C-N 122.934 0.965 . . . . 0.8 110.865 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.83 0.82 71.38 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 111.149 -0.78 . . . . 0.26 111.149 176.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -97.24 132.43 43.01 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 118.733 1.266 . . . . 1.11 110.515 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.0 p -93.46 137.18 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.901 0.858 . . . . 1.06 111.433 -173.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.41 159.52 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.391 -0.596 . . . . 1.06 109.391 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -97.52 130.58 44.58 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.942 -0.762 . . . . 1.14 108.942 174.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.424 HG11 ' CE1' ' A' ' 7' ' ' PHE . 91.0 t -115.08 129.96 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 CA-C-O 121.318 0.58 . . . . 1.05 110.158 -171.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 35.3 mt -117.13 129.51 56.02 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 109.047 -0.723 . . . . 1.08 109.047 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.408 HD22 ' CE2' ' A' ' 27' ' ' TYR . 4.7 mt -79.77 140.61 36.84 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.718 -0.793 . . . . 1.11 109.848 172.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.9 mt -110.39 -33.38 6.64 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.788 -0.57 . . . . 2.19 110.859 -175.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.56 -175.89 38.42 Favored Glycine 0 N--CA 1.503 3.148 0 C-N-CA 119.763 -1.208 . . . . 0.25 110.953 -176.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -143.81 153.65 42.59 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.725 -0.867 . . . . 2.53 110.675 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -137.97 142.92 40.47 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.498 -0.751 . . . . 1.1 110.198 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -122.94 159.24 54.65 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.686 -0.634 . . . . 3.48 109.946 179.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -55.6 143.51 78.7 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 O-C-N 123.142 1.075 . . . . 2.02 110.976 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -128.69 140.72 51.61 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.783 -0.573 . . . . 7.62 110.165 179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 . . . . . 0 N--CA 1.495 1.806 0 CA-C-O 118.024 -0.988 . . . . 7.16 110.226 -179.898 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.0 mtp . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.172 0.511 . . . . 3.14 110.588 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.4 146.46 45.09 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.896 -0.503 . . . . 1.7 109.946 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -128.51 136.76 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.663 -0.648 . . . . 1.16 109.671 178.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 29.4 mt -84.06 -21.62 31.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.789 -0.569 . . . . 1.16 110.323 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -172.28 155.46 3.58 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.36 -0.837 . . . . 1.09 109.175 176.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 23.1 tttt -133.47 125.56 29.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.668 -0.645 . . . . 2.69 110.175 -177.258 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.447 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 15.8 p90 -150.84 162.78 40.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.22 110.757 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -113.24 139.07 49.11 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.562 -0.711 . . . . 2.35 110.264 -176.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.04 162.32 41.07 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.825 -0.547 . . . . 1.03 109.646 177.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -111.2 158.7 18.64 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.818 -0.753 . . . . 1.03 110.038 177.165 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.0 t -79.4 135.67 25.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.742 -0.599 . . . . 1.16 110.288 -176.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.0 m80 -114.79 171.9 7.36 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.354 0.597 . . . . 1.04 109.661 174.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -46.65 153.04 0.41 Allowed 'General case' 0 N--CA 1.505 2.318 0 O-C-N 121.532 -0.73 . . . . 3.63 111.956 -176.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.3 mt 62.75 7.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.662 0 O-C-N 121.599 -0.688 . . . . 1.12 112.619 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.86 16.07 80.43 Favored Glycine 0 N--CA 1.496 2.682 0 O-C-N 120.932 -1.105 . . . . 0.26 110.369 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.4 ttp180 -83.78 143.04 30.24 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.167 -1.196 . . . . 2.55 110.382 -176.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -131.89 154.66 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 109.365 -0.606 . . . . 1.1 109.365 171.17 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.65 129.19 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 C-N-CA 120.08 -0.648 . . . . 1.04 109.999 176.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.429 HG12 ' CE2' ' A' ' 7' ' ' PHE . 29.1 mt -79.75 145.08 61.54 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.04 -0.664 . . . . 1.05 109.359 175.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -63.5 143.66 88.51 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.986 0.993 . . . . 0.38 109.723 174.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.04 -26.5 60.42 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 120.449 -0.5 . . . . 1.12 110.426 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.35 -45.19 94.07 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 109.958 -1.257 . . . . 0.42 109.958 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 85.3 m -69.37 -36.98 77.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.66 -0.906 . . . . 1.08 110.117 -179.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.8 mtt180 -56.41 -41.91 77.12 Favored 'General case' 0 N--CA 1.509 2.502 0 O-C-N 121.323 -0.861 . . . . 0.49 109.662 178.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.5 tptp -66.37 -50.14 64.51 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 120.275 -0.57 . . . . 3.4 110.262 -177.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.8 t80 -57.06 -38.19 72.92 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.925 -0.484 . . . . 0.74 110.694 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.428 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.1 t80 -87.03 -14.28 42.01 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.803 -0.561 . . . . 1.76 111.249 -177.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.94 42.71 24.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.493 -1.443 . . . . 0.32 109.493 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.415 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.7 mt -88.06 127.5 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.566 -0.961 . . . . 1.15 110.501 -177.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.26 154.24 45.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.877 -0.786 . . . . 1.82 108.877 171.384 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -55.18 139.42 42.07 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.245 -0.91 . . . . 2.7 110.706 -177.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -15.76 62.41 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 110.898 -0.881 . . . . 0.21 110.898 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -76.19 158.5 31.61 Favored 'General case' 0 N--CA 1.5 2.031 0 CA-C-N 118.749 1.274 . . . . 1.12 109.992 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -111.57 138.63 47.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.568 -0.708 . . . . 0.24 109.614 175.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.72 154.79 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 109.213 -0.662 . . . . 1.06 109.213 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.85 123.6 48.57 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.318 -0.993 . . . . 1.09 108.318 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.2 tt -140.11 159.5 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.627 -0.829 . . . . 1.05 110.897 -168.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.6 ttpt -133.77 146.01 50.33 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.784 -0.573 . . . . 1.77 110.374 177.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.1 pt -114.74 150.4 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.627 -0.671 . . . . 1.06 110.359 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.9 t -140.89 124.53 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.219 0.533 . . . . 1.03 109.807 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.0 tttm -132.06 149.86 52.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.363 -0.606 . . . . 2.39 109.363 175.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -100.3 129.18 46.26 Favored 'General case' 0 N--CA 1.497 1.923 0 C-N-CA 119.993 -0.683 . . . . 0.91 110.367 -179.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -132.6 131.32 41.32 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.688 -0.633 . . . . 1.48 110.061 178.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.74 -128.12 45.91 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.809 -1.316 . . . . 0.46 109.809 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 17.8 pt-20 -105.03 9.92 34.25 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.821 -0.811 . . . . 1.27 111.717 177.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -131.1 138.74 33.62 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.238 -0.913 . . . . 1.37 110.837 -178.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -75.4 139.83 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.879 0 O-C-N 122.939 0.968 . . . . 0.38 110.598 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 44.5 mmtt -112.93 136.58 52.44 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.502 -0.749 . . . . 1.71 109.583 171.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -138.62 167.9 20.96 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.664 -0.647 . . . . 1.42 110.974 -178.154 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.64 135.71 4.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.405 -1.478 . . . . 0.18 109.405 177.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -122.74 137.28 54.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.645 -0.915 . . . . 1.07 109.862 177.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.423 ' CE2' ' HB1' ' A' ' 54' ' ' ALA . 11.3 p90 -155.81 173.6 16.52 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.013 -0.675 . . . . 0.18 110.942 178.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 m -106.69 140.38 39.64 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.737 -0.602 . . . . 1.01 109.575 173.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.423 ' HB1' ' CE2' ' A' ' 52' ' ' PHE . . . -141.81 146.03 35.41 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.739 -0.6 . . . . 1.01 110.563 -175.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.9 ttp-105 -93.69 145.28 24.68 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.797 -0.565 . . . . 2.71 109.684 175.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 98.3 t -78.85 126.57 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.244 0.545 . . . . 1.08 109.861 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.66 -170.6 26.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.834 -1.306 . . . . 0.22 109.834 177.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -61.78 156.04 21.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.673 -0.898 . . . . 1.39 109.909 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.04 19.05 2.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.506 -0.746 . . . . 1.13 112.138 -177.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.45 20.46 79.41 Favored Glycine 0 N--CA 1.498 2.827 0 C-N-CA 119.863 -1.161 . . . . 0.2 110.714 172.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.64 146.76 33.91 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -1.005 . . . . 1.74 110.373 -176.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -138.9 146.44 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.751 -0.593 . . . . 1.04 109.553 174.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.3 mm -109.04 122.15 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.513 -0.742 . . . . 1.12 110.704 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.2 mt -78.84 142.25 60.44 Favored Pre-proline 0 N--CA 1.498 1.96 0 O-C-N 121.423 -0.798 . . . . 1.17 109.486 172.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.419 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.6 Cg_endo -64.83 135.01 42.72 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.938 0.967 . . . . 0.29 110.705 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -55.12 -34.21 63.53 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.499 -0.751 . . . . 3.08 110.766 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.69 -37.73 76.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.752 -0.592 . . . . 1.16 110.319 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 67.0 mt -77.03 -32.82 57.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.636 -0.665 . . . . 2.43 110.482 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -57.72 -45.85 85.2 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.419 -0.801 . . . . 3.27 109.951 178.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.33 -47.29 61.76 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 120.532 -0.467 . . . . 1.68 110.483 -175.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.49 -38.25 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 O-C-N 121.699 -0.626 . . . . 1.08 109.932 -178.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.7 mt -82.49 -18.01 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.791 -0.568 . . . . 1.08 110.915 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.34 35.19 43.26 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.704 -1.358 . . . . 0.23 109.704 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.7 mm -92.65 142.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.576 -0.955 . . . . 1.42 110.64 -174.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 34.9 mtpt -130.25 163.22 49.36 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.748 -0.595 . . . . 3.68 110.792 -177.181 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.76 135.41 63.58 Favored 'Trans proline' 0 N--CA 1.487 1.111 0 O-C-N 122.922 0.959 . . . . 0.8 110.92 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.72 -0.15 73.18 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 111.08 -0.808 . . . . 0.26 111.08 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -97.47 133.11 42.49 Favored 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 118.691 1.246 . . . . 1.11 110.552 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.02 133.37 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.67 0.747 . . . . 1.06 111.26 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 41.4 pt -123.48 159.52 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 109.272 -0.64 . . . . 1.06 109.272 176.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -98.44 131.1 44.98 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.963 -0.754 . . . . 1.14 108.963 176.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 83.9 t -114.95 130.24 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.394 0.616 . . . . 1.05 110.28 -170.524 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.5 mt -116.3 130.74 56.93 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 109.074 -0.713 . . . . 1.08 109.074 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.411 HD23 ' CE2' ' A' ' 27' ' ' TYR . 5.7 mt -80.55 140.86 35.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.356 -0.84 . . . . 1.11 109.791 172.204 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -113.18 -31.01 6.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.654 -0.654 . . . . 2.19 111.046 -175.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.18 -177.78 39.58 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.65 -1.262 . . . . 0.25 110.978 -176.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 p80 -144.94 153.52 41.62 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.719 -0.871 . . . . 2.53 110.59 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -135.95 138.69 42.6 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.527 -0.733 . . . . 1.1 110.278 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -117.66 110.56 40.36 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.786 -0.571 . . . . 3.48 110.205 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -54.22 147.27 45.87 Favored 'Trans proline' 0 N--CA 1.499 1.824 0 O-C-N 122.988 0.994 . . . . 2.02 111.109 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 16.8 tpt180 -120.39 144.08 48.1 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 7.62 110.271 -178.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 . . . . . 0 N--CA 1.496 1.866 0 CA-C-O 118.021 -0.99 . . . . 7.16 110.161 179.826 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.9 ttm . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.005 0.431 . . . . 3.14 110.162 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -78.28 140.18 38.85 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.718 -0.614 . . . . 1.7 110.025 178.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -128.11 136.04 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.781 -0.575 . . . . 1.16 109.655 178.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.7 mt -83.91 -19.1 35.34 Favored 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 120.198 -0.601 . . . . 1.16 110.378 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.4 153.3 3.51 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.292 -0.88 . . . . 1.09 109.335 176.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -134.16 125.45 27.93 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.697 -0.627 . . . . 2.69 110.089 -177.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.445 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 14.8 p90 -150.26 162.62 40.14 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.591 -0.693 . . . . 0.22 110.852 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -113.53 138.29 50.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.61 -0.681 . . . . 2.35 110.102 -176.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.08 162.29 41.12 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.661 -0.649 . . . . 1.03 109.679 177.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.11 157.83 18.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.465 -0.772 . . . . 1.03 110.03 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.401 ' CG2' ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.61 136.43 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.783 -0.573 . . . . 1.16 110.319 -176.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -113.32 171.95 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.215 0.531 . . . . 1.04 109.686 173.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -46.67 152.31 0.49 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.607 -0.683 . . . . 3.63 111.896 -175.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 55.6 mt 62.6 7.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.635 0 O-C-N 121.559 -0.713 . . . . 1.12 112.601 -175.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.84 16.12 80.39 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 110.364 -1.095 . . . . 0.26 110.364 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.8 ttt180 -83.92 140.73 31.76 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.18 -1.188 . . . . 2.55 110.249 -176.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.6 pt -133.67 155.48 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.698 -0.626 . . . . 1.1 109.757 174.091 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.3 mm -118.16 129.79 73.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.62 -0.675 . . . . 1.04 109.998 175.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.5 mt -79.61 145.97 64.19 Favored Pre-proline 0 N--CA 1.495 1.777 0 C-N-CA 120.052 -0.659 . . . . 1.05 109.396 175.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.16 142.89 88.66 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 O-C-N 123.012 1.006 . . . . 0.38 109.823 174.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.22 -26.56 60.91 Favored 'General case' 0 N--CA 1.498 1.955 0 C-N-CA 120.403 -0.519 . . . . 1.12 110.49 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.43 -45.01 94.45 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 109.973 -1.251 . . . . 0.42 109.973 -179.015 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 96.6 m -69.66 -37.0 76.54 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.63 -0.923 . . . . 1.08 109.878 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -56.2 -42.27 76.93 Favored 'General case' 0 N--CA 1.509 2.508 0 O-C-N 121.298 -0.876 . . . . 0.49 109.77 178.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -65.91 -50.14 65.5 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.282 0.563 . . . . 3.4 110.116 -177.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -56.46 -37.54 70.43 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.136 0.493 . . . . 0.74 110.725 -179.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.427 ' O ' ' CD1' ' A' ' 27' ' ' TYR . 23.0 t80 -88.19 -14.15 39.33 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.784 -0.572 . . . . 1.76 111.315 -176.649 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 42.89 24.18 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.543 -1.423 . . . . 0.32 109.543 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.421 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.4 mt -87.84 126.92 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.519 -0.989 . . . . 1.15 110.653 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.91 155.64 43.87 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.134 -0.691 . . . . 1.82 109.134 171.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.56 137.49 48.71 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.308 -0.87 . . . . 2.7 110.79 -177.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.51 -15.08 64.07 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.926 -0.87 . . . . 0.21 110.926 178.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -76.01 157.55 32.9 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 118.76 1.28 . . . . 1.12 109.862 177.146 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -111.51 138.16 48.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.631 -0.668 . . . . 0.24 109.611 175.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.99 152.06 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 120.087 -0.645 . . . . 1.06 109.309 174.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -113.74 123.51 50.05 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.172 -1.047 . . . . 1.09 108.172 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 12.2 tt -139.87 157.57 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.584 -0.846 . . . . 1.05 110.886 -167.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -133.1 146.06 51.29 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.801 -0.562 . . . . 1.77 110.474 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 27.9 pt -114.9 151.1 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.758 -0.589 . . . . 1.06 110.54 178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.38 127.37 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.674 -0.491 . . . . 1.03 109.674 176.333 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.8 tttm -133.47 144.43 49.45 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 109.538 -0.542 . . . . 2.39 109.538 175.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -105.84 129.4 54.02 Favored 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 120.262 -0.575 . . . . 0.91 110.355 -178.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -133.48 131.43 39.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.682 -0.636 . . . . 1.48 110.14 176.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.84 -128.18 45.92 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.785 -1.326 . . . . 0.46 109.785 -177.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -105.16 13.92 29.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.725 -0.867 . . . . 1.27 111.624 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -131.13 122.84 19.42 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.302 -0.874 . . . . 1.37 111.214 -177.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -75.48 142.35 26.34 Favored 'Trans proline' 0 N--CA 1.483 0.89 0 N-CA-C 109.936 -0.832 . . . . 0.38 109.936 173.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -120.73 149.77 42.01 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.34 -0.85 . . . . 1.71 110.147 171.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -137.2 167.66 21.14 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.851 -0.531 . . . . 1.42 110.731 -177.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.57 135.86 4.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.342 -1.503 . . . . 0.18 109.342 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.2 m -122.95 137.99 54.8 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.658 -0.907 . . . . 1.07 109.887 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.424 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.3 p90 -155.96 172.61 18.09 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.88 -0.728 . . . . 0.18 110.969 175.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.2 m -107.54 140.45 40.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.685 -0.634 . . . . 1.01 109.598 174.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.424 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 144.49 34.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.62 -0.675 . . . . 1.01 110.527 -176.032 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.78 145.7 24.4 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.693 -0.629 . . . . 2.71 109.67 175.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 99.3 t -78.11 126.66 38.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.821 -0.55 . . . . 1.08 109.93 -178.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.92 -166.4 25.08 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.101 -1.2 . . . . 0.22 110.101 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.71 152.79 30.08 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.779 -0.836 . . . . 1.39 110.131 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.4 mt-30 53.64 21.02 2.39 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.557 -0.715 . . . . 1.13 112.03 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.49 79.91 Favored Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.802 -1.189 . . . . 0.2 110.776 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 51.5 p -79.08 148.36 32.45 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.465 -1.021 . . . . 1.74 110.43 -176.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.9 p -139.67 147.14 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.878 -0.514 . . . . 1.04 109.67 174.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.2 mm -108.5 121.85 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.536 -0.728 . . . . 1.12 110.535 -175.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 78.6 mt -78.68 143.02 62.16 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.6 -0.687 . . . . 1.17 109.619 173.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 58.0 Cg_endo -64.92 131.46 29.03 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.936 0.966 . . . . 0.29 110.784 -179.02 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 50.3 tttp -55.12 -34.07 63.4 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.424 -0.797 . . . . 3.08 110.846 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.72 -37.72 76.77 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.722 -0.611 . . . . 1.16 110.269 -178.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.9 mt -77.16 -32.71 56.43 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.21 -0.596 . . . . 2.43 110.494 178.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtt180 -57.55 -45.57 84.96 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.231 -0.918 . . . . 3.27 109.829 178.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.97 64.26 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 120.441 -0.504 . . . . 1.68 110.371 -174.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.8 t -60.56 -38.6 78.76 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.678 -0.639 . . . . 1.08 109.901 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.8 mt -83.26 -15.8 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.896 -0.503 . . . . 1.08 111.143 -176.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.931 -1.268 . . . . 0.23 109.931 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.401 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 51.4 mm -89.96 141.06 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.574 -0.957 . . . . 1.42 110.716 -174.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -130.61 159.26 71.8 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.808 -0.558 . . . . 3.68 110.69 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -54.63 133.63 57.97 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 122.98 0.99 . . . . 0.8 111.391 177.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.02 0.34 71.51 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 111.205 -0.758 . . . . 0.26 111.205 175.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -98.05 134.1 41.6 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-N 118.769 1.285 . . . . 1.11 110.603 179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.34 132.9 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 CA-C-O 121.55 0.691 . . . . 1.06 111.15 -174.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.8 pt -122.39 159.4 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 109.353 -0.61 . . . . 1.06 109.353 175.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 48.3 tt0 -98.85 131.71 44.75 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.007 -0.738 . . . . 1.14 109.007 175.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.424 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.1 t -116.16 129.88 71.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 CA-C-O 121.298 0.57 . . . . 1.05 110.362 -170.207 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.1 mt -115.83 130.94 57.04 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.188 -0.671 . . . . 1.08 109.188 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.416 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.27 140.18 36.32 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.375 -0.828 . . . . 1.11 109.797 171.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -109.36 -31.21 7.63 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.825 -0.547 . . . . 2.19 110.898 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.05 179.39 41.29 Favored Glycine 0 N--CA 1.503 3.136 0 C-N-CA 119.728 -1.225 . . . . 0.25 110.986 -177.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.406 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 29.2 p80 -140.6 145.67 37.0 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.728 -0.866 . . . . 2.53 110.072 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.406 ' CD1' ' O ' ' A' ' 87' ' ' HIS . 17.8 m-85 -131.34 138.95 49.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.506 -0.746 . . . . 1.1 109.943 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -83.73 156.31 64.79 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.783 -0.573 . . . . 3.48 110.251 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -55.12 142.52 77.41 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.171 1.09 . . . . 2.02 110.936 179.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -128.29 141.34 51.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.703 -0.623 . . . . 7.62 110.163 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 118.015 -0.993 . . . . 7.16 110.178 179.846 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.4 ptm . . . . . 0 N--CA 1.496 1.874 0 CA-C-O 121.479 0.657 . . . . 3.14 110.12 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -100.34 146.77 26.56 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 120.893 0.378 . . . . 1.7 110.127 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 p -127.93 141.07 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 121.795 -0.566 . . . . 1.16 109.644 178.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 30.9 mt -87.57 -17.93 30.87 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.744 -0.598 . . . . 1.16 110.708 -177.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.83 155.96 4.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.253 -0.904 . . . . 1.09 109.742 176.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -133.29 126.6 31.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.762 -0.586 . . . . 2.69 110.096 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 17.2 p90 -149.48 161.94 41.12 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.651 -0.656 . . . . 0.22 110.871 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.6 m-70 -111.73 138.02 48.86 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.617 -0.677 . . . . 2.35 110.17 -176.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.41 162.29 41.2 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.727 -0.608 . . . . 1.03 109.774 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.5 t -111.71 159.33 18.34 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 119.925 -0.71 . . . . 1.03 109.89 176.094 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.8 t -77.83 138.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 120.304 -0.558 . . . . 1.16 110.103 -177.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.67 171.9 7.57 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.327 0.584 . . . . 1.04 109.672 174.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -46.91 153.13 0.44 Allowed 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.537 -0.727 . . . . 3.63 111.927 -175.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 54.0 mt 63.1 7.22 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.681 0 O-C-N 121.601 -0.687 . . . . 1.12 112.643 -175.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.54 15.98 80.79 Favored Glycine 0 N--CA 1.498 2.791 0 O-C-N 120.829 -1.169 . . . . 0.26 110.292 179.455 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.0 ttm180 -85.94 145.39 27.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.324 -1.104 . . . . 2.55 110.352 -177.221 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.18 154.52 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.727 -0.608 . . . . 1.1 109.466 172.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.83 128.72 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.57 -0.706 . . . . 1.04 109.99 176.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.7 mt -79.98 145.09 60.57 Favored Pre-proline 0 N--CA 1.495 1.802 0 C-N-CA 120.084 -0.646 . . . . 1.05 109.37 175.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.27 143.06 88.53 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 122.917 0.956 . . . . 0.38 109.812 174.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.6 -26.42 61.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.867 -0.521 . . . . 1.12 110.489 -178.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.82 -44.37 94.8 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.42 109.914 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.8 m -69.69 -38.13 76.89 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.637 -0.919 . . . . 1.08 110.179 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -56.18 -41.23 75.19 Favored 'General case' 0 N--CA 1.512 2.648 0 O-C-N 121.274 -0.891 . . . . 0.49 109.493 176.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.5 tttp -65.53 -50.0 66.83 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.166 0.508 . . . . 3.4 110.142 -176.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -57.39 -37.96 73.5 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.749 -0.594 . . . . 0.74 110.725 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.448 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 18.6 t80 -87.99 -14.31 39.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.766 -0.584 . . . . 1.76 111.239 -176.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.48 42.45 27.32 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.548 -1.421 . . . . 0.32 109.548 177.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.448 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 76.4 mt -88.49 129.18 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.545 -0.974 . . . . 1.15 110.572 -176.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -129.07 158.76 38.02 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.929 -0.767 . . . . 1.82 108.929 170.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -57.45 140.54 50.26 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.315 -0.865 . . . . 2.7 110.426 -178.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.73 -16.06 61.65 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.843 -0.903 . . . . 0.21 110.843 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -77.06 157.95 30.81 Favored 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 118.724 1.262 . . . . 1.12 110.121 178.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -111.55 138.67 47.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.582 -0.699 . . . . 0.24 109.611 174.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.88 154.16 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 109.272 -0.64 . . . . 1.06 109.272 174.179 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -116.32 124.07 49.21 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.274 -1.01 . . . . 1.09 108.274 -179.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.402 ' CD1' ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -140.23 157.91 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.558 -0.857 . . . . 1.05 111.053 -167.181 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.81 146.07 51.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.76 -0.587 . . . . 1.77 110.517 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.94 150.94 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.598 -0.689 . . . . 1.06 110.544 178.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.9 t -138.08 125.13 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.177 0.513 . . . . 1.03 109.655 176.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 47.4 tttp -134.17 147.48 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.725 -0.609 . . . . 2.39 109.495 175.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -102.61 127.93 49.5 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.092 -0.643 . . . . 0.91 110.266 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.3 mt-10 -136.24 137.91 41.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.603 -0.685 . . . . 1.48 110.128 178.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.82 -128.27 46.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.761 -1.336 . . . . 0.46 109.761 -178.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -105.12 7.26 33.74 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.746 -0.855 . . . . 1.27 111.815 177.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.24 141.74 42.94 Favored Pre-proline 0 N--CA 1.499 2.016 0 O-C-N 121.2 -0.937 . . . . 1.37 110.956 -177.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -75.27 138.93 23.02 Favored 'Trans proline' 0 N--CA 1.481 0.768 0 O-C-N 122.839 0.915 . . . . 0.38 110.198 172.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 66.1 mmtt -111.06 137.78 48.29 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.527 -0.733 . . . . 1.71 109.432 172.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.65 164.46 27.81 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.555 -0.716 . . . . 1.42 110.997 -176.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.9 4.37 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.659 -1.377 . . . . 0.18 109.659 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.68 137.72 54.66 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.638 -0.919 . . . . 1.07 109.792 176.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.6 p90 -156.36 172.76 17.95 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.963 -0.695 . . . . 0.18 111.047 176.264 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.6 m -106.68 140.91 38.79 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.677 -0.639 . . . . 1.01 109.414 173.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.16 145.89 36.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.652 -0.655 . . . . 1.01 110.697 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.0 ttt180 -93.29 145.33 24.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.833 -0.542 . . . . 2.71 109.616 175.559 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -79.01 125.96 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 121.419 0.628 . . . . 1.08 109.722 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.7 -166.47 26.25 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.961 -1.256 . . . . 0.22 109.961 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -61.73 151.98 32.43 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.804 -0.821 . . . . 1.39 110.139 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 53.32 21.53 2.36 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.523 -0.736 . . . . 1.13 112.054 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.77 20.42 79.77 Favored Glycine 0 N--CA 1.498 2.832 0 C-N-CA 119.796 -1.192 . . . . 0.2 110.879 171.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.1 p -78.56 147.02 33.93 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.518 -0.989 . . . . 1.74 110.22 -178.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.6 p -139.26 146.39 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.8 -0.563 . . . . 1.04 109.525 175.293 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.95 123.81 66.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.58 -0.7 . . . . 1.12 110.583 -175.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 86.4 mt -78.32 144.06 65.72 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.643 -0.661 . . . . 1.17 109.432 172.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.417 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.4 Cg_endo -64.49 135.36 45.53 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.966 0.982 . . . . 0.29 110.73 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 38.2 tttp -55.08 -34.21 63.44 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.545 -0.722 . . . . 3.08 110.75 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.87 -38.33 78.57 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.779 -0.576 . . . . 1.16 110.343 -178.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.3 mt -77.13 -32.87 56.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.747 -0.595 . . . . 2.43 110.617 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.05 -45.82 86.38 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.35 -0.843 . . . . 3.27 109.882 178.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -46.76 63.96 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 120.511 -0.476 . . . . 1.68 110.425 -175.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.8 t -60.58 -38.28 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.704 -0.623 . . . . 1.08 109.853 -178.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.5 mt -82.68 -17.52 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.874 -0.516 . . . . 1.08 110.872 -176.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.89 35.11 40.51 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.693 -1.363 . . . . 0.23 109.693 175.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.1 mm -93.07 142.89 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.599 -0.942 . . . . 1.42 110.77 -173.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.2 ptmt -132.94 162.64 56.35 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.742 -0.599 . . . . 3.68 110.652 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -51.97 135.44 51.11 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.056 1.03 . . . . 0.8 111.887 178.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.95 -1.51 70.87 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 120.704 -0.76 . . . . 0.26 111.357 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -96.33 130.92 43.33 Favored 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 118.767 1.284 . . . . 1.11 110.614 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.79 134.35 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 CA-C-O 121.684 0.754 . . . . 1.06 111.296 -173.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 44.4 pt -125.58 159.46 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 109.567 -0.531 . . . . 1.06 109.567 177.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.421 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.1 tt0 -97.61 132.04 43.63 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.075 -0.713 . . . . 1.14 109.075 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 96.7 t -116.32 129.89 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.344 0.592 . . . . 1.05 110.264 -171.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -115.34 130.3 56.86 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.262 -0.644 . . . . 1.08 109.262 178.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.412 HD12 ' CD2' ' A' ' 27' ' ' TYR . 4.2 mt -79.96 138.81 37.16 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.345 -0.847 . . . . 1.11 109.914 172.479 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -105.76 -35.9 7.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.726 -0.609 . . . . 2.19 110.918 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.83 -176.03 38.69 Favored Glycine 0 N--CA 1.503 3.166 0 C-N-CA 119.79 -1.195 . . . . 0.25 110.817 -176.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -142.72 152.65 42.57 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.677 -0.896 . . . . 2.53 110.798 -177.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -135.22 139.53 44.56 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.535 -0.728 . . . . 1.1 110.064 175.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.81 135.22 19.78 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.788 -0.57 . . . . 3.48 110.282 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.28 150.48 49.38 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 O-C-N 123.107 1.056 . . . . 2.02 110.903 179.007 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -119.99 141.71 49.45 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.771 -0.58 . . . . 7.62 110.254 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 58.2 t30 . . . . . 0 N--CA 1.495 1.78 0 CA-C-O 117.971 -1.014 . . . . 7.16 110.196 -179.919 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.3 mtp . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.168 0.509 . . . . 3.14 110.557 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -73.96 142.11 45.87 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.891 -0.506 . . . . 1.7 110.105 178.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 p -127.72 136.84 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 109.522 -0.547 . . . . 1.16 109.522 178.187 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 29.0 mt -85.62 -18.36 33.49 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.728 -0.608 . . . . 1.16 110.32 178.119 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -174.5 151.27 1.51 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.244 -0.91 . . . . 1.09 108.997 176.08 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -134.96 127.82 31.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.649 -0.657 . . . . 2.69 110.295 -178.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.45 ' N ' ' CD1' ' A' ' 7' ' ' PHE . 16.8 p90 -150.36 163.14 39.09 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 120.345 -0.542 . . . . 0.22 110.595 -177.426 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.7 m170 -112.65 137.7 50.54 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.648 -0.657 . . . . 2.35 110.256 -176.776 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.83 162.31 40.99 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.752 -0.592 . . . . 1.03 109.585 177.13 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.06 159.29 17.44 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.765 -0.774 . . . . 1.03 110.139 177.675 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.6 t -79.05 136.27 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 120.298 -0.561 . . . . 1.16 110.254 -177.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -115.42 171.95 7.39 Favored 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.253 0.549 . . . . 1.04 109.726 175.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -46.64 153.03 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.583 -0.698 . . . . 3.63 111.882 -176.138 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 53.9 mt 62.94 7.07 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.666 0 O-C-N 121.525 -0.735 . . . . 1.12 112.629 -175.439 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.6 16.11 80.59 Favored Glycine 0 N--CA 1.498 2.792 0 O-C-N 120.895 -1.128 . . . . 0.26 110.33 179.389 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 ttm180 -85.43 144.16 28.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.255 -1.144 . . . . 2.55 110.293 -177.147 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.46 155.09 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.725 -0.609 . . . . 1.1 109.463 172.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.74 129.43 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.665 -0.647 . . . . 1.04 109.991 176.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.3 mt -79.61 145.99 64.23 Favored Pre-proline 0 N--CA 1.494 1.768 0 C-N-CA 120.061 -0.656 . . . . 1.05 109.321 175.682 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -63.47 143.21 87.66 Favored 'Trans proline' 0 N--CA 1.489 1.228 0 O-C-N 123.069 1.036 . . . . 0.38 109.698 174.652 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.31 -26.34 60.74 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.813 -0.555 . . . . 1.12 110.438 -178.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.34 -45.23 93.98 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.015 -1.234 . . . . 0.42 110.015 -179.323 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.1 m -69.27 -37.3 77.84 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.706 -0.879 . . . . 1.08 110.187 -179.579 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -56.24 -42.06 76.73 Favored 'General case' 0 N--CA 1.509 2.487 0 O-C-N 121.434 -0.791 . . . . 0.49 109.751 178.378 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -66.62 -50.24 63.66 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 121.272 0.558 . . . . 3.4 110.233 -177.024 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -57.27 -37.87 73.04 Favored 'General case' 0 N--CA 1.501 2.109 0 CA-C-O 121.205 0.526 . . . . 0.74 110.704 -179.039 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.451 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 17.5 t80 -87.69 -14.21 40.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.744 -0.597 . . . . 1.76 111.223 -176.795 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.17 26.76 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.598 -1.401 . . . . 0.32 109.598 177.674 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.451 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 73.1 mt -89.44 127.79 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.452 -1.028 . . . . 1.15 110.462 -176.545 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -128.21 159.7 34.39 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.114 -0.699 . . . . 1.82 109.114 171.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -57.2 139.36 52.88 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.364 -0.835 . . . . 2.7 110.541 -178.219 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.43 -15.77 62.2 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 110.843 -0.903 . . . . 0.21 110.843 178.232 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.07 158.74 31.49 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 118.701 1.25 . . . . 1.12 109.991 178.037 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -111.71 138.16 48.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.634 -0.666 . . . . 0.24 109.645 175.408 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.36 153.5 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 N-CA-C 109.164 -0.68 . . . . 1.06 109.164 173.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.3 123.16 48.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.227 -1.027 . . . . 1.09 108.227 -179.628 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.6 tt -140.38 158.33 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.593 -0.843 . . . . 1.05 110.946 -167.564 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -132.07 146.14 51.87 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.815 -0.553 . . . . 1.77 110.428 177.286 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.9 pt -114.92 150.55 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 1.06 110.305 176.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.3 t -139.58 124.35 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 CA-C-O 121.292 0.567 . . . . 1.03 109.692 177.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -135.99 147.89 48.19 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.731 -0.605 . . . . 2.39 109.415 176.758 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -101.25 129.56 47.22 Favored 'General case' 0 N--CA 1.496 1.834 0 C-N-CA 120.071 -0.652 . . . . 0.91 110.403 -177.566 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.65 136.82 41.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.689 -0.632 . . . . 1.48 110.045 178.26 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.84 -128.21 45.97 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 109.817 -1.313 . . . . 0.46 109.817 -178.519 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -105.02 8.03 34.23 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.734 -0.862 . . . . 1.27 111.833 178.438 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -131.15 141.87 43.46 Favored Pre-proline 0 N--CA 1.497 1.907 0 O-C-N 121.154 -0.966 . . . . 1.37 110.93 -177.607 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -75.24 137.88 21.75 Favored 'Trans proline' 0 N--CA 1.48 0.735 0 O-C-N 122.92 0.958 . . . . 0.38 110.198 173.441 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 22.7 mmtp -110.69 137.27 48.57 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.56 -0.712 . . . . 1.71 109.577 173.217 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.09 163.91 28.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.595 -0.691 . . . . 1.42 111.027 -176.328 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.75 135.72 4.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.488 -1.445 . . . . 0.18 109.488 176.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.8 m -124.5 136.86 54.34 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.733 -0.863 . . . . 1.07 109.823 177.288 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 11.6 p90 -155.93 173.62 16.53 Favored 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.888 -0.725 . . . . 0.18 111.046 178.267 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.71 141.02 39.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.713 -0.617 . . . . 1.01 109.518 173.583 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -141.89 145.84 35.06 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.64 -0.663 . . . . 1.01 110.672 -175.709 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 43.6 ttp180 -93.72 146.03 24.15 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.758 -0.589 . . . . 2.71 109.674 175.248 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 99.0 t -78.28 127.16 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.821 -0.55 . . . . 1.08 109.995 -178.401 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.96 -168.06 26.1 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.995 -1.242 . . . . 0.22 109.995 178.869 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.7 153.47 28.15 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.712 -0.875 . . . . 1.39 110.175 -179.727 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.68 20.89 2.37 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.596 -0.69 . . . . 1.13 112.105 -179.698 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.6 20.46 79.82 Favored Glycine 0 N--CA 1.5 2.957 0 C-N-CA 119.763 -1.208 . . . . 0.2 110.826 171.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.9 p -78.67 147.26 33.61 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.541 -0.976 . . . . 1.74 110.328 -177.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.7 p -138.75 146.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 109.515 -0.55 . . . . 1.04 109.515 174.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.8 123.89 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.527 -0.733 . . . . 1.12 110.612 -174.559 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.5 mt -78.23 144.27 66.52 Favored Pre-proline 0 N--CA 1.499 2.024 0 O-C-N 121.59 -0.694 . . . . 1.17 109.392 172.368 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.418 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 57.1 Cg_endo -64.34 135.61 47.22 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 O-C-N 122.965 0.981 . . . . 0.29 110.71 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 23.0 tptm -55.02 -34.85 63.82 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.368 -0.833 . . . . 3.08 110.769 -179.772 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.92 -38.3 78.65 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.79 -0.569 . . . . 1.16 110.276 -178.494 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.4 mt -77.05 -32.81 57.13 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.727 -0.608 . . . . 2.43 110.695 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -58.15 -46.22 86.05 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.351 -0.843 . . . . 3.27 109.845 178.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.43 -47.38 61.01 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.49 -0.484 . . . . 1.68 110.468 -175.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 88.8 t -60.64 -37.96 77.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.702 -0.624 . . . . 1.08 109.94 -178.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.7 mt -82.56 -17.82 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.833 -0.542 . . . . 1.08 110.823 -176.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.7 35.22 41.23 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.776 -1.33 . . . . 0.23 109.776 175.706 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 50.5 mm -90.12 142.69 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.46 -1.023 . . . . 1.42 110.665 -173.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.94 156.29 76.3 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.789 -0.569 . . . . 3.68 110.618 -177.807 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -55.44 135.87 71.16 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.018 1.009 . . . . 0.8 111.257 178.197 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -1.53 73.06 Favored Glycine 0 N--CA 1.496 2.678 0 C-N-CA 120.622 -0.799 . . . . 0.26 111.235 176.191 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.2 mt-10 -96.2 132.27 41.81 Favored 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 118.729 1.264 . . . . 1.11 110.429 179.033 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.57 130.71 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.49 0.662 . . . . 1.06 110.98 -174.822 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 46.6 pt -119.34 159.48 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 N-CA-C 109.579 -0.526 . . . . 1.06 109.579 178.055 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.416 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 82.0 tt0 -97.34 130.05 44.54 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.012 -0.736 . . . . 1.14 109.012 174.933 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 89.0 t -115.46 127.77 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.339 0.59 . . . . 1.05 110.235 -171.809 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.3 mt -115.07 129.19 56.63 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.411 -0.589 . . . . 1.08 109.411 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.419 ' CD1' ' CD2' ' A' ' 27' ' ' TYR . 4.5 mt -79.72 140.61 36.91 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.433 -0.792 . . . . 1.11 109.856 172.651 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.09 -31.99 6.93 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.857 -0.527 . . . . 2.19 110.798 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.56 -176.95 39.22 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.71 -1.233 . . . . 0.25 110.965 -177.429 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -145.06 152.6 40.36 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.715 -0.874 . . . . 2.53 110.742 -177.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -137.01 140.88 42.43 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.507 -0.746 . . . . 1.1 110.028 175.711 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.2 ttpt -110.68 151.47 42.85 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.711 -0.618 . . . . 3.48 110.31 179.81 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -56.12 143.99 81.98 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 O-C-N 123.334 1.176 . . . . 2.02 110.909 179.555 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -125.25 147.68 48.99 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.732 -0.605 . . . . 7.62 110.155 179.209 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 43.0 p-10 . . . . . 0 N--CA 1.495 1.798 0 CA-C-O 118.005 -0.998 . . . . 7.16 110.422 179.985 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.3 mtm . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.149 0.499 . . . . 3.14 110.591 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -80.04 138.68 37.05 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.937 -0.477 . . . . 1.7 110.214 179.347 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.0 p -128.74 134.93 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.719 -0.613 . . . . 1.16 109.565 177.439 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.23 -20.22 38.12 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.213 -0.595 . . . . 1.16 110.386 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -171.74 154.58 3.69 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.418 -0.801 . . . . 1.09 109.327 175.742 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.6 tttt -134.66 125.17 26.57 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.657 -0.652 . . . . 2.69 110.246 -176.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . 0.449 ' CZ ' ' CG1' ' A' ' 82' ' ' VAL . 17.2 p90 -150.65 162.76 40.05 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.536 -0.727 . . . . 0.22 110.842 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.69 138.74 49.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.623 -0.673 . . . . 2.35 110.231 -177.368 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.11 162.31 41.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.732 -0.605 . . . . 1.03 109.72 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.0 157.81 18.91 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.52 -0.737 . . . . 1.03 109.997 177.324 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.1 t -79.33 135.82 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.748 -0.595 . . . . 1.16 110.259 -176.665 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -113.84 171.87 7.33 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.294 0.568 . . . . 1.04 109.787 174.088 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtm-85 -46.66 152.67 0.45 Allowed 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.522 -0.736 . . . . 3.63 112.026 -175.694 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 56.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.599 0 O-C-N 121.596 -0.69 . . . . 1.12 112.598 -175.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.71 16.17 80.43 Favored Glycine 0 N--CA 1.498 2.789 0 O-C-N 120.891 -1.131 . . . . 0.26 110.325 179.404 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -84.05 141.8 30.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.271 -1.135 . . . . 2.55 110.36 -176.473 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.9 pt -133.98 154.36 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.654 . . . . 1.1 109.532 172.832 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mm -117.71 128.46 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 C-N-CA 120.051 -0.66 . . . . 1.04 109.857 176.19 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 34.0 mt -80.07 144.09 58.31 Favored Pre-proline 0 N--CA 1.496 1.829 0 C-N-CA 120.02 -0.672 . . . . 1.05 109.36 176.043 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.32 143.55 89.35 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 122.953 0.975 . . . . 0.38 109.731 174.656 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.5 -26.5 61.41 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.889 -0.507 . . . . 1.12 110.47 -178.347 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.48 -44.46 95.18 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 109.914 -1.275 . . . . 0.42 109.914 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.2 m -69.97 -38.34 76.04 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.618 -0.931 . . . . 1.08 110.162 -179.392 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 8.7 mtt180 -55.89 -40.79 73.52 Favored 'General case' 0 N--CA 1.514 2.75 0 O-C-N 121.245 -0.91 . . . . 0.49 109.43 176.42 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -64.94 -49.66 69.51 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.167 0.508 . . . . 3.4 110.119 -177.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.19 -38.55 73.82 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.785 -0.572 . . . . 0.74 110.726 -179.709 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.43 ' CD1' ' CG1' ' A' ' 29' ' ' ILE . 22.3 t80 -88.07 -14.23 39.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.847 -0.533 . . . . 1.76 111.308 -176.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.97 24.59 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.55 -1.42 . . . . 0.32 109.55 178.562 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.43 ' CG1' ' CD1' ' A' ' 27' ' ' TYR . 75.9 mt -87.25 129.14 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.499 -1.001 . . . . 1.15 110.563 -177.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.31 158.97 36.73 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 109.11 -0.7 . . . . 1.82 109.11 170.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.25 138.66 54.45 Favored 'General case' 0 N--CA 1.503 2.201 0 O-C-N 121.396 -0.815 . . . . 2.7 110.539 -179.149 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.05 62.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 110.869 -0.892 . . . . 0.21 110.869 178.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.82 155.54 32.96 Favored 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 118.708 1.254 . . . . 1.12 110.076 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -110.43 138.65 46.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.557 -0.714 . . . . 0.24 109.462 174.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.38 154.43 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 C-N-CA 120.204 -0.598 . . . . 1.06 109.398 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -114.89 123.38 49.01 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.158 -1.053 . . . . 1.09 108.158 179.695 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.7 tt -139.94 158.65 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.662 -0.815 . . . . 1.05 110.812 -167.787 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 ttpt -132.67 146.21 51.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.887 -0.508 . . . . 1.77 110.42 178.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.0 pt -114.72 149.12 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.718 -0.614 . . . . 1.06 110.252 177.107 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.5 t -140.1 123.95 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 CA-C-O 121.138 0.494 . . . . 1.03 109.69 178.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 29.2 tttt -132.25 148.47 52.45 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.34 -0.615 . . . . 2.39 109.34 175.922 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 33.1 t80 -102.2 128.98 48.48 Favored 'General case' 0 N--CA 1.496 1.864 0 C-N-CA 120.008 -0.677 . . . . 0.91 110.328 179.909 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -133.76 133.16 41.39 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.685 -0.635 . . . . 1.48 109.989 178.806 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.18 45.85 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.717 -1.353 . . . . 0.46 109.717 -178.578 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.06 8.61 34.36 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.702 -0.881 . . . . 1.27 111.726 177.937 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.4 pt-20 -131.29 139.06 34.28 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.227 -0.921 . . . . 1.37 110.722 -178.775 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -75.19 142.42 27.27 Favored 'Trans proline' 0 N--CA 1.483 0.87 0 O-C-N 122.931 0.964 . . . . 0.38 110.504 175.399 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 31.7 mmtp -111.13 136.0 50.81 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.588 -0.695 . . . . 1.71 109.714 172.743 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -133.27 156.89 46.74 Favored 'General case' 0 C--N 1.311 -1.068 0 O-C-N 121.531 -0.731 . . . . 1.42 110.582 -171.381 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.67 135.86 4.57 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.544 -1.422 . . . . 0.18 109.544 176.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -126.83 138.31 53.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.647 -0.913 . . . . 1.07 109.714 177.257 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.421 ' CE2' ' HB3' ' A' ' 54' ' ' ALA . 11.1 p90 -156.26 173.79 16.34 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 119.949 -0.701 . . . . 0.18 111.107 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.9 m -106.89 141.07 38.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.633 -0.667 . . . . 1.01 109.606 173.289 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.421 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . . . -142.24 145.77 34.44 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.754 -0.591 . . . . 1.01 110.551 -175.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 57.0 ttt180 -93.77 145.26 24.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.741 -0.6 . . . . 2.71 109.778 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 95.6 t -79.68 125.5 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 CA-C-O 121.384 0.611 . . . . 1.08 109.825 179.675 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.9 -165.91 25.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.989 -1.244 . . . . 0.22 109.989 178.482 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -61.62 153.07 28.92 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.85 -0.794 . . . . 1.39 110.178 -179.335 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.55 21.15 2.38 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.602 -0.686 . . . . 1.13 112.056 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.51 79.88 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 119.812 -1.185 . . . . 0.2 110.817 172.008 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 59.4 p -78.41 146.68 34.42 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.563 -0.963 . . . . 1.74 110.439 -176.244 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 8.8 p -139.55 145.62 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.631 -0.507 . . . . 1.04 109.631 174.203 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.3 mm -111.09 123.03 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.552 -0.718 . . . . 1.12 110.478 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.8 mt -78.2 144.47 67.02 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.613 -0.679 . . . . 1.17 109.656 174.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.41 ' HD3' ' CD2' ' A' ' 52' ' ' PHE . 56.9 Cg_endo -64.31 134.58 42.67 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 O-C-N 122.928 0.962 . . . . 0.29 110.802 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -54.88 -35.02 63.63 Favored 'General case' 0 N--CA 1.503 2.207 0 O-C-N 121.489 -0.757 . . . . 3.08 110.767 -179.806 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.84 -38.29 78.38 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.738 -0.601 . . . . 1.16 110.364 -178.063 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 72.6 mt -77.21 -32.66 56.09 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 120.172 -0.611 . . . . 2.43 110.729 179.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -58.28 -46.49 85.96 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.301 -0.874 . . . . 3.27 109.761 178.551 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.02 -46.12 65.77 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.542 -0.463 . . . . 1.68 110.455 -175.179 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.4 t -60.38 -38.46 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.61 -0.681 . . . . 1.08 109.825 -178.835 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.3 mt -82.17 -18.27 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.918 -0.489 . . . . 1.08 110.912 -177.059 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.59 35.13 42.08 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 109.75 -1.34 . . . . 0.23 109.75 176.476 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 49.8 mm -92.0 140.72 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.468 -1.019 . . . . 1.42 110.569 -174.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 23.1 mmmt -125.32 161.58 49.14 Favored Pre-proline 0 N--CA 1.498 1.964 0 O-C-N 121.637 -0.665 . . . . 3.68 110.498 -175.366 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -60.75 134.6 54.89 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 O-C-N 123.0 1.0 . . . . 0.8 110.748 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.47 0.87 72.37 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 111.118 -0.793 . . . . 0.26 111.118 176.645 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -100.33 135.86 41.12 Favored 'General case' 0 N--CA 1.498 1.975 0 CA-C-N 118.704 1.252 . . . . 1.11 110.737 -179.633 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.72 133.9 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.696 0.76 . . . . 1.06 111.463 -172.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 43.1 pt -124.59 159.47 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 109.399 -0.593 . . . . 1.06 109.399 175.427 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -98.6 132.0 44.35 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.067 -0.716 . . . . 1.14 109.067 175.9 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG1' ' CZ ' ' A' ' 7' ' ' PHE . 93.6 t -115.39 129.41 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 CA-C-O 121.302 0.572 . . . . 1.05 110.282 -171.408 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.1 129.36 56.3 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 109.168 -0.679 . . . . 1.08 109.168 178.869 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.419 HD11 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.09 139.25 36.96 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.396 -0.815 . . . . 1.11 109.755 171.798 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.21 -31.25 7.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.724 -0.61 . . . . 2.19 110.971 -174.899 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -168.06 -175.9 38.14 Favored Glycine 0 N--CA 1.504 3.176 0 C-N-CA 119.671 -1.252 . . . . 0.25 111.086 -176.944 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -144.44 154.05 42.54 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.681 -0.893 . . . . 2.53 110.744 -177.277 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -140.55 146.64 38.33 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.536 -0.727 . . . . 1.1 110.131 175.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.1 pttp -121.56 155.92 58.98 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.681 -0.637 . . . . 3.48 110.43 179.416 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -56.04 150.2 48.76 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 O-C-N 123.287 1.151 . . . . 2.02 110.914 179.222 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -119.71 142.13 48.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.719 -0.613 . . . . 7.62 110.177 179.223 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.495 1.816 0 CA-C-O 117.966 -1.016 . . . . 7.16 110.228 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.399 0 N-CA-C 109.568 -0.53 . . . . 0.23000000000000001 109.568 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.56 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.0 mt -86.71 -18.0 32.28 Favored 'General case' 0 N--CA 1.496 1.825 0 C-N-CA 120.251 -0.58 . . . . 0.16 110.515 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.965 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.77 152.71 3.13 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.388 -0.82 . . . . 0.11 109.094 177.13 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 46.6 tttt -133.85 125.16 27.8 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.674 -0.641 . . . . 0.88 110.054 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.597 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.6 p90 -150.94 162.28 41.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.575 -0.703 . . . . 0.080000000000000002 110.782 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -113.41 139.12 49.17 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.713 -0.617 . . . . 1.0800000000000001 110.235 -177.105 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.463 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.57 162.3 40.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.742 -0.599 . . . . 0.089999999999999997 109.604 177.76 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.1 157.95 18.82 Favored 'General case' 0 N--CA 1.496 1.869 0 C-N-CA 119.764 -0.774 . . . . 0.10000000000000001 110.063 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.29 134.92 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 C-N-CA 120.289 -0.564 . . . . 0.11 110.161 -176.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -113.46 171.93 7.27 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.23 0.538 . . . . 0.14000000000000001 109.685 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.33 152.54 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.53 -0.731 . . . . 2.7000000000000002 112.003 -175.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.674 0 O-C-N 121.516 -0.74 . . . . 0.20999999999999999 112.533 -174.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.09 80.66 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.815 -1.178 . . . . 0.080000000000000002 110.377 179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.798 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -85.54 142.96 28.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.297 -1.12 . . . . 2.3300000000000001 110.367 -176.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.463 HD12 HG21 ' A' ' 9' ' ' THR . 43.0 pt -133.2 157.74 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.658 -0.651 . . . . 0.089999999999999997 109.602 173.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.798 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.2 mm -117.06 129.58 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.632 -0.668 . . . . 0.089999999999999997 110.113 176.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.457 HG23 ' HD2' ' A' ' 20' ' ' PRO . 23.8 mt -79.98 147.01 64.9 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.147 -0.621 . . . . 0.080000000000000002 109.396 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.457 ' HD2' HG23 ' A' ' 19' ' ' ILE . 47.0 Cg_endo -63.06 143.15 90.06 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 122.979 0.989 . . . . 0.14000000000000001 109.878 174.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.98 -26.5 62.41 Favored 'General case' 0 N--CA 1.496 1.845 0 C-N-CA 120.404 -0.518 . . . . 0.13 110.448 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.76 -43.73 95.82 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.998 -1.241 . . . . 0.10000000000000001 109.998 -179.236 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.4 m -69.69 -39.17 77.1 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.547 -0.973 . . . . 0.14000000000000001 110.051 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HA ' HD12 ' A' ' 29' ' ' ILE . 7.8 mtt180 -56.49 -42.56 78.5 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 121.353 -0.842 . . . . 0.10000000000000001 109.403 177.364 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.2 tttt -67.45 -50.25 60.05 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.025 0.441 . . . . 2.2599999999999998 110.222 -176.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -58.09 -36.16 72.47 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.735 -0.603 . . . . 0.20000000000000001 110.581 178.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.926 ' CD2' HD13 ' A' ' 84' ' ' LEU . 11.5 t80 -86.77 -14.28 42.74 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.739 -0.601 . . . . 0.20000000000000001 111.331 -174.293 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.2 39.94 35.48 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.661 -1.376 . . . . 0.11 109.661 177.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.797 ' CG2' HG21 ' A' ' 56' ' ' VAL . 85.1 mt -93.2 132.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.502 -0.999 . . . . 0.12 110.633 -175.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.15 161.65 29.59 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 109.304 -0.628 . . . . 1.99 109.304 172.325 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -57.76 138.72 55.26 Favored 'General case' 0 N--CA 1.503 2.217 0 O-C-N 121.477 -0.764 . . . . 1.95 110.397 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.47 -16.11 61.82 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.855 -0.898 . . . . 0.10000000000000001 110.855 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -77.51 160.89 28.32 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.085 -1.244 . . . . 0.089999999999999997 110.234 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -112.62 139.27 48.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.11 109.728 175.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.2 155.82 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 N-CA-C 109.152 -0.684 . . . . 0.040000000000000001 109.152 173.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -118.75 123.83 45.78 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.36 -0.978 . . . . 1.0 108.36 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.828 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.9 tt -140.33 158.53 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 C-N-CA 119.58 -0.848 . . . . 0.080000000000000002 111.144 -167.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.444 ' HB2' HG23 ' A' ' 51' ' ' THR . 36.4 tttt -132.92 146.09 51.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.91 -0.494 . . . . 1.1799999999999999 110.384 177.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.483 HG22 HG22 ' A' ' 82' ' ' VAL . 24.7 pt -114.81 151.01 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.624 -0.672 . . . . 0.12 110.528 178.522 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t -138.38 124.75 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 CA-C-O 121.136 0.493 . . . . 0.10000000000000001 109.678 176.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.572 ' HB2' HG22 ' A' ' 80' ' ' ILE . 57.9 tttm -132.84 144.87 50.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.29 -0.633 . . . . 1.9399999999999999 109.29 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 42.4 t80 . . . . . 0 N--CA 1.496 1.842 0 C-N-CA 120.09 -0.644 . . . . 0.46000000000000002 110.55 -177.291 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo . . . . . 0 N--CA 1.483 0.88 0 N-CA-C 110.423 -0.645 . . . . 0.33000000000000002 110.423 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.727 ' HB3' HG23 ' A' ' 72' ' ' ILE . 28.5 mmtp -110.36 137.51 47.98 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.577 -0.702 . . . . 1.25 109.536 172.585 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -134.61 162.43 32.33 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.645 -0.659 . . . . 1.6899999999999999 110.996 -177.702 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.89 135.92 4.45 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.418 . . . . 0.10000000000000001 109.554 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.444 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -124.06 138.05 54.49 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.651 -0.911 . . . . 0.14999999999999999 109.785 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.809 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.4 p90 -155.97 173.47 16.74 Favored 'General case' 0 N--CA 1.497 1.902 0 C-N-CA 119.884 -0.726 . . . . 0.089999999999999997 110.986 177.138 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.5 m -106.91 142.07 37.13 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.65 -0.656 . . . . 0.080000000000000002 109.464 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.809 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.07 146.17 36.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.61 -0.681 . . . . 0.080000000000000002 110.756 -175.44 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.65 146.0 24.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.841 -0.537 . . . . 2.3599999999999999 109.63 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.797 HG21 ' CG2' ' A' ' 29' ' ' ILE . 96.9 t -79.01 124.82 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 120.294 -0.562 . . . . 0.089999999999999997 110.062 179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.95 -166.54 25.07 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.088 -1.205 . . . . 0.089999999999999997 110.088 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.71 152.95 29.67 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.766 -0.843 . . . . 1.4399999999999999 110.187 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 53.51 21.1 2.32 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.668 -0.645 . . . . 1.72 112.014 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.62 20.51 79.82 Favored Glycine 0 N--CA 1.5 2.907 0 C-N-CA 119.643 -1.265 . . . . 0.070000000000000007 110.83 171.407 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.454 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.7 p -78.0 148.19 34.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.438 -1.036 . . . . 1.3 110.27 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.723 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.4 p -138.74 145.97 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 N-CA-C 109.535 -0.543 . . . . 0.080000000000000002 109.535 175.325 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.3 mm -110.81 122.73 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.561 -0.712 . . . . 0.14999999999999999 110.709 -174.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.45 HG23 ' HD2' ' A' ' 65' ' ' PRO . 50.9 mt -78.38 144.62 66.5 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.567 -0.708 . . . . 0.14000000000000001 109.465 172.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.75 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.25 133.26 37.08 Favored 'Trans proline' 0 N--CA 1.495 1.582 0 O-C-N 122.879 0.936 . . . . 0.13 110.69 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -55.23 -34.23 63.79 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.482 -0.761 . . . . 2.29 110.788 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.71 -37.87 77.07 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.747 -0.596 . . . . 0.12 110.336 -178.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.75 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.4 mt -77.08 -32.71 56.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.748 -0.595 . . . . 0.13 110.475 178.49 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.4 mtt180 -57.67 -45.49 85.49 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.258 -0.901 . . . . 0.11 109.841 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.15 62.61 Favored 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 120.534 -0.467 . . . . 1.49 110.465 -175.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.55 -38.25 77.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.646 -0.659 . . . . 0.17000000000000001 109.89 -178.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.727 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.63 -17.63 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.841 -0.537 . . . . 0.17000000000000001 110.89 -176.738 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.6 35.29 36.93 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 109.814 -1.315 . . . . 0.17000000000000001 109.814 175.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.3 mm -89.47 142.75 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.603 -0.94 . . . . 0.17999999999999999 110.587 -174.188 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -129.09 157.47 75.82 Favored Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.829 -0.544 . . . . 2.54 110.7 -177.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -55.31 133.98 61.21 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 O-C-N 122.934 0.965 . . . . 0.46000000000000002 111.287 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.95 0.23 71.88 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 111.191 -0.763 . . . . 0.14999999999999999 111.191 175.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -97.48 134.42 40.75 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-N 118.677 1.239 . . . . 0.41999999999999998 110.559 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.407 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -91.95 132.79 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-O 121.67 0.748 . . . . 0.14999999999999999 111.173 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.572 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.5 pt -121.86 159.49 24.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 109.387 -0.597 . . . . 0.11 109.387 175.42 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -97.69 131.57 44.12 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.98 -0.748 . . . . 1.1299999999999999 108.98 175.461 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.828 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.78 130.24 70.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 CA-C-O 121.324 0.583 . . . . 0.070000000000000007 110.266 -170.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.5 mt -116.5 131.01 57.06 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.264 -0.643 . . . . 0.089999999999999997 109.264 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.965 HD12 ' HB3' ' A' ' 5' ' ' ALA . 4.3 mt -80.28 141.6 35.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.415 -0.803 . . . . 0.10000000000000001 109.971 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.47 -32.52 6.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.765 -0.585 . . . . 0.34000000000000002 110.868 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.56 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.8 -178.31 40.24 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.738 -1.22 . . . . 0.10000000000000001 111.014 -177.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -148.82 151.22 34.38 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.702 -0.881 . . . . 0.27000000000000002 110.572 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.58 -0.7 . . . . 0.56000000000000005 109.893 175.055 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.2 p . . . . . 0 N--CA 1.486 1.33 0 N-CA-C 109.78 -0.452 . . . . 0.40999999999999998 109.78 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.7 mt -87.8 -18.0 30.32 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 120.238 -0.585 . . . . 0.37 110.662 -177.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.824 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.21 156.67 3.98 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.206 -0.934 . . . . 0.26000000000000001 109.853 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -134.04 126.77 30.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.758 -0.589 . . . . 2.2999999999999998 110.167 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 18.2 p90 -149.42 161.81 41.34 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.614 -0.679 . . . . 0.20000000000000001 110.874 178.395 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -111.54 137.89 48.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.574 -0.704 . . . . 1.99 110.141 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.48 162.33 41.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.69 -0.631 . . . . 0.17999999999999999 109.748 177.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.4 t -111.5 159.28 18.24 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.535 -0.728 . . . . 0.17000000000000001 109.996 176.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.922 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.0 t -78.73 136.44 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.816 -0.553 . . . . 0.48999999999999999 110.191 -177.201 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -114.26 171.95 7.3 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.285 0.564 . . . . 0.68000000000000005 109.651 174.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -46.5 151.95 0.5 Allowed 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.531 -0.731 . . . . 2.96 112.036 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.2 mt 62.52 7.93 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.651 0 O-C-N 121.547 -0.721 . . . . 0.41999999999999998 112.585 -175.508 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.68 16.06 80.59 Favored Glycine 0 N--CA 1.497 2.738 0 O-C-N 120.934 -1.104 . . . . 0.23999999999999999 110.432 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.2 ttt180 -84.49 142.51 30.0 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.256 -1.143 . . . . 1.96 110.134 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.2 pt -133.28 154.3 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.649 -0.657 . . . . 0.29999999999999999 109.671 174.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.53 128.51 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.623 -0.673 . . . . 0.25 109.952 175.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 30.4 mt -79.99 144.34 59.08 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.986 -0.686 . . . . 0.23000000000000001 109.437 175.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.31 143.23 88.67 Favored 'Trans proline' 0 N--CA 1.489 1.219 0 O-C-N 122.969 0.984 . . . . 0.34999999999999998 109.772 175.053 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.58 -26.77 61.97 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 120.442 -0.503 . . . . 0.33000000000000002 110.472 -178.53 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -44.21 95.47 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.965 -1.254 . . . . 0.39000000000000001 109.965 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.3 m -69.82 -38.39 76.54 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.593 -0.945 . . . . 0.39000000000000001 110.132 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.723 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.8 mtt180 -56.06 -40.49 73.63 Favored 'General case' 0 N--CA 1.513 2.687 0 O-C-N 121.337 -0.852 . . . . 0.40000000000000002 109.378 176.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 84.7 tttt -65.27 -50.05 67.24 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.065 0.459 . . . . 2.9700000000000002 110.164 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -57.72 -39.08 76.44 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 121.773 -0.579 . . . . 0.67000000000000004 110.681 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.7 t80 -87.28 -14.2 41.58 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.789 -0.569 . . . . 1.4399999999999999 111.258 -176.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.78 42.9 24.63 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.536 -1.425 . . . . 0.31 109.536 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.913 HG23 HG21 ' A' ' 56' ' ' VAL . 75.0 mt -87.41 127.22 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.497 -1.002 . . . . 0.41999999999999998 110.532 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -128.23 159.39 35.35 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.098 -0.704 . . . . 1.8200000000000001 109.098 170.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.41 138.71 54.66 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.403 -0.81 . . . . 1.99 110.486 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.74 -16.02 62.12 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.874 -0.89 . . . . 0.19 110.874 179.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -77.09 156.9 31.39 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 118.686 1.243 . . . . 1.1200000000000001 110.148 177.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -111.36 138.69 47.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.682 -0.636 . . . . 0.20999999999999999 109.648 174.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.81 153.32 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.709 -0.619 . . . . 0.14999999999999999 109.34 174.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -116.32 123.01 46.57 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.331 -0.989 . . . . 1.0900000000000001 108.331 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.804 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.4 tt -138.6 157.87 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.57 -0.852 . . . . 0.14000000000000001 111.324 -166.583 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.89 143.34 50.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.865 -0.522 . . . . 1.1100000000000001 110.156 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.637 HG22 HG22 ' A' ' 82' ' ' VAL . 35.7 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.553 -0.717 . . . . 0.20000000000000001 110.551 177.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.436 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.89 127.57 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.756 -0.461 . . . . 0.20000000000000001 109.756 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.706 ' HB2' HG22 ' A' ' 80' ' ' ILE . 31.0 tttm -133.68 148.36 51.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.701 -0.625 . . . . 1.98 109.633 173.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.1 t80 . . . . . 0 N--CA 1.495 1.79 0 C-N-CA 120.156 -0.618 . . . . 0.33000000000000002 110.129 178.761 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.483 0.869 0 N-CA-C 110.026 -0.798 . . . . 0.34000000000000002 110.026 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.435 ' CB ' HG23 ' A' ' 72' ' ' ILE . 45.8 mttt -122.49 147.74 45.99 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.404 -0.81 . . . . 1.1000000000000001 110.098 171.182 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -136.71 169.05 18.37 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 120.338 -0.545 . . . . 1.4199999999999999 110.991 -176.34 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.71 4.38 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.341 -1.503 . . . . 0.17000000000000001 109.341 177.294 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -127.15 136.94 52.79 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 0.20999999999999999 109.927 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.811 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.3 p90 -156.71 173.77 16.47 Favored 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 119.939 -0.704 . . . . 0.16 110.922 176.434 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.2 m -106.5 140.37 39.5 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.696 -0.627 . . . . 0.13 109.422 173.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.811 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.37 146.6 36.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.706 -0.621 . . . . 0.14000000000000001 110.749 -175.239 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.66 145.24 24.7 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.855 -0.528 . . . . 2.21 109.617 175.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.913 HG21 HG23 ' A' ' 29' ' ' ILE . 89.9 t -79.44 125.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.356 0.598 . . . . 0.17000000000000001 109.814 179.358 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.66 -165.33 25.27 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.084 -1.206 . . . . 0.19 110.084 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -61.69 151.76 32.86 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.786 -0.832 . . . . 1.3899999999999999 110.107 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 53.3 21.88 2.5 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.565 -0.709 . . . . 0.81999999999999995 112.087 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.32 20.53 79.92 Favored Glycine 0 N--CA 1.5 2.923 0 C-N-CA 119.765 -1.207 . . . . 0.19 110.795 171.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.8 m -78.26 145.55 35.37 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.458 -1.025 . . . . 1.3 110.365 -176.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 9.0 p -139.27 147.77 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.773 -0.579 . . . . 0.20999999999999999 109.721 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -108.7 123.68 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.525 -0.735 . . . . 0.34000000000000002 110.658 -175.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.417 HG23 ' HD2' ' A' ' 65' ' ' PRO . 82.9 mt -78.64 143.02 62.37 Favored Pre-proline 0 N--CA 1.499 1.975 0 O-C-N 121.592 -0.692 . . . . 0.34000000000000002 109.596 172.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.767 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.28 134.21 41.16 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.914 0.955 . . . . 0.26000000000000001 110.908 -178.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 36.0 tptt -54.98 -34.84 63.72 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.517 -0.739 . . . . 2.6200000000000001 110.859 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.413 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.95 -38.16 78.4 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.765 -0.584 . . . . 0.45000000000000001 110.313 -178.085 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.767 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.3 mt -77.16 -32.67 56.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.739 -0.601 . . . . 1.8200000000000001 110.682 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.3 mtt180 -58.35 -46.1 86.91 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.281 -0.887 . . . . 2.5299999999999998 109.769 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.52 65.24 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 120.481 -0.488 . . . . 1.6799999999999999 110.44 -175.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 67' ' ' ALA . 97.3 t -60.59 -38.82 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.685 -0.634 . . . . 0.28000000000000003 109.903 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.583 HG22 HD11 ' A' ' 74' ' ' ILE . 85.8 mt -82.95 -16.32 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.821 -0.549 . . . . 0.28000000000000003 111.063 -176.713 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.11 35.25 44.37 Favored Glycine 0 N--CA 1.498 2.794 0 N-CA-C 109.929 -1.268 . . . . 0.22 109.929 176.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.922 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -89.33 145.83 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.522 -0.987 . . . . 0.77000000000000002 110.777 -173.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmt -134.46 162.99 54.39 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.849 -0.532 . . . . 3.21 110.454 -178.723 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -57.42 134.09 61.3 Favored 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 122.896 0.945 . . . . 0.5 111.137 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 0.98 67.38 Favored Glycine 0 N--CA 1.496 2.675 0 C-N-CA 120.676 -0.773 . . . . 0.23999999999999999 111.343 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -94.1 129.87 40.49 Favored 'General case' 0 N--CA 1.501 2.102 0 CA-C-N 118.753 1.277 . . . . 1.1100000000000001 110.322 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.1 132.74 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 CA-C-O 121.616 0.722 . . . . 0.23999999999999999 111.174 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.33 159.49 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 109.451 -0.574 . . . . 0.17999999999999999 109.451 176.425 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -97.83 132.1 43.73 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.088 -0.708 . . . . 1.1399999999999999 109.088 173.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.804 ' CG1' HD11 ' A' ' 37' ' ' ILE . 98.7 t -115.04 128.83 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 121.347 0.594 . . . . 0.20000000000000001 110.143 -171.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.8 mt -115.37 128.8 56.32 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.186 -0.672 . . . . 0.25 109.186 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.6 mt -79.38 140.4 37.46 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.431 -0.793 . . . . 0.28000000000000003 109.729 172.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.71 -32.24 7.16 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.718 -0.614 . . . . 1.6000000000000001 110.971 -176.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.8 -179.07 40.23 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.674 -1.25 . . . . 0.20000000000000001 110.985 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.0 p80 -142.96 150.47 39.75 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.746 -0.855 . . . . 1.8899999999999999 110.658 -177.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.586 -0.696 . . . . 0.80000000000000004 110.045 175.848 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 84' ' ' LEU . 3.4 p . . . . . 0 N--CA 1.485 1.299 0 N-CA-C 109.758 -0.46 . . . . 0.40999999999999998 109.758 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.5 mt -86.91 -20.87 26.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.85 -0.531 . . . . 0.37 110.464 -178.013 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.904 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.06 157.23 4.28 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.363 -0.836 . . . . 0.26000000000000001 109.685 176.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -132.87 126.67 32.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.715 -0.615 . . . . 2.2999999999999998 110.223 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.612 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.6 p90 -149.27 162.48 39.95 Favored 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 120.143 -0.623 . . . . 0.20000000000000001 110.665 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.59 138.18 50.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.548 -0.72 . . . . 1.99 110.286 -176.555 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 HD12 ' A' ' 17' ' ' ILE . 14.9 t -150.9 162.37 40.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.797 -0.564 . . . . 0.17999999999999999 109.543 177.619 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.05 160.35 16.94 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 119.812 -0.755 . . . . 0.17000000000000001 110.107 177.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.4 t -79.06 136.13 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 C-N-CA 120.329 -0.548 . . . . 0.48999999999999999 110.318 -176.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -116.2 172.04 7.43 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.24 0.543 . . . . 0.68000000000000005 109.58 174.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -46.21 152.47 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.543 -0.723 . . . . 2.96 112.048 -175.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.76 7.32 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.703 0 O-C-N 121.622 -0.674 . . . . 0.41999999999999998 112.593 -175.132 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.07 80.67 Favored Glycine 0 N--CA 1.496 2.635 0 O-C-N 120.857 -1.152 . . . . 0.23999999999999999 110.438 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttp180 -84.63 145.06 28.2 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.292 -1.123 . . . . 1.96 110.191 -177.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 9' ' ' THR . 45.1 pt -132.58 155.78 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 N-CA-C 109.315 -0.624 . . . . 0.29999999999999999 109.315 172.175 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.1 mm -115.82 128.18 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 C-N-CA 120.034 -0.666 . . . . 0.25 109.904 176.315 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 33.7 mt -79.58 143.83 59.88 Favored Pre-proline 0 N--CA 1.495 1.794 0 C-N-CA 120.052 -0.659 . . . . 0.23000000000000001 109.435 176.048 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.08 143.08 89.79 Favored 'Trans proline' 0 N--CA 1.489 1.231 0 O-C-N 122.989 0.994 . . . . 0.34999999999999998 109.845 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.62 -26.9 62.24 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.882 -0.511 . . . . 0.33000000000000002 110.52 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.06 95.61 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.951 -1.26 . . . . 0.39000000000000001 109.951 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.9 m -69.94 -38.38 76.15 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.585 -0.95 . . . . 0.39000000000000001 110.116 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.87 -40.81 73.47 Favored 'General case' 0 N--CA 1.512 2.664 0 O-C-N 121.286 -0.884 . . . . 0.40000000000000002 109.429 176.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -65.75 -50.07 66.11 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.1 0.476 . . . . 2.9700000000000002 110.212 -177.334 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -57.6 -39.67 77.34 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.707 -0.621 . . . . 0.67000000000000004 110.756 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.939 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.0 t80 -87.69 -14.29 40.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.774 -0.579 . . . . 1.4399999999999999 111.275 -176.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.87 42.52 25.19 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.576 -1.409 . . . . 0.31 109.576 178.31 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.921 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.74 125.55 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.543 -0.975 . . . . 0.41999999999999998 110.445 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.55 159.94 33.07 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.235 -0.654 . . . . 1.8200000000000001 109.235 172.284 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -57.27 138.19 55.06 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.33 -0.856 . . . . 1.99 110.557 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.81 -16.09 61.99 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 110.832 -0.907 . . . . 0.19 110.832 178.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -77.23 155.96 31.79 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.693 1.246 . . . . 1.1200000000000001 109.998 177.077 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -111.27 138.78 47.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.6 -0.688 . . . . 0.20999999999999999 109.492 174.132 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 155.06 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.199 -0.6 . . . . 0.14999999999999999 109.386 174.687 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.99 122.55 45.58 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.198 -1.038 . . . . 1.0900000000000001 108.198 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.826 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.15 158.22 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.596 -0.841 . . . . 0.14000000000000001 110.936 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -133.15 145.62 50.83 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.859 -0.525 . . . . 1.1100000000000001 110.505 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' VAL . 31.9 pt -114.93 151.13 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.648 -0.657 . . . . 0.20000000000000001 110.604 178.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t -138.67 127.93 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 121.174 0.512 . . . . 0.20000000000000001 109.72 176.12 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.702 ' HB2' HG22 ' A' ' 80' ' ' ILE . 33.3 tptt -137.82 147.13 44.29 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.83 -0.544 . . . . 1.98 109.632 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 44.9 t80 . . . . . 0 N--CA 1.496 1.828 0 C-N-CA 120.266 -0.574 . . . . 0.33000000000000002 110.384 -176.794 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo . . . . . 0 N--CA 1.483 0.893 0 N-CA-C 109.994 -0.81 . . . . 0.34000000000000002 109.994 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.427 ' CB ' HG23 ' A' ' 72' ' ' ILE . 37.1 mttp -118.71 151.75 37.41 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.498 -0.751 . . . . 1.1000000000000001 110.309 173.268 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -140.03 169.09 18.34 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-O 121.216 0.532 . . . . 1.4199999999999999 110.737 -178.373 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.61 135.9 4.47 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.428 -1.469 . . . . 0.17000000000000001 109.428 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -122.64 137.48 54.89 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.629 -0.924 . . . . 0.20999999999999999 109.847 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.7 p90 -156.14 173.1 17.32 Favored 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.899 -0.721 . . . . 0.16 110.901 176.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.06 141.31 38.5 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.669 -0.644 . . . . 0.13 109.493 173.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 145.51 35.19 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.675 -0.641 . . . . 0.14000000000000001 110.695 -175.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -93.68 146.0 24.15 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.855 -0.528 . . . . 2.21 109.626 175.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.921 HG21 HG23 ' A' ' 29' ' ' ILE . 87.2 t -79.15 125.45 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.778 -0.576 . . . . 0.17000000000000001 109.919 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.33 -167.08 25.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.944 -1.262 . . . . 0.19 109.944 178.231 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.68 152.93 29.58 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.79 -0.829 . . . . 1.3899999999999999 110.138 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.28 21.4 2.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.652 -0.655 . . . . 0.81999999999999995 112.095 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.1 20.6 79.66 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.684 -1.246 . . . . 0.19 110.832 171.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.0 m -77.96 144.56 36.67 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.388 -1.066 . . . . 1.3 110.343 -176.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.735 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.64 146.51 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.881 -0.512 . . . . 0.20999999999999999 109.684 175.682 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -110.53 123.21 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.51 -0.744 . . . . 0.34000000000000002 110.783 -175.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.5 mt -78.27 144.37 66.54 Favored Pre-proline 0 N--CA 1.498 1.938 0 O-C-N 121.637 -0.664 . . . . 0.34000000000000002 109.494 172.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.17 133.82 39.74 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 O-C-N 122.98 0.99 . . . . 0.26000000000000001 110.796 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -55.21 -34.23 63.75 Favored 'General case' 0 N--CA 1.502 2.171 0 O-C-N 121.481 -0.762 . . . . 2.6200000000000001 110.768 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.408 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -37.99 77.7 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.797 -0.564 . . . . 0.45000000000000001 110.275 -178.497 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.1 mt -77.13 -32.66 56.56 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 120.151 -0.62 . . . . 1.8200000000000001 110.593 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.01 -46.33 85.44 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.349 -0.844 . . . . 2.5299999999999998 109.771 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.91 -46.51 65.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 120.543 -0.463 . . . . 1.6799999999999999 110.401 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 67' ' ' ALA . 96.5 t -60.58 -38.81 79.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.692 -0.63 . . . . 0.28000000000000003 109.843 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.549 HG22 HD11 ' A' ' 74' ' ' ILE . 82.4 mt -82.64 -16.63 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.845 -0.535 . . . . 0.28000000000000003 111.083 -176.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.24 35.18 43.86 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 109.878 -1.289 . . . . 0.22 109.878 176.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.6 142.86 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.056 0 O-C-N 121.519 -0.989 . . . . 0.77000000000000002 110.63 -174.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.0 ptmt -130.27 162.35 54.83 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.801 -0.562 . . . . 3.21 110.644 -178.569 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.51 135.55 68.37 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 O-C-N 122.946 0.971 . . . . 0.5 110.919 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.61 -0.35 70.51 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.612 -0.804 . . . . 0.23999999999999999 111.264 176.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -94.73 130.29 41.31 Favored 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 118.741 1.271 . . . . 1.1100000000000001 109.849 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 79' ' ' VAL . 11.2 p -91.92 129.9 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 121.527 0.679 . . . . 0.23999999999999999 110.809 -175.31 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -118.79 159.39 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 109.418 -0.586 . . . . 0.17999999999999999 109.418 177.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -97.91 131.91 43.96 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.017 -0.735 . . . . 1.1399999999999999 109.017 174.571 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.826 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.9 t -116.2 129.72 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.355 0.598 . . . . 0.20000000000000001 110.301 -170.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.6 mt -115.85 130.11 56.7 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 109.208 -0.664 . . . . 0.25 109.208 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.939 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.29 140.55 36.13 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.345 -0.847 . . . . 0.28000000000000003 109.803 172.411 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.8 mt -111.37 -33.1 6.51 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.649 -0.657 . . . . 1.6000000000000001 110.97 -176.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.21 -175.79 38.14 Favored Glycine 0 N--CA 1.504 3.181 0 C-N-CA 119.689 -1.244 . . . . 0.20000000000000001 111.089 -176.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -144.25 154.26 42.9 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.728 -0.866 . . . . 1.8899999999999999 110.624 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 . . . . . 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.80000000000000004 110.21 176.482 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.488 1.473 0 N-CA-C 109.626 -0.509 . . . . 0.40999999999999998 109.626 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.6 mt -86.67 -18.5 31.12 Favored 'General case' 0 N--CA 1.496 1.827 0 C-N-CA 120.164 -0.614 . . . . 0.37 110.574 -178.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.831 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.69 155.69 3.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.251 -0.905 . . . . 0.26000000000000001 109.518 175.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.8 tttt -134.76 124.66 25.54 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.696 -0.627 . . . . 2.2999999999999998 110.117 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.0 p90 -150.82 163.66 38.09 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.621 -0.674 . . . . 0.20000000000000001 110.898 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -114.05 138.0 50.97 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.623 -0.673 . . . . 1.99 110.34 -177.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.39 162.31 41.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.66 -0.65 . . . . 0.17999999999999999 109.648 177.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -109.64 160.47 16.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.367 -0.833 . . . . 0.17000000000000001 110.264 177.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.869 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.2 t -78.92 137.37 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.843 -0.536 . . . . 0.48999999999999999 110.289 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.82 171.97 7.55 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.286 0.565 . . . . 0.68000000000000005 109.628 174.54 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.1 mtt-85 -46.37 152.54 0.43 Allowed 'General case' 0 N--CA 1.506 2.354 0 O-C-N 121.509 -0.745 . . . . 2.96 111.999 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.8 mt 62.62 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.673 0 O-C-N 121.536 -0.727 . . . . 0.41999999999999998 112.604 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.78 16.1 80.45 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.901 -1.125 . . . . 0.23999999999999999 110.335 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.9 ttp180 -85.16 144.85 27.93 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.269 -1.136 . . . . 1.96 110.28 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 pt -133.3 154.76 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.706 -0.621 . . . . 0.29999999999999999 109.398 172.179 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.7 127.77 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.563 -0.711 . . . . 0.25 110.034 176.561 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 38.2 mt -79.9 144.18 59.16 Favored Pre-proline 0 N--CA 1.495 1.824 0 C-N-CA 120.087 -0.645 . . . . 0.23000000000000001 109.479 176.05 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.38 143.52 88.87 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 122.927 0.961 . . . . 0.34999999999999998 109.724 174.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.56 61.28 Favored 'General case' 0 N--CA 1.497 1.895 0 C-N-CA 120.391 -0.523 . . . . 0.33000000000000002 110.56 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.55 -44.5 95.03 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.848 -1.301 . . . . 0.39000000000000001 109.848 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.1 m -69.94 -38.13 76.07 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.662 -0.905 . . . . 0.39000000000000001 110.09 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.61 73.24 Favored 'General case' 0 N--CA 1.514 2.741 0 O-C-N 121.26 -0.9 . . . . 0.40000000000000002 109.385 176.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -64.95 -49.78 69.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.184 0.516 . . . . 2.9700000000000002 110.133 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -57.24 -38.45 73.83 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.704 -0.622 . . . . 0.67000000000000004 110.727 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.8 t80 -88.09 -14.43 38.87 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.756 -0.59 . . . . 1.4399999999999999 111.216 -177.037 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.77 42.81 24.91 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.529 -1.429 . . . . 0.31 109.529 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 56' ' ' VAL . 75.6 mt -87.26 128.32 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.481 -1.011 . . . . 0.41999999999999998 110.644 -176.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -127.85 158.85 36.63 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.115 -0.698 . . . . 1.8200000000000001 109.115 170.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -57.3 138.51 54.72 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.329 -0.857 . . . . 1.99 110.522 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.88 -15.89 62.44 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 110.873 -0.891 . . . . 0.19 110.873 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -76.95 155.61 32.59 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-N 118.71 1.255 . . . . 1.1200000000000001 110.0 177.364 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -110.72 138.83 46.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.636 -0.665 . . . . 0.20999999999999999 109.646 174.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.57 154.05 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.262 -0.644 . . . . 0.14999999999999999 109.262 175.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -115.45 123.42 48.54 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.279 -1.008 . . . . 1.0900000000000001 108.279 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.82 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.4 tt -139.87 158.45 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 C-N-CA 119.69 -0.804 . . . . 0.14000000000000001 110.861 -167.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.577 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.6 ttpt -133.03 146.06 51.38 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.767 -0.583 . . . . 1.1100000000000001 110.577 177.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.627 HG22 HG22 ' A' ' 82' ' ' VAL . 26.8 pt -114.88 151.07 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.63 -0.669 . . . . 0.20000000000000001 110.333 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.629 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.92 125.04 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-O 121.133 0.492 . . . . 0.20000000000000001 109.71 176.528 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.708 ' HB2' HG22 ' A' ' 80' ' ' ILE . 39.1 tptt -135.17 147.58 49.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.763 -0.585 . . . . 1.98 109.655 177.069 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.9 t80 . . . . . 0 N--CA 1.496 1.856 0 C-N-CA 120.233 -0.587 . . . . 0.33000000000000002 110.33 -177.628 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo . . . . . 0 N--CA 1.482 0.82 0 N-CA-C 110.108 -0.766 . . . . 0.34000000000000002 110.108 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.8 mmtt -117.62 137.31 52.71 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.522 -0.736 . . . . 1.1000000000000001 109.716 171.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.629 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -135.05 166.4 23.14 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.662 -0.649 . . . . 1.4199999999999999 110.747 -176.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.62 135.64 4.34 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.53 -1.428 . . . . 0.17000000000000001 109.53 177.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.577 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -123.03 136.43 54.83 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.711 -0.876 . . . . 0.20999999999999999 109.73 176.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.818 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.1 p90 -155.43 173.29 16.88 Favored 'General case' 0 N--CA 1.497 1.899 0 C-N-CA 119.956 -0.698 . . . . 0.16 111.014 178.571 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.0 140.57 39.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.619 -0.675 . . . . 0.13 109.525 173.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.818 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.86 146.5 35.89 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.709 -0.619 . . . . 0.14000000000000001 110.613 -175.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -93.48 145.18 24.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.757 -0.589 . . . . 2.21 109.766 175.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.888 HG21 HG23 ' A' ' 29' ' ' ILE . 94.2 t -79.5 125.95 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.744 -0.597 . . . . 0.17000000000000001 109.908 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.05 -167.37 25.96 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.992 -1.243 . . . . 0.19 109.992 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -61.68 153.45 28.12 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.67 -0.9 . . . . 1.3899999999999999 110.148 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 53.71 21.09 2.48 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.53 -0.731 . . . . 0.81999999999999995 111.984 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.14 20.55 79.98 Favored Glycine 0 N--CA 1.499 2.853 0 C-N-CA 119.804 -1.188 . . . . 0.19 110.876 171.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.414 ' HA ' HD13 ' A' ' 18' ' ' ILE . 12.4 t -78.64 144.62 35.24 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.455 -1.027 . . . . 1.3 110.294 -176.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.43 145.79 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 N-CA-C 109.577 -0.527 . . . . 0.20999999999999999 109.577 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.1 mm -111.39 123.84 67.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.546 -0.721 . . . . 0.34000000000000002 110.685 -175.408 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 81.2 mt -78.16 145.0 68.14 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.602 -0.686 . . . . 0.34000000000000002 109.458 172.529 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.14 134.45 42.63 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 O-C-N 122.957 0.977 . . . . 0.26000000000000001 110.68 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -55.21 -34.28 63.79 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.437 -0.789 . . . . 2.6200000000000001 110.797 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -37.8 77.39 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.659 -0.651 . . . . 0.45000000000000001 110.322 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.2 mt -77.12 -32.7 56.65 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.18 -0.608 . . . . 1.8200000000000001 110.579 178.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.7 mtt180 -57.94 -46.1 85.57 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.297 -0.877 . . . . 2.5299999999999998 109.944 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.01 63.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.52 -0.472 . . . . 1.6799999999999999 110.385 -175.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.59 -38.18 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.678 -0.639 . . . . 0.28000000000000003 109.943 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.22 -18.12 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.855 -0.528 . . . . 0.28000000000000003 110.817 -176.699 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.92 35.05 40.49 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.648 -1.381 . . . . 0.22 109.648 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.869 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -91.69 142.58 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.592 -0.946 . . . . 0.77000000000000002 110.549 -174.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.67 161.41 61.16 Favored Pre-proline 0 N--CA 1.498 1.944 0 O-C-N 121.782 -0.574 . . . . 3.21 110.735 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.49 137.31 79.64 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.937 0.967 . . . . 0.5 111.033 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.08 72.33 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 111.166 -0.774 . . . . 0.23999999999999999 111.166 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -94.17 130.17 40.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-N 118.692 1.246 . . . . 1.1100000000000001 110.202 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 79' ' ' VAL . 10.8 p -91.74 128.86 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 CA-C-O 121.444 0.64 . . . . 0.23999999999999999 110.759 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.708 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.9 pt -118.3 159.43 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 109.459 -0.571 . . . . 0.17999999999999999 109.459 178.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.4 tt0 -97.95 129.96 44.83 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.909 -0.774 . . . . 1.1399999999999999 108.909 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.82 ' CG1' HD11 ' A' ' 37' ' ' ILE . 94.7 t -115.18 129.29 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.288 0.566 . . . . 0.20000000000000001 110.303 -170.499 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.7 mt -115.66 128.43 55.9 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 109.167 -0.679 . . . . 0.25 109.167 179.072 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.2 mt -79.78 138.5 37.28 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.39 -0.819 . . . . 0.28000000000000003 109.542 171.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -109.91 -31.29 7.46 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.723 -0.611 . . . . 1.6000000000000001 110.968 -174.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.12 -177.33 39.25 Favored Glycine 0 N--CA 1.503 3.12 0 C-N-CA 119.672 -1.251 . . . . 0.20000000000000001 111.039 -177.008 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -143.54 152.43 41.43 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.707 -0.878 . . . . 1.8899999999999999 110.648 -177.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 . . . . . 0 N--CA 1.494 1.755 0 O-C-N 121.468 -0.77 . . . . 0.80000000000000004 110.356 176.532 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.408 HG23 ' HB3' ' A' ' 83' ' ' LEU . 3.2 p . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 109.595 -0.521 . . . . 0.40999999999999998 109.595 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.619 HD11 ' HA2' ' A' ' 86' ' ' GLY . 24.7 mt -82.51 -20.85 35.93 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.816 -0.553 . . . . 0.37 110.195 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.86 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -170.69 152.56 3.81 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.459 -0.776 . . . . 0.26000000000000001 109.199 175.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.6 tttt -133.92 125.1 27.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.2999999999999998 110.293 -175.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.618 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.99 162.55 40.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.651 -0.655 . . . . 0.20000000000000001 110.925 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 75.1 m80 -111.94 138.49 48.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.582 -0.698 . . . . 1.99 110.188 -176.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.59 162.34 41.15 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.694 -0.629 . . . . 0.17999999999999999 109.701 177.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.3 t -110.83 160.21 16.96 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.461 -0.774 . . . . 0.17000000000000001 109.83 176.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.886 HG21 ' CG2' ' A' ' 74' ' ' ILE . 61.4 t -77.65 137.47 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.754 -0.591 . . . . 0.48999999999999999 110.169 -177.436 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.3 m80 -116.14 171.99 7.45 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.66 -0.496 . . . . 0.68000000000000005 109.66 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -46.02 151.53 0.47 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.639 -0.663 . . . . 2.96 112.122 -174.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.606 -0.684 . . . . 0.41999999999999998 112.639 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.96 80.63 Favored Glycine 0 N--CA 1.498 2.801 0 N-CA-C 110.322 -1.111 . . . . 0.23999999999999999 110.322 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -85.34 145.52 27.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.96 110.211 -177.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -134.36 154.68 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.626 -0.671 . . . . 0.29999999999999999 109.476 172.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -117.19 127.99 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.57 -0.706 . . . . 0.25 110.031 176.622 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.25 144.98 59.15 Favored Pre-proline 0 N--CA 1.496 1.834 0 C-N-CA 120.038 -0.665 . . . . 0.23000000000000001 109.491 175.637 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -63.44 143.44 88.34 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 O-C-N 123.023 1.012 . . . . 0.34999999999999998 109.776 174.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.39 -26.57 61.27 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.845 -0.534 . . . . 0.33000000000000002 110.495 -178.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.45 -44.37 95.36 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.932 -1.267 . . . . 0.39000000000000001 109.932 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 83.9 m -70.22 -38.0 75.16 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.592 -0.946 . . . . 0.39000000000000001 110.13 -179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.86 -41.23 74.04 Favored 'General case' 0 N--CA 1.514 2.775 0 O-C-N 121.263 -0.898 . . . . 0.40000000000000002 109.342 176.296 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -65.41 -49.24 69.95 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.048 0.451 . . . . 2.9700000000000002 110.287 -178.2 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.34 -38.42 74.07 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.787 -0.57 . . . . 0.67000000000000004 110.781 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.9 t80 -87.58 -14.22 40.74 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.817 -0.552 . . . . 1.4399999999999999 111.257 -177.213 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.12 42.79 23.24 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.522 -1.431 . . . . 0.31 109.522 178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.906 HG23 HG21 ' A' ' 56' ' ' VAL . 77.0 mt -87.44 129.67 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.511 -0.993 . . . . 0.41999999999999998 110.574 -177.163 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.42 155.46 43.62 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 109.077 -0.712 . . . . 1.8200000000000001 109.077 171.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -55.45 137.44 48.27 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.256 -0.903 . . . . 1.99 110.794 -177.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.69 -14.66 64.91 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.91 -0.876 . . . . 0.19 110.91 178.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -76.26 155.55 34.25 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 118.848 1.324 . . . . 1.1200000000000001 109.907 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -109.33 138.24 45.98 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.518 -0.739 . . . . 0.20999999999999999 109.508 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.73 154.85 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.263 -0.643 . . . . 0.14999999999999999 109.263 175.33 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -115.95 122.95 46.79 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.277 -1.008 . . . . 1.0900000000000001 108.277 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.85 HD11 ' CG1' ' A' ' 82' ' ' VAL . 13.1 tt -139.37 157.83 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.7 -0.8 . . . . 0.14000000000000001 110.87 -167.695 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -132.83 146.03 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.814 -0.554 . . . . 1.1100000000000001 110.518 178.015 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.553 ' HB ' HD12 ' A' ' 80' ' ' ILE . 31.3 pt -114.95 150.93 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.663 -0.648 . . . . 0.20000000000000001 110.51 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.458 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.18 126.54 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-O 121.085 0.469 . . . . 0.20000000000000001 109.765 176.472 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.7 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.1 tttp -133.35 146.33 51.2 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.798 -0.564 . . . . 1.98 109.57 174.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 37.4 t80 . . . . . 0 N--CA 1.496 1.863 0 C-N-CA 120.133 -0.627 . . . . 0.33000000000000002 110.151 179.234 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo . . . . . 0 N--CA 1.483 0.861 0 N-CA-C 109.992 -0.811 . . . . 0.34000000000000002 109.992 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' A' ' 72' ' ' ILE . 17.1 mmtp -111.97 137.65 49.68 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.529 -0.732 . . . . 1.1000000000000001 109.583 172.269 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.458 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.17 164.86 26.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.582 -0.698 . . . . 1.4199999999999999 110.773 -175.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.451 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.26 135.94 4.42 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.58 -1.408 . . . . 0.17000000000000001 109.58 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.2 m -123.28 137.39 54.87 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.733 -0.863 . . . . 0.20999999999999999 109.695 176.273 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.9 p90 -156.23 173.09 17.36 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.845 -0.742 . . . . 0.16 111.037 176.744 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.6 m -107.47 141.02 39.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.668 -0.645 . . . . 0.13 109.5 173.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.92 145.95 35.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.717 -0.614 . . . . 0.14000000000000001 110.45 -176.038 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -93.72 144.23 25.59 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.749 -0.594 . . . . 2.21 109.687 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.906 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -78.82 125.98 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.267 0.556 . . . . 0.17000000000000001 110.009 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.37 -169.9 25.81 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.848 -1.301 . . . . 0.19 109.848 177.478 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -61.81 155.82 22.13 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.707 -0.878 . . . . 1.3899999999999999 109.913 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.06 19.34 2.71 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.486 -0.759 . . . . 0.81999999999999995 112.018 -177.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.56 20.59 79.58 Favored Glycine 0 N--CA 1.499 2.839 0 C-N-CA 119.813 -1.184 . . . . 0.19 110.66 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 32.4 t -78.4 144.72 35.65 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.437 -1.037 . . . . 1.3 110.479 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.75 146.27 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 109.637 -0.505 . . . . 0.20999999999999999 109.637 175.062 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -111.79 123.97 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.6 -0.688 . . . . 0.34000000000000002 110.655 -175.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.7 mt -78.33 143.47 64.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.612 -0.68 . . . . 0.34000000000000002 109.477 172.537 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.79 136.81 50.92 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 O-C-N 122.982 0.991 . . . . 0.26000000000000001 110.814 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.1 tptt -54.91 -34.46 63.14 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.395 -0.816 . . . . 2.6200000000000001 110.714 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.46 79.15 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.789 -0.569 . . . . 0.45000000000000001 110.287 -178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.9 mt -77.18 -32.82 56.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.742 -0.599 . . . . 1.8200000000000001 110.656 179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -58.35 -45.24 88.56 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.265 -0.897 . . . . 2.5299999999999998 109.91 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.14 -47.41 61.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.55 -0.46 . . . . 1.6799999999999999 110.408 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.1 t -60.54 -38.08 77.1 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 121.666 -0.646 . . . . 0.28000000000000003 109.845 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.705 HG23 ' HB3' ' A' ' 48' ' ' LYS . 79.1 mt -82.6 -17.74 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.84 -0.537 . . . . 0.28000000000000003 110.829 -176.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.06 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.621 -1.392 . . . . 0.22 109.621 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.886 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -93.71 141.86 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.558 -0.966 . . . . 0.77000000000000002 110.728 -174.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.67 162.4 56.46 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.757 -0.589 . . . . 3.21 110.691 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -51.88 135.86 51.01 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.025 1.013 . . . . 0.5 111.807 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.08 -1.92 71.06 Favored Glycine 0 N--CA 1.497 2.702 0 C-N-CA 120.72 -0.752 . . . . 0.23999999999999999 111.431 174.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -96.4 131.53 42.87 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-N 118.74 1.27 . . . . 1.1100000000000001 110.64 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.26 132.95 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.607 0.718 . . . . 0.23999999999999999 111.229 -173.246 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.7 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.72 159.52 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.948 -0.47 . . . . 0.17999999999999999 109.757 177.217 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -97.59 130.94 44.59 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.891 -0.781 . . . . 1.1399999999999999 108.891 174.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.85 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.0 t -114.41 129.48 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.803 -0.56 . . . . 0.20000000000000001 110.207 -171.533 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.408 ' HB3' HG23 ' A' ' 3' ' ' VAL . 38.2 mt -118.09 128.78 55.07 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.113 -0.699 . . . . 0.25 109.113 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -79.79 140.45 36.87 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.305 -0.872 . . . . 0.28000000000000003 109.757 172.256 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.49 -33.51 6.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.718 -0.614 . . . . 1.6000000000000001 110.887 -175.766 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.619 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.63 -172.97 36.03 Favored Glycine 0 N--CA 1.502 3.094 0 C-N-CA 119.778 -1.201 . . . . 0.20000000000000001 110.942 -176.643 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -142.88 159.0 43.07 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.706 -0.879 . . . . 1.8899999999999999 110.655 -177.407 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.683 . . . . 0.80000000000000004 110.322 177.602 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 109.605 -0.517 . . . . 0.40999999999999998 109.605 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.0 mt -84.16 -19.92 33.3 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.738 -0.601 . . . . 0.37 110.398 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.873 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.32 153.93 3.76 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.362 -0.836 . . . . 0.26000000000000001 109.427 176.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.6 tttt -133.75 125.24 28.11 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.679 -0.638 . . . . 2.2999999999999998 110.128 -177.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.609 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.9 163.12 39.43 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.627 -0.67 . . . . 0.20000000000000001 110.871 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.44 138.93 49.38 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.706 -0.621 . . . . 1.99 110.376 -176.567 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.28 162.3 41.15 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.653 -0.655 . . . . 0.17999999999999999 109.717 177.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.2 t -111.4 159.69 17.78 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.427 -0.796 . . . . 0.17000000000000001 109.917 175.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 57.5 t -77.56 138.64 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 120.302 -0.559 . . . . 0.48999999999999999 110.275 -176.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -118.31 172.01 7.75 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.583 -0.525 . . . . 0.68000000000000005 109.583 174.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -46.28 152.57 0.41 Allowed 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.574 -0.704 . . . . 2.96 112.014 -175.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.75 7.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.607 0 O-C-N 121.58 -0.7 . . . . 0.41999999999999998 112.61 -175.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.47 16.12 80.68 Favored Glycine 0 N--CA 1.497 2.7 0 O-C-N 120.901 -1.124 . . . . 0.23999999999999999 110.327 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.8 ttp180 -84.88 145.96 27.54 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.294 -1.121 . . . . 1.96 110.247 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -133.08 154.85 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 109.284 -0.636 . . . . 0.29999999999999999 109.284 171.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -115.1 128.04 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 120.039 -0.664 . . . . 0.25 110.054 176.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.0 mt -79.98 144.63 59.69 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.048 -0.661 . . . . 0.23000000000000001 109.424 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -62.87 142.6 89.16 Favored 'Trans proline' 0 N--CA 1.488 1.2 0 O-C-N 122.971 0.985 . . . . 0.34999999999999998 109.871 174.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.64 -27.36 62.74 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 120.401 -0.519 . . . . 0.33000000000000002 110.478 -178.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.54 -43.99 95.78 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.902 -1.279 . . . . 0.39000000000000001 109.902 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.2 m -70.12 -38.0 75.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.608 -0.937 . . . . 0.39000000000000001 109.914 -179.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.82 -40.94 73.49 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 121.233 -0.917 . . . . 0.40000000000000002 109.436 176.419 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -65.27 -50.08 67.14 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.14 0.495 . . . . 2.9700000000000002 110.131 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.4 -38.43 74.28 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.786 -0.571 . . . . 0.67000000000000004 110.756 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.5 t80 -87.4 -14.25 41.12 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.821 -0.549 . . . . 1.4399999999999999 111.343 -176.746 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.93 42.76 24.28 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 109.581 -1.408 . . . . 0.31 109.581 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 75.5 mt -87.63 128.45 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.57 -0.959 . . . . 0.41999999999999998 110.559 -177.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.95 158.38 38.01 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.943 -0.762 . . . . 1.8200000000000001 108.943 170.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -57.4 140.18 51.04 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.342 -0.849 . . . . 1.99 110.465 -178.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -16.07 61.71 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.828 -0.909 . . . . 0.19 110.828 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.74 157.72 31.47 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.094 -1.239 . . . . 1.1200000000000001 110.146 178.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -111.92 138.76 48.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.569 -0.707 . . . . 0.20999999999999999 109.579 174.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 154.75 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 120.15 -0.62 . . . . 0.14999999999999999 109.354 174.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -115.58 123.72 49.17 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.303 -0.999 . . . . 1.0900000000000001 108.303 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.837 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.9 158.79 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.754 -0.778 . . . . 0.14000000000000001 110.982 -167.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.408 ' HB2' HD12 ' A' ' 85' ' ' LEU . 30.2 tttt -133.33 146.21 51.12 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.885 -0.509 . . . . 1.1100000000000001 110.29 177.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.542 HG22 HG22 ' A' ' 82' ' ' VAL . 21.2 pt -114.82 150.94 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.716 -0.615 . . . . 0.20000000000000001 110.302 178.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.99 123.84 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.181 0.515 . . . . 0.20000000000000001 109.678 177.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 46.7 tttp -132.76 146.97 52.29 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.357 -0.609 . . . . 1.98 109.357 175.008 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.0 t80 . . . . . 0 N--CA 1.496 1.844 0 C-N-CA 119.957 -0.697 . . . . 0.33000000000000002 110.41 -178.798 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo . . . . . 0 N--CA 1.482 0.852 0 N-CA-C 110.298 -0.693 . . . . 0.34000000000000002 110.298 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 41.2 mmtt -109.48 137.72 46.9 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.554 -0.716 . . . . 1.1000000000000001 109.456 172.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.6 163.22 30.62 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.62 -0.675 . . . . 1.4199999999999999 110.93 -176.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.08 135.93 4.43 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.549 -1.421 . . . . 0.17000000000000001 109.549 177.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.5 m -123.23 138.2 54.69 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.568 -0.96 . . . . 0.20999999999999999 109.841 176.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -156.15 173.17 17.23 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.975 -0.69 . . . . 0.16 110.955 176.504 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -107.36 141.27 38.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.718 -0.614 . . . . 0.13 109.479 173.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.17 146.22 36.69 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 120.212 -0.595 . . . . 0.14000000000000001 110.73 -175.503 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -93.01 145.13 24.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.811 -0.556 . . . . 2.21 109.59 175.195 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 90.5 t -79.47 125.8 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.827 -0.546 . . . . 0.17000000000000001 109.779 179.368 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.1 -170.38 27.25 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.707 -1.357 . . . . 0.19 109.707 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -61.84 155.75 22.4 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.644 -0.915 . . . . 1.3899999999999999 109.961 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 54.87 19.64 2.71 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.569 -0.707 . . . . 0.81999999999999995 112.008 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.18 20.55 79.97 Favored Glycine 0 N--CA 1.499 2.837 0 C-N-CA 119.793 -1.194 . . . . 0.19 110.816 172.309 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.6 m -77.91 144.04 37.21 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.46 -1.024 . . . . 1.3 110.288 -176.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.22 145.93 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.751 -0.593 . . . . 0.20999999999999999 109.596 175.392 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -111.4 123.17 67.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.541 -0.725 . . . . 0.34000000000000002 110.699 -174.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 77.3 mt -78.62 143.87 64.07 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.532 -0.73 . . . . 0.34000000000000002 109.429 172.042 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.754 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.1 Cg_endo -65.1 136.68 49.03 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 O-C-N 122.926 0.961 . . . . 0.26000000000000001 110.757 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 43.2 tttm -55.07 -34.17 63.36 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.48 -0.763 . . . . 2.6200000000000001 110.774 179.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.11 78.34 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.711 -0.618 . . . . 0.45000000000000001 110.288 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.754 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.9 mt -77.15 -32.76 56.52 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 120.208 -0.597 . . . . 1.8200000000000001 110.519 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -58.29 -45.46 87.91 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.305 -0.872 . . . . 2.5299999999999998 109.845 178.099 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.03 -46.53 64.87 Favored 'General case' 0 N--CA 1.496 1.857 0 C-N-CA 120.476 -0.489 . . . . 1.6799999999999999 110.457 -175.163 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.7 t -60.45 -38.48 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 C-N-CA 120.168 -0.613 . . . . 0.28000000000000003 109.945 -178.531 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.56 -17.51 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.803 -0.561 . . . . 0.28000000000000003 110.876 -177.164 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.69 35.13 41.54 Favored Glycine 0 N--CA 1.497 2.742 0 N-CA-C 109.768 -1.333 . . . . 0.22 109.768 176.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.0 mm -93.19 142.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.613 -0.934 . . . . 0.77000000000000002 110.721 -174.012 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.49 162.17 57.69 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.724 -0.61 . . . . 3.21 110.309 178.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -56.51 138.11 83.16 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 O-C-N 122.817 0.904 . . . . 0.5 111.331 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 -2.63 71.83 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 120.696 -0.764 . . . . 0.23999999999999999 111.24 176.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -96.62 131.9 42.81 Favored 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 118.715 1.258 . . . . 1.1100000000000001 110.599 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.6 p -92.43 133.45 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 121.669 0.747 . . . . 0.23999999999999999 111.244 -173.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.8 pt -124.59 159.49 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 109.507 -0.553 . . . . 0.17999999999999999 109.507 176.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -98.88 132.24 44.37 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.029 -0.73 . . . . 1.1399999999999999 109.029 175.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 37' ' ' ILE . 92.8 t -115.9 131.6 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.754 -0.591 . . . . 0.20000000000000001 110.363 -170.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.9 mt -117.94 129.55 55.68 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.136 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -80.05 142.26 35.09 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.398 -0.814 . . . . 0.28000000000000003 109.798 171.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.408 HD12 ' HB2' ' A' ' 38' ' ' LYS . 15.6 mt -117.95 -26.72 6.36 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.701 -0.625 . . . . 1.6000000000000001 111.117 -174.434 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.78 40.58 Favored Glycine 0 N--CA 1.504 3.195 0 C-N-CA 119.66 -1.257 . . . . 0.20000000000000001 110.966 -176.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -146.45 150.76 36.24 Favored 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.669 -0.9 . . . . 1.8899999999999999 110.597 -178.147 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 N--CA 1.494 1.741 0 O-C-N 121.475 -0.766 . . . . 0.80000000000000004 110.136 175.445 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.486 1.354 0 N-CA-C 109.612 -0.514 . . . . 0.40999999999999998 109.612 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.87 -20.79 34.84 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.298 -0.561 . . . . 0.37 110.312 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.858 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.52 153.68 3.56 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.423 -0.798 . . . . 0.26000000000000001 109.272 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.43 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.1 tttt -134.04 125.98 29.22 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.732 -0.605 . . . . 2.2999999999999998 110.177 -176.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.611 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.5 p90 -150.61 163.56 38.2 Favored 'General case' 0 N--CA 1.498 1.941 0 C-N-CA 120.052 -0.659 . . . . 0.20000000000000001 110.957 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.02 138.58 49.67 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.695 -0.628 . . . . 1.99 110.117 -176.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.35 162.31 41.14 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.727 -0.608 . . . . 0.17999999999999999 109.664 176.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -111.28 159.74 17.66 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.873 -0.731 . . . . 0.17000000000000001 109.983 176.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.895 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.8 t -78.82 134.09 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.803 -0.56 . . . . 0.48999999999999999 110.2 -177.092 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -113.77 171.89 7.31 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-O 121.214 0.53 . . . . 0.68000000000000005 109.751 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -46.57 152.82 0.42 Allowed 'General case' 0 N--CA 1.507 2.412 0 O-C-N 121.663 -0.648 . . . . 2.96 111.996 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.77 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.598 -0.689 . . . . 0.41999999999999998 112.576 -175.256 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.42 16.11 80.73 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.906 -1.121 . . . . 0.23999999999999999 110.332 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -85.57 143.99 28.16 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.231 -1.158 . . . . 1.96 110.418 -175.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.3 pt -133.68 154.49 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.701 -0.624 . . . . 0.29999999999999999 109.616 172.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.418 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.84 128.11 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.557 -0.715 . . . . 0.25 110.132 176.581 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 36.1 mt -80.04 144.86 59.82 Favored Pre-proline 0 N--CA 1.496 1.861 0 C-N-CA 120.026 -0.67 . . . . 0.23000000000000001 109.415 175.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.37 143.35 88.58 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 122.893 0.944 . . . . 0.34999999999999998 109.77 174.416 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.63 -26.49 61.65 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.416 -0.514 . . . . 0.33000000000000002 110.499 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.47 95.14 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.894 -1.282 . . . . 0.39000000000000001 109.894 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.2 m -69.97 -38.12 75.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.531 -0.982 . . . . 0.39000000000000001 110.193 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.707 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.5 mtt180 -55.92 -40.94 73.83 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.23 -0.918 . . . . 0.40000000000000002 109.454 176.342 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -65.61 -49.98 66.74 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.204 0.526 . . . . 2.9700000000000002 110.215 -177.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -57.49 -37.72 73.42 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.689 -0.632 . . . . 0.67000000000000004 110.668 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.3 t80 -87.67 -14.19 40.57 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.752 -0.593 . . . . 1.4399999999999999 111.287 -176.594 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.91 42.87 24.05 Favored Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.587 -1.405 . . . . 0.31 109.587 178.37 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.912 HG23 HG21 ' A' ' 56' ' ' VAL . 77.1 mt -88.1 129.73 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.068 0 O-C-N 121.552 -0.969 . . . . 0.41999999999999998 110.615 -176.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -127.9 158.71 37.06 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 109.079 -0.711 . . . . 1.8200000000000001 109.079 170.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -57.34 137.68 55.79 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.333 -0.854 . . . . 1.99 110.636 -178.468 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.57 -14.49 65.21 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.9 -0.88 . . . . 0.19 110.9 178.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.19 156.9 33.23 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 118.857 1.328 . . . . 1.1200000000000001 110.072 177.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -110.62 138.14 47.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.626 -0.671 . . . . 0.20999999999999999 109.517 174.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.62 154.27 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.247 -0.649 . . . . 0.14999999999999999 109.247 174.753 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.5 123.55 48.83 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.287 -1.005 . . . . 1.0900000000000001 108.287 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.833 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.09 157.16 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 119.611 -0.835 . . . . 0.14000000000000001 110.953 -167.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -132.2 145.99 51.72 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.846 -0.534 . . . . 1.1100000000000001 110.528 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.527 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.2 pt -115.3 151.14 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.726 -0.609 . . . . 0.20000000000000001 110.584 179.051 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.454 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.51 125.76 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.264 0.554 . . . . 0.20000000000000001 109.882 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.753 ' HB2' HG22 ' A' ' 80' ' ' ILE . 3.3 tptm -130.76 146.49 52.24 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.156 -0.683 . . . . 1.98 109.156 174.201 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.7 t80 . . . . . 0 N--CA 1.495 1.814 0 C-N-CA 120.263 -0.575 . . . . 0.33000000000000002 110.471 -178.75 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo . . . . . 0 N--CA 1.483 0.859 0 N-CA-C 110.208 -0.728 . . . . 0.34000000000000002 110.208 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.694 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.4 mmtt -114.69 137.73 51.56 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.564 -0.71 . . . . 1.1000000000000001 109.617 173.054 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.454 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -134.65 164.18 28.09 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.675 -0.641 . . . . 1.4199999999999999 110.775 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.78 135.91 4.46 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.484 -1.446 . . . . 0.17000000000000001 109.484 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -123.18 137.65 54.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.65 -0.912 . . . . 0.20999999999999999 109.784 176.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.7 p90 -156.13 172.89 17.66 Favored 'General case' 0 N--CA 1.498 1.932 0 C-N-CA 119.833 -0.747 . . . . 0.16 111.014 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.4 m -107.32 140.74 39.76 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.705 -0.622 . . . . 0.13 109.499 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.7 145.21 34.61 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.14000000000000001 110.585 -175.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -94.13 144.88 25.11 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.828 -0.545 . . . . 2.21 109.647 175.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.912 HG21 HG23 ' A' ' 29' ' ' ILE . 96.7 t -78.79 126.37 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.833 -0.542 . . . . 0.17000000000000001 110.015 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.86 -165.95 25.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.123 -1.191 . . . . 0.19 110.123 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -61.68 152.07 31.95 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.771 -0.841 . . . . 1.3899999999999999 110.201 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 73.7 mt-30 53.35 21.52 2.38 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.572 -0.705 . . . . 0.81999999999999995 112.062 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.54 20.48 79.84 Favored Glycine 0 N--CA 1.5 2.906 0 C-N-CA 119.777 -1.201 . . . . 0.19 110.866 171.332 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 13.3 t -78.34 144.67 35.81 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.468 -1.019 . . . . 1.3 110.25 -177.544 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.701 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.34 146.28 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 N-CA-C 109.55 -0.537 . . . . 0.20999999999999999 109.55 175.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.9 mm -110.68 122.78 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.609 -0.682 . . . . 0.34000000000000002 110.566 -174.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.6 mt -78.72 142.61 61.47 Favored Pre-proline 0 N--CA 1.498 1.975 0 O-C-N 121.589 -0.694 . . . . 0.34000000000000002 109.437 172.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.35 133.93 39.7 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 O-C-N 122.915 0.955 . . . . 0.26000000000000001 110.763 -179.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -55.28 -34.2 63.88 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.508 -0.745 . . . . 2.6200000000000001 110.832 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.7 76.78 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.783 -0.573 . . . . 0.45000000000000001 110.334 -178.775 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.3 mt -77.09 -32.73 56.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.779 -0.575 . . . . 1.8200000000000001 110.521 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -57.76 -46.13 84.96 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.275 -0.891 . . . . 2.5299999999999998 109.833 178.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -47.2 62.59 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.503 -0.479 . . . . 1.6799999999999999 110.502 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.2 t -60.48 -38.22 77.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.708 -0.62 . . . . 0.28000000000000003 109.962 -178.505 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.694 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.2 mt -82.58 -17.76 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.818 -0.551 . . . . 0.28000000000000003 110.884 -176.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.64 35.11 41.9 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 109.726 -1.35 . . . . 0.22 109.726 176.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.895 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.2 138.94 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.535 -0.979 . . . . 0.77000000000000002 110.591 -174.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.4 mmtt -123.75 161.23 47.53 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.665 -0.647 . . . . 3.21 110.531 -176.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -60.39 135.61 62.52 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 122.951 0.974 . . . . 0.5 110.677 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.89 -0.48 73.08 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 111.139 -0.784 . . . . 0.23999999999999999 111.139 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -97.17 132.95 42.44 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.063 -1.257 . . . . 1.1100000000000001 110.44 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.407 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.2 p -91.78 132.27 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 121.504 0.668 . . . . 0.23999999999999999 111.008 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.753 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.7 pt -119.59 159.42 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 109.531 -0.544 . . . . 0.17999999999999999 109.531 176.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -98.31 130.16 45.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.815 -0.809 . . . . 1.1399999999999999 108.815 173.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.833 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.1 t -115.32 130.22 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-O 121.292 0.568 . . . . 0.20000000000000001 110.27 -170.688 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.43 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.5 mt -116.71 129.53 56.18 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 109.136 -0.691 . . . . 0.25 109.136 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.8 mt -80.15 142.46 34.74 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.3 -0.875 . . . . 0.28000000000000003 109.694 171.784 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HA ' HD23 ' A' ' 85' ' ' LEU . 29.6 mt -119.5 -25.66 5.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.668 -0.645 . . . . 1.6000000000000001 111.183 -174.202 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.41 -179.22 40.13 Favored Glycine 0 N--CA 1.503 3.16 0 C-N-CA 119.643 -1.265 . . . . 0.20000000000000001 111.1 -177.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -146.96 152.91 39.41 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.669 -0.901 . . . . 1.8899999999999999 110.571 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 . . . . . 0 N--CA 1.494 1.773 0 O-C-N 121.538 -0.726 . . . . 0.80000000000000004 110.159 176.203 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 109.566 -0.531 . . . . 0.40999999999999998 109.566 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.515 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.3 mt -85.94 -20.12 29.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.781 -0.574 . . . . 0.37 110.523 -178.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.948 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.68 156.16 3.47 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.301 -0.875 . . . . 0.26000000000000001 109.436 176.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -134.26 124.2 25.51 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.777 -0.577 . . . . 2.2999999999999998 110.104 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.599 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.6 p90 -150.28 162.61 40.17 Favored 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 120.006 -0.678 . . . . 0.20000000000000001 111.047 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -112.39 138.57 48.93 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.582 -0.699 . . . . 1.99 110.074 -177.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.0 t -151.47 162.37 41.06 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.65 -0.656 . . . . 0.17999999999999999 109.741 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.42 158.42 19.12 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.857 -0.737 . . . . 0.17000000000000001 110.072 177.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.6 t -78.95 137.18 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 C-N-CA 120.279 -0.569 . . . . 0.48999999999999999 110.323 -176.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.2 m80 -116.2 171.91 7.51 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.298 0.57 . . . . 0.68000000000000005 109.734 174.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.5 ttt85 -46.92 153.02 0.45 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.492 -0.755 . . . . 2.96 111.76 -175.176 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.9 mt 62.93 6.93 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.684 0 O-C-N 121.507 -0.746 . . . . 0.41999999999999998 112.636 -174.052 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.67 16.03 80.63 Favored Glycine 0 N--CA 1.496 2.64 0 O-C-N 120.789 -1.194 . . . . 0.23999999999999999 110.294 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -84.94 144.48 28.31 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.317 -1.108 . . . . 1.96 110.352 -177.406 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -131.79 154.62 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.751 -0.593 . . . . 0.29999999999999999 109.41 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.7 mm -116.5 128.49 73.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.598 -0.689 . . . . 0.25 110.003 176.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.438 HG12 ' CE2' ' A' ' 7' ' ' PHE . 40.1 mt -79.99 145.42 61.24 Favored Pre-proline 0 N--CA 1.496 1.826 0 C-N-CA 119.968 -0.693 . . . . 0.23000000000000001 109.39 175.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.48 143.42 88.09 Favored 'Trans proline' 0 N--CA 1.489 1.206 0 O-C-N 122.936 0.966 . . . . 0.34999999999999998 109.706 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.48 61.47 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 120.41 -0.516 . . . . 0.33000000000000002 110.496 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.61 -44.48 94.98 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.862 -1.295 . . . . 0.39000000000000001 109.862 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 84.4 m -69.92 -38.11 76.12 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.599 -0.942 . . . . 0.39000000000000001 110.16 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -56.0 -40.74 73.79 Favored 'General case' 0 N--CA 1.513 2.696 0 O-C-N 121.289 -0.882 . . . . 0.40000000000000002 109.448 176.405 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -65.17 -50.06 67.41 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.086 0.469 . . . . 2.9700000000000002 110.058 -177.435 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.26 -38.77 74.38 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.854 -0.529 . . . . 0.67000000000000004 110.772 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.907 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.9 t80 -88.42 -14.29 38.37 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.753 -0.592 . . . . 1.4399999999999999 111.163 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.9 42.59 24.85 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.497 -1.441 . . . . 0.31 109.497 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.918 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.47 125.5 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.429 -1.042 . . . . 0.41999999999999998 110.455 -177.037 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -128.17 155.35 44.62 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.996 -0.742 . . . . 1.8200000000000001 108.996 171.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -55.5 140.15 41.43 Favored 'General case' 0 N--CA 1.503 2.179 0 O-C-N 121.289 -0.882 . . . . 1.99 110.576 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.82 -16.19 61.39 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.812 -0.915 . . . . 0.19 110.812 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -77.43 158.33 30.07 Favored 'General case' 0 N--CA 1.499 2.022 0 CA-C-N 118.72 1.26 . . . . 1.1200000000000001 110.042 177.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -113.18 139.19 48.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.604 -0.685 . . . . 0.20999999999999999 109.581 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.28 154.54 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.35 -0.611 . . . . 0.14999999999999999 109.35 174.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.431 ' HB2' ' CE2' ' A' ' 88' ' ' TYR . 48.9 tt0 -116.0 123.62 48.46 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.219 -1.03 . . . . 1.0900000000000001 108.219 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.823 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -139.16 157.99 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 C-N-CA 119.588 -0.845 . . . . 0.14000000000000001 111.213 -167.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.84 143.48 50.21 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.9 -0.5 . . . . 1.1100000000000001 109.951 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.6 HG22 HG22 ' A' ' 82' ' ' VAL . 35.0 pt -114.91 150.99 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.593 -0.692 . . . . 0.20000000000000001 110.527 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -138.4 123.19 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 CA-C-O 121.238 0.542 . . . . 0.20000000000000001 109.721 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.655 ' HB2' HG22 ' A' ' 80' ' ' ILE . 50.2 tttm -130.98 147.1 52.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.191 -0.67 . . . . 1.98 109.191 174.256 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.4 t80 . . . . . 0 N--CA 1.496 1.873 0 C-N-CA 119.968 -0.693 . . . . 0.33000000000000002 110.471 -178.565 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.482 0.845 0 N-CA-C 110.529 -0.604 . . . . 0.34000000000000002 110.529 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.672 ' HB3' HG23 ' A' ' 72' ' ' ILE . 19.2 mmtp -111.63 137.73 49.1 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.462 -0.774 . . . . 1.1000000000000001 109.486 171.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.53 164.33 27.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.608 -0.682 . . . . 1.4199999999999999 110.929 -176.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.03 135.78 4.37 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.536 -1.425 . . . . 0.17000000000000001 109.536 177.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -127.55 137.05 52.5 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.793 -0.828 . . . . 0.20999999999999999 109.791 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.0 p90 -156.57 173.94 16.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 119.883 -0.727 . . . . 0.16 110.916 177.094 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.4 m -106.94 140.74 39.26 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.407 -0.59 . . . . 0.13 109.407 173.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.1 146.18 36.76 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.608 -0.683 . . . . 0.14000000000000001 110.69 -175.371 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -93.35 145.81 24.19 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 109.628 -0.508 . . . . 2.21 109.628 175.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.918 HG21 HG23 ' A' ' 29' ' ' ILE . 88.0 t -78.56 126.01 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.754 -0.591 . . . . 0.17000000000000001 109.858 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.0 -167.34 26.0 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.982 -1.247 . . . . 0.19 109.982 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.64 153.23 28.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.782 -0.834 . . . . 1.3899999999999999 110.151 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 53.51 21.12 2.34 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.579 -0.7 . . . . 0.81999999999999995 112.099 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.54 79.89 Favored Glycine 0 N--CA 1.499 2.892 0 C-N-CA 119.716 -1.231 . . . . 0.19 110.921 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.465 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -78.28 147.11 34.45 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.445 -1.032 . . . . 1.3 110.262 -177.298 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.686 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.82 145.99 26.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 109.548 -0.538 . . . . 0.20999999999999999 109.548 175.304 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -110.73 123.37 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.446 -0.784 . . . . 0.34000000000000002 110.738 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.3 mt -78.31 144.71 66.99 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.576 -0.703 . . . . 0.34000000000000002 109.452 172.031 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.7 Cg_endo -64.67 135.89 47.23 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 122.929 0.963 . . . . 0.26000000000000001 110.755 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.03 -34.36 63.44 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.499 -0.75 . . . . 2.6200000000000001 110.759 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -38.04 77.92 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.757 -0.589 . . . . 0.45000000000000001 110.317 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.1 mt -77.14 -32.79 56.58 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.734 -0.604 . . . . 1.8200000000000001 110.475 179.031 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.09 -45.66 86.82 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.319 -0.863 . . . . 2.5299999999999998 109.811 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.09 -47.25 62.64 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.515 -0.474 . . . . 1.6799999999999999 110.463 -175.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.6 t -60.52 -38.34 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.116 0 O-C-N 121.726 -0.609 . . . . 0.28000000000000003 109.916 -178.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.672 HG23 ' HB3' ' A' ' 48' ' ' LYS . 84.3 mt -82.38 -17.65 11.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.886 -0.509 . . . . 0.28000000000000003 110.917 -176.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.09 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.697 -1.361 . . . . 0.22 109.697 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.39 142.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.564 -0.962 . . . . 0.77000000000000002 110.707 -173.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.13 159.05 72.19 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.8 -0.562 . . . . 3.21 110.757 -178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -54.57 134.79 63.82 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 122.913 0.954 . . . . 0.5 111.414 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -0.94 72.17 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 120.696 -0.764 . . . . 0.23999999999999999 111.27 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.401 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 16.9 mt-10 -97.19 133.28 42.04 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.058 -1.26 . . . . 1.1100000000000001 110.552 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.3 p -92.98 136.35 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 CA-C-O 121.835 0.826 . . . . 0.23999999999999999 111.389 -174.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.655 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.3 pt -125.89 159.59 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.247 -0.649 . . . . 0.17999999999999999 109.247 177.259 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 52.4 tt0 -97.98 131.25 44.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.046 -0.724 . . . . 1.1399999999999999 109.046 175.389 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.823 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.3 t -117.06 130.7 71.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 CA-C-O 121.438 0.637 . . . . 0.20000000000000001 110.391 -170.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.8 mt -117.27 129.82 56.16 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.194 -0.669 . . . . 0.25 109.194 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.948 HD12 ' HB3' ' A' ' 5' ' ' ALA . 5.6 mt -80.08 140.75 36.33 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.36 -0.838 . . . . 0.28000000000000003 109.903 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.7 mt -111.5 -30.47 7.37 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.672 -0.642 . . . . 1.6000000000000001 111.011 -175.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.29 178.62 41.31 Favored Glycine 0 N--CA 1.505 3.254 0 C-N-CA 119.61 -1.281 . . . . 0.20000000000000001 111.012 -176.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.408 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 30.1 p80 -140.81 145.63 36.55 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.783 -0.834 . . . . 1.8899999999999999 109.99 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.431 ' CE2' ' HB2' ' A' ' 36' ' ' GLU . 18.3 m-85 . . . . . 0 N--CA 1.498 1.945 0 O-C-N 121.665 -0.647 . . . . 0.80000000000000004 109.961 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.486 1.365 0 N-CA-C 109.519 -0.548 . . . . 0.40999999999999998 109.519 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.568 HD11 ' HA2' ' A' ' 86' ' ' GLY . 28.7 mt -85.18 -18.72 33.24 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.221 -0.592 . . . . 0.37 110.246 178.017 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.823 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.79 151.83 1.48 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.214 -0.929 . . . . 0.26000000000000001 109.045 176.042 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 17.5 ttpt -134.63 128.19 32.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.625 -0.672 . . . . 2.2999999999999998 110.356 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -149.91 162.93 39.37 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.822 -0.549 . . . . 0.20000000000000001 110.685 -177.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.432 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.1 m170 -112.58 137.63 50.53 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.662 -0.649 . . . . 1.99 110.144 -176.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.37 162.35 41.07 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.724 -0.61 . . . . 0.17999999999999999 109.636 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.48 157.85 19.15 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 119.81 -0.756 . . . . 0.17000000000000001 110.137 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.923 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.3 t -80.13 136.56 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 CA-C-O 121.276 0.56 . . . . 0.48999999999999999 110.339 -176.102 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.3 m80 -113.98 171.96 7.28 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.229 0.538 . . . . 0.68000000000000005 109.672 174.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.7 mtt85 -45.99 152.44 0.38 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.558 -0.714 . . . . 2.96 112.127 -175.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.0 mt 62.75 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.654 0 O-C-N 121.611 -0.68 . . . . 0.41999999999999998 112.578 -175.057 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.48 16.06 80.74 Favored Glycine 0 N--CA 1.497 2.709 0 O-C-N 120.783 -1.198 . . . . 0.23999999999999999 110.34 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.844 ' NH1' HD11 ' A' ' 18' ' ' ILE . 69.9 ttp85 -85.47 142.63 29.07 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -1.113 . . . . 1.96 110.234 -177.482 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -133.12 156.54 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.728 -0.607 . . . . 0.29999999999999999 109.695 174.202 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.844 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.1 mm -116.52 129.16 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.65 -0.656 . . . . 0.25 109.957 176.078 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 28.2 mt -79.69 145.81 63.46 Favored Pre-proline 0 N--CA 1.495 1.814 0 C-N-CA 120.04 -0.664 . . . . 0.23000000000000001 109.331 175.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.401 ' HD2' HG23 ' A' ' 19' ' ' ILE . 44.6 Cg_endo -62.84 142.74 89.82 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 122.994 0.997 . . . . 0.34999999999999998 109.848 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.27 62.93 Favored 'General case' 0 N--CA 1.497 1.885 0 C-N-CA 120.44 -0.504 . . . . 0.33000000000000002 110.464 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -43.85 95.99 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 109.968 -1.253 . . . . 0.39000000000000001 109.968 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 98.6 m -69.81 -38.53 76.63 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.559 -0.966 . . . . 0.39000000000000001 109.958 -179.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.0 mtt180 -56.03 -41.27 74.7 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.252 -0.905 . . . . 0.40000000000000002 109.39 176.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -65.75 -50.14 65.84 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.111 0.481 . . . . 2.9700000000000002 110.224 -177.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 82.2 t80 -57.47 -38.3 74.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.788 -0.57 . . . . 0.67000000000000004 110.683 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.5 t80 -87.36 -14.16 41.49 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.739 -0.601 . . . . 1.4399999999999999 111.3 -175.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.46 42.78 26.51 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.573 -1.411 . . . . 0.31 109.573 178.056 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.915 HG23 HG21 ' A' ' 56' ' ' VAL . 77.3 mt -88.38 128.48 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.522 -0.987 . . . . 0.41999999999999998 110.556 -176.798 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -128.25 155.44 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.126 -0.694 . . . . 1.8200000000000001 109.126 171.381 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -55.71 138.72 46.96 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 121.241 -0.912 . . . . 1.99 110.646 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.62 -15.98 62.15 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.868 -0.893 . . . . 0.19 110.868 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -77.16 158.18 30.53 Favored 'General case' 0 N--CA 1.499 1.997 0 CA-C-N 118.677 1.239 . . . . 1.1200000000000001 110.11 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -112.09 138.94 48.05 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.594 -0.691 . . . . 0.20999999999999999 109.62 174.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.48 154.11 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 N-CA-C 109.312 -0.625 . . . . 0.14999999999999999 109.312 173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.98 123.57 48.35 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.277 -1.009 . . . . 1.0900000000000001 108.277 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.811 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -140.08 158.17 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.559 -0.856 . . . . 0.14000000000000001 111.128 -167.125 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -133.04 146.1 51.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.799 -0.563 . . . . 1.1100000000000001 110.418 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.511 HG22 HG22 ' A' ' 82' ' ' VAL . 27.5 pt -114.88 151.1 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.743 -0.598 . . . . 0.20000000000000001 110.571 178.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -137.62 128.72 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 109.65 -0.5 . . . . 0.20000000000000001 109.65 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.47 ' HD2' HD12 ' A' ' 74' ' ' ILE . 59.8 tttm -136.82 148.26 47.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.783 -0.573 . . . . 1.98 109.645 177.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.8 t80 . . . . . 0 N--CA 1.496 1.861 0 O-C-N 121.703 -0.623 . . . . 0.33000000000000002 110.491 -178.327 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo . . . . . 0 N--CA 1.485 0.99 0 N-CA-C 110.327 -0.682 . . . . 0.34000000000000002 110.327 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.42 ' CD ' ' HA ' ' A' ' 72' ' ' ILE . 30.1 mttp -121.37 149.8 42.42 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.426 -0.796 . . . . 1.1000000000000001 110.172 171.757 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.3 mp0 -136.99 166.96 22.43 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 120.22 -0.592 . . . . 1.4199999999999999 110.995 -177.572 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.32 135.9 4.51 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.305 -1.518 . . . . 0.17000000000000001 109.305 175.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.4 m -123.84 138.48 54.49 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.546 -0.973 . . . . 0.20999999999999999 109.894 178.676 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.6 p90 -156.62 173.09 17.46 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 119.868 -0.733 . . . . 0.16 110.986 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.2 m -107.37 141.4 38.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.67 -0.644 . . . . 0.13 109.395 173.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.04 145.64 36.15 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.681 -0.637 . . . . 0.14000000000000001 110.709 -175.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.1 ttt180 -93.51 145.13 24.74 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 109.573 -0.529 . . . . 2.21 109.573 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.915 HG21 HG23 ' A' ' 29' ' ' ILE . 93.0 t -79.06 125.05 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.223 0.535 . . . . 0.17000000000000001 109.838 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.08 -164.91 24.86 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.135 -1.186 . . . . 0.19 110.135 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 33.4 tp10 -61.67 152.69 30.16 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.819 . . . . 1.3899999999999999 110.013 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 53.43 21.04 2.23 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.59 -0.694 . . . . 0.81999999999999995 112.043 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.69 79.96 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 119.732 -1.223 . . . . 0.19 110.842 172.207 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -77.92 147.12 35.17 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.45 -1.029 . . . . 1.3 110.365 -176.258 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -139.15 146.55 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.82 -0.55 . . . . 0.20999999999999999 109.628 175.558 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -111.04 123.1 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.579 -0.701 . . . . 0.34000000000000002 110.748 -175.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.7 mt -78.57 144.65 65.76 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.614 -0.679 . . . . 0.34000000000000002 109.535 172.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.6 Cg_endo -64.13 133.27 37.45 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 O-C-N 122.873 0.933 . . . . 0.26000000000000001 110.767 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.2 tttt -55.01 -34.45 63.46 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.551 -0.718 . . . . 2.6200000000000001 110.831 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -38.22 77.89 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.737 -0.602 . . . . 0.45000000000000001 110.275 -178.471 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.8 mt -76.99 -32.8 57.48 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 120.25 -0.58 . . . . 1.8200000000000001 110.547 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.8 mtt180 -57.93 -45.61 86.32 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.287 -0.883 . . . . 2.5299999999999998 109.808 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.75 -46.67 65.34 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.479 -0.489 . . . . 1.6799999999999999 110.307 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 98.8 t -60.72 -39.11 80.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.626 -0.671 . . . . 0.28000000000000003 109.951 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.559 HG22 HD11 ' A' ' 74' ' ' ILE . 85.7 mt -83.65 -14.42 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.839 -0.538 . . . . 0.28000000000000003 111.191 -176.146 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.67 35.38 40.87 Favored Glycine 0 N--CA 1.499 2.857 0 N-CA-C 110.169 -1.172 . . . . 0.22 110.169 175.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.923 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.3 mm -88.66 140.56 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.536 -0.979 . . . . 0.77000000000000002 110.787 -174.292 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -131.38 162.62 54.88 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.782 -0.574 . . . . 3.21 110.606 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.88 134.82 59.26 Favored 'Trans proline' 0 N--CA 1.487 1.09 0 O-C-N 122.954 0.976 . . . . 0.5 110.858 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.97 0.91 70.84 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 120.639 -0.791 . . . . 0.23999999999999999 111.234 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -96.87 133.7 41.15 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.019 -1.283 . . . . 1.1100000000000001 110.498 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.08 133.22 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-O 121.584 0.706 . . . . 0.23999999999999999 111.2 -175.129 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.43 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.4 pt -123.18 159.5 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 109.499 -0.556 . . . . 0.17999999999999999 109.499 176.066 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.432 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 58.8 tt0 -97.35 131.52 43.94 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.986 -0.746 . . . . 1.1399999999999999 108.986 174.472 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.811 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.2 t -116.08 128.46 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.438 0.637 . . . . 0.20000000000000001 110.222 -171.798 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.4 mt -115.45 128.75 56.24 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 109.466 -0.568 . . . . 0.25 109.466 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.52 140.8 37.13 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.451 -0.781 . . . . 0.28000000000000003 109.948 172.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.43 -32.31 6.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.791 -0.568 . . . . 1.6000000000000001 110.828 -176.216 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.568 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.19 -177.19 39.19 Favored Glycine 0 N--CA 1.505 3.259 0 C-N-CA 119.706 -1.235 . . . . 0.20000000000000001 111.025 -176.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.3 p80 -145.17 151.71 38.88 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.708 -0.878 . . . . 1.8899999999999999 110.792 -177.278 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 N--CA 1.494 1.769 0 O-C-N 121.515 -0.741 . . . . 0.80000000000000004 109.994 175.061 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.486 1.369 0 N-CA-C 109.475 -0.565 . . . . 0.40999999999999998 109.475 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.1 mt -82.56 -20.15 37.13 Favored 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 120.248 -0.581 . . . . 0.37 110.425 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.804 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.94 153.21 3.15 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.415 -0.803 . . . . 0.26000000000000001 109.289 176.447 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.437 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.6 tttt -133.96 125.92 29.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.639 -0.663 . . . . 2.2999999999999998 110.222 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.7 p90 -151.2 163.41 38.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.605 -0.684 . . . . 0.20000000000000001 110.833 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.86 138.61 50.06 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.615 -0.678 . . . . 1.99 110.349 -176.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 162.37 41.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.774 -0.578 . . . . 0.17999999999999999 109.684 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -110.21 158.95 17.82 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.48 -0.763 . . . . 0.17000000000000001 109.933 176.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.918 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.46 136.39 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.272 -0.571 . . . . 0.48999999999999999 110.241 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -114.69 171.91 7.35 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.312 0.577 . . . . 0.68000000000000005 109.831 175.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.39 152.97 0.39 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.609 -0.682 . . . . 2.96 112.008 -176.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.5 mt 63.09 7.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.702 0 O-C-N 121.605 -0.684 . . . . 0.41999999999999998 112.522 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.51 15.98 80.8 Favored Glycine 0 N--CA 1.497 2.729 0 O-C-N 120.899 -1.125 . . . . 0.23999999999999999 110.312 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -86.02 143.81 27.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.304 -1.115 . . . . 1.96 110.361 -176.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.4 154.67 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.631 -0.668 . . . . 0.29999999999999999 109.613 172.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.6 128.79 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.623 -0.673 . . . . 0.25 109.978 176.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 27.3 mt -79.44 145.35 63.48 Favored Pre-proline 0 N--CA 1.495 1.781 0 C-N-CA 120.056 -0.658 . . . . 0.23000000000000001 109.423 175.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -63.4 143.64 89.03 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 O-C-N 122.96 0.979 . . . . 0.34999999999999998 109.748 174.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.96 -27.0 60.82 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 120.389 -0.524 . . . . 0.33000000000000002 110.484 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.39 -44.76 94.89 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.02 -1.232 . . . . 0.39000000000000001 110.02 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 91.6 m -69.31 -36.64 77.2 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.686 -0.891 . . . . 0.39000000000000001 110.061 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.612 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.9 mtt180 -56.38 -42.56 78.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.371 -0.83 . . . . 0.40000000000000002 109.812 178.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -66.2 -49.97 65.45 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 120.209 -0.596 . . . . 2.9700000000000002 110.203 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 74.7 t80 -56.26 -37.93 70.46 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.831 -0.543 . . . . 0.67000000000000004 110.589 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.91 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -88.34 -14.31 38.52 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.892 -0.505 . . . . 1.4399999999999999 111.228 -178.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.55 42.82 25.97 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.609 -1.396 . . . . 0.31 109.609 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.92 HG23 HG21 ' A' ' 56' ' ' VAL . 76.6 mt -87.52 126.95 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.526 -0.985 . . . . 0.41999999999999998 110.538 -176.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -127.19 158.98 35.65 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 109.126 -0.694 . . . . 1.8200000000000001 109.126 170.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -57.26 137.53 55.88 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.361 -0.837 . . . . 1.99 110.662 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.23 63.84 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.998 -0.841 . . . . 0.19 110.998 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.31 157.11 32.8 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-N 118.674 1.237 . . . . 1.1200000000000001 110.053 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -111.11 138.39 47.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.629 -0.67 . . . . 0.20999999999999999 109.631 174.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 153.44 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.3 -0.63 . . . . 0.14999999999999999 109.3 174.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -115.06 123.14 48.25 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.317 -0.994 . . . . 1.0900000000000001 108.317 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.3 tt -140.47 159.21 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.688 -0.805 . . . . 0.14000000000000001 110.882 -167.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.2 ttpt -133.55 145.99 50.61 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.783 -0.573 . . . . 1.1100000000000001 110.415 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.604 HG22 HG22 ' A' ' 82' ' ' VAL . 26.0 pt -115.0 151.08 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.575 -0.703 . . . . 0.20000000000000001 110.385 177.065 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.642 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.79 124.5 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 120.499 -0.48 . . . . 0.20000000000000001 109.806 176.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.698 ' HB2' HG22 ' A' ' 80' ' ' ILE . 22.0 ttpp -131.21 144.68 51.52 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.735 -0.603 . . . . 1.98 109.381 176.214 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 t80 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.654 -0.654 . . . . 0.33000000000000002 110.335 -178.916 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.482 0.85 0 N-CA-C 110.097 -0.77 . . . . 0.34000000000000002 110.097 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.681 ' HB3' HG23 ' A' ' 72' ' ' ILE . 25.1 mmtt -111.59 137.37 49.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.593 -0.692 . . . . 1.1000000000000001 109.666 173.181 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.642 ' HG2' HG13 ' A' ' 40' ' ' VAL . 48.7 mt-10 -135.17 165.3 25.72 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.645 -0.659 . . . . 1.4199999999999999 110.71 -176.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.551 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.71 135.68 4.35 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.406 -1.478 . . . . 0.17000000000000001 109.406 176.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.582 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.9 m -123.55 136.66 54.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.782 -0.834 . . . . 0.20999999999999999 109.779 176.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.822 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 10.8 p90 -156.05 173.53 16.68 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 119.942 -0.703 . . . . 0.16 111.079 178.162 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.22 140.71 39.67 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.615 -0.678 . . . . 0.13 109.472 173.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.822 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.63 146.08 35.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.656 -0.653 . . . . 0.14000000000000001 110.655 -175.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.4 ttp-105 -93.63 144.78 25.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.79 -0.569 . . . . 2.21 109.647 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.92 HG21 HG23 ' A' ' 29' ' ' ILE . 90.2 t -79.03 127.28 39.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.794 -0.566 . . . . 0.17000000000000001 109.95 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.72 -171.37 26.61 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.841 -1.304 . . . . 0.19 109.841 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 -61.85 156.61 20.24 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.636 -0.92 . . . . 1.3899999999999999 109.893 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 55.07 19.06 2.59 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.441 -0.787 . . . . 0.81999999999999995 112.075 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.64 20.49 79.62 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.831 -1.176 . . . . 0.19 110.695 172.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.4 t -78.75 144.87 34.8 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.423 -1.046 . . . . 1.3 110.333 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.623 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -137.73 146.15 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 109.555 -0.535 . . . . 0.20999999999999999 109.555 175.019 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.1 mm -110.86 123.69 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.53 -0.731 . . . . 0.34000000000000002 110.714 -174.005 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.413 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.2 mt -78.66 143.29 62.81 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.585 -0.697 . . . . 0.34000000000000002 109.455 172.27 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.4 Cg_endo -65.02 137.11 51.2 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 O-C-N 122.959 0.979 . . . . 0.26000000000000001 110.817 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 17.1 tptp -54.84 -34.79 63.27 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.446 -0.784 . . . . 2.6200000000000001 110.781 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.86 -38.35 78.56 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.792 -0.568 . . . . 0.45000000000000001 110.363 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.3 mt -77.2 -32.73 56.19 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 120.15 -0.62 . . . . 1.8200000000000001 110.683 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.31 -45.55 87.81 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.347 -0.846 . . . . 2.5299999999999998 109.831 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -70.32 -48.19 57.69 Favored 'General case' 0 N--CA 1.495 1.822 0 C-N-CA 120.519 -0.472 . . . . 1.6799999999999999 110.421 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.53 -38.02 76.84 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.732 -0.605 . . . . 0.28000000000000003 109.938 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.681 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.3 mt -82.52 -17.8 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.844 -0.535 . . . . 0.28000000000000003 110.947 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.45 35.17 42.72 Favored Glycine 0 N--CA 1.497 2.721 0 N-CA-C 109.7 -1.36 . . . . 0.22 109.7 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.918 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.13 142.01 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.514 -0.992 . . . . 0.77000000000000002 110.695 -174.305 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 44.9 mttt -130.88 162.34 55.97 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.699 -0.626 . . . . 3.21 110.663 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.93 135.58 64.07 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 O-C-N 123.037 1.019 . . . . 0.5 110.818 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.16 -0.16 71.77 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 120.686 -0.769 . . . . 0.23999999999999999 111.246 176.098 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -95.37 131.12 41.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.055 -1.262 . . . . 1.1100000000000001 110.377 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.5 p -91.66 135.87 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 CA-C-O 121.762 0.792 . . . . 0.23999999999999999 111.106 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.698 HG22 ' HB2' ' A' ' 41' ' ' LYS . 42.0 pt -126.53 159.43 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 109.477 -0.564 . . . . 0.17999999999999999 109.477 179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -98.61 128.18 44.82 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.751 -0.833 . . . . 1.1399999999999999 108.751 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 85.5 t -113.28 128.98 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-O 121.341 0.591 . . . . 0.20000000000000001 110.148 -171.171 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.8 mt -116.75 127.35 54.28 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.02 -0.733 . . . . 0.25 109.02 -179.251 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.91 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.4 mt -79.98 140.9 36.43 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.363 -0.835 . . . . 0.28000000000000003 109.757 172.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 mt -113.9 -30.13 6.83 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.658 -0.651 . . . . 1.6000000000000001 110.966 -174.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.93 -177.93 39.54 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.709 -1.234 . . . . 0.20000000000000001 111.008 -177.264 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 25.5 p80 -145.09 153.53 41.53 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.729 -0.865 . . . . 1.8899999999999999 110.694 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.6 -0.687 . . . . 0.80000000000000004 110.162 176.236 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.43 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p . . . . . 0 N--CA 1.486 1.37 0 N-CA-C 109.556 -0.535 . . . . 0.40999999999999998 109.556 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.603 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.4 mt -82.08 -20.77 37.51 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.25 -0.58 . . . . 0.37 110.252 179.178 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.784 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.17 153.42 3.69 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -0.835 . . . . 0.26000000000000001 109.245 176.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.6 tttt -133.55 125.72 29.46 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.741 -0.6 . . . . 2.2999999999999998 110.173 -176.329 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.61 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.23 162.87 39.64 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.555 -0.716 . . . . 0.20000000000000001 110.94 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -112.83 137.73 50.72 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.718 -0.614 . . . . 1.99 110.172 -176.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.1 162.3 41.12 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.729 -0.607 . . . . 0.17999999999999999 109.582 176.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -110.11 159.77 17.05 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.736 -0.786 . . . . 0.17000000000000001 110.075 177.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.908 HG21 HG21 ' A' ' 74' ' ' ILE . 60.5 t -78.74 136.24 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 C-N-CA 120.3 -0.56 . . . . 0.48999999999999999 110.233 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -115.44 171.88 7.44 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.22 0.533 . . . . 0.68000000000000005 109.589 174.254 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 69.8 mtp85 -46.27 152.54 0.41 Allowed 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.573 -0.704 . . . . 2.96 112.067 -175.67 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.591 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.7 mt 62.41 7.99 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.665 0 O-C-N 121.656 -0.653 . . . . 0.41999999999999998 112.631 -176.025 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.9 16.18 80.27 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.832 -1.168 . . . . 0.23999999999999999 110.446 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -84.45 143.27 29.51 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.314 -1.11 . . . . 1.96 110.33 -176.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -134.51 154.95 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.672 -0.642 . . . . 0.29999999999999999 109.545 172.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.7 mm -117.46 128.44 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.586 -0.696 . . . . 0.25 109.936 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.434 HG12 ' CE2' ' A' ' 7' ' ' PHE . 35.6 mt -79.79 144.04 59.4 Favored Pre-proline 0 N--CA 1.495 1.786 0 C-N-CA 120.075 -0.65 . . . . 0.23000000000000001 109.407 176.026 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.37 143.5 88.91 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.004 1.002 . . . . 0.34999999999999998 109.729 174.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.51 -26.49 61.41 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.858 -0.526 . . . . 0.33000000000000002 110.527 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.37 95.17 Favored Glycine 0 N--CA 1.497 2.722 0 N-CA-C 109.935 -1.266 . . . . 0.39000000000000001 109.935 -179.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 75.0 m -69.97 -38.2 76.02 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.58 -0.953 . . . . 0.39000000000000001 110.18 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.667 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.6 mtt180 -55.95 -41.11 74.21 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.349 -0.844 . . . . 0.40000000000000002 109.413 176.468 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.2 tttp -65.56 -49.95 66.96 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.145 0.498 . . . . 2.9700000000000002 110.197 -177.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -57.14 -38.34 73.38 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.769 -0.582 . . . . 0.67000000000000004 110.735 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.7 t80 -88.12 -14.25 39.24 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.779 -0.575 . . . . 1.4399999999999999 111.291 -176.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.81 42.69 25.05 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.484 -1.447 . . . . 0.31 109.484 178.264 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.864 HG23 HG21 ' A' ' 56' ' ' VAL . 73.6 mt -87.49 129.17 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.492 -1.005 . . . . 0.41999999999999998 110.437 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.08 154.65 45.46 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.962 -0.755 . . . . 1.8200000000000001 108.962 172.233 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -55.21 139.67 41.37 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.288 -0.882 . . . . 1.99 110.691 -177.532 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.86 -15.98 61.88 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.936 -0.866 . . . . 0.19 110.936 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -76.21 156.73 33.35 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.097 -1.237 . . . . 1.1200000000000001 110.069 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -110.18 138.59 46.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.638 -0.664 . . . . 0.20999999999999999 109.595 174.462 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.32 154.79 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 109.271 -0.64 . . . . 0.14999999999999999 109.271 174.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -116.09 123.37 47.74 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.207 -1.034 . . . . 1.0900000000000001 108.207 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.6 tt -139.45 158.25 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 119.661 -0.816 . . . . 0.14000000000000001 110.95 -167.642 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HB2' HG23 ' A' ' 51' ' ' THR . 82.4 tttt -132.7 145.86 51.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.867 -0.521 . . . . 1.1100000000000001 110.386 178.008 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 34.1 pt -114.94 150.97 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.667 -0.645 . . . . 0.20000000000000001 110.568 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.7 t -139.27 126.0 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 CA-C-O 121.231 0.539 . . . . 0.20000000000000001 109.778 176.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.705 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.5 tptp -136.26 148.79 48.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.812 -0.555 . . . . 1.98 109.511 176.006 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.9 t80 . . . . . 0 N--CA 1.495 1.808 0 C-N-CA 120.19 -0.604 . . . . 0.33000000000000002 110.251 -178.135 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo . . . . . 0 N--CA 1.483 0.906 0 N-CA-C 110.566 -0.59 . . . . 0.34000000000000002 110.566 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 73.9 mmtt -114.47 136.89 52.51 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.545 -0.722 . . . . 1.1000000000000001 109.496 171.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -137.5 168.92 18.69 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.603 -0.686 . . . . 1.4199999999999999 110.713 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.417 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -160.22 135.95 4.31 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.592 -1.403 . . . . 0.17000000000000001 109.592 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.409 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -121.55 137.49 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.755 -0.85 . . . . 0.20999999999999999 109.721 177.423 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.8 p90 -155.78 173.02 17.36 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 119.911 -0.716 . . . . 0.16 110.965 176.726 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.4 m -107.44 140.82 39.81 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.71 -0.619 . . . . 0.13 109.586 174.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.66 145.12 34.56 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.614 -0.679 . . . . 0.14000000000000001 110.552 -176.25 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.2 ttp-105 -93.4 145.31 24.58 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.773 -0.58 . . . . 2.21 109.679 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.864 HG21 HG23 ' A' ' 29' ' ' ILE . 94.7 t -79.11 126.13 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.847 -0.533 . . . . 0.17000000000000001 109.975 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.45 -170.7 26.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.79 -1.324 . . . . 0.19 109.79 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -61.88 156.03 21.83 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.61 -0.935 . . . . 1.3899999999999999 109.905 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 54.91 19.44 2.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.611 -0.68 . . . . 0.81999999999999995 112.084 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.68 20.5 79.67 Favored Glycine 0 N--CA 1.499 2.838 0 C-N-CA 119.821 -1.18 . . . . 0.19 110.783 172.456 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 54.1 p -77.97 145.7 35.88 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.451 -1.029 . . . . 1.3 110.534 -175.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.81 146.2 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.875 -0.515 . . . . 0.20999999999999999 109.628 174.497 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.62 123.61 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.499 -0.75 . . . . 0.34000000000000002 110.653 -175.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 72.9 mt -78.3 144.15 65.97 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.679 -0.638 . . . . 0.34000000000000002 109.652 174.108 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.41 134.35 41.33 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 O-C-N 123.002 1.001 . . . . 0.26000000000000001 110.808 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -55.19 -34.29 63.76 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.532 -0.73 . . . . 2.6200000000000001 110.847 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.78 -37.69 76.87 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.74 -0.6 . . . . 0.45000000000000001 110.324 -178.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.4 mt -77.18 -32.79 56.34 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.723 -0.61 . . . . 1.8200000000000001 110.544 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -57.82 -45.73 85.72 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.282 -0.886 . . . . 2.5299999999999998 109.911 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.27 -47.22 62.26 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.44 -0.504 . . . . 1.6799999999999999 110.465 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.56 -38.12 77.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.712 -0.618 . . . . 0.28000000000000003 109.987 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.9 mt -82.31 -18.06 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.849 -0.532 . . . . 0.28000000000000003 110.788 -176.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.28 40.7 Favored Glycine 0 N--CA 1.497 2.763 0 N-CA-C 109.684 -1.366 . . . . 0.22 109.684 176.231 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.908 HG21 HG21 ' A' ' 11' ' ' VAL . 50.9 mm -90.89 144.58 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.53 -0.982 . . . . 0.77000000000000002 110.613 -174.434 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.04 159.31 73.19 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.743 -0.598 . . . . 3.21 110.906 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -52.8 134.79 55.67 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 O-C-N 123.067 1.035 . . . . 0.5 111.688 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.07 -0.63 69.38 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.66 -0.781 . . . . 0.23999999999999999 111.331 175.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.65 129.0 40.1 Favored 'General case' 0 N--CA 1.501 2.083 0 CA-C-N 118.724 1.262 . . . . 1.1100000000000001 110.173 178.58 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 79' ' ' VAL . 10.7 p -91.15 128.51 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 121.4 0.619 . . . . 0.23999999999999999 110.606 -175.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.705 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -118.79 159.56 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.639 -0.504 . . . . 0.17999999999999999 109.639 179.267 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -97.6 130.13 44.66 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.938 -0.764 . . . . 1.1399999999999999 108.938 174.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.48 129.2 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-O 121.373 0.606 . . . . 0.20000000000000001 110.257 -171.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.9 mt -116.38 129.08 56.05 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.204 -0.665 . . . . 0.25 109.204 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -79.8 139.66 37.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.342 -0.849 . . . . 0.28000000000000003 109.791 172.546 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -109.34 -33.45 6.83 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.767 -0.583 . . . . 1.6000000000000001 110.927 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.603 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.22 -175.2 37.69 Favored Glycine 0 N--CA 1.504 3.184 0 C-N-CA 119.674 -1.251 . . . . 0.20000000000000001 111.031 -176.122 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p80 -143.79 153.91 42.88 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.759 -0.847 . . . . 1.8899999999999999 110.719 -177.39 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.537 -0.727 . . . . 0.80000000000000004 110.236 176.04 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.45 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p . . . . . 0 N--CA 1.487 1.42 0 N-CA-C 109.588 -0.523 . . . . 0.40999999999999998 109.588 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.8 mt -80.96 -21.49 40.32 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.269 -0.572 . . . . 0.37 110.189 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.862 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.11 152.18 3.4 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.442 -0.786 . . . . 0.26000000000000001 109.127 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.441 ' HE3' HD21 ' A' ' 83' ' ' LEU . 67.2 tttt -132.61 125.18 29.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.702 -0.624 . . . . 2.2999999999999998 110.214 -176.706 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.0 p90 -150.21 162.76 39.84 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.072 -0.651 . . . . 0.20000000000000001 110.989 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -112.52 138.23 49.58 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.626 -0.671 . . . . 1.99 110.154 -176.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.06 162.26 41.18 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.696 -0.628 . . . . 0.17999999999999999 109.627 176.834 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.62 158.78 18.2 Favored 'General case' 0 N--CA 1.498 1.939 0 C-N-CA 119.818 -0.753 . . . . 0.17000000000000001 110.136 177.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.3 t -79.24 134.89 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 C-N-CA 120.257 -0.577 . . . . 0.48999999999999999 110.245 -177.089 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.28 171.89 7.34 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-O 121.277 0.561 . . . . 0.68000000000000005 109.647 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -47.16 152.99 0.5 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.579 -0.701 . . . . 2.96 111.776 -175.324 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.7 mt 62.65 7.37 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.652 0 O-C-N 121.46 -0.775 . . . . 0.41999999999999998 112.681 -174.48 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.1 80.63 Favored Glycine 0 N--CA 1.497 2.747 0 O-C-N 120.935 -1.103 . . . . 0.23999999999999999 110.363 179.414 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -84.64 142.84 29.63 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.248 -1.148 . . . . 1.96 110.391 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.57 155.22 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.721 -0.612 . . . . 0.29999999999999999 109.39 172.398 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.6 mm -116.56 128.45 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.579 -0.701 . . . . 0.25 109.977 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 37.4 mt -79.99 144.32 59.04 Favored Pre-proline 0 N--CA 1.495 1.792 0 C-N-CA 120.015 -0.674 . . . . 0.23000000000000001 109.422 175.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -63.54 143.46 87.8 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 122.943 0.97 . . . . 0.34999999999999998 109.751 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.75 61.57 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 120.44 -0.504 . . . . 0.33000000000000002 110.481 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.17 95.56 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.954 -1.258 . . . . 0.39000000000000001 109.954 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.7 m -69.87 -38.43 76.39 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.562 -0.964 . . . . 0.39000000000000001 110.148 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.704 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.9 mtt180 -56.03 -40.58 73.66 Favored 'General case' 0 N--CA 1.513 2.689 0 O-C-N 121.29 -0.881 . . . . 0.40000000000000002 109.386 176.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -65.64 -50.01 66.56 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.043 0.449 . . . . 2.9700000000000002 110.213 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -57.74 -38.85 76.07 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.751 -0.593 . . . . 0.67000000000000004 110.683 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.96 ' CD2' HD13 ' A' ' 84' ' ' LEU . 26.7 t80 -86.74 -14.17 43.17 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.804 -0.56 . . . . 1.4399999999999999 111.346 -176.511 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 43.14 23.45 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.603 -1.399 . . . . 0.31 109.603 178.57 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.895 HG23 HG21 ' A' ' 56' ' ' VAL . 76.9 mt -87.73 128.79 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 121.523 -0.986 . . . . 0.41999999999999998 110.537 -177.352 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.1 153.97 46.24 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.868 -0.79 . . . . 1.8200000000000001 108.868 170.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -55.27 140.39 39.33 Favored 'General case' 0 N--CA 1.504 2.241 0 O-C-N 121.238 -0.913 . . . . 1.99 110.626 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.8 -16.03 61.74 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.859 -0.896 . . . . 0.19 110.859 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.91 157.54 31.3 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.67 1.235 . . . . 1.1200000000000001 110.115 178.186 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -111.71 138.92 47.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.622 -0.674 . . . . 0.20999999999999999 109.557 174.315 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.55 155.12 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 C-N-CA 120.224 -0.59 . . . . 0.14999999999999999 109.454 174.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.92 123.6 48.49 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.364 -0.976 . . . . 1.0900000000000001 108.364 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.4 tt -139.96 156.01 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.682 -0.807 . . . . 0.14000000000000001 110.95 -167.734 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -131.13 146.07 52.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.747 -0.596 . . . . 1.1100000000000001 110.55 177.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 82' ' ' VAL . 29.6 pt -114.94 151.08 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 121.731 -0.605 . . . . 0.20000000000000001 110.699 178.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.463 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.23 126.58 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.152 0.501 . . . . 0.20000000000000001 109.734 175.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.703 ' HB2' HG22 ' A' ' 80' ' ' ILE . 32.1 tptt -136.69 146.89 46.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.741 -0.6 . . . . 1.98 109.602 175.59 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 t80 . . . . . 0 N--CA 1.495 1.816 0 C-N-CA 120.231 -0.587 . . . . 0.33000000000000002 110.427 -177.275 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.482 0.801 0 N-CA-C 110.159 -0.746 . . . . 0.34000000000000002 110.159 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.75 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.0 mmtt -120.48 138.17 53.96 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.545 -0.722 . . . . 1.1000000000000001 109.564 172.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.463 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.7 mt-10 -134.57 163.41 29.79 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.635 -0.665 . . . . 1.4199999999999999 110.718 -176.807 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.91 135.89 4.43 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.618 -1.393 . . . . 0.17000000000000001 109.618 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.3 m -122.17 137.45 54.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.715 -0.873 . . . . 0.20999999999999999 109.75 176.76 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.5 p90 -155.55 172.77 17.7 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.972 -0.691 . . . . 0.16 111.036 176.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.7 m -106.9 141.03 38.77 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.691 -0.63 . . . . 0.13 109.464 173.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.31 145.4 35.42 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.564 -0.71 . . . . 0.14000000000000001 110.58 -176.048 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -92.96 144.79 24.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.809 -0.557 . . . . 2.21 109.605 175.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.895 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -79.14 125.23 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-O 121.332 0.587 . . . . 0.17000000000000001 109.79 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.68 -167.31 26.34 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.939 -1.264 . . . . 0.19 109.939 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.6 153.45 27.78 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.724 -0.868 . . . . 1.3899999999999999 110.101 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.64 21.03 2.39 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.54 -0.725 . . . . 0.81999999999999995 112.061 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.07 20.58 79.68 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.784 -1.198 . . . . 0.19 110.793 171.55 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.2 m -77.88 144.92 36.54 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.488 -1.007 . . . . 1.3 110.375 -176.311 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.722 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -138.43 144.96 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.553 -0.536 . . . . 0.20999999999999999 109.553 174.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.65 123.33 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.49 -0.756 . . . . 0.34000000000000002 110.641 -175.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.449 HG23 ' HD2' ' A' ' 65' ' ' PRO . 54.7 mt -78.44 144.43 65.93 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.643 -0.661 . . . . 0.34000000000000002 109.518 173.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.21 133.63 38.77 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.934 0.965 . . . . 0.26000000000000001 110.764 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.08 -34.23 63.46 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.443 -0.786 . . . . 2.6200000000000001 110.866 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.76 -38.09 77.71 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.745 -0.597 . . . . 0.45000000000000001 110.329 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 71.0 mt -77.15 -32.67 56.45 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 120.259 -0.576 . . . . 1.8200000000000001 110.552 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.88 -46.03 85.49 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.3 -0.875 . . . . 2.5299999999999998 109.897 178.627 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -70.16 -46.79 63.95 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 120.456 -0.498 . . . . 1.6799999999999999 110.473 -175.391 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.5 t -60.38 -38.45 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.678 -0.639 . . . . 0.28000000000000003 109.865 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.75 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.5 mt -82.53 -17.99 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.844 -0.535 . . . . 0.28000000000000003 110.822 -176.535 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.25 35.11 38.88 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 109.665 -1.374 . . . . 0.22 109.665 176.07 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.65 142.54 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.619 -0.93 . . . . 0.77000000000000002 110.581 -175.062 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -129.64 162.11 55.14 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.674 -0.641 . . . . 3.21 110.807 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.91 135.32 62.41 Favored 'Trans proline' 0 N--CA 1.488 1.159 0 O-C-N 123.063 1.033 . . . . 0.5 110.835 -179.099 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.9 -0.05 72.44 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 120.591 -0.814 . . . . 0.23999999999999999 111.235 176.011 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -96.18 131.61 42.47 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 118.715 1.257 . . . . 1.1100000000000001 110.445 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.0 p -91.87 130.1 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 CA-C-O 121.511 0.672 . . . . 0.23999999999999999 110.837 -174.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.703 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.3 pt -118.72 159.51 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 109.591 -0.522 . . . . 0.17999999999999999 109.591 177.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -97.01 130.69 44.3 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.026 -0.731 . . . . 1.1399999999999999 109.026 174.515 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.6 t -115.85 128.9 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.366 0.603 . . . . 0.20000000000000001 110.241 -171.429 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.45 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.7 mt -116.31 128.75 55.83 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.324 -0.621 . . . . 0.25 109.324 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.96 HD13 ' CD2' ' A' ' 27' ' ' TYR . 6.0 mt -79.65 142.51 35.49 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.402 -0.811 . . . . 0.28000000000000003 109.808 171.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 85' ' ' LEU . 43.7 mt -120.65 -24.95 5.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.655 . . . . 1.6000000000000001 111.206 -174.076 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.28 -179.92 40.49 Favored Glycine 0 N--CA 1.505 3.28 0 C-N-CA 119.642 -1.266 . . . . 0.20000000000000001 111.066 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 p80 -146.95 152.62 38.94 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.745 -0.856 . . . . 1.8899999999999999 110.685 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 N--CA 1.495 1.807 0 O-C-N 121.582 -0.699 . . . . 0.80000000000000004 110.07 175.657 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 109.719 -0.474 . . . . 0.40999999999999998 109.719 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.59 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.3 mt -86.61 -18.44 31.39 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.262 -0.575 . . . . 0.37 110.547 -179.604 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.79 153.74 3.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.357 -0.839 . . . . 0.26000000000000001 109.299 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -133.77 125.42 28.46 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.703 -0.623 . . . . 2.2999999999999998 110.079 -177.256 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.3 p90 -150.68 162.09 41.35 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.603 -0.686 . . . . 0.20000000000000001 110.869 -179.322 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -112.78 138.84 49.01 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.661 -0.649 . . . . 1.99 110.161 -176.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.29 41.07 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.728 -0.607 . . . . 0.17999999999999999 109.59 178.069 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -111.0 158.68 18.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.417 -0.802 . . . . 0.17000000000000001 110.044 177.152 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.906 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -79.16 136.29 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.295 -0.562 . . . . 0.48999999999999999 110.343 -176.307 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -115.25 171.94 7.38 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.42 0.629 . . . . 0.68000000000000005 109.796 175.043 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 -46.52 153.04 0.4 Allowed 'General case' 0 N--CA 1.505 2.31 0 O-C-N 121.536 -0.728 . . . . 2.96 111.981 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.8 mt 62.89 7.45 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.671 0 O-C-N 121.569 -0.707 . . . . 0.41999999999999998 112.567 -175.529 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.73 15.99 80.63 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.344 -1.102 . . . . 0.23999999999999999 110.344 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -85.5 144.0 28.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.235 -1.156 . . . . 1.96 110.429 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -132.67 154.95 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.748 -0.595 . . . . 0.29999999999999999 109.46 172.456 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.435 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -117.11 128.76 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 C-N-CA 120.073 -0.651 . . . . 0.25 110.065 176.647 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.08 145.21 60.39 Favored Pre-proline 0 N--CA 1.496 1.828 0 C-N-CA 120.062 -0.655 . . . . 0.23000000000000001 109.406 175.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.34 143.73 89.59 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 O-C-N 123.024 1.013 . . . . 0.34999999999999998 109.755 174.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.41 61.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.87 -0.519 . . . . 0.33000000000000002 110.471 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.74 -44.22 95.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 110.026 -1.23 . . . . 0.39000000000000001 110.026 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 78.5 m -69.85 -38.21 76.41 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.964 . . . . 0.39000000000000001 110.124 -179.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.613 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.4 mtt180 -56.3 -41.65 76.28 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 121.276 -0.89 . . . . 0.40000000000000002 109.377 176.676 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -65.9 -50.09 65.7 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.14 0.495 . . . . 2.9700000000000002 110.221 -177.54 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.27 -37.79 72.91 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.732 -0.605 . . . . 0.67000000000000004 110.633 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.5 t80 -88.06 -14.15 39.65 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.805 -0.559 . . . . 1.4399999999999999 111.229 -175.764 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.33 42.49 27.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.563 -1.415 . . . . 0.31 109.563 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.869 HG23 HG21 ' A' ' 56' ' ' VAL . 78.3 mt -89.62 131.14 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.453 -1.027 . . . . 0.41999999999999998 110.645 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.27 158.94 36.78 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.091 -0.707 . . . . 1.8200000000000001 109.091 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -57.47 139.45 53.23 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.38 -0.825 . . . . 1.99 110.513 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.74 -15.25 63.49 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.887 -0.885 . . . . 0.19 110.887 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.12 158.16 32.07 Favored 'General case' 0 N--CA 1.501 2.123 0 CA-C-N 118.724 1.262 . . . . 1.1200000000000001 109.932 178.182 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -110.53 138.16 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.591 -0.693 . . . . 0.20999999999999999 109.588 175.149 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.35 154.16 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 109.13 -0.693 . . . . 0.14999999999999999 109.13 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -116.05 123.8 48.84 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.317 -0.994 . . . . 1.0900000000000001 108.317 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.8 tt -140.51 158.13 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 119.635 -0.826 . . . . 0.14000000000000001 110.961 -167.852 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.3 ttpt -132.29 146.11 51.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.837 -0.539 . . . . 1.1100000000000001 110.386 177.386 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 82' ' ' VAL . 23.2 pt -114.88 150.98 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.667 -0.646 . . . . 0.20000000000000001 110.278 176.822 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.524 HG13 ' HG2' ' A' ' 49' ' ' GLU . 59.4 t -139.53 123.64 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 CA-C-O 121.251 0.548 . . . . 0.20000000000000001 109.729 177.554 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.676 ' HB2' HG22 ' A' ' 80' ' ' ILE . 53.2 tttm -132.92 147.5 52.29 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.248 -0.649 . . . . 1.98 109.248 176.161 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 t80 . . . . . 0 N--CA 1.498 1.952 0 C-N-CA 119.903 -0.719 . . . . 0.33000000000000002 110.531 -178.271 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.483 0.855 0 N-CA-C 110.399 -0.654 . . . . 0.34000000000000002 110.399 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.5 mmtt -111.37 136.89 49.85 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.657 -0.652 . . . . 1.1000000000000001 109.466 172.063 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.524 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.7 164.49 27.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.703 -0.623 . . . . 1.4199999999999999 110.996 -176.44 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.43 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.59 135.75 4.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.469 -1.453 . . . . 0.17000000000000001 109.469 176.617 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.85 136.91 54.24 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.712 -0.875 . . . . 0.20999999999999999 109.732 177.223 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -155.88 173.38 16.85 Favored 'General case' 0 N--CA 1.497 1.911 0 C-N-CA 119.867 -0.733 . . . . 0.16 111.089 178.159 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.7 m -106.95 140.39 39.83 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.722 -0.611 . . . . 0.13 109.551 173.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.28 146.11 34.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.633 -0.667 . . . . 0.14000000000000001 110.443 -175.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.65 145.58 24.45 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.774 -0.579 . . . . 2.21 109.711 175.523 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.869 HG21 HG23 ' A' ' 29' ' ' ILE . 97.9 t -77.84 126.41 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.2 0.524 . . . . 0.17000000000000001 109.973 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.53 -167.56 26.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.931 -1.268 . . . . 0.19 109.931 179.109 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -61.71 153.34 28.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.7 -0.882 . . . . 1.3899999999999999 109.965 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 54.14 20.49 2.57 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.531 -0.731 . . . . 0.81999999999999995 111.98 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 20.44 79.94 Favored Glycine 0 N--CA 1.5 2.928 0 C-N-CA 119.803 -1.189 . . . . 0.19 110.826 171.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.435 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.5 p -78.37 146.9 34.37 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -1.01 . . . . 1.3 110.203 -177.773 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.619 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.88 145.8 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.758 -0.589 . . . . 0.20999999999999999 109.565 175.006 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.15 123.15 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.588 -0.695 . . . . 0.34000000000000002 110.654 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 65.5 mt -78.41 144.02 65.29 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.504 -0.748 . . . . 0.34000000000000002 109.432 172.333 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.77 134.43 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 O-C-N 122.861 0.927 . . . . 0.26000000000000001 110.648 -179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -55.15 -34.21 63.59 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.505 -0.747 . . . . 2.6200000000000001 110.802 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -37.87 77.12 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.802 -0.562 . . . . 0.45000000000000001 110.271 -178.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.8 mt -77.11 -32.75 56.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.748 -0.595 . . . . 1.8200000000000001 110.553 178.548 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.78 -46.0 85.21 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.306 -0.871 . . . . 2.5299999999999998 109.923 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.32 -47.23 62.05 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.5 -0.48 . . . . 1.6799999999999999 110.493 -175.626 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.6 t -60.51 -38.15 77.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.684 -0.635 . . . . 0.28000000000000003 109.966 -178.5 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.711 HG22 HD11 ' A' ' 74' ' ' ILE . 83.1 mt -82.57 -17.81 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.792 -0.568 . . . . 0.28000000000000003 110.934 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.32 35.14 43.53 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.787 -1.325 . . . . 0.22 109.787 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.906 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.24 138.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.522 -0.987 . . . . 0.77000000000000002 110.715 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 57.0 mmtt -124.25 161.1 49.42 Favored Pre-proline 0 N--CA 1.498 1.931 0 O-C-N 121.675 -0.64 . . . . 3.21 110.61 -176.379 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.76 136.36 66.01 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 O-C-N 123.027 1.014 . . . . 0.5 110.78 179.386 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.63 -0.65 74.24 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 111.123 -0.791 . . . . 0.23999999999999999 111.123 176.824 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 21.7 mt-10 -98.14 134.44 41.2 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 118.682 1.241 . . . . 1.1100000000000001 110.567 179.695 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.07 133.41 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 CA-C-O 121.684 0.754 . . . . 0.23999999999999999 111.227 -174.334 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.676 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.7 pt -122.93 159.48 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 109.211 -0.663 . . . . 0.17999999999999999 109.211 175.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 49.7 tt0 -98.82 131.41 44.96 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 109.021 -0.733 . . . . 1.1399999999999999 109.021 175.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 88.5 t -115.8 129.93 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.435 0.636 . . . . 0.20000000000000001 110.365 -170.563 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.2 mt -115.73 130.7 56.95 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 109.237 -0.653 . . . . 0.25 109.237 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.09 139.88 36.7 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.449 -0.782 . . . . 0.28000000000000003 109.781 171.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.0 mt -108.71 -34.4 6.71 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.8 -0.563 . . . . 1.6000000000000001 110.887 -176.433 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.59 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.03 -174.63 37.74 Favored Glycine 0 N--CA 1.502 3.079 0 C-N-CA 119.738 -1.22 . . . . 0.20000000000000001 111.015 -177.106 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -143.91 155.62 44.14 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.738 -0.86 . . . . 1.8899999999999999 110.743 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.494 1.745 0 O-C-N 121.577 -0.702 . . . . 0.80000000000000004 110.208 176.563 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 109.578 -0.527 . . . . 0.40999999999999998 109.578 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.8 mt -83.72 -19.6 34.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.761 -0.587 . . . . 0.37 110.276 177.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.797 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.46 152.7 1.76 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.262 -0.899 . . . . 0.26000000000000001 109.124 176.222 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.1 ttpt -135.42 128.23 31.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.635 -0.665 . . . . 2.2999999999999998 110.382 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.2 p90 -149.81 163.56 37.68 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.391 -0.524 . . . . 0.20000000000000001 110.508 -178.277 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.61 137.59 51.37 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.602 -0.686 . . . . 1.99 110.4 -176.36 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.56 162.28 41.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.756 -0.59 . . . . 0.17999999999999999 109.568 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -109.63 158.56 17.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.468 -0.77 . . . . 0.17000000000000001 110.02 176.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.934 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.9 t -79.47 138.06 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.779 -0.576 . . . . 0.48999999999999999 110.355 -176.545 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -116.66 171.87 7.59 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.347 0.594 . . . . 0.68000000000000005 109.86 176.244 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -46.29 153.05 0.37 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.629 -0.669 . . . . 2.96 112.075 -175.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.579 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.9 mt 62.94 7.2 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.648 0 O-C-N 121.651 -0.655 . . . . 0.41999999999999998 112.578 -175.599 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.61 16.09 80.6 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.331 -1.108 . . . . 0.23999999999999999 110.331 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 36.7 ttp180 -85.76 144.29 27.85 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.354 -1.086 . . . . 1.96 110.198 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -132.42 155.03 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.681 -0.637 . . . . 0.29999999999999999 109.359 172.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.4 mm -115.71 128.55 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.595 -0.691 . . . . 0.25 109.952 176.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 25.5 mt -79.58 144.5 61.15 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.052 -0.659 . . . . 0.23000000000000001 109.417 175.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -63.48 143.39 87.98 Favored 'Trans proline' 0 N--CA 1.488 1.191 0 O-C-N 123.002 1.001 . . . . 0.34999999999999998 109.689 174.746 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.0 -26.37 60.13 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.838 -0.539 . . . . 0.33000000000000002 110.46 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.31 -45.32 93.78 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 109.999 -1.24 . . . . 0.39000000000000001 109.999 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 m -69.5 -36.87 76.9 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.617 -0.931 . . . . 0.39000000000000001 110.202 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.7 mtt180 -56.3 -42.05 76.94 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.418 -0.801 . . . . 0.40000000000000002 109.734 178.125 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -65.97 -50.2 65.16 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.364 0.602 . . . . 2.9700000000000002 110.162 -177.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -56.67 -37.87 71.42 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.835 -0.541 . . . . 0.67000000000000004 110.69 -178.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.947 ' CD2' HD13 ' A' ' 84' ' ' LEU . 25.0 t80 -87.89 -14.17 40.06 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.825 -0.547 . . . . 1.4399999999999999 111.364 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 43.03 23.24 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.586 -1.406 . . . . 0.31 109.586 178.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.922 HG23 HG21 ' A' ' 56' ' ' VAL . 76.1 mt -87.53 127.44 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.422 -1.046 . . . . 0.41999999999999998 110.575 -177.182 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.29 154.92 44.32 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.008 -0.738 . . . . 1.8200000000000001 109.008 170.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.52 137.75 47.95 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.253 -0.904 . . . . 1.99 110.751 -177.45 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.46 -15.1 64.01 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.927 -0.869 . . . . 0.19 110.927 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -75.97 157.51 33.02 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.735 1.268 . . . . 1.1200000000000001 109.851 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -111.21 138.17 47.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.606 -0.684 . . . . 0.20999999999999999 109.679 175.173 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.39 153.52 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 109.249 -0.649 . . . . 0.14999999999999999 109.249 174.549 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -115.33 122.98 47.55 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.242 -1.021 . . . . 1.0900000000000001 108.242 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.809 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.3 tt -139.97 157.99 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 119.604 -0.838 . . . . 0.14000000000000001 110.987 -167.171 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.5 tttt -132.61 145.98 51.53 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.8 -0.562 . . . . 1.1100000000000001 110.596 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 28.0 pt -115.13 151.03 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.728 -0.608 . . . . 0.20000000000000001 110.62 178.024 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.495 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.2 t -138.77 125.61 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.143 0.497 . . . . 0.20000000000000001 109.772 176.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.67 ' HB2' HG22 ' A' ' 80' ' ' ILE . 21.4 ttpp -131.9 143.36 50.08 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.222 -0.659 . . . . 1.98 109.222 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 t80 . . . . . 0 N--CA 1.495 1.819 0 C-N-CA 120.137 -0.625 . . . . 0.33000000000000002 110.456 -178.139 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo . . . . . 0 N--CA 1.482 0.844 0 N-CA-C 110.127 -0.759 . . . . 0.34000000000000002 110.127 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.661 ' HB3' HG23 ' A' ' 72' ' ' ILE . 68.7 mmtt -110.85 137.17 48.83 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.548 -0.72 . . . . 1.1000000000000001 109.622 172.496 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.8 mt-10 -135.5 164.23 28.28 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.614 -0.679 . . . . 1.4199999999999999 110.796 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.614 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.15 135.96 4.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.605 -1.398 . . . . 0.17000000000000001 109.605 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.3 m -123.09 137.34 54.95 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.68 -0.894 . . . . 0.20999999999999999 109.735 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.8 p90 -155.87 172.55 18.16 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.843 -0.743 . . . . 0.16 111.017 176.794 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.0 m -107.78 140.85 40.23 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.694 -0.629 . . . . 0.13 109.545 174.078 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.09 145.78 34.69 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.723 -0.61 . . . . 0.14000000000000001 110.641 -175.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.7 ttp180 -93.9 145.25 24.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.73 -0.606 . . . . 2.21 109.598 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.922 HG21 HG23 ' A' ' 29' ' ' ILE . 98.8 t -78.44 126.47 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.783 -0.573 . . . . 0.17000000000000001 109.928 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.04 -166.51 24.98 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.099 -1.201 . . . . 0.19 110.099 178.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -61.63 153.08 28.94 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.872 -0.781 . . . . 1.3899999999999999 110.218 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.57 21.18 2.41 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.547 -0.721 . . . . 0.81999999999999995 112.001 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.81 20.48 79.76 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.747 -1.216 . . . . 0.19 110.806 171.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 14.2 m -77.99 145.25 36.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.414 -1.05 . . . . 1.3 110.232 -176.573 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.27 145.51 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.789 -0.569 . . . . 0.20999999999999999 109.609 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -112.03 123.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.55 -0.719 . . . . 0.34000000000000002 110.734 -174.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.455 HG23 ' HD2' ' A' ' 65' ' ' PRO . 80.3 mt -78.5 145.12 66.99 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.591 -0.693 . . . . 0.34000000000000002 109.484 172.509 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.2 Cg_endo -64.38 136.68 52.08 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 O-C-N 122.889 0.941 . . . . 0.26000000000000001 110.821 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 20.2 tptt -54.93 -34.85 63.59 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.47 -0.769 . . . . 2.6200000000000001 110.845 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.91 -38.2 78.4 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.764 -0.585 . . . . 0.45000000000000001 110.298 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.0 mt -77.17 -32.78 56.4 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.727 -0.608 . . . . 1.8200000000000001 110.658 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.2 mtt180 -58.3 -45.85 87.24 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.22 -0.925 . . . . 2.5299999999999998 109.884 178.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.3 -47.42 61.26 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 120.383 -0.527 . . . . 1.6799999999999999 110.51 -175.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.9 t -60.58 -38.18 77.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 O-C-N 121.653 -0.654 . . . . 0.28000000000000003 109.91 -178.336 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.697 HG22 HD11 ' A' ' 74' ' ' ILE . 86.1 mt -82.28 -17.61 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.882 -0.512 . . . . 0.28000000000000003 110.966 -176.224 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.23 40.83 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.835 -1.306 . . . . 0.22 109.835 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.934 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.58 141.11 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.511 -0.994 . . . . 0.77000000000000002 110.704 -173.724 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -127.67 156.28 75.8 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.732 -0.605 . . . . 3.21 110.631 -177.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -55.98 135.42 69.67 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 122.974 0.986 . . . . 0.5 111.275 177.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.12 -0.76 72.71 Favored Glycine 0 N--CA 1.496 2.65 0 C-N-CA 120.694 -0.765 . . . . 0.23999999999999999 111.241 176.267 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -96.36 132.6 41.7 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-N 118.734 1.267 . . . . 1.1100000000000001 110.477 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.3 p -91.21 132.08 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-O 121.639 0.733 . . . . 0.23999999999999999 110.979 -174.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.67 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.4 pt -123.23 159.42 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 109.464 -0.569 . . . . 0.17999999999999999 109.464 177.382 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.7 tt0 -98.13 131.57 44.4 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.919 -0.771 . . . . 1.1399999999999999 108.919 173.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.809 ' CG1' HD11 ' A' ' 37' ' ' ILE . 99.9 t -115.1 128.01 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.20000000000000001 110.166 -171.453 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.1 mt -114.79 128.46 56.31 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.365 -0.605 . . . . 0.25 109.365 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.947 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.88 139.92 36.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.485 -0.76 . . . . 0.28000000000000003 109.821 172.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.7 mt -110.93 -31.75 7.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.769 -0.582 . . . . 1.6000000000000001 110.85 -175.434 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.25 -177.04 39.12 Favored Glycine 0 N--CA 1.504 3.225 0 C-N-CA 119.745 -1.216 . . . . 0.20000000000000001 110.958 -176.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -144.72 152.56 40.59 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.667 -0.902 . . . . 1.8899999999999999 110.72 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.80000000000000004 109.995 175.91 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.486 1.365 0 N-CA-C 109.723 -0.473 . . . . 0.40999999999999998 109.723 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.559 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.4 mt -89.58 -18.02 27.38 Favored 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 120.309 -0.556 . . . . 0.37 110.654 -177.141 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.869 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.75 154.99 3.8 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.249 -0.907 . . . . 0.26000000000000001 109.577 177.321 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -133.63 127.1 32.27 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.707 -0.621 . . . . 2.2999999999999998 110.126 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.582 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 13.2 p90 -148.75 162.64 39.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.643 -0.661 . . . . 0.20000000000000001 110.702 177.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.81 138.37 50.36 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.596 -0.69 . . . . 1.99 110.34 -176.406 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.04 162.21 41.28 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 109.459 -0.571 . . . . 0.17999999999999999 109.459 177.065 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -109.31 158.45 17.87 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.436 -0.79 . . . . 0.17000000000000001 110.152 177.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.905 HG21 HG21 ' A' ' 74' ' ' ILE . 61.2 t -79.22 136.43 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.32 -0.552 . . . . 0.48999999999999999 110.097 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.41 171.87 7.36 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-O 121.269 0.556 . . . . 0.68000000000000005 109.612 173.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -46.86 152.61 0.49 Allowed 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.579 -0.7 . . . . 2.96 111.978 -176.149 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.61 0 O-C-N 121.529 -0.732 . . . . 0.41999999999999998 112.631 -175.478 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.401 ' HA3' ' NE ' ' A' ' 69' ' ' ARG . . . 78.01 16.17 80.18 Favored Glycine 0 N--CA 1.497 2.742 0 O-C-N 120.964 -1.085 . . . . 0.23999999999999999 110.463 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -83.89 141.15 31.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.298 -1.119 . . . . 1.96 110.316 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.7 pt -133.72 155.75 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.569 -0.707 . . . . 0.29999999999999999 109.816 173.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.17 129.75 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.529 -0.732 . . . . 0.25 109.878 175.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.426 HG12 ' CE2' ' A' ' 7' ' ' PHE . 24.2 mt -79.76 145.91 63.35 Favored Pre-proline 0 N--CA 1.495 1.806 0 C-N-CA 119.962 -0.695 . . . . 0.23000000000000001 109.322 175.573 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.412 ' HD2' HG23 ' A' ' 19' ' ' ILE . 48.2 Cg_endo -63.22 143.25 89.29 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.005 1.002 . . . . 0.34999999999999998 109.819 174.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.84 -26.43 62.03 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 120.404 -0.518 . . . . 0.33000000000000002 110.462 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.94 -43.86 95.37 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 110.027 -1.229 . . . . 0.39000000000000001 110.027 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.7 m -69.87 -38.61 76.47 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.63 -0.924 . . . . 0.39000000000000001 110.136 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.594 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.2 mtt180 -56.24 -43.27 78.48 Favored 'General case' 0 N--CA 1.513 2.694 0 O-C-N 121.346 -0.846 . . . . 0.40000000000000002 109.571 176.775 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -67.16 -50.2 62.02 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-O 121.18 0.514 . . . . 2.9700000000000002 110.316 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -57.6 -36.35 71.65 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.764 -0.585 . . . . 0.67000000000000004 110.661 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 16.8 t80 -88.15 -14.06 39.65 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.705 -0.622 . . . . 1.4399999999999999 111.371 -174.322 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 74.92 41.74 32.23 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.657 -1.377 . . . . 0.31 109.657 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.843 HG23 HG21 ' A' ' 56' ' ' VAL . 81.9 mt -90.91 132.79 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.504 -0.998 . . . . 0.41999999999999998 110.615 -176.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.18 159.29 36.52 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.047 -0.723 . . . . 1.8200000000000001 109.047 172.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -57.96 140.23 52.66 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.388 -0.82 . . . . 1.99 110.367 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.77 -16.0 61.79 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.849 -0.901 . . . . 0.19 110.849 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.04 158.5 30.51 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.72 1.26 . . . . 1.1200000000000001 110.223 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -111.86 139.68 47.14 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.661 -0.649 . . . . 0.20999999999999999 109.598 174.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.09 155.02 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 109.235 -0.654 . . . . 0.14999999999999999 109.235 174.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -116.35 123.22 47.08 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.345 -0.984 . . . . 1.0900000000000001 108.345 -178.619 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.0 tt -140.53 158.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.553 -0.859 . . . . 0.14000000000000001 111.232 -166.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -132.54 145.61 51.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.878 -0.514 . . . . 1.1100000000000001 110.519 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.495 HG22 HG22 ' A' ' 82' ' ' VAL . 26.1 pt -115.06 151.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.664 -0.647 . . . . 0.20000000000000001 110.6 178.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.2 t -139.2 126.01 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 CA-C-O 121.31 0.576 . . . . 0.20000000000000001 110.049 176.025 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.776 ' HB2' HG22 ' A' ' 80' ' ' ILE . 17.2 tptt -132.59 148.7 52.37 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 109.004 -0.739 . . . . 1.98 109.004 174.784 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.8 t80 . . . . . 0 N--CA 1.495 1.785 0 C-N-CA 120.137 -0.625 . . . . 0.33000000000000002 110.246 -179.699 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo . . . . . 0 N--CA 1.483 0.888 0 N-CA-C 110.298 -0.693 . . . . 0.34000000000000002 110.298 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.737 ' HB3' HG23 ' A' ' 72' ' ' ILE . 18.0 mmtp -113.62 137.35 51.72 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.556 -0.715 . . . . 1.1000000000000001 109.559 172.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -137.97 166.27 24.49 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.59 -0.694 . . . . 1.4199999999999999 110.756 -178.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.83 135.94 4.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.692 -1.363 . . . . 0.17000000000000001 109.692 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 m -119.93 137.95 53.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.661 -0.905 . . . . 0.20999999999999999 109.766 176.539 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 15.0 p90 -156.04 173.89 16.15 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 120.0 -0.68 . . . . 0.16 110.981 176.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.0 m -106.32 140.91 38.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.731 -0.606 . . . . 0.13 109.475 173.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 144.9 35.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.679 -0.638 . . . . 0.14000000000000001 110.636 -175.473 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.815 -0.553 . . . . 2.21 109.732 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -79.47 125.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.321 0.581 . . . . 0.17000000000000001 109.871 178.321 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.08 -171.31 27.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.617 -1.393 . . . . 0.19 109.617 178.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -61.87 156.1 21.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.569 -0.959 . . . . 1.3899999999999999 109.837 178.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 54.99 19.4 2.68 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.446 -0.784 . . . . 0.81999999999999995 112.079 -177.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.21 20.47 79.93 Favored Glycine 0 N--CA 1.5 2.91 0 C-N-CA 119.81 -1.186 . . . . 0.19 110.728 172.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -78.0 146.02 35.63 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.503 -0.998 . . . . 1.3 110.409 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -138.51 146.52 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.719 -0.613 . . . . 0.20999999999999999 109.627 173.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -108.89 122.21 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 121.555 -0.715 . . . . 0.34000000000000002 110.533 -174.088 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.2 mt -79.01 142.07 59.43 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.606 -0.684 . . . . 0.34000000000000002 109.625 173.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -65.1 131.83 29.94 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.862 0.927 . . . . 0.26000000000000001 110.729 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -55.17 -33.07 62.66 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.497 -0.752 . . . . 2.6200000000000001 110.88 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.8 -37.99 77.59 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.785 -0.572 . . . . 0.45000000000000001 110.189 -178.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 76.3 mt -77.01 -32.74 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.747 -0.596 . . . . 1.8200000000000001 110.403 177.707 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.401 ' NE ' ' HA3' ' A' ' 15' ' ' GLY . 38.1 mtt180 -57.73 -46.08 84.93 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 121.352 -0.842 . . . . 2.5299999999999998 109.85 178.396 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -70.08 -47.87 60.08 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.528 -0.469 . . . . 1.6799999999999999 110.413 -175.251 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.6 t -60.57 -38.1 77.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 C-N-CA 120.157 -0.617 . . . . 0.28000000000000003 109.924 -178.32 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.737 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.3 mt -82.76 -17.66 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.866 -0.521 . . . . 0.28000000000000003 110.919 -176.081 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.498 2.829 0 N-CA-C 109.68 -1.368 . . . . 0.22 109.68 175.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.905 HG21 HG21 ' A' ' 11' ' ' VAL . 51.3 mm -89.56 143.82 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.515 -0.991 . . . . 0.77000000000000002 110.644 -174.047 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -129.22 156.96 77.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.764 -0.585 . . . . 3.21 110.719 -177.171 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.28 134.14 62.1 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.022 1.012 . . . . 0.5 111.412 177.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.37 -0.17 71.07 Favored Glycine 0 N--CA 1.497 2.761 0 C-N-CA 120.617 -0.801 . . . . 0.23999999999999999 111.205 175.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -96.26 132.39 41.77 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-N 118.732 1.266 . . . . 1.1100000000000001 110.4 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 79' ' ' VAL . 11.2 p -91.03 130.05 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.46 0.648 . . . . 0.23999999999999999 110.961 -174.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.776 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.5 pt -117.67 159.34 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.462 -0.57 . . . . 0.17999999999999999 109.462 176.705 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -98.49 130.87 45.08 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.893 -0.781 . . . . 1.1399999999999999 108.893 173.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.5 t -114.6 128.53 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 CA-C-O 121.381 0.61 . . . . 0.20000000000000001 110.18 -171.72 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.404 ' HB3' HG21 ' A' ' 3' ' ' VAL . 45.0 mt -114.96 129.8 56.79 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.22 141.57 35.49 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.28000000000000003 109.996 173.406 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.52 -32.38 6.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.839 -0.538 . . . . 1.6000000000000001 110.779 -177.7 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.559 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.16 -174.46 37.69 Favored Glycine 0 N--CA 1.504 3.171 0 C-N-CA 119.681 -1.247 . . . . 0.20000000000000001 111.058 -177.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.0 p80 -146.35 153.71 40.83 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.664 -0.904 . . . . 1.8899999999999999 110.614 -179.246 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 . . . . . 0 N--CA 1.493 1.703 0 O-C-N 121.545 -0.722 . . . . 0.80000000000000004 110.108 176.325 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.4 p . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 109.513 -0.551 . . . . 0.40999999999999998 109.513 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.614 HD11 ' HA2' ' A' ' 86' ' ' GLY . 23.2 mt -85.32 -18.04 35.03 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 120.279 -0.568 . . . . 0.37 110.462 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.96 155.47 3.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.368 -0.833 . . . . 0.26000000000000001 109.589 176.65 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.2 ttmt -132.95 127.02 33.33 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.715 -0.615 . . . . 2.2999999999999998 110.124 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.3 p90 -149.77 162.51 40.13 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.634 -0.667 . . . . 0.20000000000000001 110.728 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -113.33 138.96 49.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.604 -0.685 . . . . 1.99 110.32 -176.516 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.474 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.75 162.3 40.99 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.739 -0.601 . . . . 0.17999999999999999 109.619 177.503 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.49 159.02 17.88 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 119.787 -0.765 . . . . 0.17000000000000001 110.01 176.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.1 t -79.32 135.94 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.233 -0.587 . . . . 0.48999999999999999 110.333 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.3 m80 -115.39 171.97 7.38 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.528 -0.545 . . . . 0.68000000000000005 109.528 174.064 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -46.26 152.31 0.43 Allowed 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.562 -0.711 . . . . 2.96 112.033 -175.639 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.64 7.4 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.495 -0.753 . . . . 0.41999999999999998 112.632 -174.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.72 16.01 80.61 Favored Glycine 0 N--CA 1.497 2.723 0 O-C-N 120.915 -1.115 . . . . 0.23999999999999999 110.423 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.84 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -84.91 143.41 29.02 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.199 -1.177 . . . . 1.96 110.294 -177.092 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.474 HD12 HG21 ' A' ' 9' ' ' THR . 41.7 pt -133.21 157.49 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.759 -0.588 . . . . 0.29999999999999999 109.532 173.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.84 HD11 ' NH1' ' A' ' 16' ' ' ARG . 48.6 mm -116.29 129.6 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.591 -0.693 . . . . 0.25 109.96 176.06 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.6 mt -79.19 145.5 64.92 Favored Pre-proline 0 N--CA 1.496 1.859 0 C-N-CA 119.961 -0.695 . . . . 0.23000000000000001 109.375 175.343 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.2 142.86 88.31 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.102 1.054 . . . . 0.34999999999999998 109.79 174.47 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.56 -26.6 61.66 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.84 -0.538 . . . . 0.33000000000000002 110.447 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.8 95.0 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.036 -1.225 . . . . 0.39000000000000001 110.036 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.1 m -69.73 -37.45 76.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.699 -0.883 . . . . 0.39000000000000001 109.848 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.6 mtt180 -55.95 -42.42 76.2 Favored 'General case' 0 N--CA 1.509 2.499 0 O-C-N 121.343 -0.848 . . . . 0.40000000000000002 109.801 178.083 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -66.75 -50.37 62.96 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.302 0.573 . . . . 2.9700000000000002 110.284 -176.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -57.2 -37.15 71.76 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.868 -0.52 . . . . 0.67000000000000004 110.622 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.946 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.6 t80 -87.83 -14.17 40.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.85 -0.531 . . . . 1.4399999999999999 111.275 -176.408 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.36 42.37 28.11 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.57 -1.412 . . . . 0.31 109.57 177.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 77.8 mt -89.6 129.41 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.559 -0.965 . . . . 0.41999999999999998 110.653 -176.566 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -128.48 159.51 35.21 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 109.173 -0.677 . . . . 1.8200000000000001 109.173 171.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -57.75 138.59 55.37 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.411 -0.805 . . . . 1.99 110.478 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.1 62.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.857 -0.897 . . . . 0.19 110.857 179.328 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -77.09 157.47 31.03 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-N 118.763 1.281 . . . . 1.1200000000000001 110.03 177.493 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -111.44 138.87 47.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.671 -0.643 . . . . 0.20999999999999999 109.644 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 155.34 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 0.14999999999999999 109.269 174.536 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -117.34 123.89 47.61 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.276 -1.009 . . . . 1.0900000000000001 108.276 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.834 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.96 157.56 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.553 -0.859 . . . . 0.14000000000000001 111.044 -167.051 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.68 146.09 51.59 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.789 -0.569 . . . . 1.1100000000000001 110.427 177.547 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.498 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.6 pt -114.89 151.09 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.732 -0.605 . . . . 0.20000000000000001 110.595 178.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.0 126.72 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.123 0.487 . . . . 0.20000000000000001 109.707 176.295 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.699 ' HB2' HG22 ' A' ' 80' ' ' ILE . 30.6 tptt -138.09 147.12 43.71 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.726 -0.609 . . . . 1.98 109.636 175.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 39.5 t80 . . . . . 0 N--CA 1.495 1.784 0 C-N-CA 120.291 -0.564 . . . . 0.33000000000000002 110.369 -176.867 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.482 0.818 0 N-CA-C 110.114 -0.764 . . . . 0.34000000000000002 110.114 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.446 ' CB ' HG23 ' A' ' 72' ' ' ILE . 31.4 mttm -122.5 149.24 44.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.491 -0.756 . . . . 1.1000000000000001 110.105 171.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.2 mt-10 -136.75 167.74 20.86 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.758 -0.589 . . . . 1.4199999999999999 110.835 -176.52 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.67 135.87 4.45 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.49 -1.444 . . . . 0.17000000000000001 109.49 177.578 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -122.88 138.23 54.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.931 . . . . 0.20999999999999999 109.978 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.81 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.8 p90 -156.3 172.92 17.64 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 119.858 -0.737 . . . . 0.16 110.89 175.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -106.95 141.29 38.4 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.704 -0.623 . . . . 0.13 109.473 173.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.81 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 145.99 36.7 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.591 -0.693 . . . . 0.14000000000000001 110.759 -175.451 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -93.47 145.24 24.65 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.582 -0.525 . . . . 2.21 109.582 175.216 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 91.3 t -78.96 125.07 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.295 0.569 . . . . 0.17000000000000001 109.823 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.62 -166.62 25.38 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.117 -1.193 . . . . 0.19 110.117 178.456 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.74 153.51 28.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.768 -0.842 . . . . 1.3899999999999999 110.158 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 53.39 21.21 2.28 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.595 -0.69 . . . . 0.81999999999999995 112.167 -179.577 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.22 20.51 79.64 Favored Glycine 0 N--CA 1.501 2.982 0 C-N-CA 119.663 -1.256 . . . . 0.19 110.764 171.506 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.5 m -77.87 145.2 36.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.456 -1.026 . . . . 1.3 110.441 -175.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.46 146.65 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.806 -0.559 . . . . 0.20999999999999999 109.645 175.08 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.44 122.72 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.509 -0.744 . . . . 0.34000000000000002 110.787 -174.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.8 mt -79.11 144.33 62.81 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.584 -0.698 . . . . 0.34000000000000002 109.624 172.577 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.8 Cg_endo -64.76 134.39 40.39 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 O-C-N 122.952 0.975 . . . . 0.26000000000000001 110.841 -179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -55.19 -34.16 63.65 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.491 -0.756 . . . . 2.6200000000000001 110.814 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.66 76.68 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.729 -0.607 . . . . 0.45000000000000001 110.32 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.6 mt -77.13 -32.69 56.62 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.73 -0.607 . . . . 1.8200000000000001 110.5 178.534 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.85 -46.05 85.35 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.328 -0.857 . . . . 2.5299999999999998 109.858 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.92 -46.61 64.99 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 120.512 -0.475 . . . . 1.6799999999999999 110.411 -175.333 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.0 t -60.55 -38.7 79.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.679 -0.638 . . . . 0.28000000000000003 109.949 -178.576 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.563 HG22 HD11 ' A' ' 74' ' ' ILE . 83.6 mt -82.8 -16.44 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.791 -0.568 . . . . 0.28000000000000003 111.102 -176.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 75.77 35.18 46.45 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.91 -1.276 . . . . 0.22 109.91 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.77 142.32 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.53 -0.982 . . . . 0.77000000000000002 110.589 -174.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.2 mttt -128.9 158.73 71.63 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.82 -0.55 . . . . 3.21 110.586 -177.212 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -54.56 134.21 60.8 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.063 1.033 . . . . 0.5 111.429 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.1 -0.5 72.42 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.69 -0.766 . . . . 0.23999999999999999 111.292 175.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -97.37 133.51 41.87 Favored 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 118.711 1.255 . . . . 1.1100000000000001 110.559 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 79' ' ' VAL . 11.2 p -91.95 131.17 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-O 121.479 0.657 . . . . 0.23999999999999999 111.095 -174.481 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.699 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -119.0 159.48 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.286 -0.635 . . . . 0.17999999999999999 109.286 175.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -97.93 131.59 44.25 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.891 -0.781 . . . . 1.1399999999999999 108.891 174.109 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.834 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.8 t -115.65 129.5 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.348 0.594 . . . . 0.20000000000000001 110.263 -170.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.5 mt -115.13 130.8 57.02 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 109.279 -0.638 . . . . 0.25 109.279 179.318 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.946 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.35 139.9 36.34 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.365 -0.835 . . . . 0.28000000000000003 110.037 173.052 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -106.65 -36.4 6.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.836 -0.54 . . . . 1.6000000000000001 110.837 -176.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.614 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.88 -175.2 38.11 Favored Glycine 0 N--CA 1.502 3.061 0 C-N-CA 119.79 -1.195 . . . . 0.20000000000000001 110.935 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -143.81 153.46 42.4 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.682 -0.893 . . . . 1.8899999999999999 110.728 -177.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.622 -0.674 . . . . 0.80000000000000004 110.205 175.975 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.487 1.395 0 N-CA-C 109.47 -0.567 . . . . 0.40999999999999998 109.47 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.584 HD11 ' HA2' ' A' ' 86' ' ' GLY . 31.4 mt -82.73 -19.86 37.13 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.764 -0.585 . . . . 0.37 110.454 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.71 153.63 3.42 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.38 -0.825 . . . . 0.26000000000000001 109.241 175.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -133.48 125.17 28.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.804 -0.56 . . . . 2.2999999999999998 110.07 -176.522 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.586 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 12.9 p90 -151.0 162.55 40.61 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.638 -0.664 . . . . 0.20000000000000001 110.794 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -113.48 139.11 49.21 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.61 -0.681 . . . . 1.99 110.246 -176.831 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.96 162.37 40.95 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.785 -0.572 . . . . 0.17999999999999999 109.63 177.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 t -111.28 158.76 18.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.433 -0.792 . . . . 0.17000000000000001 109.986 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.5 t -79.33 134.7 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 C-N-CA 120.296 -0.561 . . . . 0.48999999999999999 110.239 -176.748 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -113.44 171.89 7.29 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.22 0.534 . . . . 0.68000000000000005 109.646 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -46.49 152.98 0.4 Allowed 'General case' 0 N--CA 1.506 2.334 0 O-C-N 121.594 -0.691 . . . . 2.96 111.957 -176.128 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.76 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.675 0 O-C-N 121.573 -0.705 . . . . 0.41999999999999998 112.601 -174.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.2 16.1 80.92 Favored Glycine 0 N--CA 1.498 2.787 0 O-C-N 120.875 -1.14 . . . . 0.23999999999999999 110.276 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -85.65 143.41 28.43 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.265 -1.138 . . . . 1.96 110.443 -176.048 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.1 pt -133.37 155.53 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.787 -0.571 . . . . 0.29999999999999999 109.491 172.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -116.54 129.18 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.629 -0.669 . . . . 0.25 110.038 176.227 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -79.47 145.12 62.83 Favored Pre-proline 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.23000000000000001 109.404 175.573 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -63.49 143.32 87.75 Favored 'Trans proline' 0 N--CA 1.488 1.17 0 O-C-N 122.966 0.982 . . . . 0.34999999999999998 109.775 174.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.91 -26.52 59.34 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.799 -0.563 . . . . 0.33000000000000002 110.504 -178.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.4 -45.14 94.15 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.016 -1.233 . . . . 0.39000000000000001 110.016 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 76.4 m -69.38 -37.09 77.41 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.621 -0.929 . . . . 0.39000000000000001 110.178 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.62 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.32 -42.15 77.16 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.369 -0.832 . . . . 0.40000000000000002 109.687 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.8 tptm -66.43 -50.2 64.19 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-O 121.244 0.545 . . . . 2.9700000000000002 110.214 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -57.05 -37.99 72.59 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.928 -0.482 . . . . 0.67000000000000004 110.698 -178.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.959 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.6 t80 -86.87 -14.31 42.36 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.812 -0.555 . . . . 1.4399999999999999 111.277 -177.345 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 42.52 24.61 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.631 -1.388 . . . . 0.31 109.631 178.281 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.58 129.1 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.52 -0.988 . . . . 0.41999999999999998 110.483 -177.092 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.06 158.47 37.86 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.919 -0.771 . . . . 1.8200000000000001 108.919 170.645 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -57.24 140.04 50.97 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.309 -0.869 . . . . 1.99 110.492 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.01 -16.02 61.84 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.842 -0.903 . . . . 0.19 110.842 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.88 157.94 31.08 Favored 'General case' 0 N--CA 1.5 2.047 0 CA-C-N 118.739 1.27 . . . . 1.1200000000000001 110.198 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -111.36 138.74 47.46 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.635 -0.666 . . . . 0.20999999999999999 109.603 174.549 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.22 153.78 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.282 -0.636 . . . . 0.14999999999999999 109.282 174.3 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -115.86 123.54 48.4 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.305 -0.998 . . . . 1.0900000000000001 108.305 -179.077 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.84 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -139.99 158.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 C-N-CA 119.587 -0.845 . . . . 0.14000000000000001 111.004 -167.491 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -133.09 145.97 51.22 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.874 -0.516 . . . . 1.1100000000000001 110.505 177.489 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.532 ' HB ' HD12 ' A' ' 80' ' ' ILE . 24.5 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.79 -0.569 . . . . 0.20000000000000001 110.619 178.325 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.522 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -138.96 125.5 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.917 -0.489 . . . . 0.20000000000000001 109.787 176.301 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.68 ' HB2' HG22 ' A' ' 80' ' ' ILE . 54.4 tttp -132.28 144.49 50.63 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.774 -0.579 . . . . 1.98 109.533 174.766 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.9 t80 . . . . . 0 N--CA 1.496 1.858 0 C-N-CA 120.197 -0.601 . . . . 0.33000000000000002 110.459 -178.488 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.482 0.828 0 N-CA-C 110.133 -0.757 . . . . 0.34000000000000002 110.133 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.762 ' HB3' HG23 ' A' ' 72' ' ' ILE . 16.6 mmtp -110.78 137.75 48.04 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 1.1000000000000001 109.682 173.515 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -134.94 163.94 28.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.683 -0.636 . . . . 1.4199999999999999 110.786 -177.654 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.95 135.92 4.44 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.56 -1.416 . . . . 0.17000000000000001 109.56 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.4 m -122.25 137.83 54.7 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.735 -0.862 . . . . 0.20999999999999999 109.766 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -155.82 172.88 17.59 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.562 -0.711 . . . . 0.16 110.937 176.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -106.6 140.3 39.68 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.707 -0.621 . . . . 0.13 109.556 173.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.84 144.51 35.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.664 -0.648 . . . . 0.14000000000000001 110.49 -176.322 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -93.5 144.73 25.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.845 -0.534 . . . . 2.21 109.569 176.22 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -78.47 125.75 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.789 -0.569 . . . . 0.17000000000000001 109.862 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.77 -167.54 26.26 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.892 -1.283 . . . . 0.19 109.892 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.68 153.52 27.91 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.756 -0.849 . . . . 1.3899999999999999 110.163 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 53.57 21.09 2.37 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.51 -0.744 . . . . 0.81999999999999995 112.008 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.95 20.52 79.72 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.814 -1.184 . . . . 0.19 110.837 171.182 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.3 m -77.99 145.26 36.09 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.462 -1.022 . . . . 1.3 110.296 -176.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.27 146.21 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.772 -0.58 . . . . 0.20999999999999999 109.559 174.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.8 mm -110.92 122.94 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.521 -0.737 . . . . 0.34000000000000002 110.671 -174.262 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.41 HG23 ' HD2' ' A' ' 65' ' ' PRO . 84.7 mt -78.88 143.0 61.26 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.572 -0.705 . . . . 0.34000000000000002 109.568 172.761 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.751 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.5 Cg_endo -64.57 133.48 37.15 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 O-C-N 122.954 0.976 . . . . 0.26000000000000001 110.755 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -55.2 -34.0 63.53 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.484 -0.76 . . . . 2.6200000000000001 110.84 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.95 77.34 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.734 -0.604 . . . . 0.45000000000000001 110.232 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.751 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.5 mt -77.1 -32.65 56.78 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.21 -0.596 . . . . 1.8200000000000001 110.513 178.421 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.79 -45.52 85.92 Favored 'General case' 0 N--CA 1.504 2.248 0 O-C-N 121.331 -0.856 . . . . 2.5299999999999998 109.827 178.593 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.28 -47.67 60.16 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 120.506 -0.478 . . . . 1.6799999999999999 110.467 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 90.8 t -60.58 -38.1 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.106 0 O-C-N 121.683 -0.636 . . . . 0.28000000000000003 109.816 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.762 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.4 mt -82.71 -17.47 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.795 -0.566 . . . . 0.28000000000000003 110.914 -176.488 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.4 35.2 37.97 Favored Glycine 0 N--CA 1.498 2.797 0 N-CA-C 109.78 -1.328 . . . . 0.22 109.78 175.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.6 mm -90.81 144.15 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.979 . . . . 0.77000000000000002 110.673 -174.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -131.39 163.45 49.42 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.776 -0.577 . . . . 3.21 110.685 -177.752 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.83 134.44 57.14 Favored 'Trans proline' 0 N--CA 1.487 1.142 0 O-C-N 122.934 0.965 . . . . 0.5 110.865 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.83 0.82 71.38 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 111.149 -0.78 . . . . 0.23999999999999999 111.149 176.099 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -97.24 132.43 43.01 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 118.733 1.266 . . . . 1.1100000000000001 110.515 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.0 p -93.46 137.18 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.901 0.858 . . . . 0.23999999999999999 111.433 -173.431 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.68 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -126.41 159.52 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.391 -0.596 . . . . 0.17999999999999999 109.391 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -97.52 130.58 44.58 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.942 -0.762 . . . . 1.1399999999999999 108.942 174.512 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.84 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.0 t -115.08 129.96 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 CA-C-O 121.318 0.58 . . . . 0.20000000000000001 110.158 -171.14 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 35.3 mt -117.13 129.51 56.02 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 109.047 -0.723 . . . . 0.25 109.047 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.959 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.7 mt -79.77 140.61 36.84 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.718 -0.793 . . . . 0.28000000000000003 109.848 172.37 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.9 mt -110.39 -33.38 6.64 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.788 -0.57 . . . . 1.6000000000000001 110.859 -175.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.584 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -175.89 38.42 Favored Glycine 0 N--CA 1.503 3.148 0 C-N-CA 119.763 -1.208 . . . . 0.20000000000000001 110.953 -176.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -143.81 153.65 42.59 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.725 -0.867 . . . . 1.8899999999999999 110.675 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 . . . . . 0 N--CA 1.494 1.732 0 O-C-N 121.498 -0.751 . . . . 0.80000000000000004 110.198 176.423 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.486 1.347 0 N-CA-C 109.671 -0.492 . . . . 0.40999999999999998 109.671 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.4 mt -84.06 -21.62 31.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.789 -0.569 . . . . 0.37 110.323 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.901 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.28 155.46 3.58 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.36 -0.837 . . . . 0.26000000000000001 109.175 176.466 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.403 ' HG3' HD23 ' A' ' 83' ' ' LEU . 23.1 tttt -133.47 125.56 29.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.668 -0.645 . . . . 2.2999999999999998 110.175 -177.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.8 p90 -150.84 162.78 40.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.20000000000000001 110.757 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -113.24 139.07 49.11 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.562 -0.711 . . . . 1.99 110.264 -176.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.04 162.32 41.07 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.825 -0.547 . . . . 0.17999999999999999 109.646 177.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -111.2 158.7 18.64 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.818 -0.753 . . . . 0.17000000000000001 110.038 177.165 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.4 135.67 25.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.742 -0.599 . . . . 0.48999999999999999 110.288 -176.626 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.0 m80 -114.79 171.9 7.36 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.354 0.597 . . . . 0.68000000000000005 109.661 174.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -46.65 153.04 0.41 Allowed 'General case' 0 N--CA 1.505 2.318 0 O-C-N 121.532 -0.73 . . . . 2.96 111.956 -176.319 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.3 mt 62.75 7.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.662 0 O-C-N 121.599 -0.688 . . . . 0.41999999999999998 112.619 -175.056 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.86 16.07 80.43 Favored Glycine 0 N--CA 1.496 2.682 0 O-C-N 120.932 -1.105 . . . . 0.23999999999999999 110.369 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.4 ttp180 -83.78 143.04 30.24 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.167 -1.196 . . . . 1.96 110.382 -176.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -131.89 154.66 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 109.365 -0.606 . . . . 0.29999999999999999 109.365 171.17 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.65 129.19 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 C-N-CA 120.08 -0.648 . . . . 0.25 109.999 176.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 29.1 mt -79.75 145.08 61.54 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.04 -0.664 . . . . 0.23000000000000001 109.359 175.899 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -63.5 143.66 88.51 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.986 0.993 . . . . 0.34999999999999998 109.723 174.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.04 -26.5 60.42 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 120.449 -0.5 . . . . 0.33000000000000002 110.426 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.35 -45.19 94.07 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 109.958 -1.257 . . . . 0.39000000000000001 109.958 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 85.3 m -69.37 -36.98 77.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.66 -0.906 . . . . 0.39000000000000001 110.117 -179.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.8 mtt180 -56.41 -41.91 77.12 Favored 'General case' 0 N--CA 1.509 2.502 0 O-C-N 121.323 -0.861 . . . . 0.40000000000000002 109.662 178.486 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.5 tptp -66.37 -50.14 64.51 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 120.275 -0.57 . . . . 2.9700000000000002 110.262 -177.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.8 t80 -57.06 -38.19 72.92 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.925 -0.484 . . . . 0.67000000000000004 110.694 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.932 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -87.03 -14.28 42.01 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.803 -0.561 . . . . 1.4399999999999999 111.249 -177.17 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.94 42.71 24.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.493 -1.443 . . . . 0.31 109.493 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.894 HG23 HG21 ' A' ' 56' ' ' VAL . 75.7 mt -88.06 127.5 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.566 -0.961 . . . . 0.41999999999999998 110.501 -177.354 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.26 154.24 45.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.877 -0.786 . . . . 1.8200000000000001 108.877 171.384 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -55.18 139.42 42.07 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.245 -0.91 . . . . 1.99 110.706 -177.151 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -15.76 62.41 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 110.898 -0.881 . . . . 0.19 110.898 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -76.19 158.5 31.61 Favored 'General case' 0 N--CA 1.5 2.031 0 CA-C-N 118.749 1.274 . . . . 1.1200000000000001 109.992 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -111.57 138.63 47.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.568 -0.708 . . . . 0.20999999999999999 109.614 175.088 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.72 154.79 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 109.213 -0.662 . . . . 0.14999999999999999 109.213 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.85 123.6 48.57 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.318 -0.993 . . . . 1.0900000000000001 108.318 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.11 159.5 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.627 -0.829 . . . . 0.14000000000000001 110.897 -168.066 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.547 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.6 ttpt -133.77 146.01 50.33 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.784 -0.573 . . . . 1.1100000000000001 110.374 177.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.649 ' HB ' HD12 ' A' ' 80' ' ' ILE . 26.1 pt -114.74 150.4 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.627 -0.671 . . . . 0.20000000000000001 110.359 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.9 t -140.89 124.53 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.219 0.533 . . . . 0.20000000000000001 109.807 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.682 ' HB2' HG22 ' A' ' 80' ' ' ILE . 55.0 tttm -132.06 149.86 52.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.363 -0.606 . . . . 1.98 109.363 175.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 3.1 t80 . . . . . 0 N--CA 1.497 1.923 0 C-N-CA 119.993 -0.683 . . . . 0.33000000000000002 110.367 -179.202 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo . . . . . 0 N--CA 1.483 0.879 0 N-CA-C 110.598 -0.578 . . . . 0.34000000000000002 110.598 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.642 ' HB3' HG23 ' A' ' 72' ' ' ILE . 44.5 mmtt -112.93 136.58 52.44 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.502 -0.749 . . . . 1.1000000000000001 109.583 171.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -138.62 167.9 20.96 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.664 -0.647 . . . . 1.4199999999999999 110.974 -178.154 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.432 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.64 135.71 4.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.405 -1.478 . . . . 0.17000000000000001 109.405 177.362 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.547 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.1 m -122.74 137.28 54.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.645 -0.915 . . . . 0.20999999999999999 109.862 177.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.819 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.3 p90 -155.81 173.6 16.52 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.013 -0.675 . . . . 0.16 110.942 178.195 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 m -106.69 140.38 39.64 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.737 -0.602 . . . . 0.13 109.575 173.46 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.819 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.81 146.03 35.41 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.739 -0.6 . . . . 0.14000000000000001 110.563 -175.627 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.9 ttp-105 -93.69 145.28 24.68 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.797 -0.565 . . . . 2.21 109.684 175.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.894 HG21 HG23 ' A' ' 29' ' ' ILE . 98.3 t -78.85 126.57 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.244 0.545 . . . . 0.17000000000000001 109.861 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.66 -170.6 26.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.834 -1.306 . . . . 0.19 109.834 177.794 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -61.78 156.04 21.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.673 -0.898 . . . . 1.3899999999999999 109.909 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.04 19.05 2.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.506 -0.746 . . . . 0.81999999999999995 112.138 -177.745 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.45 20.46 79.41 Favored Glycine 0 N--CA 1.498 2.827 0 C-N-CA 119.863 -1.161 . . . . 0.19 110.714 172.432 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.64 146.76 33.91 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -1.005 . . . . 1.3 110.373 -176.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.64 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.9 146.44 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.751 -0.593 . . . . 0.20999999999999999 109.553 174.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.3 mm -109.04 122.15 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.513 -0.742 . . . . 0.34000000000000002 110.704 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.2 mt -78.84 142.25 60.44 Favored Pre-proline 0 N--CA 1.498 1.96 0 O-C-N 121.423 -0.798 . . . . 0.34000000000000002 109.486 172.066 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.745 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.83 135.01 42.72 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.938 0.967 . . . . 0.26000000000000001 110.705 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -55.12 -34.21 63.53 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.499 -0.751 . . . . 2.6200000000000001 110.766 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.69 -37.73 76.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.752 -0.592 . . . . 0.45000000000000001 110.319 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.745 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.0 mt -77.03 -32.82 57.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.636 -0.665 . . . . 1.8200000000000001 110.482 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -57.72 -45.85 85.2 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.419 -0.801 . . . . 2.5299999999999998 109.951 178.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.33 -47.29 61.76 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 120.532 -0.467 . . . . 1.6799999999999999 110.483 -175.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.49 -38.25 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 O-C-N 121.699 -0.626 . . . . 0.28000000000000003 109.932 -178.393 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.642 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.7 mt -82.49 -18.01 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.791 -0.568 . . . . 0.28000000000000003 110.915 -176.529 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.34 35.19 43.26 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.704 -1.358 . . . . 0.22 109.704 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.7 mm -92.65 142.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.576 -0.955 . . . . 0.77000000000000002 110.64 -174.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 34.9 mtpt -130.25 163.22 49.36 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.748 -0.595 . . . . 3.21 110.792 -177.181 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.76 135.41 63.58 Favored 'Trans proline' 0 N--CA 1.487 1.111 0 O-C-N 122.922 0.959 . . . . 0.5 110.92 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.72 -0.15 73.18 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 111.08 -0.808 . . . . 0.23999999999999999 111.08 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -97.47 133.11 42.49 Favored 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 118.691 1.246 . . . . 1.1100000000000001 110.552 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.02 133.37 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.67 0.747 . . . . 0.23999999999999999 111.26 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.682 HG22 ' HB2' ' A' ' 41' ' ' LYS . 41.4 pt -123.48 159.52 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 109.272 -0.64 . . . . 0.17999999999999999 109.272 176.143 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -98.44 131.1 44.98 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.963 -0.754 . . . . 1.1399999999999999 108.963 176.109 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 83.9 t -114.95 130.24 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.394 0.616 . . . . 0.20000000000000001 110.28 -170.524 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.403 HD23 ' HG3' ' A' ' 6' ' ' LYS . 33.5 mt -116.3 130.74 56.93 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 109.074 -0.713 . . . . 0.25 109.074 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.932 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.7 mt -80.55 140.86 35.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.356 -0.84 . . . . 0.28000000000000003 109.791 172.204 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -113.18 -31.01 6.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.654 -0.654 . . . . 1.6000000000000001 111.046 -175.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.18 -177.78 39.58 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.65 -1.262 . . . . 0.20000000000000001 110.978 -176.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 p80 -144.94 153.52 41.62 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.719 -0.871 . . . . 1.8899999999999999 110.59 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.527 -0.733 . . . . 0.80000000000000004 110.278 176.033 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.655 -0.498 . . . . 0.40999999999999998 109.655 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.574 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.7 mt -83.91 -19.1 35.34 Favored 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 120.198 -0.601 . . . . 0.37 110.378 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.4 153.3 3.51 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.292 -0.88 . . . . 0.26000000000000001 109.335 176.047 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -134.16 125.45 27.93 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.697 -0.627 . . . . 2.2999999999999998 110.089 -177.358 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.595 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.8 p90 -150.26 162.62 40.14 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.591 -0.693 . . . . 0.20000000000000001 110.852 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -113.53 138.29 50.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.61 -0.681 . . . . 1.99 110.102 -176.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.08 162.29 41.12 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.661 -0.649 . . . . 0.17999999999999999 109.679 177.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.11 157.83 18.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.465 -0.772 . . . . 0.17000000000000001 110.03 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.61 136.43 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.783 -0.573 . . . . 0.48999999999999999 110.319 -176.647 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -113.32 171.95 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.215 0.531 . . . . 0.68000000000000005 109.686 173.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -46.67 152.31 0.49 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.607 -0.683 . . . . 2.96 111.896 -175.58 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.6 mt 62.6 7.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.635 0 O-C-N 121.559 -0.713 . . . . 0.41999999999999998 112.601 -175.341 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.84 16.12 80.39 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 110.364 -1.095 . . . . 0.23999999999999999 110.364 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.8 ttt180 -83.92 140.73 31.76 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.18 -1.188 . . . . 1.96 110.249 -176.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.6 pt -133.67 155.48 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.698 -0.626 . . . . 0.29999999999999999 109.757 174.091 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.3 mm -118.16 129.79 73.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.62 -0.675 . . . . 0.25 109.998 175.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.5 mt -79.61 145.97 64.19 Favored Pre-proline 0 N--CA 1.495 1.777 0 C-N-CA 120.052 -0.659 . . . . 0.23000000000000001 109.396 175.496 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.16 142.89 88.66 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 O-C-N 123.012 1.006 . . . . 0.34999999999999998 109.823 174.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.22 -26.56 60.91 Favored 'General case' 0 N--CA 1.498 1.955 0 C-N-CA 120.403 -0.519 . . . . 0.33000000000000002 110.49 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.43 -45.01 94.45 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 109.973 -1.251 . . . . 0.39000000000000001 109.973 -179.015 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 96.6 m -69.66 -37.0 76.54 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.63 -0.923 . . . . 0.39000000000000001 109.878 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.637 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.2 -42.27 76.93 Favored 'General case' 0 N--CA 1.509 2.508 0 O-C-N 121.298 -0.876 . . . . 0.40000000000000002 109.77 178.111 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -65.91 -50.14 65.5 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.282 0.563 . . . . 2.9700000000000002 110.116 -177.137 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -56.46 -37.54 70.43 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.136 0.493 . . . . 0.67000000000000004 110.725 -179.298 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.972 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.0 t80 -88.19 -14.15 39.33 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.784 -0.572 . . . . 1.4399999999999999 111.315 -176.649 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 42.89 24.18 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.543 -1.423 . . . . 0.31 109.543 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.933 HG23 HG21 ' A' ' 56' ' ' VAL . 75.4 mt -87.84 126.92 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.519 -0.989 . . . . 0.41999999999999998 110.653 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.91 155.64 43.87 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.134 -0.691 . . . . 1.8200000000000001 109.134 171.45 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.56 137.49 48.71 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.308 -0.87 . . . . 1.99 110.79 -177.575 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.51 -15.08 64.07 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.926 -0.87 . . . . 0.19 110.926 178.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -76.01 157.55 32.9 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 118.76 1.28 . . . . 1.1200000000000001 109.862 177.146 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -111.51 138.16 48.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.631 -0.668 . . . . 0.20999999999999999 109.611 175.453 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.99 152.06 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 120.087 -0.645 . . . . 0.14999999999999999 109.309 174.555 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -113.74 123.51 50.05 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.172 -1.047 . . . . 1.0900000000000001 108.172 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.835 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.2 tt -139.87 157.57 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.584 -0.846 . . . . 0.14000000000000001 110.886 -167.568 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -133.1 146.06 51.29 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.801 -0.562 . . . . 1.1100000000000001 110.474 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.532 HG22 HG22 ' A' ' 82' ' ' VAL . 27.9 pt -114.9 151.1 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.758 -0.589 . . . . 0.20000000000000001 110.54 178.747 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.485 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.3 t -138.38 127.37 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.674 -0.491 . . . . 0.20000000000000001 109.674 176.333 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.595 ' HB2' HG22 ' A' ' 80' ' ' ILE . 60.8 tttm -133.47 144.43 49.45 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 109.538 -0.542 . . . . 1.98 109.538 175.368 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 52.6 t80 . . . . . 0 N--CA 1.495 1.808 0 C-N-CA 120.262 -0.575 . . . . 0.33000000000000002 110.355 -178.528 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo . . . . . 0 N--CA 1.483 0.89 0 N-CA-C 109.936 -0.832 . . . . 0.34000000000000002 109.936 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.425 ' CB ' HG23 ' A' ' 72' ' ' ILE . 32.4 mttt -120.73 149.77 42.01 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.34 -0.85 . . . . 1.1000000000000001 110.147 171.641 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.485 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -137.2 167.66 21.14 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.851 -0.531 . . . . 1.4199999999999999 110.731 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.57 135.86 4.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.342 -1.503 . . . . 0.17000000000000001 109.342 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.2 m -122.95 137.99 54.8 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.658 -0.907 . . . . 0.20999999999999999 109.887 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.812 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.3 p90 -155.96 172.61 18.09 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.88 -0.728 . . . . 0.16 110.969 175.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.2 m -107.54 140.45 40.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.685 -0.634 . . . . 0.13 109.598 174.113 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.812 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 144.49 34.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.62 -0.675 . . . . 0.14000000000000001 110.527 -176.032 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.78 145.7 24.4 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.693 -0.629 . . . . 2.21 109.67 175.29 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.933 HG21 HG23 ' A' ' 29' ' ' ILE . 99.3 t -78.11 126.66 38.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.821 -0.55 . . . . 0.17000000000000001 109.93 -178.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.92 -166.4 25.08 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.101 -1.2 . . . . 0.19 110.101 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.71 152.79 30.08 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.779 -0.836 . . . . 1.3899999999999999 110.131 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.4 mt-30 53.64 21.02 2.39 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.557 -0.715 . . . . 0.81999999999999995 112.03 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.49 79.91 Favored Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.802 -1.189 . . . . 0.19 110.776 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.403 ' HA ' HD13 ' A' ' 18' ' ' ILE . 51.5 p -79.08 148.36 32.45 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.465 -1.021 . . . . 1.3 110.43 -176.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.67 147.14 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.878 -0.514 . . . . 0.20999999999999999 109.67 174.686 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.2 mm -108.5 121.85 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.536 -0.728 . . . . 0.34000000000000002 110.535 -175.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.411 HG23 ' HD2' ' A' ' 65' ' ' PRO . 78.6 mt -78.68 143.02 62.16 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.6 -0.687 . . . . 0.34000000000000002 109.619 173.506 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.92 131.46 29.03 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.936 0.966 . . . . 0.26000000000000001 110.784 -179.02 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 50.3 tttp -55.12 -34.07 63.4 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.424 -0.797 . . . . 2.6200000000000001 110.846 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.72 -37.72 76.77 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.722 -0.611 . . . . 0.45000000000000001 110.269 -178.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.9 mt -77.16 -32.71 56.43 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.21 -0.596 . . . . 1.8200000000000001 110.494 178.176 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtt180 -57.55 -45.57 84.96 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.231 -0.918 . . . . 2.5299999999999998 109.829 178.316 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.97 64.26 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 120.441 -0.504 . . . . 1.6799999999999999 110.371 -174.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.8 t -60.56 -38.6 78.76 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.678 -0.639 . . . . 0.28000000000000003 109.901 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.56 HG22 HD11 ' A' ' 74' ' ' ILE . 86.8 mt -83.26 -15.8 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.896 -0.503 . . . . 0.28000000000000003 111.143 -176.313 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.931 -1.268 . . . . 0.22 109.931 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.4 mm -89.96 141.06 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.574 -0.957 . . . . 0.77000000000000002 110.716 -174.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -130.61 159.26 71.8 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.808 -0.558 . . . . 3.21 110.69 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -54.63 133.63 57.97 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 122.98 0.99 . . . . 0.5 111.391 177.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.02 0.34 71.51 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 111.205 -0.758 . . . . 0.23999999999999999 111.205 175.461 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -98.05 134.1 41.6 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-N 118.769 1.285 . . . . 1.1100000000000001 110.603 179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.405 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -92.34 132.9 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 CA-C-O 121.55 0.691 . . . . 0.23999999999999999 111.15 -174.525 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.595 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.8 pt -122.39 159.4 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 109.353 -0.61 . . . . 0.17999999999999999 109.353 175.338 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 48.3 tt0 -98.85 131.71 44.75 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.007 -0.738 . . . . 1.1399999999999999 109.007 175.664 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.835 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.1 t -116.16 129.88 71.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 CA-C-O 121.298 0.57 . . . . 0.20000000000000001 110.362 -170.207 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.1 mt -115.83 130.94 57.04 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.188 -0.671 . . . . 0.25 109.188 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.972 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.27 140.18 36.32 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.375 -0.828 . . . . 0.28000000000000003 109.797 171.694 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -109.36 -31.21 7.63 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.825 -0.547 . . . . 1.6000000000000001 110.898 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.574 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.05 179.39 41.29 Favored Glycine 0 N--CA 1.503 3.136 0 C-N-CA 119.728 -1.225 . . . . 0.20000000000000001 110.986 -177.707 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.406 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 29.2 p80 -140.6 145.67 37.0 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.728 -0.866 . . . . 1.8899999999999999 110.072 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.406 ' CD1' ' O ' ' A' ' 87' ' ' HIS . 17.8 m-85 . . . . . 0 N--CA 1.496 1.851 0 O-C-N 121.506 -0.746 . . . . 0.80000000000000004 109.943 179.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.564 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.6 p . . . . . 0 N--CA 1.487 1.375 0 N-CA-C 109.644 -0.502 . . . . 0.40999999999999998 109.644 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.578 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.9 mt -87.57 -17.93 30.87 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.744 -0.598 . . . . 0.37 110.708 -177.341 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.868 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.83 155.96 4.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.253 -0.904 . . . . 0.26000000000000001 109.742 176.126 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -133.29 126.6 31.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.762 -0.586 . . . . 2.2999999999999998 110.096 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.605 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -149.48 161.94 41.12 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.651 -0.656 . . . . 0.20000000000000001 110.871 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -111.73 138.02 48.86 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.617 -0.677 . . . . 1.99 110.17 -176.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.41 162.29 41.2 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.727 -0.608 . . . . 0.17999999999999999 109.774 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.5 t -111.71 159.33 18.34 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 119.925 -0.71 . . . . 0.17000000000000001 109.89 176.094 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -77.83 138.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 120.304 -0.558 . . . . 0.48999999999999999 110.103 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.67 171.9 7.57 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.327 0.584 . . . . 0.68000000000000005 109.672 174.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -46.91 153.13 0.44 Allowed 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.537 -0.727 . . . . 2.96 111.927 -175.563 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.578 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.0 mt 63.1 7.22 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.681 0 O-C-N 121.601 -0.687 . . . . 0.41999999999999998 112.643 -175.244 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.54 15.98 80.79 Favored Glycine 0 N--CA 1.498 2.791 0 O-C-N 120.829 -1.169 . . . . 0.23999999999999999 110.292 179.455 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.0 ttm180 -85.94 145.39 27.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.324 -1.104 . . . . 1.96 110.352 -177.221 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.18 154.52 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.727 -0.608 . . . . 0.29999999999999999 109.466 172.062 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.453 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.83 128.72 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.57 -0.706 . . . . 0.25 109.99 176.529 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.437 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.7 mt -79.98 145.09 60.57 Favored Pre-proline 0 N--CA 1.495 1.802 0 C-N-CA 120.084 -0.646 . . . . 0.23000000000000001 109.37 175.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.27 143.06 88.53 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 122.917 0.956 . . . . 0.34999999999999998 109.812 174.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.6 -26.42 61.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.867 -0.521 . . . . 0.33000000000000002 110.489 -178.319 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.82 -44.37 94.8 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.39000000000000001 109.914 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.8 m -69.69 -38.13 76.89 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.637 -0.919 . . . . 0.39000000000000001 110.179 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -56.18 -41.23 75.19 Favored 'General case' 0 N--CA 1.512 2.648 0 O-C-N 121.274 -0.891 . . . . 0.40000000000000002 109.493 176.409 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.5 tttp -65.53 -50.0 66.83 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.166 0.508 . . . . 2.9700000000000002 110.142 -176.819 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -57.39 -37.96 73.5 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.749 -0.594 . . . . 0.67000000000000004 110.725 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.6 t80 -87.99 -14.31 39.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.766 -0.584 . . . . 1.4399999999999999 111.239 -176.166 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.48 42.45 27.32 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.548 -1.421 . . . . 0.31 109.548 177.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.899 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.49 129.18 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.545 -0.974 . . . . 0.41999999999999998 110.572 -176.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -129.07 158.76 38.02 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.929 -0.767 . . . . 1.8200000000000001 108.929 170.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -57.45 140.54 50.26 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.315 -0.865 . . . . 1.99 110.426 -178.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.73 -16.06 61.65 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -77.06 157.95 30.81 Favored 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 118.724 1.262 . . . . 1.1200000000000001 110.121 178.077 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -111.55 138.67 47.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.582 -0.699 . . . . 0.20999999999999999 109.611 174.758 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.88 154.16 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 109.272 -0.64 . . . . 0.14999999999999999 109.272 174.179 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -116.32 124.07 49.21 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.274 -1.01 . . . . 1.0900000000000001 108.274 -179.389 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -140.23 157.91 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.558 -0.857 . . . . 0.14000000000000001 111.053 -167.181 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.81 146.07 51.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.76 -0.587 . . . . 1.1100000000000001 110.517 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.562 HG22 HG22 ' A' ' 82' ' ' VAL . 33.6 pt -114.94 150.94 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.598 -0.689 . . . . 0.20000000000000001 110.544 178.203 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.9 t -138.08 125.13 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.177 0.513 . . . . 0.20000000000000001 109.655 176.104 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.4 tttp -134.17 147.48 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.725 -0.609 . . . . 1.98 109.495 175.397 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.1 t80 . . . . . 0 N--CA 1.494 1.769 0 C-N-CA 120.092 -0.643 . . . . 0.33000000000000002 110.266 179.836 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo . . . . . 0 N--CA 1.481 0.768 0 N-CA-C 110.198 -0.731 . . . . 0.34000000000000002 110.198 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.69 ' HB3' HG23 ' A' ' 72' ' ' ILE . 66.1 mmtt -111.06 137.78 48.29 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.527 -0.733 . . . . 1.1000000000000001 109.432 172.656 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.65 164.46 27.81 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.555 -0.716 . . . . 1.4199999999999999 110.997 -176.175 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.9 4.37 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.659 -1.377 . . . . 0.17000000000000001 109.659 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.68 137.72 54.66 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.638 -0.919 . . . . 0.20999999999999999 109.792 176.103 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.6 p90 -156.36 172.76 17.95 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.963 -0.695 . . . . 0.16 111.047 176.264 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.6 m -106.68 140.91 38.79 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.677 -0.639 . . . . 0.13 109.414 173.533 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.16 145.89 36.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.652 -0.655 . . . . 0.14000000000000001 110.697 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.0 ttt180 -93.29 145.33 24.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.833 -0.542 . . . . 2.21 109.616 175.559 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.899 HG21 HG23 ' A' ' 29' ' ' ILE . 90.1 t -79.01 125.96 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 121.419 0.628 . . . . 0.17000000000000001 109.722 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.7 -166.47 26.25 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.961 -1.256 . . . . 0.19 109.961 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -61.73 151.98 32.43 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.804 -0.821 . . . . 1.3899999999999999 110.139 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 53.32 21.53 2.36 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.523 -0.736 . . . . 0.81999999999999995 112.054 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.77 20.42 79.77 Favored Glycine 0 N--CA 1.498 2.832 0 C-N-CA 119.796 -1.192 . . . . 0.19 110.879 171.347 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.453 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.1 p -78.56 147.02 33.93 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.518 -0.989 . . . . 1.3 110.22 -178.004 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.727 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -139.26 146.39 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.8 -0.563 . . . . 0.20999999999999999 109.525 175.293 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.95 123.81 66.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.58 -0.7 . . . . 0.34000000000000002 110.583 -175.193 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.4 mt -78.32 144.06 65.72 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.643 -0.661 . . . . 0.34000000000000002 109.432 172.709 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.49 135.36 45.53 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.966 0.982 . . . . 0.26000000000000001 110.73 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 38.2 tttp -55.08 -34.21 63.44 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.545 -0.722 . . . . 2.6200000000000001 110.75 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.87 -38.33 78.57 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.779 -0.576 . . . . 0.45000000000000001 110.343 -178.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.3 mt -77.13 -32.87 56.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.747 -0.595 . . . . 1.8200000000000001 110.617 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.05 -45.82 86.38 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.35 -0.843 . . . . 2.5299999999999998 109.882 178.312 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -46.76 63.96 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 120.511 -0.476 . . . . 1.6799999999999999 110.425 -175.177 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.8 t -60.58 -38.28 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.704 -0.623 . . . . 0.28000000000000003 109.853 -178.592 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.695 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.68 -17.52 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.874 -0.516 . . . . 0.28000000000000003 110.872 -176.795 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.89 35.11 40.51 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.693 -1.363 . . . . 0.22 109.693 175.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.1 mm -93.07 142.89 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.599 -0.942 . . . . 0.77000000000000002 110.77 -173.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.2 ptmt -132.94 162.64 56.35 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.742 -0.599 . . . . 3.21 110.652 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -51.97 135.44 51.11 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.056 1.03 . . . . 0.5 111.887 178.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.95 -1.51 70.87 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 120.704 -0.76 . . . . 0.23999999999999999 111.357 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -96.33 130.92 43.33 Favored 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 118.767 1.284 . . . . 1.1100000000000001 110.614 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.79 134.35 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 CA-C-O 121.684 0.754 . . . . 0.23999999999999999 111.296 -173.327 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.4 pt -125.58 159.46 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 109.567 -0.531 . . . . 0.17999999999999999 109.567 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -97.61 132.04 43.63 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.075 -0.713 . . . . 1.1399999999999999 109.075 173.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.7 t -116.32 129.89 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.344 0.592 . . . . 0.20000000000000001 110.264 -171.431 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -115.34 130.3 56.86 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.262 -0.644 . . . . 0.25 109.262 178.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.2 mt -79.96 138.81 37.16 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.345 -0.847 . . . . 0.28000000000000003 109.914 172.479 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -105.76 -35.9 7.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.726 -0.609 . . . . 1.6000000000000001 110.918 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.83 -176.03 38.69 Favored Glycine 0 N--CA 1.503 3.166 0 C-N-CA 119.79 -1.195 . . . . 0.20000000000000001 110.817 -176.871 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -142.72 152.65 42.57 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.677 -0.896 . . . . 1.8899999999999999 110.798 -177.412 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 N--CA 1.493 1.705 0 O-C-N 121.535 -0.728 . . . . 0.80000000000000004 110.064 175.483 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.487 1.391 0 N-CA-C 109.522 -0.547 . . . . 0.40999999999999998 109.522 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.0 mt -85.62 -18.36 33.49 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.728 -0.608 . . . . 0.37 110.32 178.119 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.832 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.5 151.27 1.51 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.244 -0.91 . . . . 0.26000000000000001 108.997 176.08 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -134.96 127.82 31.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.649 -0.657 . . . . 2.2999999999999998 110.295 -178.138 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.8 p90 -150.36 163.14 39.09 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 120.345 -0.542 . . . . 0.20000000000000001 110.595 -177.426 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.7 m170 -112.65 137.7 50.54 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.648 -0.657 . . . . 1.99 110.256 -176.776 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.83 162.31 40.99 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.752 -0.592 . . . . 0.17999999999999999 109.585 177.13 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.06 159.29 17.44 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.765 -0.774 . . . . 0.17000000000000001 110.139 177.675 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.6 t -79.05 136.27 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 120.298 -0.561 . . . . 0.48999999999999999 110.254 -177.118 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -115.42 171.95 7.39 Favored 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.253 0.549 . . . . 0.68000000000000005 109.726 175.356 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -46.64 153.03 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.583 -0.698 . . . . 2.96 111.882 -176.138 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 53.9 mt 62.94 7.07 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.666 0 O-C-N 121.525 -0.735 . . . . 0.41999999999999998 112.629 -175.439 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.6 16.11 80.59 Favored Glycine 0 N--CA 1.498 2.792 0 O-C-N 120.895 -1.128 . . . . 0.23999999999999999 110.33 179.389 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 ttm180 -85.43 144.16 28.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.255 -1.144 . . . . 1.96 110.293 -177.147 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.46 155.09 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.725 -0.609 . . . . 0.29999999999999999 109.463 172.777 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.74 129.43 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.665 -0.647 . . . . 0.25 109.991 176.473 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.3 mt -79.61 145.99 64.23 Favored Pre-proline 0 N--CA 1.494 1.768 0 C-N-CA 120.061 -0.656 . . . . 0.23000000000000001 109.321 175.682 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.41 ' HD2' HG23 ' A' ' 19' ' ' ILE . 50.1 Cg_endo -63.47 143.21 87.66 Favored 'Trans proline' 0 N--CA 1.489 1.228 0 O-C-N 123.069 1.036 . . . . 0.34999999999999998 109.698 174.652 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.31 -26.34 60.74 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.813 -0.555 . . . . 0.33000000000000002 110.438 -178.85 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.34 -45.23 93.98 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.015 -1.234 . . . . 0.39000000000000001 110.015 -179.323 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.1 m -69.27 -37.3 77.84 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.706 -0.879 . . . . 0.39000000000000001 110.187 -179.579 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.592 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.24 -42.06 76.73 Favored 'General case' 0 N--CA 1.509 2.487 0 O-C-N 121.434 -0.791 . . . . 0.40000000000000002 109.751 178.378 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -66.62 -50.24 63.66 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 121.272 0.558 . . . . 2.9700000000000002 110.233 -177.024 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -57.27 -37.87 73.04 Favored 'General case' 0 N--CA 1.501 2.109 0 CA-C-O 121.205 0.526 . . . . 0.67000000000000004 110.704 -179.039 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.5 t80 -87.69 -14.21 40.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.744 -0.597 . . . . 1.4399999999999999 111.223 -176.795 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.17 26.76 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.598 -1.401 . . . . 0.31 109.598 177.674 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.916 HG23 HG21 ' A' ' 56' ' ' VAL . 73.1 mt -89.44 127.79 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.452 -1.028 . . . . 0.41999999999999998 110.462 -176.545 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -128.21 159.7 34.39 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.114 -0.699 . . . . 1.8200000000000001 109.114 171.637 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -57.2 139.36 52.88 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.364 -0.835 . . . . 1.99 110.541 -178.219 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.43 -15.77 62.2 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 178.232 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.07 158.74 31.49 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 118.701 1.25 . . . . 1.1200000000000001 109.991 178.037 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -111.71 138.16 48.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.634 -0.666 . . . . 0.20999999999999999 109.645 175.408 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.36 153.5 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 N-CA-C 109.164 -0.68 . . . . 0.14999999999999999 109.164 173.777 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.3 123.16 48.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.227 -1.027 . . . . 1.0900000000000001 108.227 -179.628 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.819 HD11 ' CG1' ' A' ' 82' ' ' VAL . 10.6 tt -140.38 158.33 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.593 -0.843 . . . . 0.14000000000000001 110.946 -167.564 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.9 ttpt -132.07 146.14 51.87 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.815 -0.553 . . . . 1.1100000000000001 110.428 177.286 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.581 HG22 HG22 ' A' ' 82' ' ' VAL . 23.9 pt -114.92 150.55 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.20000000000000001 110.305 176.939 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.545 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -139.58 124.35 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 CA-C-O 121.292 0.567 . . . . 0.20000000000000001 109.692 177.355 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.704 ' HB2' HG22 ' A' ' 80' ' ' ILE . 45.2 tptt -135.99 147.89 48.19 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.731 -0.605 . . . . 1.98 109.415 176.758 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.7 t80 . . . . . 0 N--CA 1.496 1.834 0 C-N-CA 120.071 -0.652 . . . . 0.33000000000000002 110.403 -177.566 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo . . . . . 0 N--CA 1.48 0.735 0 N-CA-C 110.198 -0.731 . . . . 0.34000000000000002 110.198 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.717 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.7 mmtp -110.69 137.27 48.57 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.56 -0.712 . . . . 1.1000000000000001 109.577 173.217 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.545 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -135.09 163.91 28.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.595 -0.691 . . . . 1.4199999999999999 111.027 -176.328 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.75 135.72 4.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.488 -1.445 . . . . 0.17000000000000001 109.488 176.918 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.5 136.86 54.34 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.733 -0.863 . . . . 0.20999999999999999 109.823 177.288 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.6 p90 -155.93 173.62 16.53 Favored 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.888 -0.725 . . . . 0.16 111.046 178.267 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.71 141.02 39.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.713 -0.617 . . . . 0.13 109.518 173.583 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.89 145.84 35.06 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.64 -0.663 . . . . 0.14000000000000001 110.672 -175.709 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 43.6 ttp180 -93.72 146.03 24.15 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.758 -0.589 . . . . 2.21 109.674 175.248 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.916 HG21 HG23 ' A' ' 29' ' ' ILE . 99.0 t -78.28 127.16 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.821 -0.55 . . . . 0.17000000000000001 109.995 -178.401 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.96 -168.06 26.1 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.995 -1.242 . . . . 0.19 109.995 178.869 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.7 153.47 28.15 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.712 -0.875 . . . . 1.3899999999999999 110.175 -179.727 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.68 20.89 2.37 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.596 -0.69 . . . . 0.81999999999999995 112.105 -179.698 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.6 20.46 79.82 Favored Glycine 0 N--CA 1.5 2.957 0 C-N-CA 119.763 -1.208 . . . . 0.19 110.826 171.613 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.424 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.9 p -78.67 147.26 33.61 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.541 -0.976 . . . . 1.3 110.328 -177.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.632 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.75 146.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 109.515 -0.55 . . . . 0.20999999999999999 109.515 174.78 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.8 123.89 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.527 -0.733 . . . . 0.34000000000000002 110.612 -174.559 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.44 HG23 ' HD2' ' A' ' 65' ' ' PRO . 88.5 mt -78.23 144.27 66.52 Favored Pre-proline 0 N--CA 1.499 2.024 0 O-C-N 121.59 -0.694 . . . . 0.34000000000000002 109.392 172.368 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.34 135.61 47.22 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 O-C-N 122.965 0.981 . . . . 0.26000000000000001 110.71 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 23.0 tptm -55.02 -34.85 63.82 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.368 -0.833 . . . . 2.6200000000000001 110.769 -179.772 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.92 -38.3 78.65 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.79 -0.569 . . . . 0.45000000000000001 110.276 -178.494 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.4 mt -77.05 -32.81 57.13 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.727 -0.608 . . . . 1.8200000000000001 110.695 179.432 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -58.15 -46.22 86.05 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.351 -0.843 . . . . 2.5299999999999998 109.845 178.95 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.43 -47.38 61.01 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.49 -0.484 . . . . 1.6799999999999999 110.468 -175.962 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 88.8 t -60.64 -37.96 77.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.702 -0.624 . . . . 0.28000000000000003 109.94 -178.309 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.717 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.7 mt -82.56 -17.82 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.833 -0.542 . . . . 0.28000000000000003 110.823 -176.473 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.7 35.22 41.23 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.776 -1.33 . . . . 0.22 109.776 175.706 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.12 142.69 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.46 -1.023 . . . . 0.77000000000000002 110.665 -173.86 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.94 156.29 76.3 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.789 -0.569 . . . . 3.21 110.618 -177.807 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -55.44 135.87 71.16 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.018 1.009 . . . . 0.5 111.257 178.197 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -1.53 73.06 Favored Glycine 0 N--CA 1.496 2.678 0 C-N-CA 120.622 -0.799 . . . . 0.23999999999999999 111.235 176.191 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.2 mt-10 -96.2 132.27 41.81 Favored 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 118.729 1.264 . . . . 1.1100000000000001 110.429 179.033 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.1 p -91.57 130.71 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.49 0.662 . . . . 0.23999999999999999 110.98 -174.822 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.704 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -119.34 159.48 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 N-CA-C 109.579 -0.526 . . . . 0.17999999999999999 109.579 178.055 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 82.0 tt0 -97.34 130.05 44.54 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.012 -0.736 . . . . 1.1399999999999999 109.012 174.933 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.819 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.0 t -115.46 127.77 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.339 0.59 . . . . 0.20000000000000001 110.235 -171.809 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.3 mt -115.07 129.19 56.63 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.411 -0.589 . . . . 0.25 109.411 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.5 mt -79.72 140.61 36.91 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.433 -0.792 . . . . 0.28000000000000003 109.856 172.651 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.09 -31.99 6.93 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.857 -0.527 . . . . 1.6000000000000001 110.798 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -176.95 39.22 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.71 -1.233 . . . . 0.20000000000000001 110.965 -177.429 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -145.06 152.6 40.36 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.715 -0.874 . . . . 1.8899999999999999 110.742 -177.954 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 . . . . . 0 N--CA 1.494 1.75 0 O-C-N 121.507 -0.746 . . . . 0.80000000000000004 110.028 175.711 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 109.565 -0.531 . . . . 0.40999999999999998 109.565 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.58 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.8 mt -82.23 -20.22 38.12 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.213 -0.595 . . . . 0.37 110.386 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.827 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.74 154.58 3.69 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.418 -0.801 . . . . 0.26000000000000001 109.327 175.742 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.6 tttt -134.66 125.17 26.57 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.657 -0.652 . . . . 2.2999999999999998 110.246 -176.511 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' PHE . . . . . 0.616 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.65 162.76 40.05 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.536 -0.727 . . . . 0.20000000000000001 110.842 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.69 138.74 49.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.623 -0.673 . . . . 1.99 110.231 -177.368 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.11 162.31 41.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.732 -0.605 . . . . 0.17999999999999999 109.72 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.0 157.81 18.91 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.52 -0.737 . . . . 0.17000000000000001 109.997 177.324 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.33 135.82 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.748 -0.595 . . . . 0.48999999999999999 110.259 -176.665 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -113.84 171.87 7.33 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.294 0.568 . . . . 0.68000000000000005 109.787 174.088 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtm-85 -46.66 152.67 0.45 Allowed 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.522 -0.736 . . . . 2.96 112.026 -175.694 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.59 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.599 0 O-C-N 121.596 -0.69 . . . . 0.41999999999999998 112.598 -175.636 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.71 16.17 80.43 Favored Glycine 0 N--CA 1.498 2.789 0 O-C-N 120.891 -1.131 . . . . 0.23999999999999999 110.325 179.404 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -84.05 141.8 30.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.271 -1.135 . . . . 1.96 110.36 -176.473 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.9 pt -133.98 154.36 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.654 . . . . 0.29999999999999999 109.532 172.832 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mm -117.71 128.46 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 C-N-CA 120.051 -0.66 . . . . 0.25 109.857 176.19 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 34.0 mt -80.07 144.09 58.31 Favored Pre-proline 0 N--CA 1.496 1.829 0 C-N-CA 120.02 -0.672 . . . . 0.23000000000000001 109.36 176.043 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.32 143.55 89.35 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 122.953 0.975 . . . . 0.34999999999999998 109.731 174.656 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.5 -26.5 61.41 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.889 -0.507 . . . . 0.33000000000000002 110.47 -178.347 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.48 -44.46 95.18 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 109.914 -1.275 . . . . 0.39000000000000001 109.914 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.2 m -69.97 -38.34 76.04 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.618 -0.931 . . . . 0.39000000000000001 110.162 -179.392 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.79 73.52 Favored 'General case' 0 N--CA 1.514 2.75 0 O-C-N 121.245 -0.91 . . . . 0.40000000000000002 109.43 176.42 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -64.94 -49.66 69.51 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.167 0.508 . . . . 2.9700000000000002 110.119 -177.605 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.19 -38.55 73.82 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.785 -0.572 . . . . 0.67000000000000004 110.726 -179.709 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.965 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.3 t80 -88.07 -14.23 39.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.847 -0.533 . . . . 1.4399999999999999 111.308 -176.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.97 24.59 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.55 -1.42 . . . . 0.31 109.55 178.562 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 75.9 mt -87.25 129.14 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.499 -1.001 . . . . 0.41999999999999998 110.563 -177.021 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.31 158.97 36.73 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 109.11 -0.7 . . . . 1.8200000000000001 109.11 170.636 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.25 138.66 54.45 Favored 'General case' 0 N--CA 1.503 2.201 0 O-C-N 121.396 -0.815 . . . . 1.99 110.539 -179.149 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.05 62.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 110.869 -0.892 . . . . 0.19 110.869 178.973 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.82 155.54 32.96 Favored 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 118.708 1.254 . . . . 1.1200000000000001 110.076 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -110.43 138.65 46.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.557 -0.714 . . . . 0.20999999999999999 109.462 174.089 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.38 154.43 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 C-N-CA 120.204 -0.598 . . . . 0.14999999999999999 109.398 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -114.89 123.38 49.01 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.158 -1.053 . . . . 1.0900000000000001 108.158 179.695 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.814 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.94 158.65 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.662 -0.815 . . . . 0.14000000000000001 110.812 -167.787 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.537 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.7 ttpt -132.67 146.21 51.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.887 -0.508 . . . . 1.1100000000000001 110.42 178.972 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.586 HG22 HG22 ' A' ' 82' ' ' VAL . 22.0 pt -114.72 149.12 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.718 -0.614 . . . . 0.20000000000000001 110.252 177.107 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.5 t -140.1 123.95 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 CA-C-O 121.138 0.494 . . . . 0.20000000000000001 109.69 178.636 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.701 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.2 tttt -132.25 148.47 52.45 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.34 -0.615 . . . . 1.98 109.34 175.922 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 33.1 t80 . . . . . 0 N--CA 1.496 1.864 0 C-N-CA 120.008 -0.677 . . . . 0.33000000000000002 110.328 179.909 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo . . . . . 0 N--CA 1.483 0.87 0 N-CA-C 110.504 -0.614 . . . . 0.34000000000000002 110.504 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.68 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.7 mmtp -111.13 136.0 50.81 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.588 -0.695 . . . . 1.1000000000000001 109.714 172.743 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -133.27 156.89 46.74 Favored 'General case' 0 C--N 1.311 -1.068 0 O-C-N 121.531 -0.731 . . . . 1.4199999999999999 110.582 -171.381 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.61 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -157.67 135.86 4.57 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.544 -1.422 . . . . 0.17000000000000001 109.544 176.104 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.537 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -126.83 138.31 53.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.647 -0.913 . . . . 0.20999999999999999 109.714 177.257 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -156.26 173.79 16.34 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 119.949 -0.701 . . . . 0.16 111.107 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.9 m -106.89 141.07 38.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.633 -0.667 . . . . 0.13 109.606 173.289 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.24 145.77 34.44 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.754 -0.591 . . . . 0.14000000000000001 110.551 -175.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 57.0 ttt180 -93.77 145.26 24.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.741 -0.6 . . . . 2.21 109.778 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.6 t -79.68 125.5 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 CA-C-O 121.384 0.611 . . . . 0.17000000000000001 109.825 179.675 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.9 -165.91 25.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.989 -1.244 . . . . 0.19 109.989 178.482 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -61.62 153.07 28.92 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.85 -0.794 . . . . 1.3899999999999999 110.178 -179.335 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.55 21.15 2.38 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.602 -0.686 . . . . 0.81999999999999995 112.056 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.51 79.88 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 119.812 -1.185 . . . . 0.19 110.817 172.008 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 59.4 p -78.41 146.68 34.42 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.563 -0.963 . . . . 1.3 110.439 -176.244 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.757 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -139.55 145.62 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.631 -0.507 . . . . 0.20999999999999999 109.631 174.203 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.3 mm -111.09 123.03 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.552 -0.718 . . . . 0.34000000000000002 110.478 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.8 mt -78.2 144.47 67.02 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.613 -0.679 . . . . 0.34000000000000002 109.656 174.755 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.76 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.31 134.58 42.67 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 O-C-N 122.928 0.962 . . . . 0.26000000000000001 110.802 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -54.88 -35.02 63.63 Favored 'General case' 0 N--CA 1.503 2.207 0 O-C-N 121.489 -0.757 . . . . 2.6200000000000001 110.767 -179.806 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.426 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -38.29 78.38 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.738 -0.601 . . . . 0.45000000000000001 110.364 -178.063 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.76 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.6 mt -77.21 -32.66 56.09 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 120.172 -0.611 . . . . 1.8200000000000001 110.729 179.529 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -58.28 -46.49 85.96 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.301 -0.874 . . . . 2.5299999999999998 109.761 178.551 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.02 -46.12 65.77 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.542 -0.463 . . . . 1.6799999999999999 110.455 -175.179 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 67' ' ' ALA . 95.4 t -60.38 -38.46 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.61 -0.681 . . . . 0.28000000000000003 109.825 -178.835 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.3 mt -82.17 -18.27 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.918 -0.489 . . . . 0.28000000000000003 110.912 -177.059 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.59 35.13 42.08 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 109.75 -1.34 . . . . 0.22 109.75 176.476 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.885 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.8 mm -92.0 140.72 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.468 -1.019 . . . . 0.77000000000000002 110.569 -174.529 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 23.1 mmmt -125.32 161.58 49.14 Favored Pre-proline 0 N--CA 1.498 1.964 0 O-C-N 121.637 -0.665 . . . . 3.21 110.498 -175.366 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -60.75 134.6 54.89 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 O-C-N 123.0 1.0 . . . . 0.5 110.748 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.47 0.87 72.37 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 111.118 -0.793 . . . . 0.23999999999999999 111.118 176.645 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -100.33 135.86 41.12 Favored 'General case' 0 N--CA 1.498 1.975 0 CA-C-N 118.704 1.252 . . . . 1.1100000000000001 110.737 -179.633 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.72 133.9 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.696 0.76 . . . . 0.23999999999999999 111.463 -172.605 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.701 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -124.59 159.47 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 109.399 -0.593 . . . . 0.17999999999999999 109.399 175.427 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -98.6 132.0 44.35 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.067 -0.716 . . . . 1.1399999999999999 109.067 175.9 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.814 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.6 t -115.39 129.41 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 CA-C-O 121.302 0.572 . . . . 0.20000000000000001 110.282 -171.408 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.1 129.36 56.3 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 109.168 -0.679 . . . . 0.25 109.168 178.869 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.965 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.09 139.25 36.96 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.396 -0.815 . . . . 0.28000000000000003 109.755 171.798 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.21 -31.25 7.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.724 -0.61 . . . . 1.6000000000000001 110.971 -174.899 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.58 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.06 -175.9 38.14 Favored Glycine 0 N--CA 1.504 3.176 0 C-N-CA 119.671 -1.252 . . . . 0.20000000000000001 111.086 -176.944 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p-80 -144.44 154.05 42.54 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.681 -0.893 . . . . 1.8899999999999999 110.744 -177.277 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.536 -0.727 . . . . 0.80000000000000004 110.131 175.972 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.3 mtt . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.128 0.49 . . . . 3.1600000000000001 110.533 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -73.64 144.01 46.07 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.876 -0.515 . . . . 1.27 110.048 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -128.13 137.45 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.802 -0.562 . . . . 0.23000000000000001 109.568 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.56 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.0 mt -86.71 -18.0 32.28 Favored 'General case' 0 N--CA 1.496 1.825 0 C-N-CA 120.251 -0.58 . . . . 0.16 110.515 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.965 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.77 152.71 3.13 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.388 -0.82 . . . . 0.11 109.094 177.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 46.6 tttt -133.85 125.16 27.8 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.674 -0.641 . . . . 0.88 110.054 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.597 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.6 p90 -150.94 162.28 41.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.575 -0.703 . . . . 0.080000000000000002 110.782 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -113.41 139.12 49.17 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.713 -0.617 . . . . 1.0800000000000001 110.235 -177.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.463 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.57 162.3 40.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.742 -0.599 . . . . 0.089999999999999997 109.604 177.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.1 157.95 18.82 Favored 'General case' 0 N--CA 1.496 1.869 0 C-N-CA 119.764 -0.774 . . . . 0.10000000000000001 110.063 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.29 134.92 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 C-N-CA 120.289 -0.564 . . . . 0.11 110.161 -176.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -113.46 171.93 7.27 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.23 0.538 . . . . 0.14000000000000001 109.685 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.33 152.54 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.53 -0.731 . . . . 2.7000000000000002 112.003 -175.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.674 0 O-C-N 121.516 -0.74 . . . . 0.20999999999999999 112.533 -174.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.09 80.66 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.815 -1.178 . . . . 0.080000000000000002 110.377 179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.798 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -85.54 142.96 28.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.297 -1.12 . . . . 2.3300000000000001 110.367 -176.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.463 HD12 HG21 ' A' ' 9' ' ' THR . 43.0 pt -133.2 157.74 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.658 -0.651 . . . . 0.089999999999999997 109.602 173.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.798 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.2 mm -117.06 129.58 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.632 -0.668 . . . . 0.089999999999999997 110.113 176.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.457 HG23 ' HD2' ' A' ' 20' ' ' PRO . 23.8 mt -79.98 147.01 64.9 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.147 -0.621 . . . . 0.080000000000000002 109.396 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.457 ' HD2' HG23 ' A' ' 19' ' ' ILE . 47.0 Cg_endo -63.06 143.15 90.06 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 122.979 0.989 . . . . 0.14000000000000001 109.878 174.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.98 -26.5 62.41 Favored 'General case' 0 N--CA 1.496 1.845 0 C-N-CA 120.404 -0.518 . . . . 0.13 110.448 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.76 -43.73 95.82 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.998 -1.241 . . . . 0.10000000000000001 109.998 -179.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.4 m -69.69 -39.17 77.1 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.547 -0.973 . . . . 0.14000000000000001 110.051 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HA ' HD12 ' A' ' 29' ' ' ILE . 7.8 mtt180 -56.49 -42.56 78.5 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 121.353 -0.842 . . . . 0.10000000000000001 109.403 177.364 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.2 tttt -67.45 -50.25 60.05 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.025 0.441 . . . . 2.2599999999999998 110.222 -176.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -58.09 -36.16 72.47 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.735 -0.603 . . . . 0.20000000000000001 110.581 178.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.926 ' CD2' HD13 ' A' ' 84' ' ' LEU . 11.5 t80 -86.77 -14.28 42.74 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.739 -0.601 . . . . 0.20000000000000001 111.331 -174.293 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.2 39.94 35.48 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.661 -1.376 . . . . 0.11 109.661 177.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.797 ' CG2' HG21 ' A' ' 56' ' ' VAL . 85.1 mt -93.2 132.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.502 -0.999 . . . . 0.12 110.633 -175.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.15 161.65 29.59 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 109.304 -0.628 . . . . 1.99 109.304 172.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -57.76 138.72 55.26 Favored 'General case' 0 N--CA 1.503 2.217 0 O-C-N 121.477 -0.764 . . . . 1.95 110.397 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.47 -16.11 61.82 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.855 -0.898 . . . . 0.10000000000000001 110.855 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -77.51 160.89 28.32 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.085 -1.244 . . . . 0.089999999999999997 110.234 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -112.62 139.27 48.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.11 109.728 175.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.2 155.82 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 N-CA-C 109.152 -0.684 . . . . 0.040000000000000001 109.152 173.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -118.75 123.83 45.78 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.36 -0.978 . . . . 1.0 108.36 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.828 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.9 tt -140.33 158.53 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 C-N-CA 119.58 -0.848 . . . . 0.080000000000000002 111.144 -167.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.444 ' HB2' HG23 ' A' ' 51' ' ' THR . 36.4 tttt -132.92 146.09 51.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.91 -0.494 . . . . 1.1799999999999999 110.384 177.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.483 HG22 HG22 ' A' ' 82' ' ' VAL . 24.7 pt -114.81 151.01 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.624 -0.672 . . . . 0.12 110.528 178.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t -138.38 124.75 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 CA-C-O 121.136 0.493 . . . . 0.10000000000000001 109.678 176.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.572 ' HB2' HG22 ' A' ' 80' ' ' ILE . 57.9 tttm -132.84 144.87 50.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.29 -0.633 . . . . 1.9399999999999999 109.29 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 42.4 t80 -103.14 130.01 50.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 120.09 -0.644 . . . . 0.46000000000000002 110.55 -177.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.8 129.67 40.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.713 -0.617 . . . . 1.6499999999999999 109.988 177.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.79 -128.27 46.18 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 109.816 -1.314 . . . . 0.38 109.816 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -105.06 13.9 30.12 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.744 -0.856 . . . . 1.1399999999999999 111.616 177.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -131.12 129.06 22.37 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.248 -0.907 . . . . 1.48 110.878 -178.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.15 139.72 24.22 Favored 'Trans proline' 0 N--CA 1.483 0.88 0 O-C-N 122.752 0.869 . . . . 0.33000000000000002 110.423 175.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.727 ' HB3' HG23 ' A' ' 72' ' ' ILE . 28.5 mmtp -110.36 137.51 47.98 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.577 -0.702 . . . . 1.25 109.536 172.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -134.61 162.43 32.33 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.645 -0.659 . . . . 1.6899999999999999 110.996 -177.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.89 135.92 4.45 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.418 . . . . 0.10000000000000001 109.554 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.444 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -124.06 138.05 54.49 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.651 -0.911 . . . . 0.14999999999999999 109.785 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.809 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.4 p90 -155.97 173.47 16.74 Favored 'General case' 0 N--CA 1.497 1.902 0 C-N-CA 119.884 -0.726 . . . . 0.089999999999999997 110.986 177.138 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.5 m -106.91 142.07 37.13 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.65 -0.656 . . . . 0.080000000000000002 109.464 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.809 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.07 146.17 36.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.61 -0.681 . . . . 0.080000000000000002 110.756 -175.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.65 146.0 24.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.841 -0.537 . . . . 2.3599999999999999 109.63 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.797 HG21 ' CG2' ' A' ' 29' ' ' ILE . 96.9 t -79.01 124.82 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 120.294 -0.562 . . . . 0.089999999999999997 110.062 179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.95 -166.54 25.07 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.088 -1.205 . . . . 0.089999999999999997 110.088 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.71 152.95 29.67 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.766 -0.843 . . . . 1.4399999999999999 110.187 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 53.51 21.1 2.32 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.668 -0.645 . . . . 1.72 112.014 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.62 20.51 79.82 Favored Glycine 0 N--CA 1.5 2.907 0 C-N-CA 119.643 -1.265 . . . . 0.070000000000000007 110.83 171.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.454 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.7 p -78.0 148.19 34.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.438 -1.036 . . . . 1.3 110.27 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.723 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.4 p -138.74 145.97 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 N-CA-C 109.535 -0.543 . . . . 0.080000000000000002 109.535 175.325 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.3 mm -110.81 122.73 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.561 -0.712 . . . . 0.14999999999999999 110.709 -174.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.45 HG23 ' HD2' ' A' ' 65' ' ' PRO . 50.9 mt -78.38 144.62 66.5 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.567 -0.708 . . . . 0.14000000000000001 109.465 172.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.75 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.25 133.26 37.08 Favored 'Trans proline' 0 N--CA 1.495 1.582 0 O-C-N 122.879 0.936 . . . . 0.13 110.69 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -55.23 -34.23 63.79 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.482 -0.761 . . . . 2.29 110.788 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.71 -37.87 77.07 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.747 -0.596 . . . . 0.12 110.336 -178.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.75 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.4 mt -77.08 -32.71 56.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.748 -0.595 . . . . 0.13 110.475 178.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.4 mtt180 -57.67 -45.49 85.49 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.258 -0.901 . . . . 0.11 109.841 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.15 62.61 Favored 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 120.534 -0.467 . . . . 1.49 110.465 -175.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.55 -38.25 77.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.646 -0.659 . . . . 0.17000000000000001 109.89 -178.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.727 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.63 -17.63 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.841 -0.537 . . . . 0.17000000000000001 110.89 -176.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.6 35.29 36.93 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 109.814 -1.315 . . . . 0.17000000000000001 109.814 175.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.3 mm -89.47 142.75 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.603 -0.94 . . . . 0.17999999999999999 110.587 -174.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -129.09 157.47 75.82 Favored Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.829 -0.544 . . . . 2.54 110.7 -177.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -55.31 133.98 61.21 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 O-C-N 122.934 0.965 . . . . 0.46000000000000002 111.287 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.95 0.23 71.88 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 111.191 -0.763 . . . . 0.14999999999999999 111.191 175.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -97.48 134.42 40.75 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-N 118.677 1.239 . . . . 0.41999999999999998 110.559 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.407 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -91.95 132.79 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-O 121.67 0.748 . . . . 0.14999999999999999 111.173 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.572 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.5 pt -121.86 159.49 24.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 109.387 -0.597 . . . . 0.11 109.387 175.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -97.69 131.57 44.12 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.98 -0.748 . . . . 1.1299999999999999 108.98 175.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.828 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.78 130.24 70.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 CA-C-O 121.324 0.583 . . . . 0.070000000000000007 110.266 -170.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.5 mt -116.5 131.01 57.06 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.264 -0.643 . . . . 0.089999999999999997 109.264 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.965 HD12 ' HB3' ' A' ' 5' ' ' ALA . 4.3 mt -80.28 141.6 35.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.415 -0.803 . . . . 0.10000000000000001 109.971 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.47 -32.52 6.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.765 -0.585 . . . . 0.34000000000000002 110.868 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.56 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.8 -178.31 40.24 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.738 -1.22 . . . . 0.10000000000000001 111.014 -177.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -148.82 151.22 34.38 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.702 -0.881 . . . . 0.27000000000000002 110.572 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -133.22 139.19 46.84 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.58 -0.7 . . . . 0.56000000000000005 109.893 175.055 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 ttmt -123.05 149.93 58.19 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.689 -0.632 . . . . 3.52 110.442 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.28 148.51 60.49 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 O-C-N 123.262 1.138 . . . . 1.01 110.856 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 58.4 ttt85 -121.96 141.07 51.69 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.731 -0.606 . . . . 5.0599999999999996 110.169 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 59.0 t30 . . . . . 0 N--CA 1.495 1.783 0 CA-C-O 117.999 -1.0 . . . . 4.21 110.192 -179.573 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.7 ttm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.015 0.436 . . . . 2.7599999999999998 110.203 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.31 141.26 40.01 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.676 -0.64 . . . . 1.7 109.989 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.2 p -127.43 140.53 48.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.747 -0.596 . . . . 0.40999999999999998 109.78 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.7 mt -87.8 -18.0 30.32 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 120.238 -0.585 . . . . 0.37 110.662 -177.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.824 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.21 156.67 3.98 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.206 -0.934 . . . . 0.26000000000000001 109.853 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -134.04 126.77 30.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.758 -0.589 . . . . 2.2999999999999998 110.167 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 18.2 p90 -149.42 161.81 41.34 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.614 -0.679 . . . . 0.20000000000000001 110.874 178.395 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -111.54 137.89 48.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.574 -0.704 . . . . 1.99 110.141 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.48 162.33 41.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.69 -0.631 . . . . 0.17999999999999999 109.748 177.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.4 t -111.5 159.28 18.24 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.535 -0.728 . . . . 0.17000000000000001 109.996 176.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.922 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.0 t -78.73 136.44 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.816 -0.553 . . . . 0.48999999999999999 110.191 -177.201 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -114.26 171.95 7.3 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.285 0.564 . . . . 0.68000000000000005 109.651 174.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -46.5 151.95 0.5 Allowed 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.531 -0.731 . . . . 2.96 112.036 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.2 mt 62.52 7.93 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.651 0 O-C-N 121.547 -0.721 . . . . 0.41999999999999998 112.585 -175.508 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.68 16.06 80.59 Favored Glycine 0 N--CA 1.497 2.738 0 O-C-N 120.934 -1.104 . . . . 0.23999999999999999 110.432 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.2 ttt180 -84.49 142.51 30.0 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.256 -1.143 . . . . 1.96 110.134 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.2 pt -133.28 154.3 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.649 -0.657 . . . . 0.29999999999999999 109.671 174.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.53 128.51 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.623 -0.673 . . . . 0.25 109.952 175.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 30.4 mt -79.99 144.34 59.08 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.986 -0.686 . . . . 0.23000000000000001 109.437 175.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.31 143.23 88.67 Favored 'Trans proline' 0 N--CA 1.489 1.219 0 O-C-N 122.969 0.984 . . . . 0.34999999999999998 109.772 175.053 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.58 -26.77 61.97 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 120.442 -0.503 . . . . 0.33000000000000002 110.472 -178.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -44.21 95.47 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.965 -1.254 . . . . 0.39000000000000001 109.965 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.3 m -69.82 -38.39 76.54 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.593 -0.945 . . . . 0.39000000000000001 110.132 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.723 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.8 mtt180 -56.06 -40.49 73.63 Favored 'General case' 0 N--CA 1.513 2.687 0 O-C-N 121.337 -0.852 . . . . 0.40000000000000002 109.378 176.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 84.7 tttt -65.27 -50.05 67.24 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.065 0.459 . . . . 2.9700000000000002 110.164 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -57.72 -39.08 76.44 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 121.773 -0.579 . . . . 0.67000000000000004 110.681 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.7 t80 -87.28 -14.2 41.58 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.789 -0.569 . . . . 1.4399999999999999 111.258 -176.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.78 42.9 24.63 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.536 -1.425 . . . . 0.31 109.536 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.913 HG23 HG21 ' A' ' 56' ' ' VAL . 75.0 mt -87.41 127.22 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.497 -1.002 . . . . 0.41999999999999998 110.532 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -128.23 159.39 35.35 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.098 -0.704 . . . . 1.8200000000000001 109.098 170.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.41 138.71 54.66 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.403 -0.81 . . . . 1.99 110.486 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.74 -16.02 62.12 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.874 -0.89 . . . . 0.19 110.874 179.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -77.09 156.9 31.39 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 118.686 1.243 . . . . 1.1200000000000001 110.148 177.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -111.36 138.69 47.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.682 -0.636 . . . . 0.20999999999999999 109.648 174.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.81 153.32 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.709 -0.619 . . . . 0.14999999999999999 109.34 174.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -116.32 123.01 46.57 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.331 -0.989 . . . . 1.0900000000000001 108.331 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.804 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.4 tt -138.6 157.87 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.57 -0.852 . . . . 0.14000000000000001 111.324 -166.583 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.89 143.34 50.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.865 -0.522 . . . . 1.1100000000000001 110.156 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.637 HG22 HG22 ' A' ' 82' ' ' VAL . 35.7 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.553 -0.717 . . . . 0.20000000000000001 110.551 177.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.436 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.89 127.57 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.756 -0.461 . . . . 0.20000000000000001 109.756 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.706 ' HB2' HG22 ' A' ' 80' ' ' ILE . 31.0 tttm -133.68 148.36 51.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.701 -0.625 . . . . 1.98 109.633 173.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -101.47 129.21 47.47 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.156 -0.618 . . . . 0.33000000000000002 110.129 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -137.57 134.75 35.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.675 -0.641 . . . . 1.48 110.226 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.09 45.66 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.686 -1.366 . . . . 0.40999999999999998 109.686 -177.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.07 7.27 33.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.706 -0.879 . . . . 1.27 111.763 178.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -131.24 138.06 32.0 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 121.169 -0.957 . . . . 1.3700000000000001 110.977 -178.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.47 144.89 29.25 Favored 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 122.717 0.851 . . . . 0.34000000000000002 110.026 172.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.435 ' CB ' HG23 ' A' ' 72' ' ' ILE . 45.8 mttt -122.49 147.74 45.99 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.404 -0.81 . . . . 1.1000000000000001 110.098 171.182 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -136.71 169.05 18.37 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 120.338 -0.545 . . . . 1.4199999999999999 110.991 -176.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.71 4.38 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.341 -1.503 . . . . 0.17000000000000001 109.341 177.294 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -127.15 136.94 52.79 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 0.20999999999999999 109.927 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.811 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.3 p90 -156.71 173.77 16.47 Favored 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 119.939 -0.704 . . . . 0.16 110.922 176.434 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.2 m -106.5 140.37 39.5 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.696 -0.627 . . . . 0.13 109.422 173.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.811 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.37 146.6 36.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.706 -0.621 . . . . 0.14000000000000001 110.749 -175.239 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.66 145.24 24.7 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.855 -0.528 . . . . 2.21 109.617 175.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.913 HG21 HG23 ' A' ' 29' ' ' ILE . 89.9 t -79.44 125.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.356 0.598 . . . . 0.17000000000000001 109.814 179.358 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.66 -165.33 25.27 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.084 -1.206 . . . . 0.19 110.084 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -61.69 151.76 32.86 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.786 -0.832 . . . . 1.3899999999999999 110.107 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 53.3 21.88 2.5 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.565 -0.709 . . . . 0.81999999999999995 112.087 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.32 20.53 79.92 Favored Glycine 0 N--CA 1.5 2.923 0 C-N-CA 119.765 -1.207 . . . . 0.19 110.795 171.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.8 m -78.26 145.55 35.37 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.458 -1.025 . . . . 1.3 110.365 -176.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 9.0 p -139.27 147.77 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.773 -0.579 . . . . 0.20999999999999999 109.721 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -108.7 123.68 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.525 -0.735 . . . . 0.34000000000000002 110.658 -175.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.417 HG23 ' HD2' ' A' ' 65' ' ' PRO . 82.9 mt -78.64 143.02 62.37 Favored Pre-proline 0 N--CA 1.499 1.975 0 O-C-N 121.592 -0.692 . . . . 0.34000000000000002 109.596 172.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.767 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.28 134.21 41.16 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.914 0.955 . . . . 0.26000000000000001 110.908 -178.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 36.0 tptt -54.98 -34.84 63.72 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.517 -0.739 . . . . 2.6200000000000001 110.859 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.413 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.95 -38.16 78.4 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.765 -0.584 . . . . 0.45000000000000001 110.313 -178.085 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.767 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.3 mt -77.16 -32.67 56.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.739 -0.601 . . . . 1.8200000000000001 110.682 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.3 mtt180 -58.35 -46.1 86.91 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.281 -0.887 . . . . 2.5299999999999998 109.769 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.52 65.24 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 120.481 -0.488 . . . . 1.6799999999999999 110.44 -175.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 67' ' ' ALA . 97.3 t -60.59 -38.82 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.685 -0.634 . . . . 0.28000000000000003 109.903 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.583 HG22 HD11 ' A' ' 74' ' ' ILE . 85.8 mt -82.95 -16.32 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.821 -0.549 . . . . 0.28000000000000003 111.063 -176.713 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.11 35.25 44.37 Favored Glycine 0 N--CA 1.498 2.794 0 N-CA-C 109.929 -1.268 . . . . 0.22 109.929 176.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.922 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -89.33 145.83 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.522 -0.987 . . . . 0.77000000000000002 110.777 -173.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmt -134.46 162.99 54.39 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.849 -0.532 . . . . 3.21 110.454 -178.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -57.42 134.09 61.3 Favored 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 122.896 0.945 . . . . 0.5 111.137 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 0.98 67.38 Favored Glycine 0 N--CA 1.496 2.675 0 C-N-CA 120.676 -0.773 . . . . 0.23999999999999999 111.343 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -94.1 129.87 40.49 Favored 'General case' 0 N--CA 1.501 2.102 0 CA-C-N 118.753 1.277 . . . . 1.1100000000000001 110.322 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.1 132.74 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 CA-C-O 121.616 0.722 . . . . 0.23999999999999999 111.174 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.33 159.49 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 109.451 -0.574 . . . . 0.17999999999999999 109.451 176.425 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -97.83 132.1 43.73 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.088 -0.708 . . . . 1.1399999999999999 109.088 173.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.804 ' CG1' HD11 ' A' ' 37' ' ' ILE . 98.7 t -115.04 128.83 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 121.347 0.594 . . . . 0.20000000000000001 110.143 -171.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.8 mt -115.37 128.8 56.32 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.186 -0.672 . . . . 0.25 109.186 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.6 mt -79.38 140.4 37.46 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.431 -0.793 . . . . 0.28000000000000003 109.729 172.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.71 -32.24 7.16 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.718 -0.614 . . . . 1.6000000000000001 110.971 -176.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.8 -179.07 40.23 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.674 -1.25 . . . . 0.20000000000000001 110.985 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.0 p80 -142.96 150.47 39.75 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.746 -0.855 . . . . 1.8899999999999999 110.658 -177.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -134.41 139.67 45.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.586 -0.696 . . . . 0.80000000000000004 110.045 175.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 tttm -105.16 144.6 29.1 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.73 -0.606 . . . . 2.9900000000000002 110.214 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -55.37 144.22 73.28 Favored 'Trans proline' 0 N--CA 1.497 1.68 0 O-C-N 123.197 1.104 . . . . 1.6799999999999999 110.998 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 44.7 ptt85 -136.1 158.26 44.84 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.735 -0.603 . . . . 6.8700000000000001 110.419 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 . . . . . 0 N--CA 1.504 2.256 0 CA-C-O 118.039 -0.981 . . . . 6.4699999999999998 110.956 -179.84 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.8 mtp . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.271 0.558 . . . . 2.7599999999999998 110.529 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.99 142.68 38.13 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.843 -0.536 . . . . 1.7 110.023 178.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 84' ' ' LEU . 3.4 p -128.06 140.28 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.779 -0.575 . . . . 0.40999999999999998 109.758 177.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.5 mt -86.91 -20.87 26.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.85 -0.531 . . . . 0.37 110.464 -178.013 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.904 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.06 157.23 4.28 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.363 -0.836 . . . . 0.26000000000000001 109.685 176.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -132.87 126.67 32.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.715 -0.615 . . . . 2.2999999999999998 110.223 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.612 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.6 p90 -149.27 162.48 39.95 Favored 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 120.143 -0.623 . . . . 0.20000000000000001 110.665 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.59 138.18 50.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.548 -0.72 . . . . 1.99 110.286 -176.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 HD12 ' A' ' 17' ' ' ILE . 14.9 t -150.9 162.37 40.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.797 -0.564 . . . . 0.17999999999999999 109.543 177.619 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.05 160.35 16.94 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 119.812 -0.755 . . . . 0.17000000000000001 110.107 177.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.4 t -79.06 136.13 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 C-N-CA 120.329 -0.548 . . . . 0.48999999999999999 110.318 -176.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -116.2 172.04 7.43 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.24 0.543 . . . . 0.68000000000000005 109.58 174.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -46.21 152.47 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.543 -0.723 . . . . 2.96 112.048 -175.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.76 7.32 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.703 0 O-C-N 121.622 -0.674 . . . . 0.41999999999999998 112.593 -175.132 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.07 80.67 Favored Glycine 0 N--CA 1.496 2.635 0 O-C-N 120.857 -1.152 . . . . 0.23999999999999999 110.438 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttp180 -84.63 145.06 28.2 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.292 -1.123 . . . . 1.96 110.191 -177.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 9' ' ' THR . 45.1 pt -132.58 155.78 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 N-CA-C 109.315 -0.624 . . . . 0.29999999999999999 109.315 172.175 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.1 mm -115.82 128.18 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 C-N-CA 120.034 -0.666 . . . . 0.25 109.904 176.315 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 33.7 mt -79.58 143.83 59.88 Favored Pre-proline 0 N--CA 1.495 1.794 0 C-N-CA 120.052 -0.659 . . . . 0.23000000000000001 109.435 176.048 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.08 143.08 89.79 Favored 'Trans proline' 0 N--CA 1.489 1.231 0 O-C-N 122.989 0.994 . . . . 0.34999999999999998 109.845 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.62 -26.9 62.24 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.882 -0.511 . . . . 0.33000000000000002 110.52 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.06 95.61 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.951 -1.26 . . . . 0.39000000000000001 109.951 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.9 m -69.94 -38.38 76.15 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.585 -0.95 . . . . 0.39000000000000001 110.116 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.87 -40.81 73.47 Favored 'General case' 0 N--CA 1.512 2.664 0 O-C-N 121.286 -0.884 . . . . 0.40000000000000002 109.429 176.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -65.75 -50.07 66.11 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.1 0.476 . . . . 2.9700000000000002 110.212 -177.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -57.6 -39.67 77.34 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.707 -0.621 . . . . 0.67000000000000004 110.756 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.939 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.0 t80 -87.69 -14.29 40.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.774 -0.579 . . . . 1.4399999999999999 111.275 -176.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.87 42.52 25.19 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.576 -1.409 . . . . 0.31 109.576 178.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.921 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.74 125.55 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.543 -0.975 . . . . 0.41999999999999998 110.445 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.55 159.94 33.07 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.235 -0.654 . . . . 1.8200000000000001 109.235 172.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -57.27 138.19 55.06 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.33 -0.856 . . . . 1.99 110.557 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.81 -16.09 61.99 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 110.832 -0.907 . . . . 0.19 110.832 178.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -77.23 155.96 31.79 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.693 1.246 . . . . 1.1200000000000001 109.998 177.077 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -111.27 138.78 47.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.6 -0.688 . . . . 0.20999999999999999 109.492 174.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 155.06 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.199 -0.6 . . . . 0.14999999999999999 109.386 174.687 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.99 122.55 45.58 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.198 -1.038 . . . . 1.0900000000000001 108.198 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.826 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.15 158.22 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.596 -0.841 . . . . 0.14000000000000001 110.936 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -133.15 145.62 50.83 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.859 -0.525 . . . . 1.1100000000000001 110.505 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' VAL . 31.9 pt -114.93 151.13 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.648 -0.657 . . . . 0.20000000000000001 110.604 178.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t -138.67 127.93 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 121.174 0.512 . . . . 0.20000000000000001 109.72 176.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.702 ' HB2' HG22 ' A' ' 80' ' ' ILE . 33.3 tptt -137.82 147.13 44.29 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.83 -0.544 . . . . 1.98 109.632 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -101.99 128.9 48.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.266 -0.574 . . . . 0.33000000000000002 110.384 -176.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -131.92 132.86 43.95 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.676 -0.64 . . . . 1.48 109.974 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.89 -128.23 45.95 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 109.768 -1.333 . . . . 0.40999999999999998 109.768 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -105.19 12.57 31.8 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.677 -0.896 . . . . 1.27 111.608 177.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -131.17 127.6 21.94 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.255 -0.903 . . . . 1.3700000000000001 110.991 -177.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -75.3 139.41 23.5 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 O-C-N 122.743 0.865 . . . . 0.34000000000000002 109.994 173.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.427 ' CB ' HG23 ' A' ' 72' ' ' ILE . 37.1 mttp -118.71 151.75 37.41 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.498 -0.751 . . . . 1.1000000000000001 110.309 173.268 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -140.03 169.09 18.34 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-O 121.216 0.532 . . . . 1.4199999999999999 110.737 -178.373 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.61 135.9 4.47 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.428 -1.469 . . . . 0.17000000000000001 109.428 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -122.64 137.48 54.89 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.629 -0.924 . . . . 0.20999999999999999 109.847 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.7 p90 -156.14 173.1 17.32 Favored 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.899 -0.721 . . . . 0.16 110.901 176.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.06 141.31 38.5 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.669 -0.644 . . . . 0.13 109.493 173.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 145.51 35.19 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.675 -0.641 . . . . 0.14000000000000001 110.695 -175.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -93.68 146.0 24.15 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.855 -0.528 . . . . 2.21 109.626 175.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.921 HG21 HG23 ' A' ' 29' ' ' ILE . 87.2 t -79.15 125.45 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.778 -0.576 . . . . 0.17000000000000001 109.919 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.33 -167.08 25.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.944 -1.262 . . . . 0.19 109.944 178.231 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.68 152.93 29.58 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.79 -0.829 . . . . 1.3899999999999999 110.138 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.28 21.4 2.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.652 -0.655 . . . . 0.81999999999999995 112.095 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.1 20.6 79.66 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.684 -1.246 . . . . 0.19 110.832 171.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.0 m -77.96 144.56 36.67 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.388 -1.066 . . . . 1.3 110.343 -176.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.735 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.64 146.51 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.881 -0.512 . . . . 0.20999999999999999 109.684 175.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -110.53 123.21 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.51 -0.744 . . . . 0.34000000000000002 110.783 -175.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.5 mt -78.27 144.37 66.54 Favored Pre-proline 0 N--CA 1.498 1.938 0 O-C-N 121.637 -0.664 . . . . 0.34000000000000002 109.494 172.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.17 133.82 39.74 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 O-C-N 122.98 0.99 . . . . 0.26000000000000001 110.796 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -55.21 -34.23 63.75 Favored 'General case' 0 N--CA 1.502 2.171 0 O-C-N 121.481 -0.762 . . . . 2.6200000000000001 110.768 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.408 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -37.99 77.7 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.797 -0.564 . . . . 0.45000000000000001 110.275 -178.497 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.1 mt -77.13 -32.66 56.56 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 120.151 -0.62 . . . . 1.8200000000000001 110.593 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.01 -46.33 85.44 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.349 -0.844 . . . . 2.5299999999999998 109.771 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.91 -46.51 65.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 120.543 -0.463 . . . . 1.6799999999999999 110.401 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 67' ' ' ALA . 96.5 t -60.58 -38.81 79.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.692 -0.63 . . . . 0.28000000000000003 109.843 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.549 HG22 HD11 ' A' ' 74' ' ' ILE . 82.4 mt -82.64 -16.63 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.845 -0.535 . . . . 0.28000000000000003 111.083 -176.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.24 35.18 43.86 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 109.878 -1.289 . . . . 0.22 109.878 176.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.6 142.86 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.056 0 O-C-N 121.519 -0.989 . . . . 0.77000000000000002 110.63 -174.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.0 ptmt -130.27 162.35 54.83 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.801 -0.562 . . . . 3.21 110.644 -178.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.51 135.55 68.37 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 O-C-N 122.946 0.971 . . . . 0.5 110.919 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.61 -0.35 70.51 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.612 -0.804 . . . . 0.23999999999999999 111.264 176.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -94.73 130.29 41.31 Favored 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 118.741 1.271 . . . . 1.1100000000000001 109.849 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 79' ' ' VAL . 11.2 p -91.92 129.9 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 121.527 0.679 . . . . 0.23999999999999999 110.809 -175.31 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -118.79 159.39 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 109.418 -0.586 . . . . 0.17999999999999999 109.418 177.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -97.91 131.91 43.96 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.017 -0.735 . . . . 1.1399999999999999 109.017 174.571 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.826 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.9 t -116.2 129.72 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.355 0.598 . . . . 0.20000000000000001 110.301 -170.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.6 mt -115.85 130.11 56.7 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 109.208 -0.664 . . . . 0.25 109.208 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.939 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.29 140.55 36.13 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.345 -0.847 . . . . 0.28000000000000003 109.803 172.411 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.8 mt -111.37 -33.1 6.51 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.649 -0.657 . . . . 1.6000000000000001 110.97 -176.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.21 -175.79 38.14 Favored Glycine 0 N--CA 1.504 3.181 0 C-N-CA 119.689 -1.244 . . . . 0.20000000000000001 111.089 -176.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -144.25 154.26 42.9 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.728 -0.866 . . . . 1.8899999999999999 110.624 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -141.05 147.95 39.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.80000000000000004 110.21 176.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 10.2 pttt -123.77 154.85 67.21 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.621 -0.674 . . . . 2.9900000000000002 110.253 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -56.38 140.79 89.28 Favored 'Trans proline' 0 N--CA 1.496 1.639 0 O-C-N 123.182 1.096 . . . . 1.6799999999999999 110.868 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -73.34 146.77 44.99 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.706 -0.621 . . . . 6.8700000000000001 110.121 178.687 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 43.5 p-10 . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.044 -0.979 . . . . 6.4699999999999998 110.342 179.829 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.0 ttp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 120.995 0.426 . . . . 2.7599999999999998 110.196 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -75.79 144.29 41.46 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.76 -0.587 . . . . 1.7 110.025 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.1 p -127.75 137.82 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.75 -0.594 . . . . 0.40999999999999998 109.626 178.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.6 mt -86.67 -18.5 31.12 Favored 'General case' 0 N--CA 1.496 1.827 0 C-N-CA 120.164 -0.614 . . . . 0.37 110.574 -178.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.831 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.69 155.69 3.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.251 -0.905 . . . . 0.26000000000000001 109.518 175.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.8 tttt -134.76 124.66 25.54 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.696 -0.627 . . . . 2.2999999999999998 110.117 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.0 p90 -150.82 163.66 38.09 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.621 -0.674 . . . . 0.20000000000000001 110.898 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -114.05 138.0 50.97 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.623 -0.673 . . . . 1.99 110.34 -177.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.39 162.31 41.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.66 -0.65 . . . . 0.17999999999999999 109.648 177.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -109.64 160.47 16.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.367 -0.833 . . . . 0.17000000000000001 110.264 177.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.869 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.2 t -78.92 137.37 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.843 -0.536 . . . . 0.48999999999999999 110.289 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.82 171.97 7.55 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.286 0.565 . . . . 0.68000000000000005 109.628 174.54 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.1 mtt-85 -46.37 152.54 0.43 Allowed 'General case' 0 N--CA 1.506 2.354 0 O-C-N 121.509 -0.745 . . . . 2.96 111.999 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.8 mt 62.62 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.673 0 O-C-N 121.536 -0.727 . . . . 0.41999999999999998 112.604 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.78 16.1 80.45 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.901 -1.125 . . . . 0.23999999999999999 110.335 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.9 ttp180 -85.16 144.85 27.93 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.269 -1.136 . . . . 1.96 110.28 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 pt -133.3 154.76 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.706 -0.621 . . . . 0.29999999999999999 109.398 172.179 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.7 127.77 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.563 -0.711 . . . . 0.25 110.034 176.561 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 38.2 mt -79.9 144.18 59.16 Favored Pre-proline 0 N--CA 1.495 1.824 0 C-N-CA 120.087 -0.645 . . . . 0.23000000000000001 109.479 176.05 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.38 143.52 88.87 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 122.927 0.961 . . . . 0.34999999999999998 109.724 174.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.56 61.28 Favored 'General case' 0 N--CA 1.497 1.895 0 C-N-CA 120.391 -0.523 . . . . 0.33000000000000002 110.56 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.55 -44.5 95.03 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.848 -1.301 . . . . 0.39000000000000001 109.848 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.1 m -69.94 -38.13 76.07 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.662 -0.905 . . . . 0.39000000000000001 110.09 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.61 73.24 Favored 'General case' 0 N--CA 1.514 2.741 0 O-C-N 121.26 -0.9 . . . . 0.40000000000000002 109.385 176.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -64.95 -49.78 69.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.184 0.516 . . . . 2.9700000000000002 110.133 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -57.24 -38.45 73.83 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.704 -0.622 . . . . 0.67000000000000004 110.727 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.8 t80 -88.09 -14.43 38.87 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.756 -0.59 . . . . 1.4399999999999999 111.216 -177.037 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.77 42.81 24.91 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.529 -1.429 . . . . 0.31 109.529 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 56' ' ' VAL . 75.6 mt -87.26 128.32 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.481 -1.011 . . . . 0.41999999999999998 110.644 -176.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -127.85 158.85 36.63 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.115 -0.698 . . . . 1.8200000000000001 109.115 170.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -57.3 138.51 54.72 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.329 -0.857 . . . . 1.99 110.522 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.88 -15.89 62.44 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 110.873 -0.891 . . . . 0.19 110.873 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -76.95 155.61 32.59 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-N 118.71 1.255 . . . . 1.1200000000000001 110.0 177.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 90' ' ' PRO . 76.3 m-85 -110.72 138.83 46.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.636 -0.665 . . . . 0.20999999999999999 109.646 174.302 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.57 154.05 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.262 -0.644 . . . . 0.14999999999999999 109.262 175.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -115.45 123.42 48.54 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.279 -1.008 . . . . 1.0900000000000001 108.279 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.82 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.4 tt -139.87 158.45 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 C-N-CA 119.69 -0.804 . . . . 0.14000000000000001 110.861 -167.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.577 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.6 ttpt -133.03 146.06 51.38 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.767 -0.583 . . . . 1.1100000000000001 110.577 177.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.627 HG22 HG22 ' A' ' 82' ' ' VAL . 26.8 pt -114.88 151.07 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.63 -0.669 . . . . 0.20000000000000001 110.333 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.629 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.92 125.04 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-O 121.133 0.492 . . . . 0.20000000000000001 109.71 176.528 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.708 ' HB2' HG22 ' A' ' 80' ' ' ILE . 39.1 tptt -135.17 147.58 49.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.763 -0.585 . . . . 1.98 109.655 177.069 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -106.15 129.88 54.14 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 120.233 -0.587 . . . . 0.33000000000000002 110.33 -177.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -138.25 138.15 38.19 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.585 -0.697 . . . . 1.48 110.238 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.75 -128.13 45.93 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.891 -1.284 . . . . 0.40999999999999998 109.891 -178.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.24 7.18 33.44 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.763 -0.845 . . . . 1.27 111.851 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -131.27 138.54 33.06 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.181 -0.949 . . . . 1.3700000000000001 111.17 -177.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.45 142.43 26.52 Favored 'Trans proline' 0 N--CA 1.482 0.82 0 O-C-N 122.861 0.927 . . . . 0.34000000000000002 110.108 172.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.8 mmtt -117.62 137.31 52.71 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.522 -0.736 . . . . 1.1000000000000001 109.716 171.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.629 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -135.05 166.4 23.14 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.662 -0.649 . . . . 1.4199999999999999 110.747 -176.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.62 135.64 4.34 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.53 -1.428 . . . . 0.17000000000000001 109.53 177.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.577 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -123.03 136.43 54.83 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.711 -0.876 . . . . 0.20999999999999999 109.73 176.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.818 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.1 p90 -155.43 173.29 16.88 Favored 'General case' 0 N--CA 1.497 1.899 0 C-N-CA 119.956 -0.698 . . . . 0.16 111.014 178.571 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.0 140.57 39.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.619 -0.675 . . . . 0.13 109.525 173.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.818 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.86 146.5 35.89 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.709 -0.619 . . . . 0.14000000000000001 110.613 -175.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -93.48 145.18 24.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.757 -0.589 . . . . 2.21 109.766 175.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.888 HG21 HG23 ' A' ' 29' ' ' ILE . 94.2 t -79.5 125.95 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.744 -0.597 . . . . 0.17000000000000001 109.908 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.05 -167.37 25.96 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.992 -1.243 . . . . 0.19 109.992 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -61.68 153.45 28.12 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.67 -0.9 . . . . 1.3899999999999999 110.148 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 53.71 21.09 2.48 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.53 -0.731 . . . . 0.81999999999999995 111.984 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.14 20.55 79.98 Favored Glycine 0 N--CA 1.499 2.853 0 C-N-CA 119.804 -1.188 . . . . 0.19 110.876 171.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.414 ' HA ' HD13 ' A' ' 18' ' ' ILE . 12.4 t -78.64 144.62 35.24 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.455 -1.027 . . . . 1.3 110.294 -176.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.43 145.79 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 N-CA-C 109.577 -0.527 . . . . 0.20999999999999999 109.577 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.1 mm -111.39 123.84 67.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.546 -0.721 . . . . 0.34000000000000002 110.685 -175.408 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 81.2 mt -78.16 145.0 68.14 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.602 -0.686 . . . . 0.34000000000000002 109.458 172.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.14 134.45 42.63 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 O-C-N 122.957 0.977 . . . . 0.26000000000000001 110.68 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -55.21 -34.28 63.79 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.437 -0.789 . . . . 2.6200000000000001 110.797 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -37.8 77.39 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.659 -0.651 . . . . 0.45000000000000001 110.322 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.2 mt -77.12 -32.7 56.65 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.18 -0.608 . . . . 1.8200000000000001 110.579 178.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.7 mtt180 -57.94 -46.1 85.57 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.297 -0.877 . . . . 2.5299999999999998 109.944 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.01 63.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.52 -0.472 . . . . 1.6799999999999999 110.385 -175.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.59 -38.18 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.678 -0.639 . . . . 0.28000000000000003 109.943 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.22 -18.12 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.855 -0.528 . . . . 0.28000000000000003 110.817 -176.699 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.92 35.05 40.49 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.648 -1.381 . . . . 0.22 109.648 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.869 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -91.69 142.58 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.592 -0.946 . . . . 0.77000000000000002 110.549 -174.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.67 161.41 61.16 Favored Pre-proline 0 N--CA 1.498 1.944 0 O-C-N 121.782 -0.574 . . . . 3.21 110.735 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.49 137.31 79.64 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.937 0.967 . . . . 0.5 111.033 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.08 72.33 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 111.166 -0.774 . . . . 0.23999999999999999 111.166 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -94.17 130.17 40.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-N 118.692 1.246 . . . . 1.1100000000000001 110.202 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 79' ' ' VAL . 10.8 p -91.74 128.86 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 CA-C-O 121.444 0.64 . . . . 0.23999999999999999 110.759 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.708 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.9 pt -118.3 159.43 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 109.459 -0.571 . . . . 0.17999999999999999 109.459 178.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.4 tt0 -97.95 129.96 44.83 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.909 -0.774 . . . . 1.1399999999999999 108.909 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.82 ' CG1' HD11 ' A' ' 37' ' ' ILE . 94.7 t -115.18 129.29 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.288 0.566 . . . . 0.20000000000000001 110.303 -170.499 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.7 mt -115.66 128.43 55.9 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 109.167 -0.679 . . . . 0.25 109.167 179.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.2 mt -79.78 138.5 37.28 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.39 -0.819 . . . . 0.28000000000000003 109.542 171.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -109.91 -31.29 7.46 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.723 -0.611 . . . . 1.6000000000000001 110.968 -174.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.12 -177.33 39.25 Favored Glycine 0 N--CA 1.503 3.12 0 C-N-CA 119.672 -1.251 . . . . 0.20000000000000001 111.039 -177.008 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -143.54 152.43 41.43 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.707 -0.878 . . . . 1.8899999999999999 110.648 -177.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -133.75 138.88 46.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.468 -0.77 . . . . 0.80000000000000004 110.356 176.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.0 mttt -115.74 110.1 44.75 Favored Pre-proline 0 N--CA 1.495 1.801 0 O-C-N 121.832 -0.543 . . . . 2.9900000000000002 110.161 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.436 ' HG3' ' CD1' ' A' ' 34' ' ' PHE . 85.1 Cg_exo -54.33 146.82 49.1 Favored 'Trans proline' 0 N--CA 1.499 1.802 0 O-C-N 123.033 1.018 . . . . 1.6799999999999999 111.165 -179.658 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.4 ttt180 -123.48 141.94 51.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.714 -0.616 . . . . 6.8700000000000001 110.154 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 47.8 t30 . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 118.038 -0.982 . . . . 6.4699999999999998 110.18 -179.862 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.7 mtp . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.308 0.575 . . . . 2.7599999999999998 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -73.35 146.91 44.86 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.776 -0.577 . . . . 1.7 109.973 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.408 HG23 ' HB3' ' A' ' 83' ' ' LEU . 3.2 p -128.15 135.78 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 O-C-N 121.815 -0.553 . . . . 0.40999999999999998 109.595 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.619 HD11 ' HA2' ' A' ' 86' ' ' GLY . 24.7 mt -82.51 -20.85 35.93 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.816 -0.553 . . . . 0.37 110.195 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.86 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -170.69 152.56 3.81 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.459 -0.776 . . . . 0.26000000000000001 109.199 175.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.6 tttt -133.92 125.1 27.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.2999999999999998 110.293 -175.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.618 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.99 162.55 40.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.651 -0.655 . . . . 0.20000000000000001 110.925 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 75.1 m80 -111.94 138.49 48.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.582 -0.698 . . . . 1.99 110.188 -176.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.59 162.34 41.15 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.694 -0.629 . . . . 0.17999999999999999 109.701 177.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.3 t -110.83 160.21 16.96 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.461 -0.774 . . . . 0.17000000000000001 109.83 176.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.886 HG21 ' CG2' ' A' ' 74' ' ' ILE . 61.4 t -77.65 137.47 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.754 -0.591 . . . . 0.48999999999999999 110.169 -177.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.3 m80 -116.14 171.99 7.45 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.66 -0.496 . . . . 0.68000000000000005 109.66 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -46.02 151.53 0.47 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.639 -0.663 . . . . 2.96 112.122 -174.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.606 -0.684 . . . . 0.41999999999999998 112.639 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.96 80.63 Favored Glycine 0 N--CA 1.498 2.801 0 N-CA-C 110.322 -1.111 . . . . 0.23999999999999999 110.322 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -85.34 145.52 27.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.96 110.211 -177.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -134.36 154.68 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.626 -0.671 . . . . 0.29999999999999999 109.476 172.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -117.19 127.99 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.57 -0.706 . . . . 0.25 110.031 176.622 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.25 144.98 59.15 Favored Pre-proline 0 N--CA 1.496 1.834 0 C-N-CA 120.038 -0.665 . . . . 0.23000000000000001 109.491 175.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -63.44 143.44 88.34 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 O-C-N 123.023 1.012 . . . . 0.34999999999999998 109.776 174.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.39 -26.57 61.27 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.845 -0.534 . . . . 0.33000000000000002 110.495 -178.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.45 -44.37 95.36 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.932 -1.267 . . . . 0.39000000000000001 109.932 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 83.9 m -70.22 -38.0 75.16 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.592 -0.946 . . . . 0.39000000000000001 110.13 -179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.86 -41.23 74.04 Favored 'General case' 0 N--CA 1.514 2.775 0 O-C-N 121.263 -0.898 . . . . 0.40000000000000002 109.342 176.296 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -65.41 -49.24 69.95 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.048 0.451 . . . . 2.9700000000000002 110.287 -178.2 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.34 -38.42 74.07 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.787 -0.57 . . . . 0.67000000000000004 110.781 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.9 t80 -87.58 -14.22 40.74 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.817 -0.552 . . . . 1.4399999999999999 111.257 -177.213 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.12 42.79 23.24 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.522 -1.431 . . . . 0.31 109.522 178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.906 HG23 HG21 ' A' ' 56' ' ' VAL . 77.0 mt -87.44 129.67 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.511 -0.993 . . . . 0.41999999999999998 110.574 -177.163 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.42 155.46 43.62 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 109.077 -0.712 . . . . 1.8200000000000001 109.077 171.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -55.45 137.44 48.27 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.256 -0.903 . . . . 1.99 110.794 -177.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.69 -14.66 64.91 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.91 -0.876 . . . . 0.19 110.91 178.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -76.26 155.55 34.25 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 118.848 1.324 . . . . 1.1200000000000001 109.907 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -109.33 138.24 45.98 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.518 -0.739 . . . . 0.20999999999999999 109.508 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.73 154.85 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.263 -0.643 . . . . 0.14999999999999999 109.263 175.33 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -115.95 122.95 46.79 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.277 -1.008 . . . . 1.0900000000000001 108.277 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.85 HD11 ' CG1' ' A' ' 82' ' ' VAL . 13.1 tt -139.37 157.83 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.7 -0.8 . . . . 0.14000000000000001 110.87 -167.695 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -132.83 146.03 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.814 -0.554 . . . . 1.1100000000000001 110.518 178.015 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.553 ' HB ' HD12 ' A' ' 80' ' ' ILE . 31.3 pt -114.95 150.93 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.663 -0.648 . . . . 0.20000000000000001 110.51 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.458 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.18 126.54 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-O 121.085 0.469 . . . . 0.20000000000000001 109.765 176.472 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.7 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.1 tttp -133.35 146.33 51.2 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.798 -0.564 . . . . 1.98 109.57 174.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -105.43 126.38 52.05 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.133 -0.627 . . . . 0.33000000000000002 110.151 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -139.71 141.21 36.94 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.664 . . . . 1.48 110.408 178.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.22 46.01 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.731 -1.348 . . . . 0.40999999999999998 109.731 -177.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -105.08 5.25 32.29 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.734 -0.862 . . . . 1.27 111.872 178.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.3 140.32 38.14 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.097 -1.002 . . . . 1.3700000000000001 111.262 -176.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -75.44 138.28 21.82 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 O-C-N 122.864 0.928 . . . . 0.34000000000000002 109.992 171.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' A' ' 72' ' ' ILE . 17.1 mmtp -111.97 137.65 49.68 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.529 -0.732 . . . . 1.1000000000000001 109.583 172.269 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.458 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.17 164.86 26.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.582 -0.698 . . . . 1.4199999999999999 110.773 -175.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.451 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.26 135.94 4.42 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.58 -1.408 . . . . 0.17000000000000001 109.58 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.2 m -123.28 137.39 54.87 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.733 -0.863 . . . . 0.20999999999999999 109.695 176.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.9 p90 -156.23 173.09 17.36 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.845 -0.742 . . . . 0.16 111.037 176.744 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.6 m -107.47 141.02 39.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.668 -0.645 . . . . 0.13 109.5 173.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.92 145.95 35.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.717 -0.614 . . . . 0.14000000000000001 110.45 -176.038 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -93.72 144.23 25.59 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.749 -0.594 . . . . 2.21 109.687 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.906 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -78.82 125.98 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.267 0.556 . . . . 0.17000000000000001 110.009 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.37 -169.9 25.81 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.848 -1.301 . . . . 0.19 109.848 177.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -61.81 155.82 22.13 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.707 -0.878 . . . . 1.3899999999999999 109.913 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.06 19.34 2.71 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.486 -0.759 . . . . 0.81999999999999995 112.018 -177.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.56 20.59 79.58 Favored Glycine 0 N--CA 1.499 2.839 0 C-N-CA 119.813 -1.184 . . . . 0.19 110.66 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 32.4 t -78.4 144.72 35.65 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.437 -1.037 . . . . 1.3 110.479 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.75 146.27 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 109.637 -0.505 . . . . 0.20999999999999999 109.637 175.062 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -111.79 123.97 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.6 -0.688 . . . . 0.34000000000000002 110.655 -175.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.7 mt -78.33 143.47 64.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.612 -0.68 . . . . 0.34000000000000002 109.477 172.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.79 136.81 50.92 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 O-C-N 122.982 0.991 . . . . 0.26000000000000001 110.814 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.1 tptt -54.91 -34.46 63.14 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.395 -0.816 . . . . 2.6200000000000001 110.714 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.46 79.15 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.789 -0.569 . . . . 0.45000000000000001 110.287 -178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.9 mt -77.18 -32.82 56.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.742 -0.599 . . . . 1.8200000000000001 110.656 179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -58.35 -45.24 88.56 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.265 -0.897 . . . . 2.5299999999999998 109.91 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.14 -47.41 61.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.55 -0.46 . . . . 1.6799999999999999 110.408 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.1 t -60.54 -38.08 77.1 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 121.666 -0.646 . . . . 0.28000000000000003 109.845 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.705 HG23 ' HB3' ' A' ' 48' ' ' LYS . 79.1 mt -82.6 -17.74 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.84 -0.537 . . . . 0.28000000000000003 110.829 -176.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.06 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.621 -1.392 . . . . 0.22 109.621 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.886 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -93.71 141.86 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.558 -0.966 . . . . 0.77000000000000002 110.728 -174.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.67 162.4 56.46 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.757 -0.589 . . . . 3.21 110.691 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -51.88 135.86 51.01 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.025 1.013 . . . . 0.5 111.807 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.08 -1.92 71.06 Favored Glycine 0 N--CA 1.497 2.702 0 C-N-CA 120.72 -0.752 . . . . 0.23999999999999999 111.431 174.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -96.4 131.53 42.87 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-N 118.74 1.27 . . . . 1.1100000000000001 110.64 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.26 132.95 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.607 0.718 . . . . 0.23999999999999999 111.229 -173.246 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.7 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.72 159.52 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.948 -0.47 . . . . 0.17999999999999999 109.757 177.217 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -97.59 130.94 44.59 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.891 -0.781 . . . . 1.1399999999999999 108.891 174.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.85 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.0 t -114.41 129.48 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.803 -0.56 . . . . 0.20000000000000001 110.207 -171.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.408 ' HB3' HG23 ' A' ' 3' ' ' VAL . 38.2 mt -118.09 128.78 55.07 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.113 -0.699 . . . . 0.25 109.113 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -79.79 140.45 36.87 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.305 -0.872 . . . . 0.28000000000000003 109.757 172.256 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.49 -33.51 6.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.718 -0.614 . . . . 1.6000000000000001 110.887 -175.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.619 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.63 -172.97 36.03 Favored Glycine 0 N--CA 1.502 3.094 0 C-N-CA 119.778 -1.201 . . . . 0.20000000000000001 110.942 -176.643 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -142.88 159.0 43.07 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.706 -0.879 . . . . 1.8899999999999999 110.655 -177.407 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 -141.92 147.36 36.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.683 . . . . 0.80000000000000004 110.322 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -119.48 160.03 43.48 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.656 -0.653 . . . . 2.9900000000000002 110.167 178.071 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -54.59 142.76 71.01 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 O-C-N 123.158 1.083 . . . . 1.6799999999999999 111.02 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 15.7 tpt180 -127.54 141.44 51.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.725 -0.609 . . . . 6.8700000000000001 110.259 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 33.7 t30 . . . . . 0 N--CA 1.503 2.197 0 CA-C-O 118.022 -0.989 . . . . 6.4699999999999998 110.997 179.988 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mtm . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.2 0.524 . . . . 2.7599999999999998 110.624 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -74.26 143.86 44.87 Favored 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 120.505 -0.478 . . . . 1.7 110.081 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 p -128.06 137.22 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.738 -0.601 . . . . 0.40999999999999998 109.605 178.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.0 mt -84.16 -19.92 33.3 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.738 -0.601 . . . . 0.37 110.398 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.873 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.32 153.93 3.76 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.362 -0.836 . . . . 0.26000000000000001 109.427 176.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.6 tttt -133.75 125.24 28.11 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.679 -0.638 . . . . 2.2999999999999998 110.128 -177.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.609 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.9 163.12 39.43 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.627 -0.67 . . . . 0.20000000000000001 110.871 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.44 138.93 49.38 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.706 -0.621 . . . . 1.99 110.376 -176.567 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.28 162.3 41.15 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.653 -0.655 . . . . 0.17999999999999999 109.717 177.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.2 t -111.4 159.69 17.78 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.427 -0.796 . . . . 0.17000000000000001 109.917 175.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 57.5 t -77.56 138.64 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 120.302 -0.559 . . . . 0.48999999999999999 110.275 -176.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -118.31 172.01 7.75 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.583 -0.525 . . . . 0.68000000000000005 109.583 174.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -46.28 152.57 0.41 Allowed 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.574 -0.704 . . . . 2.96 112.014 -175.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.75 7.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.607 0 O-C-N 121.58 -0.7 . . . . 0.41999999999999998 112.61 -175.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.47 16.12 80.68 Favored Glycine 0 N--CA 1.497 2.7 0 O-C-N 120.901 -1.124 . . . . 0.23999999999999999 110.327 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.8 ttp180 -84.88 145.96 27.54 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.294 -1.121 . . . . 1.96 110.247 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -133.08 154.85 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 109.284 -0.636 . . . . 0.29999999999999999 109.284 171.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -115.1 128.04 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 120.039 -0.664 . . . . 0.25 110.054 176.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.0 mt -79.98 144.63 59.69 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.048 -0.661 . . . . 0.23000000000000001 109.424 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -62.87 142.6 89.16 Favored 'Trans proline' 0 N--CA 1.488 1.2 0 O-C-N 122.971 0.985 . . . . 0.34999999999999998 109.871 174.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.64 -27.36 62.74 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 120.401 -0.519 . . . . 0.33000000000000002 110.478 -178.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.54 -43.99 95.78 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.902 -1.279 . . . . 0.39000000000000001 109.902 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.2 m -70.12 -38.0 75.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.608 -0.937 . . . . 0.39000000000000001 109.914 -179.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.82 -40.94 73.49 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 121.233 -0.917 . . . . 0.40000000000000002 109.436 176.419 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -65.27 -50.08 67.14 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.14 0.495 . . . . 2.9700000000000002 110.131 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.4 -38.43 74.28 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.786 -0.571 . . . . 0.67000000000000004 110.756 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.5 t80 -87.4 -14.25 41.12 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.821 -0.549 . . . . 1.4399999999999999 111.343 -176.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.93 42.76 24.28 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 109.581 -1.408 . . . . 0.31 109.581 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 75.5 mt -87.63 128.45 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.57 -0.959 . . . . 0.41999999999999998 110.559 -177.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.95 158.38 38.01 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.943 -0.762 . . . . 1.8200000000000001 108.943 170.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -57.4 140.18 51.04 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.342 -0.849 . . . . 1.99 110.465 -178.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -16.07 61.71 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.828 -0.909 . . . . 0.19 110.828 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.74 157.72 31.47 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.094 -1.239 . . . . 1.1200000000000001 110.146 178.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -111.92 138.76 48.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.569 -0.707 . . . . 0.20999999999999999 109.579 174.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 154.75 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 120.15 -0.62 . . . . 0.14999999999999999 109.354 174.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -115.58 123.72 49.17 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.303 -0.999 . . . . 1.0900000000000001 108.303 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.837 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.9 158.79 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.754 -0.778 . . . . 0.14000000000000001 110.982 -167.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.408 ' HB2' HD12 ' A' ' 85' ' ' LEU . 30.2 tttt -133.33 146.21 51.12 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.885 -0.509 . . . . 1.1100000000000001 110.29 177.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.542 HG22 HG22 ' A' ' 82' ' ' VAL . 21.2 pt -114.82 150.94 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.716 -0.615 . . . . 0.20000000000000001 110.302 178.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.99 123.84 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.181 0.515 . . . . 0.20000000000000001 109.678 177.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 46.7 tttp -132.76 146.97 52.29 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.357 -0.609 . . . . 1.98 109.357 175.008 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -102.09 129.73 48.5 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.957 -0.697 . . . . 0.33000000000000002 110.41 -178.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.21 134.43 40.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.682 -0.636 . . . . 1.48 110.048 178.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.9 -128.16 45.8 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.838 -1.305 . . . . 0.40999999999999998 109.838 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 17.8 pt-20 -105.15 9.8 34.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.706 -0.879 . . . . 1.27 111.791 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.15 138.4 32.81 Favored Pre-proline 0 N--CA 1.498 1.936 0 O-C-N 121.301 -0.875 . . . . 1.3700000000000001 110.961 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -75.18 138.7 22.94 Favored 'Trans proline' 0 N--CA 1.482 0.852 0 O-C-N 122.854 0.923 . . . . 0.34000000000000002 110.298 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 41.2 mmtt -109.48 137.72 46.9 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.554 -0.716 . . . . 1.1000000000000001 109.456 172.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.6 163.22 30.62 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.62 -0.675 . . . . 1.4199999999999999 110.93 -176.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.08 135.93 4.43 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.549 -1.421 . . . . 0.17000000000000001 109.549 177.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.5 m -123.23 138.2 54.69 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.568 -0.96 . . . . 0.20999999999999999 109.841 176.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -156.15 173.17 17.23 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.975 -0.69 . . . . 0.16 110.955 176.504 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -107.36 141.27 38.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.718 -0.614 . . . . 0.13 109.479 173.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.17 146.22 36.69 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 120.212 -0.595 . . . . 0.14000000000000001 110.73 -175.503 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -93.01 145.13 24.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.811 -0.556 . . . . 2.21 109.59 175.195 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 90.5 t -79.47 125.8 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.827 -0.546 . . . . 0.17000000000000001 109.779 179.368 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.1 -170.38 27.25 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.707 -1.357 . . . . 0.19 109.707 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -61.84 155.75 22.4 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.644 -0.915 . . . . 1.3899999999999999 109.961 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 54.87 19.64 2.71 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.569 -0.707 . . . . 0.81999999999999995 112.008 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.18 20.55 79.97 Favored Glycine 0 N--CA 1.499 2.837 0 C-N-CA 119.793 -1.194 . . . . 0.19 110.816 172.309 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.6 m -77.91 144.04 37.21 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.46 -1.024 . . . . 1.3 110.288 -176.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.22 145.93 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.751 -0.593 . . . . 0.20999999999999999 109.596 175.392 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -111.4 123.17 67.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.541 -0.725 . . . . 0.34000000000000002 110.699 -174.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 77.3 mt -78.62 143.87 64.07 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.532 -0.73 . . . . 0.34000000000000002 109.429 172.042 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.754 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.1 Cg_endo -65.1 136.68 49.03 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 O-C-N 122.926 0.961 . . . . 0.26000000000000001 110.757 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 43.2 tttm -55.07 -34.17 63.36 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.48 -0.763 . . . . 2.6200000000000001 110.774 179.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.11 78.34 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.711 -0.618 . . . . 0.45000000000000001 110.288 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.754 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.9 mt -77.15 -32.76 56.52 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 120.208 -0.597 . . . . 1.8200000000000001 110.519 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -58.29 -45.46 87.91 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.305 -0.872 . . . . 2.5299999999999998 109.845 178.099 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.03 -46.53 64.87 Favored 'General case' 0 N--CA 1.496 1.857 0 C-N-CA 120.476 -0.489 . . . . 1.6799999999999999 110.457 -175.163 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.7 t -60.45 -38.48 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 C-N-CA 120.168 -0.613 . . . . 0.28000000000000003 109.945 -178.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.56 -17.51 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.803 -0.561 . . . . 0.28000000000000003 110.876 -177.164 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.69 35.13 41.54 Favored Glycine 0 N--CA 1.497 2.742 0 N-CA-C 109.768 -1.333 . . . . 0.22 109.768 176.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.0 mm -93.19 142.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.613 -0.934 . . . . 0.77000000000000002 110.721 -174.012 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.49 162.17 57.69 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.724 -0.61 . . . . 3.21 110.309 178.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -56.51 138.11 83.16 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 O-C-N 122.817 0.904 . . . . 0.5 111.331 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 -2.63 71.83 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 120.696 -0.764 . . . . 0.23999999999999999 111.24 176.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -96.62 131.9 42.81 Favored 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 118.715 1.258 . . . . 1.1100000000000001 110.599 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.6 p -92.43 133.45 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 121.669 0.747 . . . . 0.23999999999999999 111.244 -173.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.8 pt -124.59 159.49 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 109.507 -0.553 . . . . 0.17999999999999999 109.507 176.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -98.88 132.24 44.37 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.029 -0.73 . . . . 1.1399999999999999 109.029 175.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 37' ' ' ILE . 92.8 t -115.9 131.6 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.754 -0.591 . . . . 0.20000000000000001 110.363 -170.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.9 mt -117.94 129.55 55.68 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.136 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -80.05 142.26 35.09 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.398 -0.814 . . . . 0.28000000000000003 109.798 171.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.408 HD12 ' HB2' ' A' ' 38' ' ' LYS . 15.6 mt -117.95 -26.72 6.36 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.701 -0.625 . . . . 1.6000000000000001 111.117 -174.434 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.78 40.58 Favored Glycine 0 N--CA 1.504 3.195 0 C-N-CA 119.66 -1.257 . . . . 0.20000000000000001 110.966 -176.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -146.45 150.76 36.24 Favored 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.669 -0.9 . . . . 1.8899999999999999 110.597 -178.147 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -135.74 139.06 43.31 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.475 -0.766 . . . . 0.80000000000000004 110.136 175.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.0 mttt -124.04 157.41 63.84 Favored Pre-proline 0 N--CA 1.494 1.773 0 O-C-N 121.716 -0.615 . . . . 2.9900000000000002 110.175 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -56.1 144.77 78.77 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 O-C-N 123.22 1.116 . . . . 1.6799999999999999 110.852 178.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -127.13 139.76 52.74 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.705 -0.622 . . . . 6.8700000000000001 110.221 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 . . . . . 0 N--CA 1.505 2.312 0 CA-C-O 117.97 -1.014 . . . . 6.4699999999999998 110.948 -179.98 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mtm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.246 0.545 . . . . 2.7599999999999998 110.571 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -77.52 141.18 39.75 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.876 -0.515 . . . . 1.7 110.058 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.95 135.85 61.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.71 -0.619 . . . . 0.40999999999999998 109.612 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.87 -20.79 34.84 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.298 -0.561 . . . . 0.37 110.312 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.858 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.52 153.68 3.56 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.423 -0.798 . . . . 0.26000000000000001 109.272 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.43 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.1 tttt -134.04 125.98 29.22 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.732 -0.605 . . . . 2.2999999999999998 110.177 -176.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.611 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.5 p90 -150.61 163.56 38.2 Favored 'General case' 0 N--CA 1.498 1.941 0 C-N-CA 120.052 -0.659 . . . . 0.20000000000000001 110.957 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.02 138.58 49.67 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.695 -0.628 . . . . 1.99 110.117 -176.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.35 162.31 41.14 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.727 -0.608 . . . . 0.17999999999999999 109.664 176.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -111.28 159.74 17.66 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.873 -0.731 . . . . 0.17000000000000001 109.983 176.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.895 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.8 t -78.82 134.09 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.803 -0.56 . . . . 0.48999999999999999 110.2 -177.092 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -113.77 171.89 7.31 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-O 121.214 0.53 . . . . 0.68000000000000005 109.751 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -46.57 152.82 0.42 Allowed 'General case' 0 N--CA 1.507 2.412 0 O-C-N 121.663 -0.648 . . . . 2.96 111.996 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.77 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.598 -0.689 . . . . 0.41999999999999998 112.576 -175.256 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.42 16.11 80.73 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.906 -1.121 . . . . 0.23999999999999999 110.332 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -85.57 143.99 28.16 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.231 -1.158 . . . . 1.96 110.418 -175.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.3 pt -133.68 154.49 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.701 -0.624 . . . . 0.29999999999999999 109.616 172.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.418 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.84 128.11 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.557 -0.715 . . . . 0.25 110.132 176.581 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 36.1 mt -80.04 144.86 59.82 Favored Pre-proline 0 N--CA 1.496 1.861 0 C-N-CA 120.026 -0.67 . . . . 0.23000000000000001 109.415 175.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.37 143.35 88.58 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 122.893 0.944 . . . . 0.34999999999999998 109.77 174.416 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.63 -26.49 61.65 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.416 -0.514 . . . . 0.33000000000000002 110.499 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.47 95.14 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.894 -1.282 . . . . 0.39000000000000001 109.894 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.2 m -69.97 -38.12 75.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.531 -0.982 . . . . 0.39000000000000001 110.193 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.707 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.5 mtt180 -55.92 -40.94 73.83 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.23 -0.918 . . . . 0.40000000000000002 109.454 176.342 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -65.61 -49.98 66.74 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.204 0.526 . . . . 2.9700000000000002 110.215 -177.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -57.49 -37.72 73.42 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.689 -0.632 . . . . 0.67000000000000004 110.668 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.3 t80 -87.67 -14.19 40.57 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.752 -0.593 . . . . 1.4399999999999999 111.287 -176.594 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.91 42.87 24.05 Favored Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.587 -1.405 . . . . 0.31 109.587 178.37 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.912 HG23 HG21 ' A' ' 56' ' ' VAL . 77.1 mt -88.1 129.73 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.068 0 O-C-N 121.552 -0.969 . . . . 0.41999999999999998 110.615 -176.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -127.9 158.71 37.06 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 109.079 -0.711 . . . . 1.8200000000000001 109.079 170.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -57.34 137.68 55.79 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.333 -0.854 . . . . 1.99 110.636 -178.468 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.57 -14.49 65.21 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.9 -0.88 . . . . 0.19 110.9 178.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.19 156.9 33.23 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 118.857 1.328 . . . . 1.1200000000000001 110.072 177.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -110.62 138.14 47.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.626 -0.671 . . . . 0.20999999999999999 109.517 174.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.62 154.27 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.247 -0.649 . . . . 0.14999999999999999 109.247 174.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.5 123.55 48.83 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.287 -1.005 . . . . 1.0900000000000001 108.287 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.833 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.09 157.16 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 119.611 -0.835 . . . . 0.14000000000000001 110.953 -167.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -132.2 145.99 51.72 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.846 -0.534 . . . . 1.1100000000000001 110.528 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.527 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.2 pt -115.3 151.14 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.726 -0.609 . . . . 0.20000000000000001 110.584 179.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.454 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.51 125.76 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.264 0.554 . . . . 0.20000000000000001 109.882 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.753 ' HB2' HG22 ' A' ' 80' ' ' ILE . 3.3 tptm -130.76 146.49 52.24 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.156 -0.683 . . . . 1.98 109.156 174.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -107.89 130.11 55.04 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.263 -0.575 . . . . 0.33000000000000002 110.471 -178.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -133.91 129.84 36.91 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.658 -0.651 . . . . 1.48 110.138 177.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.23 45.97 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.826 -1.309 . . . . 0.40999999999999998 109.826 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -105.12 14.62 28.88 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.716 -0.873 . . . . 1.27 111.649 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -131.14 126.69 21.65 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.296 -0.877 . . . . 1.3700000000000001 111.009 -178.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.23 140.18 24.56 Favored 'Trans proline' 0 N--CA 1.483 0.859 0 O-C-N 122.725 0.855 . . . . 0.34000000000000002 110.208 174.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.694 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.4 mmtt -114.69 137.73 51.56 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.564 -0.71 . . . . 1.1000000000000001 109.617 173.054 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.454 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -134.65 164.18 28.09 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.675 -0.641 . . . . 1.4199999999999999 110.775 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.78 135.91 4.46 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.484 -1.446 . . . . 0.17000000000000001 109.484 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -123.18 137.65 54.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.65 -0.912 . . . . 0.20999999999999999 109.784 176.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.7 p90 -156.13 172.89 17.66 Favored 'General case' 0 N--CA 1.498 1.932 0 C-N-CA 119.833 -0.747 . . . . 0.16 111.014 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.4 m -107.32 140.74 39.76 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.705 -0.622 . . . . 0.13 109.499 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.7 145.21 34.61 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.14000000000000001 110.585 -175.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -94.13 144.88 25.11 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.828 -0.545 . . . . 2.21 109.647 175.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.912 HG21 HG23 ' A' ' 29' ' ' ILE . 96.7 t -78.79 126.37 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.833 -0.542 . . . . 0.17000000000000001 110.015 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.86 -165.95 25.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.123 -1.191 . . . . 0.19 110.123 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -61.68 152.07 31.95 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.771 -0.841 . . . . 1.3899999999999999 110.201 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 73.7 mt-30 53.35 21.52 2.38 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.572 -0.705 . . . . 0.81999999999999995 112.062 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.54 20.48 79.84 Favored Glycine 0 N--CA 1.5 2.906 0 C-N-CA 119.777 -1.201 . . . . 0.19 110.866 171.332 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 13.3 t -78.34 144.67 35.81 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.468 -1.019 . . . . 1.3 110.25 -177.544 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.701 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.34 146.28 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 N-CA-C 109.55 -0.537 . . . . 0.20999999999999999 109.55 175.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.9 mm -110.68 122.78 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.609 -0.682 . . . . 0.34000000000000002 110.566 -174.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.6 mt -78.72 142.61 61.47 Favored Pre-proline 0 N--CA 1.498 1.975 0 O-C-N 121.589 -0.694 . . . . 0.34000000000000002 109.437 172.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.35 133.93 39.7 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 O-C-N 122.915 0.955 . . . . 0.26000000000000001 110.763 -179.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -55.28 -34.2 63.88 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.508 -0.745 . . . . 2.6200000000000001 110.832 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.7 76.78 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.783 -0.573 . . . . 0.45000000000000001 110.334 -178.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.3 mt -77.09 -32.73 56.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.779 -0.575 . . . . 1.8200000000000001 110.521 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -57.76 -46.13 84.96 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.275 -0.891 . . . . 2.5299999999999998 109.833 178.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -47.2 62.59 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.503 -0.479 . . . . 1.6799999999999999 110.502 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.2 t -60.48 -38.22 77.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.708 -0.62 . . . . 0.28000000000000003 109.962 -178.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.694 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.2 mt -82.58 -17.76 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.818 -0.551 . . . . 0.28000000000000003 110.884 -176.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.64 35.11 41.9 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 109.726 -1.35 . . . . 0.22 109.726 176.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.895 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.2 138.94 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.535 -0.979 . . . . 0.77000000000000002 110.591 -174.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.4 mmtt -123.75 161.23 47.53 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.665 -0.647 . . . . 3.21 110.531 -176.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -60.39 135.61 62.52 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 122.951 0.974 . . . . 0.5 110.677 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.89 -0.48 73.08 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 111.139 -0.784 . . . . 0.23999999999999999 111.139 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -97.17 132.95 42.44 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.063 -1.257 . . . . 1.1100000000000001 110.44 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.407 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.2 p -91.78 132.27 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 121.504 0.668 . . . . 0.23999999999999999 111.008 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.753 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.7 pt -119.59 159.42 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 109.531 -0.544 . . . . 0.17999999999999999 109.531 176.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -98.31 130.16 45.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.815 -0.809 . . . . 1.1399999999999999 108.815 173.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.833 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.1 t -115.32 130.22 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-O 121.292 0.568 . . . . 0.20000000000000001 110.27 -170.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.43 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.5 mt -116.71 129.53 56.18 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 109.136 -0.691 . . . . 0.25 109.136 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.8 mt -80.15 142.46 34.74 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.3 -0.875 . . . . 0.28000000000000003 109.694 171.784 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HA ' HD23 ' A' ' 85' ' ' LEU . 29.6 mt -119.5 -25.66 5.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.668 -0.645 . . . . 1.6000000000000001 111.183 -174.202 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.41 -179.22 40.13 Favored Glycine 0 N--CA 1.503 3.16 0 C-N-CA 119.643 -1.265 . . . . 0.20000000000000001 111.1 -177.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -146.96 152.91 39.41 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.669 -0.901 . . . . 1.8899999999999999 110.571 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -139.38 144.41 38.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.538 -0.726 . . . . 0.80000000000000004 110.159 176.203 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -114.34 154.97 46.35 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.622 -0.674 . . . . 2.9900000000000002 110.268 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -56.04 142.48 85.56 Favored 'Trans proline' 0 N--CA 1.498 1.747 0 O-C-N 123.299 1.157 . . . . 1.6799999999999999 110.89 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 -136.08 158.21 44.96 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.754 -0.591 . . . . 6.8700000000000001 110.435 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 . . . . . 0 N--CA 1.503 2.187 0 CA-C-O 117.992 -1.004 . . . . 6.4699999999999998 111.013 179.772 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.26 0.552 . . . . 2.7599999999999998 110.516 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -75.82 149.41 37.89 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.882 -0.511 . . . . 1.7 109.964 178.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -128.01 137.36 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.731 -0.606 . . . . 0.40999999999999998 109.566 178.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.515 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.3 mt -85.94 -20.12 29.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.781 -0.574 . . . . 0.37 110.523 -178.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.948 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.68 156.16 3.47 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.301 -0.875 . . . . 0.26000000000000001 109.436 176.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -134.26 124.2 25.51 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.777 -0.577 . . . . 2.2999999999999998 110.104 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.599 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.6 p90 -150.28 162.61 40.17 Favored 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 120.006 -0.678 . . . . 0.20000000000000001 111.047 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -112.39 138.57 48.93 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.582 -0.699 . . . . 1.99 110.074 -177.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.0 t -151.47 162.37 41.06 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.65 -0.656 . . . . 0.17999999999999999 109.741 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.42 158.42 19.12 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.857 -0.737 . . . . 0.17000000000000001 110.072 177.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.6 t -78.95 137.18 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 C-N-CA 120.279 -0.569 . . . . 0.48999999999999999 110.323 -176.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.2 m80 -116.2 171.91 7.51 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.298 0.57 . . . . 0.68000000000000005 109.734 174.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.5 ttt85 -46.92 153.02 0.45 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.492 -0.755 . . . . 2.96 111.76 -175.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.9 mt 62.93 6.93 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.684 0 O-C-N 121.507 -0.746 . . . . 0.41999999999999998 112.636 -174.052 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.67 16.03 80.63 Favored Glycine 0 N--CA 1.496 2.64 0 O-C-N 120.789 -1.194 . . . . 0.23999999999999999 110.294 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -84.94 144.48 28.31 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.317 -1.108 . . . . 1.96 110.352 -177.406 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -131.79 154.62 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.751 -0.593 . . . . 0.29999999999999999 109.41 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.7 mm -116.5 128.49 73.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.598 -0.689 . . . . 0.25 110.003 176.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.438 HG12 ' CE2' ' A' ' 7' ' ' PHE . 40.1 mt -79.99 145.42 61.24 Favored Pre-proline 0 N--CA 1.496 1.826 0 C-N-CA 119.968 -0.693 . . . . 0.23000000000000001 109.39 175.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.48 143.42 88.09 Favored 'Trans proline' 0 N--CA 1.489 1.206 0 O-C-N 122.936 0.966 . . . . 0.34999999999999998 109.706 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.48 61.47 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 120.41 -0.516 . . . . 0.33000000000000002 110.496 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.61 -44.48 94.98 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.862 -1.295 . . . . 0.39000000000000001 109.862 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 84.4 m -69.92 -38.11 76.12 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.599 -0.942 . . . . 0.39000000000000001 110.16 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -56.0 -40.74 73.79 Favored 'General case' 0 N--CA 1.513 2.696 0 O-C-N 121.289 -0.882 . . . . 0.40000000000000002 109.448 176.405 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -65.17 -50.06 67.41 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.086 0.469 . . . . 2.9700000000000002 110.058 -177.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.26 -38.77 74.38 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.854 -0.529 . . . . 0.67000000000000004 110.772 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.907 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.9 t80 -88.42 -14.29 38.37 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.753 -0.592 . . . . 1.4399999999999999 111.163 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.9 42.59 24.85 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.497 -1.441 . . . . 0.31 109.497 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.918 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.47 125.5 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.429 -1.042 . . . . 0.41999999999999998 110.455 -177.037 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -128.17 155.35 44.62 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.996 -0.742 . . . . 1.8200000000000001 108.996 171.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -55.5 140.15 41.43 Favored 'General case' 0 N--CA 1.503 2.179 0 O-C-N 121.289 -0.882 . . . . 1.99 110.576 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.82 -16.19 61.39 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.812 -0.915 . . . . 0.19 110.812 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -77.43 158.33 30.07 Favored 'General case' 0 N--CA 1.499 2.022 0 CA-C-N 118.72 1.26 . . . . 1.1200000000000001 110.042 177.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -113.18 139.19 48.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.604 -0.685 . . . . 0.20999999999999999 109.581 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.28 154.54 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.35 -0.611 . . . . 0.14999999999999999 109.35 174.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.431 ' HB2' ' CE2' ' A' ' 88' ' ' TYR . 48.9 tt0 -116.0 123.62 48.46 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.219 -1.03 . . . . 1.0900000000000001 108.219 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.823 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -139.16 157.99 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 C-N-CA 119.588 -0.845 . . . . 0.14000000000000001 111.213 -167.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.84 143.48 50.21 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.9 -0.5 . . . . 1.1100000000000001 109.951 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.6 HG22 HG22 ' A' ' 82' ' ' VAL . 35.0 pt -114.91 150.99 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.593 -0.692 . . . . 0.20000000000000001 110.527 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -138.4 123.19 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 CA-C-O 121.238 0.542 . . . . 0.20000000000000001 109.721 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.655 ' HB2' HG22 ' A' ' 80' ' ' ILE . 50.2 tttm -130.98 147.1 52.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.191 -0.67 . . . . 1.98 109.191 174.256 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -102.37 130.97 49.27 Favored 'General case' 0 N--CA 1.496 1.873 0 C-N-CA 119.968 -0.693 . . . . 0.33000000000000002 110.471 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -132.77 130.45 39.95 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.648 -0.657 . . . . 1.48 109.993 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.85 -128.08 45.68 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 109.79 -1.324 . . . . 0.40999999999999998 109.79 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -105.14 11.57 33.01 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.733 -0.863 . . . . 1.27 111.653 177.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.0 pt-20 -131.16 136.29 28.55 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.231 -0.918 . . . . 1.3700000000000001 110.815 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -75.16 141.18 25.89 Favored 'Trans proline' 0 N--CA 1.482 0.845 0 O-C-N 122.855 0.924 . . . . 0.34000000000000002 110.529 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.672 ' HB3' HG23 ' A' ' 72' ' ' ILE . 19.2 mmtp -111.63 137.73 49.1 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.462 -0.774 . . . . 1.1000000000000001 109.486 171.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.53 164.33 27.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.608 -0.682 . . . . 1.4199999999999999 110.929 -176.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.03 135.78 4.37 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.536 -1.425 . . . . 0.17000000000000001 109.536 177.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -127.55 137.05 52.5 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.793 -0.828 . . . . 0.20999999999999999 109.791 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.0 p90 -156.57 173.94 16.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 119.883 -0.727 . . . . 0.16 110.916 177.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.4 m -106.94 140.74 39.26 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.407 -0.59 . . . . 0.13 109.407 173.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.1 146.18 36.76 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.608 -0.683 . . . . 0.14000000000000001 110.69 -175.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -93.35 145.81 24.19 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 109.628 -0.508 . . . . 2.21 109.628 175.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.918 HG21 HG23 ' A' ' 29' ' ' ILE . 88.0 t -78.56 126.01 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.754 -0.591 . . . . 0.17000000000000001 109.858 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.0 -167.34 26.0 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.982 -1.247 . . . . 0.19 109.982 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.64 153.23 28.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.782 -0.834 . . . . 1.3899999999999999 110.151 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 53.51 21.12 2.34 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.579 -0.7 . . . . 0.81999999999999995 112.099 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.54 79.89 Favored Glycine 0 N--CA 1.499 2.892 0 C-N-CA 119.716 -1.231 . . . . 0.19 110.921 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.465 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -78.28 147.11 34.45 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.445 -1.032 . . . . 1.3 110.262 -177.298 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.686 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.82 145.99 26.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 109.548 -0.538 . . . . 0.20999999999999999 109.548 175.304 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -110.73 123.37 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.446 -0.784 . . . . 0.34000000000000002 110.738 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.3 mt -78.31 144.71 66.99 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.576 -0.703 . . . . 0.34000000000000002 109.452 172.031 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.7 Cg_endo -64.67 135.89 47.23 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 122.929 0.963 . . . . 0.26000000000000001 110.755 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.03 -34.36 63.44 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.499 -0.75 . . . . 2.6200000000000001 110.759 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -38.04 77.92 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.757 -0.589 . . . . 0.45000000000000001 110.317 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.1 mt -77.14 -32.79 56.58 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.734 -0.604 . . . . 1.8200000000000001 110.475 179.031 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.09 -45.66 86.82 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.319 -0.863 . . . . 2.5299999999999998 109.811 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.09 -47.25 62.64 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.515 -0.474 . . . . 1.6799999999999999 110.463 -175.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.6 t -60.52 -38.34 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.116 0 O-C-N 121.726 -0.609 . . . . 0.28000000000000003 109.916 -178.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.672 HG23 ' HB3' ' A' ' 48' ' ' LYS . 84.3 mt -82.38 -17.65 11.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.886 -0.509 . . . . 0.28000000000000003 110.917 -176.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.09 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.697 -1.361 . . . . 0.22 109.697 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.39 142.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.564 -0.962 . . . . 0.77000000000000002 110.707 -173.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.13 159.05 72.19 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.8 -0.562 . . . . 3.21 110.757 -178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -54.57 134.79 63.82 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 122.913 0.954 . . . . 0.5 111.414 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -0.94 72.17 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 120.696 -0.764 . . . . 0.23999999999999999 111.27 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.401 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 16.9 mt-10 -97.19 133.28 42.04 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.058 -1.26 . . . . 1.1100000000000001 110.552 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.3 p -92.98 136.35 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 CA-C-O 121.835 0.826 . . . . 0.23999999999999999 111.389 -174.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.655 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.3 pt -125.89 159.59 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.247 -0.649 . . . . 0.17999999999999999 109.247 177.259 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 52.4 tt0 -97.98 131.25 44.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.046 -0.724 . . . . 1.1399999999999999 109.046 175.389 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.823 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.3 t -117.06 130.7 71.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 CA-C-O 121.438 0.637 . . . . 0.20000000000000001 110.391 -170.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.8 mt -117.27 129.82 56.16 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.194 -0.669 . . . . 0.25 109.194 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.948 HD12 ' HB3' ' A' ' 5' ' ' ALA . 5.6 mt -80.08 140.75 36.33 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.36 -0.838 . . . . 0.28000000000000003 109.903 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.7 mt -111.5 -30.47 7.37 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.672 -0.642 . . . . 1.6000000000000001 111.011 -175.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.29 178.62 41.31 Favored Glycine 0 N--CA 1.505 3.254 0 C-N-CA 119.61 -1.281 . . . . 0.20000000000000001 111.012 -176.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.408 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 30.1 p80 -140.81 145.63 36.55 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.783 -0.834 . . . . 1.8899999999999999 109.99 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.431 ' CE2' ' HB2' ' A' ' 36' ' ' GLU . 18.3 m-85 -131.32 141.35 49.92 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.665 -0.647 . . . . 0.80000000000000004 109.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -124.0 156.55 65.72 Favored Pre-proline 0 N--CA 1.495 1.789 0 O-C-N 121.714 -0.616 . . . . 2.9900000000000002 110.075 178.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -56.01 139.54 85.03 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 O-C-N 123.208 1.11 . . . . 1.6799999999999999 110.903 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 35.0 ptt-85 -136.12 158.29 44.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.707 -0.621 . . . . 6.8700000000000001 110.433 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 58.8 t30 . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 117.979 -1.01 . . . . 6.4699999999999998 110.244 -179.906 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.6 ttp . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.056 0.455 . . . . 2.7599999999999998 110.153 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -73.2 143.17 47.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.69 -0.631 . . . . 1.7 110.088 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.6 p -127.71 136.61 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.651 -0.655 . . . . 0.40999999999999998 109.519 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.568 HD11 ' HA2' ' A' ' 86' ' ' GLY . 28.7 mt -85.18 -18.72 33.24 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.221 -0.592 . . . . 0.37 110.246 178.017 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.823 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.79 151.83 1.48 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.214 -0.929 . . . . 0.26000000000000001 109.045 176.042 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 17.5 ttpt -134.63 128.19 32.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.625 -0.672 . . . . 2.2999999999999998 110.356 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -149.91 162.93 39.37 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.822 -0.549 . . . . 0.20000000000000001 110.685 -177.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.432 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.1 m170 -112.58 137.63 50.53 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.662 -0.649 . . . . 1.99 110.144 -176.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.37 162.35 41.07 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.724 -0.61 . . . . 0.17999999999999999 109.636 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.48 157.85 19.15 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 119.81 -0.756 . . . . 0.17000000000000001 110.137 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.923 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.3 t -80.13 136.56 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 CA-C-O 121.276 0.56 . . . . 0.48999999999999999 110.339 -176.102 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.3 m80 -113.98 171.96 7.28 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.229 0.538 . . . . 0.68000000000000005 109.672 174.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.7 mtt85 -45.99 152.44 0.38 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.558 -0.714 . . . . 2.96 112.127 -175.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.0 mt 62.75 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.654 0 O-C-N 121.611 -0.68 . . . . 0.41999999999999998 112.578 -175.057 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.48 16.06 80.74 Favored Glycine 0 N--CA 1.497 2.709 0 O-C-N 120.783 -1.198 . . . . 0.23999999999999999 110.34 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.844 ' NH1' HD11 ' A' ' 18' ' ' ILE . 69.9 ttp85 -85.47 142.63 29.07 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -1.113 . . . . 1.96 110.234 -177.482 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -133.12 156.54 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.728 -0.607 . . . . 0.29999999999999999 109.695 174.202 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.844 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.1 mm -116.52 129.16 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.65 -0.656 . . . . 0.25 109.957 176.078 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 28.2 mt -79.69 145.81 63.46 Favored Pre-proline 0 N--CA 1.495 1.814 0 C-N-CA 120.04 -0.664 . . . . 0.23000000000000001 109.331 175.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.401 ' HD2' HG23 ' A' ' 19' ' ' ILE . 44.6 Cg_endo -62.84 142.74 89.82 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 122.994 0.997 . . . . 0.34999999999999998 109.848 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.27 62.93 Favored 'General case' 0 N--CA 1.497 1.885 0 C-N-CA 120.44 -0.504 . . . . 0.33000000000000002 110.464 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -43.85 95.99 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 109.968 -1.253 . . . . 0.39000000000000001 109.968 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 98.6 m -69.81 -38.53 76.63 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.559 -0.966 . . . . 0.39000000000000001 109.958 -179.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.0 mtt180 -56.03 -41.27 74.7 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.252 -0.905 . . . . 0.40000000000000002 109.39 176.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -65.75 -50.14 65.84 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.111 0.481 . . . . 2.9700000000000002 110.224 -177.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 82.2 t80 -57.47 -38.3 74.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.788 -0.57 . . . . 0.67000000000000004 110.683 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.5 t80 -87.36 -14.16 41.49 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.739 -0.601 . . . . 1.4399999999999999 111.3 -175.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.46 42.78 26.51 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.573 -1.411 . . . . 0.31 109.573 178.056 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.915 HG23 HG21 ' A' ' 56' ' ' VAL . 77.3 mt -88.38 128.48 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.522 -0.987 . . . . 0.41999999999999998 110.556 -176.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -128.25 155.44 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.126 -0.694 . . . . 1.8200000000000001 109.126 171.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -55.71 138.72 46.96 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 121.241 -0.912 . . . . 1.99 110.646 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.62 -15.98 62.15 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.868 -0.893 . . . . 0.19 110.868 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -77.16 158.18 30.53 Favored 'General case' 0 N--CA 1.499 1.997 0 CA-C-N 118.677 1.239 . . . . 1.1200000000000001 110.11 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -112.09 138.94 48.05 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.594 -0.691 . . . . 0.20999999999999999 109.62 174.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.48 154.11 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 N-CA-C 109.312 -0.625 . . . . 0.14999999999999999 109.312 173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.98 123.57 48.35 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.277 -1.009 . . . . 1.0900000000000001 108.277 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.811 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -140.08 158.17 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.559 -0.856 . . . . 0.14000000000000001 111.128 -167.125 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -133.04 146.1 51.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.799 -0.563 . . . . 1.1100000000000001 110.418 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.511 HG22 HG22 ' A' ' 82' ' ' VAL . 27.5 pt -114.88 151.1 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.743 -0.598 . . . . 0.20000000000000001 110.571 178.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -137.62 128.72 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 109.65 -0.5 . . . . 0.20000000000000001 109.65 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.47 ' HD2' HD12 ' A' ' 74' ' ' ILE . 59.8 tttm -136.82 148.26 47.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.783 -0.573 . . . . 1.98 109.645 177.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -101.0 128.94 46.8 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.703 -0.623 . . . . 0.33000000000000002 110.491 -178.327 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -133.66 133.18 41.59 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.589 -0.694 . . . . 1.48 110.149 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.79 -128.15 45.92 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.771 -1.332 . . . . 0.40999999999999998 109.771 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.08 9.83 34.19 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.778 -0.836 . . . . 1.27 111.764 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.15 137.1 29.91 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.229 -0.919 . . . . 1.3700000000000001 111.155 -177.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -75.57 145.38 29.5 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 O-C-N 122.778 0.883 . . . . 0.34000000000000002 110.327 173.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.42 ' CD ' ' HA ' ' A' ' 72' ' ' ILE . 30.1 mttp -121.37 149.8 42.42 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.426 -0.796 . . . . 1.1000000000000001 110.172 171.757 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.3 mp0 -136.99 166.96 22.43 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 120.22 -0.592 . . . . 1.4199999999999999 110.995 -177.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.32 135.9 4.51 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.305 -1.518 . . . . 0.17000000000000001 109.305 175.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.4 m -123.84 138.48 54.49 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.546 -0.973 . . . . 0.20999999999999999 109.894 178.676 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.6 p90 -156.62 173.09 17.46 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 119.868 -0.733 . . . . 0.16 110.986 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.2 m -107.37 141.4 38.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.67 -0.644 . . . . 0.13 109.395 173.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.04 145.64 36.15 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.681 -0.637 . . . . 0.14000000000000001 110.709 -175.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.1 ttt180 -93.51 145.13 24.74 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 109.573 -0.529 . . . . 2.21 109.573 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.915 HG21 HG23 ' A' ' 29' ' ' ILE . 93.0 t -79.06 125.05 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.223 0.535 . . . . 0.17000000000000001 109.838 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.08 -164.91 24.86 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.135 -1.186 . . . . 0.19 110.135 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 33.4 tp10 -61.67 152.69 30.16 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.819 . . . . 1.3899999999999999 110.013 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 53.43 21.04 2.23 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.59 -0.694 . . . . 0.81999999999999995 112.043 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.69 79.96 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 119.732 -1.223 . . . . 0.19 110.842 172.207 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -77.92 147.12 35.17 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.45 -1.029 . . . . 1.3 110.365 -176.258 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -139.15 146.55 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.82 -0.55 . . . . 0.20999999999999999 109.628 175.558 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -111.04 123.1 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.579 -0.701 . . . . 0.34000000000000002 110.748 -175.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.7 mt -78.57 144.65 65.76 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.614 -0.679 . . . . 0.34000000000000002 109.535 172.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.6 Cg_endo -64.13 133.27 37.45 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 O-C-N 122.873 0.933 . . . . 0.26000000000000001 110.767 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.2 tttt -55.01 -34.45 63.46 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.551 -0.718 . . . . 2.6200000000000001 110.831 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -38.22 77.89 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.737 -0.602 . . . . 0.45000000000000001 110.275 -178.471 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.8 mt -76.99 -32.8 57.48 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 120.25 -0.58 . . . . 1.8200000000000001 110.547 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.8 mtt180 -57.93 -45.61 86.32 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.287 -0.883 . . . . 2.5299999999999998 109.808 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.75 -46.67 65.34 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.479 -0.489 . . . . 1.6799999999999999 110.307 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 98.8 t -60.72 -39.11 80.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.626 -0.671 . . . . 0.28000000000000003 109.951 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.559 HG22 HD11 ' A' ' 74' ' ' ILE . 85.7 mt -83.65 -14.42 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.839 -0.538 . . . . 0.28000000000000003 111.191 -176.146 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.67 35.38 40.87 Favored Glycine 0 N--CA 1.499 2.857 0 N-CA-C 110.169 -1.172 . . . . 0.22 110.169 175.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.923 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.3 mm -88.66 140.56 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.536 -0.979 . . . . 0.77000000000000002 110.787 -174.292 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -131.38 162.62 54.88 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.782 -0.574 . . . . 3.21 110.606 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.88 134.82 59.26 Favored 'Trans proline' 0 N--CA 1.487 1.09 0 O-C-N 122.954 0.976 . . . . 0.5 110.858 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.97 0.91 70.84 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 120.639 -0.791 . . . . 0.23999999999999999 111.234 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -96.87 133.7 41.15 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.019 -1.283 . . . . 1.1100000000000001 110.498 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.08 133.22 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-O 121.584 0.706 . . . . 0.23999999999999999 111.2 -175.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.43 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.4 pt -123.18 159.5 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 109.499 -0.556 . . . . 0.17999999999999999 109.499 176.066 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.432 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 58.8 tt0 -97.35 131.52 43.94 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.986 -0.746 . . . . 1.1399999999999999 108.986 174.472 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.811 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.2 t -116.08 128.46 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.438 0.637 . . . . 0.20000000000000001 110.222 -171.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.4 mt -115.45 128.75 56.24 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 109.466 -0.568 . . . . 0.25 109.466 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.52 140.8 37.13 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.451 -0.781 . . . . 0.28000000000000003 109.948 172.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.43 -32.31 6.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.791 -0.568 . . . . 1.6000000000000001 110.828 -176.216 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.568 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.19 -177.19 39.19 Favored Glycine 0 N--CA 1.505 3.259 0 C-N-CA 119.706 -1.235 . . . . 0.20000000000000001 111.025 -176.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.3 p80 -145.17 151.71 38.88 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.708 -0.878 . . . . 1.8899999999999999 110.792 -177.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -135.8 140.23 44.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.515 -0.741 . . . . 0.80000000000000004 109.994 175.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.1 pttm -123.42 153.33 65.62 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.691 -0.631 . . . . 2.9900000000000002 110.589 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.38 152.61 38.55 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 O-C-N 123.314 1.165 . . . . 1.6799999999999999 110.905 178.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -118.16 142.36 47.52 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.753 -0.592 . . . . 6.8700000000000001 110.164 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 27.1 m120 . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 118.029 -0.986 . . . . 6.4699999999999998 110.179 -179.938 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.5 mtt . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.213 0.53 . . . . 2.7599999999999998 110.404 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.43 139.12 39.62 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.848 -0.533 . . . . 1.7 110.066 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 p -128.84 135.79 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.724 -0.61 . . . . 0.40999999999999998 109.475 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.1 mt -82.56 -20.15 37.13 Favored 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 120.248 -0.581 . . . . 0.37 110.425 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.804 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.94 153.21 3.15 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.415 -0.803 . . . . 0.26000000000000001 109.289 176.447 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.437 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.6 tttt -133.96 125.92 29.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.639 -0.663 . . . . 2.2999999999999998 110.222 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.7 p90 -151.2 163.41 38.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.605 -0.684 . . . . 0.20000000000000001 110.833 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.86 138.61 50.06 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.615 -0.678 . . . . 1.99 110.349 -176.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 162.37 41.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.774 -0.578 . . . . 0.17999999999999999 109.684 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -110.21 158.95 17.82 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.48 -0.763 . . . . 0.17000000000000001 109.933 176.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.918 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.46 136.39 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.272 -0.571 . . . . 0.48999999999999999 110.241 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -114.69 171.91 7.35 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.312 0.577 . . . . 0.68000000000000005 109.831 175.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.39 152.97 0.39 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.609 -0.682 . . . . 2.96 112.008 -176.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.5 mt 63.09 7.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.702 0 O-C-N 121.605 -0.684 . . . . 0.41999999999999998 112.522 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.51 15.98 80.8 Favored Glycine 0 N--CA 1.497 2.729 0 O-C-N 120.899 -1.125 . . . . 0.23999999999999999 110.312 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -86.02 143.81 27.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.304 -1.115 . . . . 1.96 110.361 -176.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.4 154.67 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.631 -0.668 . . . . 0.29999999999999999 109.613 172.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.6 128.79 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.623 -0.673 . . . . 0.25 109.978 176.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 27.3 mt -79.44 145.35 63.48 Favored Pre-proline 0 N--CA 1.495 1.781 0 C-N-CA 120.056 -0.658 . . . . 0.23000000000000001 109.423 175.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -63.4 143.64 89.03 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 O-C-N 122.96 0.979 . . . . 0.34999999999999998 109.748 174.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.96 -27.0 60.82 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 120.389 -0.524 . . . . 0.33000000000000002 110.484 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.39 -44.76 94.89 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.02 -1.232 . . . . 0.39000000000000001 110.02 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 91.6 m -69.31 -36.64 77.2 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.686 -0.891 . . . . 0.39000000000000001 110.061 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.612 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.9 mtt180 -56.38 -42.56 78.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.371 -0.83 . . . . 0.40000000000000002 109.812 178.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -66.2 -49.97 65.45 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 120.209 -0.596 . . . . 2.9700000000000002 110.203 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 74.7 t80 -56.26 -37.93 70.46 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.831 -0.543 . . . . 0.67000000000000004 110.589 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.91 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -88.34 -14.31 38.52 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.892 -0.505 . . . . 1.4399999999999999 111.228 -178.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.55 42.82 25.97 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.609 -1.396 . . . . 0.31 109.609 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.92 HG23 HG21 ' A' ' 56' ' ' VAL . 76.6 mt -87.52 126.95 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.526 -0.985 . . . . 0.41999999999999998 110.538 -176.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -127.19 158.98 35.65 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 109.126 -0.694 . . . . 1.8200000000000001 109.126 170.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -57.26 137.53 55.88 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.361 -0.837 . . . . 1.99 110.662 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.23 63.84 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.998 -0.841 . . . . 0.19 110.998 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.31 157.11 32.8 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-N 118.674 1.237 . . . . 1.1200000000000001 110.053 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -111.11 138.39 47.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.629 -0.67 . . . . 0.20999999999999999 109.631 174.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 153.44 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.3 -0.63 . . . . 0.14999999999999999 109.3 174.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -115.06 123.14 48.25 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.317 -0.994 . . . . 1.0900000000000001 108.317 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.3 tt -140.47 159.21 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.688 -0.805 . . . . 0.14000000000000001 110.882 -167.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.2 ttpt -133.55 145.99 50.61 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.783 -0.573 . . . . 1.1100000000000001 110.415 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.604 HG22 HG22 ' A' ' 82' ' ' VAL . 26.0 pt -115.0 151.08 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.575 -0.703 . . . . 0.20000000000000001 110.385 177.065 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.642 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.79 124.5 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 120.499 -0.48 . . . . 0.20000000000000001 109.806 176.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.698 ' HB2' HG22 ' A' ' 80' ' ' ILE . 22.0 ttpp -131.21 144.68 51.52 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.735 -0.603 . . . . 1.98 109.381 176.214 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 t80 -104.96 129.4 53.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.654 -0.654 . . . . 0.33000000000000002 110.335 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -133.95 130.37 37.59 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.717 -0.614 . . . . 1.48 110.144 177.262 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.18 45.98 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.796 -1.322 . . . . 0.40999999999999998 109.796 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -105.09 14.14 29.69 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.769 -0.842 . . . . 1.27 111.644 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -131.17 125.6 21.09 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.239 -0.913 . . . . 1.3700000000000001 111.081 -177.712 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.28 135.82 19.06 Favored 'Trans proline' 0 N--CA 1.482 0.85 0 O-C-N 122.796 0.893 . . . . 0.34000000000000002 110.097 173.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.681 ' HB3' HG23 ' A' ' 72' ' ' ILE . 25.1 mmtt -111.59 137.37 49.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.593 -0.692 . . . . 1.1000000000000001 109.666 173.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.642 ' HG2' HG13 ' A' ' 40' ' ' VAL . 48.7 mt-10 -135.17 165.3 25.72 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.645 -0.659 . . . . 1.4199999999999999 110.71 -176.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.551 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.71 135.68 4.35 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.406 -1.478 . . . . 0.17000000000000001 109.406 176.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.582 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.9 m -123.55 136.66 54.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.782 -0.834 . . . . 0.20999999999999999 109.779 176.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.822 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 10.8 p90 -156.05 173.53 16.68 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 119.942 -0.703 . . . . 0.16 111.079 178.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.22 140.71 39.67 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.615 -0.678 . . . . 0.13 109.472 173.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.822 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.63 146.08 35.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.656 -0.653 . . . . 0.14000000000000001 110.655 -175.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.4 ttp-105 -93.63 144.78 25.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.79 -0.569 . . . . 2.21 109.647 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.92 HG21 HG23 ' A' ' 29' ' ' ILE . 90.2 t -79.03 127.28 39.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.794 -0.566 . . . . 0.17000000000000001 109.95 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.72 -171.37 26.61 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.841 -1.304 . . . . 0.19 109.841 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 -61.85 156.61 20.24 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.636 -0.92 . . . . 1.3899999999999999 109.893 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 55.07 19.06 2.59 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.441 -0.787 . . . . 0.81999999999999995 112.075 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.64 20.49 79.62 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.831 -1.176 . . . . 0.19 110.695 172.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.4 t -78.75 144.87 34.8 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.423 -1.046 . . . . 1.3 110.333 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.623 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -137.73 146.15 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 109.555 -0.535 . . . . 0.20999999999999999 109.555 175.019 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.1 mm -110.86 123.69 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.53 -0.731 . . . . 0.34000000000000002 110.714 -174.005 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.413 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.2 mt -78.66 143.29 62.81 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.585 -0.697 . . . . 0.34000000000000002 109.455 172.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.4 Cg_endo -65.02 137.11 51.2 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 O-C-N 122.959 0.979 . . . . 0.26000000000000001 110.817 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 17.1 tptp -54.84 -34.79 63.27 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.446 -0.784 . . . . 2.6200000000000001 110.781 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.86 -38.35 78.56 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.792 -0.568 . . . . 0.45000000000000001 110.363 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.3 mt -77.2 -32.73 56.19 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 120.15 -0.62 . . . . 1.8200000000000001 110.683 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.31 -45.55 87.81 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.347 -0.846 . . . . 2.5299999999999998 109.831 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -70.32 -48.19 57.69 Favored 'General case' 0 N--CA 1.495 1.822 0 C-N-CA 120.519 -0.472 . . . . 1.6799999999999999 110.421 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.53 -38.02 76.84 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.732 -0.605 . . . . 0.28000000000000003 109.938 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.681 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.3 mt -82.52 -17.8 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.844 -0.535 . . . . 0.28000000000000003 110.947 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.45 35.17 42.72 Favored Glycine 0 N--CA 1.497 2.721 0 N-CA-C 109.7 -1.36 . . . . 0.22 109.7 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.918 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.13 142.01 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.514 -0.992 . . . . 0.77000000000000002 110.695 -174.305 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 44.9 mttt -130.88 162.34 55.97 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.699 -0.626 . . . . 3.21 110.663 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.93 135.58 64.07 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 O-C-N 123.037 1.019 . . . . 0.5 110.818 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.16 -0.16 71.77 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 120.686 -0.769 . . . . 0.23999999999999999 111.246 176.098 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -95.37 131.12 41.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.055 -1.262 . . . . 1.1100000000000001 110.377 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.5 p -91.66 135.87 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 CA-C-O 121.762 0.792 . . . . 0.23999999999999999 111.106 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.698 HG22 ' HB2' ' A' ' 41' ' ' LYS . 42.0 pt -126.53 159.43 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 109.477 -0.564 . . . . 0.17999999999999999 109.477 179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -98.61 128.18 44.82 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.751 -0.833 . . . . 1.1399999999999999 108.751 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 85.5 t -113.28 128.98 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-O 121.341 0.591 . . . . 0.20000000000000001 110.148 -171.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.8 mt -116.75 127.35 54.28 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.02 -0.733 . . . . 0.25 109.02 -179.251 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.91 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.4 mt -79.98 140.9 36.43 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.363 -0.835 . . . . 0.28000000000000003 109.757 172.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 mt -113.9 -30.13 6.83 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.658 -0.651 . . . . 1.6000000000000001 110.966 -174.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.93 -177.93 39.54 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.709 -1.234 . . . . 0.20000000000000001 111.008 -177.264 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 25.5 p80 -145.09 153.53 41.53 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.729 -0.865 . . . . 1.8899999999999999 110.694 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -139.23 144.54 38.49 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.6 -0.687 . . . . 0.80000000000000004 110.162 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -118.21 151.0 48.68 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.682 -0.636 . . . . 2.9900000000000002 110.28 178.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -56.04 143.1 84.57 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 O-C-N 123.143 1.075 . . . . 1.6799999999999999 110.885 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 44.1 ptt85 -136.08 159.05 42.91 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.725 -0.61 . . . . 6.8700000000000001 110.419 178.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 42.8 t-20 . . . . . 0 N--CA 1.495 1.818 0 CA-C-O 117.981 -1.009 . . . . 6.4699999999999998 110.152 179.832 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.3 mtm . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.16 0.505 . . . . 2.7599999999999998 110.564 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -74.61 141.47 44.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.894 -0.504 . . . . 1.7 110.096 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.43 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p -129.0 134.2 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.702 -0.624 . . . . 0.40999999999999998 109.556 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.603 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.4 mt -82.08 -20.77 37.51 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.25 -0.58 . . . . 0.37 110.252 179.178 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.784 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.17 153.42 3.69 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -0.835 . . . . 0.26000000000000001 109.245 176.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.6 tttt -133.55 125.72 29.46 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.741 -0.6 . . . . 2.2999999999999998 110.173 -176.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.61 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.23 162.87 39.64 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.555 -0.716 . . . . 0.20000000000000001 110.94 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -112.83 137.73 50.72 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.718 -0.614 . . . . 1.99 110.172 -176.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.1 162.3 41.12 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.729 -0.607 . . . . 0.17999999999999999 109.582 176.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -110.11 159.77 17.05 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.736 -0.786 . . . . 0.17000000000000001 110.075 177.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.908 HG21 HG21 ' A' ' 74' ' ' ILE . 60.5 t -78.74 136.24 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 C-N-CA 120.3 -0.56 . . . . 0.48999999999999999 110.233 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -115.44 171.88 7.44 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.22 0.533 . . . . 0.68000000000000005 109.589 174.254 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 69.8 mtp85 -46.27 152.54 0.41 Allowed 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.573 -0.704 . . . . 2.96 112.067 -175.67 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.591 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.7 mt 62.41 7.99 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.665 0 O-C-N 121.656 -0.653 . . . . 0.41999999999999998 112.631 -176.025 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.9 16.18 80.27 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.832 -1.168 . . . . 0.23999999999999999 110.446 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -84.45 143.27 29.51 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.314 -1.11 . . . . 1.96 110.33 -176.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -134.51 154.95 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.672 -0.642 . . . . 0.29999999999999999 109.545 172.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.7 mm -117.46 128.44 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.586 -0.696 . . . . 0.25 109.936 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.434 HG12 ' CE2' ' A' ' 7' ' ' PHE . 35.6 mt -79.79 144.04 59.4 Favored Pre-proline 0 N--CA 1.495 1.786 0 C-N-CA 120.075 -0.65 . . . . 0.23000000000000001 109.407 176.026 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.37 143.5 88.91 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.004 1.002 . . . . 0.34999999999999998 109.729 174.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.51 -26.49 61.41 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.858 -0.526 . . . . 0.33000000000000002 110.527 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.37 95.17 Favored Glycine 0 N--CA 1.497 2.722 0 N-CA-C 109.935 -1.266 . . . . 0.39000000000000001 109.935 -179.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 75.0 m -69.97 -38.2 76.02 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.58 -0.953 . . . . 0.39000000000000001 110.18 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.667 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.6 mtt180 -55.95 -41.11 74.21 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.349 -0.844 . . . . 0.40000000000000002 109.413 176.468 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.2 tttp -65.56 -49.95 66.96 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.145 0.498 . . . . 2.9700000000000002 110.197 -177.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -57.14 -38.34 73.38 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.769 -0.582 . . . . 0.67000000000000004 110.735 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.7 t80 -88.12 -14.25 39.24 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.779 -0.575 . . . . 1.4399999999999999 111.291 -176.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.81 42.69 25.05 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.484 -1.447 . . . . 0.31 109.484 178.264 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.864 HG23 HG21 ' A' ' 56' ' ' VAL . 73.6 mt -87.49 129.17 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.492 -1.005 . . . . 0.41999999999999998 110.437 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.08 154.65 45.46 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.962 -0.755 . . . . 1.8200000000000001 108.962 172.233 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -55.21 139.67 41.37 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.288 -0.882 . . . . 1.99 110.691 -177.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.86 -15.98 61.88 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.936 -0.866 . . . . 0.19 110.936 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -76.21 156.73 33.35 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.097 -1.237 . . . . 1.1200000000000001 110.069 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -110.18 138.59 46.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.638 -0.664 . . . . 0.20999999999999999 109.595 174.462 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.32 154.79 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 109.271 -0.64 . . . . 0.14999999999999999 109.271 174.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -116.09 123.37 47.74 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.207 -1.034 . . . . 1.0900000000000001 108.207 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.6 tt -139.45 158.25 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 119.661 -0.816 . . . . 0.14000000000000001 110.95 -167.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HB2' HG23 ' A' ' 51' ' ' THR . 82.4 tttt -132.7 145.86 51.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.867 -0.521 . . . . 1.1100000000000001 110.386 178.008 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 34.1 pt -114.94 150.97 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.667 -0.645 . . . . 0.20000000000000001 110.568 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.7 t -139.27 126.0 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 CA-C-O 121.231 0.539 . . . . 0.20000000000000001 109.778 176.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.705 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.5 tptp -136.26 148.79 48.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.812 -0.555 . . . . 1.98 109.511 176.006 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -100.63 129.0 46.49 Favored 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 120.19 -0.604 . . . . 0.33000000000000002 110.251 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.503 ' OE2' HD13 ' A' ' 74' ' ' ILE . 93.1 mt-10 -135.08 135.09 40.97 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.635 -0.666 . . . . 1.48 110.011 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.15 45.9 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.741 -1.344 . . . . 0.40999999999999998 109.741 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.1 pt-20 -105.13 7.73 33.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.748 -0.854 . . . . 1.27 111.806 178.246 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.3 pt-20 -131.17 141.47 42.02 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.129 -0.982 . . . . 1.3700000000000001 111.004 -177.052 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -75.4 139.75 23.63 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 O-C-N 123.037 1.02 . . . . 0.34000000000000002 110.566 175.304 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 73.9 mmtt -114.47 136.89 52.51 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.545 -0.722 . . . . 1.1000000000000001 109.496 171.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -137.5 168.92 18.69 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.603 -0.686 . . . . 1.4199999999999999 110.713 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.417 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -160.22 135.95 4.31 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.592 -1.403 . . . . 0.17000000000000001 109.592 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.409 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -121.55 137.49 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.755 -0.85 . . . . 0.20999999999999999 109.721 177.423 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.8 p90 -155.78 173.02 17.36 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 119.911 -0.716 . . . . 0.16 110.965 176.726 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.4 m -107.44 140.82 39.81 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.71 -0.619 . . . . 0.13 109.586 174.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.66 145.12 34.56 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.614 -0.679 . . . . 0.14000000000000001 110.552 -176.25 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.2 ttp-105 -93.4 145.31 24.58 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.773 -0.58 . . . . 2.21 109.679 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.864 HG21 HG23 ' A' ' 29' ' ' ILE . 94.7 t -79.11 126.13 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.847 -0.533 . . . . 0.17000000000000001 109.975 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.45 -170.7 26.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.79 -1.324 . . . . 0.19 109.79 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -61.88 156.03 21.83 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.61 -0.935 . . . . 1.3899999999999999 109.905 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 54.91 19.44 2.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.611 -0.68 . . . . 0.81999999999999995 112.084 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.68 20.5 79.67 Favored Glycine 0 N--CA 1.499 2.838 0 C-N-CA 119.821 -1.18 . . . . 0.19 110.783 172.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 54.1 p -77.97 145.7 35.88 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.451 -1.029 . . . . 1.3 110.534 -175.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.81 146.2 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.875 -0.515 . . . . 0.20999999999999999 109.628 174.497 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.62 123.61 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.499 -0.75 . . . . 0.34000000000000002 110.653 -175.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 72.9 mt -78.3 144.15 65.97 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.679 -0.638 . . . . 0.34000000000000002 109.652 174.108 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.41 134.35 41.33 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 O-C-N 123.002 1.001 . . . . 0.26000000000000001 110.808 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -55.19 -34.29 63.76 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.532 -0.73 . . . . 2.6200000000000001 110.847 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.78 -37.69 76.87 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.74 -0.6 . . . . 0.45000000000000001 110.324 -178.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.4 mt -77.18 -32.79 56.34 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.723 -0.61 . . . . 1.8200000000000001 110.544 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -57.82 -45.73 85.72 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.282 -0.886 . . . . 2.5299999999999998 109.911 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.27 -47.22 62.26 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.44 -0.504 . . . . 1.6799999999999999 110.465 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.56 -38.12 77.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.712 -0.618 . . . . 0.28000000000000003 109.987 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.9 mt -82.31 -18.06 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.849 -0.532 . . . . 0.28000000000000003 110.788 -176.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.28 40.7 Favored Glycine 0 N--CA 1.497 2.763 0 N-CA-C 109.684 -1.366 . . . . 0.22 109.684 176.231 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.908 HG21 HG21 ' A' ' 11' ' ' VAL . 50.9 mm -90.89 144.58 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.53 -0.982 . . . . 0.77000000000000002 110.613 -174.434 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.04 159.31 73.19 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.743 -0.598 . . . . 3.21 110.906 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -52.8 134.79 55.67 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 O-C-N 123.067 1.035 . . . . 0.5 111.688 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.07 -0.63 69.38 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.66 -0.781 . . . . 0.23999999999999999 111.331 175.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.65 129.0 40.1 Favored 'General case' 0 N--CA 1.501 2.083 0 CA-C-N 118.724 1.262 . . . . 1.1100000000000001 110.173 178.58 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 79' ' ' VAL . 10.7 p -91.15 128.51 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 121.4 0.619 . . . . 0.23999999999999999 110.606 -175.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.705 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -118.79 159.56 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.639 -0.504 . . . . 0.17999999999999999 109.639 179.267 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -97.6 130.13 44.66 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.938 -0.764 . . . . 1.1399999999999999 108.938 174.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.48 129.2 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-O 121.373 0.606 . . . . 0.20000000000000001 110.257 -171.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.9 mt -116.38 129.08 56.05 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.204 -0.665 . . . . 0.25 109.204 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -79.8 139.66 37.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.342 -0.849 . . . . 0.28000000000000003 109.791 172.546 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -109.34 -33.45 6.83 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.767 -0.583 . . . . 1.6000000000000001 110.927 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.603 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.22 -175.2 37.69 Favored Glycine 0 N--CA 1.504 3.184 0 C-N-CA 119.674 -1.251 . . . . 0.20000000000000001 111.031 -176.122 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p80 -143.79 153.91 42.88 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.759 -0.847 . . . . 1.8899999999999999 110.719 -177.39 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -137.92 139.43 39.8 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.537 -0.727 . . . . 0.80000000000000004 110.236 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 5.4 pttm -81.72 152.53 69.51 Favored Pre-proline 0 N--CA 1.496 1.875 0 O-C-N 121.715 -0.615 . . . . 2.9900000000000002 110.313 178.589 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -55.82 143.53 80.79 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 O-C-N 123.227 1.119 . . . . 1.6799999999999999 110.933 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 28.2 ptt180 -136.14 158.37 44.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.708 -0.62 . . . . 6.8700000000000001 110.426 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 117.981 -1.009 . . . . 6.4699999999999998 110.178 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.4 mtp . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.137 0.494 . . . . 2.7599999999999998 110.613 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -74.12 142.67 45.55 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.915 -0.49 . . . . 1.7 110.082 178.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.45 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p -129.11 133.76 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.766 -0.584 . . . . 0.40999999999999998 109.588 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.8 mt -80.96 -21.49 40.32 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.269 -0.572 . . . . 0.37 110.189 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.862 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.11 152.18 3.4 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.442 -0.786 . . . . 0.26000000000000001 109.127 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.441 ' HE3' HD21 ' A' ' 83' ' ' LEU . 67.2 tttt -132.61 125.18 29.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.702 -0.624 . . . . 2.2999999999999998 110.214 -176.706 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.0 p90 -150.21 162.76 39.84 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.072 -0.651 . . . . 0.20000000000000001 110.989 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 73.2 m80 -112.52 138.23 49.58 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.626 -0.671 . . . . 1.99 110.154 -176.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.06 162.26 41.18 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.696 -0.628 . . . . 0.17999999999999999 109.627 176.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.62 158.78 18.2 Favored 'General case' 0 N--CA 1.498 1.939 0 C-N-CA 119.818 -0.753 . . . . 0.17000000000000001 110.136 177.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.3 t -79.24 134.89 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 C-N-CA 120.257 -0.577 . . . . 0.48999999999999999 110.245 -177.089 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.28 171.89 7.34 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-O 121.277 0.561 . . . . 0.68000000000000005 109.647 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -47.16 152.99 0.5 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.579 -0.701 . . . . 2.96 111.776 -175.324 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.7 mt 62.65 7.37 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.652 0 O-C-N 121.46 -0.775 . . . . 0.41999999999999998 112.681 -174.48 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.1 80.63 Favored Glycine 0 N--CA 1.497 2.747 0 O-C-N 120.935 -1.103 . . . . 0.23999999999999999 110.363 179.414 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -84.64 142.84 29.63 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.248 -1.148 . . . . 1.96 110.391 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.57 155.22 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.721 -0.612 . . . . 0.29999999999999999 109.39 172.398 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.6 mm -116.56 128.45 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.579 -0.701 . . . . 0.25 109.977 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 37.4 mt -79.99 144.32 59.04 Favored Pre-proline 0 N--CA 1.495 1.792 0 C-N-CA 120.015 -0.674 . . . . 0.23000000000000001 109.422 175.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -63.54 143.46 87.8 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 122.943 0.97 . . . . 0.34999999999999998 109.751 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.75 61.57 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 120.44 -0.504 . . . . 0.33000000000000002 110.481 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.17 95.56 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.954 -1.258 . . . . 0.39000000000000001 109.954 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.7 m -69.87 -38.43 76.39 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.562 -0.964 . . . . 0.39000000000000001 110.148 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.704 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.9 mtt180 -56.03 -40.58 73.66 Favored 'General case' 0 N--CA 1.513 2.689 0 O-C-N 121.29 -0.881 . . . . 0.40000000000000002 109.386 176.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -65.64 -50.01 66.56 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.043 0.449 . . . . 2.9700000000000002 110.213 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -57.74 -38.85 76.07 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.751 -0.593 . . . . 0.67000000000000004 110.683 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.96 ' CD2' HD13 ' A' ' 84' ' ' LEU . 26.7 t80 -86.74 -14.17 43.17 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.804 -0.56 . . . . 1.4399999999999999 111.346 -176.511 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 43.14 23.45 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.603 -1.399 . . . . 0.31 109.603 178.57 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.895 HG23 HG21 ' A' ' 56' ' ' VAL . 76.9 mt -87.73 128.79 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 121.523 -0.986 . . . . 0.41999999999999998 110.537 -177.352 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.1 153.97 46.24 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.868 -0.79 . . . . 1.8200000000000001 108.868 170.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -55.27 140.39 39.33 Favored 'General case' 0 N--CA 1.504 2.241 0 O-C-N 121.238 -0.913 . . . . 1.99 110.626 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.8 -16.03 61.74 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.859 -0.896 . . . . 0.19 110.859 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.91 157.54 31.3 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.67 1.235 . . . . 1.1200000000000001 110.115 178.186 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -111.71 138.92 47.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.622 -0.674 . . . . 0.20999999999999999 109.557 174.315 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.55 155.12 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 C-N-CA 120.224 -0.59 . . . . 0.14999999999999999 109.454 174.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.92 123.6 48.49 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.364 -0.976 . . . . 1.0900000000000001 108.364 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.4 tt -139.96 156.01 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.682 -0.807 . . . . 0.14000000000000001 110.95 -167.734 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -131.13 146.07 52.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.747 -0.596 . . . . 1.1100000000000001 110.55 177.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 82' ' ' VAL . 29.6 pt -114.94 151.08 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 121.731 -0.605 . . . . 0.20000000000000001 110.699 178.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.463 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.23 126.58 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.152 0.501 . . . . 0.20000000000000001 109.734 175.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.703 ' HB2' HG22 ' A' ' 80' ' ' ILE . 32.1 tptt -136.69 146.89 46.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.741 -0.6 . . . . 1.98 109.602 175.59 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -105.96 130.98 53.79 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.231 -0.587 . . . . 0.33000000000000002 110.427 -177.275 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -136.59 135.35 38.31 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.677 -0.639 . . . . 1.48 110.145 176.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.24 46.09 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.833 -1.307 . . . . 0.40999999999999998 109.833 -178.045 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.14 9.81 34.07 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.819 -0.812 . . . . 1.27 111.878 179.497 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -131.15 135.36 27.09 Favored Pre-proline 0 N--CA 1.499 2.001 0 O-C-N 121.189 -0.945 . . . . 1.3700000000000001 111.076 -177.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.36 146.52 31.51 Favored 'Trans proline' 0 N--CA 1.482 0.801 0 O-C-N 122.811 0.901 . . . . 0.34000000000000002 110.159 173.224 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.75 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.0 mmtt -120.48 138.17 53.96 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.545 -0.722 . . . . 1.1000000000000001 109.564 172.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.463 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.7 mt-10 -134.57 163.41 29.79 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.635 -0.665 . . . . 1.4199999999999999 110.718 -176.807 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.91 135.89 4.43 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.618 -1.393 . . . . 0.17000000000000001 109.618 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.3 m -122.17 137.45 54.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.715 -0.873 . . . . 0.20999999999999999 109.75 176.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.5 p90 -155.55 172.77 17.7 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.972 -0.691 . . . . 0.16 111.036 176.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.7 m -106.9 141.03 38.77 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.691 -0.63 . . . . 0.13 109.464 173.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.31 145.4 35.42 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.564 -0.71 . . . . 0.14000000000000001 110.58 -176.048 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -92.96 144.79 24.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.809 -0.557 . . . . 2.21 109.605 175.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.895 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -79.14 125.23 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-O 121.332 0.587 . . . . 0.17000000000000001 109.79 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.68 -167.31 26.34 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.939 -1.264 . . . . 0.19 109.939 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.6 153.45 27.78 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.724 -0.868 . . . . 1.3899999999999999 110.101 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.64 21.03 2.39 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.54 -0.725 . . . . 0.81999999999999995 112.061 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.07 20.58 79.68 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.784 -1.198 . . . . 0.19 110.793 171.55 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.2 m -77.88 144.92 36.54 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.488 -1.007 . . . . 1.3 110.375 -176.311 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.722 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -138.43 144.96 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.553 -0.536 . . . . 0.20999999999999999 109.553 174.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.65 123.33 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.49 -0.756 . . . . 0.34000000000000002 110.641 -175.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.449 HG23 ' HD2' ' A' ' 65' ' ' PRO . 54.7 mt -78.44 144.43 65.93 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.643 -0.661 . . . . 0.34000000000000002 109.518 173.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.21 133.63 38.77 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.934 0.965 . . . . 0.26000000000000001 110.764 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.08 -34.23 63.46 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.443 -0.786 . . . . 2.6200000000000001 110.866 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.76 -38.09 77.71 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.745 -0.597 . . . . 0.45000000000000001 110.329 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 71.0 mt -77.15 -32.67 56.45 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 120.259 -0.576 . . . . 1.8200000000000001 110.552 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.88 -46.03 85.49 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.3 -0.875 . . . . 2.5299999999999998 109.897 178.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -70.16 -46.79 63.95 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 120.456 -0.498 . . . . 1.6799999999999999 110.473 -175.391 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.5 t -60.38 -38.45 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.678 -0.639 . . . . 0.28000000000000003 109.865 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.75 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.5 mt -82.53 -17.99 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.844 -0.535 . . . . 0.28000000000000003 110.822 -176.535 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.25 35.11 38.88 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 109.665 -1.374 . . . . 0.22 109.665 176.07 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.65 142.54 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.619 -0.93 . . . . 0.77000000000000002 110.581 -175.062 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -129.64 162.11 55.14 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.674 -0.641 . . . . 3.21 110.807 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.91 135.32 62.41 Favored 'Trans proline' 0 N--CA 1.488 1.159 0 O-C-N 123.063 1.033 . . . . 0.5 110.835 -179.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.9 -0.05 72.44 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 120.591 -0.814 . . . . 0.23999999999999999 111.235 176.011 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -96.18 131.61 42.47 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 118.715 1.257 . . . . 1.1100000000000001 110.445 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.0 p -91.87 130.1 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 CA-C-O 121.511 0.672 . . . . 0.23999999999999999 110.837 -174.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.703 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.3 pt -118.72 159.51 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 109.591 -0.522 . . . . 0.17999999999999999 109.591 177.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -97.01 130.69 44.3 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.026 -0.731 . . . . 1.1399999999999999 109.026 174.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.6 t -115.85 128.9 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.366 0.603 . . . . 0.20000000000000001 110.241 -171.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.45 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.7 mt -116.31 128.75 55.83 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.324 -0.621 . . . . 0.25 109.324 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.96 HD13 ' CD2' ' A' ' 27' ' ' TYR . 6.0 mt -79.65 142.51 35.49 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.402 -0.811 . . . . 0.28000000000000003 109.808 171.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 85' ' ' LEU . 43.7 mt -120.65 -24.95 5.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.655 . . . . 1.6000000000000001 111.206 -174.076 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.28 -179.92 40.49 Favored Glycine 0 N--CA 1.505 3.28 0 C-N-CA 119.642 -1.266 . . . . 0.20000000000000001 111.066 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 p80 -146.95 152.62 38.94 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.745 -0.856 . . . . 1.8899999999999999 110.685 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -138.28 142.92 39.82 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.582 -0.699 . . . . 0.80000000000000004 110.07 175.657 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.3 mmtt -120.87 154.53 57.66 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.9900000000000002 110.224 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -55.96 142.33 85.08 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 O-C-N 123.162 1.085 . . . . 1.6799999999999999 110.934 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 74.9 mtt85 -126.29 147.64 49.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.755 -0.591 . . . . 6.8700000000000001 110.198 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 31.7 t30 . . . . . 0 N--CA 1.494 1.771 0 CA-C-O 117.991 -1.004 . . . . 6.4699999999999998 110.153 -179.936 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.8 ttm . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 121.01 0.433 . . . . 2.7599999999999998 110.173 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -78.03 145.29 36.0 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.806 -0.558 . . . . 1.7 110.131 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -127.77 138.03 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.695 -0.628 . . . . 0.40999999999999998 109.719 178.464 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.59 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.3 mt -86.61 -18.44 31.39 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.262 -0.575 . . . . 0.37 110.547 -179.604 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.79 153.74 3.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.357 -0.839 . . . . 0.26000000000000001 109.299 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -133.77 125.42 28.46 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.703 -0.623 . . . . 2.2999999999999998 110.079 -177.256 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.3 p90 -150.68 162.09 41.35 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.603 -0.686 . . . . 0.20000000000000001 110.869 -179.322 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -112.78 138.84 49.01 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.661 -0.649 . . . . 1.99 110.161 -176.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.29 41.07 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.728 -0.607 . . . . 0.17999999999999999 109.59 178.069 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -111.0 158.68 18.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.417 -0.802 . . . . 0.17000000000000001 110.044 177.152 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.906 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -79.16 136.29 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.295 -0.562 . . . . 0.48999999999999999 110.343 -176.307 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -115.25 171.94 7.38 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.42 0.629 . . . . 0.68000000000000005 109.796 175.043 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 -46.52 153.04 0.4 Allowed 'General case' 0 N--CA 1.505 2.31 0 O-C-N 121.536 -0.728 . . . . 2.96 111.981 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.8 mt 62.89 7.45 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.671 0 O-C-N 121.569 -0.707 . . . . 0.41999999999999998 112.567 -175.529 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.73 15.99 80.63 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.344 -1.102 . . . . 0.23999999999999999 110.344 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -85.5 144.0 28.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.235 -1.156 . . . . 1.96 110.429 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -132.67 154.95 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.748 -0.595 . . . . 0.29999999999999999 109.46 172.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.435 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -117.11 128.76 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 C-N-CA 120.073 -0.651 . . . . 0.25 110.065 176.647 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.08 145.21 60.39 Favored Pre-proline 0 N--CA 1.496 1.828 0 C-N-CA 120.062 -0.655 . . . . 0.23000000000000001 109.406 175.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.34 143.73 89.59 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 O-C-N 123.024 1.013 . . . . 0.34999999999999998 109.755 174.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.41 61.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.87 -0.519 . . . . 0.33000000000000002 110.471 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.74 -44.22 95.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 110.026 -1.23 . . . . 0.39000000000000001 110.026 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 78.5 m -69.85 -38.21 76.41 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.964 . . . . 0.39000000000000001 110.124 -179.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.613 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.4 mtt180 -56.3 -41.65 76.28 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 121.276 -0.89 . . . . 0.40000000000000002 109.377 176.676 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -65.9 -50.09 65.7 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.14 0.495 . . . . 2.9700000000000002 110.221 -177.54 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.27 -37.79 72.91 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.732 -0.605 . . . . 0.67000000000000004 110.633 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.5 t80 -88.06 -14.15 39.65 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.805 -0.559 . . . . 1.4399999999999999 111.229 -175.764 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.33 42.49 27.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.563 -1.415 . . . . 0.31 109.563 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.869 HG23 HG21 ' A' ' 56' ' ' VAL . 78.3 mt -89.62 131.14 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.453 -1.027 . . . . 0.41999999999999998 110.645 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.27 158.94 36.78 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.091 -0.707 . . . . 1.8200000000000001 109.091 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -57.47 139.45 53.23 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.38 -0.825 . . . . 1.99 110.513 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.74 -15.25 63.49 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.887 -0.885 . . . . 0.19 110.887 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.12 158.16 32.07 Favored 'General case' 0 N--CA 1.501 2.123 0 CA-C-N 118.724 1.262 . . . . 1.1200000000000001 109.932 178.182 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -110.53 138.16 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.591 -0.693 . . . . 0.20999999999999999 109.588 175.149 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.35 154.16 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 109.13 -0.693 . . . . 0.14999999999999999 109.13 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -116.05 123.8 48.84 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.317 -0.994 . . . . 1.0900000000000001 108.317 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.8 tt -140.51 158.13 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 119.635 -0.826 . . . . 0.14000000000000001 110.961 -167.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.3 ttpt -132.29 146.11 51.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.837 -0.539 . . . . 1.1100000000000001 110.386 177.386 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 82' ' ' VAL . 23.2 pt -114.88 150.98 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.667 -0.646 . . . . 0.20000000000000001 110.278 176.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.524 HG13 ' HG2' ' A' ' 49' ' ' GLU . 59.4 t -139.53 123.64 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 CA-C-O 121.251 0.548 . . . . 0.20000000000000001 109.729 177.554 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.676 ' HB2' HG22 ' A' ' 80' ' ' ILE . 53.2 tttm -132.92 147.5 52.29 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.248 -0.649 . . . . 1.98 109.248 176.161 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -101.18 130.92 47.35 Favored 'General case' 0 N--CA 1.498 1.952 0 C-N-CA 119.903 -0.719 . . . . 0.33000000000000002 110.531 -178.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -132.04 131.42 42.45 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.653 -0.654 . . . . 1.48 110.016 177.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.85 -128.05 45.63 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.814 -1.315 . . . . 0.40999999999999998 109.814 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 pt-20 -104.97 10.64 34.1 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.726 -0.867 . . . . 1.27 111.729 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.2 137.99 31.86 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 1.3700000000000001 110.719 -179.258 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -75.23 140.08 24.44 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 O-C-N 122.887 0.941 . . . . 0.34000000000000002 110.399 174.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.5 mmtt -111.37 136.89 49.85 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.657 -0.652 . . . . 1.1000000000000001 109.466 172.063 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.524 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.7 164.49 27.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.703 -0.623 . . . . 1.4199999999999999 110.996 -176.44 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.43 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.59 135.75 4.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.469 -1.453 . . . . 0.17000000000000001 109.469 176.617 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.85 136.91 54.24 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.712 -0.875 . . . . 0.20999999999999999 109.732 177.223 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -155.88 173.38 16.85 Favored 'General case' 0 N--CA 1.497 1.911 0 C-N-CA 119.867 -0.733 . . . . 0.16 111.089 178.159 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.7 m -106.95 140.39 39.83 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.722 -0.611 . . . . 0.13 109.551 173.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.28 146.11 34.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.633 -0.667 . . . . 0.14000000000000001 110.443 -175.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.65 145.58 24.45 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.774 -0.579 . . . . 2.21 109.711 175.523 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.869 HG21 HG23 ' A' ' 29' ' ' ILE . 97.9 t -77.84 126.41 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.2 0.524 . . . . 0.17000000000000001 109.973 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.53 -167.56 26.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.931 -1.268 . . . . 0.19 109.931 179.109 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -61.71 153.34 28.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.7 -0.882 . . . . 1.3899999999999999 109.965 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 54.14 20.49 2.57 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.531 -0.731 . . . . 0.81999999999999995 111.98 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 20.44 79.94 Favored Glycine 0 N--CA 1.5 2.928 0 C-N-CA 119.803 -1.189 . . . . 0.19 110.826 171.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.435 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.5 p -78.37 146.9 34.37 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -1.01 . . . . 1.3 110.203 -177.773 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.619 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.88 145.8 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.758 -0.589 . . . . 0.20999999999999999 109.565 175.006 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.15 123.15 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.588 -0.695 . . . . 0.34000000000000002 110.654 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 65.5 mt -78.41 144.02 65.29 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.504 -0.748 . . . . 0.34000000000000002 109.432 172.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.77 134.43 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 O-C-N 122.861 0.927 . . . . 0.26000000000000001 110.648 -179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -55.15 -34.21 63.59 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.505 -0.747 . . . . 2.6200000000000001 110.802 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -37.87 77.12 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.802 -0.562 . . . . 0.45000000000000001 110.271 -178.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.8 mt -77.11 -32.75 56.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.748 -0.595 . . . . 1.8200000000000001 110.553 178.548 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.78 -46.0 85.21 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.306 -0.871 . . . . 2.5299999999999998 109.923 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.32 -47.23 62.05 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.5 -0.48 . . . . 1.6799999999999999 110.493 -175.626 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.6 t -60.51 -38.15 77.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.684 -0.635 . . . . 0.28000000000000003 109.966 -178.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.711 HG22 HD11 ' A' ' 74' ' ' ILE . 83.1 mt -82.57 -17.81 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.792 -0.568 . . . . 0.28000000000000003 110.934 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.32 35.14 43.53 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.787 -1.325 . . . . 0.22 109.787 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.906 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.24 138.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.522 -0.987 . . . . 0.77000000000000002 110.715 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 57.0 mmtt -124.25 161.1 49.42 Favored Pre-proline 0 N--CA 1.498 1.931 0 O-C-N 121.675 -0.64 . . . . 3.21 110.61 -176.379 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.76 136.36 66.01 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 O-C-N 123.027 1.014 . . . . 0.5 110.78 179.386 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.63 -0.65 74.24 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 111.123 -0.791 . . . . 0.23999999999999999 111.123 176.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 21.7 mt-10 -98.14 134.44 41.2 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 118.682 1.241 . . . . 1.1100000000000001 110.567 179.695 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.07 133.41 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 CA-C-O 121.684 0.754 . . . . 0.23999999999999999 111.227 -174.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.676 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.7 pt -122.93 159.48 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 109.211 -0.663 . . . . 0.17999999999999999 109.211 175.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 49.7 tt0 -98.82 131.41 44.96 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 109.021 -0.733 . . . . 1.1399999999999999 109.021 175.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 88.5 t -115.8 129.93 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.435 0.636 . . . . 0.20000000000000001 110.365 -170.563 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.2 mt -115.73 130.7 56.95 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 109.237 -0.653 . . . . 0.25 109.237 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.09 139.88 36.7 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.449 -0.782 . . . . 0.28000000000000003 109.781 171.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.0 mt -108.71 -34.4 6.71 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.8 -0.563 . . . . 1.6000000000000001 110.887 -176.433 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.59 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.03 -174.63 37.74 Favored Glycine 0 N--CA 1.502 3.079 0 C-N-CA 119.738 -1.22 . . . . 0.20000000000000001 111.015 -177.106 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -143.91 155.62 44.14 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.738 -0.86 . . . . 1.8899999999999999 110.743 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -141.17 146.69 37.3 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.577 -0.702 . . . . 0.80000000000000004 110.208 176.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 18.1 mtmm -112.07 159.92 31.88 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.722 -0.611 . . . . 2.9900000000000002 110.133 178.533 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -55.53 141.56 82.71 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 O-C-N 123.187 1.099 . . . . 1.6799999999999999 110.963 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -130.22 141.72 50.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.685 -0.634 . . . . 6.8700000000000001 110.204 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 117.994 -1.003 . . . . 6.4699999999999998 110.165 179.822 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.224 0.535 . . . . 2.7599999999999998 110.544 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -75.35 141.98 43.23 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.867 -0.521 . . . . 1.7 110.101 179.198 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -127.96 135.71 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.811 -0.556 . . . . 0.40999999999999998 109.578 177.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.8 mt -83.72 -19.6 34.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.761 -0.587 . . . . 0.37 110.276 177.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.797 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.46 152.7 1.76 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.262 -0.899 . . . . 0.26000000000000001 109.124 176.222 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.1 ttpt -135.42 128.23 31.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.635 -0.665 . . . . 2.2999999999999998 110.382 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.2 p90 -149.81 163.56 37.68 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.391 -0.524 . . . . 0.20000000000000001 110.508 -178.277 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.61 137.59 51.37 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.602 -0.686 . . . . 1.99 110.4 -176.36 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.56 162.28 41.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.756 -0.59 . . . . 0.17999999999999999 109.568 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -109.63 158.56 17.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.468 -0.77 . . . . 0.17000000000000001 110.02 176.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.934 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.9 t -79.47 138.06 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.779 -0.576 . . . . 0.48999999999999999 110.355 -176.545 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -116.66 171.87 7.59 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.347 0.594 . . . . 0.68000000000000005 109.86 176.244 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -46.29 153.05 0.37 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.629 -0.669 . . . . 2.96 112.075 -175.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.579 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.9 mt 62.94 7.2 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.648 0 O-C-N 121.651 -0.655 . . . . 0.41999999999999998 112.578 -175.599 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.61 16.09 80.6 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.331 -1.108 . . . . 0.23999999999999999 110.331 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 36.7 ttp180 -85.76 144.29 27.85 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.354 -1.086 . . . . 1.96 110.198 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -132.42 155.03 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.681 -0.637 . . . . 0.29999999999999999 109.359 172.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.4 mm -115.71 128.55 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.595 -0.691 . . . . 0.25 109.952 176.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 25.5 mt -79.58 144.5 61.15 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.052 -0.659 . . . . 0.23000000000000001 109.417 175.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -63.48 143.39 87.98 Favored 'Trans proline' 0 N--CA 1.488 1.191 0 O-C-N 123.002 1.001 . . . . 0.34999999999999998 109.689 174.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.0 -26.37 60.13 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.838 -0.539 . . . . 0.33000000000000002 110.46 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.31 -45.32 93.78 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 109.999 -1.24 . . . . 0.39000000000000001 109.999 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 m -69.5 -36.87 76.9 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.617 -0.931 . . . . 0.39000000000000001 110.202 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.7 mtt180 -56.3 -42.05 76.94 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.418 -0.801 . . . . 0.40000000000000002 109.734 178.125 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -65.97 -50.2 65.16 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.364 0.602 . . . . 2.9700000000000002 110.162 -177.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -56.67 -37.87 71.42 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.835 -0.541 . . . . 0.67000000000000004 110.69 -178.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.947 ' CD2' HD13 ' A' ' 84' ' ' LEU . 25.0 t80 -87.89 -14.17 40.06 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.825 -0.547 . . . . 1.4399999999999999 111.364 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 43.03 23.24 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.586 -1.406 . . . . 0.31 109.586 178.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.922 HG23 HG21 ' A' ' 56' ' ' VAL . 76.1 mt -87.53 127.44 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.422 -1.046 . . . . 0.41999999999999998 110.575 -177.182 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.29 154.92 44.32 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.008 -0.738 . . . . 1.8200000000000001 109.008 170.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.52 137.75 47.95 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.253 -0.904 . . . . 1.99 110.751 -177.45 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.46 -15.1 64.01 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.927 -0.869 . . . . 0.19 110.927 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -75.97 157.51 33.02 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.735 1.268 . . . . 1.1200000000000001 109.851 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -111.21 138.17 47.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.606 -0.684 . . . . 0.20999999999999999 109.679 175.173 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.39 153.52 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 109.249 -0.649 . . . . 0.14999999999999999 109.249 174.549 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -115.33 122.98 47.55 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.242 -1.021 . . . . 1.0900000000000001 108.242 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.809 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.3 tt -139.97 157.99 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 119.604 -0.838 . . . . 0.14000000000000001 110.987 -167.171 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.5 tttt -132.61 145.98 51.53 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.8 -0.562 . . . . 1.1100000000000001 110.596 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 28.0 pt -115.13 151.03 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.728 -0.608 . . . . 0.20000000000000001 110.62 178.024 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.495 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.2 t -138.77 125.61 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.143 0.497 . . . . 0.20000000000000001 109.772 176.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.67 ' HB2' HG22 ' A' ' 80' ' ' ILE . 21.4 ttpp -131.9 143.36 50.08 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.222 -0.659 . . . . 1.98 109.222 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -105.03 130.14 53.3 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.137 -0.625 . . . . 0.33000000000000002 110.456 -178.139 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -135.02 131.33 36.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.745 -0.597 . . . . 1.48 110.149 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.82 -128.18 45.94 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.857 -1.297 . . . . 0.40999999999999998 109.857 -178.253 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -105.11 12.86 31.6 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.767 -0.843 . . . . 1.27 111.672 179.216 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -131.27 128.02 21.97 Favored Pre-proline 0 N--CA 1.498 1.957 0 O-C-N 121.31 -0.869 . . . . 1.3700000000000001 110.982 -178.291 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.33 137.99 21.71 Favored 'Trans proline' 0 N--CA 1.482 0.844 0 O-C-N 122.73 0.858 . . . . 0.34000000000000002 110.127 173.579 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.661 ' HB3' HG23 ' A' ' 72' ' ' ILE . 68.7 mmtt -110.85 137.17 48.83 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.548 -0.72 . . . . 1.1000000000000001 109.622 172.496 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.8 mt-10 -135.5 164.23 28.28 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.614 -0.679 . . . . 1.4199999999999999 110.796 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.614 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.15 135.96 4.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.605 -1.398 . . . . 0.17000000000000001 109.605 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.3 m -123.09 137.34 54.95 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.68 -0.894 . . . . 0.20999999999999999 109.735 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.8 p90 -155.87 172.55 18.16 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.843 -0.743 . . . . 0.16 111.017 176.794 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.0 m -107.78 140.85 40.23 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.694 -0.629 . . . . 0.13 109.545 174.078 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.09 145.78 34.69 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.723 -0.61 . . . . 0.14000000000000001 110.641 -175.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.7 ttp180 -93.9 145.25 24.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.73 -0.606 . . . . 2.21 109.598 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.922 HG21 HG23 ' A' ' 29' ' ' ILE . 98.8 t -78.44 126.47 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.783 -0.573 . . . . 0.17000000000000001 109.928 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.04 -166.51 24.98 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.099 -1.201 . . . . 0.19 110.099 178.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -61.63 153.08 28.94 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.872 -0.781 . . . . 1.3899999999999999 110.218 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.57 21.18 2.41 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.547 -0.721 . . . . 0.81999999999999995 112.001 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.81 20.48 79.76 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.747 -1.216 . . . . 0.19 110.806 171.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 14.2 m -77.99 145.25 36.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.414 -1.05 . . . . 1.3 110.232 -176.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.27 145.51 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.789 -0.569 . . . . 0.20999999999999999 109.609 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -112.03 123.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.55 -0.719 . . . . 0.34000000000000002 110.734 -174.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.455 HG23 ' HD2' ' A' ' 65' ' ' PRO . 80.3 mt -78.5 145.12 66.99 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.591 -0.693 . . . . 0.34000000000000002 109.484 172.509 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.2 Cg_endo -64.38 136.68 52.08 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 O-C-N 122.889 0.941 . . . . 0.26000000000000001 110.821 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 20.2 tptt -54.93 -34.85 63.59 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.47 -0.769 . . . . 2.6200000000000001 110.845 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.91 -38.2 78.4 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.764 -0.585 . . . . 0.45000000000000001 110.298 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.0 mt -77.17 -32.78 56.4 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.727 -0.608 . . . . 1.8200000000000001 110.658 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.2 mtt180 -58.3 -45.85 87.24 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.22 -0.925 . . . . 2.5299999999999998 109.884 178.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.3 -47.42 61.26 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 120.383 -0.527 . . . . 1.6799999999999999 110.51 -175.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.9 t -60.58 -38.18 77.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 O-C-N 121.653 -0.654 . . . . 0.28000000000000003 109.91 -178.336 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.697 HG22 HD11 ' A' ' 74' ' ' ILE . 86.1 mt -82.28 -17.61 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.882 -0.512 . . . . 0.28000000000000003 110.966 -176.224 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.23 40.83 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.835 -1.306 . . . . 0.22 109.835 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.934 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.58 141.11 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.511 -0.994 . . . . 0.77000000000000002 110.704 -173.724 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -127.67 156.28 75.8 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.732 -0.605 . . . . 3.21 110.631 -177.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -55.98 135.42 69.67 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 122.974 0.986 . . . . 0.5 111.275 177.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.12 -0.76 72.71 Favored Glycine 0 N--CA 1.496 2.65 0 C-N-CA 120.694 -0.765 . . . . 0.23999999999999999 111.241 176.267 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -96.36 132.6 41.7 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-N 118.734 1.267 . . . . 1.1100000000000001 110.477 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.3 p -91.21 132.08 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-O 121.639 0.733 . . . . 0.23999999999999999 110.979 -174.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.67 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.4 pt -123.23 159.42 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 109.464 -0.569 . . . . 0.17999999999999999 109.464 177.382 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.7 tt0 -98.13 131.57 44.4 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.919 -0.771 . . . . 1.1399999999999999 108.919 173.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.809 ' CG1' HD11 ' A' ' 37' ' ' ILE . 99.9 t -115.1 128.01 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.20000000000000001 110.166 -171.453 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.1 mt -114.79 128.46 56.31 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.365 -0.605 . . . . 0.25 109.365 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.947 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.88 139.92 36.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.485 -0.76 . . . . 0.28000000000000003 109.821 172.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.7 mt -110.93 -31.75 7.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.769 -0.582 . . . . 1.6000000000000001 110.85 -175.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.25 -177.04 39.12 Favored Glycine 0 N--CA 1.504 3.225 0 C-N-CA 119.745 -1.216 . . . . 0.20000000000000001 110.958 -176.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -144.72 152.56 40.59 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.667 -0.902 . . . . 1.8899999999999999 110.72 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -136.29 139.92 43.01 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.80000000000000004 109.995 175.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -123.84 160.05 53.3 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.698 -0.626 . . . . 2.9900000000000002 110.279 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -55.86 147.66 60.96 Favored 'Trans proline' 0 N--CA 1.497 1.678 0 O-C-N 123.141 1.074 . . . . 1.6799999999999999 111.043 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 82.7 mmt-85 -121.12 146.86 46.3 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.719 -0.613 . . . . 6.8700000000000001 110.216 178.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 . . . . . 0 N--CA 1.504 2.249 0 CA-C-O 117.969 -1.015 . . . . 6.4699999999999998 110.998 -179.959 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 121.232 0.539 . . . . 2.7599999999999998 110.597 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.16 142.05 39.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.837 -0.539 . . . . 1.7 110.126 179.528 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.1 p -127.57 141.82 45.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.708 -0.62 . . . . 0.40999999999999998 109.723 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.559 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.4 mt -89.58 -18.02 27.38 Favored 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 120.309 -0.556 . . . . 0.37 110.654 -177.141 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.869 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.75 154.99 3.8 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.249 -0.907 . . . . 0.26000000000000001 109.577 177.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -133.63 127.1 32.27 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.707 -0.621 . . . . 2.2999999999999998 110.126 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.582 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 13.2 p90 -148.75 162.64 39.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.643 -0.661 . . . . 0.20000000000000001 110.702 177.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.81 138.37 50.36 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.596 -0.69 . . . . 1.99 110.34 -176.406 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.04 162.21 41.28 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 109.459 -0.571 . . . . 0.17999999999999999 109.459 177.065 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -109.31 158.45 17.87 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.436 -0.79 . . . . 0.17000000000000001 110.152 177.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.905 HG21 HG21 ' A' ' 74' ' ' ILE . 61.2 t -79.22 136.43 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.32 -0.552 . . . . 0.48999999999999999 110.097 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.41 171.87 7.36 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-O 121.269 0.556 . . . . 0.68000000000000005 109.612 173.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -46.86 152.61 0.49 Allowed 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.579 -0.7 . . . . 2.96 111.978 -176.149 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.61 0 O-C-N 121.529 -0.732 . . . . 0.41999999999999998 112.631 -175.478 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.401 ' HA3' ' NE ' ' A' ' 69' ' ' ARG . . . 78.01 16.17 80.18 Favored Glycine 0 N--CA 1.497 2.742 0 O-C-N 120.964 -1.085 . . . . 0.23999999999999999 110.463 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -83.89 141.15 31.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.298 -1.119 . . . . 1.96 110.316 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.7 pt -133.72 155.75 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.569 -0.707 . . . . 0.29999999999999999 109.816 173.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.17 129.75 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.529 -0.732 . . . . 0.25 109.878 175.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.426 HG12 ' CE2' ' A' ' 7' ' ' PHE . 24.2 mt -79.76 145.91 63.35 Favored Pre-proline 0 N--CA 1.495 1.806 0 C-N-CA 119.962 -0.695 . . . . 0.23000000000000001 109.322 175.573 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.412 ' HD2' HG23 ' A' ' 19' ' ' ILE . 48.2 Cg_endo -63.22 143.25 89.29 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.005 1.002 . . . . 0.34999999999999998 109.819 174.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.84 -26.43 62.03 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 120.404 -0.518 . . . . 0.33000000000000002 110.462 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.94 -43.86 95.37 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 110.027 -1.229 . . . . 0.39000000000000001 110.027 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.7 m -69.87 -38.61 76.47 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.63 -0.924 . . . . 0.39000000000000001 110.136 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.594 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.2 mtt180 -56.24 -43.27 78.48 Favored 'General case' 0 N--CA 1.513 2.694 0 O-C-N 121.346 -0.846 . . . . 0.40000000000000002 109.571 176.775 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -67.16 -50.2 62.02 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-O 121.18 0.514 . . . . 2.9700000000000002 110.316 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -57.6 -36.35 71.65 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.764 -0.585 . . . . 0.67000000000000004 110.661 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 16.8 t80 -88.15 -14.06 39.65 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.705 -0.622 . . . . 1.4399999999999999 111.371 -174.322 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 74.92 41.74 32.23 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.657 -1.377 . . . . 0.31 109.657 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.843 HG23 HG21 ' A' ' 56' ' ' VAL . 81.9 mt -90.91 132.79 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.504 -0.998 . . . . 0.41999999999999998 110.615 -176.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.18 159.29 36.52 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.047 -0.723 . . . . 1.8200000000000001 109.047 172.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -57.96 140.23 52.66 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.388 -0.82 . . . . 1.99 110.367 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.77 -16.0 61.79 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.849 -0.901 . . . . 0.19 110.849 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.04 158.5 30.51 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.72 1.26 . . . . 1.1200000000000001 110.223 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -111.86 139.68 47.14 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.661 -0.649 . . . . 0.20999999999999999 109.598 174.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.09 155.02 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 109.235 -0.654 . . . . 0.14999999999999999 109.235 174.493 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -116.35 123.22 47.08 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.345 -0.984 . . . . 1.0900000000000001 108.345 -178.619 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.0 tt -140.53 158.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.553 -0.859 . . . . 0.14000000000000001 111.232 -166.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -132.54 145.61 51.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.878 -0.514 . . . . 1.1100000000000001 110.519 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.495 HG22 HG22 ' A' ' 82' ' ' VAL . 26.1 pt -115.06 151.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.664 -0.647 . . . . 0.20000000000000001 110.6 178.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.2 t -139.2 126.01 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 CA-C-O 121.31 0.576 . . . . 0.20000000000000001 110.049 176.025 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.776 ' HB2' HG22 ' A' ' 80' ' ' ILE . 17.2 tptt -132.59 148.7 52.37 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 109.004 -0.739 . . . . 1.98 109.004 174.784 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.8 t80 -102.76 128.16 49.62 Favored 'General case' 0 N--CA 1.495 1.785 0 C-N-CA 120.137 -0.625 . . . . 0.33000000000000002 110.246 -179.699 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -134.79 134.37 40.82 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.645 -0.659 . . . . 1.48 110.089 179.22 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.22 46.01 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 109.803 -1.319 . . . . 0.40999999999999998 109.803 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -105.08 10.24 34.04 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.714 -0.874 . . . . 1.27 111.713 178.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.14 138.11 32.16 Favored Pre-proline 0 N--CA 1.499 1.976 0 O-C-N 121.242 -0.911 . . . . 1.3700000000000001 111.073 -177.531 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -75.11 139.18 23.7 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 O-C-N 122.86 0.926 . . . . 0.34000000000000002 110.298 173.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.737 ' HB3' HG23 ' A' ' 72' ' ' ILE . 18.0 mmtp -113.62 137.35 51.72 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.556 -0.715 . . . . 1.1000000000000001 109.559 172.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -137.97 166.27 24.49 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.59 -0.694 . . . . 1.4199999999999999 110.756 -178.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.83 135.94 4.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.692 -1.363 . . . . 0.17000000000000001 109.692 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 m -119.93 137.95 53.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.661 -0.905 . . . . 0.20999999999999999 109.766 176.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 15.0 p90 -156.04 173.89 16.15 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 120.0 -0.68 . . . . 0.16 110.981 176.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.0 m -106.32 140.91 38.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.731 -0.606 . . . . 0.13 109.475 173.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 144.9 35.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.679 -0.638 . . . . 0.14000000000000001 110.636 -175.473 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.815 -0.553 . . . . 2.21 109.732 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -79.47 125.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.321 0.581 . . . . 0.17000000000000001 109.871 178.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.08 -171.31 27.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.617 -1.393 . . . . 0.19 109.617 178.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -61.87 156.1 21.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.569 -0.959 . . . . 1.3899999999999999 109.837 178.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 54.99 19.4 2.68 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.446 -0.784 . . . . 0.81999999999999995 112.079 -177.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.21 20.47 79.93 Favored Glycine 0 N--CA 1.5 2.91 0 C-N-CA 119.81 -1.186 . . . . 0.19 110.728 172.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -78.0 146.02 35.63 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.503 -0.998 . . . . 1.3 110.409 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -138.51 146.52 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.719 -0.613 . . . . 0.20999999999999999 109.627 173.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -108.89 122.21 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 121.555 -0.715 . . . . 0.34000000000000002 110.533 -174.088 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.2 mt -79.01 142.07 59.43 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.606 -0.684 . . . . 0.34000000000000002 109.625 173.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -65.1 131.83 29.94 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.862 0.927 . . . . 0.26000000000000001 110.729 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -55.17 -33.07 62.66 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.497 -0.752 . . . . 2.6200000000000001 110.88 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.8 -37.99 77.59 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.785 -0.572 . . . . 0.45000000000000001 110.189 -178.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 76.3 mt -77.01 -32.74 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.747 -0.596 . . . . 1.8200000000000001 110.403 177.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.401 ' NE ' ' HA3' ' A' ' 15' ' ' GLY . 38.1 mtt180 -57.73 -46.08 84.93 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 121.352 -0.842 . . . . 2.5299999999999998 109.85 178.396 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -70.08 -47.87 60.08 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.528 -0.469 . . . . 1.6799999999999999 110.413 -175.251 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.6 t -60.57 -38.1 77.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 C-N-CA 120.157 -0.617 . . . . 0.28000000000000003 109.924 -178.32 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.737 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.3 mt -82.76 -17.66 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.866 -0.521 . . . . 0.28000000000000003 110.919 -176.081 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.498 2.829 0 N-CA-C 109.68 -1.368 . . . . 0.22 109.68 175.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.905 HG21 HG21 ' A' ' 11' ' ' VAL . 51.3 mm -89.56 143.82 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.515 -0.991 . . . . 0.77000000000000002 110.644 -174.047 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -129.22 156.96 77.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.764 -0.585 . . . . 3.21 110.719 -177.171 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.28 134.14 62.1 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.022 1.012 . . . . 0.5 111.412 177.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.37 -0.17 71.07 Favored Glycine 0 N--CA 1.497 2.761 0 C-N-CA 120.617 -0.801 . . . . 0.23999999999999999 111.205 175.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -96.26 132.39 41.77 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-N 118.732 1.266 . . . . 1.1100000000000001 110.4 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.425 HG13 ' O ' ' A' ' 79' ' ' VAL . 11.2 p -91.03 130.05 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.46 0.648 . . . . 0.23999999999999999 110.961 -174.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.776 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.5 pt -117.67 159.34 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.462 -0.57 . . . . 0.17999999999999999 109.462 176.705 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -98.49 130.87 45.08 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.893 -0.781 . . . . 1.1399999999999999 108.893 173.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.5 t -114.6 128.53 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 CA-C-O 121.381 0.61 . . . . 0.20000000000000001 110.18 -171.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.404 ' HB3' HG21 ' A' ' 3' ' ' VAL . 45.0 mt -114.96 129.8 56.79 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.22 141.57 35.49 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.28000000000000003 109.996 173.406 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.52 -32.38 6.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.839 -0.538 . . . . 1.6000000000000001 110.779 -177.7 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.559 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.16 -174.46 37.69 Favored Glycine 0 N--CA 1.504 3.171 0 C-N-CA 119.681 -1.247 . . . . 0.20000000000000001 111.058 -177.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.0 p80 -146.35 153.71 40.83 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.664 -0.904 . . . . 1.8899999999999999 110.614 -179.246 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -135.63 141.42 45.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.545 -0.722 . . . . 0.80000000000000004 110.108 176.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.2 ptpp? -108.12 160.02 28.49 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.696 -0.628 . . . . 2.9900000000000002 110.354 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -54.76 144.35 66.08 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 O-C-N 123.161 1.085 . . . . 1.6799999999999999 111.042 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 91.1 mtm-85 -123.44 147.82 46.78 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.727 -0.608 . . . . 6.8700000000000001 110.163 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 33.7 t30 . . . . . 0 N--CA 1.499 1.985 0 CA-C-O 118.019 -0.991 . . . . 6.4699999999999998 110.126 179.666 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.0 mtt . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.165 0.507 . . . . 2.7599999999999998 110.519 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -102.85 147.42 26.9 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.784 -0.573 . . . . 1.7 110.014 178.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.4 p -121.16 137.59 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.778 -0.576 . . . . 0.40999999999999998 109.513 176.175 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.614 HD11 ' HA2' ' A' ' 86' ' ' GLY . 23.2 mt -85.32 -18.04 35.03 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 120.279 -0.568 . . . . 0.37 110.462 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.96 155.47 3.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.368 -0.833 . . . . 0.26000000000000001 109.589 176.65 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.2 ttmt -132.95 127.02 33.33 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.715 -0.615 . . . . 2.2999999999999998 110.124 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.3 p90 -149.77 162.51 40.13 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.634 -0.667 . . . . 0.20000000000000001 110.728 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -113.33 138.96 49.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.604 -0.685 . . . . 1.99 110.32 -176.516 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.474 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.75 162.3 40.99 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.739 -0.601 . . . . 0.17999999999999999 109.619 177.503 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.49 159.02 17.88 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 119.787 -0.765 . . . . 0.17000000000000001 110.01 176.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.1 t -79.32 135.94 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.233 -0.587 . . . . 0.48999999999999999 110.333 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.3 m80 -115.39 171.97 7.38 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.528 -0.545 . . . . 0.68000000000000005 109.528 174.064 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -46.26 152.31 0.43 Allowed 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.562 -0.711 . . . . 2.96 112.033 -175.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.64 7.4 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.495 -0.753 . . . . 0.41999999999999998 112.632 -174.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.72 16.01 80.61 Favored Glycine 0 N--CA 1.497 2.723 0 O-C-N 120.915 -1.115 . . . . 0.23999999999999999 110.423 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.84 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -84.91 143.41 29.02 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.199 -1.177 . . . . 1.96 110.294 -177.092 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.474 HD12 HG21 ' A' ' 9' ' ' THR . 41.7 pt -133.21 157.49 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.759 -0.588 . . . . 0.29999999999999999 109.532 173.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.84 HD11 ' NH1' ' A' ' 16' ' ' ARG . 48.6 mm -116.29 129.6 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.591 -0.693 . . . . 0.25 109.96 176.06 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.6 mt -79.19 145.5 64.92 Favored Pre-proline 0 N--CA 1.496 1.859 0 C-N-CA 119.961 -0.695 . . . . 0.23000000000000001 109.375 175.343 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.2 142.86 88.31 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.102 1.054 . . . . 0.34999999999999998 109.79 174.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.56 -26.6 61.66 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.84 -0.538 . . . . 0.33000000000000002 110.447 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.8 95.0 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.036 -1.225 . . . . 0.39000000000000001 110.036 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.1 m -69.73 -37.45 76.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.699 -0.883 . . . . 0.39000000000000001 109.848 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.6 mtt180 -55.95 -42.42 76.2 Favored 'General case' 0 N--CA 1.509 2.499 0 O-C-N 121.343 -0.848 . . . . 0.40000000000000002 109.801 178.083 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -66.75 -50.37 62.96 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.302 0.573 . . . . 2.9700000000000002 110.284 -176.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -57.2 -37.15 71.76 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.868 -0.52 . . . . 0.67000000000000004 110.622 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.946 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.6 t80 -87.83 -14.17 40.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.85 -0.531 . . . . 1.4399999999999999 111.275 -176.408 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.36 42.37 28.11 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.57 -1.412 . . . . 0.31 109.57 177.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 77.8 mt -89.6 129.41 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.559 -0.965 . . . . 0.41999999999999998 110.653 -176.566 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -128.48 159.51 35.21 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 109.173 -0.677 . . . . 1.8200000000000001 109.173 171.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -57.75 138.59 55.37 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.411 -0.805 . . . . 1.99 110.478 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.1 62.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.857 -0.897 . . . . 0.19 110.857 179.328 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -77.09 157.47 31.03 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-N 118.763 1.281 . . . . 1.1200000000000001 110.03 177.493 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -111.44 138.87 47.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.671 -0.643 . . . . 0.20999999999999999 109.644 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 155.34 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 0.14999999999999999 109.269 174.536 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -117.34 123.89 47.61 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.276 -1.009 . . . . 1.0900000000000001 108.276 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.834 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.96 157.56 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.553 -0.859 . . . . 0.14000000000000001 111.044 -167.051 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.68 146.09 51.59 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.789 -0.569 . . . . 1.1100000000000001 110.427 177.547 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.498 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.6 pt -114.89 151.09 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.732 -0.605 . . . . 0.20000000000000001 110.595 178.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.0 126.72 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.123 0.487 . . . . 0.20000000000000001 109.707 176.295 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.699 ' HB2' HG22 ' A' ' 80' ' ' ILE . 30.6 tptt -138.09 147.12 43.71 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.726 -0.609 . . . . 1.98 109.636 175.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 39.5 t80 -102.09 130.28 48.65 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 120.291 -0.564 . . . . 0.33000000000000002 110.369 -176.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.412 ' OE2' HD13 ' A' ' 74' ' ' ILE . 93.8 mt-10 -134.37 135.76 42.9 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.616 -0.678 . . . . 1.48 110.042 177.418 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.16 45.88 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.774 -1.33 . . . . 0.40999999999999998 109.774 -178.166 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.12 8.91 34.36 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.835 -0.803 . . . . 1.27 111.825 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.24 135.13 26.66 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.185 -0.947 . . . . 1.3700000000000001 111.033 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.35 144.88 29.65 Favored 'Trans proline' 0 N--CA 1.482 0.818 0 O-C-N 122.801 0.895 . . . . 0.34000000000000002 110.114 173.186 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.446 ' CB ' HG23 ' A' ' 72' ' ' ILE . 31.4 mttm -122.5 149.24 44.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.491 -0.756 . . . . 1.1000000000000001 110.105 171.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.2 mt-10 -136.75 167.74 20.86 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.758 -0.589 . . . . 1.4199999999999999 110.835 -176.52 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.67 135.87 4.45 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.49 -1.444 . . . . 0.17000000000000001 109.49 177.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -122.88 138.23 54.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.931 . . . . 0.20999999999999999 109.978 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.81 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.8 p90 -156.3 172.92 17.64 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 119.858 -0.737 . . . . 0.16 110.89 175.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -106.95 141.29 38.4 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.704 -0.623 . . . . 0.13 109.473 173.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.81 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 145.99 36.7 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.591 -0.693 . . . . 0.14000000000000001 110.759 -175.451 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -93.47 145.24 24.65 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.582 -0.525 . . . . 2.21 109.582 175.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 91.3 t -78.96 125.07 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.295 0.569 . . . . 0.17000000000000001 109.823 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.62 -166.62 25.38 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.117 -1.193 . . . . 0.19 110.117 178.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.74 153.51 28.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.768 -0.842 . . . . 1.3899999999999999 110.158 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 53.39 21.21 2.28 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.595 -0.69 . . . . 0.81999999999999995 112.167 -179.577 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.22 20.51 79.64 Favored Glycine 0 N--CA 1.501 2.982 0 C-N-CA 119.663 -1.256 . . . . 0.19 110.764 171.506 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.5 m -77.87 145.2 36.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.456 -1.026 . . . . 1.3 110.441 -175.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.46 146.65 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.806 -0.559 . . . . 0.20999999999999999 109.645 175.08 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.44 122.72 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.509 -0.744 . . . . 0.34000000000000002 110.787 -174.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.8 mt -79.11 144.33 62.81 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.584 -0.698 . . . . 0.34000000000000002 109.624 172.577 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.8 Cg_endo -64.76 134.39 40.39 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 O-C-N 122.952 0.975 . . . . 0.26000000000000001 110.841 -179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -55.19 -34.16 63.65 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.491 -0.756 . . . . 2.6200000000000001 110.814 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.66 76.68 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.729 -0.607 . . . . 0.45000000000000001 110.32 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.6 mt -77.13 -32.69 56.62 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.73 -0.607 . . . . 1.8200000000000001 110.5 178.534 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.85 -46.05 85.35 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.328 -0.857 . . . . 2.5299999999999998 109.858 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.92 -46.61 64.99 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 120.512 -0.475 . . . . 1.6799999999999999 110.411 -175.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.0 t -60.55 -38.7 79.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.679 -0.638 . . . . 0.28000000000000003 109.949 -178.576 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.563 HG22 HD11 ' A' ' 74' ' ' ILE . 83.6 mt -82.8 -16.44 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.791 -0.568 . . . . 0.28000000000000003 111.102 -176.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 75.77 35.18 46.45 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.91 -1.276 . . . . 0.22 109.91 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.77 142.32 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.53 -0.982 . . . . 0.77000000000000002 110.589 -174.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.2 mttt -128.9 158.73 71.63 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.82 -0.55 . . . . 3.21 110.586 -177.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -54.56 134.21 60.8 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.063 1.033 . . . . 0.5 111.429 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.1 -0.5 72.42 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.69 -0.766 . . . . 0.23999999999999999 111.292 175.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -97.37 133.51 41.87 Favored 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 118.711 1.255 . . . . 1.1100000000000001 110.559 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 79' ' ' VAL . 11.2 p -91.95 131.17 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-O 121.479 0.657 . . . . 0.23999999999999999 111.095 -174.481 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.699 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -119.0 159.48 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.286 -0.635 . . . . 0.17999999999999999 109.286 175.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -97.93 131.59 44.25 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.891 -0.781 . . . . 1.1399999999999999 108.891 174.109 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.834 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.8 t -115.65 129.5 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.348 0.594 . . . . 0.20000000000000001 110.263 -170.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.5 mt -115.13 130.8 57.02 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 109.279 -0.638 . . . . 0.25 109.279 179.318 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.946 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.35 139.9 36.34 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.365 -0.835 . . . . 0.28000000000000003 110.037 173.052 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -106.65 -36.4 6.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.836 -0.54 . . . . 1.6000000000000001 110.837 -176.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.614 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.88 -175.2 38.11 Favored Glycine 0 N--CA 1.502 3.061 0 C-N-CA 119.79 -1.195 . . . . 0.20000000000000001 110.935 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -143.81 153.46 42.4 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.682 -0.893 . . . . 1.8899999999999999 110.728 -177.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -134.1 138.65 45.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.622 -0.674 . . . . 0.80000000000000004 110.205 175.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.4 mttt -122.64 104.22 36.9 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.79 -0.569 . . . . 2.9900000000000002 110.23 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_exo -54.37 145.19 57.74 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 O-C-N 123.104 1.055 . . . . 1.6799999999999999 111.097 -179.593 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 72.8 mtp85 -121.94 149.04 44.01 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.688 -0.632 . . . . 6.8700000000000001 110.209 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.9 m120 . . . . . 0 N--CA 1.497 1.892 0 CA-C-O 118.01 -0.995 . . . . 6.4699999999999998 110.16 179.986 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.6 mtm . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.2 0.524 . . . . 2.7599999999999998 110.622 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -81.03 138.35 36.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.822 -0.548 . . . . 1.7 110.1 178.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 p -128.69 134.32 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.725 -0.61 . . . . 0.40999999999999998 109.47 177.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.584 HD11 ' HA2' ' A' ' 86' ' ' GLY . 31.4 mt -82.73 -19.86 37.13 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.764 -0.585 . . . . 0.37 110.454 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.71 153.63 3.42 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.38 -0.825 . . . . 0.26000000000000001 109.241 175.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -133.48 125.17 28.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.804 -0.56 . . . . 2.2999999999999998 110.07 -176.522 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.586 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 12.9 p90 -151.0 162.55 40.61 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.638 -0.664 . . . . 0.20000000000000001 110.794 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -113.48 139.11 49.21 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.61 -0.681 . . . . 1.99 110.246 -176.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.96 162.37 40.95 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.785 -0.572 . . . . 0.17999999999999999 109.63 177.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 t -111.28 158.76 18.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.433 -0.792 . . . . 0.17000000000000001 109.986 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.5 t -79.33 134.7 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 C-N-CA 120.296 -0.561 . . . . 0.48999999999999999 110.239 -176.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -113.44 171.89 7.29 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.22 0.534 . . . . 0.68000000000000005 109.646 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -46.49 152.98 0.4 Allowed 'General case' 0 N--CA 1.506 2.334 0 O-C-N 121.594 -0.691 . . . . 2.96 111.957 -176.128 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.76 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.675 0 O-C-N 121.573 -0.705 . . . . 0.41999999999999998 112.601 -174.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.2 16.1 80.92 Favored Glycine 0 N--CA 1.498 2.787 0 O-C-N 120.875 -1.14 . . . . 0.23999999999999999 110.276 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -85.65 143.41 28.43 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.265 -1.138 . . . . 1.96 110.443 -176.048 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.1 pt -133.37 155.53 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.787 -0.571 . . . . 0.29999999999999999 109.491 172.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -116.54 129.18 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.629 -0.669 . . . . 0.25 110.038 176.227 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -79.47 145.12 62.83 Favored Pre-proline 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.23000000000000001 109.404 175.573 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -63.49 143.32 87.75 Favored 'Trans proline' 0 N--CA 1.488 1.17 0 O-C-N 122.966 0.982 . . . . 0.34999999999999998 109.775 174.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.91 -26.52 59.34 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.799 -0.563 . . . . 0.33000000000000002 110.504 -178.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.4 -45.14 94.15 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.016 -1.233 . . . . 0.39000000000000001 110.016 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 76.4 m -69.38 -37.09 77.41 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.621 -0.929 . . . . 0.39000000000000001 110.178 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.62 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.32 -42.15 77.16 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.369 -0.832 . . . . 0.40000000000000002 109.687 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.8 tptm -66.43 -50.2 64.19 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-O 121.244 0.545 . . . . 2.9700000000000002 110.214 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -57.05 -37.99 72.59 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.928 -0.482 . . . . 0.67000000000000004 110.698 -178.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.959 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.6 t80 -86.87 -14.31 42.36 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.812 -0.555 . . . . 1.4399999999999999 111.277 -177.345 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 42.52 24.61 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.631 -1.388 . . . . 0.31 109.631 178.281 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.58 129.1 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.52 -0.988 . . . . 0.41999999999999998 110.483 -177.092 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.06 158.47 37.86 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.919 -0.771 . . . . 1.8200000000000001 108.919 170.645 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -57.24 140.04 50.97 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.309 -0.869 . . . . 1.99 110.492 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.01 -16.02 61.84 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.842 -0.903 . . . . 0.19 110.842 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.88 157.94 31.08 Favored 'General case' 0 N--CA 1.5 2.047 0 CA-C-N 118.739 1.27 . . . . 1.1200000000000001 110.198 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -111.36 138.74 47.46 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.635 -0.666 . . . . 0.20999999999999999 109.603 174.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.22 153.78 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.282 -0.636 . . . . 0.14999999999999999 109.282 174.3 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -115.86 123.54 48.4 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.305 -0.998 . . . . 1.0900000000000001 108.305 -179.077 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.84 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -139.99 158.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 C-N-CA 119.587 -0.845 . . . . 0.14000000000000001 111.004 -167.491 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -133.09 145.97 51.22 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.874 -0.516 . . . . 1.1100000000000001 110.505 177.489 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.532 ' HB ' HD12 ' A' ' 80' ' ' ILE . 24.5 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.79 -0.569 . . . . 0.20000000000000001 110.619 178.325 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.522 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -138.96 125.5 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.917 -0.489 . . . . 0.20000000000000001 109.787 176.301 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.68 ' HB2' HG22 ' A' ' 80' ' ' ILE . 54.4 tttp -132.28 144.49 50.63 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.774 -0.579 . . . . 1.98 109.533 174.766 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -104.87 129.36 53.21 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.197 -0.601 . . . . 0.33000000000000002 110.459 -178.488 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -133.53 129.95 37.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.672 -0.642 . . . . 1.48 110.073 177.245 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.78 -128.17 45.96 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.811 -1.316 . . . . 0.40999999999999998 109.811 -177.562 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.11 14.17 29.62 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 1.27 111.562 178.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -131.06 124.44 20.54 Favored Pre-proline 0 N--CA 1.498 1.947 0 O-C-N 121.251 -0.906 . . . . 1.3700000000000001 110.994 -177.684 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.25 137.0 20.62 Favored 'Trans proline' 0 N--CA 1.482 0.828 0 O-C-N 122.704 0.844 . . . . 0.34000000000000002 110.133 174.36 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.762 ' HB3' HG23 ' A' ' 72' ' ' ILE . 16.6 mmtp -110.78 137.75 48.04 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 1.1000000000000001 109.682 173.515 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -134.94 163.94 28.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.683 -0.636 . . . . 1.4199999999999999 110.786 -177.654 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.95 135.92 4.44 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.56 -1.416 . . . . 0.17000000000000001 109.56 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.4 m -122.25 137.83 54.7 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.735 -0.862 . . . . 0.20999999999999999 109.766 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -155.82 172.88 17.59 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.562 -0.711 . . . . 0.16 110.937 176.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -106.6 140.3 39.68 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.707 -0.621 . . . . 0.13 109.556 173.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.84 144.51 35.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.664 -0.648 . . . . 0.14000000000000001 110.49 -176.322 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -93.5 144.73 25.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.845 -0.534 . . . . 2.21 109.569 176.22 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -78.47 125.75 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.789 -0.569 . . . . 0.17000000000000001 109.862 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.77 -167.54 26.26 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.892 -1.283 . . . . 0.19 109.892 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.68 153.52 27.91 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.756 -0.849 . . . . 1.3899999999999999 110.163 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 53.57 21.09 2.37 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.51 -0.744 . . . . 0.81999999999999995 112.008 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.95 20.52 79.72 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.814 -1.184 . . . . 0.19 110.837 171.182 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.3 m -77.99 145.26 36.09 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.462 -1.022 . . . . 1.3 110.296 -176.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.27 146.21 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.772 -0.58 . . . . 0.20999999999999999 109.559 174.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.8 mm -110.92 122.94 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.521 -0.737 . . . . 0.34000000000000002 110.671 -174.262 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.41 HG23 ' HD2' ' A' ' 65' ' ' PRO . 84.7 mt -78.88 143.0 61.26 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.572 -0.705 . . . . 0.34000000000000002 109.568 172.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.751 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.5 Cg_endo -64.57 133.48 37.15 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 O-C-N 122.954 0.976 . . . . 0.26000000000000001 110.755 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -55.2 -34.0 63.53 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.484 -0.76 . . . . 2.6200000000000001 110.84 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.95 77.34 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.734 -0.604 . . . . 0.45000000000000001 110.232 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.751 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.5 mt -77.1 -32.65 56.78 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.21 -0.596 . . . . 1.8200000000000001 110.513 178.421 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.79 -45.52 85.92 Favored 'General case' 0 N--CA 1.504 2.248 0 O-C-N 121.331 -0.856 . . . . 2.5299999999999998 109.827 178.593 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.28 -47.67 60.16 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 120.506 -0.478 . . . . 1.6799999999999999 110.467 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 90.8 t -60.58 -38.1 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.106 0 O-C-N 121.683 -0.636 . . . . 0.28000000000000003 109.816 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.762 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.4 mt -82.71 -17.47 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.795 -0.566 . . . . 0.28000000000000003 110.914 -176.488 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.4 35.2 37.97 Favored Glycine 0 N--CA 1.498 2.797 0 N-CA-C 109.78 -1.328 . . . . 0.22 109.78 175.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.6 mm -90.81 144.15 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.979 . . . . 0.77000000000000002 110.673 -174.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -131.39 163.45 49.42 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.776 -0.577 . . . . 3.21 110.685 -177.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.83 134.44 57.14 Favored 'Trans proline' 0 N--CA 1.487 1.142 0 O-C-N 122.934 0.965 . . . . 0.5 110.865 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.83 0.82 71.38 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 111.149 -0.78 . . . . 0.23999999999999999 111.149 176.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -97.24 132.43 43.01 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 118.733 1.266 . . . . 1.1100000000000001 110.515 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.0 p -93.46 137.18 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.901 0.858 . . . . 0.23999999999999999 111.433 -173.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.68 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -126.41 159.52 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.391 -0.596 . . . . 0.17999999999999999 109.391 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -97.52 130.58 44.58 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.942 -0.762 . . . . 1.1399999999999999 108.942 174.512 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.84 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.0 t -115.08 129.96 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 CA-C-O 121.318 0.58 . . . . 0.20000000000000001 110.158 -171.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 35.3 mt -117.13 129.51 56.02 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 109.047 -0.723 . . . . 0.25 109.047 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.959 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.7 mt -79.77 140.61 36.84 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.718 -0.793 . . . . 0.28000000000000003 109.848 172.37 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.9 mt -110.39 -33.38 6.64 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.788 -0.57 . . . . 1.6000000000000001 110.859 -175.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.584 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -175.89 38.42 Favored Glycine 0 N--CA 1.503 3.148 0 C-N-CA 119.763 -1.208 . . . . 0.20000000000000001 110.953 -176.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -143.81 153.65 42.59 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.725 -0.867 . . . . 1.8899999999999999 110.675 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -137.97 142.92 40.47 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.498 -0.751 . . . . 0.80000000000000004 110.198 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -122.94 159.24 54.65 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.686 -0.634 . . . . 2.9900000000000002 109.946 179.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -55.6 143.51 78.7 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 O-C-N 123.142 1.075 . . . . 1.6799999999999999 110.976 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -128.69 140.72 51.61 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.783 -0.573 . . . . 6.8700000000000001 110.165 179.476 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 . . . . . 0 N--CA 1.495 1.806 0 CA-C-O 118.024 -0.988 . . . . 6.4699999999999998 110.226 -179.898 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.0 mtp . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.172 0.511 . . . . 2.7599999999999998 110.588 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.4 146.46 45.09 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.896 -0.503 . . . . 1.7 109.946 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -128.51 136.76 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.663 -0.648 . . . . 0.40999999999999998 109.671 178.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.4 mt -84.06 -21.62 31.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.789 -0.569 . . . . 0.37 110.323 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.901 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.28 155.46 3.58 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.36 -0.837 . . . . 0.26000000000000001 109.175 176.466 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.403 ' HG3' HD23 ' A' ' 83' ' ' LEU . 23.1 tttt -133.47 125.56 29.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.668 -0.645 . . . . 2.2999999999999998 110.175 -177.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.8 p90 -150.84 162.78 40.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.20000000000000001 110.757 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -113.24 139.07 49.11 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.562 -0.711 . . . . 1.99 110.264 -176.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.04 162.32 41.07 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.825 -0.547 . . . . 0.17999999999999999 109.646 177.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -111.2 158.7 18.64 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.818 -0.753 . . . . 0.17000000000000001 110.038 177.165 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.4 135.67 25.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.742 -0.599 . . . . 0.48999999999999999 110.288 -176.626 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.0 m80 -114.79 171.9 7.36 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.354 0.597 . . . . 0.68000000000000005 109.661 174.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -46.65 153.04 0.41 Allowed 'General case' 0 N--CA 1.505 2.318 0 O-C-N 121.532 -0.73 . . . . 2.96 111.956 -176.319 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.3 mt 62.75 7.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.662 0 O-C-N 121.599 -0.688 . . . . 0.41999999999999998 112.619 -175.056 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.86 16.07 80.43 Favored Glycine 0 N--CA 1.496 2.682 0 O-C-N 120.932 -1.105 . . . . 0.23999999999999999 110.369 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.4 ttp180 -83.78 143.04 30.24 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.167 -1.196 . . . . 1.96 110.382 -176.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -131.89 154.66 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 109.365 -0.606 . . . . 0.29999999999999999 109.365 171.17 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.65 129.19 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 C-N-CA 120.08 -0.648 . . . . 0.25 109.999 176.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 29.1 mt -79.75 145.08 61.54 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.04 -0.664 . . . . 0.23000000000000001 109.359 175.899 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -63.5 143.66 88.51 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.986 0.993 . . . . 0.34999999999999998 109.723 174.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.04 -26.5 60.42 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 120.449 -0.5 . . . . 0.33000000000000002 110.426 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.35 -45.19 94.07 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 109.958 -1.257 . . . . 0.39000000000000001 109.958 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 85.3 m -69.37 -36.98 77.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.66 -0.906 . . . . 0.39000000000000001 110.117 -179.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.8 mtt180 -56.41 -41.91 77.12 Favored 'General case' 0 N--CA 1.509 2.502 0 O-C-N 121.323 -0.861 . . . . 0.40000000000000002 109.662 178.486 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.5 tptp -66.37 -50.14 64.51 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 120.275 -0.57 . . . . 2.9700000000000002 110.262 -177.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.8 t80 -57.06 -38.19 72.92 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.925 -0.484 . . . . 0.67000000000000004 110.694 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.932 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -87.03 -14.28 42.01 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.803 -0.561 . . . . 1.4399999999999999 111.249 -177.17 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.94 42.71 24.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.493 -1.443 . . . . 0.31 109.493 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.894 HG23 HG21 ' A' ' 56' ' ' VAL . 75.7 mt -88.06 127.5 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.566 -0.961 . . . . 0.41999999999999998 110.501 -177.354 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.26 154.24 45.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.877 -0.786 . . . . 1.8200000000000001 108.877 171.384 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -55.18 139.42 42.07 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.245 -0.91 . . . . 1.99 110.706 -177.151 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -15.76 62.41 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 110.898 -0.881 . . . . 0.19 110.898 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -76.19 158.5 31.61 Favored 'General case' 0 N--CA 1.5 2.031 0 CA-C-N 118.749 1.274 . . . . 1.1200000000000001 109.992 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -111.57 138.63 47.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.568 -0.708 . . . . 0.20999999999999999 109.614 175.088 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.72 154.79 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 109.213 -0.662 . . . . 0.14999999999999999 109.213 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.85 123.6 48.57 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.318 -0.993 . . . . 1.0900000000000001 108.318 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.11 159.5 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.627 -0.829 . . . . 0.14000000000000001 110.897 -168.066 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.547 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.6 ttpt -133.77 146.01 50.33 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.784 -0.573 . . . . 1.1100000000000001 110.374 177.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.649 ' HB ' HD12 ' A' ' 80' ' ' ILE . 26.1 pt -114.74 150.4 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.627 -0.671 . . . . 0.20000000000000001 110.359 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.9 t -140.89 124.53 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.219 0.533 . . . . 0.20000000000000001 109.807 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.682 ' HB2' HG22 ' A' ' 80' ' ' ILE . 55.0 tttm -132.06 149.86 52.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.363 -0.606 . . . . 1.98 109.363 175.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -100.3 129.18 46.26 Favored 'General case' 0 N--CA 1.497 1.923 0 C-N-CA 119.993 -0.683 . . . . 0.33000000000000002 110.367 -179.202 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -132.6 131.32 41.32 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.688 -0.633 . . . . 1.48 110.061 178.39 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.74 -128.12 45.91 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.809 -1.316 . . . . 0.40999999999999998 109.809 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 17.8 pt-20 -105.03 9.92 34.25 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.821 -0.811 . . . . 1.27 111.717 177.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -131.1 138.74 33.62 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.238 -0.913 . . . . 1.3700000000000001 110.837 -178.198 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -75.4 139.83 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.879 0 O-C-N 122.939 0.968 . . . . 0.34000000000000002 110.598 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.642 ' HB3' HG23 ' A' ' 72' ' ' ILE . 44.5 mmtt -112.93 136.58 52.44 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.502 -0.749 . . . . 1.1000000000000001 109.583 171.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -138.62 167.9 20.96 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.664 -0.647 . . . . 1.4199999999999999 110.974 -178.154 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.432 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.64 135.71 4.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.405 -1.478 . . . . 0.17000000000000001 109.405 177.362 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.547 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.1 m -122.74 137.28 54.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.645 -0.915 . . . . 0.20999999999999999 109.862 177.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.819 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.3 p90 -155.81 173.6 16.52 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.013 -0.675 . . . . 0.16 110.942 178.195 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 m -106.69 140.38 39.64 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.737 -0.602 . . . . 0.13 109.575 173.46 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.819 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.81 146.03 35.41 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.739 -0.6 . . . . 0.14000000000000001 110.563 -175.627 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.9 ttp-105 -93.69 145.28 24.68 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.797 -0.565 . . . . 2.21 109.684 175.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.894 HG21 HG23 ' A' ' 29' ' ' ILE . 98.3 t -78.85 126.57 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.244 0.545 . . . . 0.17000000000000001 109.861 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.66 -170.6 26.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.834 -1.306 . . . . 0.19 109.834 177.794 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -61.78 156.04 21.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.673 -0.898 . . . . 1.3899999999999999 109.909 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.04 19.05 2.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.506 -0.746 . . . . 0.81999999999999995 112.138 -177.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.45 20.46 79.41 Favored Glycine 0 N--CA 1.498 2.827 0 C-N-CA 119.863 -1.161 . . . . 0.19 110.714 172.432 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.64 146.76 33.91 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -1.005 . . . . 1.3 110.373 -176.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.64 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.9 146.44 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.751 -0.593 . . . . 0.20999999999999999 109.553 174.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.3 mm -109.04 122.15 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.513 -0.742 . . . . 0.34000000000000002 110.704 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.2 mt -78.84 142.25 60.44 Favored Pre-proline 0 N--CA 1.498 1.96 0 O-C-N 121.423 -0.798 . . . . 0.34000000000000002 109.486 172.066 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.745 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.83 135.01 42.72 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.938 0.967 . . . . 0.26000000000000001 110.705 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -55.12 -34.21 63.53 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.499 -0.751 . . . . 2.6200000000000001 110.766 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.69 -37.73 76.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.752 -0.592 . . . . 0.45000000000000001 110.319 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.745 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.0 mt -77.03 -32.82 57.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.636 -0.665 . . . . 1.8200000000000001 110.482 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -57.72 -45.85 85.2 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.419 -0.801 . . . . 2.5299999999999998 109.951 178.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.33 -47.29 61.76 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 120.532 -0.467 . . . . 1.6799999999999999 110.483 -175.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.49 -38.25 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 O-C-N 121.699 -0.626 . . . . 0.28000000000000003 109.932 -178.393 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.642 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.7 mt -82.49 -18.01 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.791 -0.568 . . . . 0.28000000000000003 110.915 -176.529 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.34 35.19 43.26 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.704 -1.358 . . . . 0.22 109.704 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.7 mm -92.65 142.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.576 -0.955 . . . . 0.77000000000000002 110.64 -174.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 34.9 mtpt -130.25 163.22 49.36 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.748 -0.595 . . . . 3.21 110.792 -177.181 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.76 135.41 63.58 Favored 'Trans proline' 0 N--CA 1.487 1.111 0 O-C-N 122.922 0.959 . . . . 0.5 110.92 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.72 -0.15 73.18 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 111.08 -0.808 . . . . 0.23999999999999999 111.08 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -97.47 133.11 42.49 Favored 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 118.691 1.246 . . . . 1.1100000000000001 110.552 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.02 133.37 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.67 0.747 . . . . 0.23999999999999999 111.26 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.682 HG22 ' HB2' ' A' ' 41' ' ' LYS . 41.4 pt -123.48 159.52 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 109.272 -0.64 . . . . 0.17999999999999999 109.272 176.143 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -98.44 131.1 44.98 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.963 -0.754 . . . . 1.1399999999999999 108.963 176.109 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 83.9 t -114.95 130.24 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.394 0.616 . . . . 0.20000000000000001 110.28 -170.524 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.403 HD23 ' HG3' ' A' ' 6' ' ' LYS . 33.5 mt -116.3 130.74 56.93 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 109.074 -0.713 . . . . 0.25 109.074 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.932 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.7 mt -80.55 140.86 35.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.356 -0.84 . . . . 0.28000000000000003 109.791 172.204 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -113.18 -31.01 6.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.654 -0.654 . . . . 1.6000000000000001 111.046 -175.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.18 -177.78 39.58 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.65 -1.262 . . . . 0.20000000000000001 110.978 -176.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 p80 -144.94 153.52 41.62 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.719 -0.871 . . . . 1.8899999999999999 110.59 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -135.95 138.69 42.6 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.527 -0.733 . . . . 0.80000000000000004 110.278 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -117.66 110.56 40.36 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.786 -0.571 . . . . 2.9900000000000002 110.205 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -54.22 147.27 45.87 Favored 'Trans proline' 0 N--CA 1.499 1.824 0 O-C-N 122.988 0.994 . . . . 1.6799999999999999 111.109 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 16.8 tpt180 -120.39 144.08 48.1 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 6.8700000000000001 110.271 -178.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 . . . . . 0 N--CA 1.496 1.866 0 CA-C-O 118.021 -0.99 . . . . 6.4699999999999998 110.161 179.826 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.9 ttm . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.005 0.431 . . . . 2.7599999999999998 110.162 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -78.28 140.18 38.85 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.718 -0.614 . . . . 1.7 110.025 178.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -128.11 136.04 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.781 -0.575 . . . . 0.40999999999999998 109.655 178.231 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.574 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.7 mt -83.91 -19.1 35.34 Favored 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 120.198 -0.601 . . . . 0.37 110.378 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.4 153.3 3.51 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.292 -0.88 . . . . 0.26000000000000001 109.335 176.047 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -134.16 125.45 27.93 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.697 -0.627 . . . . 2.2999999999999998 110.089 -177.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.595 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.8 p90 -150.26 162.62 40.14 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.591 -0.693 . . . . 0.20000000000000001 110.852 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -113.53 138.29 50.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.61 -0.681 . . . . 1.99 110.102 -176.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.08 162.29 41.12 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.661 -0.649 . . . . 0.17999999999999999 109.679 177.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.11 157.83 18.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.465 -0.772 . . . . 0.17000000000000001 110.03 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.61 136.43 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.783 -0.573 . . . . 0.48999999999999999 110.319 -176.647 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -113.32 171.95 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.215 0.531 . . . . 0.68000000000000005 109.686 173.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -46.67 152.31 0.49 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.607 -0.683 . . . . 2.96 111.896 -175.58 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.6 mt 62.6 7.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.635 0 O-C-N 121.559 -0.713 . . . . 0.41999999999999998 112.601 -175.341 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.84 16.12 80.39 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 110.364 -1.095 . . . . 0.23999999999999999 110.364 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.8 ttt180 -83.92 140.73 31.76 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.18 -1.188 . . . . 1.96 110.249 -176.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.6 pt -133.67 155.48 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.698 -0.626 . . . . 0.29999999999999999 109.757 174.091 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.3 mm -118.16 129.79 73.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.62 -0.675 . . . . 0.25 109.998 175.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.5 mt -79.61 145.97 64.19 Favored Pre-proline 0 N--CA 1.495 1.777 0 C-N-CA 120.052 -0.659 . . . . 0.23000000000000001 109.396 175.496 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.16 142.89 88.66 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 O-C-N 123.012 1.006 . . . . 0.34999999999999998 109.823 174.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.22 -26.56 60.91 Favored 'General case' 0 N--CA 1.498 1.955 0 C-N-CA 120.403 -0.519 . . . . 0.33000000000000002 110.49 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.43 -45.01 94.45 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 109.973 -1.251 . . . . 0.39000000000000001 109.973 -179.015 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 96.6 m -69.66 -37.0 76.54 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.63 -0.923 . . . . 0.39000000000000001 109.878 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.637 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.2 -42.27 76.93 Favored 'General case' 0 N--CA 1.509 2.508 0 O-C-N 121.298 -0.876 . . . . 0.40000000000000002 109.77 178.111 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -65.91 -50.14 65.5 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.282 0.563 . . . . 2.9700000000000002 110.116 -177.137 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -56.46 -37.54 70.43 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.136 0.493 . . . . 0.67000000000000004 110.725 -179.298 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.972 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.0 t80 -88.19 -14.15 39.33 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.784 -0.572 . . . . 1.4399999999999999 111.315 -176.649 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 42.89 24.18 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.543 -1.423 . . . . 0.31 109.543 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.933 HG23 HG21 ' A' ' 56' ' ' VAL . 75.4 mt -87.84 126.92 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.519 -0.989 . . . . 0.41999999999999998 110.653 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.91 155.64 43.87 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.134 -0.691 . . . . 1.8200000000000001 109.134 171.45 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.56 137.49 48.71 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.308 -0.87 . . . . 1.99 110.79 -177.575 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.51 -15.08 64.07 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.926 -0.87 . . . . 0.19 110.926 178.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -76.01 157.55 32.9 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 118.76 1.28 . . . . 1.1200000000000001 109.862 177.146 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -111.51 138.16 48.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.631 -0.668 . . . . 0.20999999999999999 109.611 175.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.99 152.06 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 120.087 -0.645 . . . . 0.14999999999999999 109.309 174.555 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -113.74 123.51 50.05 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.172 -1.047 . . . . 1.0900000000000001 108.172 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.835 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.2 tt -139.87 157.57 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.584 -0.846 . . . . 0.14000000000000001 110.886 -167.568 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -133.1 146.06 51.29 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.801 -0.562 . . . . 1.1100000000000001 110.474 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.532 HG22 HG22 ' A' ' 82' ' ' VAL . 27.9 pt -114.9 151.1 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.758 -0.589 . . . . 0.20000000000000001 110.54 178.747 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.485 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.3 t -138.38 127.37 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.674 -0.491 . . . . 0.20000000000000001 109.674 176.333 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.595 ' HB2' HG22 ' A' ' 80' ' ' ILE . 60.8 tttm -133.47 144.43 49.45 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 109.538 -0.542 . . . . 1.98 109.538 175.368 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -105.84 129.4 54.02 Favored 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 120.262 -0.575 . . . . 0.33000000000000002 110.355 -178.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -133.48 131.43 39.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.682 -0.636 . . . . 1.48 110.14 176.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.84 -128.18 45.92 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.785 -1.326 . . . . 0.40999999999999998 109.785 -177.161 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -105.16 13.92 29.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.725 -0.867 . . . . 1.27 111.624 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -131.13 122.84 19.42 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.302 -0.874 . . . . 1.3700000000000001 111.214 -177.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -75.48 142.35 26.34 Favored 'Trans proline' 0 N--CA 1.483 0.89 0 N-CA-C 109.936 -0.832 . . . . 0.34000000000000002 109.936 173.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.425 ' CB ' HG23 ' A' ' 72' ' ' ILE . 32.4 mttt -120.73 149.77 42.01 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.34 -0.85 . . . . 1.1000000000000001 110.147 171.641 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.485 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -137.2 167.66 21.14 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.851 -0.531 . . . . 1.4199999999999999 110.731 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.57 135.86 4.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.342 -1.503 . . . . 0.17000000000000001 109.342 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.2 m -122.95 137.99 54.8 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.658 -0.907 . . . . 0.20999999999999999 109.887 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.812 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.3 p90 -155.96 172.61 18.09 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.88 -0.728 . . . . 0.16 110.969 175.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.2 m -107.54 140.45 40.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.685 -0.634 . . . . 0.13 109.598 174.113 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.812 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 144.49 34.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.62 -0.675 . . . . 0.14000000000000001 110.527 -176.032 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.78 145.7 24.4 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.693 -0.629 . . . . 2.21 109.67 175.29 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.933 HG21 HG23 ' A' ' 29' ' ' ILE . 99.3 t -78.11 126.66 38.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.821 -0.55 . . . . 0.17000000000000001 109.93 -178.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.92 -166.4 25.08 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.101 -1.2 . . . . 0.19 110.101 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.71 152.79 30.08 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.779 -0.836 . . . . 1.3899999999999999 110.131 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.4 mt-30 53.64 21.02 2.39 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.557 -0.715 . . . . 0.81999999999999995 112.03 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.49 79.91 Favored Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.802 -1.189 . . . . 0.19 110.776 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.403 ' HA ' HD13 ' A' ' 18' ' ' ILE . 51.5 p -79.08 148.36 32.45 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.465 -1.021 . . . . 1.3 110.43 -176.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.67 147.14 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.878 -0.514 . . . . 0.20999999999999999 109.67 174.686 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.2 mm -108.5 121.85 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.536 -0.728 . . . . 0.34000000000000002 110.535 -175.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.411 HG23 ' HD2' ' A' ' 65' ' ' PRO . 78.6 mt -78.68 143.02 62.16 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.6 -0.687 . . . . 0.34000000000000002 109.619 173.506 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.92 131.46 29.03 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.936 0.966 . . . . 0.26000000000000001 110.784 -179.02 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 50.3 tttp -55.12 -34.07 63.4 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.424 -0.797 . . . . 2.6200000000000001 110.846 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.72 -37.72 76.77 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.722 -0.611 . . . . 0.45000000000000001 110.269 -178.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.9 mt -77.16 -32.71 56.43 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.21 -0.596 . . . . 1.8200000000000001 110.494 178.176 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtt180 -57.55 -45.57 84.96 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.231 -0.918 . . . . 2.5299999999999998 109.829 178.316 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.97 64.26 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 120.441 -0.504 . . . . 1.6799999999999999 110.371 -174.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.8 t -60.56 -38.6 78.76 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.678 -0.639 . . . . 0.28000000000000003 109.901 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.56 HG22 HD11 ' A' ' 74' ' ' ILE . 86.8 mt -83.26 -15.8 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.896 -0.503 . . . . 0.28000000000000003 111.143 -176.313 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.931 -1.268 . . . . 0.22 109.931 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.4 mm -89.96 141.06 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.574 -0.957 . . . . 0.77000000000000002 110.716 -174.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -130.61 159.26 71.8 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.808 -0.558 . . . . 3.21 110.69 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -54.63 133.63 57.97 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 122.98 0.99 . . . . 0.5 111.391 177.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.02 0.34 71.51 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 111.205 -0.758 . . . . 0.23999999999999999 111.205 175.461 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -98.05 134.1 41.6 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-N 118.769 1.285 . . . . 1.1100000000000001 110.603 179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.405 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -92.34 132.9 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 CA-C-O 121.55 0.691 . . . . 0.23999999999999999 111.15 -174.525 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.595 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.8 pt -122.39 159.4 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 109.353 -0.61 . . . . 0.17999999999999999 109.353 175.338 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 48.3 tt0 -98.85 131.71 44.75 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.007 -0.738 . . . . 1.1399999999999999 109.007 175.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.835 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.1 t -116.16 129.88 71.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 CA-C-O 121.298 0.57 . . . . 0.20000000000000001 110.362 -170.207 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.1 mt -115.83 130.94 57.04 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.188 -0.671 . . . . 0.25 109.188 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.972 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.27 140.18 36.32 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.375 -0.828 . . . . 0.28000000000000003 109.797 171.694 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -109.36 -31.21 7.63 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.825 -0.547 . . . . 1.6000000000000001 110.898 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.574 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.05 179.39 41.29 Favored Glycine 0 N--CA 1.503 3.136 0 C-N-CA 119.728 -1.225 . . . . 0.20000000000000001 110.986 -177.707 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.406 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 29.2 p80 -140.6 145.67 37.0 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.728 -0.866 . . . . 1.8899999999999999 110.072 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.406 ' CD1' ' O ' ' A' ' 87' ' ' HIS . 17.8 m-85 -131.34 138.95 49.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.506 -0.746 . . . . 0.80000000000000004 109.943 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -83.73 156.31 64.79 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.783 -0.573 . . . . 2.9900000000000002 110.251 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -55.12 142.52 77.41 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.171 1.09 . . . . 1.6799999999999999 110.936 179.455 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -128.29 141.34 51.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.703 -0.623 . . . . 6.8700000000000001 110.163 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 118.015 -0.993 . . . . 6.4699999999999998 110.178 179.846 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.4 ptm . . . . . 0 N--CA 1.496 1.874 0 CA-C-O 121.479 0.657 . . . . 2.7599999999999998 110.12 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -100.34 146.77 26.56 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 120.893 0.378 . . . . 1.7 110.127 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.564 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.6 p -127.93 141.07 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 121.795 -0.566 . . . . 0.40999999999999998 109.644 178.625 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.578 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.9 mt -87.57 -17.93 30.87 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.744 -0.598 . . . . 0.37 110.708 -177.341 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.868 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.83 155.96 4.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.253 -0.904 . . . . 0.26000000000000001 109.742 176.126 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -133.29 126.6 31.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.762 -0.586 . . . . 2.2999999999999998 110.096 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.605 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -149.48 161.94 41.12 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.651 -0.656 . . . . 0.20000000000000001 110.871 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -111.73 138.02 48.86 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.617 -0.677 . . . . 1.99 110.17 -176.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.41 162.29 41.2 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.727 -0.608 . . . . 0.17999999999999999 109.774 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.5 t -111.71 159.33 18.34 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 119.925 -0.71 . . . . 0.17000000000000001 109.89 176.094 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -77.83 138.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 120.304 -0.558 . . . . 0.48999999999999999 110.103 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.67 171.9 7.57 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.327 0.584 . . . . 0.68000000000000005 109.672 174.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -46.91 153.13 0.44 Allowed 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.537 -0.727 . . . . 2.96 111.927 -175.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.578 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.0 mt 63.1 7.22 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.681 0 O-C-N 121.601 -0.687 . . . . 0.41999999999999998 112.643 -175.244 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.54 15.98 80.79 Favored Glycine 0 N--CA 1.498 2.791 0 O-C-N 120.829 -1.169 . . . . 0.23999999999999999 110.292 179.455 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.0 ttm180 -85.94 145.39 27.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.324 -1.104 . . . . 1.96 110.352 -177.221 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.18 154.52 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.727 -0.608 . . . . 0.29999999999999999 109.466 172.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.453 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.83 128.72 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.57 -0.706 . . . . 0.25 109.99 176.529 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.437 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.7 mt -79.98 145.09 60.57 Favored Pre-proline 0 N--CA 1.495 1.802 0 C-N-CA 120.084 -0.646 . . . . 0.23000000000000001 109.37 175.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.27 143.06 88.53 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 122.917 0.956 . . . . 0.34999999999999998 109.812 174.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.6 -26.42 61.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.867 -0.521 . . . . 0.33000000000000002 110.489 -178.319 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.82 -44.37 94.8 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.39000000000000001 109.914 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.8 m -69.69 -38.13 76.89 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.637 -0.919 . . . . 0.39000000000000001 110.179 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -56.18 -41.23 75.19 Favored 'General case' 0 N--CA 1.512 2.648 0 O-C-N 121.274 -0.891 . . . . 0.40000000000000002 109.493 176.409 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.5 tttp -65.53 -50.0 66.83 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.166 0.508 . . . . 2.9700000000000002 110.142 -176.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -57.39 -37.96 73.5 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.749 -0.594 . . . . 0.67000000000000004 110.725 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.6 t80 -87.99 -14.31 39.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.766 -0.584 . . . . 1.4399999999999999 111.239 -176.166 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.48 42.45 27.32 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.548 -1.421 . . . . 0.31 109.548 177.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.899 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.49 129.18 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.545 -0.974 . . . . 0.41999999999999998 110.572 -176.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -129.07 158.76 38.02 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.929 -0.767 . . . . 1.8200000000000001 108.929 170.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -57.45 140.54 50.26 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.315 -0.865 . . . . 1.99 110.426 -178.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.73 -16.06 61.65 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -77.06 157.95 30.81 Favored 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 118.724 1.262 . . . . 1.1200000000000001 110.121 178.077 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -111.55 138.67 47.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.582 -0.699 . . . . 0.20999999999999999 109.611 174.758 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.88 154.16 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 109.272 -0.64 . . . . 0.14999999999999999 109.272 174.179 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -116.32 124.07 49.21 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.274 -1.01 . . . . 1.0900000000000001 108.274 -179.389 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -140.23 157.91 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.558 -0.857 . . . . 0.14000000000000001 111.053 -167.181 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.81 146.07 51.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.76 -0.587 . . . . 1.1100000000000001 110.517 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.562 HG22 HG22 ' A' ' 82' ' ' VAL . 33.6 pt -114.94 150.94 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.598 -0.689 . . . . 0.20000000000000001 110.544 178.203 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.9 t -138.08 125.13 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.177 0.513 . . . . 0.20000000000000001 109.655 176.104 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.4 tttp -134.17 147.48 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.725 -0.609 . . . . 1.98 109.495 175.397 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -102.61 127.93 49.5 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.092 -0.643 . . . . 0.33000000000000002 110.266 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.3 mt-10 -136.24 137.91 41.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.603 -0.685 . . . . 1.48 110.128 178.74 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.82 -128.27 46.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.761 -1.336 . . . . 0.40999999999999998 109.761 -178.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -105.12 7.26 33.74 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.746 -0.855 . . . . 1.27 111.815 177.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.24 141.74 42.94 Favored Pre-proline 0 N--CA 1.499 2.016 0 O-C-N 121.2 -0.937 . . . . 1.3700000000000001 110.956 -177.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -75.27 138.93 23.02 Favored 'Trans proline' 0 N--CA 1.481 0.768 0 O-C-N 122.839 0.915 . . . . 0.34000000000000002 110.198 172.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.69 ' HB3' HG23 ' A' ' 72' ' ' ILE . 66.1 mmtt -111.06 137.78 48.29 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.527 -0.733 . . . . 1.1000000000000001 109.432 172.656 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.65 164.46 27.81 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.555 -0.716 . . . . 1.4199999999999999 110.997 -176.175 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.9 4.37 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.659 -1.377 . . . . 0.17000000000000001 109.659 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.68 137.72 54.66 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.638 -0.919 . . . . 0.20999999999999999 109.792 176.103 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.6 p90 -156.36 172.76 17.95 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.963 -0.695 . . . . 0.16 111.047 176.264 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.6 m -106.68 140.91 38.79 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.677 -0.639 . . . . 0.13 109.414 173.533 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.16 145.89 36.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.652 -0.655 . . . . 0.14000000000000001 110.697 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.0 ttt180 -93.29 145.33 24.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.833 -0.542 . . . . 2.21 109.616 175.559 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.899 HG21 HG23 ' A' ' 29' ' ' ILE . 90.1 t -79.01 125.96 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 121.419 0.628 . . . . 0.17000000000000001 109.722 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.7 -166.47 26.25 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.961 -1.256 . . . . 0.19 109.961 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -61.73 151.98 32.43 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.804 -0.821 . . . . 1.3899999999999999 110.139 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 53.32 21.53 2.36 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.523 -0.736 . . . . 0.81999999999999995 112.054 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.77 20.42 79.77 Favored Glycine 0 N--CA 1.498 2.832 0 C-N-CA 119.796 -1.192 . . . . 0.19 110.879 171.347 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.453 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.1 p -78.56 147.02 33.93 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.518 -0.989 . . . . 1.3 110.22 -178.004 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.727 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -139.26 146.39 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.8 -0.563 . . . . 0.20999999999999999 109.525 175.293 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.95 123.81 66.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.58 -0.7 . . . . 0.34000000000000002 110.583 -175.193 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.4 mt -78.32 144.06 65.72 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.643 -0.661 . . . . 0.34000000000000002 109.432 172.709 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.49 135.36 45.53 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.966 0.982 . . . . 0.26000000000000001 110.73 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 38.2 tttp -55.08 -34.21 63.44 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.545 -0.722 . . . . 2.6200000000000001 110.75 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.87 -38.33 78.57 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.779 -0.576 . . . . 0.45000000000000001 110.343 -178.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.3 mt -77.13 -32.87 56.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.747 -0.595 . . . . 1.8200000000000001 110.617 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.05 -45.82 86.38 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.35 -0.843 . . . . 2.5299999999999998 109.882 178.312 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -46.76 63.96 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 120.511 -0.476 . . . . 1.6799999999999999 110.425 -175.177 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.8 t -60.58 -38.28 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.704 -0.623 . . . . 0.28000000000000003 109.853 -178.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.695 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.68 -17.52 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.874 -0.516 . . . . 0.28000000000000003 110.872 -176.795 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.89 35.11 40.51 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.693 -1.363 . . . . 0.22 109.693 175.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.1 mm -93.07 142.89 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.599 -0.942 . . . . 0.77000000000000002 110.77 -173.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.2 ptmt -132.94 162.64 56.35 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.742 -0.599 . . . . 3.21 110.652 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -51.97 135.44 51.11 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.056 1.03 . . . . 0.5 111.887 178.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.95 -1.51 70.87 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 120.704 -0.76 . . . . 0.23999999999999999 111.357 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -96.33 130.92 43.33 Favored 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 118.767 1.284 . . . . 1.1100000000000001 110.614 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.79 134.35 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 CA-C-O 121.684 0.754 . . . . 0.23999999999999999 111.296 -173.327 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.4 pt -125.58 159.46 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 109.567 -0.531 . . . . 0.17999999999999999 109.567 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -97.61 132.04 43.63 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.075 -0.713 . . . . 1.1399999999999999 109.075 173.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.7 t -116.32 129.89 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.344 0.592 . . . . 0.20000000000000001 110.264 -171.431 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -115.34 130.3 56.86 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.262 -0.644 . . . . 0.25 109.262 178.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.2 mt -79.96 138.81 37.16 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.345 -0.847 . . . . 0.28000000000000003 109.914 172.479 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -105.76 -35.9 7.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.726 -0.609 . . . . 1.6000000000000001 110.918 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.83 -176.03 38.69 Favored Glycine 0 N--CA 1.503 3.166 0 C-N-CA 119.79 -1.195 . . . . 0.20000000000000001 110.817 -176.871 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -142.72 152.65 42.57 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.677 -0.896 . . . . 1.8899999999999999 110.798 -177.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -135.22 139.53 44.56 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.535 -0.728 . . . . 0.80000000000000004 110.064 175.483 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 90' ' ' PRO . 0.1 OUTLIER -101.81 135.22 19.78 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.788 -0.57 . . . . 2.9900000000000002 110.282 -179.577 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 89' ' ' LYS . 73.4 Cg_exo -56.28 150.48 49.38 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 O-C-N 123.107 1.056 . . . . 1.6799999999999999 110.903 179.007 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -119.99 141.71 49.45 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.771 -0.58 . . . . 6.8700000000000001 110.254 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 58.2 t30 . . . . . 0 N--CA 1.495 1.78 0 CA-C-O 117.971 -1.014 . . . . 6.4699999999999998 110.196 -179.919 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.3 mtp . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.168 0.509 . . . . 2.7599999999999998 110.557 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -73.96 142.11 45.87 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.891 -0.506 . . . . 1.7 110.105 178.926 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 p -127.72 136.84 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 109.522 -0.547 . . . . 0.40999999999999998 109.522 178.187 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.0 mt -85.62 -18.36 33.49 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.728 -0.608 . . . . 0.37 110.32 178.119 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.832 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.5 151.27 1.51 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.244 -0.91 . . . . 0.26000000000000001 108.997 176.08 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -134.96 127.82 31.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.649 -0.657 . . . . 2.2999999999999998 110.295 -178.138 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.8 p90 -150.36 163.14 39.09 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 120.345 -0.542 . . . . 0.20000000000000001 110.595 -177.426 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.7 m170 -112.65 137.7 50.54 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.648 -0.657 . . . . 1.99 110.256 -176.776 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.83 162.31 40.99 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.752 -0.592 . . . . 0.17999999999999999 109.585 177.13 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.06 159.29 17.44 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.765 -0.774 . . . . 0.17000000000000001 110.139 177.675 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.6 t -79.05 136.27 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 120.298 -0.561 . . . . 0.48999999999999999 110.254 -177.118 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -115.42 171.95 7.39 Favored 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.253 0.549 . . . . 0.68000000000000005 109.726 175.356 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -46.64 153.03 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.583 -0.698 . . . . 2.96 111.882 -176.138 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 53.9 mt 62.94 7.07 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.666 0 O-C-N 121.525 -0.735 . . . . 0.41999999999999998 112.629 -175.439 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.6 16.11 80.59 Favored Glycine 0 N--CA 1.498 2.792 0 O-C-N 120.895 -1.128 . . . . 0.23999999999999999 110.33 179.389 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 ttm180 -85.43 144.16 28.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.255 -1.144 . . . . 1.96 110.293 -177.147 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.46 155.09 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.725 -0.609 . . . . 0.29999999999999999 109.463 172.777 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.74 129.43 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.665 -0.647 . . . . 0.25 109.991 176.473 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.3 mt -79.61 145.99 64.23 Favored Pre-proline 0 N--CA 1.494 1.768 0 C-N-CA 120.061 -0.656 . . . . 0.23000000000000001 109.321 175.682 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.41 ' HD2' HG23 ' A' ' 19' ' ' ILE . 50.1 Cg_endo -63.47 143.21 87.66 Favored 'Trans proline' 0 N--CA 1.489 1.228 0 O-C-N 123.069 1.036 . . . . 0.34999999999999998 109.698 174.652 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.31 -26.34 60.74 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.813 -0.555 . . . . 0.33000000000000002 110.438 -178.85 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.34 -45.23 93.98 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.015 -1.234 . . . . 0.39000000000000001 110.015 -179.323 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.1 m -69.27 -37.3 77.84 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.706 -0.879 . . . . 0.39000000000000001 110.187 -179.579 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.592 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.24 -42.06 76.73 Favored 'General case' 0 N--CA 1.509 2.487 0 O-C-N 121.434 -0.791 . . . . 0.40000000000000002 109.751 178.378 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -66.62 -50.24 63.66 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 121.272 0.558 . . . . 2.9700000000000002 110.233 -177.024 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -57.27 -37.87 73.04 Favored 'General case' 0 N--CA 1.501 2.109 0 CA-C-O 121.205 0.526 . . . . 0.67000000000000004 110.704 -179.039 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.5 t80 -87.69 -14.21 40.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.744 -0.597 . . . . 1.4399999999999999 111.223 -176.795 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.17 26.76 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.598 -1.401 . . . . 0.31 109.598 177.674 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.916 HG23 HG21 ' A' ' 56' ' ' VAL . 73.1 mt -89.44 127.79 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.452 -1.028 . . . . 0.41999999999999998 110.462 -176.545 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -128.21 159.7 34.39 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.114 -0.699 . . . . 1.8200000000000001 109.114 171.637 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -57.2 139.36 52.88 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.364 -0.835 . . . . 1.99 110.541 -178.219 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.43 -15.77 62.2 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 178.232 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.07 158.74 31.49 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 118.701 1.25 . . . . 1.1200000000000001 109.991 178.037 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -111.71 138.16 48.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.634 -0.666 . . . . 0.20999999999999999 109.645 175.408 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.36 153.5 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 N-CA-C 109.164 -0.68 . . . . 0.14999999999999999 109.164 173.777 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.3 123.16 48.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.227 -1.027 . . . . 1.0900000000000001 108.227 -179.628 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.819 HD11 ' CG1' ' A' ' 82' ' ' VAL . 10.6 tt -140.38 158.33 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.593 -0.843 . . . . 0.14000000000000001 110.946 -167.564 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.9 ttpt -132.07 146.14 51.87 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.815 -0.553 . . . . 1.1100000000000001 110.428 177.286 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.581 HG22 HG22 ' A' ' 82' ' ' VAL . 23.9 pt -114.92 150.55 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.20000000000000001 110.305 176.939 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.545 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -139.58 124.35 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 CA-C-O 121.292 0.567 . . . . 0.20000000000000001 109.692 177.355 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.704 ' HB2' HG22 ' A' ' 80' ' ' ILE . 45.2 tptt -135.99 147.89 48.19 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.731 -0.605 . . . . 1.98 109.415 176.758 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -101.25 129.56 47.22 Favored 'General case' 0 N--CA 1.496 1.834 0 C-N-CA 120.071 -0.652 . . . . 0.33000000000000002 110.403 -177.566 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.459 ' OE2' HD13 ' A' ' 74' ' ' ILE . 93.6 mt-10 -135.65 136.82 41.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.689 -0.632 . . . . 1.48 110.045 178.26 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.84 -128.21 45.97 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 109.817 -1.313 . . . . 0.40999999999999998 109.817 -178.519 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -105.02 8.03 34.23 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.734 -0.862 . . . . 1.27 111.833 178.438 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -131.15 141.87 43.46 Favored Pre-proline 0 N--CA 1.497 1.907 0 O-C-N 121.154 -0.966 . . . . 1.3700000000000001 110.93 -177.607 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -75.24 137.88 21.75 Favored 'Trans proline' 0 N--CA 1.48 0.735 0 O-C-N 122.92 0.958 . . . . 0.34000000000000002 110.198 173.441 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.717 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.7 mmtp -110.69 137.27 48.57 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.56 -0.712 . . . . 1.1000000000000001 109.577 173.217 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.545 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -135.09 163.91 28.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.595 -0.691 . . . . 1.4199999999999999 111.027 -176.328 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.75 135.72 4.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.488 -1.445 . . . . 0.17000000000000001 109.488 176.918 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.5 136.86 54.34 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.733 -0.863 . . . . 0.20999999999999999 109.823 177.288 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.6 p90 -155.93 173.62 16.53 Favored 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.888 -0.725 . . . . 0.16 111.046 178.267 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.71 141.02 39.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.713 -0.617 . . . . 0.13 109.518 173.583 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.89 145.84 35.06 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.64 -0.663 . . . . 0.14000000000000001 110.672 -175.709 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 43.6 ttp180 -93.72 146.03 24.15 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.758 -0.589 . . . . 2.21 109.674 175.248 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.916 HG21 HG23 ' A' ' 29' ' ' ILE . 99.0 t -78.28 127.16 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.821 -0.55 . . . . 0.17000000000000001 109.995 -178.401 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.96 -168.06 26.1 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.995 -1.242 . . . . 0.19 109.995 178.869 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.7 153.47 28.15 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.712 -0.875 . . . . 1.3899999999999999 110.175 -179.727 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.68 20.89 2.37 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.596 -0.69 . . . . 0.81999999999999995 112.105 -179.698 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.6 20.46 79.82 Favored Glycine 0 N--CA 1.5 2.957 0 C-N-CA 119.763 -1.208 . . . . 0.19 110.826 171.613 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.424 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.9 p -78.67 147.26 33.61 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.541 -0.976 . . . . 1.3 110.328 -177.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.632 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.75 146.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 109.515 -0.55 . . . . 0.20999999999999999 109.515 174.78 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.8 123.89 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.527 -0.733 . . . . 0.34000000000000002 110.612 -174.559 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.44 HG23 ' HD2' ' A' ' 65' ' ' PRO . 88.5 mt -78.23 144.27 66.52 Favored Pre-proline 0 N--CA 1.499 2.024 0 O-C-N 121.59 -0.694 . . . . 0.34000000000000002 109.392 172.368 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.34 135.61 47.22 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 O-C-N 122.965 0.981 . . . . 0.26000000000000001 110.71 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 23.0 tptm -55.02 -34.85 63.82 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.368 -0.833 . . . . 2.6200000000000001 110.769 -179.772 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.92 -38.3 78.65 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.79 -0.569 . . . . 0.45000000000000001 110.276 -178.494 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.4 mt -77.05 -32.81 57.13 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.727 -0.608 . . . . 1.8200000000000001 110.695 179.432 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -58.15 -46.22 86.05 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.351 -0.843 . . . . 2.5299999999999998 109.845 178.95 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.43 -47.38 61.01 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.49 -0.484 . . . . 1.6799999999999999 110.468 -175.962 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 88.8 t -60.64 -37.96 77.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.702 -0.624 . . . . 0.28000000000000003 109.94 -178.309 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.717 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.7 mt -82.56 -17.82 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.833 -0.542 . . . . 0.28000000000000003 110.823 -176.473 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.7 35.22 41.23 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.776 -1.33 . . . . 0.22 109.776 175.706 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.12 142.69 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.46 -1.023 . . . . 0.77000000000000002 110.665 -173.86 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.94 156.29 76.3 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.789 -0.569 . . . . 3.21 110.618 -177.807 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -55.44 135.87 71.16 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.018 1.009 . . . . 0.5 111.257 178.197 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -1.53 73.06 Favored Glycine 0 N--CA 1.496 2.678 0 C-N-CA 120.622 -0.799 . . . . 0.23999999999999999 111.235 176.191 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.2 mt-10 -96.2 132.27 41.81 Favored 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 118.729 1.264 . . . . 1.1100000000000001 110.429 179.033 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.1 p -91.57 130.71 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.49 0.662 . . . . 0.23999999999999999 110.98 -174.822 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.704 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -119.34 159.48 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 N-CA-C 109.579 -0.526 . . . . 0.17999999999999999 109.579 178.055 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 82.0 tt0 -97.34 130.05 44.54 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.012 -0.736 . . . . 1.1399999999999999 109.012 174.933 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.819 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.0 t -115.46 127.77 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.339 0.59 . . . . 0.20000000000000001 110.235 -171.809 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.3 mt -115.07 129.19 56.63 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.411 -0.589 . . . . 0.25 109.411 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.5 mt -79.72 140.61 36.91 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.433 -0.792 . . . . 0.28000000000000003 109.856 172.651 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.09 -31.99 6.93 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.857 -0.527 . . . . 1.6000000000000001 110.798 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -176.95 39.22 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.71 -1.233 . . . . 0.20000000000000001 110.965 -177.429 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -145.06 152.6 40.36 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.715 -0.874 . . . . 1.8899999999999999 110.742 -177.954 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -137.01 140.88 42.43 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.507 -0.746 . . . . 0.80000000000000004 110.028 175.711 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.2 ttpt -110.68 151.47 42.85 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.711 -0.618 . . . . 2.9900000000000002 110.31 179.81 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -56.12 143.99 81.98 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 O-C-N 123.334 1.176 . . . . 1.6799999999999999 110.909 179.555 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -125.25 147.68 48.99 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.732 -0.605 . . . . 6.8700000000000001 110.155 179.209 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 43.0 p-10 . . . . . 0 N--CA 1.495 1.798 0 CA-C-O 118.005 -0.998 . . . . 6.4699999999999998 110.422 179.985 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.3 mtm . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.149 0.499 . . . . 2.7599999999999998 110.591 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -80.04 138.68 37.05 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.937 -0.477 . . . . 1.7 110.214 179.347 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.0 p -128.74 134.93 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.719 -0.613 . . . . 0.40999999999999998 109.565 177.439 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.58 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.8 mt -82.23 -20.22 38.12 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.213 -0.595 . . . . 0.37 110.386 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.827 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.74 154.58 3.69 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.418 -0.801 . . . . 0.26000000000000001 109.327 175.742 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.6 tttt -134.66 125.17 26.57 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.657 -0.652 . . . . 2.2999999999999998 110.246 -176.511 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' PHE . . . . . 0.616 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.65 162.76 40.05 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.536 -0.727 . . . . 0.20000000000000001 110.842 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.69 138.74 49.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.623 -0.673 . . . . 1.99 110.231 -177.368 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.11 162.31 41.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.732 -0.605 . . . . 0.17999999999999999 109.72 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.0 157.81 18.91 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.52 -0.737 . . . . 0.17000000000000001 109.997 177.324 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.33 135.82 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.748 -0.595 . . . . 0.48999999999999999 110.259 -176.665 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -113.84 171.87 7.33 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.294 0.568 . . . . 0.68000000000000005 109.787 174.088 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtm-85 -46.66 152.67 0.45 Allowed 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.522 -0.736 . . . . 2.96 112.026 -175.694 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.59 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.599 0 O-C-N 121.596 -0.69 . . . . 0.41999999999999998 112.598 -175.636 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.71 16.17 80.43 Favored Glycine 0 N--CA 1.498 2.789 0 O-C-N 120.891 -1.131 . . . . 0.23999999999999999 110.325 179.404 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -84.05 141.8 30.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.271 -1.135 . . . . 1.96 110.36 -176.473 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.9 pt -133.98 154.36 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.654 . . . . 0.29999999999999999 109.532 172.832 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mm -117.71 128.46 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 C-N-CA 120.051 -0.66 . . . . 0.25 109.857 176.19 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 34.0 mt -80.07 144.09 58.31 Favored Pre-proline 0 N--CA 1.496 1.829 0 C-N-CA 120.02 -0.672 . . . . 0.23000000000000001 109.36 176.043 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.32 143.55 89.35 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 122.953 0.975 . . . . 0.34999999999999998 109.731 174.656 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.5 -26.5 61.41 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.889 -0.507 . . . . 0.33000000000000002 110.47 -178.347 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.48 -44.46 95.18 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 109.914 -1.275 . . . . 0.39000000000000001 109.914 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.2 m -69.97 -38.34 76.04 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.618 -0.931 . . . . 0.39000000000000001 110.162 -179.392 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.79 73.52 Favored 'General case' 0 N--CA 1.514 2.75 0 O-C-N 121.245 -0.91 . . . . 0.40000000000000002 109.43 176.42 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -64.94 -49.66 69.51 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.167 0.508 . . . . 2.9700000000000002 110.119 -177.605 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.19 -38.55 73.82 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.785 -0.572 . . . . 0.67000000000000004 110.726 -179.709 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.965 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.3 t80 -88.07 -14.23 39.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.847 -0.533 . . . . 1.4399999999999999 111.308 -176.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.97 24.59 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.55 -1.42 . . . . 0.31 109.55 178.562 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 75.9 mt -87.25 129.14 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.499 -1.001 . . . . 0.41999999999999998 110.563 -177.021 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.31 158.97 36.73 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 109.11 -0.7 . . . . 1.8200000000000001 109.11 170.636 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.25 138.66 54.45 Favored 'General case' 0 N--CA 1.503 2.201 0 O-C-N 121.396 -0.815 . . . . 1.99 110.539 -179.149 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.05 62.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 110.869 -0.892 . . . . 0.19 110.869 178.973 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.82 155.54 32.96 Favored 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 118.708 1.254 . . . . 1.1200000000000001 110.076 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -110.43 138.65 46.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.557 -0.714 . . . . 0.20999999999999999 109.462 174.089 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.38 154.43 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 C-N-CA 120.204 -0.598 . . . . 0.14999999999999999 109.398 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -114.89 123.38 49.01 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.158 -1.053 . . . . 1.0900000000000001 108.158 179.695 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.814 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.94 158.65 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.662 -0.815 . . . . 0.14000000000000001 110.812 -167.787 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.537 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.7 ttpt -132.67 146.21 51.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.887 -0.508 . . . . 1.1100000000000001 110.42 178.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.586 HG22 HG22 ' A' ' 82' ' ' VAL . 22.0 pt -114.72 149.12 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.718 -0.614 . . . . 0.20000000000000001 110.252 177.107 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.5 t -140.1 123.95 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 CA-C-O 121.138 0.494 . . . . 0.20000000000000001 109.69 178.636 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.701 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.2 tttt -132.25 148.47 52.45 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.34 -0.615 . . . . 1.98 109.34 175.922 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 33.1 t80 -102.2 128.98 48.48 Favored 'General case' 0 N--CA 1.496 1.864 0 C-N-CA 120.008 -0.677 . . . . 0.33000000000000002 110.328 179.909 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -133.76 133.16 41.39 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.685 -0.635 . . . . 1.48 109.989 178.806 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.18 45.85 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.717 -1.353 . . . . 0.40999999999999998 109.717 -178.578 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.06 8.61 34.36 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.702 -0.881 . . . . 1.27 111.726 177.937 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.4 pt-20 -131.29 139.06 34.28 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.227 -0.921 . . . . 1.3700000000000001 110.722 -178.775 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -75.19 142.42 27.27 Favored 'Trans proline' 0 N--CA 1.483 0.87 0 O-C-N 122.931 0.964 . . . . 0.34000000000000002 110.504 175.399 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.68 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.7 mmtp -111.13 136.0 50.81 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.588 -0.695 . . . . 1.1000000000000001 109.714 172.743 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -133.27 156.89 46.74 Favored 'General case' 0 C--N 1.311 -1.068 0 O-C-N 121.531 -0.731 . . . . 1.4199999999999999 110.582 -171.381 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.61 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -157.67 135.86 4.57 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.544 -1.422 . . . . 0.17000000000000001 109.544 176.104 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.537 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -126.83 138.31 53.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.647 -0.913 . . . . 0.20999999999999999 109.714 177.257 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -156.26 173.79 16.34 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 119.949 -0.701 . . . . 0.16 111.107 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.9 m -106.89 141.07 38.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.633 -0.667 . . . . 0.13 109.606 173.289 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.24 145.77 34.44 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.754 -0.591 . . . . 0.14000000000000001 110.551 -175.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 57.0 ttt180 -93.77 145.26 24.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.741 -0.6 . . . . 2.21 109.778 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.6 t -79.68 125.5 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 CA-C-O 121.384 0.611 . . . . 0.17000000000000001 109.825 179.675 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.9 -165.91 25.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.989 -1.244 . . . . 0.19 109.989 178.482 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -61.62 153.07 28.92 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.85 -0.794 . . . . 1.3899999999999999 110.178 -179.335 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.55 21.15 2.38 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.602 -0.686 . . . . 0.81999999999999995 112.056 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.51 79.88 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 119.812 -1.185 . . . . 0.19 110.817 172.008 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 59.4 p -78.41 146.68 34.42 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.563 -0.963 . . . . 1.3 110.439 -176.244 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.757 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -139.55 145.62 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.631 -0.507 . . . . 0.20999999999999999 109.631 174.203 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.3 mm -111.09 123.03 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.552 -0.718 . . . . 0.34000000000000002 110.478 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.8 mt -78.2 144.47 67.02 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.613 -0.679 . . . . 0.34000000000000002 109.656 174.755 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.76 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.31 134.58 42.67 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 O-C-N 122.928 0.962 . . . . 0.26000000000000001 110.802 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -54.88 -35.02 63.63 Favored 'General case' 0 N--CA 1.503 2.207 0 O-C-N 121.489 -0.757 . . . . 2.6200000000000001 110.767 -179.806 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.426 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -38.29 78.38 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.738 -0.601 . . . . 0.45000000000000001 110.364 -178.063 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.76 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.6 mt -77.21 -32.66 56.09 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 120.172 -0.611 . . . . 1.8200000000000001 110.729 179.529 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -58.28 -46.49 85.96 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.301 -0.874 . . . . 2.5299999999999998 109.761 178.551 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.02 -46.12 65.77 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.542 -0.463 . . . . 1.6799999999999999 110.455 -175.179 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 67' ' ' ALA . 95.4 t -60.38 -38.46 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.61 -0.681 . . . . 0.28000000000000003 109.825 -178.835 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.3 mt -82.17 -18.27 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.918 -0.489 . . . . 0.28000000000000003 110.912 -177.059 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.59 35.13 42.08 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 109.75 -1.34 . . . . 0.22 109.75 176.476 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.885 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.8 mm -92.0 140.72 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.468 -1.019 . . . . 0.77000000000000002 110.569 -174.529 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 23.1 mmmt -125.32 161.58 49.14 Favored Pre-proline 0 N--CA 1.498 1.964 0 O-C-N 121.637 -0.665 . . . . 3.21 110.498 -175.366 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -60.75 134.6 54.89 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 O-C-N 123.0 1.0 . . . . 0.5 110.748 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.47 0.87 72.37 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 111.118 -0.793 . . . . 0.23999999999999999 111.118 176.645 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -100.33 135.86 41.12 Favored 'General case' 0 N--CA 1.498 1.975 0 CA-C-N 118.704 1.252 . . . . 1.1100000000000001 110.737 -179.633 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.72 133.9 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.696 0.76 . . . . 0.23999999999999999 111.463 -172.605 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.701 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -124.59 159.47 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 109.399 -0.593 . . . . 0.17999999999999999 109.399 175.427 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -98.6 132.0 44.35 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.067 -0.716 . . . . 1.1399999999999999 109.067 175.9 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.814 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.6 t -115.39 129.41 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 CA-C-O 121.302 0.572 . . . . 0.20000000000000001 110.282 -171.408 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.1 129.36 56.3 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 109.168 -0.679 . . . . 0.25 109.168 178.869 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.965 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.09 139.25 36.96 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.396 -0.815 . . . . 0.28000000000000003 109.755 171.798 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.21 -31.25 7.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.724 -0.61 . . . . 1.6000000000000001 110.971 -174.899 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.58 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.06 -175.9 38.14 Favored Glycine 0 N--CA 1.504 3.176 0 C-N-CA 119.671 -1.252 . . . . 0.20000000000000001 111.086 -176.944 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p-80 -144.44 154.05 42.54 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.681 -0.893 . . . . 1.8899999999999999 110.744 -177.277 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -140.55 146.64 38.33 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.536 -0.727 . . . . 0.80000000000000004 110.131 175.972 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.1 pttp -121.56 155.92 58.98 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.681 -0.637 . . . . 2.9900000000000002 110.43 179.416 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -56.04 150.2 48.76 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 O-C-N 123.287 1.151 . . . . 1.6799999999999999 110.914 179.222 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -119.71 142.13 48.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.719 -0.613 . . . . 6.8700000000000001 110.177 179.223 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.495 1.816 0 CA-C-O 117.966 -1.016 . . . . 6.4699999999999998 110.228 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.399 0 N-CA-C 109.568 -0.53 . . . . 0.23 109.568 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.56 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.0 mt -86.71 -18.0 32.28 Favored 'General case' 0 N--CA 1.496 1.825 0 C-N-CA 120.251 -0.58 . . . . 0.16 110.515 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.965 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.77 152.71 3.13 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.388 -0.82 . . . . 0.11 109.094 177.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 46.6 tttt -133.85 125.16 27.8 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.674 -0.641 . . . . 0.88 110.054 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.597 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.6 p90 -150.94 162.28 41.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.575 -0.703 . . . . 0.08 110.782 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -113.41 139.12 49.17 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.713 -0.617 . . . . 1.08 110.235 -177.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.463 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.57 162.3 40.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.742 -0.599 . . . . 0.09 109.604 177.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.1 157.95 18.82 Favored 'General case' 0 N--CA 1.496 1.869 0 C-N-CA 119.764 -0.774 . . . . 0.1 110.063 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.29 134.92 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 C-N-CA 120.289 -0.564 . . . . 0.11 110.161 -176.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -113.46 171.93 7.27 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.23 0.538 . . . . 0.14 109.685 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.33 152.54 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.53 -0.731 . . . . 2.7 112.003 -175.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.674 0 O-C-N 121.516 -0.74 . . . . 0.21 112.533 -174.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.09 80.66 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.815 -1.178 . . . . 0.08 110.377 179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.798 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -85.54 142.96 28.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.297 -1.12 . . . . 2.33 110.367 -176.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.463 HD12 HG21 ' A' ' 9' ' ' THR . 43.0 pt -133.2 157.74 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.658 -0.651 . . . . 0.09 109.602 173.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.798 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.2 mm -117.06 129.58 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.632 -0.668 . . . . 0.09 110.113 176.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.457 HG23 ' HD2' ' A' ' 20' ' ' PRO . 23.8 mt -79.98 147.01 64.9 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.147 -0.621 . . . . 0.08 109.396 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.457 ' HD2' HG23 ' A' ' 19' ' ' ILE . 47.0 Cg_endo -63.06 143.15 90.06 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 122.979 0.989 . . . . 0.14 109.878 174.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.98 -26.5 62.41 Favored 'General case' 0 N--CA 1.496 1.845 0 C-N-CA 120.404 -0.518 . . . . 0.13 110.448 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.76 -43.73 95.82 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.998 -1.241 . . . . 0.1 109.998 -179.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.4 m -69.69 -39.17 77.1 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.547 -0.973 . . . . 0.14 110.051 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HA ' HD12 ' A' ' 29' ' ' ILE . 7.8 mtt180 -56.49 -42.56 78.5 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 121.353 -0.842 . . . . 0.1 109.403 177.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.2 tttt -67.45 -50.25 60.05 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.025 0.441 . . . . 2.26 110.222 -176.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -58.09 -36.16 72.47 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.735 -0.603 . . . . 0.2 110.581 178.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.926 ' CD2' HD13 ' A' ' 84' ' ' LEU . 11.5 t80 -86.77 -14.28 42.74 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.739 -0.601 . . . . 0.2 111.331 -174.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.2 39.94 35.48 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.661 -1.376 . . . . 0.11 109.661 177.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.797 ' CG2' HG21 ' A' ' 56' ' ' VAL . 85.1 mt -93.2 132.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.502 -0.999 . . . . 0.12 110.633 -175.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.15 161.65 29.59 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 109.304 -0.628 . . . . 1.99 109.304 172.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -57.76 138.72 55.26 Favored 'General case' 0 N--CA 1.503 2.217 0 O-C-N 121.477 -0.764 . . . . 1.95 110.397 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.47 -16.11 61.82 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.855 -0.898 . . . . 0.1 110.855 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -77.51 160.89 28.32 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.085 -1.244 . . . . 0.09 110.234 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -112.62 139.27 48.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.11 109.728 175.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.2 155.82 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 N-CA-C 109.152 -0.684 . . . . 0.04 109.152 173.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -118.75 123.83 45.78 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.36 -0.978 . . . . 1.0 108.36 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.828 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.9 tt -140.33 158.53 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 C-N-CA 119.58 -0.848 . . . . 0.08 111.144 -167.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.444 ' HB2' HG23 ' A' ' 51' ' ' THR . 36.4 tttt -132.92 146.09 51.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.91 -0.494 . . . . 1.18 110.384 177.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.483 HG22 HG22 ' A' ' 82' ' ' VAL . 24.7 pt -114.81 151.01 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.624 -0.672 . . . . 0.12 110.528 178.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t -138.38 124.75 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 CA-C-O 121.136 0.493 . . . . 0.1 109.678 176.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.572 ' HB2' HG22 ' A' ' 80' ' ' ILE . 57.9 tttm -132.84 144.87 50.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.29 -0.633 . . . . 1.94 109.29 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 42.4 t80 . . . . . 0 N--CA 1.496 1.842 0 C-N-CA 120.09 -0.644 . . . . 0.46 110.55 -177.291 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo . . . . . 0 N--CA 1.483 0.88 0 N-CA-C 110.423 -0.645 . . . . 0.33 110.423 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.727 ' HB3' HG23 ' A' ' 72' ' ' ILE . 28.5 mmtp -110.36 137.51 47.98 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.577 -0.702 . . . . 1.25 109.536 172.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -134.61 162.43 32.33 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.645 -0.659 . . . . 1.69 110.996 -177.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.89 135.92 4.45 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.418 . . . . 0.1 109.554 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.444 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -124.06 138.05 54.49 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.651 -0.911 . . . . 0.15 109.785 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.809 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.4 p90 -155.97 173.47 16.74 Favored 'General case' 0 N--CA 1.497 1.902 0 C-N-CA 119.884 -0.726 . . . . 0.09 110.986 177.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.5 m -106.91 142.07 37.13 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.65 -0.656 . . . . 0.08 109.464 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.809 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.07 146.17 36.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.61 -0.681 . . . . 0.08 110.756 -175.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.65 146.0 24.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.841 -0.537 . . . . 2.36 109.63 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.797 HG21 ' CG2' ' A' ' 29' ' ' ILE . 96.9 t -79.01 124.82 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 120.294 -0.562 . . . . 0.09 110.062 179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.95 -166.54 25.07 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.088 -1.205 . . . . 0.09 110.088 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.71 152.95 29.67 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.766 -0.843 . . . . 1.44 110.187 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 53.51 21.1 2.32 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.668 -0.645 . . . . 1.72 112.014 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.62 20.51 79.82 Favored Glycine 0 N--CA 1.5 2.907 0 C-N-CA 119.643 -1.265 . . . . 0.07 110.83 171.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.454 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.7 p -78.0 148.19 34.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.438 -1.036 . . . . 1.3 110.27 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.723 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.4 p -138.74 145.97 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 N-CA-C 109.535 -0.543 . . . . 0.08 109.535 175.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.3 mm -110.81 122.73 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.561 -0.712 . . . . 0.15 110.709 -174.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.45 HG23 ' HD2' ' A' ' 65' ' ' PRO . 50.9 mt -78.38 144.62 66.5 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.567 -0.708 . . . . 0.14 109.465 172.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.75 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.25 133.26 37.08 Favored 'Trans proline' 0 N--CA 1.495 1.582 0 O-C-N 122.879 0.936 . . . . 0.13 110.69 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -55.23 -34.23 63.79 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.482 -0.761 . . . . 2.29 110.788 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.71 -37.87 77.07 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.747 -0.596 . . . . 0.12 110.336 -178.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.75 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.4 mt -77.08 -32.71 56.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.748 -0.595 . . . . 0.13 110.475 178.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.4 mtt180 -57.67 -45.49 85.49 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.258 -0.901 . . . . 0.11 109.841 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.15 62.61 Favored 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 120.534 -0.467 . . . . 1.49 110.465 -175.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.55 -38.25 77.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.646 -0.659 . . . . 0.17 109.89 -178.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.727 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.63 -17.63 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.841 -0.537 . . . . 0.17 110.89 -176.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.6 35.29 36.93 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 109.814 -1.315 . . . . 0.17 109.814 175.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.3 mm -89.47 142.75 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.603 -0.94 . . . . 0.18 110.587 -174.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -129.09 157.47 75.82 Favored Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.829 -0.544 . . . . 2.54 110.7 -177.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -55.31 133.98 61.21 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 O-C-N 122.934 0.965 . . . . 0.46 111.287 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.95 0.23 71.88 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 111.191 -0.763 . . . . 0.15 111.191 175.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -97.48 134.42 40.75 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-N 118.677 1.239 . . . . 0.42 110.559 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.407 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -91.95 132.79 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-O 121.67 0.748 . . . . 0.15 111.173 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.572 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.5 pt -121.86 159.49 24.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 109.387 -0.597 . . . . 0.11 109.387 175.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -97.69 131.57 44.12 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.98 -0.748 . . . . 1.13 108.98 175.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.828 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.78 130.24 70.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 CA-C-O 121.324 0.583 . . . . 0.07 110.266 -170.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.5 mt -116.5 131.01 57.06 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.264 -0.643 . . . . 0.09 109.264 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.965 HD12 ' HB3' ' A' ' 5' ' ' ALA . 4.3 mt -80.28 141.6 35.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.415 -0.803 . . . . 0.1 109.971 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.47 -32.52 6.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.765 -0.585 . . . . 0.34 110.868 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.56 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.8 -178.31 40.24 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.738 -1.22 . . . . 0.1 111.014 -177.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -148.82 151.22 34.38 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.702 -0.881 . . . . 0.27 110.572 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.58 -0.7 . . . . 0.56 109.893 175.055 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.2 p . . . . . 0 N--CA 1.486 1.33 0 N-CA-C 109.78 -0.452 . . . . 0.41 109.78 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.7 mt -87.8 -18.0 30.32 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 120.238 -0.585 . . . . 0.37 110.662 -177.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.824 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.21 156.67 3.98 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.206 -0.934 . . . . 0.26 109.853 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -134.04 126.77 30.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.758 -0.589 . . . . 2.3 110.167 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 18.2 p90 -149.42 161.81 41.34 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.614 -0.679 . . . . 0.2 110.874 178.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.418 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.0 m-70 -111.54 137.89 48.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.574 -0.704 . . . . 1.99 110.141 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.48 162.33 41.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.69 -0.631 . . . . 0.18 109.748 177.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.4 t -111.5 159.28 18.24 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.535 -0.728 . . . . 0.17 109.996 176.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.922 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.0 t -78.73 136.44 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.816 -0.553 . . . . 0.49 110.191 -177.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -114.26 171.95 7.3 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.285 0.564 . . . . 0.68 109.651 174.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -46.5 151.95 0.5 Allowed 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.531 -0.731 . . . . 2.96 112.036 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.2 mt 62.52 7.93 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.651 0 O-C-N 121.547 -0.721 . . . . 0.42 112.585 -175.508 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.68 16.06 80.59 Favored Glycine 0 N--CA 1.497 2.738 0 O-C-N 120.934 -1.104 . . . . 0.24 110.432 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.2 ttt180 -84.49 142.51 30.0 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.256 -1.143 . . . . 1.96 110.134 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.2 pt -133.28 154.3 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.649 -0.657 . . . . 0.3 109.671 174.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.53 128.51 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.623 -0.673 . . . . 0.25 109.952 175.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 30.4 mt -79.99 144.34 59.08 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.986 -0.686 . . . . 0.23 109.437 175.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.31 143.23 88.67 Favored 'Trans proline' 0 N--CA 1.489 1.219 0 O-C-N 122.969 0.984 . . . . 0.35 109.772 175.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.58 -26.77 61.97 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 120.442 -0.503 . . . . 0.33 110.472 -178.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -44.21 95.47 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.965 -1.254 . . . . 0.39 109.965 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.3 m -69.82 -38.39 76.54 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.593 -0.945 . . . . 0.39 110.132 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.723 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.8 mtt180 -56.06 -40.49 73.63 Favored 'General case' 0 N--CA 1.513 2.687 0 O-C-N 121.337 -0.852 . . . . 0.4 109.378 176.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 84.7 tttt -65.27 -50.05 67.24 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.065 0.459 . . . . 2.97 110.164 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -57.72 -39.08 76.44 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 121.773 -0.579 . . . . 0.67 110.681 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.7 t80 -87.28 -14.2 41.58 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.789 -0.569 . . . . 1.44 111.258 -176.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.78 42.9 24.63 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.536 -1.425 . . . . 0.31 109.536 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.913 HG23 HG21 ' A' ' 56' ' ' VAL . 75.0 mt -87.41 127.22 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.497 -1.002 . . . . 0.42 110.532 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -128.23 159.39 35.35 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.098 -0.704 . . . . 1.82 109.098 170.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.41 138.71 54.66 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.403 -0.81 . . . . 1.99 110.486 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.74 -16.02 62.12 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.874 -0.89 . . . . 0.19 110.874 179.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -77.09 156.9 31.39 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 118.686 1.243 . . . . 1.12 110.148 177.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -111.36 138.69 47.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.682 -0.636 . . . . 0.21 109.648 174.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.81 153.32 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.709 -0.619 . . . . 0.15 109.34 174.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -116.32 123.01 46.57 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.331 -0.989 . . . . 1.09 108.331 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.804 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.4 tt -138.6 157.87 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.57 -0.852 . . . . 0.14 111.324 -166.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.89 143.34 50.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.865 -0.522 . . . . 1.11 110.156 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.637 HG22 HG22 ' A' ' 82' ' ' VAL . 35.7 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.553 -0.717 . . . . 0.2 110.551 177.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.436 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.89 127.57 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.756 -0.461 . . . . 0.2 109.756 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.706 ' HB2' HG22 ' A' ' 80' ' ' ILE . 31.0 tttm -133.68 148.36 51.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.701 -0.625 . . . . 1.98 109.633 173.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.1 t80 . . . . . 0 N--CA 1.495 1.79 0 C-N-CA 120.156 -0.618 . . . . 0.33 110.129 178.761 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.483 0.869 0 N-CA-C 110.026 -0.798 . . . . 0.34 110.026 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.435 ' CB ' HG23 ' A' ' 72' ' ' ILE . 45.8 mttt -122.49 147.74 45.99 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.404 -0.81 . . . . 1.1 110.098 171.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -136.71 169.05 18.37 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 120.338 -0.545 . . . . 1.42 110.991 -176.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.71 4.38 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.341 -1.503 . . . . 0.17 109.341 177.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -127.15 136.94 52.79 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 0.21 109.927 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.811 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.3 p90 -156.71 173.77 16.47 Favored 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 119.939 -0.704 . . . . 0.16 110.922 176.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.2 m -106.5 140.37 39.5 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.696 -0.627 . . . . 0.13 109.422 173.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.811 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.37 146.6 36.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.706 -0.621 . . . . 0.14 110.749 -175.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.66 145.24 24.7 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.855 -0.528 . . . . 2.21 109.617 175.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.913 HG21 HG23 ' A' ' 29' ' ' ILE . 89.9 t -79.44 125.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.356 0.598 . . . . 0.17 109.814 179.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.66 -165.33 25.27 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.084 -1.206 . . . . 0.19 110.084 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -61.69 151.76 32.86 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.786 -0.832 . . . . 1.39 110.107 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 53.3 21.88 2.5 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.565 -0.709 . . . . 0.82 112.087 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.32 20.53 79.92 Favored Glycine 0 N--CA 1.5 2.923 0 C-N-CA 119.765 -1.207 . . . . 0.19 110.795 171.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.8 m -78.26 145.55 35.37 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.458 -1.025 . . . . 1.3 110.365 -176.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 9.0 p -139.27 147.77 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.773 -0.579 . . . . 0.21 109.721 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -108.7 123.68 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.525 -0.735 . . . . 0.34 110.658 -175.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.417 HG23 ' HD2' ' A' ' 65' ' ' PRO . 82.9 mt -78.64 143.02 62.37 Favored Pre-proline 0 N--CA 1.499 1.975 0 O-C-N 121.592 -0.692 . . . . 0.34 109.596 172.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.767 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.28 134.21 41.16 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.914 0.955 . . . . 0.26 110.908 -178.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 36.0 tptt -54.98 -34.84 63.72 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.517 -0.739 . . . . 2.62 110.859 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.413 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.95 -38.16 78.4 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.765 -0.584 . . . . 0.45 110.313 -178.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.767 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.3 mt -77.16 -32.67 56.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.739 -0.601 . . . . 1.82 110.682 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.3 mtt180 -58.35 -46.1 86.91 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.281 -0.887 . . . . 2.53 109.769 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.52 65.24 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 120.481 -0.488 . . . . 1.68 110.44 -175.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 67' ' ' ALA . 97.3 t -60.59 -38.82 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.685 -0.634 . . . . 0.28 109.903 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.583 HG22 HD11 ' A' ' 74' ' ' ILE . 85.8 mt -82.95 -16.32 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.821 -0.549 . . . . 0.28 111.063 -176.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.11 35.25 44.37 Favored Glycine 0 N--CA 1.498 2.794 0 N-CA-C 109.929 -1.268 . . . . 0.22 109.929 176.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.922 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -89.33 145.83 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.522 -0.987 . . . . 0.77 110.777 -173.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmt -134.46 162.99 54.39 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.849 -0.532 . . . . 3.21 110.454 -178.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -57.42 134.09 61.3 Favored 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 122.896 0.945 . . . . 0.5 111.137 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 0.98 67.38 Favored Glycine 0 N--CA 1.496 2.675 0 C-N-CA 120.676 -0.773 . . . . 0.24 111.343 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -94.1 129.87 40.49 Favored 'General case' 0 N--CA 1.501 2.102 0 CA-C-N 118.753 1.277 . . . . 1.11 110.322 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.1 132.74 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 CA-C-O 121.616 0.722 . . . . 0.24 111.174 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.33 159.49 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 109.451 -0.574 . . . . 0.18 109.451 176.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.418 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.5 tt0 -97.83 132.1 43.73 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.088 -0.708 . . . . 1.14 109.088 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.804 ' CG1' HD11 ' A' ' 37' ' ' ILE . 98.7 t -115.04 128.83 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 121.347 0.594 . . . . 0.2 110.143 -171.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.8 mt -115.37 128.8 56.32 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.186 -0.672 . . . . 0.25 109.186 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.6 mt -79.38 140.4 37.46 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.431 -0.793 . . . . 0.28 109.729 172.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.71 -32.24 7.16 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.718 -0.614 . . . . 1.6 110.971 -176.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.8 -179.07 40.23 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.674 -1.25 . . . . 0.2 110.985 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.0 p80 -142.96 150.47 39.75 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.746 -0.855 . . . . 1.89 110.658 -177.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.586 -0.696 . . . . 0.8 110.045 175.848 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 84' ' ' LEU . 3.4 p . . . . . 0 N--CA 1.485 1.299 0 N-CA-C 109.758 -0.46 . . . . 0.41 109.758 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.5 mt -86.91 -20.87 26.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.85 -0.531 . . . . 0.37 110.464 -178.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.904 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.06 157.23 4.28 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.363 -0.836 . . . . 0.26 109.685 176.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -132.87 126.67 32.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.715 -0.615 . . . . 2.3 110.223 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.612 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.6 p90 -149.27 162.48 39.95 Favored 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 120.143 -0.623 . . . . 0.2 110.665 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.59 138.18 50.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.548 -0.72 . . . . 1.99 110.286 -176.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 HD12 ' A' ' 17' ' ' ILE . 14.9 t -150.9 162.37 40.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.797 -0.564 . . . . 0.18 109.543 177.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.05 160.35 16.94 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 119.812 -0.755 . . . . 0.17 110.107 177.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.4 t -79.06 136.13 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 C-N-CA 120.329 -0.548 . . . . 0.49 110.318 -176.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -116.2 172.04 7.43 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.24 0.543 . . . . 0.68 109.58 174.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -46.21 152.47 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.543 -0.723 . . . . 2.96 112.048 -175.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.76 7.32 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.703 0 O-C-N 121.622 -0.674 . . . . 0.42 112.593 -175.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.07 80.67 Favored Glycine 0 N--CA 1.496 2.635 0 O-C-N 120.857 -1.152 . . . . 0.24 110.438 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttp180 -84.63 145.06 28.2 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.292 -1.123 . . . . 1.96 110.191 -177.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 9' ' ' THR . 45.1 pt -132.58 155.78 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 N-CA-C 109.315 -0.624 . . . . 0.3 109.315 172.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.1 mm -115.82 128.18 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 C-N-CA 120.034 -0.666 . . . . 0.25 109.904 176.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 33.7 mt -79.58 143.83 59.88 Favored Pre-proline 0 N--CA 1.495 1.794 0 C-N-CA 120.052 -0.659 . . . . 0.23 109.435 176.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.08 143.08 89.79 Favored 'Trans proline' 0 N--CA 1.489 1.231 0 O-C-N 122.989 0.994 . . . . 0.35 109.845 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.62 -26.9 62.24 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.882 -0.511 . . . . 0.33 110.52 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.06 95.61 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.951 -1.26 . . . . 0.39 109.951 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.9 m -69.94 -38.38 76.15 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.585 -0.95 . . . . 0.39 110.116 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.87 -40.81 73.47 Favored 'General case' 0 N--CA 1.512 2.664 0 O-C-N 121.286 -0.884 . . . . 0.4 109.429 176.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -65.75 -50.07 66.11 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.1 0.476 . . . . 2.97 110.212 -177.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -57.6 -39.67 77.34 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.707 -0.621 . . . . 0.67 110.756 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.939 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.0 t80 -87.69 -14.29 40.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.774 -0.579 . . . . 1.44 111.275 -176.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.87 42.52 25.19 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.576 -1.409 . . . . 0.31 109.576 178.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.921 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.74 125.55 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.543 -0.975 . . . . 0.42 110.445 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.55 159.94 33.07 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.235 -0.654 . . . . 1.82 109.235 172.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -57.27 138.19 55.06 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.33 -0.856 . . . . 1.99 110.557 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.81 -16.09 61.99 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 110.832 -0.907 . . . . 0.19 110.832 178.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -77.23 155.96 31.79 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.693 1.246 . . . . 1.12 109.998 177.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -111.27 138.78 47.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.6 -0.688 . . . . 0.21 109.492 174.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 155.06 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.199 -0.6 . . . . 0.15 109.386 174.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.99 122.55 45.58 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.198 -1.038 . . . . 1.09 108.198 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.826 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.15 158.22 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.596 -0.841 . . . . 0.14 110.936 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -133.15 145.62 50.83 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.859 -0.525 . . . . 1.11 110.505 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' VAL . 31.9 pt -114.93 151.13 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.648 -0.657 . . . . 0.2 110.604 178.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t -138.67 127.93 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 121.174 0.512 . . . . 0.2 109.72 176.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.702 ' HB2' HG22 ' A' ' 80' ' ' ILE . 33.3 tptt -137.82 147.13 44.29 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.83 -0.544 . . . . 1.98 109.632 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 44.9 t80 . . . . . 0 N--CA 1.496 1.828 0 C-N-CA 120.266 -0.574 . . . . 0.33 110.384 -176.794 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo . . . . . 0 N--CA 1.483 0.893 0 N-CA-C 109.994 -0.81 . . . . 0.34 109.994 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.427 ' CB ' HG23 ' A' ' 72' ' ' ILE . 37.1 mttp -118.71 151.75 37.41 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.498 -0.751 . . . . 1.1 110.309 173.268 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -140.03 169.09 18.34 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-O 121.216 0.532 . . . . 1.42 110.737 -178.373 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.61 135.9 4.47 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.428 -1.469 . . . . 0.17 109.428 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -122.64 137.48 54.89 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.629 -0.924 . . . . 0.21 109.847 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.7 p90 -156.14 173.1 17.32 Favored 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.899 -0.721 . . . . 0.16 110.901 176.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.06 141.31 38.5 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.669 -0.644 . . . . 0.13 109.493 173.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 145.51 35.19 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.675 -0.641 . . . . 0.14 110.695 -175.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -93.68 146.0 24.15 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.855 -0.528 . . . . 2.21 109.626 175.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.921 HG21 HG23 ' A' ' 29' ' ' ILE . 87.2 t -79.15 125.45 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.778 -0.576 . . . . 0.17 109.919 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.33 -167.08 25.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.944 -1.262 . . . . 0.19 109.944 178.231 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.68 152.93 29.58 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.79 -0.829 . . . . 1.39 110.138 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.28 21.4 2.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.652 -0.655 . . . . 0.82 112.095 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.1 20.6 79.66 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.684 -1.246 . . . . 0.19 110.832 171.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.0 m -77.96 144.56 36.67 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.388 -1.066 . . . . 1.3 110.343 -176.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.735 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.64 146.51 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.881 -0.512 . . . . 0.21 109.684 175.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -110.53 123.21 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.51 -0.744 . . . . 0.34 110.783 -175.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.5 mt -78.27 144.37 66.54 Favored Pre-proline 0 N--CA 1.498 1.938 0 O-C-N 121.637 -0.664 . . . . 0.34 109.494 172.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.17 133.82 39.74 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 O-C-N 122.98 0.99 . . . . 0.26 110.796 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -55.21 -34.23 63.75 Favored 'General case' 0 N--CA 1.502 2.171 0 O-C-N 121.481 -0.762 . . . . 2.62 110.768 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.408 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -37.99 77.7 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.797 -0.564 . . . . 0.45 110.275 -178.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.1 mt -77.13 -32.66 56.56 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 120.151 -0.62 . . . . 1.82 110.593 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.01 -46.33 85.44 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.349 -0.844 . . . . 2.53 109.771 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.91 -46.51 65.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 120.543 -0.463 . . . . 1.68 110.401 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 67' ' ' ALA . 96.5 t -60.58 -38.81 79.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.692 -0.63 . . . . 0.28 109.843 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.549 HG22 HD11 ' A' ' 74' ' ' ILE . 82.4 mt -82.64 -16.63 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.845 -0.535 . . . . 0.28 111.083 -176.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.24 35.18 43.86 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 109.878 -1.289 . . . . 0.22 109.878 176.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.6 142.86 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.056 0 O-C-N 121.519 -0.989 . . . . 0.77 110.63 -174.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.0 ptmt -130.27 162.35 54.83 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.801 -0.562 . . . . 3.21 110.644 -178.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.51 135.55 68.37 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 O-C-N 122.946 0.971 . . . . 0.5 110.919 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.61 -0.35 70.51 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.612 -0.804 . . . . 0.24 111.264 176.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -94.73 130.29 41.31 Favored 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 118.741 1.271 . . . . 1.11 109.849 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.2 p -91.92 129.9 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 121.527 0.679 . . . . 0.24 110.809 -175.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -118.79 159.39 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 109.418 -0.586 . . . . 0.18 109.418 177.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -97.91 131.91 43.96 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.017 -0.735 . . . . 1.14 109.017 174.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.826 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.9 t -116.2 129.72 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.355 0.598 . . . . 0.2 110.301 -170.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.6 mt -115.85 130.11 56.7 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 109.208 -0.664 . . . . 0.25 109.208 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.939 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.29 140.55 36.13 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.345 -0.847 . . . . 0.28 109.803 172.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.8 mt -111.37 -33.1 6.51 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.649 -0.657 . . . . 1.6 110.97 -176.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.21 -175.79 38.14 Favored Glycine 0 N--CA 1.504 3.181 0 C-N-CA 119.689 -1.244 . . . . 0.2 111.089 -176.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -144.25 154.26 42.9 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.728 -0.866 . . . . 1.89 110.624 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 . . . . . 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.8 110.21 176.482 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.488 1.473 0 N-CA-C 109.626 -0.509 . . . . 0.41 109.626 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.6 mt -86.67 -18.5 31.12 Favored 'General case' 0 N--CA 1.496 1.827 0 C-N-CA 120.164 -0.614 . . . . 0.37 110.574 -178.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.831 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.69 155.69 3.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.251 -0.905 . . . . 0.26 109.518 175.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.8 tttt -134.76 124.66 25.54 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.696 -0.627 . . . . 2.3 110.117 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.0 p90 -150.82 163.66 38.09 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.621 -0.674 . . . . 0.2 110.898 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -114.05 138.0 50.97 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.623 -0.673 . . . . 1.99 110.34 -177.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.39 162.31 41.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.66 -0.65 . . . . 0.18 109.648 177.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -109.64 160.47 16.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.367 -0.833 . . . . 0.17 110.264 177.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.869 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.2 t -78.92 137.37 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.843 -0.536 . . . . 0.49 110.289 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.82 171.97 7.55 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.286 0.565 . . . . 0.68 109.628 174.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.1 mtt-85 -46.37 152.54 0.43 Allowed 'General case' 0 N--CA 1.506 2.354 0 O-C-N 121.509 -0.745 . . . . 2.96 111.999 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.8 mt 62.62 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.673 0 O-C-N 121.536 -0.727 . . . . 0.42 112.604 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.78 16.1 80.45 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.901 -1.125 . . . . 0.24 110.335 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.9 ttp180 -85.16 144.85 27.93 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.269 -1.136 . . . . 1.96 110.28 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 pt -133.3 154.76 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.706 -0.621 . . . . 0.3 109.398 172.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.7 127.77 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.563 -0.711 . . . . 0.25 110.034 176.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 38.2 mt -79.9 144.18 59.16 Favored Pre-proline 0 N--CA 1.495 1.824 0 C-N-CA 120.087 -0.645 . . . . 0.23 109.479 176.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.38 143.52 88.87 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 122.927 0.961 . . . . 0.35 109.724 174.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.56 61.28 Favored 'General case' 0 N--CA 1.497 1.895 0 C-N-CA 120.391 -0.523 . . . . 0.33 110.56 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.55 -44.5 95.03 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.848 -1.301 . . . . 0.39 109.848 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.1 m -69.94 -38.13 76.07 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.662 -0.905 . . . . 0.39 110.09 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.61 73.24 Favored 'General case' 0 N--CA 1.514 2.741 0 O-C-N 121.26 -0.9 . . . . 0.4 109.385 176.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -64.95 -49.78 69.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.184 0.516 . . . . 2.97 110.133 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -57.24 -38.45 73.83 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.704 -0.622 . . . . 0.67 110.727 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.8 t80 -88.09 -14.43 38.87 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.756 -0.59 . . . . 1.44 111.216 -177.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.77 42.81 24.91 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.529 -1.429 . . . . 0.31 109.529 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 56' ' ' VAL . 75.6 mt -87.26 128.32 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.481 -1.011 . . . . 0.42 110.644 -176.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -127.85 158.85 36.63 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.115 -0.698 . . . . 1.82 109.115 170.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -57.3 138.51 54.72 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.329 -0.857 . . . . 1.99 110.522 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.88 -15.89 62.44 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 110.873 -0.891 . . . . 0.19 110.873 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -76.95 155.61 32.59 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-N 118.71 1.255 . . . . 1.12 110.0 177.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -110.72 138.83 46.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.636 -0.665 . . . . 0.21 109.646 174.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.57 154.05 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.262 -0.644 . . . . 0.15 109.262 175.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -115.45 123.42 48.54 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.279 -1.008 . . . . 1.09 108.279 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.82 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.4 tt -139.87 158.45 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 C-N-CA 119.69 -0.804 . . . . 0.14 110.861 -167.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.577 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.6 ttpt -133.03 146.06 51.38 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.767 -0.583 . . . . 1.11 110.577 177.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.627 HG22 HG22 ' A' ' 82' ' ' VAL . 26.8 pt -114.88 151.07 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.63 -0.669 . . . . 0.2 110.333 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.629 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.92 125.04 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-O 121.133 0.492 . . . . 0.2 109.71 176.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.708 ' HB2' HG22 ' A' ' 80' ' ' ILE . 39.1 tptt -135.17 147.58 49.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.763 -0.585 . . . . 1.98 109.655 177.069 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.9 t80 . . . . . 0 N--CA 1.496 1.856 0 C-N-CA 120.233 -0.587 . . . . 0.33 110.33 -177.628 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo . . . . . 0 N--CA 1.482 0.82 0 N-CA-C 110.108 -0.766 . . . . 0.34 110.108 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.8 mmtt -117.62 137.31 52.71 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.522 -0.736 . . . . 1.1 109.716 171.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.629 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -135.05 166.4 23.14 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.662 -0.649 . . . . 1.42 110.747 -176.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.62 135.64 4.34 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.53 -1.428 . . . . 0.17 109.53 177.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.577 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -123.03 136.43 54.83 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.711 -0.876 . . . . 0.21 109.73 176.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.818 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.1 p90 -155.43 173.29 16.88 Favored 'General case' 0 N--CA 1.497 1.899 0 C-N-CA 119.956 -0.698 . . . . 0.16 111.014 178.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.0 140.57 39.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.619 -0.675 . . . . 0.13 109.525 173.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.818 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.86 146.5 35.89 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.709 -0.619 . . . . 0.14 110.613 -175.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -93.48 145.18 24.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.757 -0.589 . . . . 2.21 109.766 175.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.888 HG21 HG23 ' A' ' 29' ' ' ILE . 94.2 t -79.5 125.95 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.744 -0.597 . . . . 0.17 109.908 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.05 -167.37 25.96 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.992 -1.243 . . . . 0.19 109.992 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -61.68 153.45 28.12 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.67 -0.9 . . . . 1.39 110.148 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 53.71 21.09 2.48 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.53 -0.731 . . . . 0.82 111.984 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.14 20.55 79.98 Favored Glycine 0 N--CA 1.499 2.853 0 C-N-CA 119.804 -1.188 . . . . 0.19 110.876 171.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.414 ' HA ' HD13 ' A' ' 18' ' ' ILE . 12.4 t -78.64 144.62 35.24 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.455 -1.027 . . . . 1.3 110.294 -176.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.43 145.79 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 N-CA-C 109.577 -0.527 . . . . 0.21 109.577 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.1 mm -111.39 123.84 67.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.546 -0.721 . . . . 0.34 110.685 -175.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 81.2 mt -78.16 145.0 68.14 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.602 -0.686 . . . . 0.34 109.458 172.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.14 134.45 42.63 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 O-C-N 122.957 0.977 . . . . 0.26 110.68 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -55.21 -34.28 63.79 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.437 -0.789 . . . . 2.62 110.797 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -37.8 77.39 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.659 -0.651 . . . . 0.45 110.322 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.2 mt -77.12 -32.7 56.65 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.18 -0.608 . . . . 1.82 110.579 178.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.7 mtt180 -57.94 -46.1 85.57 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.297 -0.877 . . . . 2.53 109.944 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.01 63.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.52 -0.472 . . . . 1.68 110.385 -175.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.59 -38.18 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.678 -0.639 . . . . 0.28 109.943 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.22 -18.12 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.855 -0.528 . . . . 0.28 110.817 -176.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.92 35.05 40.49 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.648 -1.381 . . . . 0.22 109.648 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.869 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -91.69 142.58 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.592 -0.946 . . . . 0.77 110.549 -174.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.67 161.41 61.16 Favored Pre-proline 0 N--CA 1.498 1.944 0 O-C-N 121.782 -0.574 . . . . 3.21 110.735 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.49 137.31 79.64 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.937 0.967 . . . . 0.5 111.033 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.08 72.33 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 111.166 -0.774 . . . . 0.24 111.166 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -94.17 130.17 40.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-N 118.692 1.246 . . . . 1.11 110.202 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 79' ' ' VAL . 10.8 p -91.74 128.86 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 CA-C-O 121.444 0.64 . . . . 0.24 110.759 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.708 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.9 pt -118.3 159.43 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 109.459 -0.571 . . . . 0.18 109.459 178.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.4 tt0 -97.95 129.96 44.83 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.909 -0.774 . . . . 1.14 108.909 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.82 ' CG1' HD11 ' A' ' 37' ' ' ILE . 94.7 t -115.18 129.29 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.288 0.566 . . . . 0.2 110.303 -170.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.7 mt -115.66 128.43 55.9 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 109.167 -0.679 . . . . 0.25 109.167 179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.2 mt -79.78 138.5 37.28 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.39 -0.819 . . . . 0.28 109.542 171.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -109.91 -31.29 7.46 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.723 -0.611 . . . . 1.6 110.968 -174.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.12 -177.33 39.25 Favored Glycine 0 N--CA 1.503 3.12 0 C-N-CA 119.672 -1.251 . . . . 0.2 111.039 -177.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -143.54 152.43 41.43 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.707 -0.878 . . . . 1.89 110.648 -177.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 . . . . . 0 N--CA 1.494 1.755 0 O-C-N 121.468 -0.77 . . . . 0.8 110.356 176.532 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.408 HG23 ' HB3' ' A' ' 83' ' ' LEU . 3.2 p . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 109.595 -0.521 . . . . 0.41 109.595 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.619 HD11 ' HA2' ' A' ' 86' ' ' GLY . 24.7 mt -82.51 -20.85 35.93 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.816 -0.553 . . . . 0.37 110.195 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.86 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -170.69 152.56 3.81 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.459 -0.776 . . . . 0.26 109.199 175.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.6 tttt -133.92 125.1 27.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.3 110.293 -175.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.618 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.99 162.55 40.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.651 -0.655 . . . . 0.2 110.925 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.415 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.4 m-70 -111.94 138.49 48.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.582 -0.698 . . . . 1.99 110.188 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.59 162.34 41.15 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.694 -0.629 . . . . 0.18 109.701 177.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.3 t -110.83 160.21 16.96 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.461 -0.774 . . . . 0.17 109.83 176.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.886 HG21 ' CG2' ' A' ' 74' ' ' ILE . 61.4 t -77.65 137.47 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.754 -0.591 . . . . 0.49 110.169 -177.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.3 m80 -116.14 171.99 7.45 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.66 -0.496 . . . . 0.68 109.66 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -46.02 151.53 0.47 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.639 -0.663 . . . . 2.96 112.122 -174.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.606 -0.684 . . . . 0.42 112.639 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.96 80.63 Favored Glycine 0 N--CA 1.498 2.801 0 N-CA-C 110.322 -1.111 . . . . 0.24 110.322 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -85.34 145.52 27.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.96 110.211 -177.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -134.36 154.68 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.626 -0.671 . . . . 0.3 109.476 172.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -117.19 127.99 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.57 -0.706 . . . . 0.25 110.031 176.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.25 144.98 59.15 Favored Pre-proline 0 N--CA 1.496 1.834 0 C-N-CA 120.038 -0.665 . . . . 0.23 109.491 175.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -63.44 143.44 88.34 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 O-C-N 123.023 1.012 . . . . 0.35 109.776 174.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.39 -26.57 61.27 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.845 -0.534 . . . . 0.33 110.495 -178.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.45 -44.37 95.36 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.932 -1.267 . . . . 0.39 109.932 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 83.9 m -70.22 -38.0 75.16 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.592 -0.946 . . . . 0.39 110.13 -179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.86 -41.23 74.04 Favored 'General case' 0 N--CA 1.514 2.775 0 O-C-N 121.263 -0.898 . . . . 0.4 109.342 176.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -65.41 -49.24 69.95 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.048 0.451 . . . . 2.97 110.287 -178.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.34 -38.42 74.07 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.787 -0.57 . . . . 0.67 110.781 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.9 t80 -87.58 -14.22 40.74 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.817 -0.552 . . . . 1.44 111.257 -177.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.12 42.79 23.24 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.522 -1.431 . . . . 0.31 109.522 178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.906 HG23 HG21 ' A' ' 56' ' ' VAL . 77.0 mt -87.44 129.67 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.511 -0.993 . . . . 0.42 110.574 -177.163 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.42 155.46 43.62 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 109.077 -0.712 . . . . 1.82 109.077 171.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -55.45 137.44 48.27 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.256 -0.903 . . . . 1.99 110.794 -177.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.69 -14.66 64.91 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.91 -0.876 . . . . 0.19 110.91 178.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -76.26 155.55 34.25 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 118.848 1.324 . . . . 1.12 109.907 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -109.33 138.24 45.98 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.518 -0.739 . . . . 0.21 109.508 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.73 154.85 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.263 -0.643 . . . . 0.15 109.263 175.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -115.95 122.95 46.79 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.277 -1.008 . . . . 1.09 108.277 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.85 HD11 ' CG1' ' A' ' 82' ' ' VAL . 13.1 tt -139.37 157.83 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.7 -0.8 . . . . 0.14 110.87 -167.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -132.83 146.03 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.814 -0.554 . . . . 1.11 110.518 178.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.553 ' HB ' HD12 ' A' ' 80' ' ' ILE . 31.3 pt -114.95 150.93 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.663 -0.648 . . . . 0.2 110.51 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.458 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.18 126.54 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-O 121.085 0.469 . . . . 0.2 109.765 176.472 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.7 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.1 tttp -133.35 146.33 51.2 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.798 -0.564 . . . . 1.98 109.57 174.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 37.4 t80 . . . . . 0 N--CA 1.496 1.863 0 C-N-CA 120.133 -0.627 . . . . 0.33 110.151 179.234 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo . . . . . 0 N--CA 1.483 0.861 0 N-CA-C 109.992 -0.811 . . . . 0.34 109.992 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' A' ' 72' ' ' ILE . 17.1 mmtp -111.97 137.65 49.68 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.529 -0.732 . . . . 1.1 109.583 172.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.458 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.17 164.86 26.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.582 -0.698 . . . . 1.42 110.773 -175.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.451 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.26 135.94 4.42 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.58 -1.408 . . . . 0.17 109.58 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.2 m -123.28 137.39 54.87 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.733 -0.863 . . . . 0.21 109.695 176.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.9 p90 -156.23 173.09 17.36 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.845 -0.742 . . . . 0.16 111.037 176.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.6 m -107.47 141.02 39.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.668 -0.645 . . . . 0.13 109.5 173.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.92 145.95 35.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.717 -0.614 . . . . 0.14 110.45 -176.038 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -93.72 144.23 25.59 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.749 -0.594 . . . . 2.21 109.687 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.906 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -78.82 125.98 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.267 0.556 . . . . 0.17 110.009 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.37 -169.9 25.81 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.848 -1.301 . . . . 0.19 109.848 177.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -61.81 155.82 22.13 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.707 -0.878 . . . . 1.39 109.913 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.06 19.34 2.71 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.486 -0.759 . . . . 0.82 112.018 -177.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.56 20.59 79.58 Favored Glycine 0 N--CA 1.499 2.839 0 C-N-CA 119.813 -1.184 . . . . 0.19 110.66 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 32.4 t -78.4 144.72 35.65 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.437 -1.037 . . . . 1.3 110.479 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.75 146.27 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 109.637 -0.505 . . . . 0.21 109.637 175.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -111.79 123.97 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.6 -0.688 . . . . 0.34 110.655 -175.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.7 mt -78.33 143.47 64.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.612 -0.68 . . . . 0.34 109.477 172.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.79 136.81 50.92 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 O-C-N 122.982 0.991 . . . . 0.26 110.814 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.1 tptt -54.91 -34.46 63.14 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.395 -0.816 . . . . 2.62 110.714 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.46 79.15 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.789 -0.569 . . . . 0.45 110.287 -178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.9 mt -77.18 -32.82 56.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.742 -0.599 . . . . 1.82 110.656 179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -58.35 -45.24 88.56 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.265 -0.897 . . . . 2.53 109.91 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.14 -47.41 61.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.55 -0.46 . . . . 1.68 110.408 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.1 t -60.54 -38.08 77.1 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 121.666 -0.646 . . . . 0.28 109.845 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.705 HG23 ' HB3' ' A' ' 48' ' ' LYS . 79.1 mt -82.6 -17.74 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.84 -0.537 . . . . 0.28 110.829 -176.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.06 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.621 -1.392 . . . . 0.22 109.621 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.886 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -93.71 141.86 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.558 -0.966 . . . . 0.77 110.728 -174.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.67 162.4 56.46 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.757 -0.589 . . . . 3.21 110.691 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -51.88 135.86 51.01 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.025 1.013 . . . . 0.5 111.807 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.08 -1.92 71.06 Favored Glycine 0 N--CA 1.497 2.702 0 C-N-CA 120.72 -0.752 . . . . 0.24 111.431 174.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -96.4 131.53 42.87 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-N 118.74 1.27 . . . . 1.11 110.64 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.26 132.95 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.607 0.718 . . . . 0.24 111.229 -173.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.7 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.72 159.52 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.948 -0.47 . . . . 0.18 109.757 177.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.415 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 41.6 tt0 -97.59 130.94 44.59 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.85 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.0 t -114.41 129.48 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.803 -0.56 . . . . 0.2 110.207 -171.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.408 ' HB3' HG23 ' A' ' 3' ' ' VAL . 38.2 mt -118.09 128.78 55.07 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.113 -0.699 . . . . 0.25 109.113 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -79.79 140.45 36.87 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.305 -0.872 . . . . 0.28 109.757 172.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.49 -33.51 6.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.718 -0.614 . . . . 1.6 110.887 -175.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.619 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.63 -172.97 36.03 Favored Glycine 0 N--CA 1.502 3.094 0 C-N-CA 119.778 -1.201 . . . . 0.2 110.942 -176.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -142.88 159.0 43.07 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.706 -0.879 . . . . 1.89 110.655 -177.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.683 . . . . 0.8 110.322 177.602 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 109.605 -0.517 . . . . 0.41 109.605 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.0 mt -84.16 -19.92 33.3 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.738 -0.601 . . . . 0.37 110.398 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.873 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.32 153.93 3.76 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.362 -0.836 . . . . 0.26 109.427 176.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.6 tttt -133.75 125.24 28.11 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.679 -0.638 . . . . 2.3 110.128 -177.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.609 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.9 163.12 39.43 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.627 -0.67 . . . . 0.2 110.871 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.44 138.93 49.38 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.706 -0.621 . . . . 1.99 110.376 -176.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.28 162.3 41.15 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.653 -0.655 . . . . 0.18 109.717 177.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.2 t -111.4 159.69 17.78 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.427 -0.796 . . . . 0.17 109.917 175.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 57.5 t -77.56 138.64 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 120.302 -0.559 . . . . 0.49 110.275 -176.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -118.31 172.01 7.75 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.583 -0.525 . . . . 0.68 109.583 174.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -46.28 152.57 0.41 Allowed 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.574 -0.704 . . . . 2.96 112.014 -175.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.75 7.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.607 0 O-C-N 121.58 -0.7 . . . . 0.42 112.61 -175.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.47 16.12 80.68 Favored Glycine 0 N--CA 1.497 2.7 0 O-C-N 120.901 -1.124 . . . . 0.24 110.327 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.8 ttp180 -84.88 145.96 27.54 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.294 -1.121 . . . . 1.96 110.247 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -133.08 154.85 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 109.284 -0.636 . . . . 0.3 109.284 171.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -115.1 128.04 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 120.039 -0.664 . . . . 0.25 110.054 176.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.0 mt -79.98 144.63 59.69 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.048 -0.661 . . . . 0.23 109.424 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -62.87 142.6 89.16 Favored 'Trans proline' 0 N--CA 1.488 1.2 0 O-C-N 122.971 0.985 . . . . 0.35 109.871 174.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.64 -27.36 62.74 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 120.401 -0.519 . . . . 0.33 110.478 -178.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.54 -43.99 95.78 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.902 -1.279 . . . . 0.39 109.902 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.2 m -70.12 -38.0 75.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.608 -0.937 . . . . 0.39 109.914 -179.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.82 -40.94 73.49 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 121.233 -0.917 . . . . 0.4 109.436 176.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -65.27 -50.08 67.14 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.14 0.495 . . . . 2.97 110.131 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.4 -38.43 74.28 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.786 -0.571 . . . . 0.67 110.756 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.5 t80 -87.4 -14.25 41.12 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.821 -0.549 . . . . 1.44 111.343 -176.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.93 42.76 24.28 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 109.581 -1.408 . . . . 0.31 109.581 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 75.5 mt -87.63 128.45 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.57 -0.959 . . . . 0.42 110.559 -177.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.95 158.38 38.01 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.943 -0.762 . . . . 1.82 108.943 170.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -57.4 140.18 51.04 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.342 -0.849 . . . . 1.99 110.465 -178.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -16.07 61.71 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.828 -0.909 . . . . 0.19 110.828 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.74 157.72 31.47 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.094 -1.239 . . . . 1.12 110.146 178.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -111.92 138.76 48.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.569 -0.707 . . . . 0.21 109.579 174.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 154.75 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 120.15 -0.62 . . . . 0.15 109.354 174.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -115.58 123.72 49.17 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.303 -0.999 . . . . 1.09 108.303 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.837 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.9 158.79 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.754 -0.778 . . . . 0.14 110.982 -167.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.408 ' HB2' HD12 ' A' ' 85' ' ' LEU . 30.2 tttt -133.33 146.21 51.12 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.885 -0.509 . . . . 1.11 110.29 177.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.542 HG22 HG22 ' A' ' 82' ' ' VAL . 21.2 pt -114.82 150.94 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.716 -0.615 . . . . 0.2 110.302 178.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.99 123.84 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.181 0.515 . . . . 0.2 109.678 177.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 46.7 tttp -132.76 146.97 52.29 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.357 -0.609 . . . . 1.98 109.357 175.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.0 t80 . . . . . 0 N--CA 1.496 1.844 0 C-N-CA 119.957 -0.697 . . . . 0.33 110.41 -178.798 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo . . . . . 0 N--CA 1.482 0.852 0 N-CA-C 110.298 -0.693 . . . . 0.34 110.298 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 41.2 mmtt -109.48 137.72 46.9 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.554 -0.716 . . . . 1.1 109.456 172.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.6 163.22 30.62 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.62 -0.675 . . . . 1.42 110.93 -176.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.08 135.93 4.43 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.549 -1.421 . . . . 0.17 109.549 177.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.5 m -123.23 138.2 54.69 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.568 -0.96 . . . . 0.21 109.841 176.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -156.15 173.17 17.23 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.975 -0.69 . . . . 0.16 110.955 176.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -107.36 141.27 38.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.718 -0.614 . . . . 0.13 109.479 173.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.17 146.22 36.69 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 120.212 -0.595 . . . . 0.14 110.73 -175.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -93.01 145.13 24.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.811 -0.556 . . . . 2.21 109.59 175.195 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 90.5 t -79.47 125.8 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.827 -0.546 . . . . 0.17 109.779 179.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.1 -170.38 27.25 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.707 -1.357 . . . . 0.19 109.707 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -61.84 155.75 22.4 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.644 -0.915 . . . . 1.39 109.961 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 54.87 19.64 2.71 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.569 -0.707 . . . . 0.82 112.008 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.18 20.55 79.97 Favored Glycine 0 N--CA 1.499 2.837 0 C-N-CA 119.793 -1.194 . . . . 0.19 110.816 172.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.6 m -77.91 144.04 37.21 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.46 -1.024 . . . . 1.3 110.288 -176.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.22 145.93 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.751 -0.593 . . . . 0.21 109.596 175.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -111.4 123.17 67.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.541 -0.725 . . . . 0.34 110.699 -174.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 77.3 mt -78.62 143.87 64.07 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.532 -0.73 . . . . 0.34 109.429 172.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.754 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.1 Cg_endo -65.1 136.68 49.03 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 O-C-N 122.926 0.961 . . . . 0.26 110.757 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 43.2 tttm -55.07 -34.17 63.36 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.48 -0.763 . . . . 2.62 110.774 179.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.11 78.34 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.711 -0.618 . . . . 0.45 110.288 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.754 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.9 mt -77.15 -32.76 56.52 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 120.208 -0.597 . . . . 1.82 110.519 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -58.29 -45.46 87.91 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.305 -0.872 . . . . 2.53 109.845 178.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.03 -46.53 64.87 Favored 'General case' 0 N--CA 1.496 1.857 0 C-N-CA 120.476 -0.489 . . . . 1.68 110.457 -175.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.7 t -60.45 -38.48 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 C-N-CA 120.168 -0.613 . . . . 0.28 109.945 -178.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.56 -17.51 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.803 -0.561 . . . . 0.28 110.876 -177.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.69 35.13 41.54 Favored Glycine 0 N--CA 1.497 2.742 0 N-CA-C 109.768 -1.333 . . . . 0.22 109.768 176.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.0 mm -93.19 142.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.613 -0.934 . . . . 0.77 110.721 -174.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.49 162.17 57.69 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.724 -0.61 . . . . 3.21 110.309 178.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -56.51 138.11 83.16 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 O-C-N 122.817 0.904 . . . . 0.5 111.331 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 -2.63 71.83 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 120.696 -0.764 . . . . 0.24 111.24 176.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -96.62 131.9 42.81 Favored 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 118.715 1.258 . . . . 1.11 110.599 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.6 p -92.43 133.45 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 121.669 0.747 . . . . 0.24 111.244 -173.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.8 pt -124.59 159.49 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 109.507 -0.553 . . . . 0.18 109.507 176.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -98.88 132.24 44.37 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.029 -0.73 . . . . 1.14 109.029 175.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 37' ' ' ILE . 92.8 t -115.9 131.6 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.754 -0.591 . . . . 0.2 110.363 -170.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.9 mt -117.94 129.55 55.68 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -80.05 142.26 35.09 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.398 -0.814 . . . . 0.28 109.798 171.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.408 HD12 ' HB2' ' A' ' 38' ' ' LYS . 15.6 mt -117.95 -26.72 6.36 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.701 -0.625 . . . . 1.6 111.117 -174.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.78 40.58 Favored Glycine 0 N--CA 1.504 3.195 0 C-N-CA 119.66 -1.257 . . . . 0.2 110.966 -176.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -146.45 150.76 36.24 Favored 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.669 -0.9 . . . . 1.89 110.597 -178.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 N--CA 1.494 1.741 0 O-C-N 121.475 -0.766 . . . . 0.8 110.136 175.445 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.486 1.354 0 N-CA-C 109.612 -0.514 . . . . 0.41 109.612 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.87 -20.79 34.84 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.298 -0.561 . . . . 0.37 110.312 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.858 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.52 153.68 3.56 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.423 -0.798 . . . . 0.26 109.272 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.43 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.1 tttt -134.04 125.98 29.22 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.732 -0.605 . . . . 2.3 110.177 -176.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.611 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.5 p90 -150.61 163.56 38.2 Favored 'General case' 0 N--CA 1.498 1.941 0 C-N-CA 120.052 -0.659 . . . . 0.2 110.957 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.415 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 91.7 m-70 -113.02 138.58 49.67 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.695 -0.628 . . . . 1.99 110.117 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.35 162.31 41.14 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.727 -0.608 . . . . 0.18 109.664 176.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -111.28 159.74 17.66 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.873 -0.731 . . . . 0.17 109.983 176.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.895 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.8 t -78.82 134.09 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.803 -0.56 . . . . 0.49 110.2 -177.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -113.77 171.89 7.31 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-O 121.214 0.53 . . . . 0.68 109.751 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -46.57 152.82 0.42 Allowed 'General case' 0 N--CA 1.507 2.412 0 O-C-N 121.663 -0.648 . . . . 2.96 111.996 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.77 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.598 -0.689 . . . . 0.42 112.576 -175.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.42 16.11 80.73 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.906 -1.121 . . . . 0.24 110.332 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -85.57 143.99 28.16 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.231 -1.158 . . . . 1.96 110.418 -175.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.3 pt -133.68 154.49 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.701 -0.624 . . . . 0.3 109.616 172.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.418 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.84 128.11 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.557 -0.715 . . . . 0.25 110.132 176.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 36.1 mt -80.04 144.86 59.82 Favored Pre-proline 0 N--CA 1.496 1.861 0 C-N-CA 120.026 -0.67 . . . . 0.23 109.415 175.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.37 143.35 88.58 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 122.893 0.944 . . . . 0.35 109.77 174.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.63 -26.49 61.65 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.416 -0.514 . . . . 0.33 110.499 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.47 95.14 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.894 -1.282 . . . . 0.39 109.894 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.2 m -69.97 -38.12 75.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.531 -0.982 . . . . 0.39 110.193 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.707 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.5 mtt180 -55.92 -40.94 73.83 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.23 -0.918 . . . . 0.4 109.454 176.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -65.61 -49.98 66.74 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.204 0.526 . . . . 2.97 110.215 -177.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -57.49 -37.72 73.42 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.689 -0.632 . . . . 0.67 110.668 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.3 t80 -87.67 -14.19 40.57 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.752 -0.593 . . . . 1.44 111.287 -176.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.91 42.87 24.05 Favored Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.587 -1.405 . . . . 0.31 109.587 178.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.912 HG23 HG21 ' A' ' 56' ' ' VAL . 77.1 mt -88.1 129.73 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.068 0 O-C-N 121.552 -0.969 . . . . 0.42 110.615 -176.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -127.9 158.71 37.06 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 109.079 -0.711 . . . . 1.82 109.079 170.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -57.34 137.68 55.79 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.333 -0.854 . . . . 1.99 110.636 -178.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.57 -14.49 65.21 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.9 -0.88 . . . . 0.19 110.9 178.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.19 156.9 33.23 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 118.857 1.328 . . . . 1.12 110.072 177.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -110.62 138.14 47.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.626 -0.671 . . . . 0.21 109.517 174.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.62 154.27 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.247 -0.649 . . . . 0.15 109.247 174.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.5 123.55 48.83 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.287 -1.005 . . . . 1.09 108.287 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.833 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.09 157.16 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 119.611 -0.835 . . . . 0.14 110.953 -167.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -132.2 145.99 51.72 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.846 -0.534 . . . . 1.11 110.528 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.527 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.2 pt -115.3 151.14 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.726 -0.609 . . . . 0.2 110.584 179.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.454 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.51 125.76 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.264 0.554 . . . . 0.2 109.882 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.753 ' HB2' HG22 ' A' ' 80' ' ' ILE . 3.3 tptm -130.76 146.49 52.24 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.156 -0.683 . . . . 1.98 109.156 174.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.7 t80 . . . . . 0 N--CA 1.495 1.814 0 C-N-CA 120.263 -0.575 . . . . 0.33 110.471 -178.75 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo . . . . . 0 N--CA 1.483 0.859 0 N-CA-C 110.208 -0.728 . . . . 0.34 110.208 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.694 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.4 mmtt -114.69 137.73 51.56 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.564 -0.71 . . . . 1.1 109.617 173.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.454 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -134.65 164.18 28.09 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.675 -0.641 . . . . 1.42 110.775 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.78 135.91 4.46 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.484 -1.446 . . . . 0.17 109.484 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -123.18 137.65 54.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.65 -0.912 . . . . 0.21 109.784 176.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.7 p90 -156.13 172.89 17.66 Favored 'General case' 0 N--CA 1.498 1.932 0 C-N-CA 119.833 -0.747 . . . . 0.16 111.014 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.4 m -107.32 140.74 39.76 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.705 -0.622 . . . . 0.13 109.499 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.7 145.21 34.61 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.14 110.585 -175.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -94.13 144.88 25.11 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.828 -0.545 . . . . 2.21 109.647 175.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.912 HG21 HG23 ' A' ' 29' ' ' ILE . 96.7 t -78.79 126.37 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.833 -0.542 . . . . 0.17 110.015 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.86 -165.95 25.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.123 -1.191 . . . . 0.19 110.123 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -61.68 152.07 31.95 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.771 -0.841 . . . . 1.39 110.201 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 73.7 mt-30 53.35 21.52 2.38 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.572 -0.705 . . . . 0.82 112.062 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.54 20.48 79.84 Favored Glycine 0 N--CA 1.5 2.906 0 C-N-CA 119.777 -1.201 . . . . 0.19 110.866 171.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 13.3 t -78.34 144.67 35.81 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.468 -1.019 . . . . 1.3 110.25 -177.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.701 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.34 146.28 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 N-CA-C 109.55 -0.537 . . . . 0.21 109.55 175.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.9 mm -110.68 122.78 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.609 -0.682 . . . . 0.34 110.566 -174.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.6 mt -78.72 142.61 61.47 Favored Pre-proline 0 N--CA 1.498 1.975 0 O-C-N 121.589 -0.694 . . . . 0.34 109.437 172.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.35 133.93 39.7 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 O-C-N 122.915 0.955 . . . . 0.26 110.763 -179.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -55.28 -34.2 63.88 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.508 -0.745 . . . . 2.62 110.832 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.7 76.78 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.783 -0.573 . . . . 0.45 110.334 -178.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.3 mt -77.09 -32.73 56.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.779 -0.575 . . . . 1.82 110.521 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -57.76 -46.13 84.96 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.275 -0.891 . . . . 2.53 109.833 178.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -47.2 62.59 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.503 -0.479 . . . . 1.68 110.502 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.2 t -60.48 -38.22 77.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.708 -0.62 . . . . 0.28 109.962 -178.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.694 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.2 mt -82.58 -17.76 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.818 -0.551 . . . . 0.28 110.884 -176.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.64 35.11 41.9 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 109.726 -1.35 . . . . 0.22 109.726 176.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.895 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.2 138.94 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.535 -0.979 . . . . 0.77 110.591 -174.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.4 mmtt -123.75 161.23 47.53 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.665 -0.647 . . . . 3.21 110.531 -176.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -60.39 135.61 62.52 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 122.951 0.974 . . . . 0.5 110.677 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.89 -0.48 73.08 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 111.139 -0.784 . . . . 0.24 111.139 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -97.17 132.95 42.44 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.063 -1.257 . . . . 1.11 110.44 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.407 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.2 p -91.78 132.27 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 121.504 0.668 . . . . 0.24 111.008 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.753 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.7 pt -119.59 159.42 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 109.531 -0.544 . . . . 0.18 109.531 176.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.415 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 46.9 tt0 -98.31 130.16 45.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.815 -0.809 . . . . 1.14 108.815 173.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.833 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.1 t -115.32 130.22 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-O 121.292 0.568 . . . . 0.2 110.27 -170.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.43 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.5 mt -116.71 129.53 56.18 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 109.136 -0.691 . . . . 0.25 109.136 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.8 mt -80.15 142.46 34.74 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.3 -0.875 . . . . 0.28 109.694 171.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HA ' HD23 ' A' ' 85' ' ' LEU . 29.6 mt -119.5 -25.66 5.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.668 -0.645 . . . . 1.6 111.183 -174.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.41 -179.22 40.13 Favored Glycine 0 N--CA 1.503 3.16 0 C-N-CA 119.643 -1.265 . . . . 0.2 111.1 -177.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -146.96 152.91 39.41 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.669 -0.901 . . . . 1.89 110.571 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 . . . . . 0 N--CA 1.494 1.773 0 O-C-N 121.538 -0.726 . . . . 0.8 110.159 176.203 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.488 1.459 0 N-CA-C 109.566 -0.531 . . . . 0.41 109.566 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.515 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.3 mt -85.94 -20.12 29.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.781 -0.574 . . . . 0.37 110.523 -178.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.948 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.68 156.16 3.47 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.301 -0.875 . . . . 0.26 109.436 176.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -134.26 124.2 25.51 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.777 -0.577 . . . . 2.3 110.104 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.599 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.6 p90 -150.28 162.61 40.17 Favored 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 120.006 -0.678 . . . . 0.2 111.047 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.41 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 92.5 m-70 -112.39 138.57 48.93 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.582 -0.699 . . . . 1.99 110.074 -177.461 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.0 t -151.47 162.37 41.06 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.65 -0.656 . . . . 0.18 109.741 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.42 158.42 19.12 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.857 -0.737 . . . . 0.17 110.072 177.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.6 t -78.95 137.18 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 C-N-CA 120.279 -0.569 . . . . 0.49 110.323 -176.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.2 m80 -116.2 171.91 7.51 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.298 0.57 . . . . 0.68 109.734 174.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.5 ttt85 -46.92 153.02 0.45 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.492 -0.755 . . . . 2.96 111.76 -175.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.9 mt 62.93 6.93 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.684 0 O-C-N 121.507 -0.746 . . . . 0.42 112.636 -174.052 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.67 16.03 80.63 Favored Glycine 0 N--CA 1.496 2.64 0 O-C-N 120.789 -1.194 . . . . 0.24 110.294 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -84.94 144.48 28.31 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.317 -1.108 . . . . 1.96 110.352 -177.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -131.79 154.62 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.751 -0.593 . . . . 0.3 109.41 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.7 mm -116.5 128.49 73.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.598 -0.689 . . . . 0.25 110.003 176.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.438 HG12 ' CE2' ' A' ' 7' ' ' PHE . 40.1 mt -79.99 145.42 61.24 Favored Pre-proline 0 N--CA 1.496 1.826 0 C-N-CA 119.968 -0.693 . . . . 0.23 109.39 175.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.48 143.42 88.09 Favored 'Trans proline' 0 N--CA 1.489 1.206 0 O-C-N 122.936 0.966 . . . . 0.35 109.706 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.48 61.47 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 120.41 -0.516 . . . . 0.33 110.496 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.61 -44.48 94.98 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.862 -1.295 . . . . 0.39 109.862 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 84.4 m -69.92 -38.11 76.12 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.599 -0.942 . . . . 0.39 110.16 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -56.0 -40.74 73.79 Favored 'General case' 0 N--CA 1.513 2.696 0 O-C-N 121.289 -0.882 . . . . 0.4 109.448 176.405 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -65.17 -50.06 67.41 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.086 0.469 . . . . 2.97 110.058 -177.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.26 -38.77 74.38 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.854 -0.529 . . . . 0.67 110.772 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.907 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.9 t80 -88.42 -14.29 38.37 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.753 -0.592 . . . . 1.44 111.163 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.9 42.59 24.85 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.497 -1.441 . . . . 0.31 109.497 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.918 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.47 125.5 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.429 -1.042 . . . . 0.42 110.455 -177.037 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -128.17 155.35 44.62 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.996 -0.742 . . . . 1.82 108.996 171.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -55.5 140.15 41.43 Favored 'General case' 0 N--CA 1.503 2.179 0 O-C-N 121.289 -0.882 . . . . 1.99 110.576 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.82 -16.19 61.39 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.812 -0.915 . . . . 0.19 110.812 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -77.43 158.33 30.07 Favored 'General case' 0 N--CA 1.499 2.022 0 CA-C-N 118.72 1.26 . . . . 1.12 110.042 177.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -113.18 139.19 48.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.604 -0.685 . . . . 0.21 109.581 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.28 154.54 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.35 -0.611 . . . . 0.15 109.35 174.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.431 ' HB2' ' CE2' ' A' ' 88' ' ' TYR . 48.9 tt0 -116.0 123.62 48.46 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.219 -1.03 . . . . 1.09 108.219 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.823 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -139.16 157.99 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 C-N-CA 119.588 -0.845 . . . . 0.14 111.213 -167.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.84 143.48 50.21 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.9 -0.5 . . . . 1.11 109.951 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.6 HG22 HG22 ' A' ' 82' ' ' VAL . 35.0 pt -114.91 150.99 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.593 -0.692 . . . . 0.2 110.527 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -138.4 123.19 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 CA-C-O 121.238 0.542 . . . . 0.2 109.721 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.655 ' HB2' HG22 ' A' ' 80' ' ' ILE . 50.2 tttm -130.98 147.1 52.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.191 -0.67 . . . . 1.98 109.191 174.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.4 t80 . . . . . 0 N--CA 1.496 1.873 0 C-N-CA 119.968 -0.693 . . . . 0.33 110.471 -178.565 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.482 0.845 0 N-CA-C 110.529 -0.604 . . . . 0.34 110.529 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.672 ' HB3' HG23 ' A' ' 72' ' ' ILE . 19.2 mmtp -111.63 137.73 49.1 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.462 -0.774 . . . . 1.1 109.486 171.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.53 164.33 27.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.608 -0.682 . . . . 1.42 110.929 -176.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.03 135.78 4.37 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.536 -1.425 . . . . 0.17 109.536 177.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -127.55 137.05 52.5 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.793 -0.828 . . . . 0.21 109.791 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.0 p90 -156.57 173.94 16.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 119.883 -0.727 . . . . 0.16 110.916 177.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.4 m -106.94 140.74 39.26 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.407 -0.59 . . . . 0.13 109.407 173.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.1 146.18 36.76 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.608 -0.683 . . . . 0.14 110.69 -175.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -93.35 145.81 24.19 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 109.628 -0.508 . . . . 2.21 109.628 175.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.918 HG21 HG23 ' A' ' 29' ' ' ILE . 88.0 t -78.56 126.01 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.754 -0.591 . . . . 0.17 109.858 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.0 -167.34 26.0 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.982 -1.247 . . . . 0.19 109.982 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.64 153.23 28.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.782 -0.834 . . . . 1.39 110.151 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 53.51 21.12 2.34 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.579 -0.7 . . . . 0.82 112.099 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.54 79.89 Favored Glycine 0 N--CA 1.499 2.892 0 C-N-CA 119.716 -1.231 . . . . 0.19 110.921 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.465 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -78.28 147.11 34.45 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.445 -1.032 . . . . 1.3 110.262 -177.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.686 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.82 145.99 26.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 109.548 -0.538 . . . . 0.21 109.548 175.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -110.73 123.37 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.446 -0.784 . . . . 0.34 110.738 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.3 mt -78.31 144.71 66.99 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.576 -0.703 . . . . 0.34 109.452 172.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.7 Cg_endo -64.67 135.89 47.23 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 122.929 0.963 . . . . 0.26 110.755 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.03 -34.36 63.44 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.499 -0.75 . . . . 2.62 110.759 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -38.04 77.92 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.757 -0.589 . . . . 0.45 110.317 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.1 mt -77.14 -32.79 56.58 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.734 -0.604 . . . . 1.82 110.475 179.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.09 -45.66 86.82 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.319 -0.863 . . . . 2.53 109.811 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.09 -47.25 62.64 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.515 -0.474 . . . . 1.68 110.463 -175.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.6 t -60.52 -38.34 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.116 0 O-C-N 121.726 -0.609 . . . . 0.28 109.916 -178.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.672 HG23 ' HB3' ' A' ' 48' ' ' LYS . 84.3 mt -82.38 -17.65 11.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.886 -0.509 . . . . 0.28 110.917 -176.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.09 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.697 -1.361 . . . . 0.22 109.697 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.39 142.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.564 -0.962 . . . . 0.77 110.707 -173.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.13 159.05 72.19 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.8 -0.562 . . . . 3.21 110.757 -178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -54.57 134.79 63.82 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 122.913 0.954 . . . . 0.5 111.414 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -0.94 72.17 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 120.696 -0.764 . . . . 0.24 111.27 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.401 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 16.9 mt-10 -97.19 133.28 42.04 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.058 -1.26 . . . . 1.11 110.552 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.3 p -92.98 136.35 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 CA-C-O 121.835 0.826 . . . . 0.24 111.389 -174.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.655 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.3 pt -125.89 159.59 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.247 -0.649 . . . . 0.18 109.247 177.259 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.41 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 52.4 tt0 -97.98 131.25 44.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.046 -0.724 . . . . 1.14 109.046 175.389 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.823 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.3 t -117.06 130.7 71.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 CA-C-O 121.438 0.637 . . . . 0.2 110.391 -170.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.8 mt -117.27 129.82 56.16 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.194 -0.669 . . . . 0.25 109.194 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.948 HD12 ' HB3' ' A' ' 5' ' ' ALA . 5.6 mt -80.08 140.75 36.33 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.36 -0.838 . . . . 0.28 109.903 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.7 mt -111.5 -30.47 7.37 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.672 -0.642 . . . . 1.6 111.011 -175.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.29 178.62 41.31 Favored Glycine 0 N--CA 1.505 3.254 0 C-N-CA 119.61 -1.281 . . . . 0.2 111.012 -176.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.408 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 30.1 p80 -140.81 145.63 36.55 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.783 -0.834 . . . . 1.89 109.99 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.431 ' CE2' ' HB2' ' A' ' 36' ' ' GLU . 18.3 m-85 . . . . . 0 N--CA 1.498 1.945 0 O-C-N 121.665 -0.647 . . . . 0.8 109.961 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.486 1.365 0 N-CA-C 109.519 -0.548 . . . . 0.41 109.519 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.568 HD11 ' HA2' ' A' ' 86' ' ' GLY . 28.7 mt -85.18 -18.72 33.24 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.221 -0.592 . . . . 0.37 110.246 178.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.823 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.79 151.83 1.48 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.214 -0.929 . . . . 0.26 109.045 176.042 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 17.5 ttpt -134.63 128.19 32.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.625 -0.672 . . . . 2.3 110.356 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -149.91 162.93 39.37 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.822 -0.549 . . . . 0.2 110.685 -177.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.432 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.1 m170 -112.58 137.63 50.53 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.662 -0.649 . . . . 1.99 110.144 -176.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.37 162.35 41.07 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.724 -0.61 . . . . 0.18 109.636 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.48 157.85 19.15 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 119.81 -0.756 . . . . 0.17 110.137 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.923 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.3 t -80.13 136.56 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 CA-C-O 121.276 0.56 . . . . 0.49 110.339 -176.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.3 m80 -113.98 171.96 7.28 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.229 0.538 . . . . 0.68 109.672 174.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.7 mtt85 -45.99 152.44 0.38 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.558 -0.714 . . . . 2.96 112.127 -175.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.0 mt 62.75 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.654 0 O-C-N 121.611 -0.68 . . . . 0.42 112.578 -175.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.48 16.06 80.74 Favored Glycine 0 N--CA 1.497 2.709 0 O-C-N 120.783 -1.198 . . . . 0.24 110.34 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.844 ' NH1' HD11 ' A' ' 18' ' ' ILE . 69.9 ttp85 -85.47 142.63 29.07 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -1.113 . . . . 1.96 110.234 -177.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -133.12 156.54 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.728 -0.607 . . . . 0.3 109.695 174.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.844 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.1 mm -116.52 129.16 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.65 -0.656 . . . . 0.25 109.957 176.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 28.2 mt -79.69 145.81 63.46 Favored Pre-proline 0 N--CA 1.495 1.814 0 C-N-CA 120.04 -0.664 . . . . 0.23 109.331 175.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.401 ' HD2' HG23 ' A' ' 19' ' ' ILE . 44.6 Cg_endo -62.84 142.74 89.82 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 122.994 0.997 . . . . 0.35 109.848 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.27 62.93 Favored 'General case' 0 N--CA 1.497 1.885 0 C-N-CA 120.44 -0.504 . . . . 0.33 110.464 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -43.85 95.99 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 109.968 -1.253 . . . . 0.39 109.968 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 98.6 m -69.81 -38.53 76.63 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.559 -0.966 . . . . 0.39 109.958 -179.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.0 mtt180 -56.03 -41.27 74.7 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.252 -0.905 . . . . 0.4 109.39 176.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -65.75 -50.14 65.84 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.111 0.481 . . . . 2.97 110.224 -177.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 82.2 t80 -57.47 -38.3 74.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.788 -0.57 . . . . 0.67 110.683 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.5 t80 -87.36 -14.16 41.49 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.739 -0.601 . . . . 1.44 111.3 -175.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.46 42.78 26.51 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.573 -1.411 . . . . 0.31 109.573 178.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.915 HG23 HG21 ' A' ' 56' ' ' VAL . 77.3 mt -88.38 128.48 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.522 -0.987 . . . . 0.42 110.556 -176.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -128.25 155.44 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 171.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -55.71 138.72 46.96 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 121.241 -0.912 . . . . 1.99 110.646 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.62 -15.98 62.15 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.868 -0.893 . . . . 0.19 110.868 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -77.16 158.18 30.53 Favored 'General case' 0 N--CA 1.499 1.997 0 CA-C-N 118.677 1.239 . . . . 1.12 110.11 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -112.09 138.94 48.05 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.594 -0.691 . . . . 0.21 109.62 174.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.48 154.11 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 N-CA-C 109.312 -0.625 . . . . 0.15 109.312 173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.98 123.57 48.35 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.277 -1.009 . . . . 1.09 108.277 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.811 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -140.08 158.17 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.559 -0.856 . . . . 0.14 111.128 -167.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -133.04 146.1 51.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.799 -0.563 . . . . 1.11 110.418 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.511 HG22 HG22 ' A' ' 82' ' ' VAL . 27.5 pt -114.88 151.1 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.743 -0.598 . . . . 0.2 110.571 178.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -137.62 128.72 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 109.65 -0.5 . . . . 0.2 109.65 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.47 ' HD2' HD12 ' A' ' 74' ' ' ILE . 59.8 tttm -136.82 148.26 47.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.783 -0.573 . . . . 1.98 109.645 177.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.8 t80 . . . . . 0 N--CA 1.496 1.861 0 O-C-N 121.703 -0.623 . . . . 0.33 110.491 -178.327 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo . . . . . 0 N--CA 1.485 0.99 0 N-CA-C 110.327 -0.682 . . . . 0.34 110.327 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.42 ' CD ' ' HA ' ' A' ' 72' ' ' ILE . 30.1 mttp -121.37 149.8 42.42 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.426 -0.796 . . . . 1.1 110.172 171.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.3 mp0 -136.99 166.96 22.43 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 120.22 -0.592 . . . . 1.42 110.995 -177.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.32 135.9 4.51 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.305 -1.518 . . . . 0.17 109.305 175.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.4 m -123.84 138.48 54.49 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.546 -0.973 . . . . 0.21 109.894 178.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.6 p90 -156.62 173.09 17.46 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 119.868 -0.733 . . . . 0.16 110.986 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.2 m -107.37 141.4 38.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.67 -0.644 . . . . 0.13 109.395 173.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.04 145.64 36.15 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.681 -0.637 . . . . 0.14 110.709 -175.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.1 ttt180 -93.51 145.13 24.74 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 109.573 -0.529 . . . . 2.21 109.573 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.915 HG21 HG23 ' A' ' 29' ' ' ILE . 93.0 t -79.06 125.05 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.223 0.535 . . . . 0.17 109.838 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.08 -164.91 24.86 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.135 -1.186 . . . . 0.19 110.135 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 33.4 tp10 -61.67 152.69 30.16 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.819 . . . . 1.39 110.013 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 53.43 21.04 2.23 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.59 -0.694 . . . . 0.82 112.043 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.69 79.96 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 119.732 -1.223 . . . . 0.19 110.842 172.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -77.92 147.12 35.17 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.45 -1.029 . . . . 1.3 110.365 -176.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -139.15 146.55 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.82 -0.55 . . . . 0.21 109.628 175.558 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -111.04 123.1 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.579 -0.701 . . . . 0.34 110.748 -175.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.7 mt -78.57 144.65 65.76 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.614 -0.679 . . . . 0.34 109.535 172.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.6 Cg_endo -64.13 133.27 37.45 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 O-C-N 122.873 0.933 . . . . 0.26 110.767 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.2 tttt -55.01 -34.45 63.46 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.551 -0.718 . . . . 2.62 110.831 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -38.22 77.89 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.737 -0.602 . . . . 0.45 110.275 -178.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.8 mt -76.99 -32.8 57.48 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 120.25 -0.58 . . . . 1.82 110.547 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.8 mtt180 -57.93 -45.61 86.32 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.287 -0.883 . . . . 2.53 109.808 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.75 -46.67 65.34 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.479 -0.489 . . . . 1.68 110.307 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 98.8 t -60.72 -39.11 80.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.626 -0.671 . . . . 0.28 109.951 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.559 HG22 HD11 ' A' ' 74' ' ' ILE . 85.7 mt -83.65 -14.42 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.839 -0.538 . . . . 0.28 111.191 -176.146 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.67 35.38 40.87 Favored Glycine 0 N--CA 1.499 2.857 0 N-CA-C 110.169 -1.172 . . . . 0.22 110.169 175.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.923 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.3 mm -88.66 140.56 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.536 -0.979 . . . . 0.77 110.787 -174.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -131.38 162.62 54.88 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.782 -0.574 . . . . 3.21 110.606 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.88 134.82 59.26 Favored 'Trans proline' 0 N--CA 1.487 1.09 0 O-C-N 122.954 0.976 . . . . 0.5 110.858 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.97 0.91 70.84 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 120.639 -0.791 . . . . 0.24 111.234 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -96.87 133.7 41.15 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.019 -1.283 . . . . 1.11 110.498 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.08 133.22 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-O 121.584 0.706 . . . . 0.24 111.2 -175.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.43 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.4 pt -123.18 159.5 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 109.499 -0.556 . . . . 0.18 109.499 176.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.432 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 58.8 tt0 -97.35 131.52 43.94 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.986 -0.746 . . . . 1.14 108.986 174.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.811 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.2 t -116.08 128.46 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.438 0.637 . . . . 0.2 110.222 -171.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.4 mt -115.45 128.75 56.24 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 109.466 -0.568 . . . . 0.25 109.466 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.52 140.8 37.13 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.451 -0.781 . . . . 0.28 109.948 172.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.43 -32.31 6.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.791 -0.568 . . . . 1.6 110.828 -176.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.568 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.19 -177.19 39.19 Favored Glycine 0 N--CA 1.505 3.259 0 C-N-CA 119.706 -1.235 . . . . 0.2 111.025 -176.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.3 p80 -145.17 151.71 38.88 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.708 -0.878 . . . . 1.89 110.792 -177.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 N--CA 1.494 1.769 0 O-C-N 121.515 -0.741 . . . . 0.8 109.994 175.061 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.486 1.369 0 N-CA-C 109.475 -0.565 . . . . 0.41 109.475 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.1 mt -82.56 -20.15 37.13 Favored 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 120.248 -0.581 . . . . 0.37 110.425 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.804 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.94 153.21 3.15 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.415 -0.803 . . . . 0.26 109.289 176.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.437 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.6 tttt -133.96 125.92 29.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.639 -0.663 . . . . 2.3 110.222 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.7 p90 -151.2 163.41 38.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.605 -0.684 . . . . 0.2 110.833 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.86 138.61 50.06 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.615 -0.678 . . . . 1.99 110.349 -176.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 162.37 41.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.774 -0.578 . . . . 0.18 109.684 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -110.21 158.95 17.82 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.48 -0.763 . . . . 0.17 109.933 176.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.918 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.46 136.39 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.272 -0.571 . . . . 0.49 110.241 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -114.69 171.91 7.35 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.312 0.577 . . . . 0.68 109.831 175.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.39 152.97 0.39 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.609 -0.682 . . . . 2.96 112.008 -176.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.5 mt 63.09 7.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.702 0 O-C-N 121.605 -0.684 . . . . 0.42 112.522 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.51 15.98 80.8 Favored Glycine 0 N--CA 1.497 2.729 0 O-C-N 120.899 -1.125 . . . . 0.24 110.312 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -86.02 143.81 27.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.304 -1.115 . . . . 1.96 110.361 -176.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.4 154.67 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.631 -0.668 . . . . 0.3 109.613 172.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.6 128.79 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.623 -0.673 . . . . 0.25 109.978 176.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 27.3 mt -79.44 145.35 63.48 Favored Pre-proline 0 N--CA 1.495 1.781 0 C-N-CA 120.056 -0.658 . . . . 0.23 109.423 175.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -63.4 143.64 89.03 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 O-C-N 122.96 0.979 . . . . 0.35 109.748 174.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.96 -27.0 60.82 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 120.389 -0.524 . . . . 0.33 110.484 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.39 -44.76 94.89 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.02 -1.232 . . . . 0.39 110.02 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 91.6 m -69.31 -36.64 77.2 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.686 -0.891 . . . . 0.39 110.061 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.612 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.9 mtt180 -56.38 -42.56 78.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.371 -0.83 . . . . 0.4 109.812 178.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -66.2 -49.97 65.45 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 120.209 -0.596 . . . . 2.97 110.203 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 74.7 t80 -56.26 -37.93 70.46 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.831 -0.543 . . . . 0.67 110.589 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.91 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -88.34 -14.31 38.52 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.892 -0.505 . . . . 1.44 111.228 -178.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.55 42.82 25.97 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.609 -1.396 . . . . 0.31 109.609 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.92 HG23 HG21 ' A' ' 56' ' ' VAL . 76.6 mt -87.52 126.95 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.526 -0.985 . . . . 0.42 110.538 -176.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -127.19 158.98 35.65 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 170.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -57.26 137.53 55.88 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.361 -0.837 . . . . 1.99 110.662 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.23 63.84 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.998 -0.841 . . . . 0.19 110.998 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.31 157.11 32.8 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-N 118.674 1.237 . . . . 1.12 110.053 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -111.11 138.39 47.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.629 -0.67 . . . . 0.21 109.631 174.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 153.44 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.3 -0.63 . . . . 0.15 109.3 174.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -115.06 123.14 48.25 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.3 tt -140.47 159.21 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.688 -0.805 . . . . 0.14 110.882 -167.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.2 ttpt -133.55 145.99 50.61 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.783 -0.573 . . . . 1.11 110.415 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.604 HG22 HG22 ' A' ' 82' ' ' VAL . 26.0 pt -115.0 151.08 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.575 -0.703 . . . . 0.2 110.385 177.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.642 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.79 124.5 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 120.499 -0.48 . . . . 0.2 109.806 176.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.698 ' HB2' HG22 ' A' ' 80' ' ' ILE . 22.0 ttpp -131.21 144.68 51.52 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.735 -0.603 . . . . 1.98 109.381 176.214 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 t80 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.654 -0.654 . . . . 0.33 110.335 -178.916 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.482 0.85 0 N-CA-C 110.097 -0.77 . . . . 0.34 110.097 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.681 ' HB3' HG23 ' A' ' 72' ' ' ILE . 25.1 mmtt -111.59 137.37 49.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.593 -0.692 . . . . 1.1 109.666 173.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.642 ' HG2' HG13 ' A' ' 40' ' ' VAL . 48.7 mt-10 -135.17 165.3 25.72 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.645 -0.659 . . . . 1.42 110.71 -176.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.551 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.71 135.68 4.35 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.406 -1.478 . . . . 0.17 109.406 176.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.582 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.9 m -123.55 136.66 54.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.782 -0.834 . . . . 0.21 109.779 176.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.822 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 10.8 p90 -156.05 173.53 16.68 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 119.942 -0.703 . . . . 0.16 111.079 178.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.22 140.71 39.67 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.615 -0.678 . . . . 0.13 109.472 173.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.822 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.63 146.08 35.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.656 -0.653 . . . . 0.14 110.655 -175.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.4 ttp-105 -93.63 144.78 25.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.79 -0.569 . . . . 2.21 109.647 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.92 HG21 HG23 ' A' ' 29' ' ' ILE . 90.2 t -79.03 127.28 39.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.794 -0.566 . . . . 0.17 109.95 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.72 -171.37 26.61 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.841 -1.304 . . . . 0.19 109.841 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 -61.85 156.61 20.24 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.636 -0.92 . . . . 1.39 109.893 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 55.07 19.06 2.59 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.441 -0.787 . . . . 0.82 112.075 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.64 20.49 79.62 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.831 -1.176 . . . . 0.19 110.695 172.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.4 t -78.75 144.87 34.8 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.423 -1.046 . . . . 1.3 110.333 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.623 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -137.73 146.15 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 109.555 -0.535 . . . . 0.21 109.555 175.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.1 mm -110.86 123.69 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.53 -0.731 . . . . 0.34 110.714 -174.005 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.413 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.2 mt -78.66 143.29 62.81 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.585 -0.697 . . . . 0.34 109.455 172.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.4 Cg_endo -65.02 137.11 51.2 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 O-C-N 122.959 0.979 . . . . 0.26 110.817 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 17.1 tptp -54.84 -34.79 63.27 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.446 -0.784 . . . . 2.62 110.781 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.86 -38.35 78.56 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.792 -0.568 . . . . 0.45 110.363 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.3 mt -77.2 -32.73 56.19 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 120.15 -0.62 . . . . 1.82 110.683 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.31 -45.55 87.81 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.347 -0.846 . . . . 2.53 109.831 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -70.32 -48.19 57.69 Favored 'General case' 0 N--CA 1.495 1.822 0 C-N-CA 120.519 -0.472 . . . . 1.68 110.421 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.53 -38.02 76.84 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.732 -0.605 . . . . 0.28 109.938 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.681 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.3 mt -82.52 -17.8 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.844 -0.535 . . . . 0.28 110.947 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.45 35.17 42.72 Favored Glycine 0 N--CA 1.497 2.721 0 N-CA-C 109.7 -1.36 . . . . 0.22 109.7 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.918 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.13 142.01 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.514 -0.992 . . . . 0.77 110.695 -174.305 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 44.9 mttt -130.88 162.34 55.97 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.699 -0.626 . . . . 3.21 110.663 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.93 135.58 64.07 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 O-C-N 123.037 1.019 . . . . 0.5 110.818 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.16 -0.16 71.77 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 120.686 -0.769 . . . . 0.24 111.246 176.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -95.37 131.12 41.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.055 -1.262 . . . . 1.11 110.377 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.5 p -91.66 135.87 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 CA-C-O 121.762 0.792 . . . . 0.24 111.106 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.698 HG22 ' HB2' ' A' ' 41' ' ' LYS . 42.0 pt -126.53 159.43 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 109.477 -0.564 . . . . 0.18 109.477 179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -98.61 128.18 44.82 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.751 -0.833 . . . . 1.14 108.751 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 85.5 t -113.28 128.98 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-O 121.341 0.591 . . . . 0.2 110.148 -171.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.8 mt -116.75 127.35 54.28 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.02 -0.733 . . . . 0.25 109.02 -179.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.91 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.4 mt -79.98 140.9 36.43 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.363 -0.835 . . . . 0.28 109.757 172.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 mt -113.9 -30.13 6.83 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.658 -0.651 . . . . 1.6 110.966 -174.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.93 -177.93 39.54 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.709 -1.234 . . . . 0.2 111.008 -177.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 25.5 p80 -145.09 153.53 41.53 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.729 -0.865 . . . . 1.89 110.694 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.6 -0.687 . . . . 0.8 110.162 176.236 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.43 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p . . . . . 0 N--CA 1.486 1.37 0 N-CA-C 109.556 -0.535 . . . . 0.41 109.556 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.603 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.4 mt -82.08 -20.77 37.51 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.25 -0.58 . . . . 0.37 110.252 179.178 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.784 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.17 153.42 3.69 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -0.835 . . . . 0.26 109.245 176.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.6 tttt -133.55 125.72 29.46 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.741 -0.6 . . . . 2.3 110.173 -176.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.61 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.23 162.87 39.64 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.555 -0.716 . . . . 0.2 110.94 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.417 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 95.5 m-70 -112.83 137.73 50.72 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.718 -0.614 . . . . 1.99 110.172 -176.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.1 162.3 41.12 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.729 -0.607 . . . . 0.18 109.582 176.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -110.11 159.77 17.05 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.736 -0.786 . . . . 0.17 110.075 177.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.908 HG21 HG21 ' A' ' 74' ' ' ILE . 60.5 t -78.74 136.24 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 C-N-CA 120.3 -0.56 . . . . 0.49 110.233 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -115.44 171.88 7.44 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.22 0.533 . . . . 0.68 109.589 174.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 69.8 mtp85 -46.27 152.54 0.41 Allowed 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.573 -0.704 . . . . 2.96 112.067 -175.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.591 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.7 mt 62.41 7.99 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.665 0 O-C-N 121.656 -0.653 . . . . 0.42 112.631 -176.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.9 16.18 80.27 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.832 -1.168 . . . . 0.24 110.446 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -84.45 143.27 29.51 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.314 -1.11 . . . . 1.96 110.33 -176.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -134.51 154.95 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.672 -0.642 . . . . 0.3 109.545 172.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.7 mm -117.46 128.44 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.586 -0.696 . . . . 0.25 109.936 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.434 HG12 ' CE2' ' A' ' 7' ' ' PHE . 35.6 mt -79.79 144.04 59.4 Favored Pre-proline 0 N--CA 1.495 1.786 0 C-N-CA 120.075 -0.65 . . . . 0.23 109.407 176.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.37 143.5 88.91 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.004 1.002 . . . . 0.35 109.729 174.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.51 -26.49 61.41 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.858 -0.526 . . . . 0.33 110.527 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.37 95.17 Favored Glycine 0 N--CA 1.497 2.722 0 N-CA-C 109.935 -1.266 . . . . 0.39 109.935 -179.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 75.0 m -69.97 -38.2 76.02 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.58 -0.953 . . . . 0.39 110.18 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.667 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.6 mtt180 -55.95 -41.11 74.21 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.349 -0.844 . . . . 0.4 109.413 176.468 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.2 tttp -65.56 -49.95 66.96 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.145 0.498 . . . . 2.97 110.197 -177.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -57.14 -38.34 73.38 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.769 -0.582 . . . . 0.67 110.735 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.7 t80 -88.12 -14.25 39.24 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.779 -0.575 . . . . 1.44 111.291 -176.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.81 42.69 25.05 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.484 -1.447 . . . . 0.31 109.484 178.264 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.864 HG23 HG21 ' A' ' 56' ' ' VAL . 73.6 mt -87.49 129.17 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.492 -1.005 . . . . 0.42 110.437 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.08 154.65 45.46 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.962 -0.755 . . . . 1.82 108.962 172.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -55.21 139.67 41.37 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.288 -0.882 . . . . 1.99 110.691 -177.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.86 -15.98 61.88 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.936 -0.866 . . . . 0.19 110.936 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -76.21 156.73 33.35 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.097 -1.237 . . . . 1.12 110.069 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -110.18 138.59 46.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.638 -0.664 . . . . 0.21 109.595 174.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.32 154.79 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 109.271 -0.64 . . . . 0.15 109.271 174.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -116.09 123.37 47.74 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.207 -1.034 . . . . 1.09 108.207 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.6 tt -139.45 158.25 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 119.661 -0.816 . . . . 0.14 110.95 -167.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HB2' HG23 ' A' ' 51' ' ' THR . 82.4 tttt -132.7 145.86 51.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.867 -0.521 . . . . 1.11 110.386 178.008 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 34.1 pt -114.94 150.97 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.667 -0.645 . . . . 0.2 110.568 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.7 t -139.27 126.0 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 CA-C-O 121.231 0.539 . . . . 0.2 109.778 176.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.705 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.5 tptp -136.26 148.79 48.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.812 -0.555 . . . . 1.98 109.511 176.006 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.9 t80 . . . . . 0 N--CA 1.495 1.808 0 C-N-CA 120.19 -0.604 . . . . 0.33 110.251 -178.135 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo . . . . . 0 N--CA 1.483 0.906 0 N-CA-C 110.566 -0.59 . . . . 0.34 110.566 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 73.9 mmtt -114.47 136.89 52.51 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.545 -0.722 . . . . 1.1 109.496 171.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -137.5 168.92 18.69 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.603 -0.686 . . . . 1.42 110.713 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.417 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -160.22 135.95 4.31 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.592 -1.403 . . . . 0.17 109.592 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.409 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -121.55 137.49 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.755 -0.85 . . . . 0.21 109.721 177.423 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.8 p90 -155.78 173.02 17.36 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 119.911 -0.716 . . . . 0.16 110.965 176.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.4 m -107.44 140.82 39.81 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.71 -0.619 . . . . 0.13 109.586 174.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.66 145.12 34.56 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.614 -0.679 . . . . 0.14 110.552 -176.25 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.2 ttp-105 -93.4 145.31 24.58 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.773 -0.58 . . . . 2.21 109.679 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.864 HG21 HG23 ' A' ' 29' ' ' ILE . 94.7 t -79.11 126.13 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.847 -0.533 . . . . 0.17 109.975 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.45 -170.7 26.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.79 -1.324 . . . . 0.19 109.79 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -61.88 156.03 21.83 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.61 -0.935 . . . . 1.39 109.905 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 54.91 19.44 2.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.611 -0.68 . . . . 0.82 112.084 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.68 20.5 79.67 Favored Glycine 0 N--CA 1.499 2.838 0 C-N-CA 119.821 -1.18 . . . . 0.19 110.783 172.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 54.1 p -77.97 145.7 35.88 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.451 -1.029 . . . . 1.3 110.534 -175.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.81 146.2 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.875 -0.515 . . . . 0.21 109.628 174.497 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.62 123.61 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.499 -0.75 . . . . 0.34 110.653 -175.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 72.9 mt -78.3 144.15 65.97 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.679 -0.638 . . . . 0.34 109.652 174.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.41 134.35 41.33 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 O-C-N 123.002 1.001 . . . . 0.26 110.808 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -55.19 -34.29 63.76 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.532 -0.73 . . . . 2.62 110.847 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.78 -37.69 76.87 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.74 -0.6 . . . . 0.45 110.324 -178.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.4 mt -77.18 -32.79 56.34 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.723 -0.61 . . . . 1.82 110.544 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -57.82 -45.73 85.72 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.282 -0.886 . . . . 2.53 109.911 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.27 -47.22 62.26 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.44 -0.504 . . . . 1.68 110.465 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.56 -38.12 77.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.712 -0.618 . . . . 0.28 109.987 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.9 mt -82.31 -18.06 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.849 -0.532 . . . . 0.28 110.788 -176.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.28 40.7 Favored Glycine 0 N--CA 1.497 2.763 0 N-CA-C 109.684 -1.366 . . . . 0.22 109.684 176.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.908 HG21 HG21 ' A' ' 11' ' ' VAL . 50.9 mm -90.89 144.58 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.53 -0.982 . . . . 0.77 110.613 -174.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.04 159.31 73.19 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.743 -0.598 . . . . 3.21 110.906 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -52.8 134.79 55.67 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 O-C-N 123.067 1.035 . . . . 0.5 111.688 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.07 -0.63 69.38 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.66 -0.781 . . . . 0.24 111.331 175.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.65 129.0 40.1 Favored 'General case' 0 N--CA 1.501 2.083 0 CA-C-N 118.724 1.262 . . . . 1.11 110.173 178.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 79' ' ' VAL . 10.7 p -91.15 128.51 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 121.4 0.619 . . . . 0.24 110.606 -175.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.705 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -118.79 159.56 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.639 -0.504 . . . . 0.18 109.639 179.267 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.417 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.3 tt0 -97.6 130.13 44.66 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.938 -0.764 . . . . 1.14 108.938 174.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.48 129.2 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-O 121.373 0.606 . . . . 0.2 110.257 -171.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.9 mt -116.38 129.08 56.05 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.204 -0.665 . . . . 0.25 109.204 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -79.8 139.66 37.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.342 -0.849 . . . . 0.28 109.791 172.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -109.34 -33.45 6.83 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.767 -0.583 . . . . 1.6 110.927 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.603 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.22 -175.2 37.69 Favored Glycine 0 N--CA 1.504 3.184 0 C-N-CA 119.674 -1.251 . . . . 0.2 111.031 -176.122 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p80 -143.79 153.91 42.88 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.759 -0.847 . . . . 1.89 110.719 -177.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.537 -0.727 . . . . 0.8 110.236 176.04 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.45 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p . . . . . 0 N--CA 1.487 1.42 0 N-CA-C 109.588 -0.523 . . . . 0.41 109.588 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.8 mt -80.96 -21.49 40.32 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.269 -0.572 . . . . 0.37 110.189 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.862 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.11 152.18 3.4 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.442 -0.786 . . . . 0.26 109.127 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.441 ' HE3' HD21 ' A' ' 83' ' ' LEU . 67.2 tttt -132.61 125.18 29.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.702 -0.624 . . . . 2.3 110.214 -176.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.0 p90 -150.21 162.76 39.84 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.072 -0.651 . . . . 0.2 110.989 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.412 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 96.2 m-70 -112.52 138.23 49.58 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.626 -0.671 . . . . 1.99 110.154 -176.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.06 162.26 41.18 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.696 -0.628 . . . . 0.18 109.627 176.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.62 158.78 18.2 Favored 'General case' 0 N--CA 1.498 1.939 0 C-N-CA 119.818 -0.753 . . . . 0.17 110.136 177.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.3 t -79.24 134.89 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 C-N-CA 120.257 -0.577 . . . . 0.49 110.245 -177.089 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.28 171.89 7.34 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-O 121.277 0.561 . . . . 0.68 109.647 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -47.16 152.99 0.5 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.579 -0.701 . . . . 2.96 111.776 -175.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.7 mt 62.65 7.37 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.652 0 O-C-N 121.46 -0.775 . . . . 0.42 112.681 -174.48 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.1 80.63 Favored Glycine 0 N--CA 1.497 2.747 0 O-C-N 120.935 -1.103 . . . . 0.24 110.363 179.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -84.64 142.84 29.63 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.248 -1.148 . . . . 1.96 110.391 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.57 155.22 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.721 -0.612 . . . . 0.3 109.39 172.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.6 mm -116.56 128.45 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.579 -0.701 . . . . 0.25 109.977 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 37.4 mt -79.99 144.32 59.04 Favored Pre-proline 0 N--CA 1.495 1.792 0 C-N-CA 120.015 -0.674 . . . . 0.23 109.422 175.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -63.54 143.46 87.8 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 122.943 0.97 . . . . 0.35 109.751 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.75 61.57 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 120.44 -0.504 . . . . 0.33 110.481 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.17 95.56 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.954 -1.258 . . . . 0.39 109.954 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.7 m -69.87 -38.43 76.39 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.562 -0.964 . . . . 0.39 110.148 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.704 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.9 mtt180 -56.03 -40.58 73.66 Favored 'General case' 0 N--CA 1.513 2.689 0 O-C-N 121.29 -0.881 . . . . 0.4 109.386 176.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -65.64 -50.01 66.56 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.043 0.449 . . . . 2.97 110.213 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -57.74 -38.85 76.07 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.751 -0.593 . . . . 0.67 110.683 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.96 ' CD2' HD13 ' A' ' 84' ' ' LEU . 26.7 t80 -86.74 -14.17 43.17 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.804 -0.56 . . . . 1.44 111.346 -176.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 43.14 23.45 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.603 -1.399 . . . . 0.31 109.603 178.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.895 HG23 HG21 ' A' ' 56' ' ' VAL . 76.9 mt -87.73 128.79 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 121.523 -0.986 . . . . 0.42 110.537 -177.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.1 153.97 46.24 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.868 -0.79 . . . . 1.82 108.868 170.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -55.27 140.39 39.33 Favored 'General case' 0 N--CA 1.504 2.241 0 O-C-N 121.238 -0.913 . . . . 1.99 110.626 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.8 -16.03 61.74 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.859 -0.896 . . . . 0.19 110.859 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.91 157.54 31.3 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.67 1.235 . . . . 1.12 110.115 178.186 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -111.71 138.92 47.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.622 -0.674 . . . . 0.21 109.557 174.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.55 155.12 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 C-N-CA 120.224 -0.59 . . . . 0.15 109.454 174.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.92 123.6 48.49 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.364 -0.976 . . . . 1.09 108.364 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.4 tt -139.96 156.01 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.682 -0.807 . . . . 0.14 110.95 -167.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -131.13 146.07 52.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.747 -0.596 . . . . 1.11 110.55 177.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 82' ' ' VAL . 29.6 pt -114.94 151.08 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 121.731 -0.605 . . . . 0.2 110.699 178.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.463 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.23 126.58 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.152 0.501 . . . . 0.2 109.734 175.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.703 ' HB2' HG22 ' A' ' 80' ' ' ILE . 32.1 tptt -136.69 146.89 46.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.741 -0.6 . . . . 1.98 109.602 175.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 t80 . . . . . 0 N--CA 1.495 1.816 0 C-N-CA 120.231 -0.587 . . . . 0.33 110.427 -177.275 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.482 0.801 0 N-CA-C 110.159 -0.746 . . . . 0.34 110.159 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.75 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.0 mmtt -120.48 138.17 53.96 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.545 -0.722 . . . . 1.1 109.564 172.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.463 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.7 mt-10 -134.57 163.41 29.79 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.635 -0.665 . . . . 1.42 110.718 -176.807 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.91 135.89 4.43 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.618 -1.393 . . . . 0.17 109.618 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.3 m -122.17 137.45 54.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.715 -0.873 . . . . 0.21 109.75 176.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.5 p90 -155.55 172.77 17.7 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.972 -0.691 . . . . 0.16 111.036 176.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.7 m -106.9 141.03 38.77 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.691 -0.63 . . . . 0.13 109.464 173.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.31 145.4 35.42 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.564 -0.71 . . . . 0.14 110.58 -176.048 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -92.96 144.79 24.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.809 -0.557 . . . . 2.21 109.605 175.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.895 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -79.14 125.23 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-O 121.332 0.587 . . . . 0.17 109.79 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.68 -167.31 26.34 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.939 -1.264 . . . . 0.19 109.939 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.6 153.45 27.78 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.724 -0.868 . . . . 1.39 110.101 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.64 21.03 2.39 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.54 -0.725 . . . . 0.82 112.061 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.07 20.58 79.68 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.784 -1.198 . . . . 0.19 110.793 171.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.2 m -77.88 144.92 36.54 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.488 -1.007 . . . . 1.3 110.375 -176.311 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.722 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -138.43 144.96 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.553 -0.536 . . . . 0.21 109.553 174.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.65 123.33 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.49 -0.756 . . . . 0.34 110.641 -175.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.449 HG23 ' HD2' ' A' ' 65' ' ' PRO . 54.7 mt -78.44 144.43 65.93 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.643 -0.661 . . . . 0.34 109.518 173.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.21 133.63 38.77 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.934 0.965 . . . . 0.26 110.764 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.08 -34.23 63.46 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.443 -0.786 . . . . 2.62 110.866 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.76 -38.09 77.71 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.745 -0.597 . . . . 0.45 110.329 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 71.0 mt -77.15 -32.67 56.45 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 120.259 -0.576 . . . . 1.82 110.552 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.88 -46.03 85.49 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.3 -0.875 . . . . 2.53 109.897 178.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -70.16 -46.79 63.95 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 120.456 -0.498 . . . . 1.68 110.473 -175.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.5 t -60.38 -38.45 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.678 -0.639 . . . . 0.28 109.865 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.75 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.5 mt -82.53 -17.99 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.844 -0.535 . . . . 0.28 110.822 -176.535 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.25 35.11 38.88 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 109.665 -1.374 . . . . 0.22 109.665 176.07 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.65 142.54 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.619 -0.93 . . . . 0.77 110.581 -175.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -129.64 162.11 55.14 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.674 -0.641 . . . . 3.21 110.807 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.91 135.32 62.41 Favored 'Trans proline' 0 N--CA 1.488 1.159 0 O-C-N 123.063 1.033 . . . . 0.5 110.835 -179.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.9 -0.05 72.44 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 120.591 -0.814 . . . . 0.24 111.235 176.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -96.18 131.61 42.47 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 118.715 1.257 . . . . 1.11 110.445 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.0 p -91.87 130.1 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 CA-C-O 121.511 0.672 . . . . 0.24 110.837 -174.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.703 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.3 pt -118.72 159.51 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 109.591 -0.522 . . . . 0.18 109.591 177.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.412 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.5 tt0 -97.01 130.69 44.3 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.026 -0.731 . . . . 1.14 109.026 174.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.6 t -115.85 128.9 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.366 0.603 . . . . 0.2 110.241 -171.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.45 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.7 mt -116.31 128.75 55.83 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.324 -0.621 . . . . 0.25 109.324 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.96 HD13 ' CD2' ' A' ' 27' ' ' TYR . 6.0 mt -79.65 142.51 35.49 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.402 -0.811 . . . . 0.28 109.808 171.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 85' ' ' LEU . 43.7 mt -120.65 -24.95 5.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.655 . . . . 1.6 111.206 -174.076 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.28 -179.92 40.49 Favored Glycine 0 N--CA 1.505 3.28 0 C-N-CA 119.642 -1.266 . . . . 0.2 111.066 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 p80 -146.95 152.62 38.94 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.745 -0.856 . . . . 1.89 110.685 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 N--CA 1.495 1.807 0 O-C-N 121.582 -0.699 . . . . 0.8 110.07 175.657 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 109.719 -0.474 . . . . 0.41 109.719 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.59 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.3 mt -86.61 -18.44 31.39 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.262 -0.575 . . . . 0.37 110.547 -179.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.79 153.74 3.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.357 -0.839 . . . . 0.26 109.299 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -133.77 125.42 28.46 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.703 -0.623 . . . . 2.3 110.079 -177.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.3 p90 -150.68 162.09 41.35 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.603 -0.686 . . . . 0.2 110.869 -179.322 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -112.78 138.84 49.01 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.661 -0.649 . . . . 1.99 110.161 -176.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.29 41.07 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.728 -0.607 . . . . 0.18 109.59 178.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -111.0 158.68 18.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.417 -0.802 . . . . 0.17 110.044 177.152 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.906 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -79.16 136.29 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.295 -0.562 . . . . 0.49 110.343 -176.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -115.25 171.94 7.38 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.42 0.629 . . . . 0.68 109.796 175.043 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 -46.52 153.04 0.4 Allowed 'General case' 0 N--CA 1.505 2.31 0 O-C-N 121.536 -0.728 . . . . 2.96 111.981 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.8 mt 62.89 7.45 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.671 0 O-C-N 121.569 -0.707 . . . . 0.42 112.567 -175.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.73 15.99 80.63 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.344 -1.102 . . . . 0.24 110.344 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -85.5 144.0 28.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.235 -1.156 . . . . 1.96 110.429 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -132.67 154.95 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.748 -0.595 . . . . 0.3 109.46 172.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.435 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -117.11 128.76 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 C-N-CA 120.073 -0.651 . . . . 0.25 110.065 176.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.08 145.21 60.39 Favored Pre-proline 0 N--CA 1.496 1.828 0 C-N-CA 120.062 -0.655 . . . . 0.23 109.406 175.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.34 143.73 89.59 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 O-C-N 123.024 1.013 . . . . 0.35 109.755 174.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.41 61.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.87 -0.519 . . . . 0.33 110.471 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.74 -44.22 95.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 110.026 -1.23 . . . . 0.39 110.026 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 78.5 m -69.85 -38.21 76.41 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.964 . . . . 0.39 110.124 -179.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.613 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.4 mtt180 -56.3 -41.65 76.28 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 121.276 -0.89 . . . . 0.4 109.377 176.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -65.9 -50.09 65.7 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.14 0.495 . . . . 2.97 110.221 -177.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.27 -37.79 72.91 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.732 -0.605 . . . . 0.67 110.633 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.5 t80 -88.06 -14.15 39.65 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.805 -0.559 . . . . 1.44 111.229 -175.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.33 42.49 27.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.563 -1.415 . . . . 0.31 109.563 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.869 HG23 HG21 ' A' ' 56' ' ' VAL . 78.3 mt -89.62 131.14 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.453 -1.027 . . . . 0.42 110.645 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.27 158.94 36.78 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.091 -0.707 . . . . 1.82 109.091 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -57.47 139.45 53.23 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.38 -0.825 . . . . 1.99 110.513 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.74 -15.25 63.49 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.887 -0.885 . . . . 0.19 110.887 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.12 158.16 32.07 Favored 'General case' 0 N--CA 1.501 2.123 0 CA-C-N 118.724 1.262 . . . . 1.12 109.932 178.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -110.53 138.16 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.591 -0.693 . . . . 0.21 109.588 175.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.35 154.16 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 109.13 -0.693 . . . . 0.15 109.13 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -116.05 123.8 48.84 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.8 tt -140.51 158.13 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 119.635 -0.826 . . . . 0.14 110.961 -167.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.3 ttpt -132.29 146.11 51.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.837 -0.539 . . . . 1.11 110.386 177.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 82' ' ' VAL . 23.2 pt -114.88 150.98 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.667 -0.646 . . . . 0.2 110.278 176.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.524 HG13 ' HG2' ' A' ' 49' ' ' GLU . 59.4 t -139.53 123.64 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 CA-C-O 121.251 0.548 . . . . 0.2 109.729 177.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.676 ' HB2' HG22 ' A' ' 80' ' ' ILE . 53.2 tttm -132.92 147.5 52.29 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.248 -0.649 . . . . 1.98 109.248 176.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 t80 . . . . . 0 N--CA 1.498 1.952 0 C-N-CA 119.903 -0.719 . . . . 0.33 110.531 -178.271 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.483 0.855 0 N-CA-C 110.399 -0.654 . . . . 0.34 110.399 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.5 mmtt -111.37 136.89 49.85 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.657 -0.652 . . . . 1.1 109.466 172.063 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.524 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.7 164.49 27.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.703 -0.623 . . . . 1.42 110.996 -176.44 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.43 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.59 135.75 4.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.469 -1.453 . . . . 0.17 109.469 176.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.85 136.91 54.24 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.712 -0.875 . . . . 0.21 109.732 177.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -155.88 173.38 16.85 Favored 'General case' 0 N--CA 1.497 1.911 0 C-N-CA 119.867 -0.733 . . . . 0.16 111.089 178.159 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.7 m -106.95 140.39 39.83 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.722 -0.611 . . . . 0.13 109.551 173.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.28 146.11 34.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.633 -0.667 . . . . 0.14 110.443 -175.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.65 145.58 24.45 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.774 -0.579 . . . . 2.21 109.711 175.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.869 HG21 HG23 ' A' ' 29' ' ' ILE . 97.9 t -77.84 126.41 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.2 0.524 . . . . 0.17 109.973 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.53 -167.56 26.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.931 -1.268 . . . . 0.19 109.931 179.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -61.71 153.34 28.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.7 -0.882 . . . . 1.39 109.965 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 54.14 20.49 2.57 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.531 -0.731 . . . . 0.82 111.98 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 20.44 79.94 Favored Glycine 0 N--CA 1.5 2.928 0 C-N-CA 119.803 -1.189 . . . . 0.19 110.826 171.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.435 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.5 p -78.37 146.9 34.37 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -1.01 . . . . 1.3 110.203 -177.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.619 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.88 145.8 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.758 -0.589 . . . . 0.21 109.565 175.006 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.15 123.15 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.588 -0.695 . . . . 0.34 110.654 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 65.5 mt -78.41 144.02 65.29 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.504 -0.748 . . . . 0.34 109.432 172.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.77 134.43 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 O-C-N 122.861 0.927 . . . . 0.26 110.648 -179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -55.15 -34.21 63.59 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.505 -0.747 . . . . 2.62 110.802 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -37.87 77.12 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.802 -0.562 . . . . 0.45 110.271 -178.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.8 mt -77.11 -32.75 56.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.748 -0.595 . . . . 1.82 110.553 178.548 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.78 -46.0 85.21 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.306 -0.871 . . . . 2.53 109.923 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.32 -47.23 62.05 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.5 -0.48 . . . . 1.68 110.493 -175.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.6 t -60.51 -38.15 77.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.684 -0.635 . . . . 0.28 109.966 -178.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.711 HG22 HD11 ' A' ' 74' ' ' ILE . 83.1 mt -82.57 -17.81 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.792 -0.568 . . . . 0.28 110.934 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.32 35.14 43.53 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.787 -1.325 . . . . 0.22 109.787 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.906 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.24 138.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.522 -0.987 . . . . 0.77 110.715 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 57.0 mmtt -124.25 161.1 49.42 Favored Pre-proline 0 N--CA 1.498 1.931 0 O-C-N 121.675 -0.64 . . . . 3.21 110.61 -176.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.76 136.36 66.01 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 O-C-N 123.027 1.014 . . . . 0.5 110.78 179.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.63 -0.65 74.24 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 111.123 -0.791 . . . . 0.24 111.123 176.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 21.7 mt-10 -98.14 134.44 41.2 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 118.682 1.241 . . . . 1.11 110.567 179.695 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.07 133.41 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 CA-C-O 121.684 0.754 . . . . 0.24 111.227 -174.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.676 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.7 pt -122.93 159.48 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 109.211 -0.663 . . . . 0.18 109.211 175.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 49.7 tt0 -98.82 131.41 44.96 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 109.021 -0.733 . . . . 1.14 109.021 175.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 88.5 t -115.8 129.93 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.435 0.636 . . . . 0.2 110.365 -170.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.2 mt -115.73 130.7 56.95 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 109.237 -0.653 . . . . 0.25 109.237 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.09 139.88 36.7 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.449 -0.782 . . . . 0.28 109.781 171.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.0 mt -108.71 -34.4 6.71 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.8 -0.563 . . . . 1.6 110.887 -176.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.59 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.03 -174.63 37.74 Favored Glycine 0 N--CA 1.502 3.079 0 C-N-CA 119.738 -1.22 . . . . 0.2 111.015 -177.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -143.91 155.62 44.14 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.738 -0.86 . . . . 1.89 110.743 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.494 1.745 0 O-C-N 121.577 -0.702 . . . . 0.8 110.208 176.563 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 109.578 -0.527 . . . . 0.41 109.578 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.8 mt -83.72 -19.6 34.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.761 -0.587 . . . . 0.37 110.276 177.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.797 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.46 152.7 1.76 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.262 -0.899 . . . . 0.26 109.124 176.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.1 ttpt -135.42 128.23 31.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.635 -0.665 . . . . 2.3 110.382 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.2 p90 -149.81 163.56 37.68 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.391 -0.524 . . . . 0.2 110.508 -178.277 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.61 137.59 51.37 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.602 -0.686 . . . . 1.99 110.4 -176.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.56 162.28 41.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.756 -0.59 . . . . 0.18 109.568 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -109.63 158.56 17.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.468 -0.77 . . . . 0.17 110.02 176.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.934 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.9 t -79.47 138.06 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.779 -0.576 . . . . 0.49 110.355 -176.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -116.66 171.87 7.59 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.347 0.594 . . . . 0.68 109.86 176.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -46.29 153.05 0.37 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.629 -0.669 . . . . 2.96 112.075 -175.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.579 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.9 mt 62.94 7.2 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.648 0 O-C-N 121.651 -0.655 . . . . 0.42 112.578 -175.599 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.61 16.09 80.6 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.331 -1.108 . . . . 0.24 110.331 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 36.7 ttp180 -85.76 144.29 27.85 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.354 -1.086 . . . . 1.96 110.198 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -132.42 155.03 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.681 -0.637 . . . . 0.3 109.359 172.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.4 mm -115.71 128.55 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.595 -0.691 . . . . 0.25 109.952 176.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 25.5 mt -79.58 144.5 61.15 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.052 -0.659 . . . . 0.23 109.417 175.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -63.48 143.39 87.98 Favored 'Trans proline' 0 N--CA 1.488 1.191 0 O-C-N 123.002 1.001 . . . . 0.35 109.689 174.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.0 -26.37 60.13 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.838 -0.539 . . . . 0.33 110.46 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.31 -45.32 93.78 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 109.999 -1.24 . . . . 0.39 109.999 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 m -69.5 -36.87 76.9 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.617 -0.931 . . . . 0.39 110.202 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.7 mtt180 -56.3 -42.05 76.94 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.418 -0.801 . . . . 0.4 109.734 178.125 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -65.97 -50.2 65.16 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.364 0.602 . . . . 2.97 110.162 -177.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -56.67 -37.87 71.42 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.835 -0.541 . . . . 0.67 110.69 -178.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.947 ' CD2' HD13 ' A' ' 84' ' ' LEU . 25.0 t80 -87.89 -14.17 40.06 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.825 -0.547 . . . . 1.44 111.364 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 43.03 23.24 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.586 -1.406 . . . . 0.31 109.586 178.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.922 HG23 HG21 ' A' ' 56' ' ' VAL . 76.1 mt -87.53 127.44 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.422 -1.046 . . . . 0.42 110.575 -177.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.29 154.92 44.32 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.008 -0.738 . . . . 1.82 109.008 170.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.52 137.75 47.95 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.253 -0.904 . . . . 1.99 110.751 -177.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.46 -15.1 64.01 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.927 -0.869 . . . . 0.19 110.927 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -75.97 157.51 33.02 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.735 1.268 . . . . 1.12 109.851 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -111.21 138.17 47.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.606 -0.684 . . . . 0.21 109.679 175.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.39 153.52 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 109.249 -0.649 . . . . 0.15 109.249 174.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -115.33 122.98 47.55 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.242 -1.021 . . . . 1.09 108.242 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.809 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.3 tt -139.97 157.99 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 119.604 -0.838 . . . . 0.14 110.987 -167.171 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.5 tttt -132.61 145.98 51.53 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.8 -0.562 . . . . 1.11 110.596 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 28.0 pt -115.13 151.03 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.728 -0.608 . . . . 0.2 110.62 178.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.495 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.2 t -138.77 125.61 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.143 0.497 . . . . 0.2 109.772 176.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.67 ' HB2' HG22 ' A' ' 80' ' ' ILE . 21.4 ttpp -131.9 143.36 50.08 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.222 -0.659 . . . . 1.98 109.222 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 t80 . . . . . 0 N--CA 1.495 1.819 0 C-N-CA 120.137 -0.625 . . . . 0.33 110.456 -178.139 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo . . . . . 0 N--CA 1.482 0.844 0 N-CA-C 110.127 -0.759 . . . . 0.34 110.127 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.661 ' HB3' HG23 ' A' ' 72' ' ' ILE . 68.7 mmtt -110.85 137.17 48.83 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.548 -0.72 . . . . 1.1 109.622 172.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.8 mt-10 -135.5 164.23 28.28 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.614 -0.679 . . . . 1.42 110.796 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.614 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.15 135.96 4.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.605 -1.398 . . . . 0.17 109.605 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.3 m -123.09 137.34 54.95 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.68 -0.894 . . . . 0.21 109.735 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.8 p90 -155.87 172.55 18.16 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.843 -0.743 . . . . 0.16 111.017 176.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.0 m -107.78 140.85 40.23 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.694 -0.629 . . . . 0.13 109.545 174.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.09 145.78 34.69 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.723 -0.61 . . . . 0.14 110.641 -175.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.7 ttp180 -93.9 145.25 24.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.73 -0.606 . . . . 2.21 109.598 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.922 HG21 HG23 ' A' ' 29' ' ' ILE . 98.8 t -78.44 126.47 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.783 -0.573 . . . . 0.17 109.928 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.04 -166.51 24.98 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.099 -1.201 . . . . 0.19 110.099 178.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -61.63 153.08 28.94 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.872 -0.781 . . . . 1.39 110.218 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.57 21.18 2.41 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.547 -0.721 . . . . 0.82 112.001 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.81 20.48 79.76 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.747 -1.216 . . . . 0.19 110.806 171.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 14.2 m -77.99 145.25 36.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.414 -1.05 . . . . 1.3 110.232 -176.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.27 145.51 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.789 -0.569 . . . . 0.21 109.609 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -112.03 123.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.55 -0.719 . . . . 0.34 110.734 -174.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.455 HG23 ' HD2' ' A' ' 65' ' ' PRO . 80.3 mt -78.5 145.12 66.99 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.591 -0.693 . . . . 0.34 109.484 172.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.2 Cg_endo -64.38 136.68 52.08 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 O-C-N 122.889 0.941 . . . . 0.26 110.821 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 20.2 tptt -54.93 -34.85 63.59 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.47 -0.769 . . . . 2.62 110.845 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.91 -38.2 78.4 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.764 -0.585 . . . . 0.45 110.298 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.0 mt -77.17 -32.78 56.4 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.727 -0.608 . . . . 1.82 110.658 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.2 mtt180 -58.3 -45.85 87.24 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.22 -0.925 . . . . 2.53 109.884 178.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.3 -47.42 61.26 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 120.383 -0.527 . . . . 1.68 110.51 -175.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.9 t -60.58 -38.18 77.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 O-C-N 121.653 -0.654 . . . . 0.28 109.91 -178.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.697 HG22 HD11 ' A' ' 74' ' ' ILE . 86.1 mt -82.28 -17.61 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.882 -0.512 . . . . 0.28 110.966 -176.224 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.23 40.83 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.835 -1.306 . . . . 0.22 109.835 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.934 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.58 141.11 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.511 -0.994 . . . . 0.77 110.704 -173.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -127.67 156.28 75.8 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.732 -0.605 . . . . 3.21 110.631 -177.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -55.98 135.42 69.67 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 122.974 0.986 . . . . 0.5 111.275 177.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.12 -0.76 72.71 Favored Glycine 0 N--CA 1.496 2.65 0 C-N-CA 120.694 -0.765 . . . . 0.24 111.241 176.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -96.36 132.6 41.7 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-N 118.734 1.267 . . . . 1.11 110.477 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.3 p -91.21 132.08 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-O 121.639 0.733 . . . . 0.24 110.979 -174.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.67 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.4 pt -123.23 159.42 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 109.464 -0.569 . . . . 0.18 109.464 177.382 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.7 tt0 -98.13 131.57 44.4 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.919 -0.771 . . . . 1.14 108.919 173.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.809 ' CG1' HD11 ' A' ' 37' ' ' ILE . 99.9 t -115.1 128.01 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.2 110.166 -171.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.1 mt -114.79 128.46 56.31 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.365 -0.605 . . . . 0.25 109.365 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.947 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.88 139.92 36.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.485 -0.76 . . . . 0.28 109.821 172.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.7 mt -110.93 -31.75 7.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.769 -0.582 . . . . 1.6 110.85 -175.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.25 -177.04 39.12 Favored Glycine 0 N--CA 1.504 3.225 0 C-N-CA 119.745 -1.216 . . . . 0.2 110.958 -176.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -144.72 152.56 40.59 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.667 -0.902 . . . . 1.89 110.72 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.8 109.995 175.91 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.1 p . . . . . 0 N--CA 1.486 1.365 0 N-CA-C 109.723 -0.473 . . . . 0.41 109.723 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.559 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.4 mt -89.58 -18.02 27.38 Favored 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 120.309 -0.556 . . . . 0.37 110.654 -177.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.869 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.75 154.99 3.8 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.249 -0.907 . . . . 0.26 109.577 177.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -133.63 127.1 32.27 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.707 -0.621 . . . . 2.3 110.126 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.582 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 13.2 p90 -148.75 162.64 39.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.643 -0.661 . . . . 0.2 110.702 177.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.81 138.37 50.36 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.596 -0.69 . . . . 1.99 110.34 -176.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.04 162.21 41.28 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 109.459 -0.571 . . . . 0.18 109.459 177.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -109.31 158.45 17.87 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.436 -0.79 . . . . 0.17 110.152 177.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.905 HG21 HG21 ' A' ' 74' ' ' ILE . 61.2 t -79.22 136.43 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.32 -0.552 . . . . 0.49 110.097 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.41 171.87 7.36 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-O 121.269 0.556 . . . . 0.68 109.612 173.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -46.86 152.61 0.49 Allowed 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.579 -0.7 . . . . 2.96 111.978 -176.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.61 0 O-C-N 121.529 -0.732 . . . . 0.42 112.631 -175.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.401 ' HA3' ' NE ' ' A' ' 69' ' ' ARG . . . 78.01 16.17 80.18 Favored Glycine 0 N--CA 1.497 2.742 0 O-C-N 120.964 -1.085 . . . . 0.24 110.463 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -83.89 141.15 31.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.298 -1.119 . . . . 1.96 110.316 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.7 pt -133.72 155.75 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.569 -0.707 . . . . 0.3 109.816 173.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.17 129.75 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.529 -0.732 . . . . 0.25 109.878 175.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.426 HG12 ' CE2' ' A' ' 7' ' ' PHE . 24.2 mt -79.76 145.91 63.35 Favored Pre-proline 0 N--CA 1.495 1.806 0 C-N-CA 119.962 -0.695 . . . . 0.23 109.322 175.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.412 ' HD2' HG23 ' A' ' 19' ' ' ILE . 48.2 Cg_endo -63.22 143.25 89.29 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.005 1.002 . . . . 0.35 109.819 174.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.84 -26.43 62.03 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 120.404 -0.518 . . . . 0.33 110.462 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.94 -43.86 95.37 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 110.027 -1.229 . . . . 0.39 110.027 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.7 m -69.87 -38.61 76.47 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.63 -0.924 . . . . 0.39 110.136 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.594 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.2 mtt180 -56.24 -43.27 78.48 Favored 'General case' 0 N--CA 1.513 2.694 0 O-C-N 121.346 -0.846 . . . . 0.4 109.571 176.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -67.16 -50.2 62.02 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-O 121.18 0.514 . . . . 2.97 110.316 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -57.6 -36.35 71.65 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.764 -0.585 . . . . 0.67 110.661 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 16.8 t80 -88.15 -14.06 39.65 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.705 -0.622 . . . . 1.44 111.371 -174.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 74.92 41.74 32.23 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.657 -1.377 . . . . 0.31 109.657 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.843 HG23 HG21 ' A' ' 56' ' ' VAL . 81.9 mt -90.91 132.79 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.504 -0.998 . . . . 0.42 110.615 -176.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.18 159.29 36.52 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.047 -0.723 . . . . 1.82 109.047 172.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -57.96 140.23 52.66 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.388 -0.82 . . . . 1.99 110.367 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.77 -16.0 61.79 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.849 -0.901 . . . . 0.19 110.849 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.04 158.5 30.51 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.72 1.26 . . . . 1.12 110.223 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -111.86 139.68 47.14 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.661 -0.649 . . . . 0.21 109.598 174.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.09 155.02 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 109.235 -0.654 . . . . 0.15 109.235 174.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -116.35 123.22 47.08 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.345 -0.984 . . . . 1.09 108.345 -178.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.0 tt -140.53 158.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.553 -0.859 . . . . 0.14 111.232 -166.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -132.54 145.61 51.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.878 -0.514 . . . . 1.11 110.519 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.495 HG22 HG22 ' A' ' 82' ' ' VAL . 26.1 pt -115.06 151.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.664 -0.647 . . . . 0.2 110.6 178.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.2 t -139.2 126.01 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 CA-C-O 121.31 0.576 . . . . 0.2 110.049 176.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.776 ' HB2' HG22 ' A' ' 80' ' ' ILE . 17.2 tptt -132.59 148.7 52.37 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 109.004 -0.739 . . . . 1.98 109.004 174.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.8 t80 . . . . . 0 N--CA 1.495 1.785 0 C-N-CA 120.137 -0.625 . . . . 0.33 110.246 -179.699 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo . . . . . 0 N--CA 1.483 0.888 0 N-CA-C 110.298 -0.693 . . . . 0.34 110.298 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.737 ' HB3' HG23 ' A' ' 72' ' ' ILE . 18.0 mmtp -113.62 137.35 51.72 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.556 -0.715 . . . . 1.1 109.559 172.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -137.97 166.27 24.49 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.59 -0.694 . . . . 1.42 110.756 -178.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.83 135.94 4.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.692 -1.363 . . . . 0.17 109.692 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 m -119.93 137.95 53.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.661 -0.905 . . . . 0.21 109.766 176.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 15.0 p90 -156.04 173.89 16.15 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 120.0 -0.68 . . . . 0.16 110.981 176.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.0 m -106.32 140.91 38.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.731 -0.606 . . . . 0.13 109.475 173.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 144.9 35.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.679 -0.638 . . . . 0.14 110.636 -175.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.815 -0.553 . . . . 2.21 109.732 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -79.47 125.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.321 0.581 . . . . 0.17 109.871 178.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.08 -171.31 27.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.617 -1.393 . . . . 0.19 109.617 178.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -61.87 156.1 21.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.569 -0.959 . . . . 1.39 109.837 178.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 54.99 19.4 2.68 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.446 -0.784 . . . . 0.82 112.079 -177.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.21 20.47 79.93 Favored Glycine 0 N--CA 1.5 2.91 0 C-N-CA 119.81 -1.186 . . . . 0.19 110.728 172.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -78.0 146.02 35.63 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.503 -0.998 . . . . 1.3 110.409 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -138.51 146.52 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.719 -0.613 . . . . 0.21 109.627 173.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -108.89 122.21 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 121.555 -0.715 . . . . 0.34 110.533 -174.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.2 mt -79.01 142.07 59.43 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.606 -0.684 . . . . 0.34 109.625 173.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -65.1 131.83 29.94 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.862 0.927 . . . . 0.26 110.729 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -55.17 -33.07 62.66 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.497 -0.752 . . . . 2.62 110.88 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.8 -37.99 77.59 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.785 -0.572 . . . . 0.45 110.189 -178.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 76.3 mt -77.01 -32.74 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.747 -0.596 . . . . 1.82 110.403 177.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.401 ' NE ' ' HA3' ' A' ' 15' ' ' GLY . 38.1 mtt180 -57.73 -46.08 84.93 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 121.352 -0.842 . . . . 2.53 109.85 178.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -70.08 -47.87 60.08 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.528 -0.469 . . . . 1.68 110.413 -175.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.6 t -60.57 -38.1 77.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 C-N-CA 120.157 -0.617 . . . . 0.28 109.924 -178.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.737 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.3 mt -82.76 -17.66 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.866 -0.521 . . . . 0.28 110.919 -176.081 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.498 2.829 0 N-CA-C 109.68 -1.368 . . . . 0.22 109.68 175.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.905 HG21 HG21 ' A' ' 11' ' ' VAL . 51.3 mm -89.56 143.82 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.515 -0.991 . . . . 0.77 110.644 -174.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -129.22 156.96 77.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.764 -0.585 . . . . 3.21 110.719 -177.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.28 134.14 62.1 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.022 1.012 . . . . 0.5 111.412 177.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.37 -0.17 71.07 Favored Glycine 0 N--CA 1.497 2.761 0 C-N-CA 120.617 -0.801 . . . . 0.24 111.205 175.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -96.26 132.39 41.77 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-N 118.732 1.266 . . . . 1.11 110.4 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.2 p -91.03 130.05 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.46 0.648 . . . . 0.24 110.961 -174.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.776 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.5 pt -117.67 159.34 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.462 -0.57 . . . . 0.18 109.462 176.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -98.49 130.87 45.08 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.893 -0.781 . . . . 1.14 108.893 173.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.5 t -114.6 128.53 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 CA-C-O 121.381 0.61 . . . . 0.2 110.18 -171.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.404 ' HB3' HG21 ' A' ' 3' ' ' VAL . 45.0 mt -114.96 129.8 56.79 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.22 141.57 35.49 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.28 109.996 173.406 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.52 -32.38 6.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.839 -0.538 . . . . 1.6 110.779 -177.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.559 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.16 -174.46 37.69 Favored Glycine 0 N--CA 1.504 3.171 0 C-N-CA 119.681 -1.247 . . . . 0.2 111.058 -177.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.0 p80 -146.35 153.71 40.83 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.664 -0.904 . . . . 1.89 110.614 -179.246 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 . . . . . 0 N--CA 1.493 1.703 0 O-C-N 121.545 -0.722 . . . . 0.8 110.108 176.325 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.4 p . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 109.513 -0.551 . . . . 0.41 109.513 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.614 HD11 ' HA2' ' A' ' 86' ' ' GLY . 23.2 mt -85.32 -18.04 35.03 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 120.279 -0.568 . . . . 0.37 110.462 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.96 155.47 3.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.368 -0.833 . . . . 0.26 109.589 176.65 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.2 ttmt -132.95 127.02 33.33 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.715 -0.615 . . . . 2.3 110.124 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.3 p90 -149.77 162.51 40.13 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.634 -0.667 . . . . 0.2 110.728 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -113.33 138.96 49.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.604 -0.685 . . . . 1.99 110.32 -176.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.474 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.75 162.3 40.99 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.739 -0.601 . . . . 0.18 109.619 177.503 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.49 159.02 17.88 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 119.787 -0.765 . . . . 0.17 110.01 176.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.1 t -79.32 135.94 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.233 -0.587 . . . . 0.49 110.333 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.3 m80 -115.39 171.97 7.38 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.528 -0.545 . . . . 0.68 109.528 174.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -46.26 152.31 0.43 Allowed 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.562 -0.711 . . . . 2.96 112.033 -175.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.64 7.4 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.495 -0.753 . . . . 0.42 112.632 -174.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.72 16.01 80.61 Favored Glycine 0 N--CA 1.497 2.723 0 O-C-N 120.915 -1.115 . . . . 0.24 110.423 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.84 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -84.91 143.41 29.02 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.199 -1.177 . . . . 1.96 110.294 -177.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.474 HD12 HG21 ' A' ' 9' ' ' THR . 41.7 pt -133.21 157.49 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.759 -0.588 . . . . 0.3 109.532 173.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.84 HD11 ' NH1' ' A' ' 16' ' ' ARG . 48.6 mm -116.29 129.6 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.591 -0.693 . . . . 0.25 109.96 176.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.6 mt -79.19 145.5 64.92 Favored Pre-proline 0 N--CA 1.496 1.859 0 C-N-CA 119.961 -0.695 . . . . 0.23 109.375 175.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.2 142.86 88.31 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.102 1.054 . . . . 0.35 109.79 174.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.56 -26.6 61.66 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.84 -0.538 . . . . 0.33 110.447 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.8 95.0 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.036 -1.225 . . . . 0.39 110.036 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.1 m -69.73 -37.45 76.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.699 -0.883 . . . . 0.39 109.848 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.6 mtt180 -55.95 -42.42 76.2 Favored 'General case' 0 N--CA 1.509 2.499 0 O-C-N 121.343 -0.848 . . . . 0.4 109.801 178.083 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -66.75 -50.37 62.96 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.302 0.573 . . . . 2.97 110.284 -176.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -57.2 -37.15 71.76 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.868 -0.52 . . . . 0.67 110.622 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.946 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.6 t80 -87.83 -14.17 40.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.85 -0.531 . . . . 1.44 111.275 -176.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.36 42.37 28.11 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.57 -1.412 . . . . 0.31 109.57 177.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 77.8 mt -89.6 129.41 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.559 -0.965 . . . . 0.42 110.653 -176.566 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -128.48 159.51 35.21 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 109.173 -0.677 . . . . 1.82 109.173 171.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -57.75 138.59 55.37 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.411 -0.805 . . . . 1.99 110.478 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.1 62.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.857 -0.897 . . . . 0.19 110.857 179.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -77.09 157.47 31.03 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-N 118.763 1.281 . . . . 1.12 110.03 177.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -111.44 138.87 47.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.671 -0.643 . . . . 0.21 109.644 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 155.34 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 0.15 109.269 174.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -117.34 123.89 47.61 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.276 -1.009 . . . . 1.09 108.276 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.834 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.96 157.56 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.553 -0.859 . . . . 0.14 111.044 -167.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.68 146.09 51.59 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.789 -0.569 . . . . 1.11 110.427 177.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.498 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.6 pt -114.89 151.09 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.732 -0.605 . . . . 0.2 110.595 178.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.0 126.72 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.123 0.487 . . . . 0.2 109.707 176.295 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.699 ' HB2' HG22 ' A' ' 80' ' ' ILE . 30.6 tptt -138.09 147.12 43.71 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.726 -0.609 . . . . 1.98 109.636 175.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 39.5 t80 . . . . . 0 N--CA 1.495 1.784 0 C-N-CA 120.291 -0.564 . . . . 0.33 110.369 -176.867 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo . . . . . 0 N--CA 1.482 0.818 0 N-CA-C 110.114 -0.764 . . . . 0.34 110.114 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.446 ' CB ' HG23 ' A' ' 72' ' ' ILE . 31.4 mttm -122.5 149.24 44.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.491 -0.756 . . . . 1.1 110.105 171.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.2 mt-10 -136.75 167.74 20.86 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.758 -0.589 . . . . 1.42 110.835 -176.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.67 135.87 4.45 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.49 -1.444 . . . . 0.17 109.49 177.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -122.88 138.23 54.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.931 . . . . 0.21 109.978 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.81 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.8 p90 -156.3 172.92 17.64 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 119.858 -0.737 . . . . 0.16 110.89 175.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -106.95 141.29 38.4 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.704 -0.623 . . . . 0.13 109.473 173.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.81 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 145.99 36.7 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.591 -0.693 . . . . 0.14 110.759 -175.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -93.47 145.24 24.65 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.582 -0.525 . . . . 2.21 109.582 175.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 91.3 t -78.96 125.07 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.295 0.569 . . . . 0.17 109.823 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.62 -166.62 25.38 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.117 -1.193 . . . . 0.19 110.117 178.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.74 153.51 28.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.768 -0.842 . . . . 1.39 110.158 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 53.39 21.21 2.28 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.595 -0.69 . . . . 0.82 112.167 -179.577 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.22 20.51 79.64 Favored Glycine 0 N--CA 1.501 2.982 0 C-N-CA 119.663 -1.256 . . . . 0.19 110.764 171.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.5 m -77.87 145.2 36.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.456 -1.026 . . . . 1.3 110.441 -175.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.46 146.65 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.806 -0.559 . . . . 0.21 109.645 175.08 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.44 122.72 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.509 -0.744 . . . . 0.34 110.787 -174.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.8 mt -79.11 144.33 62.81 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.584 -0.698 . . . . 0.34 109.624 172.577 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.8 Cg_endo -64.76 134.39 40.39 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 O-C-N 122.952 0.975 . . . . 0.26 110.841 -179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -55.19 -34.16 63.65 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.491 -0.756 . . . . 2.62 110.814 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.66 76.68 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.729 -0.607 . . . . 0.45 110.32 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.6 mt -77.13 -32.69 56.62 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.73 -0.607 . . . . 1.82 110.5 178.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.85 -46.05 85.35 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.328 -0.857 . . . . 2.53 109.858 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.92 -46.61 64.99 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 120.512 -0.475 . . . . 1.68 110.411 -175.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.0 t -60.55 -38.7 79.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.679 -0.638 . . . . 0.28 109.949 -178.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.563 HG22 HD11 ' A' ' 74' ' ' ILE . 83.6 mt -82.8 -16.44 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.791 -0.568 . . . . 0.28 111.102 -176.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 75.77 35.18 46.45 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.91 -1.276 . . . . 0.22 109.91 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.77 142.32 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.53 -0.982 . . . . 0.77 110.589 -174.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.2 mttt -128.9 158.73 71.63 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.82 -0.55 . . . . 3.21 110.586 -177.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -54.56 134.21 60.8 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.063 1.033 . . . . 0.5 111.429 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.1 -0.5 72.42 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.69 -0.766 . . . . 0.24 111.292 175.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -97.37 133.51 41.87 Favored 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 118.711 1.255 . . . . 1.11 110.559 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.2 p -91.95 131.17 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-O 121.479 0.657 . . . . 0.24 111.095 -174.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.699 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -119.0 159.48 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.286 -0.635 . . . . 0.18 109.286 175.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -97.93 131.59 44.25 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.834 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.8 t -115.65 129.5 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.348 0.594 . . . . 0.2 110.263 -170.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.5 mt -115.13 130.8 57.02 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 109.279 -0.638 . . . . 0.25 109.279 179.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.946 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.35 139.9 36.34 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.365 -0.835 . . . . 0.28 110.037 173.052 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -106.65 -36.4 6.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.836 -0.54 . . . . 1.6 110.837 -176.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.614 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.88 -175.2 38.11 Favored Glycine 0 N--CA 1.502 3.061 0 C-N-CA 119.79 -1.195 . . . . 0.2 110.935 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -143.81 153.46 42.4 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.682 -0.893 . . . . 1.89 110.728 -177.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.622 -0.674 . . . . 0.8 110.205 175.975 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.487 1.395 0 N-CA-C 109.47 -0.567 . . . . 0.41 109.47 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.584 HD11 ' HA2' ' A' ' 86' ' ' GLY . 31.4 mt -82.73 -19.86 37.13 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.764 -0.585 . . . . 0.37 110.454 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.71 153.63 3.42 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.38 -0.825 . . . . 0.26 109.241 175.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -133.48 125.17 28.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.804 -0.56 . . . . 2.3 110.07 -176.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.586 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 12.9 p90 -151.0 162.55 40.61 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.638 -0.664 . . . . 0.2 110.794 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -113.48 139.11 49.21 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.61 -0.681 . . . . 1.99 110.246 -176.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.96 162.37 40.95 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.785 -0.572 . . . . 0.18 109.63 177.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 t -111.28 158.76 18.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.433 -0.792 . . . . 0.17 109.986 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.5 t -79.33 134.7 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 C-N-CA 120.296 -0.561 . . . . 0.49 110.239 -176.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -113.44 171.89 7.29 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.22 0.534 . . . . 0.68 109.646 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -46.49 152.98 0.4 Allowed 'General case' 0 N--CA 1.506 2.334 0 O-C-N 121.594 -0.691 . . . . 2.96 111.957 -176.128 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.76 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.675 0 O-C-N 121.573 -0.705 . . . . 0.42 112.601 -174.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.2 16.1 80.92 Favored Glycine 0 N--CA 1.498 2.787 0 O-C-N 120.875 -1.14 . . . . 0.24 110.276 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -85.65 143.41 28.43 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.265 -1.138 . . . . 1.96 110.443 -176.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.1 pt -133.37 155.53 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.787 -0.571 . . . . 0.3 109.491 172.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -116.54 129.18 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.629 -0.669 . . . . 0.25 110.038 176.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -79.47 145.12 62.83 Favored Pre-proline 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.23 109.404 175.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -63.49 143.32 87.75 Favored 'Trans proline' 0 N--CA 1.488 1.17 0 O-C-N 122.966 0.982 . . . . 0.35 109.775 174.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.91 -26.52 59.34 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.799 -0.563 . . . . 0.33 110.504 -178.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.4 -45.14 94.15 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.016 -1.233 . . . . 0.39 110.016 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 76.4 m -69.38 -37.09 77.41 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.621 -0.929 . . . . 0.39 110.178 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.62 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.32 -42.15 77.16 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.369 -0.832 . . . . 0.4 109.687 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.8 tptm -66.43 -50.2 64.19 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-O 121.244 0.545 . . . . 2.97 110.214 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -57.05 -37.99 72.59 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.928 -0.482 . . . . 0.67 110.698 -178.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.959 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.6 t80 -86.87 -14.31 42.36 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.812 -0.555 . . . . 1.44 111.277 -177.345 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 42.52 24.61 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.631 -1.388 . . . . 0.31 109.631 178.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.58 129.1 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.52 -0.988 . . . . 0.42 110.483 -177.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.06 158.47 37.86 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.919 -0.771 . . . . 1.82 108.919 170.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -57.24 140.04 50.97 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.309 -0.869 . . . . 1.99 110.492 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.01 -16.02 61.84 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.842 -0.903 . . . . 0.19 110.842 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.88 157.94 31.08 Favored 'General case' 0 N--CA 1.5 2.047 0 CA-C-N 118.739 1.27 . . . . 1.12 110.198 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -111.36 138.74 47.46 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.635 -0.666 . . . . 0.21 109.603 174.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.22 153.78 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.282 -0.636 . . . . 0.15 109.282 174.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -115.86 123.54 48.4 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.305 -0.998 . . . . 1.09 108.305 -179.077 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.84 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -139.99 158.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 C-N-CA 119.587 -0.845 . . . . 0.14 111.004 -167.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -133.09 145.97 51.22 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.874 -0.516 . . . . 1.11 110.505 177.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.532 ' HB ' HD12 ' A' ' 80' ' ' ILE . 24.5 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.79 -0.569 . . . . 0.2 110.619 178.325 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.522 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -138.96 125.5 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.917 -0.489 . . . . 0.2 109.787 176.301 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.68 ' HB2' HG22 ' A' ' 80' ' ' ILE . 54.4 tttp -132.28 144.49 50.63 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.774 -0.579 . . . . 1.98 109.533 174.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.9 t80 . . . . . 0 N--CA 1.496 1.858 0 C-N-CA 120.197 -0.601 . . . . 0.33 110.459 -178.488 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 N--CA 1.482 0.828 0 N-CA-C 110.133 -0.757 . . . . 0.34 110.133 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.762 ' HB3' HG23 ' A' ' 72' ' ' ILE . 16.6 mmtp -110.78 137.75 48.04 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 1.1 109.682 173.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -134.94 163.94 28.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.683 -0.636 . . . . 1.42 110.786 -177.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.95 135.92 4.44 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.56 -1.416 . . . . 0.17 109.56 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.4 m -122.25 137.83 54.7 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.735 -0.862 . . . . 0.21 109.766 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -155.82 172.88 17.59 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.562 -0.711 . . . . 0.16 110.937 176.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -106.6 140.3 39.68 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.707 -0.621 . . . . 0.13 109.556 173.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.84 144.51 35.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.664 -0.648 . . . . 0.14 110.49 -176.322 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -93.5 144.73 25.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.845 -0.534 . . . . 2.21 109.569 176.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -78.47 125.75 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.789 -0.569 . . . . 0.17 109.862 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.77 -167.54 26.26 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.892 -1.283 . . . . 0.19 109.892 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.68 153.52 27.91 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.756 -0.849 . . . . 1.39 110.163 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 53.57 21.09 2.37 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.51 -0.744 . . . . 0.82 112.008 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.95 20.52 79.72 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.814 -1.184 . . . . 0.19 110.837 171.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.3 m -77.99 145.26 36.09 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.462 -1.022 . . . . 1.3 110.296 -176.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.27 146.21 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.772 -0.58 . . . . 0.21 109.559 174.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.8 mm -110.92 122.94 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.521 -0.737 . . . . 0.34 110.671 -174.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.41 HG23 ' HD2' ' A' ' 65' ' ' PRO . 84.7 mt -78.88 143.0 61.26 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.572 -0.705 . . . . 0.34 109.568 172.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.751 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.5 Cg_endo -64.57 133.48 37.15 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 O-C-N 122.954 0.976 . . . . 0.26 110.755 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -55.2 -34.0 63.53 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.484 -0.76 . . . . 2.62 110.84 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.95 77.34 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.734 -0.604 . . . . 0.45 110.232 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.751 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.5 mt -77.1 -32.65 56.78 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.21 -0.596 . . . . 1.82 110.513 178.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.79 -45.52 85.92 Favored 'General case' 0 N--CA 1.504 2.248 0 O-C-N 121.331 -0.856 . . . . 2.53 109.827 178.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.28 -47.67 60.16 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 120.506 -0.478 . . . . 1.68 110.467 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 90.8 t -60.58 -38.1 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.106 0 O-C-N 121.683 -0.636 . . . . 0.28 109.816 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.762 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.4 mt -82.71 -17.47 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.795 -0.566 . . . . 0.28 110.914 -176.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.4 35.2 37.97 Favored Glycine 0 N--CA 1.498 2.797 0 N-CA-C 109.78 -1.328 . . . . 0.22 109.78 175.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.6 mm -90.81 144.15 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.979 . . . . 0.77 110.673 -174.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -131.39 163.45 49.42 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.776 -0.577 . . . . 3.21 110.685 -177.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.83 134.44 57.14 Favored 'Trans proline' 0 N--CA 1.487 1.142 0 O-C-N 122.934 0.965 . . . . 0.5 110.865 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.83 0.82 71.38 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 111.149 -0.78 . . . . 0.24 111.149 176.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -97.24 132.43 43.01 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 118.733 1.266 . . . . 1.11 110.515 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.0 p -93.46 137.18 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.901 0.858 . . . . 0.24 111.433 -173.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.68 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -126.41 159.52 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.391 -0.596 . . . . 0.18 109.391 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -97.52 130.58 44.58 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.942 -0.762 . . . . 1.14 108.942 174.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.84 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.0 t -115.08 129.96 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 CA-C-O 121.318 0.58 . . . . 0.2 110.158 -171.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 35.3 mt -117.13 129.51 56.02 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 109.047 -0.723 . . . . 0.25 109.047 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.959 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.7 mt -79.77 140.61 36.84 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.718 -0.793 . . . . 0.28 109.848 172.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.9 mt -110.39 -33.38 6.64 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.788 -0.57 . . . . 1.6 110.859 -175.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.584 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -175.89 38.42 Favored Glycine 0 N--CA 1.503 3.148 0 C-N-CA 119.763 -1.208 . . . . 0.2 110.953 -176.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -143.81 153.65 42.59 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.725 -0.867 . . . . 1.89 110.675 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 . . . . . 0 N--CA 1.494 1.732 0 O-C-N 121.498 -0.751 . . . . 0.8 110.198 176.423 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.486 1.347 0 N-CA-C 109.671 -0.492 . . . . 0.41 109.671 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.4 mt -84.06 -21.62 31.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.789 -0.569 . . . . 0.37 110.323 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.901 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.28 155.46 3.58 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.36 -0.837 . . . . 0.26 109.175 176.466 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.403 ' HG3' HD23 ' A' ' 83' ' ' LEU . 23.1 tttt -133.47 125.56 29.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.668 -0.645 . . . . 2.3 110.175 -177.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.8 p90 -150.84 162.78 40.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.2 110.757 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -113.24 139.07 49.11 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.562 -0.711 . . . . 1.99 110.264 -176.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.04 162.32 41.07 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.825 -0.547 . . . . 0.18 109.646 177.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -111.2 158.7 18.64 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.818 -0.753 . . . . 0.17 110.038 177.165 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.4 135.67 25.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.742 -0.599 . . . . 0.49 110.288 -176.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.0 m80 -114.79 171.9 7.36 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.354 0.597 . . . . 0.68 109.661 174.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -46.65 153.04 0.41 Allowed 'General case' 0 N--CA 1.505 2.318 0 O-C-N 121.532 -0.73 . . . . 2.96 111.956 -176.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.3 mt 62.75 7.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.662 0 O-C-N 121.599 -0.688 . . . . 0.42 112.619 -175.056 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.86 16.07 80.43 Favored Glycine 0 N--CA 1.496 2.682 0 O-C-N 120.932 -1.105 . . . . 0.24 110.369 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.4 ttp180 -83.78 143.04 30.24 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.167 -1.196 . . . . 1.96 110.382 -176.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -131.89 154.66 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 109.365 -0.606 . . . . 0.3 109.365 171.17 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.65 129.19 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 C-N-CA 120.08 -0.648 . . . . 0.25 109.999 176.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 29.1 mt -79.75 145.08 61.54 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.04 -0.664 . . . . 0.23 109.359 175.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -63.5 143.66 88.51 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.986 0.993 . . . . 0.35 109.723 174.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.04 -26.5 60.42 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 120.449 -0.5 . . . . 0.33 110.426 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.35 -45.19 94.07 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 109.958 -1.257 . . . . 0.39 109.958 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 85.3 m -69.37 -36.98 77.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.66 -0.906 . . . . 0.39 110.117 -179.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.8 mtt180 -56.41 -41.91 77.12 Favored 'General case' 0 N--CA 1.509 2.502 0 O-C-N 121.323 -0.861 . . . . 0.4 109.662 178.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.5 tptp -66.37 -50.14 64.51 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 120.275 -0.57 . . . . 2.97 110.262 -177.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.8 t80 -57.06 -38.19 72.92 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.925 -0.484 . . . . 0.67 110.694 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.932 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -87.03 -14.28 42.01 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.803 -0.561 . . . . 1.44 111.249 -177.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.94 42.71 24.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.493 -1.443 . . . . 0.31 109.493 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.894 HG23 HG21 ' A' ' 56' ' ' VAL . 75.7 mt -88.06 127.5 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.566 -0.961 . . . . 0.42 110.501 -177.354 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.26 154.24 45.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.877 -0.786 . . . . 1.82 108.877 171.384 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -55.18 139.42 42.07 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.245 -0.91 . . . . 1.99 110.706 -177.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -15.76 62.41 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 110.898 -0.881 . . . . 0.19 110.898 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -76.19 158.5 31.61 Favored 'General case' 0 N--CA 1.5 2.031 0 CA-C-N 118.749 1.274 . . . . 1.12 109.992 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -111.57 138.63 47.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.568 -0.708 . . . . 0.21 109.614 175.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.72 154.79 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 109.213 -0.662 . . . . 0.15 109.213 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.85 123.6 48.57 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.318 -0.993 . . . . 1.09 108.318 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.11 159.5 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.627 -0.829 . . . . 0.14 110.897 -168.066 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.547 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.6 ttpt -133.77 146.01 50.33 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.784 -0.573 . . . . 1.11 110.374 177.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.649 ' HB ' HD12 ' A' ' 80' ' ' ILE . 26.1 pt -114.74 150.4 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.627 -0.671 . . . . 0.2 110.359 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.9 t -140.89 124.53 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.219 0.533 . . . . 0.2 109.807 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.682 ' HB2' HG22 ' A' ' 80' ' ' ILE . 55.0 tttm -132.06 149.86 52.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.363 -0.606 . . . . 1.98 109.363 175.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 3.1 t80 . . . . . 0 N--CA 1.497 1.923 0 C-N-CA 119.993 -0.683 . . . . 0.33 110.367 -179.202 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo . . . . . 0 N--CA 1.483 0.879 0 N-CA-C 110.598 -0.578 . . . . 0.34 110.598 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.642 ' HB3' HG23 ' A' ' 72' ' ' ILE . 44.5 mmtt -112.93 136.58 52.44 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.502 -0.749 . . . . 1.1 109.583 171.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -138.62 167.9 20.96 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.664 -0.647 . . . . 1.42 110.974 -178.154 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.432 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.64 135.71 4.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.405 -1.478 . . . . 0.17 109.405 177.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.547 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.1 m -122.74 137.28 54.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.645 -0.915 . . . . 0.21 109.862 177.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.819 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.3 p90 -155.81 173.6 16.52 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.013 -0.675 . . . . 0.16 110.942 178.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 m -106.69 140.38 39.64 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.737 -0.602 . . . . 0.13 109.575 173.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.819 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.81 146.03 35.41 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.739 -0.6 . . . . 0.14 110.563 -175.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.9 ttp-105 -93.69 145.28 24.68 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.797 -0.565 . . . . 2.21 109.684 175.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.894 HG21 HG23 ' A' ' 29' ' ' ILE . 98.3 t -78.85 126.57 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.244 0.545 . . . . 0.17 109.861 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.66 -170.6 26.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.834 -1.306 . . . . 0.19 109.834 177.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -61.78 156.04 21.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.673 -0.898 . . . . 1.39 109.909 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.04 19.05 2.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.506 -0.746 . . . . 0.82 112.138 -177.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.45 20.46 79.41 Favored Glycine 0 N--CA 1.498 2.827 0 C-N-CA 119.863 -1.161 . . . . 0.19 110.714 172.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.64 146.76 33.91 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -1.005 . . . . 1.3 110.373 -176.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.64 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.9 146.44 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.751 -0.593 . . . . 0.21 109.553 174.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.3 mm -109.04 122.15 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.513 -0.742 . . . . 0.34 110.704 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.2 mt -78.84 142.25 60.44 Favored Pre-proline 0 N--CA 1.498 1.96 0 O-C-N 121.423 -0.798 . . . . 0.34 109.486 172.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.745 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.83 135.01 42.72 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.938 0.967 . . . . 0.26 110.705 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -55.12 -34.21 63.53 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.499 -0.751 . . . . 2.62 110.766 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.69 -37.73 76.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.752 -0.592 . . . . 0.45 110.319 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.745 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.0 mt -77.03 -32.82 57.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.636 -0.665 . . . . 1.82 110.482 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -57.72 -45.85 85.2 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.419 -0.801 . . . . 2.53 109.951 178.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.33 -47.29 61.76 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 120.532 -0.467 . . . . 1.68 110.483 -175.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.49 -38.25 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 O-C-N 121.699 -0.626 . . . . 0.28 109.932 -178.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.642 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.7 mt -82.49 -18.01 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.791 -0.568 . . . . 0.28 110.915 -176.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.34 35.19 43.26 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.704 -1.358 . . . . 0.22 109.704 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.7 mm -92.65 142.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.576 -0.955 . . . . 0.77 110.64 -174.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 34.9 mtpt -130.25 163.22 49.36 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.748 -0.595 . . . . 3.21 110.792 -177.181 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.76 135.41 63.58 Favored 'Trans proline' 0 N--CA 1.487 1.111 0 O-C-N 122.922 0.959 . . . . 0.5 110.92 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.72 -0.15 73.18 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 111.08 -0.808 . . . . 0.24 111.08 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -97.47 133.11 42.49 Favored 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 118.691 1.246 . . . . 1.11 110.552 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.02 133.37 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.67 0.747 . . . . 0.24 111.26 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.682 HG22 ' HB2' ' A' ' 41' ' ' LYS . 41.4 pt -123.48 159.52 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 109.272 -0.64 . . . . 0.18 109.272 176.143 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -98.44 131.1 44.98 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.963 -0.754 . . . . 1.14 108.963 176.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 83.9 t -114.95 130.24 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.394 0.616 . . . . 0.2 110.28 -170.524 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.403 HD23 ' HG3' ' A' ' 6' ' ' LYS . 33.5 mt -116.3 130.74 56.93 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 109.074 -0.713 . . . . 0.25 109.074 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.932 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.7 mt -80.55 140.86 35.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.356 -0.84 . . . . 0.28 109.791 172.204 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -113.18 -31.01 6.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.654 -0.654 . . . . 1.6 111.046 -175.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.18 -177.78 39.58 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.65 -1.262 . . . . 0.2 110.978 -176.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 p80 -144.94 153.52 41.62 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.719 -0.871 . . . . 1.89 110.59 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.527 -0.733 . . . . 0.8 110.278 176.033 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.655 -0.498 . . . . 0.41 109.655 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.574 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.7 mt -83.91 -19.1 35.34 Favored 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 120.198 -0.601 . . . . 0.37 110.378 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.4 153.3 3.51 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.292 -0.88 . . . . 0.26 109.335 176.047 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -134.16 125.45 27.93 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.697 -0.627 . . . . 2.3 110.089 -177.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.595 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.8 p90 -150.26 162.62 40.14 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.591 -0.693 . . . . 0.2 110.852 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -113.53 138.29 50.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.61 -0.681 . . . . 1.99 110.102 -176.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.08 162.29 41.12 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.661 -0.649 . . . . 0.18 109.679 177.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.11 157.83 18.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.465 -0.772 . . . . 0.17 110.03 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.61 136.43 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.783 -0.573 . . . . 0.49 110.319 -176.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -113.32 171.95 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.215 0.531 . . . . 0.68 109.686 173.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -46.67 152.31 0.49 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.607 -0.683 . . . . 2.96 111.896 -175.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.6 mt 62.6 7.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.635 0 O-C-N 121.559 -0.713 . . . . 0.42 112.601 -175.341 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.84 16.12 80.39 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 110.364 -1.095 . . . . 0.24 110.364 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.8 ttt180 -83.92 140.73 31.76 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.18 -1.188 . . . . 1.96 110.249 -176.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.6 pt -133.67 155.48 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.698 -0.626 . . . . 0.3 109.757 174.091 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.3 mm -118.16 129.79 73.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.62 -0.675 . . . . 0.25 109.998 175.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.5 mt -79.61 145.97 64.19 Favored Pre-proline 0 N--CA 1.495 1.777 0 C-N-CA 120.052 -0.659 . . . . 0.23 109.396 175.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.16 142.89 88.66 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 O-C-N 123.012 1.006 . . . . 0.35 109.823 174.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.22 -26.56 60.91 Favored 'General case' 0 N--CA 1.498 1.955 0 C-N-CA 120.403 -0.519 . . . . 0.33 110.49 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.43 -45.01 94.45 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 109.973 -1.251 . . . . 0.39 109.973 -179.015 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 96.6 m -69.66 -37.0 76.54 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.63 -0.923 . . . . 0.39 109.878 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.637 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.2 -42.27 76.93 Favored 'General case' 0 N--CA 1.509 2.508 0 O-C-N 121.298 -0.876 . . . . 0.4 109.77 178.111 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -65.91 -50.14 65.5 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.282 0.563 . . . . 2.97 110.116 -177.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -56.46 -37.54 70.43 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.136 0.493 . . . . 0.67 110.725 -179.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.972 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.0 t80 -88.19 -14.15 39.33 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.784 -0.572 . . . . 1.44 111.315 -176.649 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 42.89 24.18 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.543 -1.423 . . . . 0.31 109.543 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.933 HG23 HG21 ' A' ' 56' ' ' VAL . 75.4 mt -87.84 126.92 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.519 -0.989 . . . . 0.42 110.653 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.91 155.64 43.87 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.134 -0.691 . . . . 1.82 109.134 171.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.56 137.49 48.71 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.308 -0.87 . . . . 1.99 110.79 -177.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.51 -15.08 64.07 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.926 -0.87 . . . . 0.19 110.926 178.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -76.01 157.55 32.9 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 118.76 1.28 . . . . 1.12 109.862 177.146 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -111.51 138.16 48.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.631 -0.668 . . . . 0.21 109.611 175.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.99 152.06 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 120.087 -0.645 . . . . 0.15 109.309 174.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -113.74 123.51 50.05 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.172 -1.047 . . . . 1.09 108.172 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.835 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.2 tt -139.87 157.57 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.584 -0.846 . . . . 0.14 110.886 -167.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -133.1 146.06 51.29 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.801 -0.562 . . . . 1.11 110.474 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.532 HG22 HG22 ' A' ' 82' ' ' VAL . 27.9 pt -114.9 151.1 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.758 -0.589 . . . . 0.2 110.54 178.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.485 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.3 t -138.38 127.37 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.674 -0.491 . . . . 0.2 109.674 176.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.595 ' HB2' HG22 ' A' ' 80' ' ' ILE . 60.8 tttm -133.47 144.43 49.45 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 109.538 -0.542 . . . . 1.98 109.538 175.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 52.6 t80 . . . . . 0 N--CA 1.495 1.808 0 C-N-CA 120.262 -0.575 . . . . 0.33 110.355 -178.528 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo . . . . . 0 N--CA 1.483 0.89 0 N-CA-C 109.936 -0.832 . . . . 0.34 109.936 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.425 ' CB ' HG23 ' A' ' 72' ' ' ILE . 32.4 mttt -120.73 149.77 42.01 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.34 -0.85 . . . . 1.1 110.147 171.641 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.485 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -137.2 167.66 21.14 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.851 -0.531 . . . . 1.42 110.731 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.57 135.86 4.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.342 -1.503 . . . . 0.17 109.342 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.2 m -122.95 137.99 54.8 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.658 -0.907 . . . . 0.21 109.887 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.812 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.3 p90 -155.96 172.61 18.09 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.88 -0.728 . . . . 0.16 110.969 175.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.2 m -107.54 140.45 40.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.685 -0.634 . . . . 0.13 109.598 174.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.812 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 144.49 34.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.62 -0.675 . . . . 0.14 110.527 -176.032 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.78 145.7 24.4 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.693 -0.629 . . . . 2.21 109.67 175.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.933 HG21 HG23 ' A' ' 29' ' ' ILE . 99.3 t -78.11 126.66 38.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.821 -0.55 . . . . 0.17 109.93 -178.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.92 -166.4 25.08 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.101 -1.2 . . . . 0.19 110.101 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.71 152.79 30.08 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.779 -0.836 . . . . 1.39 110.131 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.4 mt-30 53.64 21.02 2.39 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.557 -0.715 . . . . 0.82 112.03 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.49 79.91 Favored Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.802 -1.189 . . . . 0.19 110.776 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.403 ' HA ' HD13 ' A' ' 18' ' ' ILE . 51.5 p -79.08 148.36 32.45 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.465 -1.021 . . . . 1.3 110.43 -176.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.67 147.14 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.878 -0.514 . . . . 0.21 109.67 174.686 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.2 mm -108.5 121.85 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.536 -0.728 . . . . 0.34 110.535 -175.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.411 HG23 ' HD2' ' A' ' 65' ' ' PRO . 78.6 mt -78.68 143.02 62.16 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.6 -0.687 . . . . 0.34 109.619 173.506 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.92 131.46 29.03 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.936 0.966 . . . . 0.26 110.784 -179.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 50.3 tttp -55.12 -34.07 63.4 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.424 -0.797 . . . . 2.62 110.846 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.72 -37.72 76.77 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.722 -0.611 . . . . 0.45 110.269 -178.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.9 mt -77.16 -32.71 56.43 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.21 -0.596 . . . . 1.82 110.494 178.176 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtt180 -57.55 -45.57 84.96 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.231 -0.918 . . . . 2.53 109.829 178.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.97 64.26 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 120.441 -0.504 . . . . 1.68 110.371 -174.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.8 t -60.56 -38.6 78.76 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.678 -0.639 . . . . 0.28 109.901 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.56 HG22 HD11 ' A' ' 74' ' ' ILE . 86.8 mt -83.26 -15.8 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.896 -0.503 . . . . 0.28 111.143 -176.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.931 -1.268 . . . . 0.22 109.931 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.4 mm -89.96 141.06 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.574 -0.957 . . . . 0.77 110.716 -174.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -130.61 159.26 71.8 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.808 -0.558 . . . . 3.21 110.69 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -54.63 133.63 57.97 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 122.98 0.99 . . . . 0.5 111.391 177.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.02 0.34 71.51 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 111.205 -0.758 . . . . 0.24 111.205 175.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -98.05 134.1 41.6 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-N 118.769 1.285 . . . . 1.11 110.603 179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.405 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -92.34 132.9 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 CA-C-O 121.55 0.691 . . . . 0.24 111.15 -174.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.595 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.8 pt -122.39 159.4 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 109.353 -0.61 . . . . 0.18 109.353 175.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 48.3 tt0 -98.85 131.71 44.75 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.007 -0.738 . . . . 1.14 109.007 175.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.835 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.1 t -116.16 129.88 71.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 CA-C-O 121.298 0.57 . . . . 0.2 110.362 -170.207 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.1 mt -115.83 130.94 57.04 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.188 -0.671 . . . . 0.25 109.188 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.972 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.27 140.18 36.32 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.375 -0.828 . . . . 0.28 109.797 171.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -109.36 -31.21 7.63 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.825 -0.547 . . . . 1.6 110.898 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.574 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.05 179.39 41.29 Favored Glycine 0 N--CA 1.503 3.136 0 C-N-CA 119.728 -1.225 . . . . 0.2 110.986 -177.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.406 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 29.2 p80 -140.6 145.67 37.0 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.728 -0.866 . . . . 1.89 110.072 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.406 ' CD1' ' O ' ' A' ' 87' ' ' HIS . 17.8 m-85 . . . . . 0 N--CA 1.496 1.851 0 O-C-N 121.506 -0.746 . . . . 0.8 109.943 179.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.564 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.6 p . . . . . 0 N--CA 1.487 1.375 0 N-CA-C 109.644 -0.502 . . . . 0.41 109.644 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.578 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.9 mt -87.57 -17.93 30.87 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.744 -0.598 . . . . 0.37 110.708 -177.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.868 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.83 155.96 4.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.253 -0.904 . . . . 0.26 109.742 176.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -133.29 126.6 31.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.762 -0.586 . . . . 2.3 110.096 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.605 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -149.48 161.94 41.12 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.651 -0.656 . . . . 0.2 110.871 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.6 m-70 -111.73 138.02 48.86 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.617 -0.677 . . . . 1.99 110.17 -176.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.41 162.29 41.2 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.727 -0.608 . . . . 0.18 109.774 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.5 t -111.71 159.33 18.34 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 119.925 -0.71 . . . . 0.17 109.89 176.094 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -77.83 138.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 120.304 -0.558 . . . . 0.49 110.103 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.67 171.9 7.57 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.327 0.584 . . . . 0.68 109.672 174.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -46.91 153.13 0.44 Allowed 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.537 -0.727 . . . . 2.96 111.927 -175.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.578 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.0 mt 63.1 7.22 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.681 0 O-C-N 121.601 -0.687 . . . . 0.42 112.643 -175.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.54 15.98 80.79 Favored Glycine 0 N--CA 1.498 2.791 0 O-C-N 120.829 -1.169 . . . . 0.24 110.292 179.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.0 ttm180 -85.94 145.39 27.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.324 -1.104 . . . . 1.96 110.352 -177.221 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.18 154.52 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.727 -0.608 . . . . 0.3 109.466 172.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.453 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.83 128.72 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.57 -0.706 . . . . 0.25 109.99 176.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.437 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.7 mt -79.98 145.09 60.57 Favored Pre-proline 0 N--CA 1.495 1.802 0 C-N-CA 120.084 -0.646 . . . . 0.23 109.37 175.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.27 143.06 88.53 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 122.917 0.956 . . . . 0.35 109.812 174.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.6 -26.42 61.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.867 -0.521 . . . . 0.33 110.489 -178.319 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.82 -44.37 94.8 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.39 109.914 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.8 m -69.69 -38.13 76.89 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.637 -0.919 . . . . 0.39 110.179 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -56.18 -41.23 75.19 Favored 'General case' 0 N--CA 1.512 2.648 0 O-C-N 121.274 -0.891 . . . . 0.4 109.493 176.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.5 tttp -65.53 -50.0 66.83 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.166 0.508 . . . . 2.97 110.142 -176.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -57.39 -37.96 73.5 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.749 -0.594 . . . . 0.67 110.725 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.6 t80 -87.99 -14.31 39.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.766 -0.584 . . . . 1.44 111.239 -176.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.48 42.45 27.32 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.548 -1.421 . . . . 0.31 109.548 177.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.899 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.49 129.18 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.545 -0.974 . . . . 0.42 110.572 -176.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -129.07 158.76 38.02 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.929 -0.767 . . . . 1.82 108.929 170.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -57.45 140.54 50.26 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.315 -0.865 . . . . 1.99 110.426 -178.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.73 -16.06 61.65 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -77.06 157.95 30.81 Favored 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 118.724 1.262 . . . . 1.12 110.121 178.077 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -111.55 138.67 47.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.582 -0.699 . . . . 0.21 109.611 174.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.88 154.16 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 109.272 -0.64 . . . . 0.15 109.272 174.179 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -116.32 124.07 49.21 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.274 -1.01 . . . . 1.09 108.274 -179.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -140.23 157.91 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.558 -0.857 . . . . 0.14 111.053 -167.181 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.81 146.07 51.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.76 -0.587 . . . . 1.11 110.517 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.562 HG22 HG22 ' A' ' 82' ' ' VAL . 33.6 pt -114.94 150.94 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.598 -0.689 . . . . 0.2 110.544 178.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.9 t -138.08 125.13 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.177 0.513 . . . . 0.2 109.655 176.104 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.4 tttp -134.17 147.48 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.725 -0.609 . . . . 1.98 109.495 175.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.1 t80 . . . . . 0 N--CA 1.494 1.769 0 C-N-CA 120.092 -0.643 . . . . 0.33 110.266 179.836 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo . . . . . 0 N--CA 1.481 0.768 0 N-CA-C 110.198 -0.731 . . . . 0.34 110.198 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.69 ' HB3' HG23 ' A' ' 72' ' ' ILE . 66.1 mmtt -111.06 137.78 48.29 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.527 -0.733 . . . . 1.1 109.432 172.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.65 164.46 27.81 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.555 -0.716 . . . . 1.42 110.997 -176.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.9 4.37 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.659 -1.377 . . . . 0.17 109.659 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.68 137.72 54.66 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.638 -0.919 . . . . 0.21 109.792 176.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.6 p90 -156.36 172.76 17.95 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.963 -0.695 . . . . 0.16 111.047 176.264 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.6 m -106.68 140.91 38.79 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.677 -0.639 . . . . 0.13 109.414 173.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.16 145.89 36.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.652 -0.655 . . . . 0.14 110.697 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.0 ttt180 -93.29 145.33 24.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.833 -0.542 . . . . 2.21 109.616 175.559 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.899 HG21 HG23 ' A' ' 29' ' ' ILE . 90.1 t -79.01 125.96 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 121.419 0.628 . . . . 0.17 109.722 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.7 -166.47 26.25 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.961 -1.256 . . . . 0.19 109.961 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -61.73 151.98 32.43 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.804 -0.821 . . . . 1.39 110.139 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 53.32 21.53 2.36 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.523 -0.736 . . . . 0.82 112.054 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.77 20.42 79.77 Favored Glycine 0 N--CA 1.498 2.832 0 C-N-CA 119.796 -1.192 . . . . 0.19 110.879 171.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.453 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.1 p -78.56 147.02 33.93 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.518 -0.989 . . . . 1.3 110.22 -178.004 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.727 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -139.26 146.39 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.8 -0.563 . . . . 0.21 109.525 175.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.95 123.81 66.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.58 -0.7 . . . . 0.34 110.583 -175.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.4 mt -78.32 144.06 65.72 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.643 -0.661 . . . . 0.34 109.432 172.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.49 135.36 45.53 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.966 0.982 . . . . 0.26 110.73 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 38.2 tttp -55.08 -34.21 63.44 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.545 -0.722 . . . . 2.62 110.75 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.87 -38.33 78.57 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.779 -0.576 . . . . 0.45 110.343 -178.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.3 mt -77.13 -32.87 56.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.747 -0.595 . . . . 1.82 110.617 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.05 -45.82 86.38 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.35 -0.843 . . . . 2.53 109.882 178.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -46.76 63.96 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 120.511 -0.476 . . . . 1.68 110.425 -175.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.8 t -60.58 -38.28 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.704 -0.623 . . . . 0.28 109.853 -178.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.695 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.68 -17.52 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.874 -0.516 . . . . 0.28 110.872 -176.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.89 35.11 40.51 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.693 -1.363 . . . . 0.22 109.693 175.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.1 mm -93.07 142.89 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.599 -0.942 . . . . 0.77 110.77 -173.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.2 ptmt -132.94 162.64 56.35 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.742 -0.599 . . . . 3.21 110.652 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -51.97 135.44 51.11 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.056 1.03 . . . . 0.5 111.887 178.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.95 -1.51 70.87 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 120.704 -0.76 . . . . 0.24 111.357 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -96.33 130.92 43.33 Favored 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 118.767 1.284 . . . . 1.11 110.614 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.79 134.35 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 CA-C-O 121.684 0.754 . . . . 0.24 111.296 -173.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.4 pt -125.58 159.46 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 109.567 -0.531 . . . . 0.18 109.567 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.416 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.1 tt0 -97.61 132.04 43.63 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.075 -0.713 . . . . 1.14 109.075 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.7 t -116.32 129.89 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.344 0.592 . . . . 0.2 110.264 -171.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -115.34 130.3 56.86 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.262 -0.644 . . . . 0.25 109.262 178.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.2 mt -79.96 138.81 37.16 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.345 -0.847 . . . . 0.28 109.914 172.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -105.76 -35.9 7.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.726 -0.609 . . . . 1.6 110.918 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.83 -176.03 38.69 Favored Glycine 0 N--CA 1.503 3.166 0 C-N-CA 119.79 -1.195 . . . . 0.2 110.817 -176.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -142.72 152.65 42.57 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.677 -0.896 . . . . 1.89 110.798 -177.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 N--CA 1.493 1.705 0 O-C-N 121.535 -0.728 . . . . 0.8 110.064 175.483 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.487 1.391 0 N-CA-C 109.522 -0.547 . . . . 0.41 109.522 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.0 mt -85.62 -18.36 33.49 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.728 -0.608 . . . . 0.37 110.32 178.119 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.832 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.5 151.27 1.51 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.244 -0.91 . . . . 0.26 108.997 176.08 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -134.96 127.82 31.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.649 -0.657 . . . . 2.3 110.295 -178.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.8 p90 -150.36 163.14 39.09 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 120.345 -0.542 . . . . 0.2 110.595 -177.426 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.7 m170 -112.65 137.7 50.54 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.648 -0.657 . . . . 1.99 110.256 -176.776 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.83 162.31 40.99 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.752 -0.592 . . . . 0.18 109.585 177.13 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.06 159.29 17.44 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.765 -0.774 . . . . 0.17 110.139 177.675 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.6 t -79.05 136.27 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 120.298 -0.561 . . . . 0.49 110.254 -177.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -115.42 171.95 7.39 Favored 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.253 0.549 . . . . 0.68 109.726 175.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -46.64 153.03 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.583 -0.698 . . . . 2.96 111.882 -176.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 53.9 mt 62.94 7.07 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.666 0 O-C-N 121.525 -0.735 . . . . 0.42 112.629 -175.439 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.6 16.11 80.59 Favored Glycine 0 N--CA 1.498 2.792 0 O-C-N 120.895 -1.128 . . . . 0.24 110.33 179.389 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 ttm180 -85.43 144.16 28.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.255 -1.144 . . . . 1.96 110.293 -177.147 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.46 155.09 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.725 -0.609 . . . . 0.3 109.463 172.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.74 129.43 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.665 -0.647 . . . . 0.25 109.991 176.473 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.3 mt -79.61 145.99 64.23 Favored Pre-proline 0 N--CA 1.494 1.768 0 C-N-CA 120.061 -0.656 . . . . 0.23 109.321 175.682 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.41 ' HD2' HG23 ' A' ' 19' ' ' ILE . 50.1 Cg_endo -63.47 143.21 87.66 Favored 'Trans proline' 0 N--CA 1.489 1.228 0 O-C-N 123.069 1.036 . . . . 0.35 109.698 174.652 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.31 -26.34 60.74 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.813 -0.555 . . . . 0.33 110.438 -178.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.34 -45.23 93.98 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.015 -1.234 . . . . 0.39 110.015 -179.323 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.1 m -69.27 -37.3 77.84 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.706 -0.879 . . . . 0.39 110.187 -179.579 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.592 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.24 -42.06 76.73 Favored 'General case' 0 N--CA 1.509 2.487 0 O-C-N 121.434 -0.791 . . . . 0.4 109.751 178.378 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -66.62 -50.24 63.66 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 121.272 0.558 . . . . 2.97 110.233 -177.024 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -57.27 -37.87 73.04 Favored 'General case' 0 N--CA 1.501 2.109 0 CA-C-O 121.205 0.526 . . . . 0.67 110.704 -179.039 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.5 t80 -87.69 -14.21 40.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.744 -0.597 . . . . 1.44 111.223 -176.795 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.17 26.76 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.598 -1.401 . . . . 0.31 109.598 177.674 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.916 HG23 HG21 ' A' ' 56' ' ' VAL . 73.1 mt -89.44 127.79 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.452 -1.028 . . . . 0.42 110.462 -176.545 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -128.21 159.7 34.39 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.114 -0.699 . . . . 1.82 109.114 171.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -57.2 139.36 52.88 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.364 -0.835 . . . . 1.99 110.541 -178.219 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.43 -15.77 62.2 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 178.232 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.07 158.74 31.49 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 118.701 1.25 . . . . 1.12 109.991 178.037 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -111.71 138.16 48.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.634 -0.666 . . . . 0.21 109.645 175.408 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.36 153.5 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 N-CA-C 109.164 -0.68 . . . . 0.15 109.164 173.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.3 123.16 48.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.227 -1.027 . . . . 1.09 108.227 -179.628 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.819 HD11 ' CG1' ' A' ' 82' ' ' VAL . 10.6 tt -140.38 158.33 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.593 -0.843 . . . . 0.14 110.946 -167.564 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.9 ttpt -132.07 146.14 51.87 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.815 -0.553 . . . . 1.11 110.428 177.286 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.581 HG22 HG22 ' A' ' 82' ' ' VAL . 23.9 pt -114.92 150.55 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.2 110.305 176.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.545 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -139.58 124.35 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 CA-C-O 121.292 0.567 . . . . 0.2 109.692 177.355 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.704 ' HB2' HG22 ' A' ' 80' ' ' ILE . 45.2 tptt -135.99 147.89 48.19 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.731 -0.605 . . . . 1.98 109.415 176.758 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.7 t80 . . . . . 0 N--CA 1.496 1.834 0 C-N-CA 120.071 -0.652 . . . . 0.33 110.403 -177.566 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo . . . . . 0 N--CA 1.48 0.735 0 N-CA-C 110.198 -0.731 . . . . 0.34 110.198 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.717 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.7 mmtp -110.69 137.27 48.57 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.56 -0.712 . . . . 1.1 109.577 173.217 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.545 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -135.09 163.91 28.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.595 -0.691 . . . . 1.42 111.027 -176.328 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.75 135.72 4.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.488 -1.445 . . . . 0.17 109.488 176.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.5 136.86 54.34 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.733 -0.863 . . . . 0.21 109.823 177.288 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.6 p90 -155.93 173.62 16.53 Favored 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.888 -0.725 . . . . 0.16 111.046 178.267 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.71 141.02 39.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.713 -0.617 . . . . 0.13 109.518 173.583 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.89 145.84 35.06 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.64 -0.663 . . . . 0.14 110.672 -175.709 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 43.6 ttp180 -93.72 146.03 24.15 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.758 -0.589 . . . . 2.21 109.674 175.248 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.916 HG21 HG23 ' A' ' 29' ' ' ILE . 99.0 t -78.28 127.16 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.821 -0.55 . . . . 0.17 109.995 -178.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.96 -168.06 26.1 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.995 -1.242 . . . . 0.19 109.995 178.869 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.7 153.47 28.15 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.712 -0.875 . . . . 1.39 110.175 -179.727 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.68 20.89 2.37 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.596 -0.69 . . . . 0.82 112.105 -179.698 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.6 20.46 79.82 Favored Glycine 0 N--CA 1.5 2.957 0 C-N-CA 119.763 -1.208 . . . . 0.19 110.826 171.613 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.424 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.9 p -78.67 147.26 33.61 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.541 -0.976 . . . . 1.3 110.328 -177.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.632 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.75 146.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 109.515 -0.55 . . . . 0.21 109.515 174.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.8 123.89 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.527 -0.733 . . . . 0.34 110.612 -174.559 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.44 HG23 ' HD2' ' A' ' 65' ' ' PRO . 88.5 mt -78.23 144.27 66.52 Favored Pre-proline 0 N--CA 1.499 2.024 0 O-C-N 121.59 -0.694 . . . . 0.34 109.392 172.368 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.34 135.61 47.22 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 O-C-N 122.965 0.981 . . . . 0.26 110.71 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 23.0 tptm -55.02 -34.85 63.82 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.368 -0.833 . . . . 2.62 110.769 -179.772 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.92 -38.3 78.65 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.79 -0.569 . . . . 0.45 110.276 -178.494 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.4 mt -77.05 -32.81 57.13 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.727 -0.608 . . . . 1.82 110.695 179.432 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -58.15 -46.22 86.05 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.351 -0.843 . . . . 2.53 109.845 178.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.43 -47.38 61.01 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.49 -0.484 . . . . 1.68 110.468 -175.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 88.8 t -60.64 -37.96 77.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.702 -0.624 . . . . 0.28 109.94 -178.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.717 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.7 mt -82.56 -17.82 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.833 -0.542 . . . . 0.28 110.823 -176.473 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.7 35.22 41.23 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.776 -1.33 . . . . 0.22 109.776 175.706 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.12 142.69 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.46 -1.023 . . . . 0.77 110.665 -173.86 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.94 156.29 76.3 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.789 -0.569 . . . . 3.21 110.618 -177.807 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -55.44 135.87 71.16 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.018 1.009 . . . . 0.5 111.257 178.197 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -1.53 73.06 Favored Glycine 0 N--CA 1.496 2.678 0 C-N-CA 120.622 -0.799 . . . . 0.24 111.235 176.191 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.2 mt-10 -96.2 132.27 41.81 Favored 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 118.729 1.264 . . . . 1.11 110.429 179.033 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.1 p -91.57 130.71 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.49 0.662 . . . . 0.24 110.98 -174.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.704 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -119.34 159.48 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 N-CA-C 109.579 -0.526 . . . . 0.18 109.579 178.055 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 82.0 tt0 -97.34 130.05 44.54 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.012 -0.736 . . . . 1.14 109.012 174.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.819 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.0 t -115.46 127.77 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.339 0.59 . . . . 0.2 110.235 -171.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.3 mt -115.07 129.19 56.63 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.411 -0.589 . . . . 0.25 109.411 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.5 mt -79.72 140.61 36.91 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.433 -0.792 . . . . 0.28 109.856 172.651 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.09 -31.99 6.93 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.857 -0.527 . . . . 1.6 110.798 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -176.95 39.22 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.71 -1.233 . . . . 0.2 110.965 -177.429 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -145.06 152.6 40.36 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.715 -0.874 . . . . 1.89 110.742 -177.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 . . . . . 0 N--CA 1.494 1.75 0 O-C-N 121.507 -0.746 . . . . 0.8 110.028 175.711 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 109.565 -0.531 . . . . 0.41 109.565 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.58 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.8 mt -82.23 -20.22 38.12 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.213 -0.595 . . . . 0.37 110.386 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.827 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.74 154.58 3.69 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.418 -0.801 . . . . 0.26 109.327 175.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.6 tttt -134.66 125.17 26.57 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.657 -0.652 . . . . 2.3 110.246 -176.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . 0.616 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.65 162.76 40.05 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.536 -0.727 . . . . 0.2 110.842 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.69 138.74 49.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.623 -0.673 . . . . 1.99 110.231 -177.368 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.11 162.31 41.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.732 -0.605 . . . . 0.18 109.72 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.0 157.81 18.91 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.52 -0.737 . . . . 0.17 109.997 177.324 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.33 135.82 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.748 -0.595 . . . . 0.49 110.259 -176.665 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -113.84 171.87 7.33 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.294 0.568 . . . . 0.68 109.787 174.088 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtm-85 -46.66 152.67 0.45 Allowed 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.522 -0.736 . . . . 2.96 112.026 -175.694 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.59 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.599 0 O-C-N 121.596 -0.69 . . . . 0.42 112.598 -175.636 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.71 16.17 80.43 Favored Glycine 0 N--CA 1.498 2.789 0 O-C-N 120.891 -1.131 . . . . 0.24 110.325 179.404 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -84.05 141.8 30.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.271 -1.135 . . . . 1.96 110.36 -176.473 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.9 pt -133.98 154.36 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.654 . . . . 0.3 109.532 172.832 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mm -117.71 128.46 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 C-N-CA 120.051 -0.66 . . . . 0.25 109.857 176.19 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 34.0 mt -80.07 144.09 58.31 Favored Pre-proline 0 N--CA 1.496 1.829 0 C-N-CA 120.02 -0.672 . . . . 0.23 109.36 176.043 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.32 143.55 89.35 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 122.953 0.975 . . . . 0.35 109.731 174.656 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.5 -26.5 61.41 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.889 -0.507 . . . . 0.33 110.47 -178.347 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.48 -44.46 95.18 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 109.914 -1.275 . . . . 0.39 109.914 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.2 m -69.97 -38.34 76.04 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.618 -0.931 . . . . 0.39 110.162 -179.392 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.79 73.52 Favored 'General case' 0 N--CA 1.514 2.75 0 O-C-N 121.245 -0.91 . . . . 0.4 109.43 176.42 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -64.94 -49.66 69.51 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.167 0.508 . . . . 2.97 110.119 -177.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.19 -38.55 73.82 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.785 -0.572 . . . . 0.67 110.726 -179.709 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.965 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.3 t80 -88.07 -14.23 39.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.847 -0.533 . . . . 1.44 111.308 -176.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.97 24.59 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.55 -1.42 . . . . 0.31 109.55 178.562 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 75.9 mt -87.25 129.14 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.499 -1.001 . . . . 0.42 110.563 -177.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.31 158.97 36.73 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 109.11 -0.7 . . . . 1.82 109.11 170.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.25 138.66 54.45 Favored 'General case' 0 N--CA 1.503 2.201 0 O-C-N 121.396 -0.815 . . . . 1.99 110.539 -179.149 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.05 62.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 110.869 -0.892 . . . . 0.19 110.869 178.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.82 155.54 32.96 Favored 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 118.708 1.254 . . . . 1.12 110.076 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -110.43 138.65 46.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.557 -0.714 . . . . 0.21 109.462 174.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.38 154.43 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 C-N-CA 120.204 -0.598 . . . . 0.15 109.398 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -114.89 123.38 49.01 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.158 -1.053 . . . . 1.09 108.158 179.695 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.814 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.94 158.65 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.662 -0.815 . . . . 0.14 110.812 -167.787 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.537 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.7 ttpt -132.67 146.21 51.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.887 -0.508 . . . . 1.11 110.42 178.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.586 HG22 HG22 ' A' ' 82' ' ' VAL . 22.0 pt -114.72 149.12 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.718 -0.614 . . . . 0.2 110.252 177.107 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.5 t -140.1 123.95 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 CA-C-O 121.138 0.494 . . . . 0.2 109.69 178.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.701 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.2 tttt -132.25 148.47 52.45 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.34 -0.615 . . . . 1.98 109.34 175.922 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 33.1 t80 . . . . . 0 N--CA 1.496 1.864 0 C-N-CA 120.008 -0.677 . . . . 0.33 110.328 179.909 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo . . . . . 0 N--CA 1.483 0.87 0 N-CA-C 110.504 -0.614 . . . . 0.34 110.504 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.68 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.7 mmtp -111.13 136.0 50.81 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.588 -0.695 . . . . 1.1 109.714 172.743 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -133.27 156.89 46.74 Favored 'General case' 0 C--N 1.311 -1.068 0 O-C-N 121.531 -0.731 . . . . 1.42 110.582 -171.381 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.61 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -157.67 135.86 4.57 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.544 -1.422 . . . . 0.17 109.544 176.104 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.537 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -126.83 138.31 53.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.647 -0.913 . . . . 0.21 109.714 177.257 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -156.26 173.79 16.34 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 119.949 -0.701 . . . . 0.16 111.107 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.9 m -106.89 141.07 38.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.633 -0.667 . . . . 0.13 109.606 173.289 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.24 145.77 34.44 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.754 -0.591 . . . . 0.14 110.551 -175.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 57.0 ttt180 -93.77 145.26 24.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.741 -0.6 . . . . 2.21 109.778 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.6 t -79.68 125.5 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 CA-C-O 121.384 0.611 . . . . 0.17 109.825 179.675 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.9 -165.91 25.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.989 -1.244 . . . . 0.19 109.989 178.482 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -61.62 153.07 28.92 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.85 -0.794 . . . . 1.39 110.178 -179.335 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.55 21.15 2.38 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.602 -0.686 . . . . 0.82 112.056 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.51 79.88 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 119.812 -1.185 . . . . 0.19 110.817 172.008 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 59.4 p -78.41 146.68 34.42 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.563 -0.963 . . . . 1.3 110.439 -176.244 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.757 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -139.55 145.62 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.631 -0.507 . . . . 0.21 109.631 174.203 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.3 mm -111.09 123.03 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.552 -0.718 . . . . 0.34 110.478 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.8 mt -78.2 144.47 67.02 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.613 -0.679 . . . . 0.34 109.656 174.755 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.76 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.31 134.58 42.67 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 O-C-N 122.928 0.962 . . . . 0.26 110.802 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -54.88 -35.02 63.63 Favored 'General case' 0 N--CA 1.503 2.207 0 O-C-N 121.489 -0.757 . . . . 2.62 110.767 -179.806 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.426 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -38.29 78.38 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.738 -0.601 . . . . 0.45 110.364 -178.063 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.76 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.6 mt -77.21 -32.66 56.09 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 120.172 -0.611 . . . . 1.82 110.729 179.529 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -58.28 -46.49 85.96 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.301 -0.874 . . . . 2.53 109.761 178.551 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.02 -46.12 65.77 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.542 -0.463 . . . . 1.68 110.455 -175.179 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 67' ' ' ALA . 95.4 t -60.38 -38.46 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.61 -0.681 . . . . 0.28 109.825 -178.835 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.3 mt -82.17 -18.27 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.918 -0.489 . . . . 0.28 110.912 -177.059 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.59 35.13 42.08 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 109.75 -1.34 . . . . 0.22 109.75 176.476 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.885 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.8 mm -92.0 140.72 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.468 -1.019 . . . . 0.77 110.569 -174.529 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 23.1 mmmt -125.32 161.58 49.14 Favored Pre-proline 0 N--CA 1.498 1.964 0 O-C-N 121.637 -0.665 . . . . 3.21 110.498 -175.366 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -60.75 134.6 54.89 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 O-C-N 123.0 1.0 . . . . 0.5 110.748 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.47 0.87 72.37 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 111.118 -0.793 . . . . 0.24 111.118 176.645 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -100.33 135.86 41.12 Favored 'General case' 0 N--CA 1.498 1.975 0 CA-C-N 118.704 1.252 . . . . 1.11 110.737 -179.633 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.72 133.9 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.696 0.76 . . . . 0.24 111.463 -172.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.701 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -124.59 159.47 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 109.399 -0.593 . . . . 0.18 109.399 175.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -98.6 132.0 44.35 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.067 -0.716 . . . . 1.14 109.067 175.9 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.814 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.6 t -115.39 129.41 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 CA-C-O 121.302 0.572 . . . . 0.2 110.282 -171.408 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.1 129.36 56.3 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 109.168 -0.679 . . . . 0.25 109.168 178.869 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.965 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.09 139.25 36.96 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.396 -0.815 . . . . 0.28 109.755 171.798 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.21 -31.25 7.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.724 -0.61 . . . . 1.6 110.971 -174.899 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.58 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.06 -175.9 38.14 Favored Glycine 0 N--CA 1.504 3.176 0 C-N-CA 119.671 -1.252 . . . . 0.2 111.086 -176.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -144.44 154.05 42.54 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.681 -0.893 . . . . 1.89 110.744 -177.277 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.536 -0.727 . . . . 0.8 110.131 175.972 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.3 mtt . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.128 0.49 . . . . 3.16 110.533 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -73.64 144.01 46.07 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.876 -0.515 . . . . 1.27 110.048 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -128.13 137.45 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.802 -0.562 . . . . 0.23 109.568 178.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.56 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.0 mt -86.71 -18.0 32.28 Favored 'General case' 0 N--CA 1.496 1.825 0 C-N-CA 120.251 -0.58 . . . . 0.16 110.515 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.965 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.77 152.71 3.13 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.388 -0.82 . . . . 0.11 109.094 177.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 46.6 tttt -133.85 125.16 27.8 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.674 -0.641 . . . . 0.88 110.054 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.597 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.6 p90 -150.94 162.28 41.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.575 -0.703 . . . . 0.08 110.782 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -113.41 139.12 49.17 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.713 -0.617 . . . . 1.08 110.235 -177.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.463 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.57 162.3 40.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.742 -0.599 . . . . 0.09 109.604 177.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.1 157.95 18.82 Favored 'General case' 0 N--CA 1.496 1.869 0 C-N-CA 119.764 -0.774 . . . . 0.1 110.063 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.29 134.92 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 C-N-CA 120.289 -0.564 . . . . 0.11 110.161 -176.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -113.46 171.93 7.27 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-O 121.23 0.538 . . . . 0.14 109.685 174.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.33 152.54 0.42 Allowed 'General case' 0 N--CA 1.506 2.345 0 O-C-N 121.53 -0.731 . . . . 2.7 112.003 -175.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.674 0 O-C-N 121.516 -0.74 . . . . 0.21 112.533 -174.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.09 80.66 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.815 -1.178 . . . . 0.08 110.377 179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.798 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -85.54 142.96 28.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.297 -1.12 . . . . 2.33 110.367 -176.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.463 HD12 HG21 ' A' ' 9' ' ' THR . 43.0 pt -133.2 157.74 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.658 -0.651 . . . . 0.09 109.602 173.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.798 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.2 mm -117.06 129.58 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.632 -0.668 . . . . 0.09 110.113 176.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.457 HG23 ' HD2' ' A' ' 20' ' ' PRO . 23.8 mt -79.98 147.01 64.9 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.147 -0.621 . . . . 0.08 109.396 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.457 ' HD2' HG23 ' A' ' 19' ' ' ILE . 47.0 Cg_endo -63.06 143.15 90.06 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 122.979 0.989 . . . . 0.14 109.878 174.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.98 -26.5 62.41 Favored 'General case' 0 N--CA 1.496 1.845 0 C-N-CA 120.404 -0.518 . . . . 0.13 110.448 -178.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.76 -43.73 95.82 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.998 -1.241 . . . . 0.1 109.998 -179.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.4 m -69.69 -39.17 77.1 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.547 -0.973 . . . . 0.14 110.051 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HA ' HD12 ' A' ' 29' ' ' ILE . 7.8 mtt180 -56.49 -42.56 78.5 Favored 'General case' 0 N--CA 1.513 2.707 0 O-C-N 121.353 -0.842 . . . . 0.1 109.403 177.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.2 tttt -67.45 -50.25 60.05 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.025 0.441 . . . . 2.26 110.222 -176.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -58.09 -36.16 72.47 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.735 -0.603 . . . . 0.2 110.581 178.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.926 ' CD2' HD13 ' A' ' 84' ' ' LEU . 11.5 t80 -86.77 -14.28 42.74 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.739 -0.601 . . . . 0.2 111.331 -174.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.2 39.94 35.48 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.661 -1.376 . . . . 0.11 109.661 177.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.797 ' CG2' HG21 ' A' ' 56' ' ' VAL . 85.1 mt -93.2 132.38 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.133 0 O-C-N 121.502 -0.999 . . . . 0.12 110.633 -175.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.15 161.65 29.59 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 109.304 -0.628 . . . . 1.99 109.304 172.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -57.76 138.72 55.26 Favored 'General case' 0 N--CA 1.503 2.217 0 O-C-N 121.477 -0.764 . . . . 1.95 110.397 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.47 -16.11 61.82 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.855 -0.898 . . . . 0.1 110.855 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -77.51 160.89 28.32 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.085 -1.244 . . . . 0.09 110.234 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -112.62 139.27 48.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.11 109.728 175.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.2 155.82 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 N-CA-C 109.152 -0.684 . . . . 0.04 109.152 173.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -118.75 123.83 45.78 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.36 -0.978 . . . . 1.0 108.36 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.828 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.9 tt -140.33 158.53 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 C-N-CA 119.58 -0.848 . . . . 0.08 111.144 -167.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.444 ' HB2' HG23 ' A' ' 51' ' ' THR . 36.4 tttt -132.92 146.09 51.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.91 -0.494 . . . . 1.18 110.384 177.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.483 HG22 HG22 ' A' ' 82' ' ' VAL . 24.7 pt -114.81 151.01 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.624 -0.672 . . . . 0.12 110.528 178.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t -138.38 124.75 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 CA-C-O 121.136 0.493 . . . . 0.1 109.678 176.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.572 ' HB2' HG22 ' A' ' 80' ' ' ILE . 57.9 tttm -132.84 144.87 50.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.29 -0.633 . . . . 1.94 109.29 175.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 42.4 t80 -103.14 130.01 50.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 120.09 -0.644 . . . . 0.46 110.55 -177.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.8 129.67 40.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.713 -0.617 . . . . 1.65 109.988 177.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.79 -128.27 46.18 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 109.816 -1.314 . . . . 0.38 109.816 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -105.06 13.9 30.12 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.744 -0.856 . . . . 1.14 111.616 177.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -131.12 129.06 22.37 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.248 -0.907 . . . . 1.48 110.878 -178.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -75.15 139.72 24.22 Favored 'Trans proline' 0 N--CA 1.483 0.88 0 O-C-N 122.752 0.869 . . . . 0.33 110.423 175.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.727 ' HB3' HG23 ' A' ' 72' ' ' ILE . 28.5 mmtp -110.36 137.51 47.98 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.577 -0.702 . . . . 1.25 109.536 172.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -134.61 162.43 32.33 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.645 -0.659 . . . . 1.69 110.996 -177.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.89 135.92 4.45 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.418 . . . . 0.1 109.554 178.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.444 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -124.06 138.05 54.49 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.651 -0.911 . . . . 0.15 109.785 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.809 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.4 p90 -155.97 173.47 16.74 Favored 'General case' 0 N--CA 1.497 1.902 0 C-N-CA 119.884 -0.726 . . . . 0.09 110.986 177.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.5 m -106.91 142.07 37.13 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.65 -0.656 . . . . 0.08 109.464 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.809 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.07 146.17 36.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.61 -0.681 . . . . 0.08 110.756 -175.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.65 146.0 24.14 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.841 -0.537 . . . . 2.36 109.63 176.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.797 HG21 ' CG2' ' A' ' 29' ' ' ILE . 96.9 t -79.01 124.82 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 120.294 -0.562 . . . . 0.09 110.062 179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.95 -166.54 25.07 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.088 -1.205 . . . . 0.09 110.088 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.71 152.95 29.67 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.766 -0.843 . . . . 1.44 110.187 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 53.51 21.1 2.32 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.668 -0.645 . . . . 1.72 112.014 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.62 20.51 79.82 Favored Glycine 0 N--CA 1.5 2.907 0 C-N-CA 119.643 -1.265 . . . . 0.07 110.83 171.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.454 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.7 p -78.0 148.19 34.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.438 -1.036 . . . . 1.3 110.27 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.723 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.4 p -138.74 145.97 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 N-CA-C 109.535 -0.543 . . . . 0.08 109.535 175.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.3 mm -110.81 122.73 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.561 -0.712 . . . . 0.15 110.709 -174.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.45 HG23 ' HD2' ' A' ' 65' ' ' PRO . 50.9 mt -78.38 144.62 66.5 Favored Pre-proline 0 N--CA 1.498 1.959 0 O-C-N 121.567 -0.708 . . . . 0.14 109.465 172.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.75 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.25 133.26 37.08 Favored 'Trans proline' 0 N--CA 1.495 1.582 0 O-C-N 122.879 0.936 . . . . 0.13 110.69 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -55.23 -34.23 63.79 Favored 'General case' 0 N--CA 1.503 2.225 0 O-C-N 121.482 -0.761 . . . . 2.29 110.788 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.71 -37.87 77.07 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.747 -0.596 . . . . 0.12 110.336 -178.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.75 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.4 mt -77.08 -32.71 56.93 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.748 -0.595 . . . . 0.13 110.475 178.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.4 mtt180 -57.67 -45.49 85.49 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.258 -0.901 . . . . 0.11 109.841 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.15 62.61 Favored 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 120.534 -0.467 . . . . 1.49 110.465 -175.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.55 -38.25 77.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.646 -0.659 . . . . 0.17 109.89 -178.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.727 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.63 -17.63 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.841 -0.537 . . . . 0.17 110.89 -176.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.6 35.29 36.93 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 109.814 -1.315 . . . . 0.17 109.814 175.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.3 mm -89.47 142.75 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.603 -0.94 . . . . 0.18 110.587 -174.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -129.09 157.47 75.82 Favored Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.829 -0.544 . . . . 2.54 110.7 -177.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -55.31 133.98 61.21 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 O-C-N 122.934 0.965 . . . . 0.46 111.287 177.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.95 0.23 71.88 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 111.191 -0.763 . . . . 0.15 111.191 175.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -97.48 134.42 40.75 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-N 118.677 1.239 . . . . 0.42 110.559 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.407 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -91.95 132.79 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-O 121.67 0.748 . . . . 0.15 111.173 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.572 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.5 pt -121.86 159.49 24.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 109.387 -0.597 . . . . 0.11 109.387 175.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -97.69 131.57 44.12 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.98 -0.748 . . . . 1.13 108.98 175.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.828 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.78 130.24 70.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 CA-C-O 121.324 0.583 . . . . 0.07 110.266 -170.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.5 mt -116.5 131.01 57.06 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.264 -0.643 . . . . 0.09 109.264 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.965 HD12 ' HB3' ' A' ' 5' ' ' ALA . 4.3 mt -80.28 141.6 35.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.415 -0.803 . . . . 0.1 109.971 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.47 -32.52 6.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.765 -0.585 . . . . 0.34 110.868 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.56 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.8 -178.31 40.24 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.738 -1.22 . . . . 0.1 111.014 -177.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.9 p80 -148.82 151.22 34.38 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.702 -0.881 . . . . 0.27 110.572 -179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -133.22 139.19 46.84 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.58 -0.7 . . . . 0.56 109.893 175.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 ttmt -123.05 149.93 58.19 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.689 -0.632 . . . . 3.52 110.442 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.28 148.51 60.49 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 O-C-N 123.262 1.138 . . . . 1.01 110.856 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 58.4 ttt85 -121.96 141.07 51.69 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.731 -0.606 . . . . 5.06 110.169 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 59.0 t30 . . . . . 0 N--CA 1.495 1.783 0 CA-C-O 117.999 -1.0 . . . . 4.21 110.192 -179.573 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.7 ttm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.015 0.436 . . . . 2.76 110.203 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.31 141.26 40.01 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.676 -0.64 . . . . 1.7 109.989 178.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.2 p -127.43 140.53 48.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.747 -0.596 . . . . 0.41 109.78 178.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.7 mt -87.8 -18.0 30.32 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 120.238 -0.585 . . . . 0.37 110.662 -177.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.824 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.21 156.67 3.98 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.206 -0.934 . . . . 0.26 109.853 176.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -134.04 126.77 30.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.758 -0.589 . . . . 2.3 110.167 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 18.2 p90 -149.42 161.81 41.34 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.614 -0.679 . . . . 0.2 110.874 178.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.418 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.0 m-70 -111.54 137.89 48.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.574 -0.704 . . . . 1.99 110.141 -176.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.48 162.33 41.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.69 -0.631 . . . . 0.18 109.748 177.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.4 t -111.5 159.28 18.24 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.535 -0.728 . . . . 0.17 109.996 176.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.922 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.0 t -78.73 136.44 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.816 -0.553 . . . . 0.49 110.191 -177.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -114.26 171.95 7.3 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.285 0.564 . . . . 0.68 109.651 174.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -46.5 151.95 0.5 Allowed 'General case' 0 N--CA 1.505 2.3 0 O-C-N 121.531 -0.731 . . . . 2.96 112.036 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.2 mt 62.52 7.93 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.651 0 O-C-N 121.547 -0.721 . . . . 0.42 112.585 -175.508 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.68 16.06 80.59 Favored Glycine 0 N--CA 1.497 2.738 0 O-C-N 120.934 -1.104 . . . . 0.24 110.432 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.2 ttt180 -84.49 142.51 30.0 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.256 -1.143 . . . . 1.96 110.134 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.2 pt -133.28 154.3 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.649 -0.657 . . . . 0.3 109.671 174.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.53 128.51 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.623 -0.673 . . . . 0.25 109.952 175.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 30.4 mt -79.99 144.34 59.08 Favored Pre-proline 0 N--CA 1.496 1.839 0 C-N-CA 119.986 -0.686 . . . . 0.23 109.437 175.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -63.31 143.23 88.67 Favored 'Trans proline' 0 N--CA 1.489 1.219 0 O-C-N 122.969 0.984 . . . . 0.35 109.772 175.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.58 -26.77 61.97 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 120.442 -0.503 . . . . 0.33 110.472 -178.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -44.21 95.47 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.965 -1.254 . . . . 0.39 109.965 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 88.3 m -69.82 -38.39 76.54 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.593 -0.945 . . . . 0.39 110.132 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.723 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.8 mtt180 -56.06 -40.49 73.63 Favored 'General case' 0 N--CA 1.513 2.687 0 O-C-N 121.337 -0.852 . . . . 0.4 109.378 176.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 84.7 tttt -65.27 -50.05 67.24 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.065 0.459 . . . . 2.97 110.164 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -57.72 -39.08 76.44 Favored 'General case' 0 N--CA 1.503 2.175 0 O-C-N 121.773 -0.579 . . . . 0.67 110.681 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.7 t80 -87.28 -14.2 41.58 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.789 -0.569 . . . . 1.44 111.258 -176.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.78 42.9 24.63 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.536 -1.425 . . . . 0.31 109.536 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.913 HG23 HG21 ' A' ' 56' ' ' VAL . 75.0 mt -87.41 127.22 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.497 -1.002 . . . . 0.42 110.532 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -128.23 159.39 35.35 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.098 -0.704 . . . . 1.82 109.098 170.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.41 138.71 54.66 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.403 -0.81 . . . . 1.99 110.486 -179.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.74 -16.02 62.12 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.874 -0.89 . . . . 0.19 110.874 179.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -77.09 156.9 31.39 Favored 'General case' 0 N--CA 1.499 1.976 0 CA-C-N 118.686 1.243 . . . . 1.12 110.148 177.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -111.36 138.69 47.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.682 -0.636 . . . . 0.21 109.648 174.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.81 153.32 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.709 -0.619 . . . . 0.15 109.34 174.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -116.32 123.01 46.57 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.331 -0.989 . . . . 1.09 108.331 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.804 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.4 tt -138.6 157.87 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.57 -0.852 . . . . 0.14 111.324 -166.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.89 143.34 50.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.865 -0.522 . . . . 1.11 110.156 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.637 HG22 HG22 ' A' ' 82' ' ' VAL . 35.7 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.553 -0.717 . . . . 0.2 110.551 177.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.436 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.89 127.57 29.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 N-CA-C 109.756 -0.461 . . . . 0.2 109.756 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.706 ' HB2' HG22 ' A' ' 80' ' ' ILE . 31.0 tttm -133.68 148.36 51.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.701 -0.625 . . . . 1.98 109.633 173.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.1 t80 -101.47 129.21 47.47 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.156 -0.618 . . . . 0.33 110.129 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -137.57 134.75 35.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.675 -0.641 . . . . 1.48 110.226 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.09 45.66 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.686 -1.366 . . . . 0.41 109.686 -177.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.07 7.27 33.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.706 -0.879 . . . . 1.27 111.763 178.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -131.24 138.06 32.0 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 121.169 -0.957 . . . . 1.37 110.977 -178.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.47 144.89 29.25 Favored 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 122.717 0.851 . . . . 0.34 110.026 172.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.435 ' CB ' HG23 ' A' ' 72' ' ' ILE . 45.8 mttt -122.49 147.74 45.99 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.404 -0.81 . . . . 1.1 110.098 171.182 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -136.71 169.05 18.37 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 120.338 -0.545 . . . . 1.42 110.991 -176.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.62 135.71 4.38 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.341 -1.503 . . . . 0.17 109.341 177.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -127.15 136.94 52.79 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 0.21 109.927 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.811 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.3 p90 -156.71 173.77 16.47 Favored 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 119.939 -0.704 . . . . 0.16 110.922 176.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.2 m -106.5 140.37 39.5 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.696 -0.627 . . . . 0.13 109.422 173.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.811 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.37 146.6 36.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.706 -0.621 . . . . 0.14 110.749 -175.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.2 ttt180 -93.66 145.24 24.7 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.855 -0.528 . . . . 2.21 109.617 175.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.913 HG21 HG23 ' A' ' 29' ' ' ILE . 89.9 t -79.44 125.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.356 0.598 . . . . 0.17 109.814 179.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.66 -165.33 25.27 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 110.084 -1.206 . . . . 0.19 110.084 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -61.69 151.76 32.86 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.786 -0.832 . . . . 1.39 110.107 -179.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.1 mt-30 53.3 21.88 2.5 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.565 -0.709 . . . . 0.82 112.087 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.32 20.53 79.92 Favored Glycine 0 N--CA 1.5 2.923 0 C-N-CA 119.765 -1.207 . . . . 0.19 110.795 171.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 7.8 m -78.26 145.55 35.37 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.458 -1.025 . . . . 1.3 110.365 -176.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 9.0 p -139.27 147.77 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.773 -0.579 . . . . 0.21 109.721 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -108.7 123.68 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.525 -0.735 . . . . 0.34 110.658 -175.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.417 HG23 ' HD2' ' A' ' 65' ' ' PRO . 82.9 mt -78.64 143.02 62.37 Favored Pre-proline 0 N--CA 1.499 1.975 0 O-C-N 121.592 -0.692 . . . . 0.34 109.596 172.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.767 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.0 Cg_endo -64.28 134.21 41.16 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.914 0.955 . . . . 0.26 110.908 -178.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 36.0 tptt -54.98 -34.84 63.72 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.517 -0.739 . . . . 2.62 110.859 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.413 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.95 -38.16 78.4 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.765 -0.584 . . . . 0.45 110.313 -178.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.767 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.3 mt -77.16 -32.67 56.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.739 -0.601 . . . . 1.82 110.682 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.3 mtt180 -58.35 -46.1 86.91 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.281 -0.887 . . . . 2.53 109.769 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.52 65.24 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 120.481 -0.488 . . . . 1.68 110.44 -175.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 67' ' ' ALA . 97.3 t -60.59 -38.82 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 121.685 -0.634 . . . . 0.28 109.903 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.583 HG22 HD11 ' A' ' 74' ' ' ILE . 85.8 mt -82.95 -16.32 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.821 -0.549 . . . . 0.28 111.063 -176.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.11 35.25 44.37 Favored Glycine 0 N--CA 1.498 2.794 0 N-CA-C 109.929 -1.268 . . . . 0.22 109.929 176.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.922 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -89.33 145.83 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.522 -0.987 . . . . 0.77 110.777 -173.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.6 ptmt -134.46 162.99 54.39 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.849 -0.532 . . . . 3.21 110.454 -178.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -57.42 134.09 61.3 Favored 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 122.896 0.945 . . . . 0.5 111.137 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 0.98 67.38 Favored Glycine 0 N--CA 1.496 2.675 0 C-N-CA 120.676 -0.773 . . . . 0.24 111.343 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -94.1 129.87 40.49 Favored 'General case' 0 N--CA 1.501 2.102 0 CA-C-N 118.753 1.277 . . . . 1.11 110.322 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.1 132.74 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 CA-C-O 121.616 0.722 . . . . 0.24 111.174 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.706 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.33 159.49 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 109.451 -0.574 . . . . 0.18 109.451 176.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.418 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.5 tt0 -97.83 132.1 43.73 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.088 -0.708 . . . . 1.14 109.088 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.804 ' CG1' HD11 ' A' ' 37' ' ' ILE . 98.7 t -115.04 128.83 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 121.347 0.594 . . . . 0.2 110.143 -171.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 43.8 mt -115.37 128.8 56.32 Favored 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 109.186 -0.672 . . . . 0.25 109.186 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.6 mt -79.38 140.4 37.46 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.431 -0.793 . . . . 0.28 109.729 172.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.4 mt -109.71 -32.24 7.16 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.718 -0.614 . . . . 1.6 110.971 -176.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.8 -179.07 40.23 Favored Glycine 0 N--CA 1.503 3.162 0 C-N-CA 119.674 -1.25 . . . . 0.2 110.985 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.0 p80 -142.96 150.47 39.75 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.746 -0.855 . . . . 1.89 110.658 -177.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -134.41 139.67 45.73 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.586 -0.696 . . . . 0.8 110.045 175.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 tttm -105.16 144.6 29.1 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.73 -0.606 . . . . 2.99 110.214 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -55.37 144.22 73.28 Favored 'Trans proline' 0 N--CA 1.497 1.68 0 O-C-N 123.197 1.104 . . . . 1.68 110.998 178.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 44.7 ptt85 -136.1 158.26 44.84 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.735 -0.603 . . . . 6.87 110.419 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 . . . . . 0 N--CA 1.504 2.256 0 CA-C-O 118.039 -0.981 . . . . 6.47 110.956 -179.84 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.8 mtp . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.271 0.558 . . . . 2.76 110.529 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.99 142.68 38.13 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.843 -0.536 . . . . 1.7 110.023 178.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 84' ' ' LEU . 3.4 p -128.06 140.28 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.779 -0.575 . . . . 0.41 109.758 177.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.5 mt -86.91 -20.87 26.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.85 -0.531 . . . . 0.37 110.464 -178.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.904 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.06 157.23 4.28 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.363 -0.836 . . . . 0.26 109.685 176.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -132.87 126.67 32.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.715 -0.615 . . . . 2.3 110.223 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.612 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.6 p90 -149.27 162.48 39.95 Favored 'General case' 0 N--CA 1.497 1.909 0 C-N-CA 120.143 -0.623 . . . . 0.2 110.665 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.59 138.18 50.53 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.548 -0.72 . . . . 1.99 110.286 -176.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.439 HG21 HD12 ' A' ' 17' ' ' ILE . 14.9 t -150.9 162.37 40.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.797 -0.564 . . . . 0.18 109.543 177.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.05 160.35 16.94 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 119.812 -0.755 . . . . 0.17 110.107 177.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.4 t -79.06 136.13 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 C-N-CA 120.329 -0.548 . . . . 0.49 110.318 -176.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -116.2 172.04 7.43 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.24 0.543 . . . . 0.68 109.58 174.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -46.21 152.47 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.543 -0.723 . . . . 2.96 112.048 -175.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.76 7.32 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.703 0 O-C-N 121.622 -0.674 . . . . 0.42 112.593 -175.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.55 16.07 80.67 Favored Glycine 0 N--CA 1.496 2.635 0 O-C-N 120.857 -1.152 . . . . 0.24 110.438 179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttp180 -84.63 145.06 28.2 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.292 -1.123 . . . . 1.96 110.191 -177.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 9' ' ' THR . 45.1 pt -132.58 155.78 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 N-CA-C 109.315 -0.624 . . . . 0.3 109.315 172.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.1 mm -115.82 128.18 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 C-N-CA 120.034 -0.666 . . . . 0.25 109.904 176.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 33.7 mt -79.58 143.83 59.88 Favored Pre-proline 0 N--CA 1.495 1.794 0 C-N-CA 120.052 -0.659 . . . . 0.23 109.435 176.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.08 143.08 89.79 Favored 'Trans proline' 0 N--CA 1.489 1.231 0 O-C-N 122.989 0.994 . . . . 0.35 109.845 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.62 -26.9 62.24 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.882 -0.511 . . . . 0.33 110.52 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.06 95.61 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.951 -1.26 . . . . 0.39 109.951 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.9 m -69.94 -38.38 76.15 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.585 -0.95 . . . . 0.39 110.116 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.87 -40.81 73.47 Favored 'General case' 0 N--CA 1.512 2.664 0 O-C-N 121.286 -0.884 . . . . 0.4 109.429 176.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -65.75 -50.07 66.11 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.1 0.476 . . . . 2.97 110.212 -177.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.5 t80 -57.6 -39.67 77.34 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.707 -0.621 . . . . 0.67 110.756 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.939 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.0 t80 -87.69 -14.29 40.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.774 -0.579 . . . . 1.44 111.275 -176.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.87 42.52 25.19 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.576 -1.409 . . . . 0.31 109.576 178.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.921 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.74 125.55 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.543 -0.975 . . . . 0.42 110.445 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.55 159.94 33.07 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.235 -0.654 . . . . 1.82 109.235 172.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -57.27 138.19 55.06 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.33 -0.856 . . . . 1.99 110.557 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.81 -16.09 61.99 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 110.832 -0.907 . . . . 0.19 110.832 178.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -77.23 155.96 31.79 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.693 1.246 . . . . 1.12 109.998 177.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -111.27 138.78 47.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.6 -0.688 . . . . 0.21 109.492 174.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 155.06 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.199 -0.6 . . . . 0.15 109.386 174.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.99 122.55 45.58 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.198 -1.038 . . . . 1.09 108.198 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.826 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.15 158.22 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.596 -0.841 . . . . 0.14 110.936 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -133.15 145.62 50.83 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.859 -0.525 . . . . 1.11 110.505 178.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' VAL . 31.9 pt -114.93 151.13 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.648 -0.657 . . . . 0.2 110.604 178.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t -138.67 127.93 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 CA-C-O 121.174 0.512 . . . . 0.2 109.72 176.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.702 ' HB2' HG22 ' A' ' 80' ' ' ILE . 33.3 tptt -137.82 147.13 44.29 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.83 -0.544 . . . . 1.98 109.632 175.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -101.99 128.9 48.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.266 -0.574 . . . . 0.33 110.384 -176.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -131.92 132.86 43.95 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.676 -0.64 . . . . 1.48 109.974 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.89 -128.23 45.95 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 109.768 -1.333 . . . . 0.41 109.768 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -105.19 12.57 31.8 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.677 -0.896 . . . . 1.27 111.608 177.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -131.17 127.6 21.94 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.255 -0.903 . . . . 1.37 110.991 -177.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -75.3 139.41 23.5 Favored 'Trans proline' 0 N--CA 1.483 0.893 0 O-C-N 122.743 0.865 . . . . 0.34 109.994 173.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.427 ' CB ' HG23 ' A' ' 72' ' ' ILE . 37.1 mttp -118.71 151.75 37.41 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.498 -0.751 . . . . 1.1 110.309 173.268 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -140.03 169.09 18.34 Favored 'General case' 0 N--CA 1.496 1.836 0 CA-C-O 121.216 0.532 . . . . 1.42 110.737 -178.373 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.61 135.9 4.47 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.428 -1.469 . . . . 0.17 109.428 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.4 m -122.64 137.48 54.89 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.629 -0.924 . . . . 0.21 109.847 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.7 p90 -156.14 173.1 17.32 Favored 'General case' 0 N--CA 1.497 1.903 0 C-N-CA 119.899 -0.721 . . . . 0.16 110.901 176.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.06 141.31 38.5 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.669 -0.644 . . . . 0.13 109.493 173.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 145.51 35.19 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.675 -0.641 . . . . 0.14 110.695 -175.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -93.68 146.0 24.15 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.855 -0.528 . . . . 2.21 109.626 175.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.921 HG21 HG23 ' A' ' 29' ' ' ILE . 87.2 t -79.15 125.45 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.778 -0.576 . . . . 0.17 109.919 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.33 -167.08 25.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.944 -1.262 . . . . 0.19 109.944 178.231 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.68 152.93 29.58 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.79 -0.829 . . . . 1.39 110.138 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.28 21.4 2.27 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.652 -0.655 . . . . 0.82 112.095 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.1 20.6 79.66 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.684 -1.246 . . . . 0.19 110.832 171.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.0 m -77.96 144.56 36.67 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.388 -1.066 . . . . 1.3 110.343 -176.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.735 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.64 146.51 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.881 -0.512 . . . . 0.21 109.684 175.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -110.53 123.21 66.23 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.51 -0.744 . . . . 0.34 110.783 -175.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.5 mt -78.27 144.37 66.54 Favored Pre-proline 0 N--CA 1.498 1.938 0 O-C-N 121.637 -0.664 . . . . 0.34 109.494 172.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.17 133.82 39.74 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 O-C-N 122.98 0.99 . . . . 0.26 110.796 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -55.21 -34.23 63.75 Favored 'General case' 0 N--CA 1.502 2.171 0 O-C-N 121.481 -0.762 . . . . 2.62 110.768 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.408 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -37.99 77.7 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.797 -0.564 . . . . 0.45 110.275 -178.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.1 mt -77.13 -32.66 56.56 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 120.151 -0.62 . . . . 1.82 110.593 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.01 -46.33 85.44 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.349 -0.844 . . . . 2.53 109.771 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.91 -46.51 65.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 120.543 -0.463 . . . . 1.68 110.401 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 67' ' ' ALA . 96.5 t -60.58 -38.81 79.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.692 -0.63 . . . . 0.28 109.843 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.549 HG22 HD11 ' A' ' 74' ' ' ILE . 82.4 mt -82.64 -16.63 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.845 -0.535 . . . . 0.28 111.083 -176.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.24 35.18 43.86 Favored Glycine 0 N--CA 1.497 2.766 0 N-CA-C 109.878 -1.289 . . . . 0.22 109.878 176.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.6 142.86 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.056 0 O-C-N 121.519 -0.989 . . . . 0.77 110.63 -174.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.0 ptmt -130.27 162.35 54.83 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.801 -0.562 . . . . 3.21 110.644 -178.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.51 135.55 68.37 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 O-C-N 122.946 0.971 . . . . 0.5 110.919 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.61 -0.35 70.51 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.612 -0.804 . . . . 0.24 111.264 176.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -94.73 130.29 41.31 Favored 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 118.741 1.271 . . . . 1.11 109.849 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.2 p -91.92 129.9 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-O 121.527 0.679 . . . . 0.24 110.809 -175.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.702 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -118.79 159.39 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 109.418 -0.586 . . . . 0.18 109.418 177.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -97.91 131.91 43.96 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.017 -0.735 . . . . 1.14 109.017 174.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.826 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.9 t -116.2 129.72 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.355 0.598 . . . . 0.2 110.301 -170.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 44.6 mt -115.85 130.11 56.7 Favored 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 109.208 -0.664 . . . . 0.25 109.208 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.939 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.29 140.55 36.13 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.345 -0.847 . . . . 0.28 109.803 172.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.8 mt -111.37 -33.1 6.51 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.649 -0.657 . . . . 1.6 110.97 -176.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.21 -175.79 38.14 Favored Glycine 0 N--CA 1.504 3.181 0 C-N-CA 119.689 -1.244 . . . . 0.2 111.089 -176.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -144.25 154.26 42.9 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.728 -0.866 . . . . 1.89 110.624 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -141.05 147.95 39.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.8 110.21 176.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 10.2 pttt -123.77 154.85 67.21 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.621 -0.674 . . . . 2.99 110.253 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -56.38 140.79 89.28 Favored 'Trans proline' 0 N--CA 1.496 1.639 0 O-C-N 123.182 1.096 . . . . 1.68 110.868 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -73.34 146.77 44.99 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.706 -0.621 . . . . 6.87 110.121 178.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 43.5 p-10 . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.044 -0.979 . . . . 6.47 110.342 179.829 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.0 ttp . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 120.995 0.426 . . . . 2.76 110.196 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -75.79 144.29 41.46 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.76 -0.587 . . . . 1.7 110.025 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.1 p -127.75 137.82 56.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.75 -0.594 . . . . 0.41 109.626 178.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.583 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.6 mt -86.67 -18.5 31.12 Favored 'General case' 0 N--CA 1.496 1.827 0 C-N-CA 120.164 -0.614 . . . . 0.37 110.574 -178.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.831 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.69 155.69 3.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.251 -0.905 . . . . 0.26 109.518 175.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.8 tttt -134.76 124.66 25.54 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.696 -0.627 . . . . 2.3 110.117 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.0 p90 -150.82 163.66 38.09 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.621 -0.674 . . . . 0.2 110.898 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -114.05 138.0 50.97 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.623 -0.673 . . . . 1.99 110.34 -177.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.39 162.31 41.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.66 -0.65 . . . . 0.18 109.648 177.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -109.64 160.47 16.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.367 -0.833 . . . . 0.17 110.264 177.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.869 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.2 t -78.92 137.37 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.843 -0.536 . . . . 0.49 110.289 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.82 171.97 7.55 Favored 'General case' 0 N--CA 1.493 1.707 0 CA-C-O 121.286 0.565 . . . . 0.68 109.628 174.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.1 mtt-85 -46.37 152.54 0.43 Allowed 'General case' 0 N--CA 1.506 2.354 0 O-C-N 121.509 -0.745 . . . . 2.96 111.999 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.8 mt 62.62 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.673 0 O-C-N 121.536 -0.727 . . . . 0.42 112.604 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.78 16.1 80.45 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.901 -1.125 . . . . 0.24 110.335 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.9 ttp180 -85.16 144.85 27.93 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.269 -1.136 . . . . 1.96 110.28 -177.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.7 pt -133.3 154.76 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.706 -0.621 . . . . 0.3 109.398 172.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.7 127.77 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.563 -0.711 . . . . 0.25 110.034 176.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 38.2 mt -79.9 144.18 59.16 Favored Pre-proline 0 N--CA 1.495 1.824 0 C-N-CA 120.087 -0.645 . . . . 0.23 109.479 176.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.38 143.52 88.87 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 122.927 0.961 . . . . 0.35 109.724 174.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.56 61.28 Favored 'General case' 0 N--CA 1.497 1.895 0 C-N-CA 120.391 -0.523 . . . . 0.33 110.56 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.55 -44.5 95.03 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.848 -1.301 . . . . 0.39 109.848 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.1 m -69.94 -38.13 76.07 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.662 -0.905 . . . . 0.39 110.09 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.61 73.24 Favored 'General case' 0 N--CA 1.514 2.741 0 O-C-N 121.26 -0.9 . . . . 0.4 109.385 176.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.3 tttt -64.95 -49.78 69.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-O 121.184 0.516 . . . . 2.97 110.133 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -57.24 -38.45 73.83 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.704 -0.622 . . . . 0.67 110.727 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.8 t80 -88.09 -14.43 38.87 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.756 -0.59 . . . . 1.44 111.216 -177.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.77 42.81 24.91 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.529 -1.429 . . . . 0.31 109.529 178.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 56' ' ' VAL . 75.6 mt -87.26 128.32 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.481 -1.011 . . . . 0.42 110.644 -176.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -127.85 158.85 36.63 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.115 -0.698 . . . . 1.82 109.115 170.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -57.3 138.51 54.72 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.329 -0.857 . . . . 1.99 110.522 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.88 -15.89 62.44 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 110.873 -0.891 . . . . 0.19 110.873 179.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -76.95 155.61 32.59 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-N 118.71 1.255 . . . . 1.12 110.0 177.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 90' ' ' PRO . 76.3 m-85 -110.72 138.83 46.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.636 -0.665 . . . . 0.21 109.646 174.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.57 154.05 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.262 -0.644 . . . . 0.15 109.262 175.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -115.45 123.42 48.54 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.279 -1.008 . . . . 1.09 108.279 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.82 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.4 tt -139.87 158.45 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 C-N-CA 119.69 -0.804 . . . . 0.14 110.861 -167.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.577 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.6 ttpt -133.03 146.06 51.38 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.767 -0.583 . . . . 1.11 110.577 177.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.627 HG22 HG22 ' A' ' 82' ' ' VAL . 26.8 pt -114.88 151.07 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.63 -0.669 . . . . 0.2 110.333 177.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.629 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.92 125.04 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-O 121.133 0.492 . . . . 0.2 109.71 176.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.708 ' HB2' HG22 ' A' ' 80' ' ' ILE . 39.1 tptt -135.17 147.58 49.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.763 -0.585 . . . . 1.98 109.655 177.069 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -106.15 129.88 54.14 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 120.233 -0.587 . . . . 0.33 110.33 -177.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -138.25 138.15 38.19 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.585 -0.697 . . . . 1.48 110.238 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.75 -128.13 45.93 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.891 -1.284 . . . . 0.41 109.891 -178.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.24 7.18 33.44 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.763 -0.845 . . . . 1.27 111.851 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -131.27 138.54 33.06 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.181 -0.949 . . . . 1.37 111.17 -177.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -75.45 142.43 26.52 Favored 'Trans proline' 0 N--CA 1.482 0.82 0 O-C-N 122.861 0.927 . . . . 0.34 110.108 172.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.8 mmtt -117.62 137.31 52.71 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.522 -0.736 . . . . 1.1 109.716 171.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.629 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -135.05 166.4 23.14 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.662 -0.649 . . . . 1.42 110.747 -176.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.62 135.64 4.34 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.53 -1.428 . . . . 0.17 109.53 177.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.577 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -123.03 136.43 54.83 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.711 -0.876 . . . . 0.21 109.73 176.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.818 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.1 p90 -155.43 173.29 16.88 Favored 'General case' 0 N--CA 1.497 1.899 0 C-N-CA 119.956 -0.698 . . . . 0.16 111.014 178.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.0 140.57 39.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.619 -0.675 . . . . 0.13 109.525 173.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.818 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.86 146.5 35.89 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.709 -0.619 . . . . 0.14 110.613 -175.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.9 ttt180 -93.48 145.18 24.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.757 -0.589 . . . . 2.21 109.766 175.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.888 HG21 HG23 ' A' ' 29' ' ' ILE . 94.2 t -79.5 125.95 38.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.744 -0.597 . . . . 0.17 109.908 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.05 -167.37 25.96 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.992 -1.243 . . . . 0.19 109.992 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -61.68 153.45 28.12 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.67 -0.9 . . . . 1.39 110.148 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.9 mt-30 53.71 21.09 2.48 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.53 -0.731 . . . . 0.82 111.984 -179.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.14 20.55 79.98 Favored Glycine 0 N--CA 1.499 2.853 0 C-N-CA 119.804 -1.188 . . . . 0.19 110.876 171.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.414 ' HA ' HD13 ' A' ' 18' ' ' ILE . 12.4 t -78.64 144.62 35.24 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.455 -1.027 . . . . 1.3 110.294 -176.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.43 145.79 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 N-CA-C 109.577 -0.527 . . . . 0.21 109.577 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.1 mm -111.39 123.84 67.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.546 -0.721 . . . . 0.34 110.685 -175.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 81.2 mt -78.16 145.0 68.14 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.602 -0.686 . . . . 0.34 109.458 172.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.14 134.45 42.63 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 O-C-N 122.957 0.977 . . . . 0.26 110.68 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -55.21 -34.28 63.79 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.437 -0.789 . . . . 2.62 110.797 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -37.8 77.39 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.659 -0.651 . . . . 0.45 110.322 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.2 mt -77.12 -32.7 56.65 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.18 -0.608 . . . . 1.82 110.579 178.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.7 mtt180 -57.94 -46.1 85.57 Favored 'General case' 0 N--CA 1.504 2.249 0 O-C-N 121.297 -0.877 . . . . 2.53 109.944 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -70.25 -47.01 63.21 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 120.52 -0.472 . . . . 1.68 110.385 -175.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.0 t -60.59 -38.18 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.678 -0.639 . . . . 0.28 109.943 -178.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.0 mt -82.22 -18.12 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.855 -0.528 . . . . 0.28 110.817 -176.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.92 35.05 40.49 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.648 -1.381 . . . . 0.22 109.648 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.869 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.4 mm -91.69 142.58 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.592 -0.946 . . . . 0.77 110.549 -174.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.67 161.41 61.16 Favored Pre-proline 0 N--CA 1.498 1.944 0 O-C-N 121.782 -0.574 . . . . 3.21 110.735 -179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -58.49 137.31 79.64 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.937 0.967 . . . . 0.5 111.033 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.78 -2.08 72.33 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 111.166 -0.774 . . . . 0.24 111.166 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -94.17 130.17 40.49 Favored 'General case' 0 N--CA 1.499 2.011 0 CA-C-N 118.692 1.246 . . . . 1.11 110.202 178.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 79' ' ' VAL . 10.8 p -91.74 128.86 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 CA-C-O 121.444 0.64 . . . . 0.24 110.759 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.708 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.9 pt -118.3 159.43 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 109.459 -0.571 . . . . 0.18 109.459 178.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.4 tt0 -97.95 129.96 44.83 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.909 -0.774 . . . . 1.14 108.909 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.82 ' CG1' HD11 ' A' ' 37' ' ' ILE . 94.7 t -115.18 129.29 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 121.288 0.566 . . . . 0.2 110.303 -170.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 40.7 mt -115.66 128.43 55.9 Favored 'General case' 0 N--CA 1.494 1.754 0 N-CA-C 109.167 -0.679 . . . . 0.25 109.167 179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.2 mt -79.78 138.5 37.28 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.39 -0.819 . . . . 0.28 109.542 171.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -109.91 -31.29 7.46 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.723 -0.611 . . . . 1.6 110.968 -174.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.583 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.12 -177.33 39.25 Favored Glycine 0 N--CA 1.503 3.12 0 C-N-CA 119.672 -1.251 . . . . 0.2 111.039 -177.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -143.54 152.43 41.43 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.707 -0.878 . . . . 1.89 110.648 -177.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -133.75 138.88 46.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.468 -0.77 . . . . 0.8 110.356 176.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.0 mttt -115.74 110.1 44.75 Favored Pre-proline 0 N--CA 1.495 1.801 0 O-C-N 121.832 -0.543 . . . . 2.99 110.161 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.436 ' HG3' ' CD1' ' A' ' 34' ' ' PHE . 85.1 Cg_exo -54.33 146.82 49.1 Favored 'Trans proline' 0 N--CA 1.499 1.802 0 O-C-N 123.033 1.018 . . . . 1.68 111.165 -179.658 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.4 ttt180 -123.48 141.94 51.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.714 -0.616 . . . . 6.87 110.154 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 47.8 t30 . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 118.038 -0.982 . . . . 6.47 110.18 -179.862 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.7 mtp . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.308 0.575 . . . . 2.76 110.561 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -73.35 146.91 44.86 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.776 -0.577 . . . . 1.7 109.973 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.408 HG23 ' HB3' ' A' ' 83' ' ' LEU . 3.2 p -128.15 135.78 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 O-C-N 121.815 -0.553 . . . . 0.41 109.595 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.619 HD11 ' HA2' ' A' ' 86' ' ' GLY . 24.7 mt -82.51 -20.85 35.93 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.816 -0.553 . . . . 0.37 110.195 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.86 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -170.69 152.56 3.81 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.459 -0.776 . . . . 0.26 109.199 175.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.6 tttt -133.92 125.1 27.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.3 110.293 -175.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.618 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.99 162.55 40.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.651 -0.655 . . . . 0.2 110.925 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.415 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.4 m-70 -111.94 138.49 48.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.582 -0.698 . . . . 1.99 110.188 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.59 162.34 41.15 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.694 -0.629 . . . . 0.18 109.701 177.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.3 t -110.83 160.21 16.96 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.461 -0.774 . . . . 0.17 109.83 176.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.886 HG21 ' CG2' ' A' ' 74' ' ' ILE . 61.4 t -77.65 137.47 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.754 -0.591 . . . . 0.49 110.169 -177.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.3 m80 -116.14 171.99 7.45 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.66 -0.496 . . . . 0.68 109.66 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -46.02 151.53 0.47 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.639 -0.663 . . . . 2.96 112.122 -174.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.5 mt 62.74 7.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.606 -0.684 . . . . 0.42 112.639 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.96 80.63 Favored Glycine 0 N--CA 1.498 2.801 0 N-CA-C 110.322 -1.111 . . . . 0.24 110.322 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -85.34 145.52 27.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.96 110.211 -177.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -134.36 154.68 37.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.626 -0.671 . . . . 0.3 109.476 172.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -117.19 127.99 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.57 -0.706 . . . . 0.25 110.031 176.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.25 144.98 59.15 Favored Pre-proline 0 N--CA 1.496 1.834 0 C-N-CA 120.038 -0.665 . . . . 0.23 109.491 175.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -63.44 143.44 88.34 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 O-C-N 123.023 1.012 . . . . 0.35 109.776 174.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.39 -26.57 61.27 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.845 -0.534 . . . . 0.33 110.495 -178.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.45 -44.37 95.36 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.932 -1.267 . . . . 0.39 109.932 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 83.9 m -70.22 -38.0 75.16 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.592 -0.946 . . . . 0.39 110.13 -179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.86 -41.23 74.04 Favored 'General case' 0 N--CA 1.514 2.775 0 O-C-N 121.263 -0.898 . . . . 0.4 109.342 176.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -65.41 -49.24 69.95 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.048 0.451 . . . . 2.97 110.287 -178.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.34 -38.42 74.07 Favored 'General case' 0 N--CA 1.502 2.125 0 O-C-N 121.787 -0.57 . . . . 0.67 110.781 -179.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.9 t80 -87.58 -14.22 40.74 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.817 -0.552 . . . . 1.44 111.257 -177.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.12 42.79 23.24 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.522 -1.431 . . . . 0.31 109.522 178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.906 HG23 HG21 ' A' ' 56' ' ' VAL . 77.0 mt -87.44 129.67 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.511 -0.993 . . . . 0.42 110.574 -177.163 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.42 155.46 43.62 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 109.077 -0.712 . . . . 1.82 109.077 171.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -55.45 137.44 48.27 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.256 -0.903 . . . . 1.99 110.794 -177.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.69 -14.66 64.91 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.91 -0.876 . . . . 0.19 110.91 178.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -76.26 155.55 34.25 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 118.848 1.324 . . . . 1.12 109.907 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -109.33 138.24 45.98 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.518 -0.739 . . . . 0.21 109.508 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.73 154.85 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.263 -0.643 . . . . 0.15 109.263 175.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -115.95 122.95 46.79 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.277 -1.008 . . . . 1.09 108.277 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.85 HD11 ' CG1' ' A' ' 82' ' ' VAL . 13.1 tt -139.37 157.83 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.7 -0.8 . . . . 0.14 110.87 -167.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -132.83 146.03 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.814 -0.554 . . . . 1.11 110.518 178.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.553 ' HB ' HD12 ' A' ' 80' ' ' ILE . 31.3 pt -114.95 150.93 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.663 -0.648 . . . . 0.2 110.51 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.458 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.18 126.54 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-O 121.085 0.469 . . . . 0.2 109.765 176.472 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.7 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.1 tttp -133.35 146.33 51.2 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.798 -0.564 . . . . 1.98 109.57 174.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 37.4 t80 -105.43 126.38 52.05 Favored 'General case' 0 N--CA 1.496 1.863 0 C-N-CA 120.133 -0.627 . . . . 0.33 110.151 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -139.71 141.21 36.94 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.664 . . . . 1.48 110.408 178.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.22 46.01 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.731 -1.348 . . . . 0.41 109.731 -177.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -105.08 5.25 32.29 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.734 -0.862 . . . . 1.27 111.872 178.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.3 140.32 38.14 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.097 -1.002 . . . . 1.37 111.262 -176.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -75.44 138.28 21.82 Favored 'Trans proline' 0 N--CA 1.483 0.861 0 O-C-N 122.864 0.928 . . . . 0.34 109.992 171.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' A' ' 72' ' ' ILE . 17.1 mmtp -111.97 137.65 49.68 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.529 -0.732 . . . . 1.1 109.583 172.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.458 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.17 164.86 26.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.582 -0.698 . . . . 1.42 110.773 -175.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.451 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.26 135.94 4.42 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.58 -1.408 . . . . 0.17 109.58 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.2 m -123.28 137.39 54.87 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.733 -0.863 . . . . 0.21 109.695 176.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.9 p90 -156.23 173.09 17.36 Favored 'General case' 0 N--CA 1.497 1.901 0 C-N-CA 119.845 -0.742 . . . . 0.16 111.037 176.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.6 m -107.47 141.02 39.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.668 -0.645 . . . . 0.13 109.5 173.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.92 145.95 35.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.717 -0.614 . . . . 0.14 110.45 -176.038 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -93.72 144.23 25.59 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.749 -0.594 . . . . 2.21 109.687 175.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.906 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -78.82 125.98 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.267 0.556 . . . . 0.17 110.009 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.37 -169.9 25.81 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.848 -1.301 . . . . 0.19 109.848 177.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -61.81 155.82 22.13 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.707 -0.878 . . . . 1.39 109.913 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.06 19.34 2.71 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.486 -0.759 . . . . 0.82 112.018 -177.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.56 20.59 79.58 Favored Glycine 0 N--CA 1.499 2.839 0 C-N-CA 119.813 -1.184 . . . . 0.19 110.66 172.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 32.4 t -78.4 144.72 35.65 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.437 -1.037 . . . . 1.3 110.479 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.75 146.27 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 109.637 -0.505 . . . . 0.21 109.637 175.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -111.79 123.97 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.6 -0.688 . . . . 0.34 110.655 -175.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.7 mt -78.33 143.47 64.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.612 -0.68 . . . . 0.34 109.477 172.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.79 136.81 50.92 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 O-C-N 122.982 0.991 . . . . 0.26 110.814 -179.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.1 tptt -54.91 -34.46 63.14 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.395 -0.816 . . . . 2.62 110.714 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.46 79.15 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.789 -0.569 . . . . 0.45 110.287 -178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.9 mt -77.18 -32.82 56.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.742 -0.599 . . . . 1.82 110.656 179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.5 mtt180 -58.35 -45.24 88.56 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.265 -0.897 . . . . 2.53 109.91 178.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.14 -47.41 61.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 120.55 -0.46 . . . . 1.68 110.408 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.1 t -60.54 -38.08 77.1 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 121.666 -0.646 . . . . 0.28 109.845 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.705 HG23 ' HB3' ' A' ' 48' ' ' LYS . 79.1 mt -82.6 -17.74 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.84 -0.537 . . . . 0.28 110.829 -176.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.06 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.621 -1.392 . . . . 0.22 109.621 176.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.886 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -93.71 141.86 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.558 -0.966 . . . . 0.77 110.728 -174.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.67 162.4 56.46 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.757 -0.589 . . . . 3.21 110.691 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -51.88 135.86 51.01 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.025 1.013 . . . . 0.5 111.807 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.08 -1.92 71.06 Favored Glycine 0 N--CA 1.497 2.702 0 C-N-CA 120.72 -0.752 . . . . 0.24 111.431 174.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -96.4 131.53 42.87 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-N 118.74 1.27 . . . . 1.11 110.64 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.26 132.95 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 CA-C-O 121.607 0.718 . . . . 0.24 111.229 -173.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.7 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.6 pt -124.72 159.52 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.948 -0.47 . . . . 0.18 109.757 177.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.415 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 41.6 tt0 -97.59 130.94 44.59 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.85 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.0 t -114.41 129.48 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.803 -0.56 . . . . 0.2 110.207 -171.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.408 ' HB3' HG23 ' A' ' 3' ' ' VAL . 38.2 mt -118.09 128.78 55.07 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.113 -0.699 . . . . 0.25 109.113 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -79.79 140.45 36.87 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.305 -0.872 . . . . 0.28 109.757 172.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.49 -33.51 6.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.718 -0.614 . . . . 1.6 110.887 -175.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.619 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.63 -172.97 36.03 Favored Glycine 0 N--CA 1.502 3.094 0 C-N-CA 119.778 -1.201 . . . . 0.2 110.942 -176.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -142.88 159.0 43.07 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.706 -0.879 . . . . 1.89 110.655 -177.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 -141.92 147.36 36.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.683 . . . . 0.8 110.322 177.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -119.48 160.03 43.48 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.656 -0.653 . . . . 2.99 110.167 178.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -54.59 142.76 71.01 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 O-C-N 123.158 1.083 . . . . 1.68 111.02 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 15.7 tpt180 -127.54 141.44 51.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.725 -0.609 . . . . 6.87 110.259 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 33.7 t30 . . . . . 0 N--CA 1.503 2.197 0 CA-C-O 118.022 -0.989 . . . . 6.47 110.997 179.988 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mtm . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.2 0.524 . . . . 2.76 110.624 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -74.26 143.86 44.87 Favored 'General case' 0 N--CA 1.496 1.849 0 C-N-CA 120.505 -0.478 . . . . 1.7 110.081 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 p -128.06 137.22 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.738 -0.601 . . . . 0.41 109.605 178.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 26.0 mt -84.16 -19.92 33.3 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.738 -0.601 . . . . 0.37 110.398 -179.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.873 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.32 153.93 3.76 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.362 -0.836 . . . . 0.26 109.427 176.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 20.6 tttt -133.75 125.24 28.11 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.679 -0.638 . . . . 2.3 110.128 -177.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.609 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -150.9 163.12 39.43 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.627 -0.67 . . . . 0.2 110.871 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -113.44 138.93 49.38 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.706 -0.621 . . . . 1.99 110.376 -176.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.28 162.3 41.15 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.653 -0.655 . . . . 0.18 109.717 177.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.2 t -111.4 159.69 17.78 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.427 -0.796 . . . . 0.17 109.917 175.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.898 HG21 ' CG2' ' A' ' 74' ' ' ILE . 57.5 t -77.56 138.64 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 120.302 -0.559 . . . . 0.49 110.275 -176.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -118.31 172.01 7.75 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.583 -0.525 . . . . 0.68 109.583 174.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -46.28 152.57 0.41 Allowed 'General case' 0 N--CA 1.506 2.36 0 O-C-N 121.574 -0.704 . . . . 2.96 112.014 -175.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.75 7.46 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.607 0 O-C-N 121.58 -0.7 . . . . 0.42 112.61 -175.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.47 16.12 80.68 Favored Glycine 0 N--CA 1.497 2.7 0 O-C-N 120.901 -1.124 . . . . 0.24 110.327 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.8 ttp180 -84.88 145.96 27.54 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.294 -1.121 . . . . 1.96 110.247 -177.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -133.08 154.85 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 109.284 -0.636 . . . . 0.3 109.284 171.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -115.1 128.04 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 C-N-CA 120.039 -0.664 . . . . 0.25 110.054 176.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.0 mt -79.98 144.63 59.69 Favored Pre-proline 0 N--CA 1.495 1.81 0 C-N-CA 120.048 -0.661 . . . . 0.23 109.424 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -62.87 142.6 89.16 Favored 'Trans proline' 0 N--CA 1.488 1.2 0 O-C-N 122.971 0.985 . . . . 0.35 109.871 174.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.64 -27.36 62.74 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 120.401 -0.519 . . . . 0.33 110.478 -178.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.54 -43.99 95.78 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 109.902 -1.279 . . . . 0.39 109.902 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.2 m -70.12 -38.0 75.46 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.608 -0.937 . . . . 0.39 109.914 -179.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.702 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -55.82 -40.94 73.49 Favored 'General case' 0 N--CA 1.513 2.709 0 O-C-N 121.233 -0.917 . . . . 0.4 109.436 176.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -65.27 -50.08 67.14 Favored 'General case' 0 N--CA 1.495 1.79 0 CA-C-O 121.14 0.495 . . . . 2.97 110.131 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.4 -38.43 74.28 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.786 -0.571 . . . . 0.67 110.756 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.5 t80 -87.4 -14.25 41.12 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.821 -0.549 . . . . 1.44 111.343 -176.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.93 42.76 24.28 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 109.581 -1.408 . . . . 0.31 109.581 178.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 75.5 mt -87.63 128.45 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.57 -0.959 . . . . 0.42 110.559 -177.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -127.95 158.38 38.01 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.943 -0.762 . . . . 1.82 108.943 170.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -57.4 140.18 51.04 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.342 -0.849 . . . . 1.99 110.465 -178.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -16.07 61.71 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 110.828 -0.909 . . . . 0.19 110.828 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.74 157.72 31.47 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.094 -1.239 . . . . 1.12 110.146 178.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -111.92 138.76 48.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.569 -0.707 . . . . 0.21 109.579 174.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 154.75 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 120.15 -0.62 . . . . 0.15 109.354 174.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -115.58 123.72 49.17 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.303 -0.999 . . . . 1.09 108.303 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.837 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.9 158.79 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.754 -0.778 . . . . 0.14 110.982 -167.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.408 ' HB2' HD12 ' A' ' 85' ' ' LEU . 30.2 tttt -133.33 146.21 51.12 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.885 -0.509 . . . . 1.11 110.29 177.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.542 HG22 HG22 ' A' ' 82' ' ' VAL . 21.2 pt -114.82 150.94 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.716 -0.615 . . . . 0.2 110.302 178.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -138.99 123.84 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.181 0.515 . . . . 0.2 109.678 177.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 46.7 tttp -132.76 146.97 52.29 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 109.357 -0.609 . . . . 1.98 109.357 175.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -102.09 129.73 48.5 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.957 -0.697 . . . . 0.33 110.41 -178.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.21 134.43 40.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.682 -0.636 . . . . 1.48 110.048 178.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.9 -128.16 45.8 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.838 -1.305 . . . . 0.41 109.838 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 17.8 pt-20 -105.15 9.8 34.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.706 -0.879 . . . . 1.27 111.791 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.15 138.4 32.81 Favored Pre-proline 0 N--CA 1.498 1.936 0 O-C-N 121.301 -0.875 . . . . 1.37 110.961 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -75.18 138.7 22.94 Favored 'Trans proline' 0 N--CA 1.482 0.852 0 O-C-N 122.854 0.923 . . . . 0.34 110.298 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 41.2 mmtt -109.48 137.72 46.9 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.554 -0.716 . . . . 1.1 109.456 172.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 92.4 mt-10 -135.6 163.22 30.62 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.62 -0.675 . . . . 1.42 110.93 -176.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.08 135.93 4.43 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.549 -1.421 . . . . 0.17 109.549 177.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.5 m -123.23 138.2 54.69 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.568 -0.96 . . . . 0.21 109.841 176.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -156.15 173.17 17.23 Favored 'General case' 0 N--CA 1.497 1.891 0 C-N-CA 119.975 -0.69 . . . . 0.16 110.955 176.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -107.36 141.27 38.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.718 -0.614 . . . . 0.13 109.479 173.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.17 146.22 36.69 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 120.212 -0.595 . . . . 0.14 110.73 -175.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 53.3 ttt180 -93.01 145.13 24.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.811 -0.556 . . . . 2.21 109.59 175.195 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 90.5 t -79.47 125.8 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.827 -0.546 . . . . 0.17 109.779 179.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.1 -170.38 27.25 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.707 -1.357 . . . . 0.19 109.707 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 31.2 tp10 -61.84 155.75 22.4 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.644 -0.915 . . . . 1.39 109.961 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 54.87 19.64 2.71 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.569 -0.707 . . . . 0.82 112.008 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.18 20.55 79.97 Favored Glycine 0 N--CA 1.499 2.837 0 C-N-CA 119.793 -1.194 . . . . 0.19 110.816 172.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 16.6 m -77.91 144.04 37.21 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.46 -1.024 . . . . 1.3 110.288 -176.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.22 145.93 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.751 -0.593 . . . . 0.21 109.596 175.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -111.4 123.17 67.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.541 -0.725 . . . . 0.34 110.699 -174.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 77.3 mt -78.62 143.87 64.07 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.532 -0.73 . . . . 0.34 109.429 172.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.754 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.1 Cg_endo -65.1 136.68 49.03 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 O-C-N 122.926 0.961 . . . . 0.26 110.757 -179.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 43.2 tttm -55.07 -34.17 63.36 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.48 -0.763 . . . . 2.62 110.774 179.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.97 -38.11 78.34 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.711 -0.618 . . . . 0.45 110.288 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.754 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.9 mt -77.15 -32.76 56.52 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 120.208 -0.597 . . . . 1.82 110.519 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.0 mtt180 -58.29 -45.46 87.91 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.305 -0.872 . . . . 2.53 109.845 178.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.03 -46.53 64.87 Favored 'General case' 0 N--CA 1.496 1.857 0 C-N-CA 120.476 -0.489 . . . . 1.68 110.457 -175.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.7 t -60.45 -38.48 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 C-N-CA 120.168 -0.613 . . . . 0.28 109.945 -178.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.56 -17.51 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.803 -0.561 . . . . 0.28 110.876 -177.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.69 35.13 41.54 Favored Glycine 0 N--CA 1.497 2.742 0 N-CA-C 109.768 -1.333 . . . . 0.22 109.768 176.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.898 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.0 mm -93.19 142.33 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.613 -0.934 . . . . 0.77 110.721 -174.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.49 162.17 57.69 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.724 -0.61 . . . . 3.21 110.309 178.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -56.51 138.11 83.16 Favored 'Trans proline' 0 N--CA 1.488 1.18 0 O-C-N 122.817 0.904 . . . . 0.5 111.331 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.16 -2.63 71.83 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 120.696 -0.764 . . . . 0.24 111.24 176.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -96.62 131.9 42.81 Favored 'General case' 0 N--CA 1.499 2.019 0 CA-C-N 118.715 1.258 . . . . 1.11 110.599 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.6 p -92.43 133.45 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 CA-C-O 121.669 0.747 . . . . 0.24 111.244 -173.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.8 pt -124.59 159.49 30.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 109.507 -0.553 . . . . 0.18 109.507 176.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -98.88 132.24 44.37 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.029 -0.73 . . . . 1.14 109.029 175.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.837 ' CG1' HD11 ' A' ' 37' ' ' ILE . 92.8 t -115.9 131.6 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.754 -0.591 . . . . 0.2 110.363 -170.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 33.9 mt -117.94 129.55 55.68 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.5 mt -80.05 142.26 35.09 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.398 -0.814 . . . . 0.28 109.798 171.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.408 HD12 ' HB2' ' A' ' 38' ' ' LYS . 15.6 mt -117.95 -26.72 6.36 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.701 -0.625 . . . . 1.6 111.117 -174.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.78 40.58 Favored Glycine 0 N--CA 1.504 3.195 0 C-N-CA 119.66 -1.257 . . . . 0.2 110.966 -176.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -146.45 150.76 36.24 Favored 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.669 -0.9 . . . . 1.89 110.597 -178.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -135.74 139.06 43.31 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.475 -0.766 . . . . 0.8 110.136 175.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.0 mttt -124.04 157.41 63.84 Favored Pre-proline 0 N--CA 1.494 1.773 0 O-C-N 121.716 -0.615 . . . . 2.99 110.175 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -56.1 144.77 78.77 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 O-C-N 123.22 1.116 . . . . 1.68 110.852 178.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -127.13 139.76 52.74 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.705 -0.622 . . . . 6.87 110.221 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 . . . . . 0 N--CA 1.505 2.312 0 CA-C-O 117.97 -1.014 . . . . 6.47 110.948 -179.98 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mtm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.246 0.545 . . . . 2.76 110.571 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -77.52 141.18 39.75 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.876 -0.515 . . . . 1.7 110.058 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.95 135.85 61.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.71 -0.619 . . . . 0.41 109.612 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 27.8 mt -82.87 -20.79 34.84 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.298 -0.561 . . . . 0.37 110.312 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.858 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.52 153.68 3.56 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.423 -0.798 . . . . 0.26 109.272 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.43 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.1 tttt -134.04 125.98 29.22 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.732 -0.605 . . . . 2.3 110.177 -176.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.611 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.5 p90 -150.61 163.56 38.2 Favored 'General case' 0 N--CA 1.498 1.941 0 C-N-CA 120.052 -0.659 . . . . 0.2 110.957 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.415 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 91.7 m-70 -113.02 138.58 49.67 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.695 -0.628 . . . . 1.99 110.117 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.35 162.31 41.14 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.727 -0.608 . . . . 0.18 109.664 176.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -111.28 159.74 17.66 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 119.873 -0.731 . . . . 0.17 109.983 176.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.895 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.8 t -78.82 134.09 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.803 -0.56 . . . . 0.49 110.2 -177.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -113.77 171.89 7.31 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-O 121.214 0.53 . . . . 0.68 109.751 174.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -46.57 152.82 0.42 Allowed 'General case' 0 N--CA 1.507 2.412 0 O-C-N 121.663 -0.648 . . . . 2.96 111.996 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.77 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.598 -0.689 . . . . 0.42 112.576 -175.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.42 16.11 80.73 Favored Glycine 0 N--CA 1.497 2.764 0 O-C-N 120.906 -1.121 . . . . 0.24 110.332 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -85.57 143.99 28.16 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.231 -1.158 . . . . 1.96 110.418 -175.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.3 pt -133.68 154.49 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.701 -0.624 . . . . 0.3 109.616 172.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.418 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.2 mm -116.84 128.11 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.557 -0.715 . . . . 0.25 110.132 176.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 36.1 mt -80.04 144.86 59.82 Favored Pre-proline 0 N--CA 1.496 1.861 0 C-N-CA 120.026 -0.67 . . . . 0.23 109.415 175.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.37 143.35 88.58 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 122.893 0.944 . . . . 0.35 109.77 174.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.63 -26.49 61.65 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.416 -0.514 . . . . 0.33 110.499 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.47 95.14 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.894 -1.282 . . . . 0.39 109.894 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.2 m -69.97 -38.12 75.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.531 -0.982 . . . . 0.39 110.193 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.707 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.5 mtt180 -55.92 -40.94 73.83 Favored 'General case' 0 N--CA 1.513 2.692 0 O-C-N 121.23 -0.918 . . . . 0.4 109.454 176.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -65.61 -49.98 66.74 Favored 'General case' 0 N--CA 1.495 1.823 0 CA-C-O 121.204 0.526 . . . . 2.97 110.215 -177.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -57.49 -37.72 73.42 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.689 -0.632 . . . . 0.67 110.668 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.953 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.3 t80 -87.67 -14.19 40.57 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.752 -0.593 . . . . 1.44 111.287 -176.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.91 42.87 24.05 Favored Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.587 -1.405 . . . . 0.31 109.587 178.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.912 HG23 HG21 ' A' ' 56' ' ' VAL . 77.1 mt -88.1 129.73 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.068 0 O-C-N 121.552 -0.969 . . . . 0.42 110.615 -176.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -127.9 158.71 37.06 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 109.079 -0.711 . . . . 1.82 109.079 170.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -57.34 137.68 55.79 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.333 -0.854 . . . . 1.99 110.636 -178.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.57 -14.49 65.21 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.9 -0.88 . . . . 0.19 110.9 178.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.19 156.9 33.23 Favored 'General case' 0 N--CA 1.499 1.979 0 CA-C-N 118.857 1.328 . . . . 1.12 110.072 177.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -110.62 138.14 47.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.626 -0.671 . . . . 0.21 109.517 174.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.62 154.27 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.247 -0.649 . . . . 0.15 109.247 174.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.5 123.55 48.83 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.287 -1.005 . . . . 1.09 108.287 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.833 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.09 157.16 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 119.611 -0.835 . . . . 0.14 110.953 -167.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -132.2 145.99 51.72 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.846 -0.534 . . . . 1.11 110.528 177.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.527 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.2 pt -115.3 151.14 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.726 -0.609 . . . . 0.2 110.584 179.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.454 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.51 125.76 27.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.264 0.554 . . . . 0.2 109.882 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.753 ' HB2' HG22 ' A' ' 80' ' ' ILE . 3.3 tptm -130.76 146.49 52.24 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 109.156 -0.683 . . . . 1.98 109.156 174.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -107.89 130.11 55.04 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.263 -0.575 . . . . 0.33 110.471 -178.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -133.91 129.84 36.91 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.658 -0.651 . . . . 1.48 110.138 177.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.23 45.97 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.826 -1.309 . . . . 0.41 109.826 -177.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -105.12 14.62 28.88 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.716 -0.873 . . . . 1.27 111.649 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -131.14 126.69 21.65 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.296 -0.877 . . . . 1.37 111.009 -178.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.23 140.18 24.56 Favored 'Trans proline' 0 N--CA 1.483 0.859 0 O-C-N 122.725 0.855 . . . . 0.34 110.208 174.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.694 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.4 mmtt -114.69 137.73 51.56 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.564 -0.71 . . . . 1.1 109.617 173.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.454 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.4 mt-10 -134.65 164.18 28.09 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.675 -0.641 . . . . 1.42 110.775 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.497 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.78 135.91 4.46 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.484 -1.446 . . . . 0.17 109.484 178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -123.18 137.65 54.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.65 -0.912 . . . . 0.21 109.784 176.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.7 p90 -156.13 172.89 17.66 Favored 'General case' 0 N--CA 1.498 1.932 0 C-N-CA 119.833 -0.747 . . . . 0.16 111.014 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.4 m -107.32 140.74 39.76 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.705 -0.622 . . . . 0.13 109.499 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.7 145.21 34.61 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.14 110.585 -175.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -94.13 144.88 25.11 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.828 -0.545 . . . . 2.21 109.647 175.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.912 HG21 HG23 ' A' ' 29' ' ' ILE . 96.7 t -78.79 126.37 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.833 -0.542 . . . . 0.17 110.015 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.86 -165.95 25.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.123 -1.191 . . . . 0.19 110.123 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -61.68 152.07 31.95 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.771 -0.841 . . . . 1.39 110.201 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 73.7 mt-30 53.35 21.52 2.38 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.572 -0.705 . . . . 0.82 112.062 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.54 20.48 79.84 Favored Glycine 0 N--CA 1.5 2.906 0 C-N-CA 119.777 -1.201 . . . . 0.19 110.866 171.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 13.3 t -78.34 144.67 35.81 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.468 -1.019 . . . . 1.3 110.25 -177.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.701 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.34 146.28 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 N-CA-C 109.55 -0.537 . . . . 0.21 109.55 175.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.9 mm -110.68 122.78 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.609 -0.682 . . . . 0.34 110.566 -174.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.6 mt -78.72 142.61 61.47 Favored Pre-proline 0 N--CA 1.498 1.975 0 O-C-N 121.589 -0.694 . . . . 0.34 109.437 172.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.35 133.93 39.7 Favored 'Trans proline' 0 N--CA 1.495 1.564 0 O-C-N 122.915 0.955 . . . . 0.26 110.763 -179.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -55.28 -34.2 63.88 Favored 'General case' 0 N--CA 1.503 2.185 0 O-C-N 121.508 -0.745 . . . . 2.62 110.832 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.7 76.78 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.783 -0.573 . . . . 0.45 110.334 -178.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.3 mt -77.09 -32.73 56.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.779 -0.575 . . . . 1.82 110.521 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -57.76 -46.13 84.96 Favored 'General case' 0 N--CA 1.503 2.223 0 O-C-N 121.275 -0.891 . . . . 2.53 109.833 178.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -47.2 62.59 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.503 -0.479 . . . . 1.68 110.502 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.2 t -60.48 -38.22 77.32 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.708 -0.62 . . . . 0.28 109.962 -178.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.694 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.2 mt -82.58 -17.76 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.818 -0.551 . . . . 0.28 110.884 -176.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.64 35.11 41.9 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 109.726 -1.35 . . . . 0.22 109.726 176.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.895 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.2 138.94 18.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.535 -0.979 . . . . 0.77 110.591 -174.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.4 mmtt -123.75 161.23 47.53 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.665 -0.647 . . . . 3.21 110.531 -176.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -60.39 135.61 62.52 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 122.951 0.974 . . . . 0.5 110.677 179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.89 -0.48 73.08 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 111.139 -0.784 . . . . 0.24 111.139 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -97.17 132.95 42.44 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.063 -1.257 . . . . 1.11 110.44 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.407 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.2 p -91.78 132.27 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 CA-C-O 121.504 0.668 . . . . 0.24 111.008 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.753 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.7 pt -119.59 159.42 20.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 109.531 -0.544 . . . . 0.18 109.531 176.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.415 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 46.9 tt0 -98.31 130.16 45.0 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.815 -0.809 . . . . 1.14 108.815 173.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.833 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.1 t -115.32 130.22 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 CA-C-O 121.292 0.568 . . . . 0.2 110.27 -170.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.43 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.5 mt -116.71 129.53 56.18 Favored 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 109.136 -0.691 . . . . 0.25 109.136 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.953 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.8 mt -80.15 142.46 34.74 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.3 -0.875 . . . . 0.28 109.694 171.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HA ' HD23 ' A' ' 85' ' ' LEU . 29.6 mt -119.5 -25.66 5.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.668 -0.645 . . . . 1.6 111.183 -174.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.41 -179.22 40.13 Favored Glycine 0 N--CA 1.503 3.16 0 C-N-CA 119.643 -1.265 . . . . 0.2 111.1 -177.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -146.96 152.91 39.41 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.669 -0.901 . . . . 1.89 110.571 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -139.38 144.41 38.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.538 -0.726 . . . . 0.8 110.159 176.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.5 mttm -114.34 154.97 46.35 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.622 -0.674 . . . . 2.99 110.268 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -56.04 142.48 85.56 Favored 'Trans proline' 0 N--CA 1.498 1.747 0 O-C-N 123.299 1.157 . . . . 1.68 110.89 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 -136.08 158.21 44.96 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.754 -0.591 . . . . 6.87 110.435 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 . . . . . 0 N--CA 1.503 2.187 0 CA-C-O 117.992 -1.004 . . . . 6.47 111.013 179.772 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.26 0.552 . . . . 2.76 110.516 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -75.82 149.41 37.89 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.882 -0.511 . . . . 1.7 109.964 178.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -128.01 137.36 57.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.731 -0.606 . . . . 0.41 109.566 178.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.515 HD11 ' HA2' ' A' ' 86' ' ' GLY . 35.3 mt -85.94 -20.12 29.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.781 -0.574 . . . . 0.37 110.523 -178.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.948 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.68 156.16 3.47 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.301 -0.875 . . . . 0.26 109.436 176.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.9 tttt -134.26 124.2 25.51 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.777 -0.577 . . . . 2.3 110.104 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.599 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.6 p90 -150.28 162.61 40.17 Favored 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 120.006 -0.678 . . . . 0.2 111.047 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.41 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 92.5 m-70 -112.39 138.57 48.93 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.582 -0.699 . . . . 1.99 110.074 -177.461 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.0 t -151.47 162.37 41.06 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.65 -0.656 . . . . 0.18 109.741 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -111.42 158.42 19.12 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.857 -0.737 . . . . 0.17 110.072 177.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.6 t -78.95 137.18 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 C-N-CA 120.279 -0.569 . . . . 0.49 110.323 -176.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.2 m80 -116.2 171.91 7.51 Favored 'General case' 0 N--CA 1.492 1.657 0 CA-C-O 121.298 0.57 . . . . 0.68 109.734 174.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.5 ttt85 -46.92 153.02 0.45 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.492 -0.755 . . . . 2.96 111.76 -175.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.9 mt 62.93 6.93 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.684 0 O-C-N 121.507 -0.746 . . . . 0.42 112.636 -174.052 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.67 16.03 80.63 Favored Glycine 0 N--CA 1.496 2.64 0 O-C-N 120.789 -1.194 . . . . 0.24 110.294 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -84.94 144.48 28.31 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.317 -1.108 . . . . 1.96 110.352 -177.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.1 pt -131.79 154.62 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.751 -0.593 . . . . 0.3 109.41 171.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.7 mm -116.5 128.49 73.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.598 -0.689 . . . . 0.25 110.003 176.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.438 HG12 ' CE2' ' A' ' 7' ' ' PHE . 40.1 mt -79.99 145.42 61.24 Favored Pre-proline 0 N--CA 1.496 1.826 0 C-N-CA 119.968 -0.693 . . . . 0.23 109.39 175.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.48 143.42 88.09 Favored 'Trans proline' 0 N--CA 1.489 1.206 0 O-C-N 122.936 0.966 . . . . 0.35 109.706 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.48 61.47 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 120.41 -0.516 . . . . 0.33 110.496 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.61 -44.48 94.98 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.862 -1.295 . . . . 0.39 109.862 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 84.4 m -69.92 -38.11 76.12 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.599 -0.942 . . . . 0.39 110.16 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.2 mtt180 -56.0 -40.74 73.79 Favored 'General case' 0 N--CA 1.513 2.696 0 O-C-N 121.289 -0.882 . . . . 0.4 109.448 176.405 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -65.17 -50.06 67.41 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.086 0.469 . . . . 2.97 110.058 -177.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 81.5 t80 -57.26 -38.77 74.38 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.854 -0.529 . . . . 0.67 110.772 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.907 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.9 t80 -88.42 -14.29 38.37 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.753 -0.592 . . . . 1.44 111.163 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.9 42.59 24.85 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.497 -1.441 . . . . 0.31 109.497 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.918 HG23 HG21 ' A' ' 56' ' ' VAL . 73.2 mt -87.47 125.5 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.429 -1.042 . . . . 0.42 110.455 -177.037 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -128.17 155.35 44.62 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.996 -0.742 . . . . 1.82 108.996 171.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -55.5 140.15 41.43 Favored 'General case' 0 N--CA 1.503 2.179 0 O-C-N 121.289 -0.882 . . . . 1.99 110.576 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.82 -16.19 61.39 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.812 -0.915 . . . . 0.19 110.812 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -77.43 158.33 30.07 Favored 'General case' 0 N--CA 1.499 2.022 0 CA-C-N 118.72 1.26 . . . . 1.12 110.042 177.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -113.18 139.19 48.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.604 -0.685 . . . . 0.21 109.581 174.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.28 154.54 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 109.35 -0.611 . . . . 0.15 109.35 174.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.431 ' HB2' ' CE2' ' A' ' 88' ' ' TYR . 48.9 tt0 -116.0 123.62 48.46 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.219 -1.03 . . . . 1.09 108.219 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.823 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -139.16 157.99 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 C-N-CA 119.588 -0.845 . . . . 0.14 111.213 -167.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.84 143.48 50.21 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.9 -0.5 . . . . 1.11 109.951 178.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.6 HG22 HG22 ' A' ' 82' ' ' VAL . 35.0 pt -114.91 150.99 16.7 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.593 -0.692 . . . . 0.2 110.527 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -138.4 123.19 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 CA-C-O 121.238 0.542 . . . . 0.2 109.721 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.655 ' HB2' HG22 ' A' ' 80' ' ' ILE . 50.2 tttm -130.98 147.1 52.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.191 -0.67 . . . . 1.98 109.191 174.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -102.37 130.97 49.27 Favored 'General case' 0 N--CA 1.496 1.873 0 C-N-CA 119.968 -0.693 . . . . 0.33 110.471 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -132.77 130.45 39.95 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.648 -0.657 . . . . 1.48 109.993 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.85 -128.08 45.68 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 109.79 -1.324 . . . . 0.41 109.79 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -105.14 11.57 33.01 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.733 -0.863 . . . . 1.27 111.653 177.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.0 pt-20 -131.16 136.29 28.55 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.231 -0.918 . . . . 1.37 110.815 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -75.16 141.18 25.89 Favored 'Trans proline' 0 N--CA 1.482 0.845 0 O-C-N 122.855 0.924 . . . . 0.34 110.529 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.672 ' HB3' HG23 ' A' ' 72' ' ' ILE . 19.2 mmtp -111.63 137.73 49.1 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.462 -0.774 . . . . 1.1 109.486 171.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -134.53 164.33 27.72 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.608 -0.682 . . . . 1.42 110.929 -176.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.03 135.78 4.37 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.536 -1.425 . . . . 0.17 109.536 177.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 m -127.55 137.05 52.5 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.793 -0.828 . . . . 0.21 109.791 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.0 p90 -156.57 173.94 16.19 Favored 'General case' 0 N--CA 1.496 1.842 0 C-N-CA 119.883 -0.727 . . . . 0.16 110.916 177.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.4 m -106.94 140.74 39.26 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.407 -0.59 . . . . 0.13 109.407 173.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.1 146.18 36.76 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.608 -0.683 . . . . 0.14 110.69 -175.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -93.35 145.81 24.19 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 109.628 -0.508 . . . . 2.21 109.628 175.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.918 HG21 HG23 ' A' ' 29' ' ' ILE . 88.0 t -78.56 126.01 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.754 -0.591 . . . . 0.17 109.858 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.0 -167.34 26.0 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.982 -1.247 . . . . 0.19 109.982 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.64 153.23 28.57 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.782 -0.834 . . . . 1.39 110.151 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 53.51 21.12 2.34 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.579 -0.7 . . . . 0.82 112.099 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.54 79.89 Favored Glycine 0 N--CA 1.499 2.892 0 C-N-CA 119.716 -1.231 . . . . 0.19 110.921 171.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.465 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -78.28 147.11 34.45 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.445 -1.032 . . . . 1.3 110.262 -177.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.686 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.82 145.99 26.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 109.548 -0.538 . . . . 0.21 109.548 175.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.9 mm -110.73 123.37 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.446 -0.784 . . . . 0.34 110.738 -174.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.3 mt -78.31 144.71 66.99 Favored Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.576 -0.703 . . . . 0.34 109.452 172.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.7 Cg_endo -64.67 135.89 47.23 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 122.929 0.963 . . . . 0.26 110.755 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.03 -34.36 63.44 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.499 -0.75 . . . . 2.62 110.759 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.88 -38.04 77.92 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.757 -0.589 . . . . 0.45 110.317 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.1 mt -77.14 -32.79 56.58 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.734 -0.604 . . . . 1.82 110.475 179.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.09 -45.66 86.82 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.319 -0.863 . . . . 2.53 109.811 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.09 -47.25 62.64 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.515 -0.474 . . . . 1.68 110.463 -175.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.6 t -60.52 -38.34 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.116 0 O-C-N 121.726 -0.609 . . . . 0.28 109.916 -178.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.672 HG23 ' HB3' ' A' ' 48' ' ' LYS . 84.3 mt -82.38 -17.65 11.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.886 -0.509 . . . . 0.28 110.917 -176.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.73 35.21 41.09 Favored Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.697 -1.361 . . . . 0.22 109.697 176.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.39 142.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.564 -0.962 . . . . 0.77 110.707 -173.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.13 159.05 72.19 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.8 -0.562 . . . . 3.21 110.757 -178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -54.57 134.79 63.82 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 122.913 0.954 . . . . 0.5 111.414 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -0.94 72.17 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 120.696 -0.764 . . . . 0.24 111.27 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.401 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 16.9 mt-10 -97.19 133.28 42.04 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.058 -1.26 . . . . 1.11 110.552 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.3 p -92.98 136.35 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 CA-C-O 121.835 0.826 . . . . 0.24 111.389 -174.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.655 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.3 pt -125.89 159.59 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.247 -0.649 . . . . 0.18 109.247 177.259 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.41 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 52.4 tt0 -97.98 131.25 44.58 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 109.046 -0.724 . . . . 1.14 109.046 175.389 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.823 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.3 t -117.06 130.7 71.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 CA-C-O 121.438 0.637 . . . . 0.2 110.391 -170.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.8 mt -117.27 129.82 56.16 Favored 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.194 -0.669 . . . . 0.25 109.194 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.948 HD12 ' HB3' ' A' ' 5' ' ' ALA . 5.6 mt -80.08 140.75 36.33 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.36 -0.838 . . . . 0.28 109.903 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.7 mt -111.5 -30.47 7.37 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.672 -0.642 . . . . 1.6 111.011 -175.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.29 178.62 41.31 Favored Glycine 0 N--CA 1.505 3.254 0 C-N-CA 119.61 -1.281 . . . . 0.2 111.012 -176.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.408 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 30.1 p80 -140.81 145.63 36.55 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.783 -0.834 . . . . 1.89 109.99 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.431 ' CE2' ' HB2' ' A' ' 36' ' ' GLU . 18.3 m-85 -131.32 141.35 49.92 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.665 -0.647 . . . . 0.8 109.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -124.0 156.55 65.72 Favored Pre-proline 0 N--CA 1.495 1.789 0 O-C-N 121.714 -0.616 . . . . 2.99 110.075 178.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -56.01 139.54 85.03 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 O-C-N 123.208 1.11 . . . . 1.68 110.903 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 35.0 ptt-85 -136.12 158.29 44.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.707 -0.621 . . . . 6.87 110.433 179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 58.8 t30 . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 117.979 -1.01 . . . . 6.47 110.244 -179.906 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.6 ttp . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.056 0.455 . . . . 2.76 110.153 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -73.2 143.17 47.28 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.69 -0.631 . . . . 1.7 110.088 179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.6 p -127.71 136.61 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.651 -0.655 . . . . 0.41 109.519 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.568 HD11 ' HA2' ' A' ' 86' ' ' GLY . 28.7 mt -85.18 -18.72 33.24 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.221 -0.592 . . . . 0.37 110.246 178.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.823 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.79 151.83 1.48 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.214 -0.929 . . . . 0.26 109.045 176.042 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 17.5 ttpt -134.63 128.19 32.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.625 -0.672 . . . . 2.3 110.356 -178.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.6 p90 -149.91 162.93 39.37 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.822 -0.549 . . . . 0.2 110.685 -177.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.432 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.1 m170 -112.58 137.63 50.53 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.662 -0.649 . . . . 1.99 110.144 -176.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.37 162.35 41.07 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.724 -0.61 . . . . 0.18 109.636 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.48 157.85 19.15 Favored 'General case' 0 N--CA 1.497 1.91 0 C-N-CA 119.81 -0.756 . . . . 0.17 110.137 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.923 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.3 t -80.13 136.56 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 CA-C-O 121.276 0.56 . . . . 0.49 110.339 -176.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.3 m80 -113.98 171.96 7.28 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.229 0.538 . . . . 0.68 109.672 174.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 73.7 mtt85 -45.99 152.44 0.38 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.558 -0.714 . . . . 2.96 112.127 -175.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.0 mt 62.75 7.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.654 0 O-C-N 121.611 -0.68 . . . . 0.42 112.578 -175.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.48 16.06 80.74 Favored Glycine 0 N--CA 1.497 2.709 0 O-C-N 120.783 -1.198 . . . . 0.24 110.34 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.844 ' NH1' HD11 ' A' ' 18' ' ' ILE . 69.9 ttp85 -85.47 142.63 29.07 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -1.113 . . . . 1.96 110.234 -177.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -133.12 156.54 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.728 -0.607 . . . . 0.3 109.695 174.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.844 HD11 ' NH1' ' A' ' 16' ' ' ARG . 49.1 mm -116.52 129.16 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.65 -0.656 . . . . 0.25 109.957 176.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 28.2 mt -79.69 145.81 63.46 Favored Pre-proline 0 N--CA 1.495 1.814 0 C-N-CA 120.04 -0.664 . . . . 0.23 109.331 175.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.401 ' HD2' HG23 ' A' ' 19' ' ' ILE . 44.6 Cg_endo -62.84 142.74 89.82 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 122.994 0.997 . . . . 0.35 109.848 174.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.78 -27.27 62.93 Favored 'General case' 0 N--CA 1.497 1.885 0 C-N-CA 120.44 -0.504 . . . . 0.33 110.464 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.53 -43.85 95.99 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 109.968 -1.253 . . . . 0.39 109.968 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 98.6 m -69.81 -38.53 76.63 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.559 -0.966 . . . . 0.39 109.958 -179.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.0 mtt180 -56.03 -41.27 74.7 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.252 -0.905 . . . . 0.4 109.39 176.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -65.75 -50.14 65.84 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.111 0.481 . . . . 2.97 110.224 -177.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 82.2 t80 -57.47 -38.3 74.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.788 -0.57 . . . . 0.67 110.683 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.5 t80 -87.36 -14.16 41.49 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.739 -0.601 . . . . 1.44 111.3 -175.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.46 42.78 26.51 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.573 -1.411 . . . . 0.31 109.573 178.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.915 HG23 HG21 ' A' ' 56' ' ' VAL . 77.3 mt -88.38 128.48 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.522 -0.987 . . . . 0.42 110.556 -176.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -128.25 155.44 44.57 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 171.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -55.71 138.72 46.96 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 121.241 -0.912 . . . . 1.99 110.646 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.62 -15.98 62.15 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.868 -0.893 . . . . 0.19 110.868 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -77.16 158.18 30.53 Favored 'General case' 0 N--CA 1.499 1.997 0 CA-C-N 118.677 1.239 . . . . 1.12 110.11 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -112.09 138.94 48.05 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.594 -0.691 . . . . 0.21 109.62 174.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.48 154.11 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 N-CA-C 109.312 -0.625 . . . . 0.15 109.312 173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -115.98 123.57 48.35 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.277 -1.009 . . . . 1.09 108.277 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.811 HD11 ' CG1' ' A' ' 82' ' ' VAL . 7.7 tt -140.08 158.17 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 C-N-CA 119.559 -0.856 . . . . 0.14 111.128 -167.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -133.04 146.1 51.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.799 -0.563 . . . . 1.11 110.418 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.511 HG22 HG22 ' A' ' 82' ' ' VAL . 27.5 pt -114.88 151.1 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.743 -0.598 . . . . 0.2 110.571 178.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.3 t -137.62 128.72 39.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 109.65 -0.5 . . . . 0.2 109.65 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.47 ' HD2' HD12 ' A' ' 74' ' ' ILE . 59.8 tttm -136.82 148.26 47.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.783 -0.573 . . . . 1.98 109.645 177.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -101.0 128.94 46.8 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.703 -0.623 . . . . 0.33 110.491 -178.327 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -133.66 133.18 41.59 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.589 -0.694 . . . . 1.48 110.149 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.79 -128.15 45.92 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.771 -1.332 . . . . 0.41 109.771 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.08 9.83 34.19 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.778 -0.836 . . . . 1.27 111.764 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.15 137.1 29.91 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.229 -0.919 . . . . 1.37 111.155 -177.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -75.57 145.38 29.5 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 O-C-N 122.778 0.883 . . . . 0.34 110.327 173.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.42 ' CD ' ' HA ' ' A' ' 72' ' ' ILE . 30.1 mttp -121.37 149.8 42.42 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.426 -0.796 . . . . 1.1 110.172 171.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.3 mp0 -136.99 166.96 22.43 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 120.22 -0.592 . . . . 1.42 110.995 -177.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.32 135.9 4.51 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.305 -1.518 . . . . 0.17 109.305 175.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.4 m -123.84 138.48 54.49 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.546 -0.973 . . . . 0.21 109.894 178.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.6 p90 -156.62 173.09 17.46 Favored 'General case' 0 N--CA 1.497 1.907 0 C-N-CA 119.868 -0.733 . . . . 0.16 110.986 175.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.2 m -107.37 141.4 38.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.67 -0.644 . . . . 0.13 109.395 173.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.04 145.64 36.15 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.681 -0.637 . . . . 0.14 110.709 -175.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.1 ttt180 -93.51 145.13 24.74 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 109.573 -0.529 . . . . 2.21 109.573 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.915 HG21 HG23 ' A' ' 29' ' ' ILE . 93.0 t -79.06 125.05 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.223 0.535 . . . . 0.17 109.838 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.08 -164.91 24.86 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.135 -1.186 . . . . 0.19 110.135 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 33.4 tp10 -61.67 152.69 30.16 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.819 . . . . 1.39 110.013 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 53.43 21.04 2.23 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.59 -0.694 . . . . 0.82 112.043 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.69 79.96 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 119.732 -1.223 . . . . 0.19 110.842 172.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.418 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.6 p -77.92 147.12 35.17 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.45 -1.029 . . . . 1.3 110.365 -176.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.737 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -139.15 146.55 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.82 -0.55 . . . . 0.21 109.628 175.558 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -111.04 123.1 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.579 -0.701 . . . . 0.34 110.748 -175.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.7 mt -78.57 144.65 65.76 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.614 -0.679 . . . . 0.34 109.535 172.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.6 Cg_endo -64.13 133.27 37.45 Favored 'Trans proline' 0 N--CA 1.494 1.555 0 O-C-N 122.873 0.933 . . . . 0.26 110.767 -179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.2 tttt -55.01 -34.45 63.46 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.551 -0.718 . . . . 2.62 110.831 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -38.22 77.89 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.737 -0.602 . . . . 0.45 110.275 -178.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.8 mt -76.99 -32.8 57.48 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 120.25 -0.58 . . . . 1.82 110.547 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 36.8 mtt180 -57.93 -45.61 86.32 Favored 'General case' 0 N--CA 1.504 2.24 0 O-C-N 121.287 -0.883 . . . . 2.53 109.808 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -69.75 -46.67 65.34 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.479 -0.489 . . . . 1.68 110.307 -174.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 98.8 t -60.72 -39.11 80.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.626 -0.671 . . . . 0.28 109.951 -178.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.559 HG22 HD11 ' A' ' 74' ' ' ILE . 85.7 mt -83.65 -14.42 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.839 -0.538 . . . . 0.28 111.191 -176.146 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.67 35.38 40.87 Favored Glycine 0 N--CA 1.499 2.857 0 N-CA-C 110.169 -1.172 . . . . 0.22 110.169 175.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.923 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.3 mm -88.66 140.56 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.536 -0.979 . . . . 0.77 110.787 -174.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -131.38 162.62 54.88 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.782 -0.574 . . . . 3.21 110.606 -178.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.88 134.82 59.26 Favored 'Trans proline' 0 N--CA 1.487 1.09 0 O-C-N 122.954 0.976 . . . . 0.5 110.858 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.97 0.91 70.84 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 120.639 -0.791 . . . . 0.24 111.234 175.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -96.87 133.7 41.15 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.019 -1.283 . . . . 1.11 110.498 179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.4 p -92.08 133.22 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 CA-C-O 121.584 0.706 . . . . 0.24 111.2 -175.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.43 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.4 pt -123.18 159.5 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 109.499 -0.556 . . . . 0.18 109.499 176.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.432 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 58.8 tt0 -97.35 131.52 43.94 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.986 -0.746 . . . . 1.14 108.986 174.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.811 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.2 t -116.08 128.46 73.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 CA-C-O 121.438 0.637 . . . . 0.2 110.222 -171.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 47.4 mt -115.45 128.75 56.24 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 109.466 -0.568 . . . . 0.25 109.466 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.52 140.8 37.13 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.451 -0.781 . . . . 0.28 109.948 172.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.43 -32.31 6.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.791 -0.568 . . . . 1.6 110.828 -176.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.568 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.19 -177.19 39.19 Favored Glycine 0 N--CA 1.505 3.259 0 C-N-CA 119.706 -1.235 . . . . 0.2 111.025 -176.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.3 p80 -145.17 151.71 38.88 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.708 -0.878 . . . . 1.89 110.792 -177.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -135.8 140.23 44.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.515 -0.741 . . . . 0.8 109.994 175.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.1 pttm -123.42 153.33 65.62 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.691 -0.631 . . . . 2.99 110.589 -179.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.38 152.61 38.55 Favored 'Trans proline' 0 N--CA 1.497 1.702 0 O-C-N 123.314 1.165 . . . . 1.68 110.905 178.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -118.16 142.36 47.52 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.753 -0.592 . . . . 6.87 110.164 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 27.1 m120 . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 118.029 -0.986 . . . . 6.47 110.179 -179.938 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.5 mtt . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.213 0.53 . . . . 2.76 110.404 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.43 139.12 39.62 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.848 -0.533 . . . . 1.7 110.066 178.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 p -128.84 135.79 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.724 -0.61 . . . . 0.41 109.475 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.1 mt -82.56 -20.15 37.13 Favored 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 120.248 -0.581 . . . . 0.37 110.425 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.804 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.94 153.21 3.15 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.415 -0.803 . . . . 0.26 109.289 176.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.437 ' HG3' HD23 ' A' ' 83' ' ' LEU . 24.6 tttt -133.96 125.92 29.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.639 -0.663 . . . . 2.3 110.222 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.614 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.7 p90 -151.2 163.41 38.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.605 -0.684 . . . . 0.2 110.833 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.86 138.61 50.06 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.615 -0.678 . . . . 1.99 110.349 -176.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.61 162.37 41.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.774 -0.578 . . . . 0.18 109.684 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -110.21 158.95 17.82 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.48 -0.763 . . . . 0.17 109.933 176.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.918 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.46 136.39 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.272 -0.571 . . . . 0.49 110.241 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -114.69 171.91 7.35 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.312 0.577 . . . . 0.68 109.831 175.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -46.39 152.97 0.39 Allowed 'General case' 0 N--CA 1.506 2.333 0 O-C-N 121.609 -0.682 . . . . 2.96 112.008 -176.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.5 mt 63.09 7.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.702 0 O-C-N 121.605 -0.684 . . . . 0.42 112.522 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.51 15.98 80.8 Favored Glycine 0 N--CA 1.497 2.729 0 O-C-N 120.899 -1.125 . . . . 0.24 110.312 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -86.02 143.81 27.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.304 -1.115 . . . . 1.96 110.361 -176.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.4 154.67 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.631 -0.668 . . . . 0.3 109.613 172.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.5 mm -116.6 128.79 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.623 -0.673 . . . . 0.25 109.978 176.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 27.3 mt -79.44 145.35 63.48 Favored Pre-proline 0 N--CA 1.495 1.781 0 C-N-CA 120.056 -0.658 . . . . 0.23 109.423 175.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -63.4 143.64 89.03 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 O-C-N 122.96 0.979 . . . . 0.35 109.748 174.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.96 -27.0 60.82 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 120.389 -0.524 . . . . 0.33 110.484 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.39 -44.76 94.89 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.02 -1.232 . . . . 0.39 110.02 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 91.6 m -69.31 -36.64 77.2 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.686 -0.891 . . . . 0.39 110.061 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.612 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.9 mtt180 -56.38 -42.56 78.07 Favored 'General case' 0 N--CA 1.507 2.407 0 O-C-N 121.371 -0.83 . . . . 0.4 109.812 178.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -66.2 -49.97 65.45 Favored 'General case' 0 N--CA 1.498 1.97 0 C-N-CA 120.209 -0.596 . . . . 2.97 110.203 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 74.7 t80 -56.26 -37.93 70.46 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.831 -0.543 . . . . 0.67 110.589 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.91 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -88.34 -14.31 38.52 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.892 -0.505 . . . . 1.44 111.228 -178.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.55 42.82 25.97 Favored Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.609 -1.396 . . . . 0.31 109.609 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.92 HG23 HG21 ' A' ' 56' ' ' VAL . 76.6 mt -87.52 126.95 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.526 -0.985 . . . . 0.42 110.538 -176.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -127.19 158.98 35.65 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 109.126 -0.694 . . . . 1.82 109.126 170.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -57.26 137.53 55.88 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.361 -0.837 . . . . 1.99 110.662 -178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.23 63.84 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.998 -0.841 . . . . 0.19 110.998 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.31 157.11 32.8 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-N 118.674 1.237 . . . . 1.12 110.053 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -111.11 138.39 47.59 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.629 -0.67 . . . . 0.21 109.631 174.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 153.44 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 109.3 -0.63 . . . . 0.15 109.3 174.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -115.06 123.14 48.25 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.3 tt -140.47 159.21 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.688 -0.805 . . . . 0.14 110.882 -167.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.582 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.2 ttpt -133.55 145.99 50.61 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.783 -0.573 . . . . 1.11 110.415 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.604 HG22 HG22 ' A' ' 82' ' ' VAL . 26.0 pt -115.0 151.08 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.575 -0.703 . . . . 0.2 110.385 177.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.642 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.9 t -139.79 124.5 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 C-N-CA 120.499 -0.48 . . . . 0.2 109.806 176.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.698 ' HB2' HG22 ' A' ' 80' ' ' ILE . 22.0 ttpp -131.21 144.68 51.52 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.735 -0.603 . . . . 1.98 109.381 176.214 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 45.0 t80 -104.96 129.4 53.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.654 -0.654 . . . . 0.33 110.335 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -133.95 130.37 37.59 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.717 -0.614 . . . . 1.48 110.144 177.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.18 45.98 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.796 -1.322 . . . . 0.41 109.796 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -105.09 14.14 29.69 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.769 -0.842 . . . . 1.27 111.644 178.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -131.17 125.6 21.09 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.239 -0.913 . . . . 1.37 111.081 -177.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.28 135.82 19.06 Favored 'Trans proline' 0 N--CA 1.482 0.85 0 O-C-N 122.796 0.893 . . . . 0.34 110.097 173.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.681 ' HB3' HG23 ' A' ' 72' ' ' ILE . 25.1 mmtt -111.59 137.37 49.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.593 -0.692 . . . . 1.1 109.666 173.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.642 ' HG2' HG13 ' A' ' 40' ' ' VAL . 48.7 mt-10 -135.17 165.3 25.72 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.645 -0.659 . . . . 1.42 110.71 -176.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.551 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.71 135.68 4.35 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.406 -1.478 . . . . 0.17 109.406 176.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.582 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.9 m -123.55 136.66 54.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.782 -0.834 . . . . 0.21 109.779 176.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.822 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 10.8 p90 -156.05 173.53 16.68 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 119.942 -0.703 . . . . 0.16 111.079 178.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -107.22 140.71 39.67 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.615 -0.678 . . . . 0.13 109.472 173.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.822 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.63 146.08 35.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.656 -0.653 . . . . 0.14 110.655 -175.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.4 ttp-105 -93.63 144.78 25.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.79 -0.569 . . . . 2.21 109.647 175.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.92 HG21 HG23 ' A' ' 29' ' ' ILE . 90.2 t -79.03 127.28 39.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.794 -0.566 . . . . 0.17 109.95 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.72 -171.37 26.61 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.841 -1.304 . . . . 0.19 109.841 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 -61.85 156.61 20.24 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.636 -0.92 . . . . 1.39 109.893 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 55.07 19.06 2.59 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.441 -0.787 . . . . 0.82 112.075 -177.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.64 20.49 79.62 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.831 -1.176 . . . . 0.19 110.695 172.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 13.4 t -78.75 144.87 34.8 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.423 -1.046 . . . . 1.3 110.333 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.623 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -137.73 146.15 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 N-CA-C 109.555 -0.535 . . . . 0.21 109.555 175.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.1 mm -110.86 123.69 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.53 -0.731 . . . . 0.34 110.714 -174.005 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.413 HG23 ' HD2' ' A' ' 65' ' ' PRO . 68.2 mt -78.66 143.29 62.81 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.585 -0.697 . . . . 0.34 109.455 172.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.759 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.4 Cg_endo -65.02 137.11 51.2 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 O-C-N 122.959 0.979 . . . . 0.26 110.817 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 17.1 tptp -54.84 -34.79 63.27 Favored 'General case' 0 N--CA 1.504 2.246 0 O-C-N 121.446 -0.784 . . . . 2.62 110.781 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.86 -38.35 78.56 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.792 -0.568 . . . . 0.45 110.363 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.759 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.3 mt -77.2 -32.73 56.19 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 120.15 -0.62 . . . . 1.82 110.683 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -58.31 -45.55 87.81 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.347 -0.846 . . . . 2.53 109.831 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -70.32 -48.19 57.69 Favored 'General case' 0 N--CA 1.495 1.822 0 C-N-CA 120.519 -0.472 . . . . 1.68 110.421 -176.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.5 t -60.53 -38.02 76.84 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 121.732 -0.605 . . . . 0.28 109.938 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.681 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.3 mt -82.52 -17.8 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.844 -0.535 . . . . 0.28 110.947 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.45 35.17 42.72 Favored Glycine 0 N--CA 1.497 2.721 0 N-CA-C 109.7 -1.36 . . . . 0.22 109.7 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.918 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.1 mm -91.13 142.01 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.514 -0.992 . . . . 0.77 110.695 -174.305 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 44.9 mttt -130.88 162.34 55.97 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.699 -0.626 . . . . 3.21 110.663 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.93 135.58 64.07 Favored 'Trans proline' 0 N--CA 1.487 1.108 0 O-C-N 123.037 1.019 . . . . 0.5 110.818 -179.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.16 -0.16 71.77 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 120.686 -0.769 . . . . 0.24 111.246 176.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -95.37 131.12 41.83 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.055 -1.262 . . . . 1.11 110.377 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.5 p -91.66 135.87 25.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 CA-C-O 121.762 0.792 . . . . 0.24 111.106 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.698 HG22 ' HB2' ' A' ' 41' ' ' LYS . 42.0 pt -126.53 159.43 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 109.477 -0.564 . . . . 0.18 109.477 179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.5 tt0 -98.61 128.18 44.82 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.751 -0.833 . . . . 1.14 108.751 174.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 85.5 t -113.28 128.98 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 CA-C-O 121.341 0.591 . . . . 0.2 110.148 -171.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 6' ' ' LYS . 31.8 mt -116.75 127.35 54.28 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.02 -0.733 . . . . 0.25 109.02 -179.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.91 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.4 mt -79.98 140.9 36.43 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.363 -0.835 . . . . 0.28 109.757 172.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 mt -113.9 -30.13 6.83 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.658 -0.651 . . . . 1.6 110.966 -174.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -167.93 -177.93 39.54 Favored Glycine 0 N--CA 1.503 3.117 0 C-N-CA 119.709 -1.234 . . . . 0.2 111.008 -177.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 25.5 p80 -145.09 153.53 41.53 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.729 -0.865 . . . . 1.89 110.694 -177.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -139.23 144.54 38.49 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.6 -0.687 . . . . 0.8 110.162 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 11.2 ttmt -118.21 151.0 48.68 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 121.682 -0.636 . . . . 2.99 110.28 178.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -56.04 143.1 84.57 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 O-C-N 123.143 1.075 . . . . 1.68 110.885 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 44.1 ptt85 -136.08 159.05 42.91 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.725 -0.61 . . . . 6.87 110.419 178.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 42.8 t-20 . . . . . 0 N--CA 1.495 1.818 0 CA-C-O 117.981 -1.009 . . . . 6.47 110.152 179.832 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.3 mtm . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.16 0.505 . . . . 2.76 110.564 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -74.61 141.47 44.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.894 -0.504 . . . . 1.7 110.096 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.43 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p -129.0 134.2 64.64 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.702 -0.624 . . . . 0.41 109.556 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.603 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.4 mt -82.08 -20.77 37.51 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.25 -0.58 . . . . 0.37 110.252 179.178 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.784 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.17 153.42 3.69 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -0.835 . . . . 0.26 109.245 176.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.6 tttt -133.55 125.72 29.46 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.741 -0.6 . . . . 2.3 110.173 -176.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.61 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.23 162.87 39.64 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.555 -0.716 . . . . 0.2 110.94 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.417 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 95.5 m-70 -112.83 137.73 50.72 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.718 -0.614 . . . . 1.99 110.172 -176.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.1 162.3 41.12 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.729 -0.607 . . . . 0.18 109.582 176.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -110.11 159.77 17.05 Favored 'General case' 0 N--CA 1.498 1.972 0 C-N-CA 119.736 -0.786 . . . . 0.17 110.075 177.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.908 HG21 HG21 ' A' ' 74' ' ' ILE . 60.5 t -78.74 136.24 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 C-N-CA 120.3 -0.56 . . . . 0.49 110.233 -177.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -115.44 171.88 7.44 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.22 0.533 . . . . 0.68 109.589 174.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 69.8 mtp85 -46.27 152.54 0.41 Allowed 'General case' 0 N--CA 1.506 2.359 0 O-C-N 121.573 -0.704 . . . . 2.96 112.067 -175.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.591 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.7 mt 62.41 7.99 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.665 0 O-C-N 121.656 -0.653 . . . . 0.42 112.631 -176.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.9 16.18 80.27 Favored Glycine 0 N--CA 1.497 2.717 0 O-C-N 120.832 -1.168 . . . . 0.24 110.446 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -84.45 143.27 29.51 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.314 -1.11 . . . . 1.96 110.33 -176.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -134.51 154.95 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.672 -0.642 . . . . 0.3 109.545 172.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.7 mm -117.46 128.44 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.586 -0.696 . . . . 0.25 109.936 175.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.434 HG12 ' CE2' ' A' ' 7' ' ' PHE . 35.6 mt -79.79 144.04 59.4 Favored Pre-proline 0 N--CA 1.495 1.786 0 C-N-CA 120.075 -0.65 . . . . 0.23 109.407 176.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.37 143.5 88.91 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.004 1.002 . . . . 0.35 109.729 174.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.51 -26.49 61.41 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.858 -0.526 . . . . 0.33 110.527 -178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.58 -44.37 95.17 Favored Glycine 0 N--CA 1.497 2.722 0 N-CA-C 109.935 -1.266 . . . . 0.39 109.935 -179.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 75.0 m -69.97 -38.2 76.02 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.58 -0.953 . . . . 0.39 110.18 -179.41 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.667 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.6 mtt180 -55.95 -41.11 74.21 Favored 'General case' 0 N--CA 1.513 2.703 0 O-C-N 121.349 -0.844 . . . . 0.4 109.413 176.468 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.2 tttp -65.56 -49.95 66.96 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-O 121.145 0.498 . . . . 2.97 110.197 -177.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -57.14 -38.34 73.38 Favored 'General case' 0 N--CA 1.503 2.178 0 O-C-N 121.769 -0.582 . . . . 0.67 110.735 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.957 ' CD2' HD13 ' A' ' 84' ' ' LEU . 20.7 t80 -88.12 -14.25 39.24 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.779 -0.575 . . . . 1.44 111.291 -176.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.81 42.69 25.05 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.484 -1.447 . . . . 0.31 109.484 178.264 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.864 HG23 HG21 ' A' ' 56' ' ' VAL . 73.6 mt -87.49 129.17 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.492 -1.005 . . . . 0.42 110.437 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.08 154.65 45.46 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.962 -0.755 . . . . 1.82 108.962 172.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -55.21 139.67 41.37 Favored 'General case' 0 N--CA 1.504 2.231 0 O-C-N 121.288 -0.882 . . . . 1.99 110.691 -177.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.86 -15.98 61.88 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.936 -0.866 . . . . 0.19 110.936 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -76.21 156.73 33.35 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.097 -1.237 . . . . 1.12 110.069 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -110.18 138.59 46.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.638 -0.664 . . . . 0.21 109.595 174.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.3 m -130.32 154.79 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 109.271 -0.64 . . . . 0.15 109.271 174.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -116.09 123.37 47.74 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.207 -1.034 . . . . 1.09 108.207 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.6 tt -139.45 158.25 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 C-N-CA 119.661 -0.816 . . . . 0.14 110.95 -167.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HB2' HG23 ' A' ' 51' ' ' THR . 82.4 tttt -132.7 145.86 51.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.867 -0.521 . . . . 1.11 110.386 178.008 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 34.1 pt -114.94 150.97 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.667 -0.645 . . . . 0.2 110.568 177.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.7 t -139.27 126.0 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 CA-C-O 121.231 0.539 . . . . 0.2 109.778 176.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.705 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.5 tptp -136.26 148.79 48.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.812 -0.555 . . . . 1.98 109.511 176.006 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -100.63 129.0 46.49 Favored 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 120.19 -0.604 . . . . 0.33 110.251 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.503 ' OE2' HD13 ' A' ' 74' ' ' ILE . 93.1 mt-10 -135.08 135.09 40.97 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.635 -0.666 . . . . 1.48 110.011 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.15 45.9 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.741 -1.344 . . . . 0.41 109.741 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.1 pt-20 -105.13 7.73 33.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.748 -0.854 . . . . 1.27 111.806 178.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.3 pt-20 -131.17 141.47 42.02 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.129 -0.982 . . . . 1.37 111.004 -177.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -75.4 139.75 23.63 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 O-C-N 123.037 1.02 . . . . 0.34 110.566 175.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HB3' HG23 ' A' ' 72' ' ' ILE . 73.9 mmtt -114.47 136.89 52.51 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.545 -0.722 . . . . 1.1 109.496 171.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -137.5 168.92 18.69 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.603 -0.686 . . . . 1.42 110.713 -178.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.417 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -160.22 135.95 4.31 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.592 -1.403 . . . . 0.17 109.592 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.409 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.4 m -121.55 137.49 54.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.755 -0.85 . . . . 0.21 109.721 177.423 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.8 p90 -155.78 173.02 17.36 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 119.911 -0.716 . . . . 0.16 110.965 176.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.4 m -107.44 140.82 39.81 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.71 -0.619 . . . . 0.13 109.586 174.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.66 145.12 34.56 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.614 -0.679 . . . . 0.14 110.552 -176.25 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.2 ttp-105 -93.4 145.31 24.58 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.773 -0.58 . . . . 2.21 109.679 175.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.864 HG21 HG23 ' A' ' 29' ' ' ILE . 94.7 t -79.11 126.13 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.847 -0.533 . . . . 0.17 109.975 -179.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.45 -170.7 26.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.79 -1.324 . . . . 0.19 109.79 177.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -61.88 156.03 21.83 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.61 -0.935 . . . . 1.39 109.905 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 54.91 19.44 2.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.611 -0.68 . . . . 0.82 112.084 -177.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.68 20.5 79.67 Favored Glycine 0 N--CA 1.499 2.838 0 C-N-CA 119.821 -1.18 . . . . 0.19 110.783 172.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 54.1 p -77.97 145.7 35.88 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.451 -1.029 . . . . 1.3 110.534 -175.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.81 146.2 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.875 -0.515 . . . . 0.21 109.628 174.497 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.62 123.61 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.499 -0.75 . . . . 0.34 110.653 -175.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.445 HG23 ' HD2' ' A' ' 65' ' ' PRO . 72.9 mt -78.3 144.15 65.97 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.679 -0.638 . . . . 0.34 109.652 174.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.41 134.35 41.33 Favored 'Trans proline' 0 N--CA 1.495 1.586 0 O-C-N 123.002 1.001 . . . . 0.26 110.808 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 70.0 tttt -55.19 -34.29 63.76 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.532 -0.73 . . . . 2.62 110.847 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.78 -37.69 76.87 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.74 -0.6 . . . . 0.45 110.324 -178.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.4 mt -77.18 -32.79 56.34 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.723 -0.61 . . . . 1.82 110.544 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -57.82 -45.73 85.72 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.282 -0.886 . . . . 2.53 109.911 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.27 -47.22 62.26 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 120.44 -0.504 . . . . 1.68 110.465 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.4 t -60.56 -38.12 77.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.712 -0.618 . . . . 0.28 109.987 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.695 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.9 mt -82.31 -18.06 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.849 -0.532 . . . . 0.28 110.788 -176.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.28 40.7 Favored Glycine 0 N--CA 1.497 2.763 0 N-CA-C 109.684 -1.366 . . . . 0.22 109.684 176.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.908 HG21 HG21 ' A' ' 11' ' ' VAL . 50.9 mm -90.89 144.58 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.53 -0.982 . . . . 0.77 110.613 -174.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.04 159.31 73.19 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.743 -0.598 . . . . 3.21 110.906 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -52.8 134.79 55.67 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 O-C-N 123.067 1.035 . . . . 0.5 111.688 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 93.07 -0.63 69.38 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.66 -0.781 . . . . 0.24 111.331 175.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.65 129.0 40.1 Favored 'General case' 0 N--CA 1.501 2.083 0 CA-C-N 118.724 1.262 . . . . 1.11 110.173 178.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 79' ' ' VAL . 10.7 p -91.15 128.51 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 121.4 0.619 . . . . 0.24 110.606 -175.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.705 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -118.79 159.56 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 109.639 -0.504 . . . . 0.18 109.639 179.267 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.417 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.3 tt0 -97.6 130.13 44.66 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.938 -0.764 . . . . 1.14 108.938 174.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 87.4 t -115.48 129.2 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-O 121.373 0.606 . . . . 0.2 110.257 -171.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.9 mt -116.38 129.08 56.05 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 109.204 -0.665 . . . . 0.25 109.204 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.957 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -79.8 139.66 37.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.342 -0.849 . . . . 0.28 109.791 172.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -109.34 -33.45 6.83 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.767 -0.583 . . . . 1.6 110.927 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.603 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.22 -175.2 37.69 Favored Glycine 0 N--CA 1.504 3.184 0 C-N-CA 119.674 -1.251 . . . . 0.2 111.031 -176.122 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.1 p80 -143.79 153.91 42.88 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.759 -0.847 . . . . 1.89 110.719 -177.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -137.92 139.43 39.8 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.537 -0.727 . . . . 0.8 110.236 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 5.4 pttm -81.72 152.53 69.51 Favored Pre-proline 0 N--CA 1.496 1.875 0 O-C-N 121.715 -0.615 . . . . 2.99 110.313 178.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_exo -55.82 143.53 80.79 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 O-C-N 123.227 1.119 . . . . 1.68 110.933 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 28.2 ptt180 -136.14 158.37 44.57 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.708 -0.62 . . . . 6.87 110.426 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 117.981 -1.009 . . . . 6.47 110.178 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.4 mtp . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.137 0.494 . . . . 2.76 110.613 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -74.12 142.67 45.55 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.915 -0.49 . . . . 1.7 110.082 178.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.45 HG23 ' HB3' ' A' ' 83' ' ' LEU . 2.6 p -129.11 133.76 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.766 -0.584 . . . . 0.41 109.588 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.8 mt -80.96 -21.49 40.32 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.269 -0.572 . . . . 0.37 110.189 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.862 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.11 152.18 3.4 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.442 -0.786 . . . . 0.26 109.127 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.441 ' HE3' HD21 ' A' ' 83' ' ' LEU . 67.2 tttt -132.61 125.18 29.82 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.702 -0.624 . . . . 2.3 110.214 -176.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.0 p90 -150.21 162.76 39.84 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.072 -0.651 . . . . 0.2 110.989 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.412 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 96.2 m-70 -112.52 138.23 49.58 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.626 -0.671 . . . . 1.99 110.154 -176.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.06 162.26 41.18 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.696 -0.628 . . . . 0.18 109.627 176.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.62 158.78 18.2 Favored 'General case' 0 N--CA 1.498 1.939 0 C-N-CA 119.818 -0.753 . . . . 0.17 110.136 177.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.3 t -79.24 134.89 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 C-N-CA 120.257 -0.577 . . . . 0.49 110.245 -177.089 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.28 171.89 7.34 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-O 121.277 0.561 . . . . 0.68 109.647 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -47.16 152.99 0.5 Allowed 'General case' 0 N--CA 1.505 2.304 0 O-C-N 121.579 -0.701 . . . . 2.96 111.776 -175.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.7 mt 62.65 7.37 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.652 0 O-C-N 121.46 -0.775 . . . . 0.42 112.681 -174.48 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.57 16.1 80.63 Favored Glycine 0 N--CA 1.497 2.747 0 O-C-N 120.935 -1.103 . . . . 0.24 110.363 179.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -84.64 142.84 29.63 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.248 -1.148 . . . . 1.96 110.391 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -133.57 155.22 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.721 -0.612 . . . . 0.3 109.39 172.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.6 mm -116.56 128.45 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.579 -0.701 . . . . 0.25 109.977 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 37.4 mt -79.99 144.32 59.04 Favored Pre-proline 0 N--CA 1.495 1.792 0 C-N-CA 120.015 -0.674 . . . . 0.23 109.422 175.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -63.54 143.46 87.8 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 122.943 0.97 . . . . 0.35 109.751 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.4 -26.75 61.57 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 120.44 -0.504 . . . . 0.33 110.481 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.51 -44.17 95.56 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.954 -1.258 . . . . 0.39 109.954 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 87.7 m -69.87 -38.43 76.39 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.562 -0.964 . . . . 0.39 110.148 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.704 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.9 mtt180 -56.03 -40.58 73.66 Favored 'General case' 0 N--CA 1.513 2.689 0 O-C-N 121.29 -0.881 . . . . 0.4 109.386 176.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -65.64 -50.01 66.56 Favored 'General case' 0 N--CA 1.495 1.808 0 CA-C-O 121.043 0.449 . . . . 2.97 110.213 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -57.74 -38.85 76.07 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.751 -0.593 . . . . 0.67 110.683 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.96 ' CD2' HD13 ' A' ' 84' ' ' LEU . 26.7 t80 -86.74 -14.17 43.17 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.804 -0.56 . . . . 1.44 111.346 -176.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 43.14 23.45 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 109.603 -1.399 . . . . 0.31 109.603 178.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.895 HG23 HG21 ' A' ' 56' ' ' VAL . 76.9 mt -87.73 128.79 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.046 0 O-C-N 121.523 -0.986 . . . . 0.42 110.537 -177.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -128.1 153.97 46.24 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.868 -0.79 . . . . 1.82 108.868 170.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -55.27 140.39 39.33 Favored 'General case' 0 N--CA 1.504 2.241 0 O-C-N 121.238 -0.913 . . . . 1.99 110.626 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.8 -16.03 61.74 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.859 -0.896 . . . . 0.19 110.859 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.91 157.54 31.3 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.67 1.235 . . . . 1.12 110.115 178.186 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -111.71 138.92 47.64 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.622 -0.674 . . . . 0.21 109.557 174.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.55 155.12 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 C-N-CA 120.224 -0.59 . . . . 0.15 109.454 174.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.92 123.6 48.49 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.364 -0.976 . . . . 1.09 108.364 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.4 tt -139.96 156.01 24.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.682 -0.807 . . . . 0.14 110.95 -167.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -131.13 146.07 52.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.747 -0.596 . . . . 1.11 110.55 177.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 82' ' ' VAL . 29.6 pt -114.94 151.08 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.02 0 O-C-N 121.731 -0.605 . . . . 0.2 110.699 178.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.463 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.6 t -138.23 126.58 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.152 0.501 . . . . 0.2 109.734 175.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.703 ' HB2' HG22 ' A' ' 80' ' ' ILE . 32.1 tptt -136.69 146.89 46.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.741 -0.6 . . . . 1.98 109.602 175.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -105.96 130.98 53.79 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.231 -0.587 . . . . 0.33 110.427 -177.275 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -136.59 135.35 38.31 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.677 -0.639 . . . . 1.48 110.145 176.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.8 -128.24 46.09 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.833 -1.307 . . . . 0.41 109.833 -178.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -105.14 9.81 34.07 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.819 -0.812 . . . . 1.27 111.878 179.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -131.15 135.36 27.09 Favored Pre-proline 0 N--CA 1.499 2.001 0 O-C-N 121.189 -0.945 . . . . 1.37 111.076 -177.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.36 146.52 31.51 Favored 'Trans proline' 0 N--CA 1.482 0.801 0 O-C-N 122.811 0.901 . . . . 0.34 110.159 173.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.75 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.0 mmtt -120.48 138.17 53.96 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.545 -0.722 . . . . 1.1 109.564 172.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.463 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.7 mt-10 -134.57 163.41 29.79 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.635 -0.665 . . . . 1.42 110.718 -176.807 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.425 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.91 135.89 4.43 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.618 -1.393 . . . . 0.17 109.618 178.371 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.3 m -122.17 137.45 54.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.715 -0.873 . . . . 0.21 109.75 176.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.5 p90 -155.55 172.77 17.7 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.972 -0.691 . . . . 0.16 111.036 176.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.7 m -106.9 141.03 38.77 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.691 -0.63 . . . . 0.13 109.464 173.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.31 145.4 35.42 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.564 -0.71 . . . . 0.14 110.58 -176.048 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.2 ttt180 -92.96 144.79 24.91 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.809 -0.557 . . . . 2.21 109.605 175.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.895 HG21 HG23 ' A' ' 29' ' ' ILE . 96.1 t -79.14 125.23 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-O 121.332 0.587 . . . . 0.17 109.79 179.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.68 -167.31 26.34 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.939 -1.264 . . . . 0.19 109.939 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.6 153.45 27.78 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.724 -0.868 . . . . 1.39 110.101 179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.6 mt-30 53.64 21.03 2.39 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.54 -0.725 . . . . 0.82 112.061 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.07 20.58 79.68 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.784 -1.198 . . . . 0.19 110.793 171.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 17.2 m -77.88 144.92 36.54 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.488 -1.007 . . . . 1.3 110.375 -176.311 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.722 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -138.43 144.96 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.553 -0.536 . . . . 0.21 109.553 174.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.0 mm -111.65 123.33 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.49 -0.756 . . . . 0.34 110.641 -175.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.449 HG23 ' HD2' ' A' ' 65' ' ' PRO . 54.7 mt -78.44 144.43 65.93 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.643 -0.661 . . . . 0.34 109.518 173.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.746 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.8 Cg_endo -64.21 133.63 38.77 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.934 0.965 . . . . 0.26 110.764 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -55.08 -34.23 63.46 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.443 -0.786 . . . . 2.62 110.866 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.76 -38.09 77.71 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.745 -0.597 . . . . 0.45 110.329 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.746 HD12 ' CG ' ' A' ' 65' ' ' PRO . 71.0 mt -77.15 -32.67 56.45 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 120.259 -0.576 . . . . 1.82 110.552 178.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.88 -46.03 85.49 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.3 -0.875 . . . . 2.53 109.897 178.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -70.16 -46.79 63.95 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 120.456 -0.498 . . . . 1.68 110.473 -175.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 95.5 t -60.38 -38.45 77.77 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.678 -0.639 . . . . 0.28 109.865 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.75 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.5 mt -82.53 -17.99 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.844 -0.535 . . . . 0.28 110.822 -176.535 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.25 35.11 38.88 Favored Glycine 0 N--CA 1.498 2.78 0 N-CA-C 109.665 -1.374 . . . . 0.22 109.665 176.07 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.65 142.54 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.035 0 O-C-N 121.619 -0.93 . . . . 0.77 110.581 -175.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.9 mtpt -129.64 162.11 55.14 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.674 -0.641 . . . . 3.21 110.807 -177.109 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.91 135.32 62.41 Favored 'Trans proline' 0 N--CA 1.488 1.159 0 O-C-N 123.063 1.033 . . . . 0.5 110.835 -179.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.9 -0.05 72.44 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 120.591 -0.814 . . . . 0.24 111.235 176.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -96.18 131.61 42.47 Favored 'General case' 0 N--CA 1.498 1.939 0 CA-C-N 118.715 1.257 . . . . 1.11 110.445 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' H ' ' A' ' 79' ' ' VAL . 11.0 p -91.87 130.1 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 CA-C-O 121.511 0.672 . . . . 0.24 110.837 -174.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.703 HG22 ' HB2' ' A' ' 41' ' ' LYS . 47.3 pt -118.72 159.51 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 109.591 -0.522 . . . . 0.18 109.591 177.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.412 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 35.5 tt0 -97.01 130.69 44.3 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.026 -0.731 . . . . 1.14 109.026 174.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.6 t -115.85 128.9 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.366 0.603 . . . . 0.2 110.241 -171.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.45 ' HB3' HG23 ' A' ' 3' ' ' VAL . 41.7 mt -116.31 128.75 55.83 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.324 -0.621 . . . . 0.25 109.324 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.96 HD13 ' CD2' ' A' ' 27' ' ' TYR . 6.0 mt -79.65 142.51 35.49 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.402 -0.811 . . . . 0.28 109.808 171.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 85' ' ' LEU . 43.7 mt -120.65 -24.95 5.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.652 -0.655 . . . . 1.6 111.206 -174.076 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -167.28 -179.92 40.49 Favored Glycine 0 N--CA 1.505 3.28 0 C-N-CA 119.642 -1.266 . . . . 0.2 111.066 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.6 p80 -146.95 152.62 38.94 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.745 -0.856 . . . . 1.89 110.685 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -138.28 142.92 39.82 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.582 -0.699 . . . . 0.8 110.07 175.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.3 mmtt -120.87 154.53 57.66 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.663 -0.648 . . . . 2.99 110.224 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -55.96 142.33 85.08 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 O-C-N 123.162 1.085 . . . . 1.68 110.934 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 74.9 mtt85 -126.29 147.64 49.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.755 -0.591 . . . . 6.87 110.198 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 31.7 t30 . . . . . 0 N--CA 1.494 1.771 0 CA-C-O 117.991 -1.004 . . . . 6.47 110.153 -179.936 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.8 ttm . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 121.01 0.433 . . . . 2.76 110.173 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -78.03 145.29 36.0 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.806 -0.558 . . . . 1.7 110.131 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -127.77 138.03 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.695 -0.628 . . . . 0.41 109.719 178.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.59 HD11 ' HA2' ' A' ' 86' ' ' GLY . 32.3 mt -86.61 -18.44 31.39 Favored 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 120.262 -0.575 . . . . 0.37 110.547 -179.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.859 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.79 153.74 3.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.357 -0.839 . . . . 0.26 109.299 175.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -133.77 125.42 28.46 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.703 -0.623 . . . . 2.3 110.079 -177.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.3 p90 -150.68 162.09 41.35 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.603 -0.686 . . . . 0.2 110.869 -179.322 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.7 m80 -112.78 138.84 49.01 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.661 -0.649 . . . . 1.99 110.161 -176.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.9 162.29 41.07 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.728 -0.607 . . . . 0.18 109.59 178.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -111.0 158.68 18.51 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.417 -0.802 . . . . 0.17 110.044 177.152 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.906 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -79.16 136.29 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 C-N-CA 120.295 -0.562 . . . . 0.49 110.343 -176.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -115.25 171.94 7.38 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.42 0.629 . . . . 0.68 109.796 175.043 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 -46.52 153.04 0.4 Allowed 'General case' 0 N--CA 1.505 2.31 0 O-C-N 121.536 -0.728 . . . . 2.96 111.981 -175.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.583 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.8 mt 62.89 7.45 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.671 0 O-C-N 121.569 -0.707 . . . . 0.42 112.567 -175.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.73 15.99 80.63 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.344 -1.102 . . . . 0.24 110.344 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -85.5 144.0 28.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.235 -1.156 . . . . 1.96 110.429 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -132.67 154.95 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.748 -0.595 . . . . 0.3 109.46 172.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.435 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -117.11 128.76 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 C-N-CA 120.073 -0.651 . . . . 0.25 110.065 176.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -80.08 145.21 60.39 Favored Pre-proline 0 N--CA 1.496 1.828 0 C-N-CA 120.062 -0.655 . . . . 0.23 109.406 175.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.34 143.73 89.59 Favored 'Trans proline' 0 N--CA 1.489 1.216 0 O-C-N 123.024 1.013 . . . . 0.35 109.755 174.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.55 -26.41 61.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.87 -0.519 . . . . 0.33 110.471 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.74 -44.22 95.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 110.026 -1.23 . . . . 0.39 110.026 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 78.5 m -69.85 -38.21 76.41 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.964 . . . . 0.39 110.124 -179.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.613 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.4 mtt180 -56.3 -41.65 76.28 Favored 'General case' 0 N--CA 1.513 2.713 0 O-C-N 121.276 -0.89 . . . . 0.4 109.377 176.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -65.9 -50.09 65.7 Favored 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.14 0.495 . . . . 2.97 110.221 -177.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.27 -37.79 72.91 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.732 -0.605 . . . . 0.67 110.633 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.5 t80 -88.06 -14.15 39.65 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.805 -0.559 . . . . 1.44 111.229 -175.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.33 42.49 27.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.563 -1.415 . . . . 0.31 109.563 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.869 HG23 HG21 ' A' ' 56' ' ' VAL . 78.3 mt -89.62 131.14 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.453 -1.027 . . . . 0.42 110.645 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.27 158.94 36.78 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.091 -0.707 . . . . 1.82 109.091 171.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -57.47 139.45 53.23 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.38 -0.825 . . . . 1.99 110.513 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.74 -15.25 63.49 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.887 -0.885 . . . . 0.19 110.887 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.12 158.16 32.07 Favored 'General case' 0 N--CA 1.501 2.123 0 CA-C-N 118.724 1.262 . . . . 1.12 109.932 178.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -110.53 138.16 47.28 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.591 -0.693 . . . . 0.21 109.588 175.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.35 154.16 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 109.13 -0.693 . . . . 0.15 109.13 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -116.05 123.8 48.84 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.317 -0.994 . . . . 1.09 108.317 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.8 tt -140.51 158.13 24.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 119.635 -0.826 . . . . 0.14 110.961 -167.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.3 ttpt -132.29 146.11 51.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.837 -0.539 . . . . 1.11 110.386 177.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 82' ' ' VAL . 23.2 pt -114.88 150.98 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.667 -0.646 . . . . 0.2 110.278 176.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.524 HG13 ' HG2' ' A' ' 49' ' ' GLU . 59.4 t -139.53 123.64 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 CA-C-O 121.251 0.548 . . . . 0.2 109.729 177.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.676 ' HB2' HG22 ' A' ' 80' ' ' ILE . 53.2 tttm -132.92 147.5 52.29 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.248 -0.649 . . . . 1.98 109.248 176.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -101.18 130.92 47.35 Favored 'General case' 0 N--CA 1.498 1.952 0 C-N-CA 119.903 -0.719 . . . . 0.33 110.531 -178.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -132.04 131.42 42.45 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.653 -0.654 . . . . 1.48 110.016 177.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.85 -128.05 45.63 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.814 -1.315 . . . . 0.41 109.814 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 pt-20 -104.97 10.64 34.1 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.726 -0.867 . . . . 1.27 111.729 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.2 137.99 31.86 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 1.37 110.719 -179.258 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -75.23 140.08 24.44 Favored 'Trans proline' 0 N--CA 1.483 0.855 0 O-C-N 122.887 0.941 . . . . 0.34 110.399 174.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.66 ' HB3' HG23 ' A' ' 72' ' ' ILE . 55.5 mmtt -111.37 136.89 49.85 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.657 -0.652 . . . . 1.1 109.466 172.063 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.524 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -135.7 164.49 27.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.703 -0.623 . . . . 1.42 110.996 -176.44 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.43 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -158.59 135.75 4.4 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.469 -1.453 . . . . 0.17 109.469 176.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.85 136.91 54.24 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.712 -0.875 . . . . 0.21 109.732 177.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -155.88 173.38 16.85 Favored 'General case' 0 N--CA 1.497 1.911 0 C-N-CA 119.867 -0.733 . . . . 0.16 111.089 178.159 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.7 m -106.95 140.39 39.83 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.722 -0.611 . . . . 0.13 109.551 173.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.28 146.11 34.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.633 -0.667 . . . . 0.14 110.443 -175.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.65 145.58 24.45 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.774 -0.579 . . . . 2.21 109.711 175.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.869 HG21 HG23 ' A' ' 29' ' ' ILE . 97.9 t -77.84 126.41 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 CA-C-O 121.2 0.524 . . . . 0.17 109.973 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.53 -167.56 26.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.931 -1.268 . . . . 0.19 109.931 179.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -61.71 153.34 28.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.7 -0.882 . . . . 1.39 109.965 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 54.14 20.49 2.57 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.531 -0.731 . . . . 0.82 111.98 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 20.44 79.94 Favored Glycine 0 N--CA 1.5 2.928 0 C-N-CA 119.803 -1.189 . . . . 0.19 110.826 171.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.435 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.5 p -78.37 146.9 34.37 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -1.01 . . . . 1.3 110.203 -177.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.619 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.88 145.8 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.758 -0.589 . . . . 0.21 109.565 175.006 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.15 123.15 65.8 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.588 -0.695 . . . . 0.34 110.654 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 65.5 mt -78.41 144.02 65.29 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.504 -0.748 . . . . 0.34 109.432 172.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.77 134.43 40.54 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 O-C-N 122.861 0.927 . . . . 0.26 110.648 -179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 35.0 ttpt -55.15 -34.21 63.59 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.505 -0.747 . . . . 2.62 110.802 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.73 -37.87 77.12 Favored 'General case' 0 N--CA 1.5 2.07 0 O-C-N 121.802 -0.562 . . . . 0.45 110.271 -178.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.8 mt -77.11 -32.75 56.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.748 -0.595 . . . . 1.82 110.553 178.548 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.78 -46.0 85.21 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.306 -0.871 . . . . 2.53 109.923 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.32 -47.23 62.05 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 120.5 -0.48 . . . . 1.68 110.493 -175.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.6 t -60.51 -38.15 77.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.684 -0.635 . . . . 0.28 109.966 -178.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.711 HG22 HD11 ' A' ' 74' ' ' ILE . 83.1 mt -82.57 -17.81 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.792 -0.568 . . . . 0.28 110.934 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.32 35.14 43.53 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.787 -1.325 . . . . 0.22 109.787 176.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.906 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.9 mm -92.24 138.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.522 -0.987 . . . . 0.77 110.715 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 57.0 mmtt -124.25 161.1 49.42 Favored Pre-proline 0 N--CA 1.498 1.931 0 O-C-N 121.675 -0.64 . . . . 3.21 110.61 -176.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.76 136.36 66.01 Favored 'Trans proline' 0 N--CA 1.488 1.149 0 O-C-N 123.027 1.014 . . . . 0.5 110.78 179.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.63 -0.65 74.24 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 111.123 -0.791 . . . . 0.24 111.123 176.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' ' HE3' ' A' ' 41' ' ' LYS . 21.7 mt-10 -98.14 134.44 41.2 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 118.682 1.241 . . . . 1.11 110.567 179.695 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.07 133.41 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 CA-C-O 121.684 0.754 . . . . 0.24 111.227 -174.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.676 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.7 pt -122.93 159.48 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 109.211 -0.663 . . . . 0.18 109.211 175.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 49.7 tt0 -98.82 131.41 44.96 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 109.021 -0.733 . . . . 1.14 109.021 175.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 88.5 t -115.8 129.93 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.435 0.636 . . . . 0.2 110.365 -170.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.2 mt -115.73 130.7 56.95 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 109.237 -0.653 . . . . 0.25 109.237 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.09 139.88 36.7 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.449 -0.782 . . . . 0.28 109.781 171.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.0 mt -108.71 -34.4 6.71 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.8 -0.563 . . . . 1.6 110.887 -176.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.59 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.03 -174.63 37.74 Favored Glycine 0 N--CA 1.502 3.079 0 C-N-CA 119.738 -1.22 . . . . 0.2 111.015 -177.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -143.91 155.62 44.14 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.738 -0.86 . . . . 1.89 110.743 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -141.17 146.69 37.3 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.577 -0.702 . . . . 0.8 110.208 176.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 18.1 mtmm -112.07 159.92 31.88 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.722 -0.611 . . . . 2.99 110.133 178.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -55.53 141.56 82.71 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 O-C-N 123.187 1.099 . . . . 1.68 110.963 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 59.1 ttt180 -130.22 141.72 50.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.685 -0.634 . . . . 6.87 110.204 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 117.994 -1.003 . . . . 6.47 110.165 179.822 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.224 0.535 . . . . 2.76 110.544 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -75.35 141.98 43.23 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.867 -0.521 . . . . 1.7 110.101 179.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -127.96 135.71 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.811 -0.556 . . . . 0.41 109.578 177.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.8 mt -83.72 -19.6 34.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.761 -0.587 . . . . 0.37 110.276 177.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.797 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.46 152.7 1.76 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.262 -0.899 . . . . 0.26 109.124 176.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.1 ttpt -135.42 128.23 31.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.635 -0.665 . . . . 2.3 110.382 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 19.2 p90 -149.81 163.56 37.68 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.391 -0.524 . . . . 0.2 110.508 -178.277 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -113.61 137.59 51.37 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.602 -0.686 . . . . 1.99 110.4 -176.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.56 162.28 41.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.756 -0.59 . . . . 0.18 109.568 177.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 t -109.63 158.56 17.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.468 -0.77 . . . . 0.17 110.02 176.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.934 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.9 t -79.47 138.06 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.779 -0.576 . . . . 0.49 110.355 -176.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.2 m80 -116.66 171.87 7.59 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-O 121.347 0.594 . . . . 0.68 109.86 176.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -46.29 153.05 0.37 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.629 -0.669 . . . . 2.96 112.075 -175.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.579 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.9 mt 62.94 7.2 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.648 0 O-C-N 121.651 -0.655 . . . . 0.42 112.578 -175.599 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.61 16.09 80.6 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 110.331 -1.108 . . . . 0.24 110.331 179.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 36.7 ttp180 -85.76 144.29 27.85 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.354 -1.086 . . . . 1.96 110.198 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.7 pt -132.42 155.03 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.681 -0.637 . . . . 0.3 109.359 172.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.4 mm -115.71 128.55 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.595 -0.691 . . . . 0.25 109.952 176.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.431 HG12 ' CE2' ' A' ' 7' ' ' PHE . 25.5 mt -79.58 144.5 61.15 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.052 -0.659 . . . . 0.23 109.417 175.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -63.48 143.39 87.98 Favored 'Trans proline' 0 N--CA 1.488 1.191 0 O-C-N 123.002 1.001 . . . . 0.35 109.689 174.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.0 -26.37 60.13 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.838 -0.539 . . . . 0.33 110.46 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.31 -45.32 93.78 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 109.999 -1.24 . . . . 0.39 109.999 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 m -69.5 -36.87 76.9 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.617 -0.931 . . . . 0.39 110.202 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.7 mtt180 -56.3 -42.05 76.94 Favored 'General case' 0 N--CA 1.51 2.525 0 O-C-N 121.418 -0.801 . . . . 0.4 109.734 178.125 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -65.97 -50.2 65.16 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.364 0.602 . . . . 2.97 110.162 -177.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -56.67 -37.87 71.42 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.835 -0.541 . . . . 0.67 110.69 -178.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.947 ' CD2' HD13 ' A' ' 84' ' ' LEU . 25.0 t80 -87.89 -14.17 40.06 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.825 -0.547 . . . . 1.44 111.364 -177.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 43.03 23.24 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.586 -1.406 . . . . 0.31 109.586 178.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.922 HG23 HG21 ' A' ' 56' ' ' VAL . 76.1 mt -87.53 127.44 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.422 -1.046 . . . . 0.42 110.575 -177.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.29 154.92 44.32 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.008 -0.738 . . . . 1.82 109.008 170.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.52 137.75 47.95 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.253 -0.904 . . . . 1.99 110.751 -177.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.46 -15.1 64.01 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.927 -0.869 . . . . 0.19 110.927 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -75.97 157.51 33.02 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.735 1.268 . . . . 1.12 109.851 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -111.21 138.17 47.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.606 -0.684 . . . . 0.21 109.679 175.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.39 153.52 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 109.249 -0.649 . . . . 0.15 109.249 174.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -115.33 122.98 47.55 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.242 -1.021 . . . . 1.09 108.242 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.809 HD11 ' CG1' ' A' ' 82' ' ' VAL . 9.3 tt -139.97 157.99 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 119.604 -0.838 . . . . 0.14 110.987 -167.171 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.5 tttt -132.61 145.98 51.53 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.8 -0.562 . . . . 1.11 110.596 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.574 HG22 HG22 ' A' ' 82' ' ' VAL . 28.0 pt -115.13 151.03 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.728 -0.608 . . . . 0.2 110.62 178.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.495 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.2 t -138.77 125.61 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-O 121.143 0.497 . . . . 0.2 109.772 176.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.67 ' HB2' HG22 ' A' ' 80' ' ' ILE . 21.4 ttpp -131.9 143.36 50.08 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.222 -0.659 . . . . 1.98 109.222 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -105.03 130.14 53.3 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 120.137 -0.625 . . . . 0.33 110.456 -178.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -135.02 131.33 36.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.745 -0.597 . . . . 1.48 110.149 177.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.82 -128.18 45.94 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.857 -1.297 . . . . 0.41 109.857 -178.253 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -105.11 12.86 31.6 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.767 -0.843 . . . . 1.27 111.672 179.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -131.27 128.02 21.97 Favored Pre-proline 0 N--CA 1.498 1.957 0 O-C-N 121.31 -0.869 . . . . 1.37 110.982 -178.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.33 137.99 21.71 Favored 'Trans proline' 0 N--CA 1.482 0.844 0 O-C-N 122.73 0.858 . . . . 0.34 110.127 173.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.661 ' HB3' HG23 ' A' ' 72' ' ' ILE . 68.7 mmtt -110.85 137.17 48.83 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.548 -0.72 . . . . 1.1 109.622 172.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.8 mt-10 -135.5 164.23 28.28 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.614 -0.679 . . . . 1.42 110.796 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.614 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.15 135.96 4.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.605 -1.398 . . . . 0.17 109.605 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.3 m -123.09 137.34 54.95 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.68 -0.894 . . . . 0.21 109.735 176.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.8 p90 -155.87 172.55 18.16 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.843 -0.743 . . . . 0.16 111.017 176.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.0 m -107.78 140.85 40.23 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.694 -0.629 . . . . 0.13 109.545 174.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.09 145.78 34.69 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.723 -0.61 . . . . 0.14 110.641 -175.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.7 ttp180 -93.9 145.25 24.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.73 -0.606 . . . . 2.21 109.598 174.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.922 HG21 HG23 ' A' ' 29' ' ' ILE . 98.8 t -78.44 126.47 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.783 -0.573 . . . . 0.17 109.928 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -104.04 -166.51 24.98 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.099 -1.201 . . . . 0.19 110.099 178.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -61.63 153.08 28.94 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.872 -0.781 . . . . 1.39 110.218 -179.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.57 21.18 2.41 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.547 -0.721 . . . . 0.82 112.001 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.81 20.48 79.76 Favored Glycine 0 N--CA 1.499 2.878 0 C-N-CA 119.747 -1.216 . . . . 0.19 110.806 171.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 14.2 m -77.99 145.25 36.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.414 -1.05 . . . . 1.3 110.232 -176.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.27 145.51 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.789 -0.569 . . . . 0.21 109.609 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.2 mm -112.03 123.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.027 0 O-C-N 121.55 -0.719 . . . . 0.34 110.734 -174.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.455 HG23 ' HD2' ' A' ' 65' ' ' PRO . 80.3 mt -78.5 145.12 66.99 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.591 -0.693 . . . . 0.34 109.484 172.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.2 Cg_endo -64.38 136.68 52.08 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 O-C-N 122.889 0.941 . . . . 0.26 110.821 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 20.2 tptt -54.93 -34.85 63.59 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.47 -0.769 . . . . 2.62 110.845 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.91 -38.2 78.4 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.764 -0.585 . . . . 0.45 110.298 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.0 mt -77.17 -32.78 56.4 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.727 -0.608 . . . . 1.82 110.658 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.2 mtt180 -58.3 -45.85 87.24 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.22 -0.925 . . . . 2.53 109.884 178.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -70.3 -47.42 61.26 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 120.383 -0.527 . . . . 1.68 110.51 -175.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.9 t -60.58 -38.18 77.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.077 0 O-C-N 121.653 -0.654 . . . . 0.28 109.91 -178.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.697 HG22 HD11 ' A' ' 74' ' ' ILE . 86.1 mt -82.28 -17.61 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.882 -0.512 . . . . 0.28 110.966 -176.224 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.76 35.23 40.83 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.835 -1.306 . . . . 0.22 109.835 176.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.934 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.58 141.11 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.511 -0.994 . . . . 0.77 110.704 -173.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -127.67 156.28 75.8 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.732 -0.605 . . . . 3.21 110.631 -177.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -55.98 135.42 69.67 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 122.974 0.986 . . . . 0.5 111.275 177.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.12 -0.76 72.71 Favored Glycine 0 N--CA 1.496 2.65 0 C-N-CA 120.694 -0.765 . . . . 0.24 111.241 176.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -96.36 132.6 41.7 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-N 118.734 1.267 . . . . 1.11 110.477 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.3 p -91.21 132.08 36.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-O 121.639 0.733 . . . . 0.24 110.979 -174.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.67 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.4 pt -123.23 159.42 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 109.464 -0.569 . . . . 0.18 109.464 177.382 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.7 tt0 -98.13 131.57 44.4 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.919 -0.771 . . . . 1.14 108.919 173.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.809 ' CG1' HD11 ' A' ' 37' ' ' ILE . 99.9 t -115.1 128.01 72.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.2 110.166 -171.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.1 mt -114.79 128.46 56.31 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 109.365 -0.605 . . . . 0.25 109.365 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.947 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.8 mt -79.88 139.92 36.95 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.485 -0.76 . . . . 0.28 109.821 172.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.7 mt -110.93 -31.75 7.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.769 -0.582 . . . . 1.6 110.85 -175.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.25 -177.04 39.12 Favored Glycine 0 N--CA 1.504 3.225 0 C-N-CA 119.745 -1.216 . . . . 0.2 110.958 -176.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -144.72 152.56 40.59 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.667 -0.902 . . . . 1.89 110.72 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -136.29 139.92 43.01 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.8 109.995 175.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -123.84 160.05 53.3 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.698 -0.626 . . . . 2.99 110.279 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -55.86 147.66 60.96 Favored 'Trans proline' 0 N--CA 1.497 1.678 0 O-C-N 123.141 1.074 . . . . 1.68 111.043 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 82.7 mmt-85 -121.12 146.86 46.3 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.719 -0.613 . . . . 6.87 110.216 178.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 . . . . . 0 N--CA 1.504 2.249 0 CA-C-O 117.969 -1.015 . . . . 6.47 110.998 -179.959 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.5 mtm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 121.232 0.539 . . . . 2.76 110.597 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -77.16 142.05 39.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.837 -0.539 . . . . 1.7 110.126 179.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.1 p -127.57 141.82 45.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.708 -0.62 . . . . 0.41 109.723 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.559 HD11 ' HA2' ' A' ' 86' ' ' GLY . 34.4 mt -89.58 -18.02 27.38 Favored 'General case' 0 N--CA 1.495 1.789 0 C-N-CA 120.309 -0.556 . . . . 0.37 110.654 -177.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.869 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.75 154.99 3.8 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.249 -0.907 . . . . 0.26 109.577 177.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -133.63 127.1 32.27 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.707 -0.621 . . . . 2.3 110.126 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.582 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 13.2 p90 -148.75 162.64 39.36 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.643 -0.661 . . . . 0.2 110.702 177.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.81 138.37 50.36 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.596 -0.69 . . . . 1.99 110.34 -176.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.04 162.21 41.28 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 109.459 -0.571 . . . . 0.18 109.459 177.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -109.31 158.45 17.87 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.436 -0.79 . . . . 0.17 110.152 177.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.905 HG21 HG21 ' A' ' 74' ' ' ILE . 61.2 t -79.22 136.43 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 C-N-CA 120.32 -0.552 . . . . 0.49 110.097 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -114.41 171.87 7.36 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-O 121.269 0.556 . . . . 0.68 109.612 173.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -46.86 152.61 0.49 Allowed 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.579 -0.7 . . . . 2.96 111.978 -176.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.586 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.61 0 O-C-N 121.529 -0.732 . . . . 0.42 112.631 -175.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.401 ' HA3' ' NE ' ' A' ' 69' ' ' ARG . . . 78.01 16.17 80.18 Favored Glycine 0 N--CA 1.497 2.742 0 O-C-N 120.964 -1.085 . . . . 0.24 110.463 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -83.89 141.15 31.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.298 -1.119 . . . . 1.96 110.316 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.7 pt -133.72 155.75 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.569 -0.707 . . . . 0.3 109.816 173.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -117.17 129.75 73.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.529 -0.732 . . . . 0.25 109.878 175.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.426 HG12 ' CE2' ' A' ' 7' ' ' PHE . 24.2 mt -79.76 145.91 63.35 Favored Pre-proline 0 N--CA 1.495 1.806 0 C-N-CA 119.962 -0.695 . . . . 0.23 109.322 175.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.412 ' HD2' HG23 ' A' ' 19' ' ' ILE . 48.2 Cg_endo -63.22 143.25 89.29 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.005 1.002 . . . . 0.35 109.819 174.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.84 -26.43 62.03 Favored 'General case' 0 N--CA 1.497 1.922 0 C-N-CA 120.404 -0.518 . . . . 0.33 110.462 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.94 -43.86 95.37 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 110.027 -1.229 . . . . 0.39 110.027 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.7 m -69.87 -38.61 76.47 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.63 -0.924 . . . . 0.39 110.136 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.594 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.2 mtt180 -56.24 -43.27 78.48 Favored 'General case' 0 N--CA 1.513 2.694 0 O-C-N 121.346 -0.846 . . . . 0.4 109.571 176.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -67.16 -50.2 62.02 Favored 'General case' 0 N--CA 1.496 1.831 0 CA-C-O 121.18 0.514 . . . . 2.97 110.316 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -57.6 -36.35 71.65 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.764 -0.585 . . . . 0.67 110.661 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.952 ' CD2' HD13 ' A' ' 84' ' ' LEU . 16.8 t80 -88.15 -14.06 39.65 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.705 -0.622 . . . . 1.44 111.371 -174.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 74.92 41.74 32.23 Favored Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.657 -1.377 . . . . 0.31 109.657 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.843 HG23 HG21 ' A' ' 56' ' ' VAL . 81.9 mt -90.91 132.79 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.504 -0.998 . . . . 0.42 110.615 -176.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -129.18 159.29 36.52 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 109.047 -0.723 . . . . 1.82 109.047 172.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 -57.96 140.23 52.66 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.388 -0.82 . . . . 1.99 110.367 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.77 -16.0 61.79 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.849 -0.901 . . . . 0.19 110.849 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.04 158.5 30.51 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-N 118.72 1.26 . . . . 1.12 110.223 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -111.86 139.68 47.14 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.661 -0.649 . . . . 0.21 109.598 174.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.09 155.02 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 109.235 -0.654 . . . . 0.15 109.235 174.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -116.35 123.22 47.08 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 108.345 -0.984 . . . . 1.09 108.345 -178.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.821 HD11 ' CG1' ' A' ' 82' ' ' VAL . 6.0 tt -140.53 158.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.553 -0.859 . . . . 0.14 111.232 -166.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -132.54 145.61 51.27 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.878 -0.514 . . . . 1.11 110.519 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.495 HG22 HG22 ' A' ' 82' ' ' VAL . 26.1 pt -115.06 151.08 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.053 0 O-C-N 121.664 -0.647 . . . . 0.2 110.6 178.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 59.2 t -139.2 126.01 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 CA-C-O 121.31 0.576 . . . . 0.2 110.049 176.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.776 ' HB2' HG22 ' A' ' 80' ' ' ILE . 17.2 tptt -132.59 148.7 52.37 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 109.004 -0.739 . . . . 1.98 109.004 174.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 36.8 t80 -102.76 128.16 49.62 Favored 'General case' 0 N--CA 1.495 1.785 0 C-N-CA 120.137 -0.625 . . . . 0.33 110.246 -179.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -134.79 134.37 40.82 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.645 -0.659 . . . . 1.48 110.089 179.22 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.22 46.01 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 109.803 -1.319 . . . . 0.41 109.803 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -105.08 10.24 34.04 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.714 -0.874 . . . . 1.27 111.713 178.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -131.14 138.11 32.16 Favored Pre-proline 0 N--CA 1.499 1.976 0 O-C-N 121.242 -0.911 . . . . 1.37 111.073 -177.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -75.11 139.18 23.7 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 O-C-N 122.86 0.926 . . . . 0.34 110.298 173.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.737 ' HB3' HG23 ' A' ' 72' ' ' ILE . 18.0 mmtp -113.62 137.35 51.72 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.556 -0.715 . . . . 1.1 109.559 172.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -137.97 166.27 24.49 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.59 -0.694 . . . . 1.42 110.756 -178.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.83 135.94 4.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.692 -1.363 . . . . 0.17 109.692 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 m -119.93 137.95 53.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.661 -0.905 . . . . 0.21 109.766 176.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.813 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 15.0 p90 -156.04 173.89 16.15 Favored 'General case' 0 N--CA 1.496 1.86 0 C-N-CA 120.0 -0.68 . . . . 0.16 110.981 176.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.0 m -106.32 140.91 38.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.731 -0.606 . . . . 0.13 109.475 173.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.813 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 144.9 35.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.679 -0.638 . . . . 0.14 110.636 -175.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.815 -0.553 . . . . 2.21 109.732 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -79.47 125.65 38.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 CA-C-O 121.321 0.581 . . . . 0.17 109.871 178.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.08 -171.31 27.37 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.617 -1.393 . . . . 0.19 109.617 178.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -61.87 156.1 21.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.569 -0.959 . . . . 1.39 109.837 178.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 54.99 19.4 2.68 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.446 -0.784 . . . . 0.82 112.079 -177.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.21 20.47 79.93 Favored Glycine 0 N--CA 1.5 2.91 0 C-N-CA 119.81 -1.186 . . . . 0.19 110.728 172.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -78.0 146.02 35.63 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.503 -0.998 . . . . 1.3 110.409 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.708 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -138.51 146.52 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.719 -0.613 . . . . 0.21 109.627 173.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -108.89 122.21 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 121.555 -0.715 . . . . 0.34 110.533 -174.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 88.2 mt -79.01 142.07 59.43 Favored Pre-proline 0 N--CA 1.499 1.999 0 O-C-N 121.606 -0.684 . . . . 0.34 109.625 173.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.744 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -65.1 131.83 29.94 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.862 0.927 . . . . 0.26 110.729 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -55.17 -33.07 62.66 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.497 -0.752 . . . . 2.62 110.88 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.8 -37.99 77.59 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.785 -0.572 . . . . 0.45 110.189 -178.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.744 HD12 ' CG ' ' A' ' 65' ' ' PRO . 76.3 mt -77.01 -32.74 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.747 -0.596 . . . . 1.82 110.403 177.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.401 ' NE ' ' HA3' ' A' ' 15' ' ' GLY . 38.1 mtt180 -57.73 -46.08 84.93 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 121.352 -0.842 . . . . 2.53 109.85 178.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -70.08 -47.87 60.08 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 120.528 -0.469 . . . . 1.68 110.413 -175.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.6 t -60.57 -38.1 77.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.152 0 C-N-CA 120.157 -0.617 . . . . 0.28 109.924 -178.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.737 HG23 ' HB3' ' A' ' 48' ' ' LYS . 83.3 mt -82.76 -17.66 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.866 -0.521 . . . . 0.28 110.919 -176.081 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.498 2.829 0 N-CA-C 109.68 -1.368 . . . . 0.22 109.68 175.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.905 HG21 HG21 ' A' ' 11' ' ' VAL . 51.3 mm -89.56 143.82 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.515 -0.991 . . . . 0.77 110.644 -174.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -129.22 156.96 77.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.764 -0.585 . . . . 3.21 110.719 -177.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.28 134.14 62.1 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.022 1.012 . . . . 0.5 111.412 177.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.37 -0.17 71.07 Favored Glycine 0 N--CA 1.497 2.761 0 C-N-CA 120.617 -0.801 . . . . 0.24 111.205 175.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -96.26 132.39 41.77 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-N 118.732 1.266 . . . . 1.11 110.4 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.2 p -91.03 130.05 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 CA-C-O 121.46 0.648 . . . . 0.24 110.961 -174.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.776 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.5 pt -117.67 159.34 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.462 -0.57 . . . . 0.18 109.462 176.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -98.49 130.87 45.08 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.893 -0.781 . . . . 1.14 108.893 173.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.821 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.5 t -114.6 128.53 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 CA-C-O 121.381 0.61 . . . . 0.2 110.18 -171.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.404 ' HB3' HG21 ' A' ' 3' ' ' VAL . 45.0 mt -114.96 129.8 56.79 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 109.269 -0.641 . . . . 0.25 109.269 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.952 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.22 141.57 35.49 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.28 109.996 173.406 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.52 -32.38 6.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.839 -0.538 . . . . 1.6 110.779 -177.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.559 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -169.16 -174.46 37.69 Favored Glycine 0 N--CA 1.504 3.171 0 C-N-CA 119.681 -1.247 . . . . 0.2 111.058 -177.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.0 p80 -146.35 153.71 40.83 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.664 -0.904 . . . . 1.89 110.614 -179.246 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -135.63 141.42 45.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.545 -0.722 . . . . 0.8 110.108 176.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.2 ptpp? -108.12 160.02 28.49 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.696 -0.628 . . . . 2.99 110.354 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -54.76 144.35 66.08 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 O-C-N 123.161 1.085 . . . . 1.68 111.042 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 91.1 mtm-85 -123.44 147.82 46.78 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.727 -0.608 . . . . 6.87 110.163 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 33.7 t30 . . . . . 0 N--CA 1.499 1.985 0 CA-C-O 118.019 -0.991 . . . . 6.47 110.126 179.666 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.0 mtt . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.165 0.507 . . . . 2.76 110.519 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -102.85 147.42 26.9 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.784 -0.573 . . . . 1.7 110.014 178.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.4 p -121.16 137.59 54.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.778 -0.576 . . . . 0.41 109.513 176.175 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.614 HD11 ' HA2' ' A' ' 86' ' ' GLY . 23.2 mt -85.32 -18.04 35.03 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 120.279 -0.568 . . . . 0.37 110.462 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.96 155.47 3.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.368 -0.833 . . . . 0.26 109.589 176.65 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.2 ttmt -132.95 127.02 33.33 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.715 -0.615 . . . . 2.3 110.124 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.602 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.3 p90 -149.77 162.51 40.13 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.634 -0.667 . . . . 0.2 110.728 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -113.33 138.96 49.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.604 -0.685 . . . . 1.99 110.32 -176.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.474 HG21 HD12 ' A' ' 17' ' ' ILE . 14.8 t -150.75 162.3 40.99 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.739 -0.601 . . . . 0.18 109.619 177.503 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.49 159.02 17.88 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 119.787 -0.765 . . . . 0.17 110.01 176.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.1 t -79.32 135.94 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.233 -0.587 . . . . 0.49 110.333 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 17.3 m80 -115.39 171.97 7.38 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 109.528 -0.545 . . . . 0.68 109.528 174.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -46.26 152.31 0.43 Allowed 'General case' 0 N--CA 1.506 2.372 0 O-C-N 121.562 -0.711 . . . . 2.96 112.033 -175.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.1 mt 62.64 7.4 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.644 0 O-C-N 121.495 -0.753 . . . . 0.42 112.632 -174.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.72 16.01 80.61 Favored Glycine 0 N--CA 1.497 2.723 0 O-C-N 120.915 -1.115 . . . . 0.24 110.423 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.84 ' NH1' HD11 ' A' ' 18' ' ' ILE . 70.2 ttp85 -84.91 143.41 29.02 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.199 -1.177 . . . . 1.96 110.294 -177.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.474 HD12 HG21 ' A' ' 9' ' ' THR . 41.7 pt -133.21 157.49 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.759 -0.588 . . . . 0.3 109.532 173.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.84 HD11 ' NH1' ' A' ' 16' ' ' ARG . 48.6 mm -116.29 129.6 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.591 -0.693 . . . . 0.25 109.96 176.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.6 mt -79.19 145.5 64.92 Favored Pre-proline 0 N--CA 1.496 1.859 0 C-N-CA 119.961 -0.695 . . . . 0.23 109.375 175.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.2 142.86 88.31 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.102 1.054 . . . . 0.35 109.79 174.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.56 -26.6 61.66 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.84 -0.538 . . . . 0.33 110.447 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.27 -44.8 95.0 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.036 -1.225 . . . . 0.39 110.036 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 97.1 m -69.73 -37.45 76.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.699 -0.883 . . . . 0.39 109.848 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.6 mtt180 -55.95 -42.42 76.2 Favored 'General case' 0 N--CA 1.509 2.499 0 O-C-N 121.343 -0.848 . . . . 0.4 109.801 178.083 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -66.75 -50.37 62.96 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.302 0.573 . . . . 2.97 110.284 -176.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -57.2 -37.15 71.76 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.868 -0.52 . . . . 0.67 110.622 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.946 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.6 t80 -87.83 -14.17 40.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.85 -0.531 . . . . 1.44 111.275 -176.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.36 42.37 28.11 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.57 -1.412 . . . . 0.31 109.57 177.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.891 HG23 HG21 ' A' ' 56' ' ' VAL . 77.8 mt -89.6 129.41 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.559 -0.965 . . . . 0.42 110.653 -176.566 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -128.48 159.51 35.21 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 109.173 -0.677 . . . . 1.82 109.173 171.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.3 mt-30 -57.75 138.59 55.37 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.411 -0.805 . . . . 1.99 110.478 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.1 62.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.857 -0.897 . . . . 0.19 110.857 179.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -77.09 157.47 31.03 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-N 118.763 1.281 . . . . 1.12 110.03 177.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -111.44 138.87 47.38 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.671 -0.643 . . . . 0.21 109.644 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.9 m -130.58 155.34 41.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 0.15 109.269 174.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.8 tt0 -117.34 123.89 47.61 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.276 -1.009 . . . . 1.09 108.276 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.834 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.0 tt -139.96 157.56 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.553 -0.859 . . . . 0.14 111.044 -167.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.68 146.09 51.59 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.789 -0.569 . . . . 1.11 110.427 177.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.498 ' HB ' HD12 ' A' ' 80' ' ' ILE . 29.6 pt -114.89 151.09 16.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.024 0 O-C-N 121.732 -0.605 . . . . 0.2 110.595 178.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.44 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.4 t -138.0 126.72 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.123 0.487 . . . . 0.2 109.707 176.295 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.699 ' HB2' HG22 ' A' ' 80' ' ' ILE . 30.6 tptt -138.09 147.12 43.71 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.726 -0.609 . . . . 1.98 109.636 175.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 39.5 t80 -102.09 130.28 48.65 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 120.291 -0.564 . . . . 0.33 110.369 -176.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.412 ' OE2' HD13 ' A' ' 74' ' ' ILE . 93.8 mt-10 -134.37 135.76 42.9 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.616 -0.678 . . . . 1.48 110.042 177.418 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.83 -128.16 45.88 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.774 -1.33 . . . . 0.41 109.774 -178.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.12 8.91 34.36 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.835 -0.803 . . . . 1.27 111.825 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -131.24 135.13 26.66 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.185 -0.947 . . . . 1.37 111.033 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -75.35 144.88 29.65 Favored 'Trans proline' 0 N--CA 1.482 0.818 0 O-C-N 122.801 0.895 . . . . 0.34 110.114 173.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.446 ' CB ' HG23 ' A' ' 72' ' ' ILE . 31.4 mttm -122.5 149.24 44.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.491 -0.756 . . . . 1.1 110.105 171.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.44 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.2 mt-10 -136.75 167.74 20.86 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.758 -0.589 . . . . 1.42 110.835 -176.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.67 135.87 4.45 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.49 -1.444 . . . . 0.17 109.49 177.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.7 m -122.88 138.23 54.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.931 . . . . 0.21 109.978 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.81 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 14.8 p90 -156.3 172.92 17.64 Favored 'General case' 0 N--CA 1.498 1.927 0 C-N-CA 119.858 -0.737 . . . . 0.16 110.89 175.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 59.4 m -106.95 141.29 38.4 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.704 -0.623 . . . . 0.13 109.473 173.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.81 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.99 145.99 36.7 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.591 -0.693 . . . . 0.14 110.759 -175.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -93.47 145.24 24.65 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.582 -0.525 . . . . 2.21 109.582 175.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.891 HG21 HG23 ' A' ' 29' ' ' ILE . 91.3 t -78.96 125.07 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 CA-C-O 121.295 0.569 . . . . 0.17 109.823 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.62 -166.62 25.38 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.117 -1.193 . . . . 0.19 110.117 178.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -61.74 153.51 28.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.768 -0.842 . . . . 1.39 110.158 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 53.39 21.21 2.28 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.595 -0.69 . . . . 0.82 112.167 -179.577 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.22 20.51 79.64 Favored Glycine 0 N--CA 1.501 2.982 0 C-N-CA 119.663 -1.256 . . . . 0.19 110.764 171.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.5 m -77.87 145.2 36.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.456 -1.026 . . . . 1.3 110.441 -175.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.46 146.65 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.806 -0.559 . . . . 0.21 109.645 175.08 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.44 122.72 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.509 -0.744 . . . . 0.34 110.787 -174.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 70.8 mt -79.11 144.33 62.81 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.584 -0.698 . . . . 0.34 109.624 172.577 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.749 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.8 Cg_endo -64.76 134.39 40.39 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 O-C-N 122.952 0.975 . . . . 0.26 110.841 -179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 72.3 tttt -55.19 -34.16 63.65 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.491 -0.756 . . . . 2.62 110.814 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.66 76.68 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.729 -0.607 . . . . 0.45 110.32 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.749 HD12 ' CG ' ' A' ' 65' ' ' PRO . 68.6 mt -77.13 -32.69 56.62 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.73 -0.607 . . . . 1.82 110.5 178.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -57.85 -46.05 85.35 Favored 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.328 -0.857 . . . . 2.53 109.858 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.92 -46.61 64.99 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 120.512 -0.475 . . . . 1.68 110.411 -175.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 96.0 t -60.55 -38.7 79.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.679 -0.638 . . . . 0.28 109.949 -178.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.563 HG22 HD11 ' A' ' 74' ' ' ILE . 83.6 mt -82.8 -16.44 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.791 -0.568 . . . . 0.28 111.102 -176.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 75.77 35.18 46.45 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.91 -1.276 . . . . 0.22 109.91 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.9 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.2 mm -90.77 142.32 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 O-C-N 121.53 -0.982 . . . . 0.77 110.589 -174.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.2 mttt -128.9 158.73 71.63 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.82 -0.55 . . . . 3.21 110.586 -177.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -54.56 134.21 60.8 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.063 1.033 . . . . 0.5 111.429 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.1 -0.5 72.42 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.69 -0.766 . . . . 0.24 111.292 175.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -97.37 133.51 41.87 Favored 'General case' 0 N--CA 1.498 1.958 0 CA-C-N 118.711 1.255 . . . . 1.11 110.559 179.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.2 p -91.95 131.17 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 CA-C-O 121.479 0.657 . . . . 0.24 111.095 -174.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.699 HG22 ' HB2' ' A' ' 41' ' ' LYS . 45.7 pt -119.0 159.48 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.286 -0.635 . . . . 0.18 109.286 175.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -97.93 131.59 44.25 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.891 -0.781 . . . . 1.14 108.891 174.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.834 ' CG1' HD11 ' A' ' 37' ' ' ILE . 90.8 t -115.65 129.5 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.348 0.594 . . . . 0.2 110.263 -170.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 45.5 mt -115.13 130.8 57.02 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 109.279 -0.638 . . . . 0.25 109.279 179.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.946 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.1 mt -80.35 139.9 36.34 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.365 -0.835 . . . . 0.28 110.037 173.052 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -106.65 -36.4 6.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.836 -0.54 . . . . 1.6 110.837 -176.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.614 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.88 -175.2 38.11 Favored Glycine 0 N--CA 1.502 3.061 0 C-N-CA 119.79 -1.195 . . . . 0.2 110.935 -176.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -143.81 153.46 42.4 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.682 -0.893 . . . . 1.89 110.728 -177.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -134.1 138.65 45.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.622 -0.674 . . . . 0.8 110.205 175.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.4 mttt -122.64 104.22 36.9 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.79 -0.569 . . . . 2.99 110.23 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_exo -54.37 145.19 57.74 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 O-C-N 123.104 1.055 . . . . 1.68 111.097 -179.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 72.8 mtp85 -121.94 149.04 44.01 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.688 -0.632 . . . . 6.87 110.209 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.9 m120 . . . . . 0 N--CA 1.497 1.892 0 CA-C-O 118.01 -0.995 . . . . 6.47 110.16 179.986 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.6 mtm . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.2 0.524 . . . . 2.76 110.622 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -81.03 138.35 36.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.822 -0.548 . . . . 1.7 110.1 178.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 p -128.69 134.32 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.725 -0.61 . . . . 0.41 109.47 177.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.584 HD11 ' HA2' ' A' ' 86' ' ' GLY . 31.4 mt -82.73 -19.86 37.13 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.764 -0.585 . . . . 0.37 110.454 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.856 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.71 153.63 3.42 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.38 -0.825 . . . . 0.26 109.241 175.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -133.48 125.17 28.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.804 -0.56 . . . . 2.3 110.07 -176.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.586 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 12.9 p90 -151.0 162.55 40.61 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.638 -0.664 . . . . 0.2 110.794 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -113.48 139.11 49.21 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.61 -0.681 . . . . 1.99 110.246 -176.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -150.96 162.37 40.95 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.785 -0.572 . . . . 0.18 109.63 177.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.1 t -111.28 158.76 18.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.433 -0.792 . . . . 0.17 109.986 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.893 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.5 t -79.33 134.7 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 C-N-CA 120.296 -0.561 . . . . 0.49 110.239 -176.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.3 m80 -113.44 171.89 7.29 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.22 0.534 . . . . 0.68 109.646 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -46.49 152.98 0.4 Allowed 'General case' 0 N--CA 1.506 2.334 0 O-C-N 121.594 -0.691 . . . . 2.96 111.957 -176.128 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.2 mt 62.76 7.34 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.675 0 O-C-N 121.573 -0.705 . . . . 0.42 112.601 -174.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.2 16.1 80.92 Favored Glycine 0 N--CA 1.498 2.787 0 O-C-N 120.875 -1.14 . . . . 0.24 110.276 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -85.65 143.41 28.43 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.265 -1.138 . . . . 1.96 110.443 -176.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.1 pt -133.37 155.53 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.787 -0.571 . . . . 0.3 109.491 172.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.9 mm -116.54 129.18 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.629 -0.669 . . . . 0.25 110.038 176.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG12 ' CE2' ' A' ' 7' ' ' PHE . 32.1 mt -79.47 145.12 62.83 Favored Pre-proline 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.23 109.404 175.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -63.49 143.32 87.75 Favored 'Trans proline' 0 N--CA 1.488 1.17 0 O-C-N 122.966 0.982 . . . . 0.35 109.775 174.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.91 -26.52 59.34 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.799 -0.563 . . . . 0.33 110.504 -178.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.4 -45.14 94.15 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.016 -1.233 . . . . 0.39 110.016 -179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 76.4 m -69.38 -37.09 77.41 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.621 -0.929 . . . . 0.39 110.178 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.62 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.32 -42.15 77.16 Favored 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.369 -0.832 . . . . 0.4 109.687 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.8 tptm -66.43 -50.2 64.19 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-O 121.244 0.545 . . . . 2.97 110.214 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -57.05 -37.99 72.59 Favored 'General case' 0 N--CA 1.503 2.208 0 O-C-N 121.928 -0.482 . . . . 0.67 110.698 -178.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.959 ' CD2' HD13 ' A' ' 84' ' ' LEU . 21.6 t80 -86.87 -14.31 42.36 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.812 -0.555 . . . . 1.44 111.277 -177.345 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.99 42.52 24.61 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.631 -1.388 . . . . 0.31 109.631 178.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.58 129.1 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.52 -0.988 . . . . 0.42 110.483 -177.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.06 158.47 37.86 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.919 -0.771 . . . . 1.82 108.919 170.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -57.24 140.04 50.97 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.309 -0.869 . . . . 1.99 110.492 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.01 -16.02 61.84 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.842 -0.903 . . . . 0.19 110.842 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.88 157.94 31.08 Favored 'General case' 0 N--CA 1.5 2.047 0 CA-C-N 118.739 1.27 . . . . 1.12 110.198 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -111.36 138.74 47.46 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.635 -0.666 . . . . 0.21 109.603 174.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.22 153.78 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.282 -0.636 . . . . 0.15 109.282 174.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 58.9 tt0 -115.86 123.54 48.4 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.305 -0.998 . . . . 1.09 108.305 -179.077 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.84 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -139.99 158.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 C-N-CA 119.587 -0.845 . . . . 0.14 111.004 -167.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -133.09 145.97 51.22 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.874 -0.516 . . . . 1.11 110.505 177.489 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.532 ' HB ' HD12 ' A' ' 80' ' ' ILE . 24.5 pt -114.95 151.09 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.79 -0.569 . . . . 0.2 110.619 178.325 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.522 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -138.96 125.5 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.917 -0.489 . . . . 0.2 109.787 176.301 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.68 ' HB2' HG22 ' A' ' 80' ' ' ILE . 54.4 tttp -132.28 144.49 50.63 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.774 -0.579 . . . . 1.98 109.533 174.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -104.87 129.36 53.21 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 120.197 -0.601 . . . . 0.33 110.459 -178.488 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -133.53 129.95 37.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.672 -0.642 . . . . 1.48 110.073 177.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.78 -128.17 45.96 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.811 -1.316 . . . . 0.41 109.811 -177.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.11 14.17 29.62 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.731 -0.864 . . . . 1.27 111.562 178.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -131.06 124.44 20.54 Favored Pre-proline 0 N--CA 1.498 1.947 0 O-C-N 121.251 -0.906 . . . . 1.37 110.994 -177.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.25 137.0 20.62 Favored 'Trans proline' 0 N--CA 1.482 0.828 0 O-C-N 122.704 0.844 . . . . 0.34 110.133 174.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.762 ' HB3' HG23 ' A' ' 72' ' ' ILE . 16.6 mmtp -110.78 137.75 48.04 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 1.1 109.682 173.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.5 mt-10 -134.94 163.94 28.72 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.683 -0.636 . . . . 1.42 110.786 -177.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.95 135.92 4.44 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.56 -1.416 . . . . 0.17 109.56 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.4 m -122.25 137.83 54.7 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.735 -0.862 . . . . 0.21 109.766 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.814 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.2 p90 -155.82 172.88 17.59 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.562 -0.711 . . . . 0.16 110.937 176.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 64.3 m -106.6 140.3 39.68 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.707 -0.621 . . . . 0.13 109.556 173.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.814 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -140.84 144.51 35.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.664 -0.648 . . . . 0.14 110.49 -176.322 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 46.4 ttt180 -93.5 144.73 25.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.845 -0.534 . . . . 2.21 109.569 176.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.4 t -78.47 125.75 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.789 -0.569 . . . . 0.17 109.862 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.77 -167.54 26.26 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.892 -1.283 . . . . 0.19 109.892 178.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -61.68 153.52 27.91 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.756 -0.849 . . . . 1.39 110.163 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 53.57 21.09 2.37 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.51 -0.744 . . . . 0.82 112.008 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.95 20.52 79.72 Favored Glycine 0 N--CA 1.5 2.932 0 C-N-CA 119.814 -1.184 . . . . 0.19 110.837 171.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 15.3 m -77.99 145.26 36.09 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.462 -1.022 . . . . 1.3 110.296 -176.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.68 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.5 p -138.27 146.21 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.772 -0.58 . . . . 0.21 109.559 174.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.8 mm -110.92 122.94 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.521 -0.737 . . . . 0.34 110.671 -174.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.41 HG23 ' HD2' ' A' ' 65' ' ' PRO . 84.7 mt -78.88 143.0 61.26 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.572 -0.705 . . . . 0.34 109.568 172.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.751 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.5 Cg_endo -64.57 133.48 37.15 Favored 'Trans proline' 0 N--CA 1.495 1.572 0 O-C-N 122.954 0.976 . . . . 0.26 110.755 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 27.3 tttp -55.2 -34.0 63.53 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.484 -0.76 . . . . 2.62 110.84 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.74 -37.95 77.34 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.734 -0.604 . . . . 0.45 110.232 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.751 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.5 mt -77.1 -32.65 56.78 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.21 -0.596 . . . . 1.82 110.513 178.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 mtt180 -57.79 -45.52 85.92 Favored 'General case' 0 N--CA 1.504 2.248 0 O-C-N 121.331 -0.856 . . . . 2.53 109.827 178.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -70.28 -47.67 60.16 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 120.506 -0.478 . . . . 1.68 110.467 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 90.8 t -60.58 -38.1 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.106 0 O-C-N 121.683 -0.636 . . . . 0.28 109.816 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.762 HG23 ' HB3' ' A' ' 48' ' ' LYS . 80.4 mt -82.71 -17.47 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.795 -0.566 . . . . 0.28 110.914 -176.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 77.4 35.2 37.97 Favored Glycine 0 N--CA 1.498 2.797 0 N-CA-C 109.78 -1.328 . . . . 0.22 109.78 175.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.893 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.6 mm -90.81 144.15 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 O-C-N 121.535 -0.979 . . . . 0.77 110.673 -174.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -131.39 163.45 49.42 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.776 -0.577 . . . . 3.21 110.685 -177.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.83 134.44 57.14 Favored 'Trans proline' 0 N--CA 1.487 1.142 0 O-C-N 122.934 0.965 . . . . 0.5 110.865 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.83 0.82 71.38 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 111.149 -0.78 . . . . 0.24 111.149 176.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -97.24 132.43 43.01 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-N 118.733 1.266 . . . . 1.11 110.515 179.297 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.0 p -93.46 137.18 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 CA-C-O 121.901 0.858 . . . . 0.24 111.433 -173.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.68 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -126.41 159.52 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 109.391 -0.596 . . . . 0.18 109.391 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -97.52 130.58 44.58 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.942 -0.762 . . . . 1.14 108.942 174.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.84 ' CG1' HD11 ' A' ' 37' ' ' ILE . 91.0 t -115.08 129.96 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 CA-C-O 121.318 0.58 . . . . 0.2 110.158 -171.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 35.3 mt -117.13 129.51 56.02 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 109.047 -0.723 . . . . 0.25 109.047 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.959 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.7 mt -79.77 140.61 36.84 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.718 -0.793 . . . . 0.28 109.848 172.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.9 mt -110.39 -33.38 6.64 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.788 -0.57 . . . . 1.6 110.859 -175.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.584 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -175.89 38.42 Favored Glycine 0 N--CA 1.503 3.148 0 C-N-CA 119.763 -1.208 . . . . 0.2 110.953 -176.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.4 p80 -143.81 153.65 42.59 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.725 -0.867 . . . . 1.89 110.675 -177.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -137.97 142.92 40.47 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.498 -0.751 . . . . 0.8 110.198 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.7 tttt -122.94 159.24 54.65 Favored Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.686 -0.634 . . . . 2.99 109.946 179.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -55.6 143.51 78.7 Favored 'Trans proline' 0 N--CA 1.497 1.718 0 O-C-N 123.142 1.075 . . . . 1.68 110.976 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -128.69 140.72 51.61 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.783 -0.573 . . . . 6.87 110.165 179.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 . . . . . 0 N--CA 1.495 1.806 0 CA-C-O 118.024 -0.988 . . . . 6.47 110.226 -179.898 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.0 mtp . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.172 0.511 . . . . 2.76 110.588 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.4 m-20 -73.4 146.46 45.09 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.896 -0.503 . . . . 1.7 109.946 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.6 p -128.51 136.76 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.663 -0.648 . . . . 0.41 109.671 178.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.571 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.4 mt -84.06 -21.62 31.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.789 -0.569 . . . . 0.37 110.323 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.901 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -172.28 155.46 3.58 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.36 -0.837 . . . . 0.26 109.175 176.466 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.403 ' HG3' HD23 ' A' ' 83' ' ' LEU . 23.1 tttt -133.47 125.56 29.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.668 -0.645 . . . . 2.3 110.175 -177.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.607 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 15.8 p90 -150.84 162.78 40.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.2 110.757 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -113.24 139.07 49.11 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.562 -0.711 . . . . 1.99 110.264 -176.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.04 162.32 41.07 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.825 -0.547 . . . . 0.18 109.646 177.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 t -111.2 158.7 18.64 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.818 -0.753 . . . . 0.17 110.038 177.165 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.4 135.67 25.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.742 -0.599 . . . . 0.49 110.288 -176.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.0 m80 -114.79 171.9 7.36 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-O 121.354 0.597 . . . . 0.68 109.661 174.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -46.65 153.04 0.41 Allowed 'General case' 0 N--CA 1.505 2.318 0 O-C-N 121.532 -0.73 . . . . 2.96 111.956 -176.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.582 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.3 mt 62.75 7.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.662 0 O-C-N 121.599 -0.688 . . . . 0.42 112.619 -175.056 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.86 16.07 80.43 Favored Glycine 0 N--CA 1.496 2.682 0 O-C-N 120.932 -1.105 . . . . 0.24 110.369 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 57.4 ttp180 -83.78 143.04 30.24 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.167 -1.196 . . . . 1.96 110.382 -176.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -131.89 154.66 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 109.365 -0.606 . . . . 0.3 109.365 171.17 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.7 mm -116.65 129.19 73.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 C-N-CA 120.08 -0.648 . . . . 0.25 109.999 176.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.433 HG12 ' CE2' ' A' ' 7' ' ' PHE . 29.1 mt -79.75 145.08 61.54 Favored Pre-proline 0 N--CA 1.495 1.821 0 C-N-CA 120.04 -0.664 . . . . 0.23 109.359 175.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -63.5 143.66 88.51 Favored 'Trans proline' 0 N--CA 1.489 1.212 0 O-C-N 122.986 0.993 . . . . 0.35 109.723 174.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.04 -26.5 60.42 Favored 'General case' 0 N--CA 1.499 1.983 0 C-N-CA 120.449 -0.5 . . . . 0.33 110.426 -178.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.35 -45.19 94.07 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 109.958 -1.257 . . . . 0.39 109.958 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 85.3 m -69.37 -36.98 77.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.66 -0.906 . . . . 0.39 110.117 -179.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.607 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.8 mtt180 -56.41 -41.91 77.12 Favored 'General case' 0 N--CA 1.509 2.502 0 O-C-N 121.323 -0.861 . . . . 0.4 109.662 178.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.5 tptp -66.37 -50.14 64.51 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 120.275 -0.57 . . . . 2.97 110.262 -177.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 76.8 t80 -57.06 -38.19 72.92 Favored 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.925 -0.484 . . . . 0.67 110.694 -178.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.932 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.1 t80 -87.03 -14.28 42.01 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.803 -0.561 . . . . 1.44 111.249 -177.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.94 42.71 24.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.493 -1.443 . . . . 0.31 109.493 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.894 HG23 HG21 ' A' ' 56' ' ' VAL . 75.7 mt -88.06 127.5 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.566 -0.961 . . . . 0.42 110.501 -177.354 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -127.26 154.24 45.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.877 -0.786 . . . . 1.82 108.877 171.384 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -55.18 139.42 42.07 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.245 -0.91 . . . . 1.99 110.706 -177.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.95 -15.76 62.41 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 110.898 -0.881 . . . . 0.19 110.898 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -76.19 158.5 31.61 Favored 'General case' 0 N--CA 1.5 2.031 0 CA-C-N 118.749 1.274 . . . . 1.12 109.992 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -111.57 138.63 47.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.568 -0.708 . . . . 0.21 109.614 175.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.72 154.79 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 109.213 -0.662 . . . . 0.15 109.213 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.85 123.6 48.57 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 108.318 -0.993 . . . . 1.09 108.318 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.827 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.2 tt -140.11 159.5 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.627 -0.829 . . . . 0.14 110.897 -168.066 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.547 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.6 ttpt -133.77 146.01 50.33 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.784 -0.573 . . . . 1.11 110.374 177.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.649 ' HB ' HD12 ' A' ' 80' ' ' ILE . 26.1 pt -114.74 150.4 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.627 -0.671 . . . . 0.2 110.359 177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 57.9 t -140.89 124.53 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.219 0.533 . . . . 0.2 109.807 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.682 ' HB2' HG22 ' A' ' 80' ' ' ILE . 55.0 tttm -132.06 149.86 52.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.363 -0.606 . . . . 1.98 109.363 175.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -100.3 129.18 46.26 Favored 'General case' 0 N--CA 1.497 1.923 0 C-N-CA 119.993 -0.683 . . . . 0.33 110.367 -179.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -132.6 131.32 41.32 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.688 -0.633 . . . . 1.48 110.061 178.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.74 -128.12 45.91 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.809 -1.316 . . . . 0.41 109.809 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 17.8 pt-20 -105.03 9.92 34.25 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.821 -0.811 . . . . 1.27 111.717 177.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -131.1 138.74 33.62 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.238 -0.913 . . . . 1.37 110.837 -178.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -75.4 139.83 23.73 Favored 'Trans proline' 0 N--CA 1.483 0.879 0 O-C-N 122.939 0.968 . . . . 0.34 110.598 176.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.642 ' HB3' HG23 ' A' ' 72' ' ' ILE . 44.5 mmtt -112.93 136.58 52.44 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.502 -0.749 . . . . 1.1 109.583 171.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -138.62 167.9 20.96 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.664 -0.647 . . . . 1.42 110.974 -178.154 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.432 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -159.64 135.71 4.26 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.405 -1.478 . . . . 0.17 109.405 177.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.547 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.1 m -122.74 137.28 54.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.645 -0.915 . . . . 0.21 109.862 177.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.819 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.3 p90 -155.81 173.6 16.52 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.013 -0.675 . . . . 0.16 110.942 178.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 m -106.69 140.38 39.64 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.737 -0.602 . . . . 0.13 109.575 173.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.819 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.81 146.03 35.41 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.739 -0.6 . . . . 0.14 110.563 -175.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 21.9 ttp-105 -93.69 145.28 24.68 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.797 -0.565 . . . . 2.21 109.684 175.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.894 HG21 HG23 ' A' ' 29' ' ' ILE . 98.3 t -78.85 126.57 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 CA-C-O 121.244 0.545 . . . . 0.17 109.861 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.66 -170.6 26.62 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.834 -1.306 . . . . 0.19 109.834 177.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 70.7 tt0 -61.78 156.04 21.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.673 -0.898 . . . . 1.39 109.909 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 55.04 19.05 2.55 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.506 -0.746 . . . . 0.82 112.138 -177.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 72.45 20.46 79.41 Favored Glycine 0 N--CA 1.498 2.827 0 C-N-CA 119.863 -1.161 . . . . 0.19 110.714 172.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 53.7 p -78.64 146.76 33.91 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -1.005 . . . . 1.3 110.373 -176.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.64 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -138.9 146.44 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.751 -0.593 . . . . 0.21 109.553 174.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.3 mm -109.04 122.15 63.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.513 -0.742 . . . . 0.34 110.704 -174.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 72.2 mt -78.84 142.25 60.44 Favored Pre-proline 0 N--CA 1.498 1.96 0 O-C-N 121.423 -0.798 . . . . 0.34 109.486 172.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.745 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.6 Cg_endo -64.83 135.01 42.72 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 O-C-N 122.938 0.967 . . . . 0.26 110.705 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -55.12 -34.21 63.53 Favored 'General case' 0 N--CA 1.503 2.215 0 O-C-N 121.499 -0.751 . . . . 2.62 110.766 179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.69 -37.73 76.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.752 -0.592 . . . . 0.45 110.319 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.745 HD12 ' CG ' ' A' ' 65' ' ' PRO . 67.0 mt -77.03 -32.82 57.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.636 -0.665 . . . . 1.82 110.482 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 39.3 mtt180 -57.72 -45.85 85.2 Favored 'General case' 0 N--CA 1.503 2.193 0 O-C-N 121.419 -0.801 . . . . 2.53 109.951 178.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.33 -47.29 61.76 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 120.532 -0.467 . . . . 1.68 110.483 -175.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.9 t -60.49 -38.25 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.108 0 O-C-N 121.699 -0.626 . . . . 0.28 109.932 -178.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.642 HG23 ' HB3' ' A' ' 48' ' ' LYS . 82.7 mt -82.49 -18.01 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.791 -0.568 . . . . 0.28 110.915 -176.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.34 35.19 43.26 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 109.704 -1.358 . . . . 0.22 109.704 176.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.7 mm -92.65 142.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.576 -0.955 . . . . 0.77 110.64 -174.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 34.9 mtpt -130.25 163.22 49.36 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.748 -0.595 . . . . 3.21 110.792 -177.181 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_endo -59.76 135.41 63.58 Favored 'Trans proline' 0 N--CA 1.487 1.111 0 O-C-N 122.922 0.959 . . . . 0.5 110.92 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.72 -0.15 73.18 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 111.08 -0.808 . . . . 0.24 111.08 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -97.47 133.11 42.49 Favored 'General case' 0 N--CA 1.498 1.929 0 CA-C-N 118.691 1.246 . . . . 1.11 110.552 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 p -92.02 133.37 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-O 121.67 0.747 . . . . 0.24 111.26 -174.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.682 HG22 ' HB2' ' A' ' 41' ' ' LYS . 41.4 pt -123.48 159.52 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 109.272 -0.64 . . . . 0.18 109.272 176.143 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 47.4 tt0 -98.44 131.1 44.98 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.963 -0.754 . . . . 1.14 108.963 176.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.827 ' CG1' HD11 ' A' ' 37' ' ' ILE . 83.9 t -114.95 130.24 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.394 0.616 . . . . 0.2 110.28 -170.524 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.403 HD23 ' HG3' ' A' ' 6' ' ' LYS . 33.5 mt -116.3 130.74 56.93 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 109.074 -0.713 . . . . 0.25 109.074 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.932 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.7 mt -80.55 140.86 35.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.356 -0.84 . . . . 0.28 109.791 172.204 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -113.18 -31.01 6.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.654 -0.654 . . . . 1.6 111.046 -175.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.571 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.18 -177.78 39.58 Favored Glycine 0 N--CA 1.504 3.186 0 C-N-CA 119.65 -1.262 . . . . 0.2 110.978 -176.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 p80 -144.94 153.52 41.62 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.719 -0.871 . . . . 1.89 110.59 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -135.95 138.69 42.6 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.527 -0.733 . . . . 0.8 110.278 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -117.66 110.56 40.36 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.786 -0.571 . . . . 2.99 110.205 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -54.22 147.27 45.87 Favored 'Trans proline' 0 N--CA 1.499 1.824 0 O-C-N 122.988 0.994 . . . . 1.68 111.109 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 16.8 tpt180 -120.39 144.08 48.1 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 6.87 110.271 -178.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 . . . . . 0 N--CA 1.496 1.866 0 CA-C-O 118.021 -0.99 . . . . 6.47 110.161 179.826 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.9 ttm . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.005 0.431 . . . . 2.76 110.162 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -78.28 140.18 38.85 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.718 -0.614 . . . . 1.7 110.025 178.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 p -128.11 136.04 61.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.781 -0.575 . . . . 0.41 109.655 178.231 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.574 HD11 ' HA2' ' A' ' 86' ' ' GLY . 26.7 mt -83.91 -19.1 35.34 Favored 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 120.198 -0.601 . . . . 0.37 110.378 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.871 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.4 153.3 3.51 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.292 -0.88 . . . . 0.26 109.335 176.047 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -134.16 125.45 27.93 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.697 -0.627 . . . . 2.3 110.089 -177.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.595 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 14.8 p90 -150.26 162.62 40.14 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.591 -0.693 . . . . 0.2 110.852 -179.241 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -113.53 138.29 50.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.61 -0.681 . . . . 1.99 110.102 -176.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -151.08 162.29 41.12 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.661 -0.649 . . . . 0.18 109.679 177.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.8 t -110.11 157.83 18.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.465 -0.772 . . . . 0.17 110.03 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.0 t -79.61 136.43 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.783 -0.573 . . . . 0.49 110.319 -176.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.7 m80 -113.32 171.95 7.25 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.215 0.531 . . . . 0.68 109.686 173.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 85.3 mtt180 -46.67 152.31 0.49 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.607 -0.683 . . . . 2.96 111.896 -175.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.588 ' O ' HG22 ' A' ' 14' ' ' ILE . 55.6 mt 62.6 7.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.635 0 O-C-N 121.559 -0.713 . . . . 0.42 112.601 -175.341 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.84 16.12 80.39 Favored Glycine 0 N--CA 1.499 2.878 0 N-CA-C 110.364 -1.095 . . . . 0.24 110.364 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 60.8 ttt180 -83.92 140.73 31.76 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.18 -1.188 . . . . 1.96 110.249 -176.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.6 pt -133.67 155.48 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.698 -0.626 . . . . 0.3 109.757 174.091 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.3 mm -118.16 129.79 73.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.62 -0.675 . . . . 0.25 109.998 175.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.5 mt -79.61 145.97 64.19 Favored Pre-proline 0 N--CA 1.495 1.777 0 C-N-CA 120.052 -0.659 . . . . 0.23 109.396 175.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.16 142.89 88.66 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 O-C-N 123.012 1.006 . . . . 0.35 109.823 174.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.22 -26.56 60.91 Favored 'General case' 0 N--CA 1.498 1.955 0 C-N-CA 120.403 -0.519 . . . . 0.33 110.49 -178.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.43 -45.01 94.45 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 109.973 -1.251 . . . . 0.39 109.973 -179.015 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 96.6 m -69.66 -37.0 76.54 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.63 -0.923 . . . . 0.39 109.878 -179.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.637 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.2 -42.27 76.93 Favored 'General case' 0 N--CA 1.509 2.508 0 O-C-N 121.298 -0.876 . . . . 0.4 109.77 178.111 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -65.91 -50.14 65.5 Favored 'General case' 0 N--CA 1.496 1.874 0 CA-C-O 121.282 0.563 . . . . 2.97 110.116 -177.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -56.46 -37.54 70.43 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.136 0.493 . . . . 0.67 110.725 -179.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.972 ' CD2' HD13 ' A' ' 84' ' ' LEU . 23.0 t80 -88.19 -14.15 39.33 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.784 -0.572 . . . . 1.44 111.315 -176.649 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.88 42.89 24.18 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.543 -1.423 . . . . 0.31 109.543 178.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.933 HG23 HG21 ' A' ' 56' ' ' VAL . 75.4 mt -87.84 126.92 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.519 -0.989 . . . . 0.42 110.653 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -127.91 155.64 43.87 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 109.134 -0.691 . . . . 1.82 109.134 171.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -55.56 137.49 48.71 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.308 -0.87 . . . . 1.99 110.79 -177.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.51 -15.08 64.07 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.926 -0.87 . . . . 0.19 110.926 178.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -76.01 157.55 32.9 Favored 'General case' 0 N--CA 1.5 2.049 0 CA-C-N 118.76 1.28 . . . . 1.12 109.862 177.146 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -111.51 138.16 48.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.631 -0.668 . . . . 0.21 109.611 175.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.99 152.06 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 120.087 -0.645 . . . . 0.15 109.309 174.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 50.8 tt0 -113.74 123.51 50.05 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.172 -1.047 . . . . 1.09 108.172 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.835 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.2 tt -139.87 157.57 26.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.584 -0.846 . . . . 0.14 110.886 -167.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -133.1 146.06 51.29 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.801 -0.562 . . . . 1.11 110.474 178.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.532 HG22 HG22 ' A' ' 82' ' ' VAL . 27.9 pt -114.9 151.1 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.758 -0.589 . . . . 0.2 110.54 178.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.485 HG13 ' HG2' ' A' ' 49' ' ' GLU . 60.3 t -138.38 127.37 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 109.674 -0.491 . . . . 0.2 109.674 176.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.595 ' HB2' HG22 ' A' ' 80' ' ' ILE . 60.8 tttm -133.47 144.43 49.45 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 109.538 -0.542 . . . . 1.98 109.538 175.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 52.6 t80 -105.84 129.4 54.02 Favored 'General case' 0 N--CA 1.495 1.808 0 C-N-CA 120.262 -0.575 . . . . 0.33 110.355 -178.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -133.48 131.43 39.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.682 -0.636 . . . . 1.48 110.14 176.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.84 -128.18 45.92 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 109.785 -1.326 . . . . 0.41 109.785 -177.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -105.16 13.92 29.92 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.725 -0.867 . . . . 1.27 111.624 178.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -131.13 122.84 19.42 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.302 -0.874 . . . . 1.37 111.214 -177.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -75.48 142.35 26.34 Favored 'Trans proline' 0 N--CA 1.483 0.89 0 N-CA-C 109.936 -0.832 . . . . 0.34 109.936 173.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.425 ' CB ' HG23 ' A' ' 72' ' ' ILE . 32.4 mttt -120.73 149.77 42.01 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.34 -0.85 . . . . 1.1 110.147 171.641 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.485 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -137.2 167.66 21.14 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.851 -0.531 . . . . 1.42 110.731 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.57 135.86 4.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.342 -1.503 . . . . 0.17 109.342 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 4.2 m -122.95 137.99 54.8 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.658 -0.907 . . . . 0.21 109.887 178.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.812 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 13.3 p90 -155.96 172.61 18.09 Favored 'General case' 0 N--CA 1.497 1.918 0 C-N-CA 119.88 -0.728 . . . . 0.16 110.969 175.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 60.2 m -107.54 140.45 40.52 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.685 -0.634 . . . . 0.13 109.598 174.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.812 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.55 144.49 34.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.62 -0.675 . . . . 0.14 110.527 -176.032 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -93.78 145.7 24.4 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.693 -0.629 . . . . 2.21 109.67 175.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.933 HG21 HG23 ' A' ' 29' ' ' ILE . 99.3 t -78.11 126.66 38.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.821 -0.55 . . . . 0.17 109.93 -178.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.92 -166.4 25.08 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.101 -1.2 . . . . 0.19 110.101 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.71 152.79 30.08 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.779 -0.836 . . . . 1.39 110.131 -179.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.4 mt-30 53.64 21.02 2.39 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.557 -0.715 . . . . 0.82 112.03 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.31 20.49 79.91 Favored Glycine 0 N--CA 1.5 2.904 0 C-N-CA 119.802 -1.189 . . . . 0.19 110.776 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.403 ' HA ' HD13 ' A' ' 18' ' ' ILE . 51.5 p -79.08 148.36 32.45 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.465 -1.021 . . . . 1.3 110.43 -176.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.9 p -139.67 147.14 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.878 -0.514 . . . . 0.21 109.67 174.686 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.2 mm -108.5 121.85 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.536 -0.728 . . . . 0.34 110.535 -175.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.411 HG23 ' HD2' ' A' ' 65' ' ' PRO . 78.6 mt -78.68 143.02 62.16 Favored Pre-proline 0 N--CA 1.498 1.967 0 O-C-N 121.6 -0.687 . . . . 0.34 109.619 173.506 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.748 ' CG ' HD12 ' A' ' 68' ' ' LEU . 58.0 Cg_endo -64.92 131.46 29.03 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 O-C-N 122.936 0.966 . . . . 0.26 110.784 -179.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 50.3 tttp -55.12 -34.07 63.4 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.424 -0.797 . . . . 2.62 110.846 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.72 -37.72 76.77 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.722 -0.611 . . . . 0.45 110.269 -178.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.748 HD12 ' CG ' ' A' ' 65' ' ' PRO . 73.9 mt -77.16 -32.71 56.43 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.21 -0.596 . . . . 1.82 110.494 178.176 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 mtt180 -57.55 -45.57 84.96 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.231 -0.918 . . . . 2.53 109.829 178.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -69.9 -46.97 64.26 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 120.441 -0.504 . . . . 1.68 110.371 -174.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 93.8 t -60.56 -38.6 78.76 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.678 -0.639 . . . . 0.28 109.901 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.56 HG22 HD11 ' A' ' 74' ' ' ILE . 86.8 mt -83.26 -15.8 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.896 -0.503 . . . . 0.28 111.143 -176.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.97 35.25 39.63 Favored Glycine 0 N--CA 1.499 2.841 0 N-CA-C 109.931 -1.268 . . . . 0.22 109.931 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 51.4 mm -89.96 141.06 14.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.086 0 O-C-N 121.574 -0.957 . . . . 0.77 110.716 -174.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -130.61 159.26 71.8 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.808 -0.558 . . . . 3.21 110.69 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -54.63 133.63 57.97 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 122.98 0.99 . . . . 0.5 111.391 177.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.02 0.34 71.51 Favored Glycine 0 N--CA 1.497 2.71 0 N-CA-C 111.205 -0.758 . . . . 0.24 111.205 175.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -98.05 134.1 41.6 Favored 'General case' 0 N--CA 1.498 1.973 0 CA-C-N 118.769 1.285 . . . . 1.11 110.603 179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.405 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.4 p -92.34 132.9 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 CA-C-O 121.55 0.691 . . . . 0.24 111.15 -174.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.595 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.8 pt -122.39 159.4 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 109.353 -0.61 . . . . 0.18 109.353 175.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 48.3 tt0 -98.85 131.71 44.75 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.007 -0.738 . . . . 1.14 109.007 175.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.835 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.1 t -116.16 129.88 71.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 CA-C-O 121.298 0.57 . . . . 0.2 110.362 -170.207 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 38.1 mt -115.83 130.94 57.04 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.188 -0.671 . . . . 0.25 109.188 178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.972 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.3 mt -80.27 140.18 36.32 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.375 -0.828 . . . . 0.28 109.797 171.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.2 mt -109.36 -31.21 7.63 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.825 -0.547 . . . . 1.6 110.898 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.574 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.05 179.39 41.29 Favored Glycine 0 N--CA 1.503 3.136 0 C-N-CA 119.728 -1.225 . . . . 0.2 110.986 -177.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.406 ' O ' ' CD1' ' A' ' 88' ' ' TYR . 29.2 p80 -140.6 145.67 37.0 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.728 -0.866 . . . . 1.89 110.072 -179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.406 ' CD1' ' O ' ' A' ' 87' ' ' HIS . 17.8 m-85 -131.34 138.95 49.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.506 -0.746 . . . . 0.8 109.943 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -83.73 156.31 64.79 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.783 -0.573 . . . . 2.99 110.251 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -55.12 142.52 77.41 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.171 1.09 . . . . 1.68 110.936 179.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -128.29 141.34 51.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.703 -0.623 . . . . 6.87 110.163 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 118.015 -0.993 . . . . 6.47 110.178 179.846 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.4 ptm . . . . . 0 N--CA 1.496 1.874 0 CA-C-O 121.479 0.657 . . . . 2.76 110.12 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -100.34 146.77 26.56 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 120.893 0.378 . . . . 1.7 110.127 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.564 HG23 ' O ' ' A' ' 84' ' ' LEU . 4.6 p -127.93 141.07 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 121.795 -0.566 . . . . 0.41 109.644 178.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.578 HD11 ' HA2' ' A' ' 86' ' ' GLY . 30.9 mt -87.57 -17.93 30.87 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.744 -0.598 . . . . 0.37 110.708 -177.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.868 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.83 155.96 4.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.253 -0.904 . . . . 0.26 109.742 176.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -133.29 126.6 31.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.762 -0.586 . . . . 2.3 110.096 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.605 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -149.48 161.94 41.12 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.651 -0.656 . . . . 0.2 110.871 179.321 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CE1' ' HG3' ' A' ' 81' ' ' GLU . 94.6 m-70 -111.73 138.02 48.86 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.617 -0.677 . . . . 1.99 110.17 -176.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.41 162.29 41.2 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.727 -0.608 . . . . 0.18 109.774 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.5 t -111.71 159.33 18.34 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 119.925 -0.71 . . . . 0.17 109.89 176.094 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.896 HG21 ' CG2' ' A' ' 74' ' ' ILE . 60.8 t -77.83 138.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 120.304 -0.558 . . . . 0.49 110.103 -177.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 15.7 m80 -116.67 171.9 7.57 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.327 0.584 . . . . 0.68 109.672 174.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 36.6 mmm-85 -46.91 153.13 0.44 Allowed 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.537 -0.727 . . . . 2.96 111.927 -175.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.578 ' O ' HG22 ' A' ' 14' ' ' ILE . 54.0 mt 63.1 7.22 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.513 2.681 0 O-C-N 121.601 -0.687 . . . . 0.42 112.643 -175.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.54 15.98 80.79 Favored Glycine 0 N--CA 1.498 2.791 0 O-C-N 120.829 -1.169 . . . . 0.24 110.292 179.455 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.0 ttm180 -85.94 145.39 27.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.324 -1.104 . . . . 1.96 110.352 -177.221 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.18 154.52 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.727 -0.608 . . . . 0.3 109.466 172.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.453 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.83 128.72 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.57 -0.706 . . . . 0.25 109.99 176.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.437 HG12 ' CE2' ' A' ' 7' ' ' PHE . 31.7 mt -79.98 145.09 60.57 Favored Pre-proline 0 N--CA 1.495 1.802 0 C-N-CA 120.084 -0.646 . . . . 0.23 109.37 175.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.27 143.06 88.53 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 122.917 0.956 . . . . 0.35 109.812 174.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.6 -26.42 61.5 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.867 -0.521 . . . . 0.33 110.489 -178.319 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.82 -44.37 94.8 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.39 109.914 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 80.8 m -69.69 -38.13 76.89 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.637 -0.919 . . . . 0.39 110.179 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.668 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -56.18 -41.23 75.19 Favored 'General case' 0 N--CA 1.512 2.648 0 O-C-N 121.274 -0.891 . . . . 0.4 109.493 176.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.5 tttp -65.53 -50.0 66.83 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.166 0.508 . . . . 2.97 110.142 -176.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.8 t80 -57.39 -37.96 73.5 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.749 -0.594 . . . . 0.67 110.725 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.945 ' CD2' HD13 ' A' ' 84' ' ' LEU . 18.6 t80 -87.99 -14.31 39.45 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.766 -0.584 . . . . 1.44 111.239 -176.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.48 42.45 27.32 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.548 -1.421 . . . . 0.31 109.548 177.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.899 HG23 HG21 ' A' ' 56' ' ' VAL . 76.4 mt -88.49 129.18 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.545 -0.974 . . . . 0.42 110.572 -176.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -129.07 158.76 38.02 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.929 -0.767 . . . . 1.82 108.929 170.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 62.1 tt0 -57.45 140.54 50.26 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.315 -0.865 . . . . 1.99 110.426 -178.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.73 -16.06 61.65 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -77.06 157.95 30.81 Favored 'General case' 0 N--CA 1.5 2.058 0 CA-C-N 118.724 1.262 . . . . 1.12 110.121 178.077 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -111.55 138.67 47.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.582 -0.699 . . . . 0.21 109.611 174.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.88 154.16 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 109.272 -0.64 . . . . 0.15 109.272 174.179 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -116.32 124.07 49.21 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.274 -1.01 . . . . 1.09 108.274 -179.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.83 HD11 ' CG1' ' A' ' 82' ' ' VAL . 12.5 tt -140.23 157.91 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 C-N-CA 119.558 -0.857 . . . . 0.14 111.053 -167.181 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 29.6 tttt -132.81 146.07 51.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.76 -0.587 . . . . 1.11 110.517 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.562 HG22 HG22 ' A' ' 82' ' ' VAL . 33.6 pt -114.94 150.94 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.598 -0.689 . . . . 0.2 110.544 178.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.9 t -138.08 125.13 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.177 0.513 . . . . 0.2 109.655 176.104 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.677 ' HB2' HG22 ' A' ' 80' ' ' ILE . 47.4 tttp -134.17 147.48 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.725 -0.609 . . . . 1.98 109.495 175.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -102.61 127.93 49.5 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.092 -0.643 . . . . 0.33 110.266 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 91.3 mt-10 -136.24 137.91 41.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.603 -0.685 . . . . 1.48 110.128 178.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.82 -128.27 46.14 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.761 -1.336 . . . . 0.41 109.761 -178.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -105.12 7.26 33.74 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.746 -0.855 . . . . 1.27 111.815 177.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.24 141.74 42.94 Favored Pre-proline 0 N--CA 1.499 2.016 0 O-C-N 121.2 -0.937 . . . . 1.37 110.956 -177.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -75.27 138.93 23.02 Favored 'Trans proline' 0 N--CA 1.481 0.768 0 O-C-N 122.839 0.915 . . . . 0.34 110.198 172.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.69 ' HB3' HG23 ' A' ' 72' ' ' ILE . 66.1 mmtt -111.06 137.78 48.29 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.527 -0.733 . . . . 1.1 109.432 172.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.65 164.46 27.81 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.555 -0.716 . . . . 1.42 110.997 -176.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.9 4.37 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.659 -1.377 . . . . 0.17 109.659 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.0 m -123.68 137.72 54.66 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.638 -0.919 . . . . 0.21 109.792 176.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 12.6 p90 -156.36 172.76 17.95 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.963 -0.695 . . . . 0.16 111.047 176.264 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.6 m -106.68 140.91 38.79 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.677 -0.639 . . . . 0.13 109.414 173.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.16 145.89 36.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.652 -0.655 . . . . 0.14 110.697 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 55.0 ttt180 -93.29 145.33 24.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.833 -0.542 . . . . 2.21 109.616 175.559 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.899 HG21 HG23 ' A' ' 29' ' ' ILE . 90.1 t -79.01 125.96 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 121.419 0.628 . . . . 0.17 109.722 179.594 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.7 -166.47 26.25 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.961 -1.256 . . . . 0.19 109.961 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -61.73 151.98 32.43 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.804 -0.821 . . . . 1.39 110.139 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 53.32 21.53 2.36 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.523 -0.736 . . . . 0.82 112.054 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.77 20.42 79.77 Favored Glycine 0 N--CA 1.498 2.832 0 C-N-CA 119.796 -1.192 . . . . 0.19 110.879 171.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.453 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.1 p -78.56 147.02 33.93 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.518 -0.989 . . . . 1.3 110.22 -178.004 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.727 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.6 p -139.26 146.39 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.8 -0.563 . . . . 0.21 109.525 175.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.95 123.81 66.16 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.58 -0.7 . . . . 0.34 110.583 -175.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.434 HG23 ' HD2' ' A' ' 65' ' ' PRO . 86.4 mt -78.32 144.06 65.72 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.643 -0.661 . . . . 0.34 109.432 172.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.755 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.4 Cg_endo -64.49 135.36 45.53 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 O-C-N 122.966 0.982 . . . . 0.26 110.73 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 38.2 tttp -55.08 -34.21 63.44 Favored 'General case' 0 N--CA 1.503 2.206 0 O-C-N 121.545 -0.722 . . . . 2.62 110.75 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.87 -38.33 78.57 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.779 -0.576 . . . . 0.45 110.343 -178.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.755 HD12 ' CG ' ' A' ' 65' ' ' PRO . 70.3 mt -77.13 -32.87 56.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.747 -0.595 . . . . 1.82 110.617 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.1 mtt180 -58.05 -45.82 86.38 Favored 'General case' 0 N--CA 1.504 2.245 0 O-C-N 121.35 -0.843 . . . . 2.53 109.882 178.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.18 -46.76 63.96 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 120.511 -0.476 . . . . 1.68 110.425 -175.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 89.8 t -60.58 -38.28 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.704 -0.623 . . . . 0.28 109.853 -178.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.695 HG22 HD11 ' A' ' 74' ' ' ILE . 81.5 mt -82.68 -17.52 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.874 -0.516 . . . . 0.28 110.872 -176.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.89 35.11 40.51 Favored Glycine 0 N--CA 1.497 2.73 0 N-CA-C 109.693 -1.363 . . . . 0.22 109.693 175.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.896 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.1 mm -93.07 142.89 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.599 -0.942 . . . . 0.77 110.77 -173.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.2 ptmt -132.94 162.64 56.35 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.742 -0.599 . . . . 3.21 110.652 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -51.97 135.44 51.11 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.056 1.03 . . . . 0.5 111.887 178.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.95 -1.51 70.87 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 120.704 -0.76 . . . . 0.24 111.357 174.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -96.33 130.92 43.33 Favored 'General case' 0 N--CA 1.5 2.046 0 CA-C-N 118.767 1.284 . . . . 1.11 110.614 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.79 134.35 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 CA-C-O 121.684 0.754 . . . . 0.24 111.296 -173.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.677 HG22 ' HB2' ' A' ' 41' ' ' LYS . 44.4 pt -125.58 159.46 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 109.567 -0.531 . . . . 0.18 109.567 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.416 ' HG3' ' CE1' ' A' ' 8' ' ' HIS . 85.1 tt0 -97.61 132.04 43.63 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.075 -0.713 . . . . 1.14 109.075 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.83 ' CG1' HD11 ' A' ' 37' ' ' ILE . 96.7 t -116.32 129.89 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 CA-C-O 121.344 0.592 . . . . 0.2 110.264 -171.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -115.34 130.3 56.86 Favored 'General case' 0 N--CA 1.495 1.809 0 N-CA-C 109.262 -0.644 . . . . 0.25 109.262 178.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.945 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.2 mt -79.96 138.81 37.16 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.345 -0.847 . . . . 0.28 109.914 172.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.0 mt -105.76 -35.9 7.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.726 -0.609 . . . . 1.6 110.918 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.83 -176.03 38.69 Favored Glycine 0 N--CA 1.503 3.166 0 C-N-CA 119.79 -1.195 . . . . 0.2 110.817 -176.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -142.72 152.65 42.57 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.677 -0.896 . . . . 1.89 110.798 -177.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -135.22 139.53 44.56 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.535 -0.728 . . . . 0.8 110.064 175.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 90' ' ' PRO . 0.1 OUTLIER -101.81 135.22 19.78 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.788 -0.57 . . . . 2.99 110.282 -179.577 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 89' ' ' LYS . 73.4 Cg_exo -56.28 150.48 49.38 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 O-C-N 123.107 1.056 . . . . 1.68 110.903 179.007 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -119.99 141.71 49.45 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.771 -0.58 . . . . 6.87 110.254 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 58.2 t30 . . . . . 0 N--CA 1.495 1.78 0 CA-C-O 117.971 -1.014 . . . . 6.47 110.196 -179.919 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.3 mtp . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.168 0.509 . . . . 2.76 110.557 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -73.96 142.11 45.87 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.891 -0.506 . . . . 1.7 110.105 178.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 p -127.72 136.84 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 109.522 -0.547 . . . . 0.41 109.522 178.187 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.572 HD11 ' HA2' ' A' ' 86' ' ' GLY . 29.0 mt -85.62 -18.36 33.49 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.728 -0.608 . . . . 0.37 110.32 178.119 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.832 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -174.5 151.27 1.51 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.244 -0.91 . . . . 0.26 108.997 176.08 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 14.8 ttpt -134.96 127.82 31.3 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.649 -0.657 . . . . 2.3 110.295 -178.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.603 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 16.8 p90 -150.36 163.14 39.09 Favored 'General case' 0 N--CA 1.495 1.824 0 C-N-CA 120.345 -0.542 . . . . 0.2 110.595 -177.426 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.423 ' CD2' ' HG3' ' A' ' 81' ' ' GLU . 62.7 m170 -112.65 137.7 50.54 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.648 -0.657 . . . . 1.99 110.256 -176.776 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.8 t -150.83 162.31 40.99 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.752 -0.592 . . . . 0.18 109.585 177.13 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.6 t -110.06 159.29 17.44 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.765 -0.774 . . . . 0.17 110.139 177.675 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.901 HG21 ' CG2' ' A' ' 74' ' ' ILE . 59.6 t -79.05 136.27 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 120.298 -0.561 . . . . 0.49 110.254 -177.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -115.42 171.95 7.39 Favored 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.253 0.549 . . . . 0.68 109.726 175.356 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -46.64 153.03 0.41 Allowed 'General case' 0 N--CA 1.506 2.366 0 O-C-N 121.583 -0.698 . . . . 2.96 111.882 -176.138 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.581 ' O ' HG22 ' A' ' 14' ' ' ILE . 53.9 mt 62.94 7.07 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.666 0 O-C-N 121.525 -0.735 . . . . 0.42 112.629 -175.439 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.6 16.11 80.59 Favored Glycine 0 N--CA 1.498 2.792 0 O-C-N 120.895 -1.128 . . . . 0.24 110.33 179.389 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 ttm180 -85.43 144.16 28.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.255 -1.144 . . . . 1.96 110.293 -177.147 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 41.9 pt -132.46 155.09 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.725 -0.609 . . . . 0.3 109.463 172.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 61' ' ' SER . 48.5 mm -116.74 129.43 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.665 -0.647 . . . . 0.25 109.991 176.473 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.436 HG12 ' CE2' ' A' ' 7' ' ' PHE . 23.3 mt -79.61 145.99 64.23 Favored Pre-proline 0 N--CA 1.494 1.768 0 C-N-CA 120.061 -0.656 . . . . 0.23 109.321 175.682 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.41 ' HD2' HG23 ' A' ' 19' ' ' ILE . 50.1 Cg_endo -63.47 143.21 87.66 Favored 'Trans proline' 0 N--CA 1.489 1.228 0 O-C-N 123.069 1.036 . . . . 0.35 109.698 174.652 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.31 -26.34 60.74 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.813 -0.555 . . . . 0.33 110.438 -178.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.34 -45.23 93.98 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.015 -1.234 . . . . 0.39 110.015 -179.323 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 73.1 m -69.27 -37.3 77.84 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.706 -0.879 . . . . 0.39 110.187 -179.579 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.592 ' HA ' HD12 ' A' ' 29' ' ' ILE . 9.4 mtt180 -56.24 -42.06 76.73 Favored 'General case' 0 N--CA 1.509 2.487 0 O-C-N 121.434 -0.791 . . . . 0.4 109.751 178.378 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -66.62 -50.24 63.66 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-O 121.272 0.558 . . . . 2.97 110.233 -177.024 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -57.27 -37.87 73.04 Favored 'General case' 0 N--CA 1.501 2.109 0 CA-C-O 121.205 0.526 . . . . 0.67 110.704 -179.039 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.95 ' CD2' HD13 ' A' ' 84' ' ' LEU . 17.5 t80 -87.69 -14.21 40.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.744 -0.597 . . . . 1.44 111.223 -176.795 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.17 26.76 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.598 -1.401 . . . . 0.31 109.598 177.674 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.916 HG23 HG21 ' A' ' 56' ' ' VAL . 73.1 mt -89.44 127.79 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.062 0 O-C-N 121.452 -1.028 . . . . 0.42 110.462 -176.545 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -128.21 159.7 34.39 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.114 -0.699 . . . . 1.82 109.114 171.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -57.2 139.36 52.88 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.364 -0.835 . . . . 1.99 110.541 -178.219 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 93.43 -15.77 62.2 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 110.843 -0.903 . . . . 0.19 110.843 178.232 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -76.07 158.74 31.49 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 118.701 1.25 . . . . 1.12 109.991 178.037 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -111.71 138.16 48.65 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.634 -0.666 . . . . 0.21 109.645 175.408 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.36 153.5 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 N-CA-C 109.164 -0.68 . . . . 0.15 109.164 173.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -115.3 123.16 48.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.227 -1.027 . . . . 1.09 108.227 -179.628 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.819 HD11 ' CG1' ' A' ' 82' ' ' VAL . 10.6 tt -140.38 158.33 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.593 -0.843 . . . . 0.14 110.946 -167.564 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.561 ' HB2' HG23 ' A' ' 51' ' ' THR . 18.9 ttpt -132.07 146.14 51.87 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.815 -0.553 . . . . 1.11 110.428 177.286 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.581 HG22 HG22 ' A' ' 82' ' ' VAL . 23.9 pt -114.92 150.55 16.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.2 110.305 176.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.545 HG13 ' HG2' ' A' ' 49' ' ' GLU . 61.3 t -139.58 124.35 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 CA-C-O 121.292 0.567 . . . . 0.2 109.692 177.355 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.704 ' HB2' HG22 ' A' ' 80' ' ' ILE . 45.2 tptt -135.99 147.89 48.19 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.731 -0.605 . . . . 1.98 109.415 176.758 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -101.25 129.56 47.22 Favored 'General case' 0 N--CA 1.496 1.834 0 C-N-CA 120.071 -0.652 . . . . 0.33 110.403 -177.566 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.459 ' OE2' HD13 ' A' ' 74' ' ' ILE . 93.6 mt-10 -135.65 136.82 41.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.689 -0.632 . . . . 1.48 110.045 178.26 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.84 -128.21 45.97 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 109.817 -1.313 . . . . 0.41 109.817 -178.519 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -105.02 8.03 34.23 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.734 -0.862 . . . . 1.27 111.833 178.438 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -131.15 141.87 43.46 Favored Pre-proline 0 N--CA 1.497 1.907 0 O-C-N 121.154 -0.966 . . . . 1.37 110.93 -177.607 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -75.24 137.88 21.75 Favored 'Trans proline' 0 N--CA 1.48 0.735 0 O-C-N 122.92 0.958 . . . . 0.34 110.198 173.441 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.717 ' HB3' HG23 ' A' ' 72' ' ' ILE . 22.7 mmtp -110.69 137.27 48.57 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.56 -0.712 . . . . 1.1 109.577 173.217 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.545 ' HG2' HG13 ' A' ' 40' ' ' VAL . 93.6 mt-10 -135.09 163.91 28.83 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.595 -0.691 . . . . 1.42 111.027 -176.328 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -158.75 135.72 4.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.488 -1.445 . . . . 0.17 109.488 176.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 38' ' ' LYS . 2.8 m -124.5 136.86 54.34 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.733 -0.863 . . . . 0.21 109.823 177.288 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.816 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.6 p90 -155.93 173.62 16.53 Favored 'General case' 0 N--CA 1.497 1.897 0 C-N-CA 119.888 -0.725 . . . . 0.16 111.046 178.267 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.7 m -107.71 141.02 39.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.713 -0.617 . . . . 0.13 109.518 173.583 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.816 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -141.89 145.84 35.06 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.64 -0.663 . . . . 0.14 110.672 -175.709 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 43.6 ttp180 -93.72 146.03 24.15 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.758 -0.589 . . . . 2.21 109.674 175.248 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.916 HG21 HG23 ' A' ' 29' ' ' ILE . 99.0 t -78.28 127.16 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.821 -0.55 . . . . 0.17 109.995 -178.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -102.96 -168.06 26.1 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.995 -1.242 . . . . 0.19 109.995 178.869 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -61.7 153.47 28.15 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.712 -0.875 . . . . 1.39 110.175 -179.727 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.68 20.89 2.37 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.596 -0.69 . . . . 0.82 112.105 -179.698 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.6 20.46 79.82 Favored Glycine 0 N--CA 1.5 2.957 0 C-N-CA 119.763 -1.208 . . . . 0.19 110.826 171.613 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.424 ' HA ' HD13 ' A' ' 18' ' ' ILE . 53.9 p -78.67 147.26 33.61 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.541 -0.976 . . . . 1.3 110.328 -177.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.632 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.7 p -138.75 146.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 109.515 -0.55 . . . . 0.21 109.515 174.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 48.8 mm -109.8 123.89 66.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.527 -0.733 . . . . 0.34 110.612 -174.559 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.44 HG23 ' HD2' ' A' ' 65' ' ' PRO . 88.5 mt -78.23 144.27 66.52 Favored Pre-proline 0 N--CA 1.499 2.024 0 O-C-N 121.59 -0.694 . . . . 0.34 109.392 172.368 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.753 ' CG ' HD12 ' A' ' 68' ' ' LEU . 57.1 Cg_endo -64.34 135.61 47.22 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 O-C-N 122.965 0.981 . . . . 0.26 110.71 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 23.0 tptm -55.02 -34.85 63.82 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.368 -0.833 . . . . 2.62 110.769 -179.772 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -58.92 -38.3 78.65 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.79 -0.569 . . . . 0.45 110.276 -178.494 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.753 HD12 ' CG ' ' A' ' 65' ' ' PRO . 69.4 mt -77.05 -32.81 57.13 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.727 -0.608 . . . . 1.82 110.695 179.432 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.2 mtt180 -58.15 -46.22 86.05 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.351 -0.843 . . . . 2.53 109.845 178.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -70.43 -47.38 61.01 Favored 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 120.49 -0.484 . . . . 1.68 110.468 -175.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 88.8 t -60.64 -37.96 77.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 O-C-N 121.702 -0.624 . . . . 0.28 109.94 -178.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.717 HG23 ' HB3' ' A' ' 48' ' ' LYS . 85.7 mt -82.56 -17.82 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.833 -0.542 . . . . 0.28 110.823 -176.473 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.7 35.22 41.23 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.776 -1.33 . . . . 0.22 109.776 175.706 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.901 ' CG2' HG21 ' A' ' 11' ' ' VAL . 50.5 mm -90.12 142.69 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.46 -1.023 . . . . 0.77 110.665 -173.86 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -127.94 156.29 76.3 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.789 -0.569 . . . . 3.21 110.618 -177.807 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -55.44 135.87 71.16 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.018 1.009 . . . . 0.5 111.257 178.197 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 92.35 -1.53 73.06 Favored Glycine 0 N--CA 1.496 2.678 0 C-N-CA 120.622 -0.799 . . . . 0.24 111.235 176.191 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.2 mt-10 -96.2 132.27 41.81 Favored 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 118.729 1.264 . . . . 1.11 110.429 179.033 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 79' ' ' VAL . 11.1 p -91.57 130.71 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.49 0.662 . . . . 0.24 110.98 -174.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.704 HG22 ' HB2' ' A' ' 41' ' ' LYS . 46.6 pt -119.34 159.48 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 N-CA-C 109.579 -0.526 . . . . 0.18 109.579 178.055 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.423 ' HG3' ' CD2' ' A' ' 8' ' ' HIS . 82.0 tt0 -97.34 130.05 44.54 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.012 -0.736 . . . . 1.14 109.012 174.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.819 ' CG1' HD11 ' A' ' 37' ' ' ILE . 89.0 t -115.46 127.77 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-O 121.339 0.59 . . . . 0.2 110.235 -171.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 46.3 mt -115.07 129.19 56.63 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.411 -0.589 . . . . 0.25 109.411 179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.95 HD13 ' CD2' ' A' ' 27' ' ' TYR . 4.5 mt -79.72 140.61 36.91 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.433 -0.792 . . . . 0.28 109.856 172.651 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.09 -31.99 6.93 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.857 -0.527 . . . . 1.6 110.798 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.56 -176.95 39.22 Favored Glycine 0 N--CA 1.504 3.228 0 C-N-CA 119.71 -1.233 . . . . 0.2 110.965 -177.429 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 29.3 p80 -145.06 152.6 40.36 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.715 -0.874 . . . . 1.89 110.742 -177.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -137.01 140.88 42.43 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.507 -0.746 . . . . 0.8 110.028 175.711 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.2 ttpt -110.68 151.47 42.85 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.711 -0.618 . . . . 2.99 110.31 179.81 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -56.12 143.99 81.98 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 O-C-N 123.334 1.176 . . . . 1.68 110.909 179.555 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -125.25 147.68 48.99 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.732 -0.605 . . . . 6.87 110.155 179.209 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 43.0 p-10 . . . . . 0 N--CA 1.495 1.798 0 CA-C-O 118.005 -0.998 . . . . 6.47 110.422 179.985 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.3 mtm . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.149 0.499 . . . . 2.76 110.591 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -80.04 138.68 37.05 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.937 -0.477 . . . . 1.7 110.214 179.347 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.0 p -128.74 134.93 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.719 -0.613 . . . . 0.41 109.565 177.439 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.58 HD11 ' HA2' ' A' ' 86' ' ' GLY . 27.8 mt -82.23 -20.22 38.12 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 120.213 -0.595 . . . . 0.37 110.386 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.827 ' HB3' HD12 ' A' ' 84' ' ' LEU . . . -171.74 154.58 3.69 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.418 -0.801 . . . . 0.26 109.327 175.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.6 tttt -134.66 125.17 26.57 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.657 -0.652 . . . . 2.3 110.246 -176.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . 0.616 ' CZ ' HG11 ' A' ' 82' ' ' VAL . 17.2 p90 -150.65 162.76 40.05 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.536 -0.727 . . . . 0.2 110.842 179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -113.69 138.74 49.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.623 -0.673 . . . . 1.99 110.231 -177.368 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 14.9 t -151.11 162.31 41.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.732 -0.605 . . . . 0.18 109.72 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.7 t -110.0 157.81 18.91 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.52 -0.737 . . . . 0.17 109.997 177.324 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 74' ' ' ILE . 62.1 t -79.33 135.82 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.748 -0.595 . . . . 0.49 110.259 -176.665 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -113.84 171.87 7.33 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.294 0.568 . . . . 0.68 109.787 174.088 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 92.7 mtm-85 -46.66 152.67 0.45 Allowed 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.522 -0.736 . . . . 2.96 112.026 -175.694 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.59 ' O ' HG22 ' A' ' 14' ' ' ILE . 56.6 mt 62.5 7.89 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.599 0 O-C-N 121.596 -0.69 . . . . 0.42 112.598 -175.636 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.71 16.17 80.43 Favored Glycine 0 N--CA 1.498 2.789 0 O-C-N 120.891 -1.131 . . . . 0.24 110.325 179.404 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 59.2 ttt180 -84.05 141.8 30.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.271 -1.135 . . . . 1.96 110.36 -176.473 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.9 pt -133.98 154.36 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.654 . . . . 0.3 109.532 172.832 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.8 mm -117.71 128.46 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 C-N-CA 120.051 -0.66 . . . . 0.25 109.857 176.19 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.435 HG12 ' CE2' ' A' ' 7' ' ' PHE . 34.0 mt -80.07 144.09 58.31 Favored Pre-proline 0 N--CA 1.496 1.829 0 C-N-CA 120.02 -0.672 . . . . 0.23 109.36 176.043 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.32 143.55 89.35 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 122.953 0.975 . . . . 0.35 109.731 174.656 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.5 -26.5 61.41 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.889 -0.507 . . . . 0.33 110.47 -178.347 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.48 -44.46 95.18 Favored Glycine 0 N--CA 1.497 2.753 0 N-CA-C 109.914 -1.275 . . . . 0.39 109.914 -179.771 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 82.2 m -69.97 -38.34 76.04 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.618 -0.931 . . . . 0.39 110.162 -179.392 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HA ' HD12 ' A' ' 29' ' ' ILE . 8.7 mtt180 -55.89 -40.79 73.52 Favored 'General case' 0 N--CA 1.514 2.75 0 O-C-N 121.245 -0.91 . . . . 0.4 109.43 176.42 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.3 tttp -64.94 -49.66 69.51 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.167 0.508 . . . . 2.97 110.119 -177.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -57.19 -38.55 73.82 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.785 -0.572 . . . . 0.67 110.726 -179.709 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.965 ' CD2' HD13 ' A' ' 84' ' ' LEU . 22.3 t80 -88.07 -14.23 39.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.847 -0.533 . . . . 1.44 111.308 -176.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 75.75 42.97 24.59 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.55 -1.42 . . . . 0.31 109.55 178.562 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.884 HG23 HG21 ' A' ' 56' ' ' VAL . 75.9 mt -87.25 129.14 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.499 -1.001 . . . . 0.42 110.563 -177.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -128.31 158.97 36.73 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 109.11 -0.7 . . . . 1.82 109.11 170.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -57.25 138.66 54.45 Favored 'General case' 0 N--CA 1.503 2.201 0 O-C-N 121.396 -0.815 . . . . 1.99 110.539 -179.149 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.89 -16.05 62.1 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 110.869 -0.892 . . . . 0.19 110.869 178.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -76.82 155.54 32.96 Favored 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 118.708 1.254 . . . . 1.12 110.076 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -110.43 138.65 46.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.557 -0.714 . . . . 0.21 109.462 174.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.38 154.43 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 C-N-CA 120.204 -0.598 . . . . 0.15 109.398 174.796 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -114.89 123.38 49.01 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.158 -1.053 . . . . 1.09 108.158 179.695 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.814 HD11 ' CG1' ' A' ' 82' ' ' VAL . 11.7 tt -139.94 158.65 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 C-N-CA 119.662 -0.815 . . . . 0.14 110.812 -167.787 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.537 ' HB2' HG23 ' A' ' 51' ' ' THR . 23.7 ttpt -132.67 146.21 51.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.887 -0.508 . . . . 1.11 110.42 178.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.586 HG22 HG22 ' A' ' 82' ' ' VAL . 22.0 pt -114.72 149.12 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.718 -0.614 . . . . 0.2 110.252 177.107 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 58.5 t -140.1 123.95 18.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 CA-C-O 121.138 0.494 . . . . 0.2 109.69 178.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.701 ' HB2' HG22 ' A' ' 80' ' ' ILE . 29.2 tttt -132.25 148.47 52.45 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 109.34 -0.615 . . . . 1.98 109.34 175.922 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 33.1 t80 -102.2 128.98 48.48 Favored 'General case' 0 N--CA 1.496 1.864 0 C-N-CA 120.008 -0.677 . . . . 0.33 110.328 179.909 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -133.76 133.16 41.39 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.685 -0.635 . . . . 1.48 109.989 178.806 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 59.88 -128.18 45.85 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.717 -1.353 . . . . 0.41 109.717 -178.578 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.8 pt-20 -105.06 8.61 34.36 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.702 -0.881 . . . . 1.27 111.726 177.937 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 20.4 pt-20 -131.29 139.06 34.28 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.227 -0.921 . . . . 1.37 110.722 -178.775 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -75.19 142.42 27.27 Favored 'Trans proline' 0 N--CA 1.483 0.87 0 O-C-N 122.931 0.964 . . . . 0.34 110.504 175.399 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.68 ' HB3' HG23 ' A' ' 72' ' ' ILE . 31.7 mmtp -111.13 136.0 50.81 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.588 -0.695 . . . . 1.1 109.714 172.743 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -133.27 156.89 46.74 Favored 'General case' 0 C--N 1.311 -1.068 0 O-C-N 121.531 -0.731 . . . . 1.42 110.582 -171.381 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.61 ' HA3' HD11 ' A' ' 72' ' ' ILE . . . -157.67 135.86 4.57 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.544 -1.422 . . . . 0.17 109.544 176.104 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.537 HG23 ' HB2' ' A' ' 38' ' ' LYS . 3.0 m -126.83 138.31 53.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.647 -0.913 . . . . 0.21 109.714 177.257 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.815 ' CE2' ' HB2' ' A' ' 54' ' ' ALA . 11.1 p90 -156.26 173.79 16.34 Favored 'General case' 0 N--CA 1.498 1.95 0 C-N-CA 119.949 -0.701 . . . . 0.16 111.107 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.9 m -106.89 141.07 38.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.633 -0.667 . . . . 0.13 109.606 173.289 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.815 ' HB2' ' CE2' ' A' ' 52' ' ' PHE . . . -142.24 145.77 34.44 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.754 -0.591 . . . . 0.14 110.551 -175.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 57.0 ttt180 -93.77 145.26 24.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.741 -0.6 . . . . 2.21 109.778 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.884 HG21 HG23 ' A' ' 29' ' ' ILE . 95.6 t -79.68 125.5 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 CA-C-O 121.384 0.611 . . . . 0.17 109.825 179.675 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -103.9 -165.91 25.08 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.989 -1.244 . . . . 0.19 109.989 178.482 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -61.62 153.07 28.92 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.85 -0.794 . . . . 1.39 110.178 -179.335 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 53.55 21.15 2.38 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.602 -0.686 . . . . 0.82 112.056 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.42 20.51 79.88 Favored Glycine 0 N--CA 1.499 2.851 0 C-N-CA 119.812 -1.185 . . . . 0.19 110.817 172.008 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 59.4 p -78.41 146.68 34.42 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.563 -0.963 . . . . 1.3 110.439 -176.244 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.757 HG23 ' HB1' ' A' ' 54' ' ' ALA . 8.8 p -139.55 145.62 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.631 -0.507 . . . . 0.21 109.631 174.203 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.3 mm -111.09 123.03 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.552 -0.718 . . . . 0.34 110.478 -176.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.447 HG23 ' HD2' ' A' ' 65' ' ' PRO . 76.8 mt -78.2 144.47 67.02 Favored Pre-proline 0 N--CA 1.498 1.937 0 O-C-N 121.613 -0.679 . . . . 0.34 109.656 174.755 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.76 ' CG ' HD12 ' A' ' 68' ' ' LEU . 56.9 Cg_endo -64.31 134.58 42.67 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 O-C-N 122.928 0.962 . . . . 0.26 110.802 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -54.88 -35.02 63.63 Favored 'General case' 0 N--CA 1.503 2.207 0 O-C-N 121.489 -0.757 . . . . 2.62 110.767 -179.806 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.426 ' O ' HG23 ' A' ' 71' ' ' VAL . . . -58.84 -38.29 78.38 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.738 -0.601 . . . . 0.45 110.364 -178.063 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.76 HD12 ' CG ' ' A' ' 65' ' ' PRO . 72.6 mt -77.21 -32.66 56.09 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 120.172 -0.611 . . . . 1.82 110.729 179.529 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -58.28 -46.49 85.96 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.301 -0.874 . . . . 2.53 109.761 178.551 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -70.02 -46.12 65.77 Favored 'General case' 0 N--CA 1.494 1.764 0 C-N-CA 120.542 -0.463 . . . . 1.68 110.455 -175.179 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 67' ' ' ALA . 95.4 t -60.38 -38.46 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.61 -0.681 . . . . 0.28 109.825 -178.835 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.683 HG22 HD11 ' A' ' 74' ' ' ILE . 81.3 mt -82.17 -18.27 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.918 -0.489 . . . . 0.28 110.912 -177.059 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.59 35.13 42.08 Favored Glycine 0 N--CA 1.497 2.752 0 N-CA-C 109.75 -1.34 . . . . 0.22 109.75 176.476 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.885 ' CG2' HG21 ' A' ' 11' ' ' VAL . 49.8 mm -92.0 140.72 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.468 -1.019 . . . . 0.77 110.569 -174.529 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 23.1 mmmt -125.32 161.58 49.14 Favored Pre-proline 0 N--CA 1.498 1.964 0 O-C-N 121.637 -0.665 . . . . 3.21 110.498 -175.366 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -60.75 134.6 54.89 Favored 'Trans proline' 0 N--CA 1.487 1.12 0 O-C-N 123.0 1.0 . . . . 0.5 110.748 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 91.47 0.87 72.37 Favored Glycine 0 N--CA 1.496 2.653 0 N-CA-C 111.118 -0.793 . . . . 0.24 111.118 176.645 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -100.33 135.86 41.12 Favored 'General case' 0 N--CA 1.498 1.975 0 CA-C-N 118.704 1.252 . . . . 1.11 110.737 -179.633 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.72 133.9 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 CA-C-O 121.696 0.76 . . . . 0.24 111.463 -172.605 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.701 HG22 ' HB2' ' A' ' 41' ' ' LYS . 43.1 pt -124.59 159.47 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 109.399 -0.593 . . . . 0.18 109.399 175.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -98.6 132.0 44.35 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.067 -0.716 . . . . 1.14 109.067 175.9 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.814 ' CG1' HD11 ' A' ' 37' ' ' ILE . 93.6 t -115.39 129.41 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 CA-C-O 121.302 0.572 . . . . 0.2 110.282 -171.408 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 41.9 mt -116.1 129.36 56.3 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 109.168 -0.679 . . . . 0.25 109.168 178.869 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.965 HD13 ' CD2' ' A' ' 27' ' ' TYR . 5.3 mt -80.09 139.25 36.96 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.396 -0.815 . . . . 0.28 109.755 171.798 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -111.21 -31.25 7.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.724 -0.61 . . . . 1.6 110.971 -174.899 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.58 ' HA2' HD11 ' A' ' 4' ' ' LEU . . . -168.06 -175.9 38.14 Favored Glycine 0 N--CA 1.504 3.176 0 C-N-CA 119.671 -1.252 . . . . 0.2 111.086 -176.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -144.44 154.05 42.54 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.681 -0.893 . . . . 1.89 110.744 -177.277 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -140.55 146.64 38.33 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.536 -0.727 . . . . 0.8 110.131 175.972 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.1 pttp -121.56 155.92 58.98 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.681 -0.637 . . . . 2.99 110.43 179.416 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -56.04 150.2 48.76 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 O-C-N 123.287 1.151 . . . . 1.68 110.914 179.222 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -119.71 142.13 48.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.719 -0.613 . . . . 6.87 110.177 179.223 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.495 1.816 0 CA-C-O 117.966 -1.016 . . . . 6.47 110.228 -179.995 . . . . . . . . 0 0 . 1 stop_ save_